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2016 ACVIM Forum Research Abstract Program
Denver, Colorado, June 9–10, 2016
Index of Abstracts
ORAL PRESENTATIONS – Thursday, June 9
Time # Presenting Author Abstract Title
CARDIOLOGY
9:00 am C01 Bryan Eason Sinus Rate Approximation with VVI, VVIR, and VDD in Dogs with Third Degree
Atrioventricular Block (ACVIM Resident Research Award Eligible)
9:15 am C02 Janne Lyngby Validation of a Method for Quantitation of Clopidogrel and Clopidogrel Active
Metabolite in Feline Plasma (ACVIM Resident Research Award Eligible)
9:30 am C03 Dar Ozer Eﬃcacy of Bronchial Stenting in Dogs With Myxomatous Mitral Valve Disease and
Bronchial Collapse (ACVIM Resident Research Award Eligible)
9:45 am C04 J.D. Rhinehart Study of Echocardiographic Variability in Estimating Pulmonary Artery Pressure and
Pulmonary Vascular Resistance in Dogs (ACVIM Resident Research Award Eligible)
10:30 am C05 Kursten Roderick Changes in NT-PROBNP Associated with Treatment and Survival Time in Cats with
Congestive Heart Failure (ACVIM Resident Research Award Eligible)
10:45 am C06 Courtney Smith Right Ventricular Outﬂow Tract Obstruction and Coronary Anatomy in French and
English Bulldogs with PS (ACVIM Resident Research Award Eligible)
11:00 am C07 Melissa Tropf Cardiac Function and Metabolic Parameters in Obese Dogs (ACVIM Resident Research
Award Eligible)
11:15 am C08 Darcy Adin Comparison of Furosemide Infusion Diluted with 2.4% Hypertonic Saline Vs. Dextrose
5% in Water (D5W)
11:30 am C09 Amelie Beaumier Medical Management and Survival Time Associated with Congestive Heart Failure
Stage D: A Retrospective Study
11:45 am C10 A. Ray Dillon MRI 7T Resonance Spectroscopy (MRS) Predicts Cardiac Energetic Reserves in Dogs
with Preclinical Mitral Insuﬃciency
12:00 pm C11 Chris Lam Immunohistochemical Study of the Pro-Natriuretic Peptide Convertase Corin in Severe
Canine Myxomatous Mitral Valve Disease
12:15 pm C12 Giulio Menciotti Anatomic Regurgitant Oriﬁce Area Using 3D-Echocardiography in Dogs with
Myxomatous Mitral Valve Disease
2:15 pm C13 Takeshi Mizuno Analysis of Mitral Valve Morphology with Real-Time 3-Dimensional Echocardiography
in Dogs Undergoing Mitral Valve Repair
J Vet Intern Med 2016;30:1407–1519
2:30 pm C14 Lisbeth Olsen Low-Density Lipoprotein Oxidation Is Breed and Gender Dependent in Dogs with
Myxomatous Mitral Valve Disease
2:45 pm C15 Nicole LeBlanc Cardiac Output Measured By Echocardiography and Cardiac-Gated Computed
Tomography Compared to Thermodilution
3:00 pm C16 Kathryn Meurs Angiotensin Converting Enzyme Activity and Response to Enalapril in Dogs with an
Ace Gene Polymorphism
3:15 pm C17 Kathryn Meurs Angiotensin Converting Enzyme Activity in Cavalier King Charles Spaniels with an
Ace Gene Polymorphism
3:30 pm C18 Laura Nafe Prevalence of Diroﬁlaria immitis Antigen in Client-Owned Pet Dogs Before and After
Serum Heat Treatment
3:45 pm C19 Lena Pelander Cardiac Biomarkers Troponin I and N-Terminal Pro-B-Type Natriuretic Peptide in
Canine Chronic Kidney Disease Patients
4:30 pm C20 Rebecca Tracey Establishing Normal 24 Hour Holter Monitor Values in Healthy Puppies
4:45 pm C21 Jessica Ward Distribution of Alveolar-Interstitial Syndrome in Dyspneic Veterinary Patients Assessed
By Lung Ultrasound Versus Thoracic Radiographs
ONCOLOGY
9:00 am O01 Zachary Neuman The Association of Endothelin-1 Signaling with Bone Alkaline Phosphatase Expression
and Pro-tumorigenic Activities in Canine Osteosarcoma (VCS Award Winner)
9:15 am O02 MacKenzie Pellin Safety Evaluation of Combination Doxorubicin and Toceranib Phosphate (Palladia) in
Tumor Bearing Dogs: a Phase I Dose Finding Study (VCS Award Winner)
9:30 am O03 Jerome Calvalido Comparison of Serum Cytokine Levels Between Dogs with Multicentric Lymphoma
and Healthy Dogs (ACVIM Resident Research Award Eligible)
9:45 am O04 Zachary Crouse Post-Chemotherapy Perforation in Cats with a Diagnosis of Intermediate or High
Grade Gastrointestinal Lymphoma (ACVIM Resident Research Award Eligible)
10:30 am O05 Sindy Piscoya A Retrospective Study on the Incidence of Proteinuria Associated with the Use of
Toceranib Phosphate (ACVIM Resident Research Award Eligible)
10:45 am O06 Krystal Harris Growth Pathways in Feline Oral Squamous Cell Carcinoma
11:00 am O07 Michelle Turek A Retrospective Analysis of Multimodality Treatment for Canine Oral Melanoma: 126
Cases
11:15 am O08 Lucia Borlle Enhancement of Doxorubicin Eﬀectiveness When Combined with Salinomycin in FISS
Cell Lines
11:30 am O09 Martha MaloneyHuss Clinical Advancement of a RNA-Transfected CD40-B Cell Vaccine for the Treatment
of Canine Non-Hodgkin’s Lymphoma
11:45 am O10 Nicole Weidner Vitamin D Status and Acute Phase Protein Concentrations in Canine Cancer Patients
12:00 pm O11 Jenny Ellis Retrospective Evaluation of Metronomic Cyclophosphamide in Epithelial and
Mesenchymal Malignant Tumours
NEUROLOGY
9:00 am N01 Michele Provencher Kinematic Magnetic Resonance Imaging for Evaluation of Disc-Associated Cervical
Spondylomyelopathy in Doberman Pinschers (ACVIM Resident Research Award
Eligible)
9:15 am N02 Melissa Carpentier-Anderson 3D Magnetic Resonance Imaging of the Dog Spine in Hansen Type I Intervertebral
Disk Disease (ACVIM Resident Research Award Eligible)
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9:30 am N03 Aude Castel Clinical Characteristics of Dogs with Progressive Myelomalacia Following Acute
Intervertebral Disc Herniation (ACVIM Resident Research Award Eligible)
9:45 am N04 Serene Lai In Vitro Anti-Tubulin Eﬀects of Benzimidazole Anthelmintics Mebendazole and
Fenbendazole on Canine Glioblastoma Cells (ACVIM Resident Research Award
Eligible)
10:30 am N05 Ilyssa Meren Subarachnoid-Subarachnoid Shunting for Treatment of Subarachnoid Cerebrospinal
Fluid Flow Obstruction in 9 Dogs (ACVIM Resident Research Award Eligible)
10:45 am N06 Jessica Rivera 11-Dehydro Thromboxane B2 As a Biomarker for Intracranial Neoplasia in Dogs
(ACVIM Resident Research Award Eligible)
11:00 am N07 Christine Sibigtroth Lumbar Fractalkine and M2 Microglia Increase Throughout Disease Progresssion in
Canine Degenerative Myelopathy (ACVIM Resident Research Award Eligible)
11:15 am N08 Christine Sibigtroth Increased Phosphorylated Neuroﬁlament Heavy in Cerebrospinal Fluid As a Disease
Marker of Canine Degenerative Myelopathy (ACVIM Resident Research Award
Eligible)
11:30 am N09 Muna Qahwash Etiology of Feline Juvenile Onset Seizures (ACVIM Resident Research Award Eligible)
11:45 am N10 Samantha Vitale Comparison of Serum Trace Nutrient Concentration in Dogs with Primary Genetic
Epilepsy Versus Healthy Dogs
12:00 pm N11 Devon Hague Lactate As a Prognostic Factor in Dogs and Cats with Head Trauma: 93 Cases (2003–
2014)
12:15 pm N12 Nick Jeﬀery Comparison of Fecal Microbiomes Between Dogs with Meningoencephalomyelitis of
Unknown Origin and Controls
SMALL ANIMAL INTERNAL MEDICINE – ENDOCRINOLGY**
2:15 pm EN01 Nubia Lopes Glucose Homeostasis Deteriorates More Rapidly with Age in Burmese Cats Compared
to Non-Burmese
2:30 pm EN02 Arnon Gal Perturbations in Serum Fructosamine Level in Diabetic Hyperthyroid Cats – A
Retrospective Study
2:45 pm EN03 Hannah Pipe-Martin Pharmacodynamic and Pharmacokinetic Properties of Insulin Aspart Following
Subcutaneous and Intramuscular Injection in Cats (ACVIM Resident Research Award
Eligible)
3:00 pm EN04 Isabelle Rast The Eﬀect of Tetra-Hydroxylated Bile Acid on Adipocyte Size and Insulin Sensitivity in
Healthy Cats (ACVIM Resident Research Award Eligible)
3:15 pm EN05 Chen Gilor The Eﬀect of Adiposity and Diet on Secretion of Incretin Hormones in Cats
3:30 pm EN06 Victoria Crossley Breed, Coat Colour and Hair Length As Risk Factors for Feline Hyperthyroidism
3:45 pm EN07 Allison Rowland Does a Limited Iodine Diet Aﬀect the Response to Radioactive Iodine Therapy in
Hyperthyroid Cats?
4:30 pm EN08 Vincent Ziglioli Eﬀects of Levothyroxine Adminstration and withdrawal on the Hypothalamic-Pituitary-
Thyroid Axis in Euthyroid Dogs (ACVIM Resident Research Award Eligible)
4:45 pm EN09 Alisdair Boag Variability of P450scc Autoantibody Persistence in Dogs Aﬀected with
Hypoadrenocorticism
5:00 pm EN10 Emily Brown Juvenile Hypoadrenocorticism in the Nova Scotia Duck Tolling Retriever: A Recessive
Monogenic Autoimmune Disease
5:15 pm EN11 Arnon Gal Variability in Post ACTH Stimulation Serum Cortisol Following Administration of
Cortisone Acetate in Healthy Dogs
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5:30 pm EN12 Muzzammil Sayyid Ionized Hypercalcemia in Cats: Etiologies and Associated Clinical Signs
**Also See Small Animal Internal Medicine – Endocrinology abstracts, Friday, June 10.
SMALL ANIMAL INTERNAL MEDICINE – GASTROENTEROLOGY**
2:15 pm GI01 Lauren Cochran Serum Pancreatic Lipase Immunoreactivity Concentrations in Dogs with
Gastrointestinal Foreign Bodies (ACVIM Resident Research Award Eligible)
2:30 pm GI02 Sarah Cocker Serum Pancreatic Lipase Immunoreactivity Concentrations After Chronic
Administration of Supraphysiologic Doses of Glucocorticoids to Dogs (ACVIM
Resident Research Award Eligible)
2:45 pm GI03 Agostino Buono Serum Il-2, Il-6, Il-8, and TNF-a Concentrations in Dogs with Increased Serum Spec
CPL Sup Concentrations
3:00 pm GI04 Micah Bishop Fishhook Foreign Bodies in Dogs and Cats: 107 Cases (2004–2015)
3:15 pm GI05 Alana Redfern-Allen Perturbations of the Intestinal Microbiota and Bile Acid Metabolism in Dogs with
Diabetes Mellitus (ACVIM Resident Research Award Eligible)
3:30 pm GI06 J.B. Honneﬀer Variation of the Microbiome and Metabolome Along the Canine Gastrointestinal Tract
3:45 pm GI07 Jan Suchodolski Eﬀects of Hydrolyzed Protein and Metronidazole on the Fecal Microbiome and
Metabolome in Healthy Dogs
4:30 pm GI08 Blake Guard Altered Fecal Bile Acid Metabolism in Dogs with Chronic Enteropathy
4:45 pm GI09 J.B. Honneﬀer Altered Fecal Sterol Proﬁles in Dogs with Chronic Inﬂammatory Enteropathy
5:00 pm GI10 Jan Suchodolski The Fecal Microbiome of Dogs with Exocrine Pancreatic Insuﬃciency
5:15 pm GI11 Adam Rudinsky Eﬀect of Weight Loss and Diet on Fecal Microbiota and Fecal Metabolomics in Cats
5:30 pm GI12 Albert Jergens Probiotic Mixture Vsl#3 Increases Beneﬁcial Fecal and Mucosal Microbiota in Canine
Inﬂammatory Bowel Disease
5:45 pm GI13 Julien Dandrieux Changes in Intestinal Macrophage Populations Following Clinical Resolution in Dogs
with Chronic Enteropathy
6:00 pm GI14 Sara Wennogle Histopathologic Characteristics of Intestinal Biopsies From Dogs with Chronic
Enteropathy with and without Hypoalbuminemia (ACVIM Resident Research Award
Eligible)
**Also See Small Animal Internal Medicine – Gastroenerology abstracts, Friday, June 10.
SMALL ANIMAL INTERNAL MEDICINE – HEMATOLOGY
9:00 am HM01 Beno^ıt Cuq Reproducibility, Stability and Biological Variability of Thrombin Generation Using
Calibrated Automated Thrombography in Healthy Dogs (ACVIM Resident Research
Award Eligible)
9:15 am HM02 Kelly Makielski Development and Validation of a Novel Canine Immune Thrombocytopenia Bleeding
Score (ACVIM Resident Research Award Eligible)
9:30 am HM03 Natalie McLewee Eﬀects of Aspirin Dose Escalation on Canine Platelet Function and Urinary
Thromboxane and Prostacyclin Levels (ACVIM Resident Research Award Eligible)
9:45 am HM04 Jessica Pritchard B Cell Activating Factor As a Biomarker in Dogs with Primary Immune Mediated
Thrombocytopenia
10:30 am HM05 Sophie Saati Comparison of Multiplate, Platelet Function Analyzer-200, and Plateletworks in Dogs
Treated with Aspirin and Clopidogrel (ACVIM Resident Research Award Eligible)
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10:45 am HM06 Jenny Ellis Evaluation of the Risk of Relapse of Canine Immune-Mediated Thrombocytopenia
After Routine Vaccination
11:00 am HM07 Rachel Hegedus Predicting In Vivo Response to Low-Dose Aspirin in Healthy Dogs Using In Vitro
Platelet Aggregometry
11:15 am HM08 Cyril Parachini-Winter Retrospective Evaluation of Anemia and Erythrocyte Morphology in Dogs with
Lymphoma and Inﬂammatory Bowel Disease
11:30 am HM09 Michele Wilkinson An In-Vitro Assessment of Canine to Feline Red Blood Cell Xenotransfusion
11:45 am HM10 James Swann Characterization of the Immunophenotype of Dogs with Immune-Mediated Hemolytic
Anemia (ACVIM Resident Research Award Eligible)
12:00 pm HM11 Masahiko Sato A Retrospective Study on Use of Leﬂunomide in Dogs with Immune Mediated
Diseases (ACVIM Resident Research Award Eligible)
12:15 pm HM12 Samantha Muro Eﬀects of Leukoreduction and Storage on Eicosanoid Concentrations in Units of
Canine Packed Red Cells (ACVIM Resident Research Award Eligible)
SMALL ANIMAL INTERNAL MEDICINE – INFECTIOUS DISEASE
2:15 pm ID01 Elena Contreras Evidence for Genetic Predispositon to Borrelia burgdorferi Infection in Purpose Bred
Beagles
2:30 pm ID02 Kirsten Cooke Rapid Diagnosis of Babesia gibsoni Using Point-of-Care Insulated Isothermic
Polymerase Chain Reaction Assay
2:45 pm ID03 Robert Six Prevention of Borrelia burgdorferi and Anaplasma phagocytophilum Transmission From
Ixodes scapularis to Dogs By Sarolaner
3:00 pm ID04 Milica Kovacevic Filipovic Molecular and Serological Analysis of Canine Vector Borne Disease Prevalence in Most
Populated Serbian Area
3:15 pm ID05 Diana Scorpio Enhanced Serologic Surveillance to Detect Prevalence of Canine Vector-Borne
Infections on St. Kitts, West Indies
3:30 pm ID06 Julie Levy Performance of Point-of-Care Assays for FELV and FIV
3:45 pm ID07 Cynda Crawford Does a Diva Test Exist for Diﬀerentiating FIV Infection From FIV Vaccination?
4:30 pm ID08 Morihiro Tateno An Epidemiological Study of Gammaherpesviruses in Domestic Cats in Japan
4:45 pm ID09 Nyssa Reine-Salz Canine Inﬂuenza H3N2 Infection in Four Dogs
5:00 pm ID10 Rhonda LaFleur Demonstration of Protection Against Canine Inﬂuenza Virus H3N2 Infection Following
Vaccination with Inactivated CIV H3N2
5:15 pm ID11 Nyssa Reine-Salz Prevalence of Canine Infectious Respiratory Disease Complex Pathogens in Dogs in
Georgia and North Carolina
5:30 pm ID12 Jason Stull Frequency, Beneﬁts and Health Risks of Animals in Nursing Homes: Cross-Sectional
Study of Ohio Facilities
5:45 pm ID13 Modest Vengust Eﬀect of Quorum Quenching with Azithromycin on Pseudomonas aeruginosa Associated
Otitis Externa/Media in Dogs
SMALL ANIMAL INTERNAL MEDICINE – NUTRITION/METABOLISM
9:00 am NM01 Hanna Mila Eﬀect of the Hyper-Immune Egg Yolk Supplementation on Weight Gain in Neonate
Puppies
9:15 am NM02 Yuanlong Pan Eﬀects of Dietary Medium Chain Triglycerides on Voluntary Activity in Dogs and Cats
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9:30 am NM03 Dagmar Tarkosova Eﬀects of Dietary Macronutrient Content and Feeding Pattern on Leptin
Concentrations in Lean Healthy Cats
9:45 am NM04 Hui Xu Eﬀect of High Sodium Diet on Blood Pressure and Cardiac Function in Healthy Adult
Dogs.
SMALL ANIMAL INTERNAL MEDICINE – NEPHROLOGY/UROLOGY
9:00 am NU01 Sarah Guess Longitudinal Evaluation of Serum Symmetric Dimethylarginine (SDMA) and
Creatinine (SCR) in Dogs with Early CKD (ACVIM Resident Research Award Eligible)
9:15 am NU02 Julie Cross SDMA Correlates Better with Creatinine Than High Throughput Immunoturbidometric
Cystatin C Assay in Feline Serum
9:30 am NU03 Laura Harjes Fibroblast Growth Factor-23 in Canine Chronic Kidney Disease (ACVIM Resident
Research Award Eligible)
9:45 am NU04 E. Hathaway Fiocchi The Use of Darbepoetin Alfa to Stimulate Erythropoiesis in Dogs with Chronic Kidney
Disease (ACVIM Resident Research Award Eligible)
10:30 am NU05 Fernanda Chacar Vitamin D-Binding Protein – Early Marker of Tubular Injury in Dogs with Chronic
Kidney Disease
10:45 am NU06 Stacie Summers Assessment of Repeated Administration of a Feline FVRCP Vaccine As a Model for
Interstitial Nephritis (ACVIM Resident Research Award Eligible)
11:00 am NU07 Ellen Behrend Comparison of Visual and Automated Interpretation of Urinary Dipsticks with
Glucose:Creatinine Ratio and Glucose Concentration
11:15 am NU08 Kanae Takada Impact of Canine Pancreas-Speciﬁc Lipase on the Outcome of Dogs with Hemodialysis-
Dependent Acute Kidney Injury
11:30 am NU09 Jonathan Foster Characterization of Subclinical Bacteriuria, Urinary Tract Infection, and Pyelonephritis
in Dogs with Chronic Kidney Disease
11:45 am NU10 Ewan Wolﬀ Initial Outcomes and Complications of the Subcutaneous Ureteral Bypass Procedure at
Two University Hospitals (2012–2015) (ACVIM Resident Research Award Eligible)
12:00 pm NU11 Melanie Puchot Occult Urinary Tract Infection in Cats: Prevalence and Findings on Contemporaneous
Urinalysis (ACVIM Resident Research Award Eligible)
12:15 pm NU12 Romy Heilmann Diagnostic Performance of Urinary Canine Calgranulins in Dogs with Lower Urinary
Tract Carcinoma
SMALL ANIMAL INTERNAL MEDICINE – PHARMACOLOGY
10:30 am P01 Leanne Fowler Itraconazole Absorption From Proprietary and Compounded Formulations in Healthy
Cats
10:45 am P02 David Griﬃn Bioavailability of a Novel Formulation of S-Adenosylmethioine Given with Food in
Beagle Dogs
11:00 am P03 Dianne Mawby Posaconazole Pharmacokinetics in Cats After oral and IV Administration
11:15 am P04 J.E. Slovak Evaluation of Intravenous Mycophenolate Mofetil Use in Healthy Cats
SMALL ANIMAL INTERNAL MEDICINE – RESPIRATORY
11:30 am R01 Kimberly Hooi Comparison of Bronchoalveolar Lavage Techniques for Sampling Lower Airways in
Cats (ACVIM Resident Research Award Eligible)
11:45 am R02 Aida Vientos-Plotts Characterization of the Feline Respiratory Microbiome (ACVIM Resident Research
Award Eligible)
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EQUINE**
9:00 am E01 Kate Echeverria Pulmonary Disposition and Pharmacokinetics of Oral Minocycline in the Adult Horse
(ACVIM Resident Research Award Eligible)
9:15 am E02 Teresa Burns Intravenous Administration of Cobalt Chloride Is Associated with Hemodynamic
Alterations in Horses
9:30 am E03 Andrew Gestrich The Pharmacokinetics of Intravenous Gentamicin in Healthy Young-Adult Versus
Geriatric Horses
9:45 am E04 Nicholas Parkinson Endotoxin-Induced Microrna Expression in Equine Peripheral Blood Mononuclear
Cells (ACVIM Resident Research Award Eligible)
10:30 am E05 Nicolas Herteman Severe Equine Asthma (Heaves) Is Associated with an Increased Number of Circulating
Low-Density Granulocytes
10:45 am E06 Amy Santonastaso Can Levamisole Upregulate the Equine Cell-Mediated Immune Response In Vitro?
11:00 am E07 Helena Carstensen Novel Pharmacological Treatment Regimes in Equine Atrial Fibrillation
11:15 am E08 Linda Frellstedt Can Exercising Electrocardiography Predict Performance in Young Standardbred
Horses at the Start of Training?
11:30 am E09 Eva Hesselkilde Is ECG in Horses Only for Dysrhythmia Diagnosis? Introducing a New Method for 12-
Lead ECG
11:45 am E10 Kate Hepworth-Warren Humoral Hypercalcemia of Malignancy in Horses: A Retrospective Study (2010–2015)
12:00 pm E11 Goncalo Silva Development of a Technique for Determination of Pulmonary Artery Pulse Wave
Velocity in Horses (ACVIM Resident Research Award Eligible)
12:15 pm E12 Olivia Lorello Repeated Measurements of Autonomic Tone Markers Over a Training Season in
Eventing and Endurance Horses
12:30 pm E35 Breanna Sheahan Normal Ultrasonographic Pleural Thickness in Clinically Healthy Adult Horses
(ACVIM Resident Research Award Eligible)
2:15 pm E13 Steven Grubbs Epidemiological Characteristics of Horses with Hyperinsulinemia in a Large Population
of Horses
2:30 pm E14 Steven Grubbs Management of Early PPID in Horses
2:45 pm E15 Nicholas Frank Development of an Octreotide Response Test for Detection of Insulin Dysregulation in
Horses
3:00 pm E16 Nicholas Frank Insulin and Incretin Hormone Concentrations in Horses During an Oral Sugar Test
and Pasture Challenge
3:15 pm E17 Katarzyna Dembek Association of Androgens and Pregnanes Response to ACTH Stimulation with Adrenal
Dysfunction in Hospitalized Foals
3:30 pm E18 Katarzyna Dembek Association of Oxytocin and Neurosteroids with Neonatal Maladjustment Syndrome
(NMS) in Hospitalized Foals
3:45 pm E19 Elaine Norton Identiﬁcation of Genetic Loci Underlying Equine Metabolic Syndrome and Laminitis
Risk in Welsh Ponies
4:30 pm E20 Ramiro Toribio The Fibroblast Growth Factor-23/Klotho Axis in Healthy and Hospitalized Foals
4:45 pm E21 Jennifer Brown Eﬀect of RRR-Alpha-Tocopherol Formulation on Serum and CSF Alpha-Tocopherol
Concentrations in Vitamin E Deﬁcient Horses (ACVIM Resident Research Award
Eligible)
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5:00 pm E22 Ann Kemper Diﬀerential Gene Expression in Equine Subcutaneous and Internal Adipose Depots
(ACVIM Resident Research Award Eligible)
5:15 pm E23 Elizabeth Nelson Eﬀects of a Commercial Anionic Supplement on Urinary Acidiﬁcation in Horses
(ACVIM Resident Research Award Eligible)
5:30 pm E24 Katherine Williamson Eﬀects of Abrupt Concentrate Increase and Prebiotic Supplementation on Equine Cecal
pH and Lactate
5:45 pm E25 Frank Andrews Eﬀects of a Supplement (Alfa-Lox Forage) on Equine Gastric Ulcer Scores and
Gastric Juice pH
6:00 pm E26 Angelika Schoster Changes of the Equine Neonatal Intestinal Microbiota Associated with Age and
Diarrhea
6:15 pm E27 Daniela Luethy Comparison of Tube, Gel, and Immunochromatographic Strip Methods for Evaluation
of Equine Blood Transfusion Compatibility (ACVIM Resident Research Award Eligible)
**Also See Equine abstracts, Friday, June 10.
FOOD ANIMAL
9:00 am F01 Veronique Bernier Gosselin Prevalence of Coagulase-Negative Staphylococci Species in Intramammary Infection in
Dairy Goats (ACVIM Resident Research Award Eligible)
9:15 am F02 Diego Gomez Assessment of an Antimicrobial-Use Algorithm for Treatment of Diarrhea in Dairy
Calves
9:30 am F03 Diego Gomez Prevalence of Bovine Coronavirus in Feces of Healthy and Diarrheic Calves
9:45 am F04 Joe Smith Use of an Alivecor Heart Monitor for Heart Rate and Rhythm Evaluation in Domestic
Goats
10:30 am F05 Rachel Oman Left Displacement of te Abomasum in Four Beef Calves (ACVIM Resident Research
Award Eligible)
10:45 am F06 Jennifer Halleran Apparent Eﬃciency of Colostral Immunoglobulin Absorption in Holstein Heifers
(ACVIM Resident Research Award Eligible)
11:00 am F07 Kevin Washburn Concentrations of Chlortetracycline in Fetal Tissues Following Oral Administration in
the Ewe
11:15 am F08 Vincent Dore Hyperketonemia As a Tool to Predict Mortality in Dairy Goat During Last Month of
Pregnancy (ACVIM Resident Research Award Eligible)
11:30 am F09 Christie Balcomb Eﬃcacy and Pharmacokinetics of Intravenous Famotidine in Adult Cattle
11:45 am F10 Andrew Gestrich The Pharmacokinetics of Intravenous Gentamicin in Healthy Young-Adult Versus
Aged Alpacas
12:00 pm F11 Marie-Eve Bilodeau Prognosis Associated with Cerebrospinal Fluid Analysis Results in Recumbent Dairy
Cattle: Retrospective Study (2006–2014) (ACVIM Resident Research Award Eligible)
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ORAL PRESENTATIONS – Friday, June 10
Time # Presenting Author Abstract Title
EQUINE
2:15 pm E28 Amanda Adams Inﬂuenza-Speciﬁc Immune Responses to a Combination Vaccine in Na€ıve Ponies
2:30 pm E29 Amanda Adams WNV-Speciﬁc Immune Responses to a Combination Vaccine in Na€ıve Ponies
2:45 pm E30 Brandy Burgess Characteristics of Infection Control Practices at North American Veterinary Teaching
Hospitals
3:00 pm E31 Sandra Taylor Anti-Endotoxic Properties of Ketorolac Tromethamine and Flunixin Meglumine in
Horses
3:15 pm E32 Amy Stieler Eﬀects on Sweating of Chloramphenicol and the Macrolide Gamithromycin:
Comparison with Erythromycin
3:30 pm E33 Arlie Manship Comparison of the Clinicopathologic Signatures of Equine Coronavirus and Salmonella
enterocolitis
3:45 pm E34 JunJie Liu Phenotypic Characterization of Sarcocystis neurona Lesions in Gravely Aﬀected Horses
4:30 pm E36 Jacquelyn Bowser Syringe Versus Mechanical Suction with N-Butylscopolammonium Eﬀects on BAL
Parameters in Horses with Pasture RAO
4:45 pm E37 Julie Dauvillier Prevalence of Fungi in Respiratory Samples of Horses with Inﬂammatory Airway
Disease
5:00 pm E38 Cyprianna Swiderski Intravenous Magnesium Sulfate As a Rescue Therapeutic for Bronchoconstriction in
Horses
5:15 pm E39 Emily Medlin Martin Investigation of Misoprostol As a Novel Anti-Inﬂammatory in Equine Leukocytes
5:30 pm E40 Sian Durward-Akhurst Do Endocrine Disrupting Chemicals Play a Role in Horses with Equine Metabolic
Syndrome?
5:45 pm E41 Jane Manfredi Evaluation of an Oral Sugar Test for Dynamic Assessment of Five Equine Breeds’
Insulin Response/Sensitivity
SMALL ANIMAL INTERNAL MEDICINE – GASTROENTEROLOGY
9:00 am GI15 Karin Allenspach Human Granulocyte Immunoﬂuorescence Assay for Anti-Neutrophil Antibodies Shows
Strong Association with Canine Food Responsive Diarrhea
9:15 am GI16 Jonathan Lidbury Serum Citrulline Concentrations in Dogs with Chronic Enteropathy
9:30 am GI17 Linda Toresson Oral Versus Parenteral Cobalamin Supplementation in Dogs with Chronic
Enteropathies and Hypocobalaminemia
9:45 am GI18 Nozomu Yokoyama Plasma Essential Trace Element Concentrations in Dogs with Chronic Enteropathy
2:15 pm GI19 Roman Husnik Validation of Ultrasonographic Measurement of Gastric Emptying Time in Healthy
Cats Using Radionuclide Scintigraphy
2:30 pm GI20 Toshiaki Kakimoto Eﬀect of Mosapride on Postprandial Gallbladder Motility and Plasma Levels of
Motilin in Dogs
2:45 pm GI21 M. Katherine Tolbert Evaluation of the Presence and Role of Cysteine Protease 30 in Feline T. foetus
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3:00 pm GI22 Emily Gould Evaluation of the Eﬀect of Omeprazole on Serum Calcium, Magnesium, Gastrin and
Bone in Cats
3:15 pm GI23 Jillian Haines Gravity-Assisted Esophageal Transit Characteristics in Dogs with Megaesophagus
3:30 pm GI24 Jonathan Lidbury Feasibility of Measuring Gastrointestinal Transit Time in Healthy Dogs Using ALICAM
3:45 pm GI25 Jill Pomrantz Comparison of Gastric Transit Time in Healthy Dogs and Dogs with Signs of Gastric
Hypomotility
4:00 pm GI26 Jill Pomrantz Feasibility of a Novel Gastrointestinal Imaging Device for Use in Dogs
SMALL ANIMAL INTERNAL MEDICINE – HEPATOLOGY
8:00 am HP01 Sara Wennogle Fluorescence in Situ Hybridization Identiﬁes Occult Bacterial Infection in Gallbladder
Mucoceles (ACVIM Resident Research Award Eligible)
8:15 am HP02 Kathleen Aicher Association of Gallbladder Mucocele Formation with Occult Hypothyroidism in Dogs:
A Matched Case-Controlled Study (ACVIM Resident Research Award Eligible)
8:30 am HP03 Jonathan Lidbury Interobserver Agreement for Histological Scoring of Canine Hepatic Fibrosis
8:45 am HP04 Matthias Schneider Embolization of Intratrahepatic Portosystemic Shunts in Dogs with a Prototype Coil
SMALL ANIMAL INTERNAL MEDICINE – OTHER
8:00 am OT01 Alison Khoo Eﬀect of Three Resuscitative Fluid Protocols on N-Terminal Prohormone Brain
Natriuretic Peptide in Healthy Dogs (ACVIM Resident Research Award Eligible)
8:15 am OT02 Mira Korpivaara Dexmedetomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear
Associated with Noise in Dogs
8:30 am OT03 Katherine Scotti Prognostic Indicators in Cats with Septic Peritonitis: 55 Cases (2002–2015)
8:45 am OT04 Franck Jolivet Reliability of Thermometer Protective Sheaths for Measurement of Rectal Temperature
in Dogs
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On Display: Thursday, June 9, 9:30 am–5:00 pm Friday, June 10, 9:30 am–5:00 pm
Attended by ALL Authors
Thursday, June 9, 9:50 am–10:30 am Friday, June 10, 9:50 am–10:30 am
Attended by ALL Authors – Wine & Cheese Reception:
Thursday, June 9, 5:45 pm–7:30 pm
# Presenting Author Abstract Title
CARDIOLOGY
C22 SeungWoo Jung Circulating Plasma Mirna As Novel Molecular Biomarkers in Congestive Heart Failure
C23 Randolph Winter A Multicenter Evaluation of Signalment and Comorbid Conditions Associated with
Aortic Thrombosis in 291 Dogs
C24 Marlos Goncalves
Sousa
Right Ventricular Systolic Function in Dogs with Post-Capillary Pulmonary
Hypertension
C25 Marlos Goncalves
Sousa
Vasovagal Tonus Index in Dogs with Myxomatous Mitral Valve Disease
C26 Maria Helena
Matiko Akao
Larsson
Sick Sinus Syndrome and Sinus Node Dysfunction: Case Series Reports of FMVZ-USP
Cardiology Service (2007-2015)
C27 Kensuke Nakamura The Utility of Spectral Doppler of the Hepatic Veins in Dogs with Tricuspid
Regurgitation
C28 Emily Menzen Cutaneous Use of an Implantable Loop Recorder (Reveal LINQTM) for Cardiac Event
Monitoring in Dogs
C29 Lilian Shen Aortoseptal Angle and Response to Balloon Valvuloplasty in Dogs Aﬀected with
Severe Subaortic Stenosis
C30 Melissa Wilson Evaluation of Pulmonary Hypertension in Cats with Cardiac Disease and Pleural
Eﬀusion Versus Pulmonary Edema
C31 Junseok Lee Post-Operative Dysrhythmias After Cardiac Surgery Under Cardiopulmonary Bypass
NEUROLOGY
N13 Jourdan Brune Characterization of Iatrogenic Blood Contamination on Lactate Dehydrogenase and
Creatine Kinase in Canine Cerebrospinal Fluid
N14 Lorenzo Mari Outcome Comparison in Dogs with Thoracolumbar Acute Non-Compressive Nucleus
Pulposus Extrusion or Fibrocartilaginous Embolic Myelopathy
N15 Katia Marioni-
Henry
Morphology of the Caudal Fossa in Mesaticephalic and Brachycephalic Cats and
Associated Clinical Signs
N16 Pablo Amengual Diagnostic Investigation in 13 Cats with Suspected Feline Hyperesthesia Syndrome
N17 Hilary Hu Cystometric Characterization of Urinary Bladder Dysfunction in Chronically Paralyzed
Dogs (ACVIM Resident Research Award Eligible)
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N18 Michele Provencher Evaluation of Kinematic Magnetic Resonance Imaging in Dogs with Osseous-
Associated Cervical Spondylomyelopathy (ACVIM Resident Research Award Eligible)
N19 Lisa Bartner Bartonella Spp. PCR Assay Results Using Cerebrospinal Fluid of Dogs with Central
Nervous System Disease
N20 Hilary Levitin Preictal, Postictal and Interictal Behavioral Changes in Dogs with Genetic Epilepsy
Compared to Control Dogs
ONCOLOGY
O12 Erika Berger Evaluation of Toceranib Phosphate (Palladia) in the Treatment of Feline Mast Cell
Neoplasia: 53 Cases
O13 Valter de Medeiros
Winkel
Expression of P Glycoprotein (ABCB1) in Cats with T-Cell Lymphocytic
Gastrointestinal Lmyphoma
O14 Tracy Gieger Early Experiences with Stereotactic Radiation Therapy for the Treatment of Canine
Non-Lymphomatous Nasal Tumors
O15 Tracy Gieger Treatment of Canine Appendicular Osteosarcoma with Amputation, Carboplatin, and
Toceranib Phosphate
O16 J. Paul Woods Safety Assessment of a Novel Oncolytic Maraba Virus in Cats
O17 Daniel Regan Role of Monocyte Recruitment in Hemangiosarcoma Metastasis in Dogs (VCS Award
Winner)
O18 Nicholas Szigetvari Phase I Clinical Trial of the Targeted Chemotherapeutic Drug, Folate-Tubulysin, in
Dogs with Urinary Tract Transitional Cell Carcinoma (VCS Award Winner)
SMALL ANIMAL INTERNAL MEDICINE – ENDOCRINOLOGY
EN13 Ashley Gold Evaluation of Basal Cortisol Concentrations for the Diagnosis of Hypoadrenocorticism
in Dogs (ACVIM Resident Research Award Eligible)
EN14 Christina Marino Thyroid Proﬁles in Healthy Kittens Aged Two to Sixteen Weeks of Age (ACVIM
Resident Research Award Eligible)
EN15 Eileen Seage Spectrophotometry and Ultracentrifugation for Measurement of Plasma Lipids in Dogs
with Diabetes Mellitus (ACVIM Resident Research Award Eligible)
EN16 Hye-Ryung Choo Eﬀect of Hydrocortisone Administration on Leptin and Adiponectin Synthesis in
Healthy Dogs
EN17 Jon Fletcher Using Puriﬁed Feline Insulin to Evaluate Cross-Reactivity with a Human Insulin
Analog Elisa
EN18 Maria Jerico Steroid Hormone Panel Test and Trilostane and Melatonin Therapy in Pomeranian
Dogs with Alopecia X
EN19 Mia Reeve-Johnson Metabolite Diﬀerences Between Senior Burmese and Non-Burmese Cats, and
Associations with Measures of Glucose Metabolism
EN20 Yaiza Forcada A Genome-wide Association Study Identiﬁes Novel Candidate Genes for Susceptibility
to Diabetes Mellitus in DSH Cats (ESVE Award Winner)
SMALL ANIMAL INTERNAL MEDICINE – GASTROENTEROLOGY
GI27 Alison Manchester Correlation Between Novel Immunohistochemical Markers, Histopathology and
Clinical Scores in Cats with Chronic Enteropathy (ACVIM Resident Research Award
Eligible)
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GI28 Amanda Blake Fecal D-/L-Lactate Concentrations and Abundance of Lactic Acid Bacteria in Dogs
with Exocrine Pancreatic Insuﬃciency
GI29 Gena Esposito Evaluation of Serum Beta-Hydroxybutyrate Concentrations in Dogs with Chronic
Enteropathies
GI30 Ellen Everson Eﬀect of Serum Creatinine on Feline Serum DGGR-Lipase and Serum Pancreatic
Lipase Immunoreactivity
GI31 Roman Husnik Prevalence of Helicobacter Species and Their Association with Gastric Pathology in
Dogs with Gastrointestinal Disease
GI32 Jill Pomrantz Normal and Abnormal Findings in the Canine Gastrointestinal Tract Using
Ambulatory Light-Based Imaging
GI33 Joerg Steiner Fecal a1-Proteinase Inhibitor Concentrations in Dogs with Cardiac Disease
GI34 Rebecca Timmons Evaluation of the Eﬀects of Pre-Conditioning on Female Canine Adipose-Derived
Mesenchymal Stem Cell Cytokine Production
SMALL ANIMAL INTERNAL MEDICINE – HEMATOLOGY
HM13 Ian McClure Incidence of DEA 5 in Canine Population Using Novel Canine Antisera
HM14 Keitaro Morishita Prospective Study in the Treatment of Nonregenerative Immune-Mediated Anemia in 8
Dogs
HM15 Hyeri Shin Validation of Rapid Thromboelastographic Analysis on Citrated and Native Whole
Blood From Healthy Dogs
HM16 Sarah Shropshire Serial Evaluation of Thromboelastography and Platelet Aggregometry in Healthy Dogs
SMALL ANIMAL INTERNAL MEDICINE – HEPATOLOGY
HP05 Daniel Langlois Investigation of Hepatic Copper Accumulation in Dogs From Two Time Periods (1982-
1988 and 2009-2015)
SMALL ANIMAL INTERNAL MEDICINE – INFECTIOUS DISEASE
ID14 Melissa Beall Comparative Evaluation of Five In-Clinic Rapid Tests for Feline Leukemia Virus
Infection
ID15 Ramaswamy
Chandrashekar
Detection of Giardiasis in Dogs: Comparison of Three Rapid Diagnostic Tests
ID16 Jesse Buch Seroprevalence of Antibodies to Anaplasma phagocytophilum and Borrelia burgdorferi in
Domestic Cats
ID17 Jesse Buch Validation of a High-Throughput Serological Elisa Method for FELV P27 Antigen
Detection
ID18 Amber Caress Investigation of Whether Leptospira Vaccinal Antibodies React with Borrelia Peptides
Used in a Commercial Assay
ID19 Elena Contreras Clinical and Laboratory Findings in Dogs with Ixodes-Induced Chronic Anaplasma
phagocytophilum Infection After Prednisolone Administration
ID20 Michael Lappin Serum Neutralization of Feline Caliviviruses Using Sera From Kittens Administered a
Vaccine Containing Two Strains
ID21 Michael Lappin Risk Factors Associated with Giardia and Cryptosporidium in Pet Dogs and Cats in the
USA
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ID22 Jiayou Liu Signiﬁcant Diﬀerences in Sensitivity Levels of Rapid Tests for Antibodies to Anaplasma
Spp. in Dogs
ID23 Katie MacMillan Prevalence of Select Infectious Disease Agents in Client Owned Cats in Moscow, Russia
ID24 Alison Manchester Coxiella burnetii DNA Not Identiﬁed in Fleas From Domestic Cats in Australia and
the USA
ID25 Kirk Miller Risk of Heartworm Infection in Domestic Canines of Northwestern oregon
ID26 Cody Minor Ectoparasites and Vector-Borne Pathogens of Dogs in Baja California Sur
ID27 Jason Stull Identifying Agreement and Barriers to Proposed Canine Infectious Disease Guidelines
for Dog Group Settings
ID28 Julia Veir Correlation of Mycoplasma Quantitative PCR to Severity of Conjunctivitis in Cats
SMALL ANIMAL INTERNAL MEDICINE – NUTRITION/METABOLISM
NM05 Aparecido Camacho Determining the Lactate and Glucose Thresholds and the Acid-Base Imbalances in
Beagles Dogs
NM06 Dennis Jewell When Fed Foods with Similar Palatability, Cats Choose 30%, Dogs 23% of Calories
As Protein
NM07 Jennifer MacLeay A Double Masked Clinical Trial of a Therapeutic Food in the Management of Canine
Atopy
SMALL ANIMAL INTERNAL MEDICINE – NEPHROLOGY/UROLOGY
NU13 Crystal Cooley Survey of Subcutaneous Fluid Practices in Cats with Chronic Kidney Disease (ACVIM
Resident Research Award Eligible)
NU14 Ryan Dulaney Quantifying Urine Elimination Behaviors in Cats Using a Video Recording System
(ACVIM Resident Research Award Eligible)
NU15 Alisdair Boag Evaluation of the Eﬀect of Urine Dip Versus Urine Drip on Multitest Strip Results
NU16 Jean Hall Positive Impact of Nutritional Interventions in Client-Owned Dogs with Iris Stage-1
Chronic Kidney Disease
NU17 Marcia Kogika Fibroblast Growth Factor 23 (FGF-23) in Dogs with Naturally Occurring Chronic
Kidney Disease
NU18 Maciej Parys Serum Cytokine Proﬁles of Cats with Idiopathic Cystitis
NU19 Camille Torres-
Henderson
Cystolith Dissolution in Cats Using a Commercially Available Diet
SMALL ANIMAL INTERNAL MEDICINE – OTHER
OT05 Katrina Stewart Isolation and Identiﬁcation of Microrna From the Mature Feline Erythrocyte: A Pilot
Study (ACVIM Resident Research Award Eligible)
OT06 Laura McPhee Eﬀects of Sedation and Anesthesia on Canine Hematologic and Serum Biochemical
Analyses During Preventive Healthcare
OT07 Igor Yankin Does Fine Needle Aspiration Aﬀect Management of Dogs with Incidental Splenic
Nodules or Heterogeneous Parenchyma?
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SMALL ANIMAL INTERNAL MEDICINE – PHARMACOLOGY
P05 Darren Berger The Accuracy, Precision and Stability of Compounded Milbemycin Oxime in Aqueous
Suspension
P06 Andrea Herndon Pharmacokinetics of Intravenous and Subcutaneous Dolasetron and Pharmacodynamics
of Subcutaneous Dolasetron in Purpose-Bred Cats
P07 Lara Zajic Investigation of the Pharmacokinetics of Transdermal Ondansetron in Normal Purpose-
Bred Cats
EQUINE
E42 Harold Schott Basal Insulin Concentratrations in Competition Draft Horses
E43 Kamila Gravena Matrix Metalloproteinase-2 and -9 Levels in Horses with Experimental Small Colon
Intraluminal Obstruction
E44 Michael Keowen Eﬀects of Collagen Hydrolysates on Equine Gastric Ulcer Scores and Gastric Juice Ph
in Horses
E45 James Prutton Safety, Humoral Immune Response and Fecal Shedding of Modiﬁed-Live Bovine
Coronavirus Vaccines Given to Horses
E46 Sarah Elzinga Do Horses with Equine Metabolic Syndrome Have Reduced Immune Responses to
Vaccination?
E47 Melissa Siard Immunological Comparisons of Aged Horses with Vs. without Pituitary Pars
Intermedia Dysfunction
E48 Marta Barba Corynebacterium pseudotuberculosis Antibody Detection in Horses: Synergistic
Hemolysis Inhibition Test and Small Ruminant ELISA Comparison
E49 Martha Mallicote Eﬀects of Erythromycin on Responses Induced in Foals By Intravenous Epinephrine
E50 Barbara Qurollo Equine Vector-Borne Diseases Determined By Serological and Molecular Methods
E51 Andrew Allen Selenium Deﬁciency Associated with the Deaths of Fifteen Adult Horses
E52 Frank Garza, Jr. Eﬀects of Alfa-Lox Forage on Blood Glucose and Insulin Activity After Grain
Feeding in Horses
E53 Breanna Sheahan Venous Blood Gas, Electrolyte and Metabolite Findings in Healthy Neonatal Foals
Receiving Sodium Lactate Infusions (ACVIM Resident Research Award Eligible)
E54 Randolph Winter Growth and Function of Equine Endothelial Progenitor Cells Labeled with
Semiconductor Quantum Dots
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C01
SINUS RATE APPROXIMATION WITH VVI, VVIR, AND
VDD IN DOGSWITH THIRD DEGREE ATRIOVENTRICULAR
BLOCK. Bryan Eason1, Dan Hogan1, Ryan Baumwart2. 1Purdue
University, West Lafayette, IN, USA, 2Oklahoma State University,
Stillwater, OK, USA
The purpose of this study was to investigate which pacing
modality (VVI, VVIR, or VDD) most closely approximates the
intrinsic sinus rate in dogs with third degree AV block (3AVB)
over a range of typical daily activities. A secondary aim of the
study was to determine if echocardiographic parameters were dif-
ferent between pacing modalities. We hypothesized that VDD
would most closely track the intrinsic sinus rate for all activities
and that echocardiographic dimensions would be diﬀerent between
AV asynchronous (VVI, VVIR) and AV synchronous (VDD) pac-
ing modalities.
Dogs were prospectively recruited following implantation of a
St. Jude dual-chamber pacemaker system for 3AVB; dogs with evi-
dence of sinus node dysfunction or clinically important arrhyth-
mias other than 3AVB were excluded. All dogs were programmed
to VDD at study entry. The average, lowest and highest heart
rates during VDD pacing were determined; the average heart rate
was programmed as the base rate for VVI and VVIR. The highest
heart rate was programmed as the upper tracking rate for VVIR
with a threshold of 2.5, slope of 16, and fast reaction and recovery
times. The rest function was used for all pacing modalities and
was programmed to the lowest heart rate during VDD pacing; if
the lowest heart rate was at the lower rate limit, then the rest rate
was programmed 20% slower. Dogs were randomly assigned to
VVI or VVIR after initial VDD interrogation and echocardiogra-
phy (2D, Doppler, TDI). Ambulatory ECGs were recorded for
36 hours and the owners were instructed to record the time and
duration of 5 speciﬁc activities: (1) urination/defecation, (2) eating,
(3) sleeping, (4) walking, and (5) play. After three months,
echocardiography was repeated, the dog was crossed over to VVI
or VVIR pacing, and ambulatory ECG monitoring was repeated.
After three additional months, echocardiography was repeated, the
pacing modality was programmed to VDD and ambulatory ECG
monitoring was repeated. Atrial rate, ventricular rate, and atrial-
to-ventricular ratio were determined for each of the 5 activities
after an initial 12 hours acclimatization period.
This is an ongoing study and currently 6 dogs are enrolled where
5 dogs have completed the VVI phase, 4 dogs have completed the
VVIR phase, 4 dogs have completed both the VVI and VVIR
phases, and 1 dog has completed all VVI, VVIR, and VDD phases.
Atrial rates and atrial-to-ventricular ratios for VVI, VVIR, and
VDD at each activity are as follows: urination/defecation
(156.0  42.9, 2.01  0.39),(134.4  24.0, 0.95  0.14), (105.7,
1.0); eating (116.4  20.8, 1.51  0.23),(126.2  11.7, 0.97  0.22),
(95.7, 1.0); sleeping (99.1  38.3, 1.32  0.62),(79.8  15.7,
0.88  0.30), (51.5, 0.76); walking (183.2  24.7, 2.4  0.41),
(157.4  38.9, 1.09  0.12), (91.4, 1.0); play (125.4  38.3,
1.66  0.61),(105.8  17.0, 0.83  0.07), (108.9, 1.0). Echocardio-
graphic data is available for all 6 dogs in VDD, 4 dogs in VVIR, and
2 dogs in VVI. The left ventricle appears to be larger in diastole and
systole for VVI (LVAd/Ao = 6.85  0.76, EDV/Ao = 26.08
 2.80, LVAs/Ao = 2.74  0.19, ESV/Ao = 9.23  0.08) and
VVIR (LVAd/Ao = 5.24  0.57, EDV/Ao = 24.78  3.04, LVAs/
Ao = 2.38  0.47, ESV/Ao = 10.65  3.21) than VDD pacing
(LVAd/Ao = 5.14  1.38, EDV/Ao = 23.13  7.46, LVAs/Ao =
2.30  0.84, ESV/Ao = 7.43  4.27).
As the study is ongoing no ﬁnal conclusions can be made
although synchronous VDD pacing appears to more closely
approximate sinus rate and have slower atrial rates than asyn-
chronous VVI or VVIR pacing. All dogs will have completed the
study within the next two months at which time ﬁnal conclusions
can be made.
C02
VALIDATION OF A METHOD FOR QUANTITATION
OF CLOPIDOGREL AND CLOPIDOGREL ACTIVE
METABOLITE IN FELINE PLASMA. Janne G. Lyngby,
Michael H. Court, Pamela M. Lee. Program in Individualized
Medicine (PrIMe), Department of Veterinary Clinical Sciences,
College of Veterinary Medicine, Washington State University,
Pullman, WA, USA
Clopidogrel is considered mainstay therapy for the prevention
of cardiogenic thromboemboli in cats and has been shown to be
superior to aspirin. Clopidogrel is a pro-drug and requires hepatic
bioactivation through cytochrome p450 for formation of the clopi-
dogrel active metabolite (CAM), which is unstable and challenging
to quantitate. After bioactivation, CAM binds to the ADP-
receptor on platelets and inhibits platelet aggregation. Recently, a
method to stabilize CAM in human plasma has been developed by
adding 2-bromo-3’methoxyacetophenone (BMAP) to blood tubes.
Once stabilized, the derivatized CAM (CAM-D) can be quanti-
tated using high-performance liquid chromatography and tandem
mass spectrometry (HPLC-MS/MS).
Our aim is to validate HPLC-MS/MS for the detection of clopi-
dogrel, CAM-D, and other metabolites in feline plasma. We
hypothesized that HPLC-MS/MS is both accurate and precise.
The quantitation of CAM is the ﬁrst step in determining if cats
can consistently metabolize clopidogrel or if signiﬁcant interindi-
vidual variation exists as in humans with genetic polymorphisms
of hepatic cytochrome P450. Furthermore, having an accurate and
precise method for measuring the plasma concentration of CAM
will allow safer use of clopidogrel by potentially establishing a
therapeutic index and by evaluating whether coadministration of
drugs like omeprazole inhibit CAM formation in cats.
FDA guidelines to assess accuracy and precision were followed.
The in vitro stability of clopidogrel, CAM-D, and clopidogrel acid
in both citrate and EDTA feline plasma was evaluated at room
temperature, 4°C, 20°C and 80°C at 0, 6, 12, 24, 48, 72 hours,
and 7 days. Linear regression was performed on an 8 point stan-
dard curve (clopidogrel and CAM-D at 1–100 ng/mL, clopidogrel
acid at 0.2–20 µg/mL). To evaluate clinical application, two
healthy cats were given clopidogrel (Plavix) at the clinically used
dose of 18.75 mg orally once daily. Blood was taken prior to
clopidogrel administration and at 20, 40, 60, 90 minutes, 4 hours,
6 hours, 8 hours, and 12 hours post clopidogrel administration.
All blood samples were collected aseptically into 2 mL cryotubes
containing 10 uL of 500 mM BMAP and 20 uL of 500 mM
EDTA and then centrifuged. The supernatant was then transferred
to new cryotubes and stored at 80°C. All samples were analyzed
using HPLC-MS/MS in duplicate with a standard curve.
In vitro samples were stable at all temperatures for a minimum
of 72 hours. No diﬀerence was appreciated in the stability of
clopidogrel and its metabolites between EDTA and citrated
plasma. Standard curves showed linearity for clopidogrel, CAM-
D, and clopidogrel acid (r = 0.99). The assay measured clopido-
grel, CAM-D, and clopidogrel acid with an accuracy of <18.7%
and a precision within runs of <7%. Plasma concentrations of
clopidogrel, CAM-D, and clopidogrel acid were readily detected in
plasma from healthy cats receiving clopidogrel.
This is the ﬁrst simultaneous quantitation of clopidogrel, CAM-
D, and clopidogrel acid in feline plasma. HPLC-MS/MS is an
accurate and precise method for simultaneous quantitation of
clopidogrel and metabolites in feline plasma both in vitro and from
healthy cats receiving oral clopidogrel.
C03
EFFICACY OF BRONCHIAL STENTING IN DOGS
WITH MYXOMATOUS MITRAL VALVE DISEASE AND
BRONCHIAL COLLAPSE. Dar Ozer1, Samantha Siess2, Brienne
Williams1, Nikki Gaudette1, George Kramer1. 1Atlantic Coast
Veterinary Specialists, Bohemia, NY, USA, 2Stony Brook Univer-
sity, Stony Brook, NY, USA
Chronic airway disease and myxomatous mitral valve disease
(MMVD) are frequent comorbidities in small breed dogs. Bron-
chial collapse can cause coughing, tachypnea and hypoxemia. Pul-
monary hypertension can be seen with both MMVD and chronic
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airway disease. The purpose of this study was to review outcomes
in dogs that had bronchial stents placed due to bronchial collapse.
It was hypothesized that moderate to severe MMVD or the pres-
ence of pulmonary hypertension would not have a negative eﬀect
on lifespan after stent placement.
Medical records of 18 small breed dogs that had bronchial stent
placement for chronic coughing secondary to bronchial collapse
were reviewed. A hierarchical multiple linear regression analysis
was conducted to predict lifespan after bronchial stent placement
based on age at time of stent placement, severity of MMVD and
the presence of pulmonary hypertension.
Eighteen dogs had bronchial stents placed over a period of
7 years. Age at the time of stent placement ranged from 6.5 years
to 14 years of age (M = 10.47  1.85). Breeds represented
included Cavalier King Charles spaniel (2), beagle (2), Chihuahua
(4), Pomeranian (3), toy poodle (2), Yorkshire terrier (2), Maltese
(1), Coton de Tulear (1) and shih tzu (1). There were 11 males and
7 females. Twelve dogs (66.67%) had evidence of moderate to sev-
ere MMVD and 4 (22.22%) had evidence of pulmonary hyperten-
sion. Six dogs (33.33%) had CHF prior to stent placement and 6
dogs (33.33%) had CHF after stent placement. Syncope was
reported in 6 dogs prior to stent placement and 5 dogs after stent
placement. The average lifespan after stent placement was
203.56  250.72 days. Three dogs are currently alive post-stent
placement (1013, 559 and 411 days).
A hierarchical multiple linear regression was calculated to pre-
dict lifespan after placement of a bronchial stent based on age at
the time of stent placement, the presence of pulmonary hyperten-
sion, and severity of MMVD. In stage one, age at the time of stent
placement signiﬁcantly predicted lifespan after placement of a
bronchial stent (b = 7.10, P < .02); with lifespan decreasing by
7.10 days for each additional month of age at the time of stent
placement. The presence of pulmonary hypertension did not signif-
icantly predict lifespan (b = 235.32, P = .10). Severity of MMVD
did not contribute signiﬁcantly to the model in stage two
(b = 101.38, P = 0.43).
Results from this study indicate that the severity of MMVD or
the presence of pulmonary hypertension did not negatively aﬀect
lifespan after bronchial stent placement. As such, moderate to sev-
ere MMVD and the presence of pulmonary hypertension should
not be viewed as exclusion criteria when assessing candidates for
possible bronchial stenting. Prospective studies should be con-
ducted to further investigate the clinical beneﬁt of bronchial stent-
ing in dogs with severe bronchial collapse.
C04
STUDY OF ECHOCARDIOGRAPHIC VARIABILITY IN
ESTIMATING PULMONARY ARTERY PRESSURE AND
PULMONARY VASCULAR RESISTANCE IN DOGS.
JD Rhinehart, JD Bonagura, BA Scansen, KE Schober. College of
Veterinary Medicine, The Ohio State University, Columbus, OH,
USA
Pulmonary hypertension (PH) is important in clinical practice
and is related to clinical symptoms and prognosis. We hypothe-
sized that Doppler echocardiographic (DE) indices of PH and pul-
monary vascular resistance (PVR) are inﬂuenced by a variety of
independent factors leading to clinically important variability of
DE-based pressure estimates in dogs.
Dogs with naturally acquired tricuspid regurgitation (TR) were
studied prospectively. All dogs had degenerative valve disease.
Target variables were acquired during 4 study periods (dogs in lat-
eral recumbency or standing, after a 6-minute walk test [6-MWT]
and after sedation [0.25 mg/kg butorphanol, IM]), and by two dif-
ferent observers. Heart rate (HR), TR ﬂow velocity (TRFV),
PVR, estimates of right atrial pressure, stroke volume, cardiac out-
put, and 23 other variables were quantiﬁed. Statistical methods
included repeated-measures ANOVA and mixed model analysis.
P < 0.05 was considered signiﬁcant.
Thirty-two dogs of 10 small breeds with varying TRFVs (1.9–
5.28 m/s) and PVR (2.9–33.0 WU) were studied. There was a sig-
niﬁcant eﬀect of observer (P < 0.05), respiration (P < 0.01), and
image quality (P < 0.05) on outcome variables whereas imaging
position (dogs lying versus standing) did not cause diﬀerences
(P > 0.20). Sedation signiﬁcantly increased mean TRFV (P < 0.05,
from 3.15  0.71 m/s to 3.51  0.83 m/s; increase observed in
55% dogs) whereas 6-MWT had no eﬀect (3.16  0.75 m/s,
P > 0.05). HR declined after sedation (mean reduction
13  19 bpm; P < 0.05) and increased after 6MWT (mean
increase 30  28 bpm; P < 0.05) but had no correlation to TVFV
or PVR. 6-MWT did not inﬂuence TRFV and PVR.
These data document relevant variability of DE estimates of PH
that deserve clinical consideration.
C05
CHANGES IN NT-PROBNP ASSOCIATED WITH
TREATMENT AND SURVIVAL TIME IN CATS WITH
CONGESTIVE HEART FAILURE. Kursten Roderick, John
Rush, Lisa Freeman, Vicky Yang, Suzanne Cunningham.
Cummings School of Veterinary Medicine at Tufts University,
North Grafton, MA, USA
Survival time in cats with congestive heart failure (CHF) is
variable, and predictors of outcome would be useful to help
guide treatment and patient assessment. In people with CHF,
the change in NT-proBNP concentrations after initiating treat-
ment and/or targeting NT-proBNP concentrations below an
absolute level provide valuable information that can be used to
help guide treatment. The change in NT-proBNP concentrations
in cats with CHF after treatment and their association with sur-
vival have not been reported. Therefore, the purpose of this
study was to measure the change in NT-proBNP in cats with
CHF after treatment and to determine whether serial NT-
proBNP measurements provide prognostic information in this
population.
Client-owned cats presenting with new onset CHF secondary to
cardiomyopathy were eligible for enrollment. Blood was collected
for NT-proBNP analysis within 4 hours of admission, on the day
of discharge, and at the re-evaluation 7–10 days later.
Thirty-two cats were enrolled (25 male, 7 female; all neutered),
with a median age of 9.6 years (range 1.1 to 18.0 years). Thirty-
one (97%) cats survived to discharge and 28 cats (88%) survived
to the 7–10 day re-evaluation. Median NT-proBNP concentrations
at admission and hospital discharge were 1,713 pmol/L (range, 160
to 3,784 pmol/L) and 902 pmol/L (range, 147 to 3,223 pmol/L),
respectively. Median NT-proBNP concentration at re-evaluation
was 1,124 pmol/L (range, 111 to 2,727 pmol/L). Median NT-
proBNP concentrations decreased signiﬁcantly from admission to
discharge (P < 0.001) and from admission to re-evaluation
(P < 0.001), but not from discharge to re-evaluation (P = 0.28).
Median survival time was 109 days (range, 1 to 606 days), with 6
cats (19%) still alive at the time of analysis. Cats that received
pimobendan had a signiﬁcantly greater decrease in NT-proBNP
concentrations [821 pmol/L (range, 2,163 to 267 pmol/L)
from admission to discharge compared to cats that did not receive
pimobendan [561 pmol/L (range, 2137 to 889 pmol/L);
P = 0.045]. Cats whose owners had diﬃculty administering medi-
cations (n = 11) had a shorter survival time [median 60 days
(range, 2 to 234 days)] compared to owners who did not report
diﬃculty [n = 21, median 115 days (range, 1 to 606 days)]; how-
ever this was not statistically signiﬁcant (P = 0.12).
The association between pimobendan and a larger decrease in
NT-proBNP concentration warrants additional research. Larger
studies are needed to determine whether NT-proBNP can be used
to help guide treatment in cats with CHF.
C06
RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
AND CORONARY ANATOMY IN FRENCH AND ENGLISH
BULLDOGS WITH PULMONIC STENOSIS. Courtney Smith,
Katherine Scollan, David Sisson, Nicole LeBlanc. Oregon State
University, Corvallis, OR, USA
Pulmonic stenosis (PS) is one of the most common congenital
cardiac defects in dogs. Stenotic lesions described range from a
normal pulmonic annulus with domed leaﬂets to a hypoplastic
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pulmonary annulus with thickened leaﬂets. Additionally, anoma-
lous coronary artery anatomy (commonly described as an R2A)
has been reported impinging on the right ventricular outﬂow tract
(RVOT) in English Bulldogs and a Boxer dog with PS. The aim of
this study was to investigate the stenotic lesion morphology and
coronary artery anatomy in French Bulldogs in comparison to
English Bulldogs to assess similarities and/or diﬀerences between
the breeds.
Medical records were reviewed for French and English Bulldogs
presented to Oregon State University for heart murmur evaluation
or imaging prior to balloon valvuloplasty (BVP). Dogs were
included if they had severe PS (pressure gradient >80 mmHg esti-
mated via echocardiography) and conﬁrmation of their coronary
artery anatomy by either angiography or computed tomography
(CT). Echocardiographic, angiographic, and CT images were
reviewed. The pulmonic annulus (PA), aortic annulus (Ao), PA:Ao
ratio, valvular anatomy, and coronary anatomy were assessed on
each imaging modality by three observers (CS, KS, DDS) and
averaged. Tricuspid regurgitation (TR) was assessed on echocar-
diographic and angiographic studies. Breed medians or means
were compared by Mann-Whitney U test or unpaired t-tests as
indicated. In the dogs that had both CT and angiographic studies,
values were compared by paired t-tests.
Twenty-six dogs were reviewed and 6 dogs (all English Bull-
dogs) were excluded due to lack of deﬁnitive coronary artery anat-
omy imaging. Of the 20 included dogs, 7 were English (7 male)
and 13 were French Bulldogs (4 female and 9 male). Mean weight
was 13.8  4.5 kg in the English and 8.9  3.9 kg in the French
Bulldogs (P = 0.02). CT and angiographic imaging was performed
on 6/7 and 2/7 English, and 9/13 and 12/13 French Bulldogs,
respectively. An R2A coronary artery anomaly was deﬁnitively
identiﬁed in 6/7 English Bulldogs and 0/13 French Bulldogs.
Median PA:Ao annulus ratio was not statistically diﬀerent
between the English (0.88, range 0.64–1.0) and French Bulldogs
(0.89, range 0.85–1.1; P = 0.37). In addition, no diﬀerence was
found between CT and angiographic measurements of the PA:Ao
ratio (P = 0.38). The mean PA annulus indexed to body weight to
the 1/3 power was not diﬀerent between English (0.54  0.07) and
French Bulldogs (0.53  0.04; P = 0.73). TR was noted in 9/13
French Bulldogs (4 mild, 2 moderate, 3 severe) while 3/7 English
Bulldogs had TR (1 mild, 1 moderate, 1 severe).
Anomalous development of the coronary arteries was not
observed in any of the French Bulldogs evaluated in this study,
whereas the R2A coronary anomaly was identiﬁed in 6/7 English
Bulldogs with a RVOT obstruction. Marked thickening of the pul-
monic valve leaﬂets with markedly reduced leaﬂet mobility was
observed in all of the French Bulldogs and annular hypoplasia
was not present or was very modest in both breeds. In the dogs
with R2A anomalies, the curvature and degree of encroachment
from the left coronary artery on the RVOT was markedly vari-
able. A combination of valvular and supravalvular obstruction
was identiﬁed in the only English Bulldog with normal coronary
anatomy.
C07
CARDIAC FUNCTION AND METABOLIC PARAMETERS IN
OBESE DOGS. Melissa Tropf, O. Lynne Nelson, Pamela Lee.
Washington State University, Pullman, WA, USA
In people, obesity is an independent risk factor for the develop-
ment of obesity related cardiac dysfunction (ORCD) characterized
by systolic dysfunction, diastolic dysfunction, and/or vascular
endothelial dysfunction. Components of metabolic syndrome
including dyslipidemias, elevated inﬂammatory markers, and insu-
lin resistance are believed to play an important role in the patho-
physiology of ORCD. Obesity is reaching epidemic proportions in
dogs and it is estimated that approximately 34% of dogs are over-
weight and 5% are obese in the United States. Recent studies per-
formed in dogs suggest that metabolic syndrome also exists in
obese dogs, warranting further investigation into the risk for
ORCD.
We hypothesized that obese dogs have cardiac dysfunction and
have elevations in inﬂammatory markers, altered insulin sensitiv-
ity, and dyslipidemia consistent with metabolic syndrome when
compared with non-obese dogs. The aims of this study were ﬁrst,
to assess the presence of cardiac dysfunction in obese dogs
compared to dogs with ideal body composition and second, to
compare metabolic parameters including lipid analysis and inﬂam-
matory markers in obese versus normal dogs.
Healthy dogs weighing less than 25 pounds with ideal body con-
dition (n = 17) and obese body condition (n = 29) were enrolled.
All dogs had normal physical exam and thoracic auscultation with
no evidence of systemic illness on routine laboratory diagnostics.
A body composition using a validated 9 point scale, systolic arte-
rial Doppler blood pressure, a 6-lead electrocardiogram, and an
echocardiogram (M-mode, B-mode, Doppler and strain imaging)
were obtained. Finally, metabolic parameters including a lipid pro-
ﬁle (cholesterol, triglyceride, HDL, LDL), insulin, adiponectin,
and a canine inﬂammatory marker ELISA panel (GM-CSF, IL2-
18, TNF-alpha, INF-gamma, TNF-gamma CRP, MCP-1, IP-10,
KC-like) were evaluated. Paired T tests were performed to com-
pare the study groups and a P-value of less than 0.05 considered
statistically signiﬁcant.
Compared to dogs with ideal body condition scores, obese dogs
had signiﬁcantly increased septal wall thickness, increased systolic
function measures, and signiﬁcantly reduced diastolic function
measures. Obese dogs had signiﬁcantly increased insulin, insulin:
glucose ratio, cholesterol, triglyceride, and HDL levels. The
remaining metabolic parameters including adiponectin were not
signiﬁcantly diﬀerent between the groups. IL-8 and KC-like
inﬂammatory markers were signiﬁcantly higher in the obese group.
While the mean blood pressure was higher in obese patients, the
diﬀerence was not statistically signiﬁcant. A number of obese dogs
(n = 6) were conﬁrmed to have systemic hypertension on subse-
quent examinations.
In conclusion, obese dogs do have alterations in cardiac struc-
ture and function as well as dyslipidaemia, altered insulin sensitiv-
ity, and elevated inﬂammatory markers. These ﬁndings warrant
additional studies to investigate inﬂammation, dyslipidaemia, or
possibly systemic hypertension as potential etiologies of altered
cardiac function.
C08
COMPARISON OF FUROSEMIDE INFUSION DILUTED
WITH 2.4% HYPERTONIC SALINE VERSUS DEXTROSE
5% IN WATER (D5W). Darcy Adin1, Teresa DeFrancesco1,
Clarke Atkins1, Kari Kurtz1, Manoela Penteado2. 1North Carolina
State University, Raleigh, NC, USA, 22University of Sao Paulo,
Sao Paulo, Brazil
Continuous rate infusion (CRI) of furosemide causes more
diuresis than intermittent bolus administration, but can exacerbate
dehydration and renal dysfunction. The co-administration of
hypertonic saline (HS) may mitigate this, however, volume expan-
sion could be detrimental in heart failure.
Furosemide CRI with D5W (FCRI-D5W) was compared to
furosemide CRI with 2.4% hypertonic saline (FCRI-HS) in 6 nor-
mal dogs, in a randomized, blinded, crossover study. Furosemide
was diluted to 2.2% with either 1.5 mL/kg D5W for the FCRI-
D5W treatment or with 1.0 mL/kg D5W and 0.5 mL/kg of 7.2%
hypertonic saline for the FCRI-HS treatment. The furosemide
CRI rate was 0.66 mg/kg/hr for 5 hours in equal volume for both
treatments and was preceded by a 0.66 mg/kg furosemide IV
bolus.
Mean PCV and %increase in BUN were less for FCRI-HS ver-
sus FCRI-D5W (P = 0.046 both). Mean CVP decreased over time
(P < 0.001), with no treatment diﬀerence (P = 0.4). Urine output,
water intake, and creatinine increased signiﬁcantly, while serum
osmolality, serum/urine electrolytes, urine furosemide, and body
weight decreased signiﬁcantly, without diﬀerences between treat-
ments. The %decrease in serum potassium (P = 0.09) and %in-
crease in urinary sodium (P = 0.08) trended higher in FCRI-HS.
Plasma furosemide was stable and not diﬀerent between treat-
ments. Urinary neutrophil gelatinase-associated lipocalin (NGAL)
was unchanged, while both treatments doubled urinary aldos-
terone excretion suggesting similar activation of RAAS.
Diuresis was similar for both treatments however, FCRI-HS
appeared to produce less dehydration (lower PCV, smaller %in-
crease in BUN). Absence of intravascular volume expansion, based
on CVP, suggests FCRI-HS may be safe in heart failure.
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MEDICAL MANAGEMENT AND SURVIVAL TIME
ASSOCIATED WITH CONGESTIVE HEART FAILURE
STAGE D: A RETROSPECTIVE STUDY. Amelie Beaumier,
John E. Rush, Lisa M. Freeman. Tufts Cummings School of
Veterinary Medicine, North Grafton, MA, USA
Degenerative mitral valve disease (DMVD) is the most common
acquired heart disease in dogs. The ACVIM consensus statement
for dogs with DMVD provided recommendations for diagnosis
and management of Stages A through D. Recommendations for
Stage D were limited by the paucity of published information for
dogs with advanced congestive heart failure (CHF).
The objective of this retrospective study was to investigate the
survival and treatment of dogs diagnosed with stage D CHF. For
the purpose of this study, we deﬁned stage D as the persistence of
CHF despite receiving the label-approved dose of pimobendan, an
angiotensin-converting-enzyme inhibitor (ACEI), and furosemide
≥4 mg/kg/day. Dogs receiving a dosage of furosemide <4 mg/kg/
day were enrolled only if the dose was increased to ≥4 mg/kg/day
and if a new medication to control CHF was introduced at the
same visit.
Forty-three dogs (27 male and 16 female, all neutered) met eligi-
bility criteria and were included in the study. Mean age at the time
of diagnosis of Stage D CHF was 10.1  1.8 years. The most
common breeds represented were Cavalier King Charles spaniel
(n = 9), Chihuahua (n = 4), Dachshund (n = 4), and Shih Tzu
(n = 3). Twelve dogs were hospitalized on the day of diagnosis of
stage D CHF [median duration of hospitalization = 1 day (range,
1–3 days)]. The median duration between the ﬁrst diagnosis of
CHF and diagnosis of stage D was 157 days (range, 11–743 days).
At the time of diagnosis of stage D, 29 dogs had medications
added [1 medication added (n = 26), >1 medication added (n = 3)],
the diuretic dose was escalated in 27 dogs, and the pimobendan
dose was increased to >0.6 mg/kg/day in 20 dogs.
Thirty-two (74%) dogs had subsequent additional changes in
medications during the course of stage D CHF. Most dogs
(n = 31; 72%) dogs were ultimately receiving at least 5 cardiac
medications for the management of stage D CHF. Ultimate medi-
cation dosages during Stage D were: Furosemide (7.4  2.7 mg/
kg/day), pimobendan (1.0  0.3 mg/kg/day), and ACEI
(0.9  0.2 mg/kg/day). Additional medications administered to
these dogs included spironolactone (n = 31), sildenaﬁl (n = 21),
torsemide (n = 16), digoxin (n = 8), and hydrochlorothiazide with
spironolactone (n = 8). Median survival time after onset of Stage
D CHF was 311 days (range, 9–658 days), with 14 dogs still alive
at the time of analysis.
Multiple medication adjustments were necessary to manage
dogs with stage D CHF. However, the survival time may be
encouraging to the dedicated owner.
C10
MRI 7T RESONANCE SPECTROSCOPY (MRS) PREDICTS
CARDIAC ENERGETIC RESERVES IN DOGS WITH
PRECLINICAL MITRAL INSUFFICIENCY. A Ray Dillon1,
Tom Denney2, Seungwoo Jung1, Randolph Winter1, Juming
Zhong1, Michael Tillson1, Xiaoxia Zhang2, Nouha Salibi3,
Sharron Barney1. 1College of Veterinary Medicine, Auburn
University, Auburn, AL, USA, 2College of Engineering, MRI
Center, Auburn University, Auburn, AL, USA, 3Siemens Health-
care, MR Research and Development, MRI Center, Auburn
University, Auburn, AL, USA
Early stages of heart disease are characterized by reduction in
energy reserves with impairment of myocardial contractility and
relaxation. However, these alterations are diﬃcult to measure with
existing clinical imaging modalities such as echocardiography.
Recent advances in phosphorous (31P) magnetic resonance spec-
troscopy (MRS) enable changes in energy reserves to be measured
non-invasively.
The creatine kinase (CK) reaction is the primary energy reser-
voir of the heart. The CK reaction reversibly converts adenosine
diphosphate (ADP) and phosphocreatine (PCr) to ATP and crea-
tine. In heart failure, the ﬂux through the CK reaction decreases
as both creatine concentration (Cr) and CK activity decreases.
Unlike ATP, which can be generated by de novo synthesis path-
ways in the myocyte, Cr is not produced in excitable tissues.
Therefore, in heart failure the decrease in Cr occurs earlier and is
faster than the decrease in ATP. In this study, the PCr/ATP ratio
was used as a marker of cardiac energetics. The hypothesis was
that changes in cardiac energetic reserves measured by MRS pre-
cede global MRI, echocardiographic, and biochemical markers in
volume overload heart failure.
This hypothesis was evaluated in a canine model of preclinical
isolated mitral regurgitation (MR) via chordal rupture. In each
group, 2 dogs had minimal and 2 dogs had more severe MR at
induction. One group of dogs (4) was evaluated at baseline and
data collected at 2, 6, 12, 16 and 18 weeks after induction. A sec-
ond group of dogs (4) was evaluated at baseline and 2, 4, and
6 weeks after induction. At these parallel time points, cardiac eval-
uation, thoracic radiographs, echocardiography, and MRS and
standard 7T MRI were collected. In addition, peripheral blood
samples were collected for microRNA and biomarker evaluation
(NTproBNP). Baseline and endpoint cardiac catheterization were
recorded for cardiac output, right and left ventricular function and
vascular resistance. At the conclusion of the study, myocardial
function was assessed by measuring isolated myocyte morphology,
size, and myocyte contractility and Ca ﬂux. Left ventricle and
mitral valve tissues were collected for molecular studies of mRNA
and miRNA.
Utilizing a 7 Tesla (T) MRI scanner, 31P magnetic resonance
spectra were collected with an ungated, free breathing three-dimen-
sional chemical shift imaging sequence. In each dog, three 2.8 cc
voxels on the septal wall near midventricle were selected for analy-
sis. The PCr/ATP ratio was computed without saturation or blood
correction in each voxel and averaged.
Although there was a range in severity of MR in each group,
all dogs were asymptomatic, untreated and stage B1 or B2 during
the observation period. All data were collected at each time point.
Using each dog as its own control for echocardiographic evalua-
tion, the end-point LVDd increased in diameter (35.1% in
18 weeks dogs, 19.9% in 6 weeks dogs) and left atria dimensions
increased (27.3% in 18 weeks dogs and 31.2% in 6 weeks dogs)
and the fractional shortening increased (22.6% in 18 weeks dogs,
24.3% in 6 weeks dogs). Compared to baseline, the LVDs dimen-
sion increased (18.7% at 18 wks in the 18 weeks dogs, and 8.6%
in the 6 weeks dogs). At endpoint catheterization, the forward LV
stoke volume decreased (35.2% in 18 weeks dogs, 22.2% in
6 weeks dogs) in all dogs.
The normal PCr/ATP ratio without saturation or blood correc-
tion was determined at baseline for normal dogs (1.455 mean,
0.097 SEM). In the unloaded LV at 2 weeks, the PCr/ATP ratio
was increased in 6 of the 8 dogs. Over time with dysfunctional
remodelling in MR dogs, the PCr/ATP ratio decreased as myo-
cytes energy reserves were depleted especially in the dogs with sys-
tolic dysfunction.
PCr/ATP ratio would appear to be a measure of cardiac ener-
getics early in the remodelling phase of volume overload MR and
allows for the linear measure of the same dog over time to deter-
mine disease progression. MRS may provide a useful tool in the
evaluation of drug therapy on the cardiac energetics of MR in
dogs.
C11
IMMUNOHISTOCHEMICAL STUDY OF THE PRO-
NATRIURETIC PEPTIDE CONVERTASE CORIN IN SEVERE
CANINE MYXOMATOUS MITRAL VALVE DISEASE. Alex
Sahagian1, Chris Lam2, Bob Bao1, Sanaz Maleki1, Brett Hambly1,
Niek Beijerink2. 1Discipline of Pathology, Bosch Institute and
School of Medical Sciences, Sydney University, Sydney, NSW,
Australia, 2University Veterinary Teaching Hospital, Faculty of
Veterinary Science, Sydney University, Sydney, NSW, Australia
Corin is expressed by cardiomyocytes and converts pro-natriure-
tic peptides to their mature forms, which play a key role in ﬂuid
homeostasis and cardiac remodelling. In mice and human with
failing hearts, myocardial corin protein levels have been reported
to be increased, however without a concomitant increase in corin
activity. These ﬁndings can partly explain the clear paradox in
congestive heart failure (CHF) in that the natriuretic peptides are
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elevated, yet the body is ﬂuid retaining (ultimately resulting in
CHF). Interestingly in the Cavalier King Charles Spaniel, 2 loci
associated with development of myxomatous mitral valve disease
(MMVD) have been identiﬁed. Corin is on one of these loci on
the latest dog assembly. This further raises the question whether
deﬁciencies in myocardial corin expression or activity could be a
mechanism explaining the progression of heart disease and CHF
in dogs as well. The purpose of this study therefore was to charac-
terize the immunohistochemical expression of corin in myocardial
tissue in normal dogs and in dogs with severe MMVD.
Two groups of dogs of a variety of breeds were recruited
including 5 control dogs (euthanized for severe non-cardiac dis-
ease; age range 4 months-12 years), and 6 dogs with severe
MMVD (euthanized for refractory CHF; age range 9-14 years).
Samples were collected from the right atrium (RA), right ventricle
(RV), left atrium (LA), left ventricle (LV) and interventricular sep-
tum (IVS). Immunohistochemical staining of all tissues with a
polyclonal rabbit anti-human antibody against corin was carried
out, and computational quantiﬁcation was used to compare the
staining density between the two groups and between cardiac
regions.
Positive transmembrane and intracellular immunostaining for
corin was widely observed in all parts of the myocardium in both
groups. Corin expression was not up- or downregulated in any of
the cardiac chambers of the dogs with severe MMVD (ﬁgure 1),
nor was any diﬀerence seen between the chambers within each
group.
Our results indicate that corin expression might be a rate-limit-
ing step in dogs with CHF due to MMVD. A lack of an increase
in corin expression or activation can be postulated to be a possible
important pathophysiological mechanism responsible for the natri-
uretic peptide paradox in dogs with CHF, and warrants further
investigation.
Figure 1: Quantitative corin expression in myocardial tissue in
control dogs, and in dogs with congestive heart failure secondary
to myxomatous mitral valve disease.
C12
ANATOMIC REGURGITANT ORIFICE AREA USING 3D-
ECHOCARDIOGRAPHY IN DOGS WITH MYXOMATOUS
MITRAL VALVE DISEASE (MMVD). Giulio Menciotti1,
Michele Borgarelli1, Sandra M€uller2, Jonathan Abbott1. 1VA-MD
College of Veterinary Medicine, Blacksburg, VA, USA, 2Utrecht
University, Utrecht, The Netherlands
Aims of this study were to determine feasibility and repeatabil-
ity of measuring anatomical regurgitant oriﬁce area (AROA) using
real-time 3D transthoracic echocardiography (RT3DE) in dogs
aﬀected by MMVD, and to determine if AROA obtained using
RT3DE relates to the severity of MMVD assessed both with an
echocardiographic scoring system (MRSS) and the American Col-
lege of Veterinary Medicine (ACVIM) staging system.
RT3DE datasets of the mitral valve were acquired in 81 pri-
vately owned dogs diagnosed with MMVD and AROA was traced
and measured using dedicated software. Dogs were classiﬁed as
mild, moderate or severe according to an echocardiographic
MRSS, and as ACVIM Stage B1, B2 or C. Technique feasibility
(as % of dataset measurable) and inter- and intra-operator
repeatability were assessed. Diﬀerences in AROA between dogs in
diﬀerent MRSS and ACVIM stages were investigated.
AROA was measurable in 60 (74.1%) dogs. The inter- and
intra-operator coeﬃcients of variation were 26% and 21%, respec-
tively. AROA was signiﬁcantly greater in dogs with severe MRSS
compared to dogs with mild MRSS (P = 0.04). There were no dif-
ferences in AROA between dogs with mild versus moderate, and
moderate versus severe MRSS (P = 0.84 and P = 0.28, respec-
tively). There was no diﬀerence between AROA of dogs in diﬀer-
ent ACVIM clinical stages (P = 0.17)
In conclusion obtaining AROA using RT3DE is feasible and
oﬀers an additional, non-invasive technique to stratify MR severity
in dogs with MMVD. The relatively low repeatability suggests
standardization of the technique is desirable. Diagnostic and prog-
nostic utility of AROA deserve further investigation.
C13
ANALYSIS OF MITRAL VALVE MORPHOLOGY WITH
REAL-TIME 3-DIMENSIONAL ECHOCARDIOGRAPHY IN
DOGS UNDERGOING MITRAL VALVE REPAIR. Takeshi
Mizuno, Masashi Mizuno, Kayoko Harada, Hiroshi Takano,
Arane Takahashi, Kazuya Mamada, Junsoek Lee, Sayaka Takeu-
chi, Ayaka Chen, Tamotsu Sawada, Takahiro Mizukoshi, Asako
Shinoda, Shuhei Uchida, Takurou Mori, Kazuki Takamura,
Junichirou Takeuchi, Masami Uechi. JASMINE Veterinary Car-
diovascular Medical Center, Yokohama, Kanagawa, Japan
Three-dimensional (3D) saddle shape of the mitral valve annu-
lus was ﬁrst reported in 1987 by Levine and colleagues. Previous
studies showed annulus height to commissural width ratio
(AHCWR), an index parameter for saddle-shape of mitral annu-
lus, is preserved across mammalian species (15–20%). This sug-
gests that nature conserves the saddle-shaped annulus for
mechanical beneﬁt. Menciotti et al described 3D transthoracic
echocardiography (TTE) of normal dogs and AHCWR was
21  0.05%. There are no reports on 3D transesophageal echocar-
diography (TEE) studies on dogs with myxomatous mitral valve
disease (MMVD). This study aims to evaluate mitral valve annulus
morphology using 3D TEE in dogs with MMVD.
3D TEE was performed in dogs weighting more than 5 kg dur-
ing mitral valve repair surgery. The 3D geometry of mitral valve
apparatus was measured with dedicated quantiﬁcation software.
The classiﬁcation of MMVD dogs used in this study was the basis
of ACVIM staging. The 3D TEE measurements were compared
between each group of dogs.
Twenty-six dogs were included in the study, 2 dogs were
excluded from the study due to the uninterruptable echocardio-
graphic images. Thus, a total of 24 dogs were evaluated in this
study. The study group included 7 dogs with ACVIM Stage B2,
10 dogs with Stage C, and 7 dogs with Stage D. Characteristics of
each group were summarized below:
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AHCWR decreased as the disease progressed (Stage B2;
14.2  4.2%, Stage C; 9.0  4.2 5, Stage D; 9.5  3.3%, Figure).
Stage D dogs showed signiﬁcantly lower values (P < 0.05) com-
pared to Stage B2 dogs. Non-planarity angle measurement tends
to increase in value as the severity of MMVD worsened, however,
there were no signiﬁcant diﬀerences between the groups (B2;
157.7  8.1°, C; 167.9  9.2°, D; 164.4  8.5°, Figure). There
were no signiﬁcant diﬀerences between the groups for annular cir-
cumference and annular area values.
In conclusions, the mitral valve of dogs with MMVD loses the
saddle shape as the mitral valve disease progresses. The results of
this study suggested that as the severity of MMDV worsened,
more mechanical stress would be placed on the mitral valve, which
could increase the progression of mitral regurgitation. To the best
of our knowledge, this is the ﬁrst report about the morphological
changes of mitral valve annulus according to disease severity in
dogs with MMVD.
C14
LOW-DENSITY LIPOPROTEIN OXIDATION IS BREED
ANDGENDERDEPENDENT INDOGSWITHMYXOMATOUS
MITRAL VALVE DISEASE. Maria Joseﬁne Reimann1, Jens
H€aggstr€om2, Jacob Eifer Møller3, Jens Lykkesfeldt1, Torkel Falk4,
Lisbeth Høier Olsen1. 1University of Copenhagen, Frederiksberg
C, Denmark, 2Swedish University of Agricultural Sciences,
Uppsala, Sweden, 3Odense University Hospital, Odense, Denmark,
4Din Veterin€ar, Helsingborg, Sweden
Oxidative stress has been associated cardiovascular disease and
suggested to contribute to cardiac remodeling in human patients
with mitral regurgitation. Few previous studies have evaluated the
relationship between oxidative stress and myxomatous mitral valve
disease (MMVD) in dogs. The objective of this study was to deter-
mine plasma concentrations of certain markers of oxidative stress
and investigate if they were associated with MMVD severity,
selected clinical variables and disease progression in dogs with no
or diﬀerent severities of MMVD.
The study included 89 privately-owned dogs: 14 healthy control
Beagles, 59 cavalier King Charles spaniels (CKCS) with diﬀerent
severities of MMVD, and 16 dogs of diﬀerent breeds with clinical
signs of congestive heart failure due to MMVD.
Markers of oxidative stress including malondialdehyde (MDA),
oxidized low-density lipoprotein (oxLDL) and vitamin E (a-toco-
pherol and c-tocopherol) were measured in plasma and their inﬂu-
ence on 2-year progression of MMVD was determined.
Plasma oxLDL concentration was signiﬁcantly lower in control
Beagles compared to CKCS (P = 0.0005) and females had a signif-
icantly lower oxLDL plasma concentration compared to males
(P = 0.007). Plasma vitamin E concentrations were associated with
body condition score (BCS) (a-tocopherol, P = 0.002; c-toco-
pherol, P = 0.01). All the markers of oxidative stress (MDA,
oxLDL, vitamin E) were positively associated with serum choles-
terol (P ≤ 0.02) but none of the markers were associated with
severity or progression of MMVD. The eﬀect of BCS disappeared
when adjusting for serum cholesterol concentration.
In conclusion, Beagles and female dogs appear to have lower
plasma concentrations of oxLDL. The results cannot conﬁrm a
role of oxidative stress in dogs with MMVD.
C15
CARDIAC OUTPUT MEASURED BY ECHOCARDIOGRAPHY
AND CARDIAC-GATED COMPUTED TOMOGRAPHY
COMPARED TO THERMODILUTION. Nicole LeBlanc,
Katherine Scollan. Oregon State University, College of Veterinary
Medicine, Corvallis, OR, USA
The accurate measurement of stroke volume and cardiac out-
put (CO) has important applications in both clinical and research
arenas. Invasively measured CO by thermodilution (TD) remains
the gold standard method. To date, there are very few compara-
tive studies evaluating echocardiographic CO in dogs using non-
invasive imaging modalities. There are no direct comparisons
between noninvasive CO estimation using 64-slice multidetector
computed tomography (MDCT) and TD in dogs. The aim of
this study was to evaluate the accuracy of CO estimation by
noninvasive methods (MDCT, 1-, 2-, and 3-dimensional echocar-
diography) compared to invasively measured CO obtained
by TD.
Six intact hound cross dogs weighing between 19.5–23.8 kg were
anesthetized using a standardized protocol and spontaneous venti-
lation. Each dog underwent MDCT, echocardiography, and TD.
Dogs were randomized to the order of MDCT and echocardiogra-
phy, and TD was performed last. CO using TD was measured in
triplicate with <10% variation and minimal changes in heart rate.
For imaging methods, CO was calculated by volumetric measure-
ments of SV multiplied by the average heart rate. Echocardio-
graphic left ventricular (LV) end-diastolic volumes (EDV) and
end-systolic volumes (ESV) were measured on right long axis 1D
images (Teichholz) and right long axis and left apical 2D images
(single plane Simpson’s method of disks, MOD) on 3 averaged
consecutive beats. Real-time 3-dimensional echocardiographic
(RT3DE) LV volumes were measured using 3D functional analysis
software from both right long axis and left apical imaging planes.
MDCT EDV and ESV were measured using speciﬁc LV functional
analysis software on ECG-gated studies.
Excellent correlation was found between CO values measured
by TD and 2D MOD (r = 0.98) from the left apical window, as
well as 2D MOD (r = 0.90) and RT3DE (r = 0.92) from the right
long axis window. A less robust correlation was found between
RT3DE values obtained from the left apical window (r = 0.68)
and TD. MDCT-derived CO were also strongly correlated
(r = 0.80) with TD. CO estimation by Teichholz formula
(r = 0.05) had no signiﬁcant correlation with TD. Bland-Altman
analysis showed a systemic underestimation of CO values derived
both from echocardiographic and MDCT measurements. The bias
for RT3DE CO obtained from the right long axis window was
0.23 L/min (95% conﬁdence interval (CI) 0.56 to 0.09 L/min),
and for 2D from the left apical window was 0.66 L/min (95%
CI 0.91 to 0.42 L/min). The bias for CO values obtained from
MDCT was 0.57 L/min (95% CI 0.99 to 0.15 L/min).
These results suggest certain echocardiographic techniques avail-
able for CO measurement are comparable to invasively measured
CO. Speciﬁcally, 2D MOD using the right long axis and left apical
4-chamber views, or RT3DE from the right long axis view, had
excellent agreement with TD. The excellent correlation between
methods indicates a close relationship between select techniques,
although they are not interchangeable. CO is underestimated by
the noninvasive techniques studied here compared to TD. The dif-
ferences between TD and noninvasive measures may be due to
errors of the method, patient stroke volume variability, heart rate
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ﬂuctuation, or inaccuracies of TD. One of the major limitations of
this study is the small number of patients, which allows prelimi-
nary conclusions only. A larger prospective study is needed to
delineate the beneﬁts and constraints of these methods.
C16
ANGIOTENSIN CONVERTING ENZYME ACTIVITY AND
RESPONSE TO ENALAPRIL IN DOGS WITH AN ACE GENE
POLYMORPHISM. Kathryn Meurs1, Darcy Adin1, Brent Aona1,
Teresa DeFrancesco1, Bruce Keene1, Yamir Reina2, Josh Stern1,
Sandy Tou3, Jess Ward1, Kate Woodruﬀ1, Clarke Atkins1. 1North
Carolina State University, Raleigh, NC, USA, 2University of Cali-
fornia, Davis, Davis, CA, USA, 3Iowa State University, Ames, IA,
USA
Myxomatous mitral valve disease (MMVD) is the most com-
mon heart disease in the dog. Angiotensin converting enzyme
(ACE) inhibitors are frequently recommended for management of
dogs with MMVD and asymptomatic cardiac enlargement. How-
ever, the beneﬁt of ACE inhibition in dogs before the onset of
congestive heart failure (CHF) is controversial, with diﬀerent stud-
ies showing conﬂicting results. A variable response to ACE inhibi-
tor therapy has also been observed in human beings with heart
disease and in some cases this has been attributed to a polymor-
phism in the ACE gene. We have previously demonstrated a poly-
morphism in the canine ACE gene, although the clinical
signiﬁcance of this ﬁnding is unknown.
We hypothesized that dogs with MMVD, cardiac enlargement
and the ACE gene polymorphism would be less responsive to
ACE inhibition with enalapril, as measured by plasma ACE activ-
ity, than dogs without the polymorphism.
We evaluated dogs with pre-CHF MMVD and a vertebral heart
score of ≥ 11, presenting to the NCSU CVM in the last 18 months.
Dogs were genotyped for the ACE polymorphism. Serum samples
were collected and analyzed for ACE activity measurement by
radioimmunoassay. Dogs were prescribed enalapril, 0.5 mg/kg
orally twice a day, and revaluated in 14–21 days with a second
measurement of ACE activity. A t test was used to compare ACE
activity in the wildtype (normal canine sequence) and DNA variant
groups at baseline and after therapy. A paired t test was used to
compare each genotype’s ACE activity before and after therapy.
Thirty-one dogs were evaluated. Genotypes included 12 homozy-
gous for the DNA variant and 19 homozygous for the wild type.
Median baseline ACE activity was signiﬁcantly lower for dogs
homozygous for the DNA variant (18.05 U/L) than for dogs with
the wildtype sequence (27.4 U/L) (P = 0.01). Twenty-seven dogs
returned for re-evaluation in 14–21 days. Both genotypes showed a
signiﬁcant suppression of ACE activity on enalapril, (P = 0.0065
DNA variant dogs; P < 0.0001 wildtype dogs). Median post ther-
apy ACE Activity was not diﬀerent for the two genotypes (DNA
variant, < 5.0 U/L; wildtype dogs <5.0 U/L) (P = 0.24)).
We conclude that dogs that are homozygous for the ACE vari-
ant have lower baseline levels of ACE activity but still demon-
strate ACE inhibition in response to enalapril. Further study is
warranted to evaluate the clinical importance of these ﬁndings.
C17
ANGIOTENSIN CONVERTING ENZYME ACTIVITY IN
CAVALIER KING CHARLES SPANIELS WITH AN ACE
GENE POLYMORPHISM. Kathryn Meurs1, Maria Joseﬁne
Reimann2, Lisbeth Heier Olsen2. 1North Carolina State University,
Raleigh, NC, USA, 2University of Copenhagen, Copenhagen,
Denmark
The Cavalier King Charles Spaniel is one of the most com-
monly reported breeds of dogs aﬀected with myxomatous mitral
valve disease (MMVD). Angiotensin converting enzyme (ACE)
inhibitors are frequently recommended for management of dogs
with MMVD. However, the beneﬁt of ACE inhibition in MMVD
before congestive heart failure has developed is controversial with
diﬀerent studies showing conﬂicting results. A variable response to
ACE inhibitor therapy has also been observed in human beings
with heart disease and has been attributed to a polymorphism in
the ACE gene. We have previously demonstrated a polymorphism
in the canine ACE gene in small breed dogs.
We hypothesized that the polymorphism would be common in
CKCS dog and that this would impact ACE activity.
We collected DNA and plasma samples from CKCS with
MMVD. All dogs were genotyped for the known ACE polymor-
phism. Plasma samples were collected and analyzed for ACE activ-
ity measurement with a radioimmunoassay. A t test was used to
compare ACE activity in the wildtype (control sequence) and
DNA variant groups.
Sixty-two dogs were evaluated. Genotypes of 38 (61%) dogs
were homozygous for the DNA variant, 3 (5%) were heterozygous
and 21 (34%) were homozygous for the wild type (normal canine
sequence). Samples from 40 dogs were submitted for ACE analysis
including 20 homozygous for the wild type and 20 homozygous
for the variant. Median baseline ACE activity was signiﬁcantly
lower for dogs homozygous for the DNA variant (25.0 U/L) than
for dogs with the wildtype sequence (31.0 U/L) (P = 0.02).
We conclude that the ACE polymorphism appears to be com-
mon in the CKCS and dogs that are homozygous for the ACE
variant have lower baseline levels of ACE activity. Further study
is warranted to evaluate the clinical importance of these ﬁndings.
C18
PREVALENCE OF DIROFILARIA IMMITIS ANTIGEN IN
CLIENT-OWNED PET DOGS BEFORE AND AFTER SERUM
HEAT TREATMENT. Laura Nafe, Susan Little, Paul DeMars,
Ryan Baumwart, Nalani Yamada, Eileen Johnson. Oklahoma
State University, Stillwater, OK, USA
Pet dogs are routinely screened for heartworm disease as a com-
ponent of annual wellness evaluation. Recent evidence suggests
that antigen-antibody complexes in canine serum may preclude
accurate diagnosis of heartworm disease with commercially avail-
able Diroﬁlaria immitis antigen assays. The objective of this study
was to determine whether normal dogs presenting to the Okla-
homa State Veterinary Teaching Hospital Community Practice
Service for annual veterinary care warrant heat treatment of serum
to conﬁrm a negative heartworm antigen test by 4DX Snap
(Idexx). Serum and EDTA samples were collected from 201 client-
owned pet dogs between December 2014 and October 2015. Dogs
ranged in age from 10 months to 15 years (median 4 yrs) and
included 108 males and 93 females. Complete survey results (avail-
able for 194/201 dogs) revealed 139 dogs (72%) received heart-
worm preventative regularly over the past year. All EDTA
samples were evaluated for microﬁlaria and serum samples for D.
immitis antigen before and after heat treatment using a commeri-
cial assay (DiroCHEK, Zoetis). Four dogs (2%) tested positive for
D. immitis antigen on 4DX Snap Test (Idexx) and 2 were microﬁ-
laremic. On DiroCHEK antigen testing 2 dogs were positive
before and after heat treatment, 1 dog was positive after heat
treatment only, and 1 dog was negative before and after heat
treatment despite being microﬁlaremic. One dog received heart-
worm preventative (Heartgard; Merial) regularly (2/12 doses
missed). Heat treatment does not appear to improve detection of
D. immitis antigen in asymptomatic pet dogs undergoing routine
heartworm disease testing with 4DX Snap Test (Idexx).
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CARDIAC BIOMARKERS TROPONIN I AND N-TERMINAL
PRO-B-TYPE NATRIURETIC PEPTIDE IN CANINE
CHRONIC KIDNEY DISEASE PATIENTS. Lena Pelander, Jens
H€aggstr€om, Ingrid Ljungvall. Department of Small Animal Clini-
cal Sciences, Swedish University of Agricultural Sciences, Uppsala,
Sweden
Increased concentrations of N-terminal pro brain natriuretic
peptide (NT-proBNP) and cardiac Troponin I (cTnI) in azotemic
dogs, cats and people have been repeatedly reported. Knowledge
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of the mechanisms behind increased concentrations of these car-
diac biomarkers in azotemic dogs is warranted for correct interpre-
tation of test results. The aim of this study was to investigate the
association between measured glomerular ﬁltration rate (GFR)
and plasma concentrations of cTnI and NT-proBNP in stable
canine CKD patients.
Fifty client-owned dogs were prospectively included into the
study: Twenty-seven dogs with a diagnosis of CKD (structural
and/or functional abnormalities of one or both kidneys that had
persisted for at least 3 months) and without signs of other signiﬁ-
cant disease and twenty-three healthy dogs were included as con-
trols. All dogs were investigated by a physical examination,
repeated blood pressure measurements, a complete urinalysis, a
full hematology and biochemistry panel, an echocardiographic
examination, an ultrasound examination of the entire urinary
tract, and a scintigraphic examination for estimation of kidney
glomerular ﬁltration rate (GFR). Plasma from each dog was
stored in 70°C and assayed in batch.
Median age of included dogs was 6 years (range 0.5–14 years).
Median bodyweight was 19.5 kg (range 2–42 kg). There was no
diﬀerence in age or weight between healthy and CKD dogs.
Among dogs with CKD, 16 had a decreased GFR and 11 had a
GFR within the normal range. Dogs with CKD and a GFR in the
normal range had other evidence of kidney disease such as persis-
tent renal proteinuria or morphological abnormalities.
Univariate analyses were performed to evaluate associations
between dog characteristics and cTnI and NT-proBNP, respec-
tively. Age (r = 0.59; P < 0.0001), body weight (BW; r = 0.29;
P = 0.04), creatinine (r = 0.29; P = 0.04) and systolic blood pres-
sure (SBP; r = 0.42; P = 0.06) were associated with cTnI concen-
tration. Creatinine (r = 0.46; P = 0.001), GFR (r = 0.39;
P = 0.0063), albumin (r = 0.35; P = 0.0141), and erythrocyte vol-
ume fraction (EVF; r = 0.35; P = 0.0072) were associated with
NT-proBNP concentration.
All variables that were associated with cTnI or NT-proBNP
concentration, respectively, with a P-value of <0.2 were included
in the multiple regression analysis (except creatinine because of
covariance with GFR). Age, BW and SBP were the variables
remaining in the ﬁnal model for cTnI (adjusted R-square 0.50,
P < 0.0001). GFR, BW and serum albumin concentration were
the variables remaining in the ﬁnal model for NT-proBNP (ad-
justed R-square 0.29, P < 0.0001).
In conclusion, plasma concentration of cTnI in dogs with stable
CKD was not inﬂuenced by a decreased GFR. Plasma concentra-
tion of NT-proBNP in stable canine CKD patients on the other
hand, appeared to be inﬂuenced by GFR.
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ESTABLISHING NORMAL 24 HOUR HOLTER MONITOR
VALUES IN HEALTHY PUPPIES. Rebecca Tracey1, Dongyun
Wang2, Pamela Lee1. 1Washington State University, Pullman,
WA, USA, 2University of Idaho, Moscow, ID, USA
Currently, published literature focuses on the normal 24 hours
Holter monitor values of adult dogs greater than 1 year of age.
Studies have shown that normal healthy adult dogs may have
occasional ventricular premature complexes (VPCs) and that more
frequent or sequential VPCs on Holter monitoring may indicate
cardiac or clinical disease. This poses a problem for cardiac evalu-
ation of puppies for veterinarians. This lack of information inhi-
bits the ability to screen puppies for indicators of cardiac disease.
This is especially important in breeds that tend to have inherited
cardiac arrhythmias such as German Shepherd puppies. The pur-
pose of this study is to establish normal ambulatory ECG values
using Holter monitors in puppies in an eﬀort to enhance the abil-
ity to screen puppies for cardiac disease.
The primary objective was to determine the minimum, average,
and maximum heart rate and incidence of arrhythmias for healthy
puppies. The secondary objective was to evaluate the correlation
between Holter heart rate and age, weight or breed. We hypothe-
sized that healthy puppies will have less arrhythmias and higher
Holter minimum, average, and maximum heart rates than healthy
adult dogs.
Eligible puppies had to be healthy and between the ages of 12–
51 weeks. History, physical exam, and thorough auscultation were
performed. An echocardiogram was performed on any puppy with
a heart murmur on auscultation. Puppies with physiologic heart
murmurs were included in the study while puppies with structural
heart disease were excluded. A 24 hours 3-channel Holter monitor
was placed on all puppies included in the study. Holter placement
followed established methods from the WSU Veterinary Holter
Service.
A total of 44 puppies representing 20 breeds were included in
this study. Minimum, average, and maximum Holter heart rates
were higher in puppies compared to healthy adult dogs. The num-
ber of supraventricular complexes seen in puppies were less than
in healthy adult dogs. The range of ventricular complexes in pup-
pies were higher than in healthy adult dogs. Minimum and average
Holter heart rate decreased with increasing age while maximum
Holter heart rate was not correlated with age. No correlation
between minimum, average, and maximum Holter heart rates and
weight was appreciated. There was a statistically signiﬁcant diﬀer-
ence between maximum Holter heart rate and diﬀerent breed clas-
siﬁcations by size (small versus medium versus large versus giant
breed). No correlation between minimum and average Holter heart
rate and breed classiﬁcations was identiﬁed in healthy puppies.
This study is the ﬁrst study to evaluate normal ambulatory elec-
trocardiographic values in healthy puppies. This information can
be used to potentially screen puppies at an earlier age for cardiac
disease. The number of ventricular arrhythmias considered normal
for healthy adult dogs is thought to vary with dog breed. Whether
or not this breed variation is true in puppies is unknown. Now
that a normal baseline has been established for puppies, further
studies can be conducted to evaluate for breed variation.
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DISTRIBUTIONOF ALVEOLAR-INTERSTITIAL SYNDROME
IN DYSPNEIC VETERINARY PATIENTS ASSESSED BY
LUNG ULTRASOUND VERSUS THORACIC RADIOGRAPHS.
Jessica Ward1, Gregory Lisciandro2, Teresa DeFrancesco3. 1Iowa
State University, Ames, IA, USA, 2Hill Country Veterinary
Specialists, San Antonio, TX, USA, 3North Carolina State
University, Raleigh, NC, USA
Lung ultrasound (LUS) is a point-of-care imaging technique
that identiﬁes alveolar-interstitial syndrome (AIS) through the
observation of ultrasound artifacts called B-lines. This study
assessed distribution of AIS detected by LUS compared to tho-
racic radiographs (TXR) in a population of 100 acutely dyspneic
veterinary patients (76 dogs and 24 cats).
Patients underwent LUS and TXR within 6 hours. LUS images
were scored for presence of B-lines at 4 sites on each hemithorax.
An individual LUS site was scored positive if >3 B-lines were
observed within a single intercostal space at that site. TXR were
scored for presence of alveolar-interstitial inﬁltrates at 4 sites on
each hemithorax, analogous to LUS. An individual TXR site was
scored positive if inﬁltrate was present in least 25% of the site. Med-
ical records were evaluated for ﬁnal diagnosis. Agreement in distri-
bution of positive sites between LUS and TXR was compared using
a Cohen’s Kappa coeﬃcient. Patterns of distribution of AIS among
diﬀerent ﬁnal diagnoses were compared using Fisher’s exact tests.
When considered site-by-site, agreement in distribution of AIS
between LUS and TXR was poor to fair (Κ = 0.25–0.5). How-
ever, when considering larger spatial quadrants, agreement
between LUS and TXR was good (Κ = 0.45–0.65). Distribution
of AIS diﬀered signiﬁcantly based on ﬁnal diagnosis for both car-
diogenic and noncardiogenic causes of dyspnea. Dogs with mitral
valve disease were more likely to have a caudal distribution of
AIS (P = 0.0031), while dogs with dilated cardiomyopathy were
more likely to have diﬀuse AIS (P = 0.0008). Patients with airway
disease were more likely to have absence of AIS in all sites
(P = 0.0006), while patients with pneumonia were more likely to
have unilateral AIS (P = 0.0055).
LUS was useful for detecting AIS apparent on TXR. Agree-
ment between the two modalities improved when considering lar-
ger spatial quadrants rather than smaller focal sites. Distribution
of AIS diﬀered based on ﬁnal diagnosis, suggesting that a pattern-
based LUS approach may prove diagnostically useful.
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CIRCULATING PLASMA MIRNA AS NOVEL MOLECULAR
BIOMERKERS IN CONGESTIVE HEART FAILURE.
SeungWoo Jung, Amy Bohan. Auburn University, Auburn, AL,
USA
Congestive heart failure (CHF) carries poor prognosis in dogs
with myxomatous mitral valve disease (MMVD). Early identiﬁca-
tion of dogs predisposed to developing CHF is critical to improve
long term survival outcome. The aim of this study is to character-
ize plasma molecular proﬁles in dogs with CHF secondary to
MMVD and to develop novel molecular biomarkers via liquid
biopsy. MicroRNAs (miRNAs) are small, non-coding RNAs and
have been known to regulate expression levels of target genes
involved in human CHF. Regulatory networks of miRNAs in dogs
with MMVD need to be established to further enhance our under-
standing of CHF pathogenesis. The hypothesis tested in the study
was that plasma miRNAs may be diﬀerentially expressed in dogs
with CHF secondary to MMVD.
A minimum of seven dogs in each group (normal versus CHF)
were needed to demonstrate the statistical power with a probabil-
ity of 0.9 and type one error of P < 0.05 based on previous publi-
cations. Blood was collected in EDTA tubes from 9 normal
geriatric dogs (free of heart murmur and absent history of CHF)
and 8 dogs with CHF secondary to MMVD (conﬁrmed by clinical
signs, chest x-ray and echocardiography). Plasma samples were
subjected to isolation of miRNAs with a miRNeasy Plasma Kit
(Qiagen) and subsequently reverse-transcription reaction with a
miScript II RT Kit (Qiagen). Validated canine primers of 12 can-
didate miRNAs and miR-39 (spike-in control) were employed to
quantify relative expression levels of each miRNA between normal
and CHF dogs via real time PCR (miScript SYBR Green PCR
Kit, Qiagen).
Canine speciﬁc miRNAs were successfully isolated from plasma
and ampliﬁed. Plasma miR-21 (P = 0.015), miR-133 (P = 0.01),
and miR-1 (P = 0.01) were diﬀerentially expressed in CHF dogs
with statistical signiﬁcance when compared to normal dogs. These
miRNAs are known to be involved in extracellular matrix remod-
eling and the regulation of ﬁbrotic genes such as TGF-b and
Smad. The results suggest that alterations in the interaction
between miRNAs expression proﬁles and their downstream target
genes may play a role in cardiac progression to CHF in dogs with
MMVD. Further investigation remains warranted to determine
their diagnostic potential as molecular biomarkers for early detec-
tion of CHF in dogs with MMVD.
C23
A MULTICENTER EVALUATION OF SIGNALMENT AND
COMORBID CONDITIONS ASSOCIATED WITH AORTIC
THROMBOSIS IN 291 DOGS. Randolph L. Winter1,2, Christine
M. Budke1,2. 1Auburn University, College of Veterinary Medicine,
Auburn, AL, USA, 2Department of Veterinary Integrative Bio-
sciences, Texas A&M University, College Station, TX, USA
Aortic thrombotic disease is a primary disease or secondary
complication of a systemic disease state with devastating eﬀects to
both dogs and cats. Cats with aortic thromboembolism often have
signiﬁcant concurrent cardiac disease. While there is a substantial
amount of information available about cats with this disease pro-
cess, aortic thrombosis (AT) is not well characterized in dogs.
In order to assess signalment and concurrent disease processes
in dogs diagnosed with aortic thrombotic disease, a retrospective
review was performed of records available through the Veterinary
Medical Database of dogs examined between 1985 and 2011.
Information on age, sex, breed, weight, and concurrent disease
processes in dogs reported with AT were reviewed. Five control
dogs without a diagnosis of AT were selected for each AT case.
AT was diagnosed in 291 of 984,973 dogs included in the
VMDB from 1985 to 2011. The odds of a dog having AT did not
diﬀer signiﬁcantly by sex (P = 0.0593), age (P = 0.9833), or weight
(P = 0.7766). Compared to mixed breed dogs, Shetland sheepdogs
had a signiﬁcantly higher odds (OR=2.44, P = 0.0027) of being
diagnosed with AT. Protein-losing nephropathy was the most
commonly reported disease occurring concurrently in dogs with
AT (64/291).
Signalment data including age, sex, and weight were not signiﬁ-
cantly diﬀerent in dogs diagnosed with AT compared to dogs not
diagnosed with AT. Dogs with AT were commonly diagnosed con-
currently with PLN. Contrary to previous reports, cardiac disease
was not a common concurrent diagnosis in the dogs with AT
included in this study.
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RIGHT VENTRICULAR SYSTOLIC FUNCTION IN DOGS
WITH POST-CAPILLARY PULMONARY HYPERTENSION.
Amalia Turner Giannico1, Gustavo Dittrich1, Bruna Cristina
Bruler1, Tilde Rodrigues Froes1, Aparecido Antonio Camacho2,
Marlos Goncalves Sousa1. 1Federal University of Parana,
Curitiba, PR, Brazil, 2Sao Paulo State University, Jaboticabal, SP,
Brazil
The function of right ventricle (RV) has gained increased recog-
nition over the past years. In pulmonary hypertension (PH)
patients, this led to the reconceptualization of the RV as part of
right ventricular pulmonic circulation unit and the acknowledge-
ment that RV function is a major determinant of prognosis in pul-
monary arterial hypertension. With this in mind, we sought to
investigate the RV systolic function in dogs with post-capillary PH
ascribed to mitral valve disease (MVD). Twenty nine dogs with
PH (2.5–17.2 kg; 7–15 years) and 51 dogs without PH (1.5–
32.0 kg; 2–16 years) were recruited into this prospective cross-sec-
tional observational study. The PH group was subdivided into
mild PH (n = 19), moderate PA (n = 6), and severe PH (n = 4).
Several breeds were represented. All animals underwent a complete
echocardiogram, which included the measurement of RV fractional
area change (RV FAC); tricuspid annular plane systolic excursion
(TAPSE); RV free-wall longitudinal systolic velocity (tricuspid
annular S´ wave), and RV fractional shortening (RV FS%). For
improved statistical analysis and normalization of data according
to animal size, a body weight-indexed TAPSE (TAPSEBW-indexed)
was created. Some standard echocardiographic indices of conges-
tion and LV function, including early-to-late LV ﬁlling velocities
ratio (E/A), isovolumic relaxation time (IVRT), E-to-IVRT ratio
(E/IVRT), left atrium-to-aorta ratio (LA/Ao), and LV fractional
shortening (LV FS%) were recorded as well. The data was not nor-
mally distributed. The Mann-Whitney test showed no diﬀerences
(P > 0.05) to exist for RV FAC, RV FS%, TAPSE, TAPSEBW-
index, and tricuspid annular S´ wave between dogs with PH and
those without PH. Also, the analysis of the subdivided PH group
showed no statistical diﬀerence between the three degrees of PH.
Spearman correlation coeﬃcients between RV systolic data and
LV indices of congestion and function showed a signiﬁcant posi-
tive correlation between TAPSE and E/IVRT (R = 0.3917,
P = 0.0003), TAPSE and LA/Ao (R = 0.3298, P = 0.0029), and
TAPSEBW-indexed and LV FS% (R = 0.2757, P = 0.0166). Finally,
a signiﬁcant positive correlation was documented between RV
FAC and RV FS% (R = 0.3507, P = 0.0100), as well as between
TAPSE and tricuspid annular S´ wave (R = 0.4575, P < 0.0001).
Because only a few animals with severe PH were recruited into this
study, the absence of association between the severity of PH and
the identiﬁcation of RV systolic impairment needs further investi-
gation. Nevertheless, we observed a downward trend for RV FS
%, TAPSE, TAPSEBW-indexed, and tricuspid annular S´ wave along
with the aggravation of PH. Our study found correlations between
a few congestion and LV function parameters, which may prove
useful in monitoring RV function in dogs with severe MVD and
overt signs of post-capillary PH. Since the majority of PH cases
were mild, it is likely that only a few had reactive PH, which may
explain why RV function of either group behaved very similarly.
Also, it is not clear whether RV remodeling and impairment
would be stronger if pre-capillary PH dogs had been included in
this investigation.
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VASOVAGAL TONUS INDEX IN DOGS WITH
MYXOMATOUS MITRAL VALVE DISEASE. Bruna Cristina
Bruler1, Gustavo Dittrich1, Amalia Turner Giannico1, Tilde
Rodrigues Froes1, Aparecido Antonio Camacho2, Marlos
Goncalves Sousa1. 1Federal University of Parana, Curitiba, PR,
Brazil, 2Sao Paulo State University, Jaboticabal, SP, Brazil
Decreased heart rate variability (HRV) has been found in dogs in
congestive heart failure (CHF) and previous studies have acknowl-
edged the use of HRV indices as prognostic indicators in patients
with mitral valve disease (MVD). The vasovagal tonus index (VVTI)
is an unconventional time domain indicator of HRV, which is
mainly inﬂuenced by cardiac parasympathetic tone. In this cross-sec-
tional observational study, we sought to investigate the VVTI in
dogs with MVD. Electrocardiographic recordings of 30 dogs
(7–16 years, 3.5–15.5 kg) previously classiﬁed into ACVIM stages A
(controls), B, or C (10 dogs each group) were used to calculate the
VVTI. For this, 20 consecutive R-R intervals were measured from
each ECG recording (R-R1 to R-R20), and the index was obtained
from the formula VVTI = LN [VAR (R-R1 – R-R20)], where LN:
natural logarithm and VAR: variance. Bad quality ECG tracings
and recordings from dogs with non-sinus rhythms or animals under-
going anti-arrhythmic treatment were not included in this investiga-
tion. Also, we recorded the BW-indexed LV in diastole and systole,
wall stress index in diastole and systole, fractional shortening, left
atrium-to-aorta ratio, mitral E wave, mitral E/A, isovolumetric
relaxation time, and the E-to-IVRT ratio. All data underwent the
Shapiro-Wilk test to check for normal distribution, while ANOVA,
followed by Tukey’s test, were used to compare the VVTI between
groups. Pearson’s test was used to search for linear correlations
between the VVTI and the echocardiographic data. The mean values
(with lower and upper 95% CI of mean) of VVTI for dogs in stages
A, B, and C were, respectively: 8.45 (7.36 – 9.54), 6.09 (4.47 – 7.71)
and 6.34 (5.01 – 7.68). A signiﬁcant diﬀerence was found between
groups (P = 0.0189), with the mean VVTI being signiﬁcantly higher
in control animals as compared to dogs with stage B MVD
(P < 0.05). When it comes to the relationship between VVTI and
cardiac rhythms, a signiﬁcant diﬀerence existed between animals in
sinus rhythm (SR), sinus arrhythmia (SA), and sinus tachycardia
(ST) (P = 0.0083). The lowest VVTI was documented for dogs in ST
(5.82; 95% CI 4.14 – 7.49), while the higher was found for animals
presenting SR (8.27; 95% CI 7.40 – 9.15). Signiﬁcant negative corre-
lations were found between VVTI and LA/Ao (R = 0.3699;
P = 0.0443), as well as between VVTI and heart rate (R = 0.4864;
P = 0.0064). Although no correlation existed between body weight
and the VVTI, age and VVTI attained a signiﬁcant negative correla-
tion (R = - 0.3827; P = 0.0369). The negative correlation between
VVTI and heart rate is likely ascribed to the role played by the
parasympathetic tone in VVTI, therefore producing higher values
when slower rates and irregular rhythms are present. Even though
uncontrolled conditions during ECG recording, including stress and
agitation, may increase HR, the lower VVTI found in animals
exhibiting sinus tachycardia may suggest a sustained sympathetic
activation. Although further investigation is warranted, the conﬁ-
dence intervals of this study point to the VVTI <5 being a potential
prognostic indicator for CHF, whereas a VVTI >7.7 is likely sugges-
tive of reduced risk for congestion. This is supported by the correla-
tion between VVTI and LA/Ao, as well as the diﬀerence between the
means of control dogs (stage A) and stage B MVD animals.
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SICK SINUS SYNDROME AND SINUS NODE
DYSFUNCTION: CASE SERIES REPORTS OF FMVZ-USP
CARDIOLOGY SERVICE (2007–2015). Rebecca Bastos Pessoa1,
Guilherme Teixeira Goldfeder1, Patricia Pereira Costa Chamas2,
Denise Saretta Schwartz1, Paula Staudacher Leal de Carvalho1,
Maria Helena Matiko Akao Larsson1. 1School of Veterinary
Medicine and Animal Science – University of Sao Paulo
(FMVZ-USP), S~ao Paulo, SP, Brazil, 2Paulista University, S~ao
Paulo, SP, Brazil
Sick Sinus Syndrome is a complex disease characterized by an
abnormal cardiac impulse formation on the sinus node. The term
Sinus Node Dysfunction refers to the variety of electrocardio-
graphic features involved in this condition. When Sinus Node Dys-
function is associated with clinical manifestations it is referred to
as the Sick Sinus Syndrome. A survey of aﬀected dogs attended at
the Cardiology Service in the Department of Internal Medicine of
the Veterinary Teaching Hospital (HOVET) of the School of
Veterinary Medicine and Animal Science - University of Sao Paulo
(FMVZ-USP) from 2007 to 2015 was performed. Seventeen cases
were reviewed. Breeds involved were Schnauzer (71%), Cocker
Spaniel (6%), Poodle (6%) and Dachshund (6%), besides a mon-
grel dog (6%). There was a predominance of female dogs (71%).
The most common clinical manifestations observed were syncope
(71%), presyncope (24%), dyspnea (18%) and exercise intolerance
(12%). Twelve percent of the dogs were asymptomatic. The most
frequent electrocardiographic changes found were sinus arrest
(75%), junctional escape rhythm (73%), supraventricular tachycar-
dia (53%) and sinus arrhytmia (53%). Forty-seven percent of the
dogs presented tachycardia-bradycardia syndrome. Only 24% of
the animals received pacemaker implants, given the high percent-
age of animals unable to go through chirurgical/anesthetic proce-
dures (29%), and the presence of asymptomatic animals. The dogs
that received pacemaker implants lived for 20.4 months (mean
value), whereas the ones that were treated conservatively lived for
10.8 months (mean value). These values showed beneﬁt to those
patients who received pacemaker implants, but was hindered by
the high percentage of comorbidities in older animals, besides the
small number of patients enrolled in this retrospective study.
C27
THE UTILITY OF SPECTRAL DOPPLER OF THE HEPATIC
VEINS IN DOGS WITH TRICUSPID REGURGITATION.
Kensuke Nakamura, Tatsuyuki Osuga, Tomoya Morita, Keitaro
Morishita, Noboru Sasaki, Hiroshi Ohta, Mitsuyoshi Takiguchi.
Hokkaido University, Sapporo, Japan
Echocardiographic assessment of the severity of tricuspid regur-
gitation (TR) is less reliable compared to mitral regurgitation due
to the complicated geometry and function of right ventricle. Spec-
tral Doppler of hepatic veins (SDHV) has emerged as a useful
examination to evaluate the severity of TR in humans. The hepatic
vein blood ﬂow waveform is multiphasic and typically consisted
with four peaks. A small retrograde a-wave occurring after the P-
wave of the electrocardiographic is created by retrograde blood
ﬂow during atrial contraction. A large anterograde S-wave occur-
ring immediately after the QRX complex is created by blood ﬂow
toward the heart during ventricular systole. A small retrograde v-
wave occurs after ventricular systole. A large anterograde D-wave
occurring after T-wave is created by ventricular diastole. The
objective of the present study was to investigate the correlation
between the presence of ascites and the ﬁndings of SDHV in dogs
with TR. This is a clinical cohort study including twenty-seven cli-
ent-owned dogs with TR. Dogs were divided into two groups
based on the presence of ascites. Physical examination, SDHV and
echocardiographic variables were compared between the groups.
For the assessment of the comparative accuracy in identifying
patients with ascites, receiver operating characteristic (ROC)
curves was used. Peak velocity of v-wave and D-wave in dogs with
ascites (n = 11) was signiﬁcantly higher than dogs without ascites
(n = 16). The highest accuracy was obtained for v-wave, with an
area under the ROC curve (AUC) of 0.99, followed by D-wave,
with an AUC of 0.95; late diastolic velocity of the septal mitral
annulus (Am), with an AUC of 0.907. TR peak velocity had no
signiﬁcant diﬀerence between two groups. In conclusion, v-wave
and D-wave obtained by SDHV has strong correlation with the
presence of ascites in dogs with TR.
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CUTANEOUS USE OF AN IMPLANTABLE LOOP
RECORDER (REVEAL LINQTM) FOR CARDIAC EVENT
MONITORING IN DOGS. Emily Menzen, Amara Estrada,
Brandy Winter, Melanie Powell. University of Florida, College of
Veterinary Medicine, Gainesville, FL, USA
Event monitors are a useful diagnostic tool for evaluating
patients with episodic cardiac events. The ideal event monitor for
use in veterinary practice would be non-invasive, aﬀordable, accu-
rate and reusable. Such devices are becoming increasing diﬃcult to
obtain. This study aimed to prospectively evaluate the feasibility of
using the Medtronic Reveal LINQTM human implantable cardiac
monitor (ICM) for cutaneous event monitoring for up to 5 days in
14 clinically healthy canines (21.5 kg, range 13.4–31.2 kg; 4.5 years
range 1.5–13 years old) and two canines with reported collapse epi-
sodes (4.7 and 6.4 kg, 2.5 and 11 years old). The study consisted of
developing a method to secure the low-proﬁle device without caus-
ing discomfort at the location generating the strongest signal,
adjusting the auto activation parameters, activating the device
manually, and assessing the recordings for accuracy.
Reveal LINQTM wireless cardiac device were obtained via dona-
tion following explantation from human patients and the battery
life assessed prior to use in each canine patient using a Medtronic
Carelink programmer with appropriate software loaded. An area
on the left lateral thorax was clipped and alcohol was used to
remove oils. Adhesive electro-conductive gel pads were applied
underneath the device and it was placed within the 4th intercostal
space parallel to the ribs and then slowly moved in a grid pattern
to ﬁnd the most consistent electrocardiogram (ECG) on the pro-
grammer screen. The device was then secured to the thorax using
TegadermTM ﬁlm, gauze, and Elastikon. It was then taped
around the thorax with 2 inch white tape and VetrapTM and the
patients were ﬁtted with a Holter monitor vest to reduce likelihood
of device tampering or consumption of bandage materials and
device. The device was programmed with the patient’s information
and the pre-programmed manufacturer heart rate parameters
Patients wore the ICM for 4 to 5 days and owners were asked to
activate the monitor manually for 4 total recordings during diﬀer-
ent activities and to keep a diary. Accuracy was assessed based on
quality of ECG tracings (consistent ability to measure heart rate,
visualization of entire p-QRS-T waves) and presence of a record-
ing during manual activation. Two dogs were ﬁtted with 24 hour
Holter monitors as a control.
Of the sixteen patients, two were unable to be ﬁtted with a
device due to a weak signal, one client terminated the study after
1 day, and the device moved out of place and stopped recording
on one dog. The remaining twelve dogs had at least 3 out of 4
interpretable tracings from manually activated recordings. The
auto-activated recordings triggered by pre-set parameters were of
good quality. After each set of auto-activated recordings were
reviewed, the parameters were adjusted to deﬁne the outer range
of normal and recorded rhythms were reclassiﬁed. Over the course
of the study patient heart rates did not exceed 222 bpm for 32
beats or reach 30 bpm for 12 consecutive beats. Fewer auto-acti-
vations occurred per dog when the pause parameter was set at
4.5 seconds than 3 seconds. One symptomatic patient had three
episodes while wearing the device however there was no indication
of a rhythm abnormality in the manually activated recordings.
The other symptomatic patient did not have an episode while
wearing the monitor and the device incorrectly logged an atrial ﬁb-
rillation episode. During this time period, the ECG from the ICM
was not of suﬃcient quality to identify p waves but the control
Holter recording clearly showed a sinus arrhythmia was present.
The device was still recording at time of removal in all but one
dog. Five dogs had self-limiting, mild skin irritation after removal
of the device.
The Medtronic Reveal LINQTM ICM is a viable option for
cutaneous cardiac monitoring in dogs for up to 5 days. Veterinary
parameters for auto-activation of the device should be pro-
grammed at the upper and lower limits of the auto-activated
parameters to reduce the number of incorrectly labelled recordings
and all recordings should be reviewed by a veterinarian familiar
with normal cardiac rhythms.
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AORTOSEPTAL ANGLE AND RESPONSE TO BALLOON
VALVULOPLASTY IN DOGS AFFECTED WITH SEVERE
SUBAORTIC STENOSIS. Lilian Shen1, Amara Estrada1, Etienne
Co^te2, Brandy Winter1, Kenneth Lamb3. 1University of Florida,
Gainesville, Florida, USA, 2University of Prince Edward Island,
Charlottetown, Prince Edward Island, Canada, 3Lamb Consulting,
West St. Paul, Minnesota, USA
Subaortic stenosis (SAS) is the most common congenital cardiac
defect identiﬁed in dogs. While it is not diﬃcult to diagnose severe
forms of this disease, treatment and decisions on when to consider
interventional therapy remain a challenge. It has been suggested
that SAS, in some breeds, may be related to an abnormally steep
aortoseptal angle (AoSA) - a quality which may limit eﬃcacy of
ballooning methods. If an abnormally steep AoSA contributes to
SAS and is not remedied by ballooning, it is possible that the
magnitude of the AoSA may serve as a useful criterion for deter-
mining which dogs will respond better to balloon valvuloplasty
and are therefore better candidates for the procedure.
This study investigated the relationship between the measured
AoSA and response to combined cutting and high pressure bal-
loon valvuloplasty (CB/HPBV), in dogs with severe SAS. Retro-
spective evaluation of angiographic and echocardiographic video
loops of 22 client-owned dogs of various breeds aﬀected with sev-
ere SAS (PG mean 143.36 mmHg; range 80.49–322.5 mmHg) who
underwent CB/HPBV were evaluated at the baseline time point
immediately prior to the procedure. Two board-certiﬁed veterinary
cardiologists and 1 novice evaluated these video loops to identify
still frame images to be used to measure the AoSA. Each evalua-
tor was blinded to the other 2 evaluators’ selected images and sub-
sequent measurements of the AoSA. All evaluators were blinded
to initial PG and patient outcomes following the procedure. The
percentage decrease in PG at 24 hours, 6 months, and 12 months
after ballooning was then calculated and correlated to the mea-
sured AoSA at each recheck and for each imaging plane.
The inter-observer variability analysis suggested signiﬁcant
mean diﬀerences for the novice observer when compared to the 2
cardiologists for all angle types. Signiﬁcant diﬀerences were
observed between the cardiologists for left apical echocardio-
graphic (P = 0.0163) AoSA measurements, while no signiﬁcant dif-
ferences were observed for angiographic (P = 0.1042) or right
sided long axis LVOT echocardiographic AoSA (P = 0.7058) mea-
surements or for all measurements of AoSA combined combined
(P = 0.1937).
Based on right sided long axis LVOT echocardiographic AoSA
measurements made by the cardiologists, greater mean diﬀerences
of PG reduction ratio were observed for angles >160° compared to
angles <160°. At 24 hours, signiﬁcantly greater (P = 0.003) mean
diﬀerences of PG ratio were observed in the >160° (54.45 SE 
3.8) compared to the mean in the <160° (39.88 SE  2.09). This
diﬀerence persisted at 6 months (>160° mean 57.73 SE  10.9;
<160° mean 28.22 SE  3.42) and at 12 months (>160° mean
76.11 SE  17.5; <160° mean 27.61 SE  6.44).
The ﬁndings of this study suggest that dogs with severe SAS
with an AoSA >160° as measured on right sided long axis LVOT
echocardiographic imaging respond to CB/HPBV better than dogs
with an AoSA <160°. The diﬀerence in response to the same pro-
cedure by the two sets of dogs suggests that the magnitude of the
AoSA does play a role in SAS and its treatment, and it is possible
that measurement of the AoSA may be helpful in the screening
process and determination of prognosis following CB/HPBV.
However, further investigation of the eﬀect of LVOT PG reduc-
tion on survival times and quality of life is warranted in order to
determine if AoSA is truly a suitable criterion for selecting candi-
dates for CB/HPBV.
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ECHOCARDIOGRAPHIC EVALUATION OF PULMONARY
HYPERTENSION IN CATS WITH CARDIAC DISEASE AND
PLEURAL EFFUSION VERSUS PULMONARY EDEMA.
Melissa Wilson, Katherine Scollan, Nicole LeBlanc. Oregon State
University, Corvallis, OR, USA
Cardiomyopathies, including hypertrophic and restrictive, are
the most common acquired cardiac diseases in cats. Many aﬀected
cats develop pulmonary edema secondary to left-sided congestive
heart failure (L-CHF). Alternatively, cats with primarily left-sided
cardiomyopathy can develop pleural eﬀusion without the presence
of pulmonary edema. It is well known, but not well understood,
why cats with left-sided CHF can develop both pulmonary edema
and pleural eﬀusion. The development of pulmonary hypertension
could lead to right-sided heart failure and potentially cause pleural
eﬀusion in cats with predominately left-sided cardiac disease. The
aim of this study was to evaluate for echocardiographic evidence
of pulmonary hypertension in cats in L-CHF with pleural eﬀusion
in comparison to cats with pulmonary edema, other pulmonary
disease, and healthy cats.
Medical records and echocardiographic studies from 2008–2015
were reviewed and measured. Cats were categorized into four groups:
1) L-CHF cats with pleural eﬀusion, with or without pulmonary
edema, 2) L-CHF cats with pulmonary edema only, 3) cats with pul-
monary disease without evidence of cardiomyopathy, and 4) healthy
cats. Pulsed wave Doppler recordings of pulmonic outﬂow were used
to measure acceleration time (AT), ejection time (ET), AT:ET ratio,
and maximum velocity through the pulmonic valve (PA Vmax). The
main pulmonary artery diameter (MPA), aortic diameter (Ao),
MPA:Ao ratio, left atrial diameter (LA), and LA:Ao ratio were mea-
sured from right parasternal short axis images, while right atrial
(RA) maximum diameter, left atrial maximal diameter (LALong),
RA:LALong ratio, and RA:Ao ratio were measured from right
parasternal long axis images. Studies were reviewed for the presence
of tricuspid regurgitation (TR) and the maximum TR velocity (TR
Vmax) was measured when available. Groups were compared by
one-way ANOVA or Kruskal Wallis tests where appropriate.
Ninety-three cats were included in the study, 31 cats with
L-CHF and pleural eﬀusion, 25 cats with L-CHF and pulmonary
edema, 15 cats with pulmonary disease without evidence of car-
diomyopathy, and 21 healthy cats. The median RA:Ao of the
pleural eﬀusion group (1.54, range 0.85–2.70) was signiﬁcantly lar-
ger (P = 0.0004) than all other groups. The mean RA:LA ratio of
the pleural eﬀusion (0.73  0.2) and pulmonary disease
(0.75  0.1) groups were diﬀerent from the pulmonary edema
(0.56  0.2) and healthy (0.95  0.1) groups (P < 0.0001), though
not diﬀerent from each other. Comparison of pulsed wave Dop-
pler measurements of the pulmonic outﬂow revealed no signiﬁcant
diﬀerence in AT, ET, AT:ET, or PA Vmax between any groups.
TR Vmax was measured in 7 pleural eﬀusion cats (median 2.2 m/s,
range 1.2–3.2) and 1 healthy cat (1.7 m/s).
The results of our study indicate that cats that developed pleural
eﬀusion had signiﬁcantly more right atrial enlargement in addition
to left atrial enlargement than cats that developed only pulmonary
edema. No echocardiographic evidence of pulmonary hypertension
was found in any of the four groups of cats. The potential causes
for right atrial enlargement in the cats with pleural eﬀusion include
concurrent right-sided cardiac disease or pulmonary hypertension
that was not detected by these echocardiographic parameters.
Additional studies determining the degree of RA enlargement asso-
ciated with the development of pleural eﬀusion could be useful in
predicting CHF manifestation in cats with cardiomyopathy.
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POST-OPERATIVE DYSRHYTHMIAS AFTER CARDIAC
SURGERY UNDER CARDIOPULMONARY BYPASS. Junseok
Lee, Takeshi Mizuno, Masashi Mizuno, Kayoko Harada, Hiroshi
Takano, Arane Takahashi, Kazushi Mamada, Sayaka Takeuchi,
Ayaka Chen, Tamotsu Sawada, Takahiro Mizukoshi, Aasako
Shinoda, Shuhei Uchida, Takurou Mori, Kazuki Takamura,
Junichirou Takeuchi, Masami Uechi. Japan Animal Specialty
Medical Institute, JASMINE Veterinary Cardiovascular Medical
Center, Yokohama, Kanagawa, Japan
In human, post-operative dysrhythmia is an important compli-
cation after cardiac surgery, a major cause of increasing mortality
and lengthening hospitalization. In veterinary ﬁeld, however, there
is little knowledge on rhythmic disturbances complicated by car-
diac surgery. The aim of this study is to characterize post-opera-
tive arrhythmias and to determine peri-operative predisposing
factors to arrhythmias in dogs with open-heart surgery under car-
diopulmonary bypass (CPB).
This is a prospective and observational study of 70 consecutive
dogs undergoing mitral valve repair surgery. The incidence and the
types of post-operative arrhythmias were determined by continu-
ously monitoring electrocardiogram for the ﬁrst 7 days during hos-
pitalization. Occasional premature atrial or ventricular beats were
considered insigniﬁcant. Serologic and blood-gas parameters mea-
sured at serial time points during CPB were normalized and com-
pared between two groups with non-arrhythmic and arrhythmic
episodes. All patients showed normal sinus rhythm before surgery.
32 patients (45.7%) had a total of 55 episodes of arrhythmia after
cardiac surgery, where ventricular arrhythmias were the most fre-
quently identiﬁed (26 of 55; 47.3%). Supraventricular, nodal
arrhythmias and conduction blocks accounted for 23.6%, 14.5%
and 14.5%, respectively. 53.2% of patients with arrhythmic episodes
were recovered to normal sinus rhythm within the ﬁrst 2 days after
surgery. Patients with persistent arrhythmia until discharge were
18.8% (6 of 32). There was no case that permanent pacemaker
should be implanted. Although intravenous bolus injection of
lidocaine (2 mg/kg) was applied to 2 dogs with polymorphic ventric-
ular tachycardia lasted until 7 days, no improvement was found. No
hospital deaths were caused by post-operative arrhythmias
(deaths in hospital; 1 respiratory failure, 2 embolic events).
Furthermore, the arrhythmic group showed longer duration of CPB
(107.2  33.6 minutes, P < 0.05) and aortic cross-clamping time
(59.9  13.3 minutes, P < 0.01), and lower glucose level normalized
by CPB duration (82.6  38.9 mg/dL/CPB time, P < 0.01), com-
pared to the non-arrhythmic group (CPB time, 90.3  25.7 minutes;
cross-clamping time, 50.1  20.6 minutes; normalized glucose level,
126.8  66.7 mg/dL/CPB time). Also, logistic regression model for
the probability of post-operative arrhythmias revealed signiﬁcant
eﬀects of the aortic cross-clamping time and the normalized glucose
level (adjusted R2=0.30, P < 0.001).
The incidence of cardiac arrhythmias is quite high after open-
heart surgery under CPB in dogs. However, their clinical signiﬁ-
cance as a complication of cardiac surgery may be minimal. In
addition, hypoglycemic or myocardial ischemic environment dur-
ing CPB may predispose to post-operative cardiac dysrhythmias.
N01
KINEMATIC MAGNETIC RESONANCE IMAGING FOR
EVALUATION OF DISC-ASSOCIATED CERVICAL
SPONDYLOMYELOPATHY IN DOBERMAN PINSCHERS.
Michele Provencher, Amy Habing, Laurie Cook, Sarah Moore,
Gary Phillips, Ronaldo da Costa. The Ohio State University,
Columbus, OH, USA
Disc-associated cervical spondylomyelopathy (DA-CSM) is a
common condition in Doberman Pinschers (DPs) that is similar in
pathogenesis to cervical spondylotic myelopathy in humans
(hCSM). In patients with hCSM, kinematic MRI (kMRI) is used
to evaluate the cervical vertebral column in ﬂexion and extension.
The purpose of this study was to evaluate kMRI in DPs with
DA-CSM using a novel positioning device that allowed controlled
ﬂexion and extension of the cervical vertebral column. We hypoth-
esized that kMRI would cause worsening of compressive lesions
and the development of new compressions, especially in extension.
Nine client-owned DPs that had a neurologic examination con-
sistent with a cervical myelopathy were prospectively evaluated.
All dogs underwent standard MRI in a neutral position using a
3.0 T magnet. Following standard MRI, the patients were placed
in right lateral recumbency on a positioning device and additional
MRI sequences were obtained with the cervical vertebral column
positioned in ﬂexion and extension. Morphologic and morphomet-
ric assessments were performed using the neutral, traction, ﬂexion
and extension images. Morphologic analysis included a modiﬁed
spinal cord compression score (previously published), direction of
spinal cord compression, signal intensity changes within the spinal
cord, and worst site of spinal cord compression. Morphometric
assessment included spinal cord height, intervertebral disc width,
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spinal cord width, spinal cord area, and vertebral canal height. A
Fischer’s exact test was used to evaluate the morphologic data and
mixed-eﬀects linear regression was used to analyse the morphomet-
ric data. Interobserver and intraobserver analyses were performed.
Due to space constraints, only part of the results is presented.
With neutral positioning, 14 total compressions were noted; 5/9
patients had 1 compression, 3 patients had 2 compressions, and 1
patient had 3 compressions. With ﬂexion, 12 total compressions
were noted; 1 patient had no compressions, 5 patients had 1 com-
pression, 2 patients had 2 compressions, and 1 patient had 3 com-
pressions. With extension, 26 total compressions were noted; 1
patient had 1 compression, 6 patients had 2 compressions, 3
patients had 3 compressions, and 1 patient had 4 compressions. In
neutral, the majority of lesions were mild (11/14) and located ven-
trally (9/14). Extension was associated with worsening of compres-
sions in 7 out of 14 sites and the presence of severe compressions
(4/26). It was also associated with multiple directions of compres-
sion; there was ventral and dorsal compression at 12/26 sites with
extension. Morphometric results revealed a decrease in spinal cord
height at C6–C7 (midsagittal images) from neutral to extension
(P = 0.003) and from ﬂexion to extension (P = 0.001).
This study supports the use of kMRI to evaluate the dynamic
component of DA-CSM. Results suggest that extension is most
useful; not only did it demonstrate worsening of multiple compres-
sions but it was also able to detect new compressions not visual-
ized in a neutral position.
N02
3D SOLITARY SEQUENCE MAGNETIC RESONANCE
IMAGING OF THE DOG SPINE IN HANSEN TYPE I INTER-
VERTEBRAL DISK DISEASE. Melissa Carpentier-Anderson1,
Fred Wininger2, Shannon Holmes3, Daniela Mauler2. 1Veterinary
Specialty Servies, Manchester, MO, USA, 2University of Missouri
Veterinary Health Center, Columbia, MO, USA, 3University of
Georgia College of Veterinary Medicine, Athens, GA, USA
SPACE (Sampling Perfection with Application optimized Con-
trasts using diﬀerent ﬂip angle Evolutions) is a T2-weighted three-
dimensional magnetic resonance imaging sequence. Currently, 2
dimensional T2-weighted spin echo imaging is the gold standard
diagnostic imaging for thoracolumbar intervertebral disk disease.
SPACE is potentially advantageous to standard MRI in that it is
a single acquisition, faster, technically easier modality with higher
resolution and the potential to reconstruct the image set in any
plane of section. The purpose of this study is to determine the
agreement between SPACE and T2-weighted standard spin echo
imaging sequences in the presence of Hansen Type I intervertebral
disk disease in the thoracolumbar spine of dogs to determine if
SPACE is a viable imaging sequence in the canine patient. Our
hypothesis was that the MRI sequence SPACE is able to positively
identify Hansen Type 1 intervertebral disk disease with equal accu-
racy to standard T2-weighted spin echo imaging.
This was a double blinded controlled study of dogs with an
acute onset T3-L3 compressive myelopathy secondary to Hansen
Type I intervertebral disk disease. All patients had standard pre-
anesthetic screening and underwent magnetic resonance imaging of
the T3-L3 spine using a Siemens 1.5T scanner. Images were
obtained, in at least, the following sequences: standard T2-W sagit-
tal and transverse, STIR dorsal, and SPACE. All dogs underwent a
decompressive hemilaminectomy based on the imaging ﬁndings.
The MRI sequences were randomized and three blinded individuals
interpreted the MR images a total of three times. The evaluators
were of diﬀerent skill levels, including one ECVN diplomate, one
ACVR diplomate, and a third year neurology resident. The stan-
dard T2-weighted and SPACE sequences were individually evalu-
ated for site, side, and degree of compression as well as surgical
recommendation and subjective conﬁdence of imaging ﬁndings.
23 dogs met the inclusion criteria. There was statistically signiﬁ-
cant agreement for both site and side (P-Value <0.001) between
the standard T2-weighted spin echo imaging and SPACE. There
was complete agreement by all three researchers concerning both
the site and side of disk herniation (comparing standard T2-
weighted standard spin echo imaging and SPACE) for 20 of the
23 dogs, and partial agreement for the other 3 dogs. Compressive
Length Ratio (CLR) estimates by the two methods were similar,
with more variability due to evaluator variability than to diﬀer-
ences between the two systems, and similar internal (intra-rater)
variabilities between the two systems. The degree of compression,
as measured by the standard mild/medium/severe rating protocol
shows signiﬁcantly positive association between the two methods,
although not as strong as that between the two methods for the
CLR measurements.
The MRI sequence SPACE was able to positively identify Han-
sen Type I Intervertebral disk disease in the canine thoracolumbar
spine as conﬁrmed via surgery with equal accuracy to standard
T2-weighted imaging.
N03
CLINICAL CHARACTERISTICS OF DOGS WITH
PROGRESSIVE MYELOMALACIA FOLLOWING ACUTE
INTERVERTEBRAL DISC HERNIATION. Aude Castel,
Natasha Olby. North Carolina State University, College of
Veterinary School, Raleigh, NC, USA
Progressive myelomalacia (PMM) is a catastrophic disease asso-
ciated with acute intervertebral disc herniation (IVDH). Published
data on the clinical characteristics of this disease are limited. The
aim of this retrospective study was to describe the onset and pro-
gression of clinical signs of PMM in a large case cohort.
Dogs with conﬁrmed IVDH and either a histopathologic diag-
nosis of PMM or a high clinical suspicion (acute paraplegia, loss
of nociception, loss of patellar reﬂex and cranial advancement of
the cutaneous trunci muscle reﬂex inconsistent with location of
disc herniation) were identiﬁed by medical record search.
Forty-eight cases were identiﬁed, 16 conﬁrmed via histopathol-
ogy, and 32 suspected based on clinical signs and imaging. The
majority of dogs were chondrodystrophic, including 24 Dachs-
hunds. Onset of PMM signs ranged from present at ﬁrst evalua-
tion (n = 16) to 5 days after presentation, with 43/48 developing
signs within 3 days. Progression of signs from onset to euthanasia,
excluding 10 cases euthanized at presentation, ranged from 1 to
13 days with 32 being euthanized within 72 hours. Systemic signs
(depression, anorexia, abnormal temperature and diﬀuse pain)
were documented in 34 dogs. Focal disc herniation was present in
35 dogs, while 7 dogs had extensive herniations.
In summary, the majority of dogs that develop PMM do so
within 3 days of presentation and progress to euthanasia within
another 3 days. However, onset can be delayed up to 5 days after
presentation with progression to death taking as long as 2 weeks.
Non-speciﬁc systemic signs are commonly reported.
N04
IN VITRO ANTI-TUBULIN EFFECTS OF BENZIMIDAZOLE
ANTHELMINTICS MEBENDAZOLE AND FENBENDAZOLE
ON CANINE GLIOBLASTOMA CELLS. Serene Lai1, Jennifer
Koehler2. 1Department of Clinical Sciences, Auburn University
College of Veterinary Medicine, Auburn, AL, USA, 2Department
of Pathobiology, Auburn University College of Veterinary Medi-
cine, Auburn, AL, USA
Benzimidazole anthelmintic drugs have been reported to have
antiproliferative eﬀects on several cancers both in vitro and in vivo,
with reduced oﬀ-target toxicity as compared to other microtubule-
disrupting drugs. In addition, these small, lipophilic drugs readily
cross the blood-brain barrier. The purpose of this study was to
evaluate the in vitro chemosensitivity of canine glioblastoma J3T
cells to mebendazole (MBZ) and fenbendazole (FBZ).
Cells were exposed to drugs for 72 hours, and cell viability was
evaluated using the MTT assay. The half-maximal inhibitory con-
centration (IC50) of MBZ and FBZ was calculated using a four-
parameter variable slope curve ﬁt nonlinear regression analysis.
The IC50 was compared between the two drugs. Western blot was
used to compare the ratio of polymerized to depolymerized tubulin
between drug-treated cells and untreated controls. Immunocyto-
chemistry was performed on treated and untreated cells to visual-
ize eﬀects of treatment on tubulin.
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The mean IC50 of MBZ and FBZ were 0.026 µM  0.03 and
0.55 µM  0.02 respectively. Treatment with MBZ and FBZ
resulted in increased depolymerization of tubulin compared to the
untreated control. Immunocytochemical studies showed disruption
of tubulin and evidence of apoptotic bodies after only 2 hours of
treatment.
Our in vitro data suggest that MBZ and FBZ may be good can-
didates for treatment of canine glioblastomas. Further in vivo stud-
ies are required.
N05
SUBARACHNOID-SUBARACHNOID SHUNTING FOR
TREATMENT OF SUBARACHNOID CEREBROSPINAL
FLUID FLOW OBSTRUCTION IN 9 DOGS. Ilyssa Meren,
Jessica Chavera, Nick Jeﬀery. Iowa State University, Ames, IA,
USA
Cerebrospinal ﬂuid (CSF) ﬂow in the subarachnoid space can
be impeded by developmental anomalies of the subarachnoid space
(i.e. diverticula) or acquired adhesions in older animals. Develop-
mental lesions can occur in any type of dog and clinical signs typi-
cally present in animals less than one year old; acquired lesions
appear to be most common in middle-aged and older small dogs,
notably pugs. Clinical signs include progressive proprioceptive
ataxia and, at later stages, fecal and urinary incontinence. Tradi-
tional surgical treatment of acquired subarachnoid adhesions (con-
strictive myelopathy) is associated with unreliable outcomes. Here
we report on the surgical procedure and outcome using subarach-
noid-subarachnoid shunting as a means of bridging the area of
adhesion.
Nine dogs were treated by this technique at Iowa State Univer-
sity between November 2013 and August 2015. The spinal cord
was exposed via routine dorsal laminectomy in 8 cases (thora-
columbar spinal cord) and via C2 laminotomy in one. A durotomy
was made over the lesion site using a hypodermic needle bevel and
expanded laterally to disrupt adhesions between the pia mater and
arachnoid mater. A shunt tube consisting of the ventricular cathe-
ter from a ventriculoperitoneal shunt kit or a red rubber catheter
of appropriate diameter was trimmed to span the lesion plus
~5 mm on either side of the adhesion and secured within the sub-
arachnoid space using 5/0 non-absorbable (polypropylene [Pro-
lene]) sutures. The dura was then closed over the shunt.
One patient had a developmental subarachnoid diverticulum (the
patient with a C2 laminotomy), and the remaining 8 had an acquired
adhesion (constrictive myelopathy) documented at surgery. Four
patients showed improvement of clinical signs, of which three
showed complete recovery. The one patient that has not shown a
complete recovery in this group was the young patient with a devel-
opmental subarachnoid diverticulum, but is continuing to improve
at 3 months post-operatively. One patient had mixed success:
improvement of fecal control, but deterioration in gait (although
with subsequent gradual improvement). Three patients did not show
major improvement after surgery. Of these, one showed mild
improvement after surgery but acute progression of paraparesis at
10 months prompted euthanasia (cause of acute paraparesis was not
ascertained because of lack of post mortem examination). The other
two cases showed unchanged clinical signs at 7 and 24 months post
operatively. The last remaining case improved immediately post-
operatively, but was lost to long-term follow-up.
Obstruction of CSF ﬂow in the subarachnoid space can be asso-
ciated with severe and life-threatening (fecal incontinence is a com-
mon reason for euthanasia) neurologic deﬁcits. Our results suggest
that subarachnoid-subarachnoid shunting can be an eﬀective surgi-
cal technique to ameliorate or prevent progression of associated
clinical signs.
N06
11-DEHYDRO THROMBOXANE B2 AS A BIOMARKER FOR
INTRACRANIAL NEOPLASIA IN DOGS. Jessica A. Rivera1,
Elizabeth Hurst2, James L. Mobley2, Peter J. Dickinson1. 1Univer-
sity of California, Davis, Davis, CA, USA, 2Cayman Chemical
Company, Ann Arbor, MI, USA
Meningiomas and gliomas are the most common intracranial
neoplasms in dogs, and deﬁnitive diagnosis is often problematic
due to the cost and invasiveness of an intracranial biopsy.
Biomarkers in serum, urine, and/or CSF can provide adjunctive
diagnostic data in conjunction with standard techniques such as
magnetic resonance imaging. The cycloogygenase pathway has
been identiﬁed as a key player in cancer progression, and several
pathway products including thromboxane A2 (TxA2) are over
expressed in a variety of human cancers, including gliomas.
The purpose of this pilot study was to determine levels of 11-
dehydro-thromboxane B2 (11TxB2) (a stable hydrolysis product of
TxA2) in dogs with a variety of neurological and non-neurological
diseases, using an enzyme immunoassay. Urine, serum, and CSF
samples were stored immediately following collection at 20°C (or
at 4°C for up to 7 days prior to 20°C storage).
11TxB2 was reliably detected in urine, but not in serum or CSF.
Storage at 4°C up to 7 days did not signiﬁcantly aﬀect urine TxB2
levels, and concurrent corticosteroid or non-steroidal anti-inﬂam-
matory medication did not apparently aﬀect levels within the study
group as a whole. Overlap of 11TxB2 urine levels was seen
between clinically normal and neurological animal groups.
Although some of the highest 11TxB2 values were seen in animals
with intracranial neoplasia, overlap with other neurological disease
groups was present. Assay of 11TxB2 is feasible; however, addi-
tional analysis of a large study population will be necessary to
determine whether a threshold urine 11TxB2 level may be useful as
a diagnostic biomarker.
N07
LUMBAR FRACTALKINE AND M2 MICROGLIA INCREASE
THROUGHOUT DISEASE PROGRESSSION IN CANINE
DEGENERATIVE MYELOPATHY. Christine Sibigtroth1, Maria
Jones2, Virginia Garcia2, Gayle Johnson3, Joan Coates1, Eric Vil-
lalon2, Michael Garcia2. 1Department of Veterinary Medicine and
Surgery, College of Veterinary Medicine, University of Missouri,
Columbia, MO, USA, 2Division of Biological Sciences, College of
Arts and Sciences, University of Missouri, Columbia, MO, USA,
3Department of Veterinary Pathobiology, College of Veterinary
Medicine, Univeristy of Missouri, Columbia, MO, USA
Canine degenerative myelopathy (DM) is an adult-onset neu-
rodegenerative disorder. Clinical progression is homogeneous
within and across breeds, thus four distinct disease stages have
been identiﬁed (Kanazono et al., 2013; Coates and Wininger,
2010). DM shares similarities with some forms of amyotrophic lat-
eral sclerosis (ALS), including underlying mutations in superoxide
dismutase-1 (SOD1). SOD1-mutant microglia play a central role in
ALS progression in rodent models. Microglia behavior is complex,
as expression patterns of classic M1 and M2 molecules are vari-
able throughout disease and between species studied. The mecha-
nism(s) underlying microglial phenotype determination within ALS
is not known. Fractalkine, a neuronally produced chemokine, has
been shown to suppress SOD1 mutant microglial-mediated neuro-
toxicity in vitro. Thus, fractalkine is a possible contributor to
microglial phenotype determination in ALS. Increased spinal cord
microglia have been documented in end-stage DM-aﬀected dogs,
however, their response and phenotype throughout disease pro-
gression is unknown. The goals of this study were to (1) quantify
and phenotype microglial cells in close proximity to lumbar spinal
cord motor neurons of DM-aﬀected dogs at each disease stage
and compare these ﬁndings to age-matched, neurologically normal
dogs and (2) correlate microglial phenotype with fractalkine pro-
tein levels in lumbar spinal cord throughout disease progression.
Spinal cord tissue was collected post-mortem from client-owned
dogs donated to the University of Missouri for research purposes.
Lumbar spinal cord microglia analyses were conducted with
immunoﬂuorescence and confocal microscopy. To identify micro-
glia in close proximity to motor neurons (MNs), concentric circles
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with increasing radii of 6 lM were applied to MNs of DM-
aﬀected dogs at each disease stage (stage 1 n = 120; stage 2
n = 118; late DM (3&4) n = 149) and age-matched control dogs
(n = 145). Cells with positive immunoreactivity for Iba-1/iNOS
(M1 microglia), or Iba-1/arginase-1 (M2 microglia), were
quantiﬁed in a double-blind manner. Data were analyzed via
Kruskal-Wallis ANOVA on ranks with post-hoc Dunn’s method.
Fractalkine total protein was quantiﬁed via western blot analysis
of lumbar spinal cord from DM-aﬀected dogs (stage 1 n = 2; stage
2 n = 4; late DM n = 3) and age-matched control dogs (n = 3).
Relative optical densities were normalized to control dogs. Data
were analyzed via ANOVA with post-hoc Holm-Sidak method.
A progressive increase in total microglia closely associated with
lumbar motor neurons was observed in DM-aﬀected dogs (stage1:
19  0.7; stage 2: 25  0.9; late DM: 28  0.9; P < 0.05) com-
pared to age-matched controls (13  0.4; P < 0.05). Total M2
microglia were increased in stage 2 (7.5  0.5) and late DM-
aﬀected dogs (6.2  0.5) compared to age-matched controls
(3.3  0.7; P < 0.05). No diﬀerences were observed in total M1
microglia throughout disease progression. Lumbar spinal cord
fractalkine protein was increased in stage 1 (2.2  0.2) and late
DM-aﬀected dogs (2.2  0.3) compared to age-matched controls
(1  0.1; P < 0.05).
These data suggest that M2, but not M1, microglia are progres-
sively recruited to motor neurons during disease progression.
Increased lumbar spinal cord fractalkine correlates with progres-
sive M2 microglia in DM-aﬀected dogs.
N08
INCREASED PHOSPHORYLATED NEUROFILAMENT
HEAVY IN CEREBROSPINAL FLUID AS A DISEASE
MARKER OF CANINE DEGENERATIVE MYELOPATHY.
Christine Sibigtroth1, Virginia Garcia2, Gerry Shaw3, Joan
Coates1, Patrick Pithua1, Michael Garcia2. 1Department of
Veterinary Medicine and Surgery, College of Veterinary Medicine,
University of Missouri, Columbia, MO, USA, 2Division of
Biological Sciences, College of Arts and Sciences, University of
Missouri, Columbia, MO, USA, 3EnCor Biotechnology,
Gainesville, FL, USA
Canine degenerative myelopathy (DM) is an adult-onset neu-
rodegenerative disorder with four deﬁned disease stages. DM ini-
tially manifests as spastic upper motor neuron paraparesis and
general proprioceptive ataxia (stage 1). Progressive neurodegenera-
tion results in non-ambulatory paraparesis/paraplegia (stage 2) and
thoracic limb paresis (stage 3). End-stage disease culminates in ﬂac-
cid tetraplegia, widespread muscle atrophy and signs of brainstem
dysfunction (stage 4). The clinical spectrum of DM is homogeneous
within and across breeds. Phosphorylated neuroﬁlament heavy
(pNF-H), a major structural protein of myelinated motor axons,
has shown promise as a prognostic biomarker in other diseases of
the nervous system such as amyotrophic lateral sclerosis (ALS).
The goals of this study were to 1) quantify the concentration of
pNF-H in the CSF of DM-aﬀected dogs throughout disease pro-
gression and compare these ﬁnding to age-matched, neurologically
normal dogs with and without SOD1 mutations and 2) compare
CSF concentrations of pNF-H between DM-aﬀected and dogs with
other chronic spinal cord disease that mimic DM.
Using an enzyme-linked immunosorbent assay (ELISA), we
measured pNF-H concentration in CSF from aged control dogs
(n = 10) and DM-aﬀected dogs at all stages (stage 1 n = 9; stage 2
n = 6; stage 3 n = 6; stage 4 n = 3). Data were analyzed using
Kruskal-Wallis ANOVA on ranks with post-hoc Dunn’s method.
Additionally, CSF pNF-H concentration was compared between
DM-aﬀected dogs (n = 24) and dogs with other chronic spinal
cord disease (n = 7). Those data were analyzed by the student’s t
test. To evaluate diagnostic performance, a receiver operating
characteristic curve was generated.
CSF concentrations of pNF-H were increased in DM-aﬀected
dogs at all disease stages compared to aged control dogs
(P = 0.002); pNF-H concentrations did not diﬀer between DM dis-
ease stages (P = 0.704). DM-aﬀected dogs had increased CSF
pNF-H compared to dogs with other chronic spinal disease
(P < 0.001). Using a cut-oﬀ concentration of 1.5 ng/mL, sensitivity
and speciﬁcity for diagnosis of DM were 0.83 and 0.95, respectively.
Area under the receiver operator characteristic curve was 0.911.
These preliminary ﬁndings suggest that pNF-H in CSF is a sen-
sitive and speciﬁc disease marker for DM. These data warrant fur-
ther study of pNF-H in CSF and serum for diagnosis of disease
and longitudinal monitoring of therapeutic eﬃcacy in DM.
N09
ETIOLOGY OF FELINE JUVENILE ONSET SEIZURES.
Muna Qahwash, Heidi Barnes Heller. University of Wisconsin,
School of Veterinary Medicine, Madison, WI, USA
Seizure etiology are well documented in adult cats. Despite this
awareness, little is published about the etiology and outcome of
juvenile onset seizures in cats. Juvenile onset seizures are deﬁned
as seizures starting prior to 12 months of age for this study. The
aims of this study were to 1) identify the common etiology and 2)
describe the outcome (dead or alive) in cats with juvenile onset sei-
zures. Inclusion criteria were 1) a conﬁrmed or suspected seizure
before 12 months of age and 2) complete medical records includ-
ing a ﬁnal diagnosis. The diagnosis was reclassiﬁed for each cat
according to the 2010 ILAE guidelines. Fifteen cats met the inclu-
sion criteria. Median age at onset was 24 weeks (range, 0.4 –
40 weeks). Six cats (40%) were diagnosed with structural epilepsy,
5 cats (33%) were diagnosed with unknown epilepsy, and 4 cats
(26%) were diagnosed with reactive seizures. Generalized seizures
were documented in 9 cats, 4 cats had focal seizures and 2 cats
had both focal and generalized seizures. Six cats (40%) had cluster
seizures, and status epilepticus was documented for 1 cat. Overall
8 cats (53%) were alive, 6 cats were dead and 1 cat was lost to fol-
low up. (Follow up 16 – 173 months after diagnosis) Three cats
died, or were euthanized, secondary to seizures or the underlying
diagnosis and 3 cats died or were euthanized unrelated to their sei-
zures or seizure diagnosis and 1 cat died due to unknown causes.
N10
COMPARISON OF SERUM TRACE NUTRIENT
CONCENTRATION IN DOGS WITH PRIMARY GENETIC
EPILEPSY VERSUS HEALTHY DOGS. Samantha Vitale,
Devon Hague, Laura Selmic. University of Illinois Veterinary
Clinical Medicine, Urbana, IL, USA
Primary genetic epilepsy is the most common cause of seizures
in dogs, reportedly aﬀecting 0.5–5.7% of the population. There
have been several investigations regarding the serum concentra-
tions of trace nutrients, including copper, selenium, zinc, man-
ganese, and iron in human epileptics and animal models.
However, no research of this nature is available in dogs with pri-
mary genetic epilepsy. This is a prospective pilot study, designed
to compare the serum concentrations of several trace nutrients in
non-epileptic dogs compared to dogs with epilepsy.
Blood samples were collected from 7 healthy control dogs and 8
dogs with primary genetic epilepsy. Serum was evaluated for
concentrations of copper, selenium, zinc, cobalt, manganese,
molybdenum, and iron using inductively coupled plasma mass
spectroscopy. Mann U Whitney tests were used to compare nor-
mal and epileptic dog serum levels of the trace nutrient. A signiﬁ-
cantly higher level of copper (P = 0.006), selenium (P = 0.018),
and manganese (P = 0.017) were found in epileptic dogs compared
to normal dogs. No signiﬁcant diﬀerences were found in levels of
zinc (P = 0.64), cobalt (P = 0.82), molybdenum (P = 0.60), or iron
(P = 0.95). These results suggest that there are diﬀerences in the
concentrations of some trace nutrients in epileptic dogs compared
to normal dogs, which warrants further investigation.
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SERUM LACTATE AS A PROGNOSTIC FACTOR IN DOGS
AND CATS WITH HEAD TRAUMA: 93 CASES (2003–2014).
Dana Sengewald, Devon Hague, Jason Tarricone, Maureen
McMichael, Laura Selmic. University of Illinois Veterinary Clini-
cal Medicine, Urbana, IL, USA
Previous studies identiﬁed associations of Modiﬁed Glasgow
Coma Scale (MGCS) and hyperglycemia with survival in veteri-
nary patients with head trauma. Lactate is the product of anaero-
bic glycolysis, and hyperlactatemia has classically been associated
with decreased tissue perfusion. Some studies in dogs with various
diseases, including trauma, have showed that higher initial lactate
concentration in dogs is associated with increased risk of mortal-
ity. The main aim of this study is to determine if elevated serum
lactate following head trauma in dogs and cats is associated with
mortality and whether the degree of hyperlactatemia corresponds
with clinical outcome.
Medical records for dogs and cats diagnosed with head trauma
from the VetCOT Trauma Registry and searching the electronic
medical record at the veterinary teaching hospital from 2003–2014
were examined. Cases were included if a diagnosis of head trauma
was made and if blood lactate concentration was measured on the
day of presentation. For each animal with head trauma included
in the study, information about signalment, vital parameters, diag-
nostic testing, treatment and outcome was recorded. Based on
information from the medical records, a MGCS was assigned to
patients. Univariable logistic regression was used to evaluate asso-
ciation with survival between signalment, examination parameters,
laboratory testing, and administration of treatment.
A total of 93 animals (78 dogs and 15 cats) met the inclusion
criteria for this study. There was no evidence that hyperlactatemia
(P = 0.38) or hyperglycemia (P = 0.69) were associated with mor-
tality. The MGCS Score at initial evaluation was the only variable
signiﬁcantly associated with outcome (P = 0.011). Dogs and cats
with head trauma may have elevated serum lactate levels, but the
degree of hyperlactatemia is not associated with severity of head
trauma or with outcome.
N12
COMPARISON OF FECAL MICROBIOMES BETWEEN
DOGS WITH MENINGOENCEPHALOMYELITIS OF
UNKNOWN ORIGIN AND CONTROLS. Nick Jeﬀery1, Jan
Suchodolski2, Al Jergens1, Jon Levine2. 1Iowa State University,
Iowa, IA, USA, 2Texas A&M University, College Station, TX,
USA
Recent experiments in laboratory rodents have suggested that
the constituents of the fecal microbiome inﬂuence the activity of
the immune system. Speciﬁcally, it has been shown that gnotobi-
otic rats are resistant to development of experimental autoimmune
encephalitis (EAE), an immune-mediated disease of the CNS that
mimics aspects of multiple sclerosis in humans and meningoen-
cephalomyelitis of unknown origin (MUO) in dogs. Further exper-
iments have shown that restoration of a normal microbiome
abrogates this resistance to EAE.
In this study we investigated whether a similar susceptibility to
MUO might exist in dogs that have speciﬁc microbiome con-
stituents. Previous published work in other species suggests that
Faecalibacterium spp, speciﬁcally F. prausnitzii, may modulate the
immune system to reduce risk of inﬂammatory and immune-
mediated diseases. Therefore, in this study we tested the hypothesis
that a relative deﬁciency of Faecalibacterium spp, especially
F. prausnitzii, would be associated with development of MUO.
We obtained fecal samples from dogs diagnosed with MUO and
from controls, many of which were matched for breed, age and
gender. Dogs that had been treated with antibiotics within the pre-
vious 4 weeks were excluded. The fecal microbiome was character-
ized using 16S rRNA sequencing by Illumina and qPCR assays
targeting Faecalibacterium spp, and abundances were compared
between aﬀected dogs and controls.
In analysis of the entire sampled population there was a signiﬁ-
cant reduction (of log DNA/gram feces) in Faecalibacterium spp in
aﬀected dogs compared to controls (median 6.5 versus 3.8; Mann-
Whitney test P = 0.012). However when aﬀected dogs were
compared only with matched controls, the median population of
Faecalibacterium spp was smaller in the aﬀected dogs (3.9 versus
6.4) but the Wilcoxon signed rank P = 0.074. Moreover, in 6/19
pairs the aﬀected dogs had a smaller population of Faecalibac-
terium spp than the unaﬀected dogs. Similarly, although the popu-
lation proportion of F. prausnitzii was smaller in aﬀected dogs
than controls (0.01% versus 0.1%), comparison using the Mann-
Whitney test revealed P = 0.089. Examination of paired data again
revealed lower median proportion in the aﬀected dogs (0.03% ver-
sus 0.1%) but a Wilcoxon paired rank P = 0.15.
This study suggests that there is some, albeit limited, evidence
to suggest that abundance of Faecalibacterium spp may inﬂuence
the susceptibility of individual dogs to developing MUO. One pos-
sible explanation for our results is that the well-recognized breed
susceptibility to MUO may be mediated, at least partially, through
eﬀects on gut microbiome. Here we examined just one highly
speciﬁc hypothesis regarding gut microbiota in this disease; further
analysis of the extensive fecal microbiome results available from
this study may generate hypotheses that can be tested in future
studies.
N13
CHARACTERIZATION OF IATROGENIC BLOOD CONTAM-
INATION ON LACTATE DEHYDROGENASE AND CREA-
TINE KINASE IN CANINE CEREBROSPINAL FLUID.
Jourdan Brune, Annie Chen-Allen. Washington State University,
Pullman, WA, USA
Cerebrospinal ﬂuid (CSF) analysis is regularly performed in
patients with neurological disease but iatrogenic blood contamina-
tion can distort results. The eﬀects of iatrogenic blood contamina-
tion on canine CSF lactate dehydrogenase (LD) and creatine
kinase (CK) total and isoenzyme activity have not been previously
evaluated. CK exists as 3 isoenzymes (CK-MM, CK-MB, CK-BB)
and LD exists as 5 isoenzymes (LD1-5) in both serum and CSF.
Investigating the eﬀects of blood contamination on total LD and
CK and their isoenzyme activity could allow clinicians to better
interpret the diagnostic and prognostic value of LD and CK isoen-
zymes in canine neurologic patients.
CSF samples were contaminated with incremental amount of
whole blood via serial dilution and LD and CK total and isoen-
zyme activity values were compared to an uncontaminated CSF
sample and the established reference interval. Total LD and CK
values were determined spectrophotometrically using a Sieman
Dimension Xpand and isoenzyme activity was determined using
gel electrophoresis and densitometric scanning. In contaminated
samples, total LD and CK values were increased compared to the
uncontaminated sample after contamination with > 2000 and >
4000 RBC/ul, respectively. Additionally, CSF isoenzyme activity
began to emulate serum isoenzyme activity, where CK-BB and
LD-5 banding became more prominent, when CSF was contami-
nated with > 4000 RBC/ul.
These ﬁndings suggest there is a threshold where blood contami-
nation can artiﬁcially distort CSF LD and CK total and isoenzyme
analysis. Therefore, these values will need to be interpreted with
caution when there is iatrogenic blood contamination in CSF.
N14
OUTCOME COMPARISON IN DOGS WITH THORA-
COLUMBAR ACUTE NON-COMPRESSIVE NUCLEUS
PULPOSUS EXTRUSION OR FIBROCARTILAGINOUS
EMBOLIC MYELOPATHY. Lorenzo Mari1, Anita Shea1,
Philippa Johnson2, Luisa De Risio1. 1Neurology and Neurosurgery
Service, Centre for Small Animal Studies, Animal Health Trust,
Newmarket, UK, 2Section of Diagnostic Imaging, Cornell College
of Veterinary Medicine, Ithaca, USA
The objective of the study was to compare the clinical outcome
between dogs with acute non-compressive nucleus pulposus extru-
sion (ANNPE) or presumptive ﬁbrocartilaginous embolic myelopa-
thy (FCEM) aﬀecting the thoracolumbar spinal cord segments.
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The medical records of dogs presented to the Animal Health
Trust between May 2006 and April 2015 and diagnosed with
ANNPE or presumptive FCEM were retrospectively reviewed. A
randomized list was generated of the MRI studies of 87 cases
matching the inclusion criteria and submitted to two board-
certiﬁed neurologists (LDR and AS) and one board-certiﬁed
radiologist (PJ), blinded to any clinical data. Each observer was
requested to make a diagnosis of ANNPE or FCEM based on
previously published diagnostic criteria. Inter-observer agreement
was evaluated with Kappa statistic. The clinical outcome of the
consensus diagnoses was compared. Recovery of motor and
autonomic function was evaluated via medical records and a
telephone questionnaire with the owners. Clinical re-examinations
were performed when possible.
Based on the review of the MRI studies, 72 cases were diag-
nosed with ANNPE and 15 with presumptive FCEM. The level of
agreement between LDR-AS (95.3%; j = 0.853) or AS-PJ (95.3%;
j = 0.819) was almost perfect while that between LDR-PJ (90.6%;
j = 0.68) was substantial.
Impaired urinary and/or fecal continence was reported only in
the ANNPE group in 20/71 dogs (28%, P = 0.033); all these dogs
had concurrent persistent motor deﬁcits. Four dogs with impaired
urinary and/or fecal continence were ambulatory at presentation.
Inability to control the urge to defecate was the most frequently
reported deﬁcit in faecal continence.
All but one dog became or remained ambulatory without assis-
tance. One dog diagnosed with presumptive FCEM presented
paraplegic without nociception, did not recover an ambulatory sta-
tus after 310 days and was euthanized. Only 20% dogs with
ANNPE and 14% dogs with presumptive FCEM recovered a
completely normal gait according to their owners, including 29%
of the grade 2/5 dogs, 12.5% of the grade 3/5 dogs and none of
the dogs that were plegic at presentation. The percentage of dogs
with persistent motor deﬁcits was not statistically diﬀerent between
the two groups. The time to recovery of some motor function in
the most aﬀected limb when presented with mono- or paraplegia
was signiﬁcantly longer in dogs with presumptive FCEM com-
pared to dogs with ANNPE (P = 0.025); however only two cases
with this variable were present in the FCEM group. Dogs diag-
nosed with presumptive FCEM were signiﬁcantly younger
(P = 0.025) and lighter (P = 0.037) than dogs with ANNPE and
had a longer intramedullary hyperintense lesion in sagittal T2-
weighted MRI images (P = 0.001). Dogs with ANNPE were more
frequently reported to be performing physical activity (P = 0.001)
and to vocalise (P < 0.0001) at the time of onset of the clinical
signs and more frequently received anti-inﬂammatory drugs
after diagnosis (P = 0.012) compared to dogs with presumptive
FCEM.
In conclusion, dogs diagnosed with ANNPE aﬀecting the thora-
columbar spinal cord segment developed impaired urinary/fecal
continence signiﬁcantly more frequently than dogs with presump-
tive FCEM. Impaired urinary/fecal continence can occur also in
dogs that are ambulatory at presentation. The presence of persis-
tent motor deﬁcits is extremely common, particularly in dogs that
presented non-ambulatory; however, no statistically signiﬁcant dif-
ference was detected in the degree of recovery of motor function
between the two groups.
N15
MORPHOLOGY OF THE CAUDAL FOSSA IN
MESATICEPHALIC AND BRACHYCEPHALIC CATS AND
ASSOCIATED CLINICAL SIGNS. Georgios (Yorgo) Varotsis1,
Tobias Schwarz1, Rodolfo Cappello2, Danielle Gunn-Moore1, Katia
Marioni-Henry1. 1Hospital for Small Animals, R(D)SVS and the
Roslin Institute, University of Edinburgh, Edinburgh, Midlothian,
UK, 2North Downs Specialist Referrals, Bletchingley, Surrey, UK
Morphological abnormalities of the caudal fossa are increas-
ingly recognized as a cause of morbidity in many brachycephalic
dogs but there is little information about these conditions in cats.
The objective of this study was to investigate presence of similar
morphological abnormalities of the caudal fossa of mesaticephalic
and brachycephalic cats and possible association with clinical signs
and ﬁnal diagnosis.
Feline brain MRI studies at two referral centres were reviewed
for cases without visible disease that could alter anatomic
landmarks or raise intracranial pressure. T2 weighted median plane
images of the brain and if available spinal cord were reviewed for
the presence of caudal cerebellar indentation, coning, herniation,
syringohydromyelia, and ﬂuid accumulation in the middle ear. Area
of the cerebral hemispheres and cerebellum was also measured Blind
measurements were taken by two observers and reviewed.
There were 53 feline MRI studies meeting the inclusion criteria.
Cerebellar herniation was found in 48% of mesaticephalic and
78% of brachycephalic cats. Syringohydromyelia was not identi-
ﬁed in any of the MR studies including only the ﬁrst two cervical
spinal cord segments (36 cats) or more regions of the spinal cord
(17 cats). High signal on T2-weighted transverse images of the
middle ear was detected in 8% of mesaticephalic and 17% of
brachycephalic cat. Information on presenting complaint, results
of neurological examination and ﬁnal diagnosis in cats with and
without cerebellar herniation was reviewed.
Mesaticephalic breed of cats show indentation of the caudal
aspect of the cerebellum and caudal cerebellar coning similar to
brachycephalic breeds of cats. The dimensions of the foramen mag-
num planum and the area of the cerebral hemispheres and cerebel-
lum measured on a T2W sagittal MR image of the brain were also
similar between the two groups. However, brachycephalic cats had
a higher percentage of herniation of the cerebellar vermis through
the foramen magnum. Herniation of the cerebellar vermis does not
appear to be associated with syringomyelia in cats.
N16
DIAGNOSTIC INVESTIGATION IN 13 CATS WITH
SUSPECTED FELINE HYPERESTHESIA SYNDROME. Pablo
Amengual1, Clare Rusbridge2, Tim Nuttall1, Sarah Heath3, Katia
Marioni-Henry1. 1Hospital for Small Animals, Royal (Dick)
School of Veterinary Studies, University of Edinburgh, Roslin,
Scotland, UK, 2Faculty of Health & Medical Sciences, School of
Veterinary Medicine, University of Surrey, Guildford, UK,
3Behavioural Referrals Veterinary Practice, Chester, UK
Feline hyperesthesia syndrome (FHS) was ﬁrst reported in 1979
and described as an accentuation of an otherwise normal behavior
in cats consisting in episodes of tail chasing, biting or licking the
lumbar area, ﬂank, anal area or tail; skin rippling and muscle
spasms; excessive and unusual vocalizations, wild and uncontrolled
jumping and running and presumed hallucinations. FHS has been
anecdotally reported in association with dermatological, beha-
vioural, orthopaedic and neurological conditions. Treatment with
phenobarbital, gabapentin, prednisolone, amitriptyline, ﬂuoxetine,
clomipramine and multivitamin supplements have been used with
inconsistent responses. However, we are not aware of any clinical
scientiﬁc investigation on Feline Hyperesthesia Syndrome.
We retrospectively collected data on the history, signalment,
diagnostic workup and treatment from three referral veterinary
centers. The inclusion criteria were a history of attacking or over-
grooming the tail, ﬂank or perineal area associated with either
vocalization or lumbar hyperesthesia, manifested as rippling of the
thoracolumbar skin occurring spontaneously or induced by gentle
touch. Information on physical and neurological examination, and
diagnostic work up were also necessary for inclusion in the study.
Thirteen cats were included in the study. The median age of
presentation was 1 year (1–7 years). Eleven cats were attacking or
over-grooming their tails and two cats their ﬂank or perineal area.
Tail mutilation was reported in 9/13 cats, rippling of the thora-
columbar skin in 10/13 cats and 6 cats presented with unusual
vocalization during the episodes. The episodes occurred multiple
times per day in 12/13 of the cases, and multiple times per week in
1/13. No consistent triggers were reported. Results of CBC and
biochemistry were available for 12/13 cats, spinal radiographs for
7/13, magnetic resonance imaging for 6/13, cerebrospinal ﬂuid
analysis for 3/13, electromyography for 3/13, dermatological
assessment for 7/13, and joint ﬂuid analysis for one cat. The diag-
nostic work up led to the diagnosis of allergic dermatitis in 2 cases
and immune-mediated polyarthritis in one case, but a deﬁnitive
diagnosis was not reached in the remaining 10 cases. Treatment
included corticosteroids in 7/13 of the cats, gabapentin in 8/13,
clomipramine in 4/13, topiramate in 2/13, phenobarbital in 2/13
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and cyclosporine in 6/13. The majority of the cases (10/13)
received a combination of 2 or more drugs.
Our study conﬁrmed previous anecdotal reports of FHS aﬀect-
ing young cats and the possibility of that FHS signs are secondary
to inﬂammatory skin conditions. A deﬁnitive diagnosis was not
reached in 10 cases. However, not all the cases had the same
diagnostic work up and not all had a full behavioral and dermato-
logical assessment. Based on the results of this retrospective
study, specialists in neurology, behavior and dermatology have
formulated a standardized questionnaire and proposed a rational
diagnostic approach for investigation and treatment of this con-
stellation of clinical signs in cats and as a platform for future
prospective studies.
N17
CYSTOMETRIC CHARACTERIZATION OF URINARY
BLADDER DYSFUNCTION IN CHRONICALLY
PARALYZED DOGS. Hilary Hu, Nick Jeﬀery, Chelsea Marko,
Victoria Kichler. Iowa State University, Ames, USA
Increasing numbers of pet owners elect to keep dogs that have
suﬀered permanent thoracolumbar spinal cord injury as pets.
Although pelvic limb paralysis can be partially circumvented by
using carts to allow greater mobility, care of the urinary bladder is
often more problematic. In addition to urinary incontinence and
recurrent urinary tract infections, it is possible that many such
aﬀected animals can suﬀer from detrusor hyper-reﬂexia. This is a
risk factor for chronic elevation of bladder pressure and secondary
renal damage in both human and canine spinal cord injury
patients.
Here we describe cytometric quantiﬁcation of bladder dysfunc-
tion in chronic paraplegic pet dogs. These dogs were <20 kg and
had sustained severe T3-L3 spinal cord injury resulting in inability
to walk or control urination persisting for at least three months
post-injury. A dual-lumen sterile urinary catheter was used for cys-
tometry: one lumen was used to infuse 0.9% sterile saline into the
bladder while the other measured intravesicular pressure. Infusion
was terminated when: (1) leaking was apparent at the external
urethral oriﬁce; or, (2) when the physiologic maximum holding
capacity of 20 mL/kg was reached; or, (3) when the 50 mmHg
intra-vesicular pressure threshold was reached.
Several cystometric metrics were measured in this study: (1)
intravesicular pressure at leak; (2) bladder holding capacity
expressed as a percentage of the physiologic maximum holding
capacity of 20 mL/kg; and (3) bladder compliance, which was
determined as change in bladder volume divided by change in
intra-vesicular pressure. Two standard points were used for the
calculation of bladder compliance: (1) the intra-vesicular pressure
and bladder volume at the start of bladder ﬁlling (both were zero);
and (2) the intravesicular pressure and bladder volume at cysto-
metric capacity or immediately before the start of any detrusor
contraction that resulted in urine leakage.
Cystometric data was recorded in 42 dogs with chronic spinal
cord injury. Intravesicular pressure at leak ranged from 1 mmHg
to 50 mmHg with a mean of 18.6 mmHg and median of
17 mmHg. In 2 (5%) patients, the intravesicular pressure reached
the 50 mmHg threshold. The two additional parameters used
to quantify detrusor hyper-reﬂexia were both highly variable
within the population as a whole: (1) bladder compliance
(mean = 27.3 mL/mmHg, median = 5.1 mL/mmHg, range
= 0.4–180 mL/mmHg); and, (2) bladder holding capacity (mean
= 68%, median = 68%, range = 9–100%).
We conclude that there is evidence that detrusor hyper-reﬂexia
occurs in a small proportion of pet dogs paralyzed because of sev-
ere T3-L3 spinal cord injury. It is characterized by elevation in
intravesicular pressure and reduction in bladder compliance and
bladder holding capacity. This identiﬁcation of a speciﬁc type of
neurogenic bladder dysfunction permits timely interventions to
mitigate renal damage. Potential therapies for treating detrusor
hyper-reﬂexia can now be evaluated using these quantiﬁable blad-
der functional parameters derived from cystometry.
N18
EVALUATION OF KINEMATIC MAGNETIC RESONANCE
IMAGING IN DOGS WITH OSSEOUS-ASSOCIATED
CERVICAL SPONDYLOMYELOPATHY. Michele Provencher,
Amy Habing, Sarah Moore, Laurie Cook, Gary Phillips, Ronaldo
da Costa. The Ohio State University, Columbus, OH, USA
Osseous-associated cervical spondylomyelopathy (OA-CSM) is a
condition characterized by static and dynamic spinal cord com-
pressions. The dynamic component of cervical spondylotic
myelopathy in humans (hCSM) is evaluated with kinematic MRI
(kMRI). The purpose of this study was to evaluate kMRI in dogs
with OA-CSM using a positioning device that allowed controlled
ﬂexion and extension of the cervical vertebral column. Our
hypothesis was that kMRI would reveal new compressive lesions
not identiﬁed with standard positioning.
Ten Great Danes and 2 Doberman Pinschers with neurologic
examination ﬁndings consistent with a cervical myelopathy were
prospectively evaluated. All dogs underwent standard MRI in a
neutral position (sagittal and transverse T1 and T2 weighted
images) using a 3.0 T magnet. The patients were then placed in
right lateral recumbency on a positioning device and the cervical
vertebral column was ﬁrst ﬂexed and then extended. Sagittal and
transverse T2 weighted images were acquired in both ﬂexion and
extension. Morphologic and morphometric assessments of the cer-
vical vertebral column in neutral, ﬂexion and extension were per-
formed. Morphologic analysis included a modiﬁed spinal cord
compression score (previously published), direction of spinal cord
compression, signal intensity changes within the spinal cord, and
worst site of spinal cord compression. Morphometric assessment
included spinal cord height, intervertebral disc width, spinal cord
width, spinal cord area, and vertebral canal height. A Fischer’s
exact test was used to evaluate the morphologic data and mixed-
eﬀects linear regression was used to analyze the morphometric
data. Interobserver and intraobserver analyses were performed.
Given space constraints, only a portion of the results is
reported. In neutral 4 patients had 1 compression, 4 patients had 2
compressions, 3 patients had 3 compressions, and 1 patient had 4
compressions (25 total compressions). In ﬂexion 1 patient had 0
compressions, 4 patients had 1 compression, 4 patients had 2 com-
pressions, 2 patients had 3 compressions, and 1 patient had 4 com-
pressions (22 total compressions). In extension 2 patients had 1
compression, 1 patient had 2 compressions, 8 patients had 3 com-
pressions, and 1 patient had 4 compressions (32 total compres-
sions). Extension was associated with mild compression at C4–C5
(P = 0.02) that was not noted in neutral or ﬂexion, and extension
caused worsening of 28% (7/25 compressions) of the compressions
that were present in neutral. There were 11/32 compressions (34%)
in extension that were not present in neutral and 10/11 (91%) of
these compressions had a dorsal component; the presence of dorsal
compression with extension was signiﬁcant at C4–C5 (P = 0.01).
Flexion was associated with an increase in intervertebral disc
width at C3–C4 (P = 0.02) and extension caused widening of the
intervertebral disc at C6–C7; no other signiﬁcant morphometric
ﬁndings were noted. In 1 patient, a synovial cyst that was not
identiﬁed in neutral was noted to cause mild spinal cord compres-
sion in extension.
Our results support the use of kMRI in patients with OA-CSM
to reveal new compressive sites, dorsal compressions and to
enhance visualization of extradural compressive lesions, such as
synovial cysts.
N19
BARTONELLA SPP. PCR ASSAY RESULTS USING CERE-
BROSPINAL FLUID OF DOGS WITH CENTRAL NERVOUS
SYSTEM DISEASE. Lisa Bartner1, Stephanie McGrath1, Adam
Drury1, Annie Chen2, Arianne Morris1, Melissa Brewer1, Meri
Hall2, Michael Lappin1. 1Colorado State University, Fort Collins,
CO, USA, 2Washington State University, Pullman WA, USA
A multitude of infectious agents are on the diﬀerential list for
dogs with focal or multifocal neurological dysfunction. A number
of Bartonella spp., including B. henselae, B. vinsonii subsp.
berkhoﬃi, and B. clarridgeaie, are known to infect dogs. While
multiple human cases of neurobartonellosis have recently been
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described, the role these organisms play in clinical diseases of the
central nervous system of dogs has not been widely explored. The
purpose of this study was to use polymerase chain reaction (PCR)
to amplify Bartonella spp. DNA from cerebrospinal ﬂuid (CSF) of
naturally exposed dogs in endemic areas meeting criteria for
inﬂammatory central nervous system (CNS) disease.
CSF samples from 175 pure or mixed breed dogs were submit-
ted to Colorado State University (www.dlab.colostate.edu) from
either the Washington State University Neurology Department
between January 2012 and September 2014 or the Colorado State
University Veterinary Teaching Hospital between January 2012
and September 2015. The CSF samples were stored at 80°C until
evaluated in this study. Dogs with neurologic examinations consis-
tent with focal and multifocal neurologic dysfunction and CSF
pleocytosis (total nucleated cell count >5 nucleated cells/µL and
red blood cell <4,000 cells/µL) were included. Animals with nor-
mal neurologic examinations were also included if their CSF met
our criteria. The CSF was thawed and centrifuged at 10,000 X g
for 15 minutes. The supernatant was removed and the pellet
assayed in a previously published PCR assay that targets the 16S-
23S rRNA intergenic region. All positive amplicons were
sequenced to determine the infective Bartonella spp.
A total of 67 dogs met the inclusion criteria, none of which
were positive for Bartonella spp. DNA in CSF. Of the other 108
CSF samples, one was positive for B. henselae DNA. The CSF
from this dog contained red blood cells (94 RBC/µL).
As Bartonella spp. have an intra-erythrocytic phase, we specu-
late that minimal peripheral RBC contamination in the CSF of
dogs with systemic Bartonella spp. infection may lead to positive
Bartonella PCR assay results in the absence of a CNS disease asso-
ciation. Thus, positive PCR for Bartonella spp. DNA in the CSF
of dogs must be interpreted in light of number of RBCs within the
sample as well as the presence of inﬂammation or systemic infec-
tion. Failure to amplify Bartonella spp. DNA from the CSF of the
67 dogs with inﬂammatory disease studied suggests the organism
was not involved, the organism was in CNS tissues but not in the
CSF, or the organism was present but in quantities undetectable
by this PCR assay. The combination of PCR and culture has been
found to be the most sensitive way to detect Bartonella spp. in
samples from dogs and humans and the use of that technique
should be considered in future studies.
N20
PREICTAL, POSTICTAL AND INTERICTAL BEHAVIORAL
CHANGES IN DOGS WITH GENETIC EPILEPSY
COMPARED TO CONTROL DOGS. Hilary Levitin1, Devon
Hague1, Kelly Ballantyne2, Laura Selmic1. 1University of Illinois
Veterinary Clinical Medicine, Urbana, IL, USA, 2Medical District
Veterinary Clinic at Illinois, Chicago, IL, USA
While anxiety related behaviors have been reported in humans
diagnosed with epilepsy, only one veterinary study has shown an
increased frequency of anxiety behaviors in epileptic dogs com-
pared to other medical populations. The purpose of this study was
to determine the presence and severity of anxiety related behaviors
in dogs with genetic epilepsy when compared to control patients.
The study’s other aims were to investigate if an association exists
between increased anxiety related behaviors in the preictal and
postictal phases of a seizure episode compared to the interictal
period and whether dogs with refractory epilepsy have more severe
seizures, which could account for the increased anxiety related
behavioral side eﬀects as reported in humans and dogs.
This multi-institutional study used a questionnaire based on
the Canine Behavioral Assessment and Research Questionnaire
(CBARQ), that has been previously validated for its ability to ana-
lyze canine behavior. Owners of dogs that had been diagnosed
with genetic epilepsy were asked to complete the questionnaire and
a 10-point seizure severity scale. Sections of the CBARQ relating
to separation, attachment and attention seeking, and obedience
and training behaviors were modiﬁed to include additional param-
eters for detecting anxiety based behavioral changes associated
with diﬀerent phases of the seizure episode. The questionnaire was
also distributed to primary care clients presenting dogs for well-
ness examinations and owners of dogs with intervertebral disc
disease (IVDD). Veterinarians of the dogs in the study also
completed a brief questionnaire as well to identify and verify the
diagnoses of each dog that participated in this study. Fischer’s
exact tests were utilized, to assess for diﬀerences in behavioral
traits exhibited between the epileptic, IVDD and primary care
groups. If a signiﬁcant diﬀerence between the groups was detected,
then post hoc testing with Fischer’s exact tests for pairwise com-
parisons was performed and a Bonferroni correction was applied
to account for multiple comparisons.
Dogs in the epilepsy and IVDD groups were more likely to be
fearful/anxious when approached by an unfamiliar dog than those
dogs in the wellness group (P = 0.0011). Epileptic dogs with
increasing seizure severity were signiﬁcantly more likely to show
fear and anxiety when approached by an unfamiliar dog
(P = 0.0129) and showed signiﬁcantly less excitement just before
just before being taken on a car trip (P = 0.0126). Epileptic dogs
receiving polytherapy had a signiﬁcant decrease in excitement just
before taking a walk (P = 0.0007) and just before being taken on
a car trip when compared to dogs on monotherapy (P = 0.027).
Dogs receiving polytherapy had signiﬁcantly increased fear and
anxiety when groomed or bathed by a household member
(P = 0.0197), and had an increase in shaking, shivering, or trem-
bling when left or are about to be left on their own (P = 0.0004).
Dogs receiving polytherapy had a signiﬁcant increase in becoming
agitated when their owner or others show aﬀection for another per-
son during preictal (P = 0.005), postictal (P = 0.001) and interictal
(Pr= 0.0083) period and when their owner or others show aﬀection
for another dog or animal during preictal (P = 0.0068), postictal
(P = 0.0068) and interictal (P = 0.02) period when compared to
dogs on monotherapy. The ﬁnding of behavioral changes present
throughout diﬀerent seizure phases in this study raises further ques-
tions about how epilepsy aﬀects canine patient’s quality of life.
O01
THE ASSOCIATION OF ENDOTHELIN-1 SIGNALING
WITH BONE ALKALINE PHOSPHATASE EXPRESSION
AND PRO-TUMORIGENIC ACTIVITIES IN CANINE
OSTEOSARCOMA (VCS AWARD WINNER). ZL Neumann1,
HC Pondenis1, A Masyr1, ML Byrum1, KL Wycislo2, TM Fan1.
1Department of Veterinary Clinical Medicine, University of Illi-
nois, Urbana, IL, USA, 2Department of Pathobiology, University
of Illinois, Urbana, IL, USA
Background: Canine osteosarcoma (OS) is an aggressive sar-
coma characterized by pathologic skeletal resorption and pul-
monary metastases. A limited number of negative prognostic
factors, including bone alkaline phosphatase, have been identiﬁed
in dogs diagnosed with OS; however, the biologic underpinnings
for such observations have not been thoroughly investigated.
Endothelin-1 mediated signaling is active during bone repair, and
is responsible for osteoblast migration, proliferation, and bone
alkaline phosphatase expression.
Hypothesis: The endothelin-1 signaling axis is active in canine
OS cells, and this pathway is utilized by malignant osteoblasts for
promoting cellular migration, proliferation, and bone alkaline
phosphatase activities.
Animals: 45 dogs with appendicular OS.
Methods: The expressions of endothelin-1 and endothelin A
receptor were studied in OS cell lines and spontaneous tumor sam-
ples. The biologic activities mediated by endothelin-1 signaling
were investigated by characterizing responses in 3 OS cell lines. In
45 dogs with OS, bone alkaline phosphatase concentrations were
correlated with primary tumor osteoproductivity.
Results: Canine OS cells express endothelin-1 and endothelin A
receptor, and this signaling axis is functional and mediates OS
migration, proliferation, and bone alkaline phosphatase activities.
In OS-bearing dogs, circulating bone alkaline phosphatase activi-
ties were positively correlated with primary tumor relative bone
mineral densities.
Conclusions and clinical importance: Canine OS cells express
endothelin-1 and functional endothelin A receptors; with the
potential for an autocrine or paracrine pro-tumorigenic signaling
loop. Elevations of bone alkaline phosphatase are associated with
osteoblastic OS lesions, and might be an epiphenomenon of active
endothelin-1 signaling or excessive osteoproduction within the
localized bone microenvironment.
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SAFETY EVALUATION OF COMBINATION DOXORUBICIN
AND TOCERANIB PHOSPHATE (PALLADIA(R)) IN TUMOR
BEARING DOGS: A PHASE I DOSE FINDING STUDY (VCS
AWARD WINNER). MA Pellin1, RM Wouda2, K Robinson1, K
Tsimbas1, ID Kurzman1, DM Vail1,3. 1Department of Medical
Sciences, School of Veterinary Medicine, University of Wisconsin-
Madison, Madison, WI, USA, 2Kansas State University, College
of Veterinary Medicine, Manhattan, KS, USA, 3Carbone Cancer
Center, University of Wisconsin-Madison, Madison, WI, USA
Introduction: Combination chemotherapy holds the promise of
improved outcome in canine malignancy, but care must be taken
to avoid overlapping toxicity.
Methods: Dogs with cytologically or histologically diagnosed
tumors of any histology (excluding mast cell tumors) and any
stage were allowed. A standard, open-label, phase I, 3 + 3 dose-
cohort escalation design was employed. The toceranib dose
remained constant at 2.75 mg/kg administered orally every other
day. Doxorubicin was initiated at 20 mg/m2 administered IV every
21 days for four doses. The doxorubicin dose was escalated by
5 mg/m2 each cohort until MTD or 30 mg/m2 was reached. DLT
was deﬁned as any grade 3 adverse event with the exception of
hematopoietic AEs for which a grade 4 AE was considered dose
limiting. Any grade AE that was refractory to supportive care or
persisted beyond seven days was also considered dose-limiting.
Results: Twenty-one patients were enrolled. Represented his-
tologies included hemangiosarcoma, multicentric lymphoma, anal
sac adenocarcinoma, epitheliotropic lymphoma, and prostatic car-
cinoma. The DLT was neutropenia occurring with doxorubicin
30 mg/m2. The MTD of the combination was determined to be
doxorubicin 25 mg/m2 and toceranib 2.75 mg/kg. No grade 3 or 4
gastrointestinal or novel AEs were observed. Additionally, anti-
tumor activity was observed in several cases.
Conclusion: The combination of doxorubicin 25 mg/m2 IV
q21 days and toceranib 2.75 mg/kg PO EOD was well tolerated.
Eﬃcacy and longer term toxicity of this combination should be
further investigated in phase II/III trials.
O03
COMPARISON OF SERUM CYTOKINE LEVELS BETWEEN
DOGS WITH MULTICENTRIC LYMPHOMA AND
HEALTHY DOGS. Jerome Calvalido, Paul Woods, Geoﬀrey
Wood, Anthony Mutsaers, Darren Wood, William Sears. Univer-
sity of Guelph, Guelph, ON, Canada
In people, changes in the cytokine environment have been
linked to the development of lymphoma, and multiple circulating
cytokines have been shown to be relevant biomarkers for response
to chemotherapy and prognosis. Therefore, the purpose of this
study was to measure the serum levels of 13 cytokines in dogs with
multicentric lymphoma and compare them to a population of
healthy dogs. It was hypothesized there would be a signiﬁcant dif-
ference in cytokine levels between dogs with lymphoma and
healthy dogs, and between dogs with B cell and T cell lymphoma.
Thirty one dogs cytologically or histopathologically diagnosed
with multicentric lymphoma were prospectively enrolled in the
lymphoma group. CBC and biochemistry were performed in all
dogs. Immunophenotype was determined by ﬂow cytometry in all
dogs, separating them into 2 groups: B cell (n = 21) and T cell
(n = 10). Nineteen healthy dogs were enrolled in the control
group. All dogs had similar exclusion criteria including previous
administration of chemotherapy, systemic immunomodulatory
medication (including corticosteroids and NSAID) within the last
two weeks, and vaccination within the last four weeks.
T-test and Chi-square test were used to compare and match
continuous variables (age, weight) and categorical variables (sex),
respectively, between lymphoma and control groups. The cytokine
concentrations were measured using a commercial canine multiplex
magnetic bead-based (Luminex) assay which measured IL-2,
IL-6, IL-7, IL-8, IL-10, IL-15, IL-18, GM-CSF, TNF-a, IFN-c,
IP-10, KC-like, and MCP-1. The serum levels of each cytokine
were compared amongst the three groups (B cell lymphoma, T cell
lymphoma, healthy control) using ANOVA or Kruskal-Wallis
tests, as appropriate. Statistical signiﬁcance was set at P < 0.05.
There was no signiﬁcant diﬀerence between the lymphoma and
healthy control groups regarding sex, age and weight. IL-6, IL-10,
KC-like, and MCP-1 were signiﬁcantly higher in dogs with lym-
phoma compared to healthy dogs (P = 0.01, P = 0.03, P = 0.01,
P < 0.01, respectively). IL-10, KC-like, and MCP-1 were signiﬁ-
cantly higher in the B cell lymphoma group than in the healthy
group (P = 0.01, P < 0.01, P = 0.01, respectively). MCP-1, IL-6
and IL-15 levels were signiﬁcantly higher in the T cell lymphoma
group than in the healthy group (P = 0.02, P < 0.01, P < 0.01,
respectively). Finally, IL-6 and IL-15 were signiﬁcantly higher in
the T cell lymphoma group than in the B cell lymphoma group
(P = 0.03. P = 0.02, respectively). There were no signiﬁcant diﬀer-
ences in serum IL-2, IL-7, IL-8, IL-18, GM-CSF, TNF-a, IFN-c,
and IP-10 between the lymphoma and control groups.
In conclusion, this study found diﬀerent serum cytokine proﬁles
between dogs with lymphoma and healthy dogs, and also diﬀerent
serum cytokine proﬁles between dogs with B cell and T-cell lym-
phoma. Further study is necessary (and underway) to investigate
the role of these cytokines in lymphoma pathogenesis, response to
treatment, and prognosis.
O04
POST-CHEMOTHERAPY PERFORATION IN CATS WITH A
DIAGNOSIS OF INTERMEDIATE OR HIGH GRADE
GASTROINTESTINAL LYMPHOMA. Zachary Crouse1, Brenda
Phillips2, Andi Flory2, Jennifer Mahoney1, Keith Richter2, Linda
Kidd3. 1Angell Animal Medical Center, Boston, MA, USA,
2Veterinary Specialty Hospital of San Diego, San Diego, CA,
USA, 3Western University of Health Sciences, Pomona, CA, USA
Whether solitary gastrointestinal (GIT) mass lesions caused by
intermediate or large cell lymphoma in cats should be treated ini-
tially with surgical excision or chemotherapy is debated. There is a
theoretical risk of perforation due to rapid cell death associated
with chemotherapy. The prevalence of, and clinical ﬁndings associ-
ated with perforation have not been described.
The objective of this study was to document the prevalence and
timing of post-chemotherapy perforation in cats with GIT masses
caused by intermediate or large cell lymphoma. We hypothesized
that tumor size, presence of hypoproteinemia, or suppurative
inﬂammation within the mass at the time of diagnosis would be
associated with perforation.
Cats with a diagnosis of intermediate to large cell lymphoma
based on cytologic examination of a mass lesion of the GIT, and
treated with variable chemotherapy were identiﬁed by searching
the patient record database of two referral hospitals. Gastrointesti-
nal perforation was conﬁrmed with histopathology or using ultra-
sound and analysis of abdominal ﬂuid.
Twenty-three cats with intermediate (n = 3) or large cell
(n = 20) lymphoma were identiﬁed. Gastrointestinal perforation
was conﬁrmed in 4 of 23 cats (17.4%). Perforation occurred at 23,
56, 59, and 87 days after induction. There was no association
between tumor size, the presence of hypoproteinemia, or suppura-
tive inﬂammation within the mass at the time of diagnosis, and
subsequent perforation.
Perforation is relatively common in cats with GIT mass lesions
caused by intermediate or large cell lymphoma. However, the ﬁnd-
ings of this exploratory study suggest that acute perforation after
induction of chemotherapy is not common.
O05
A RETROSPECTIVE STUDY ON THE INCIDENCE OF
PROTEINURIA ASSOCIATED WITH THE USE OF
TOCERANIB PHOSPHATE. Sindy Piscoya, Cheryl Balkman,
Kelly Hume. Cornell University, Ithaca, NY, USA
Tyrosine kinase inhibitors (TKIs) are a commonly used therapy
in both human and veterinary medicine. The incidence of protein-
uria in humans receiving VEGFR-TKIs is reported to be as high
as 18.7%. In veterinary medicine, the TKI masitinib mesylate has
been shown to induce a protein-losing nephropathy in a subset of
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patients. Documented reports of proteinuria with the use of tocer-
anib phosphate are scarce. The purpose of this study was to
describe the overall incidence of proteinuria associated with the
use of toceranib phosphate. Medical records were retrospectively
reviewed from September 2009 through October 2014 for canine
patients with any type of malignancy receiving toceranib phos-
phate for a minimum of 3 weeks and a urinalysis and urine pro-
tein creatinine ratio (UPC) when indicated. Fifty-ﬁve cases met the
inclusion criteria. The median dose of toceranib phosphate was
2.6 mg/kg (range, 2.1–2.8 mg/kg) given on Monday/Wednesday/
Friday. Prednisone was used in conjunction with toceranib phos-
phate in 26 dogs with a median dose of 0.5 mg/kg (range 0.25–
1.5 mg/kg) given on Tuesday/Thursday/Saturday/Sunday. In the
toceranib phosphate plus prednisone group, proteinuria developed
in 7 dogs at a median of 69 days (range, 15–122 days) with a med-
ian UPC of 0.8 (range, 0.6–1.1). In the toceranib phosphate alone
group, 5 dogs developed proteinuria at a median of 47 days
(range, 19–626 days) with a median UPC of 0.7 (range, 0.6–4.9).
The use of toceranib phosphate was associated with development
of proteinuria in a subset of patients and careful monitoring
including frequent serial urine protein-creatinine ratios is
recommended.
O06
GROWTH PATHWAYS IN FELINE ORAL SQUAMOUS
CELL CARCINOMA. Krystal Harris, Howard Gelberg, Stuart
Helfand. Oregon State University, Corvallis, OR, USA
The present study was designed to reach a better understanding
of the biologic behavior of feline oral squamous cell carcinoma
(FOSCC) by evaluating a variety of growth factor pathways
known to contribute to aggressive behavior in many cancers. In
addition, we evaluated a novel transcription factor, Bcl11b, a bio-
marker for head and neck squamous cell carcinoma (HNSCC).
FOSCC biopsies were graded and immunohistochemistry used
to quantify relative expression of Bcl11b, EGFR, Ki67, and
VEGF-D. Chi-square tests determined if Bcl11b expression corre-
lated with expression of other receptors and growth factors. Wes-
tern blots on FOSCC cell lines (SCCF1, SCCF2, SCCF3) were
employed to verify expression of Bcl11b, EGFR, Src, ERK, and
VEGF-D. Western blot on FOSCC cell lines determined phospho-
rylation of Bcl11b and the eﬀect of a src inhibitor, dasatinib, on
this activation. An MTT assay was applied on FOSCC cell lines
following treatment with dasatinib. ELISA quantiﬁed VEGF pro-
duction by FOSCC cells with and without dasatinib treatment.
Bcl11b staining intensity was moderate to strong in 79.4% (27/
34) of FOSCC’s. FOSCC biopsies with intense Bcl11b staining
had the highest number of Bcl11b positive cells (P < 0.001). All
biopsies expressed VEGF-D and 85.7% (18/21) expressed EGFR
at varying intensities. A correlation between increasing Bcl11b and
EGFR expression approached signiﬁcance (P = 0.05598). All
FOSCC cell lines expressed pBcl11b, pEGFR, pSrc, pERK, and
VEGF-D. Dasatinib treatment lowered cell viability, inhibited acti-
vation of Bcl11b, and suppressed VEGF production. Ligand stim-
ulation of EGFR resulted in increased activation of EGFR and
ERK, increased VEGF/VEGF-D production, and partially rescued
FOSCC cells from the eﬀects of dasatinib.
This study represents the ﬁrst description of Bcl11b expression
in the cat and in FOSCC. We demonstrated activation of the Src
pathway by FOSCC cells making Src a strategic therapeutic target
that could be used in a clinical setting. Exposing FOSCC cells to
dasatinib has inhibitory eﬀects on cell proliferation, EGFR, and
consistently decreased production of VEGF. Based on these
results, dasatinib may have both anti-proliferative and anti-angio-
genic eﬀects in FOSCC. Since EGF is able to partially rescue cells
from the eﬀects of dasatinib, future studies should evaluate dual
target inhibition of Src and EGFR, EGFR and VEGFR, as well
as combining Src inhibition with standard chemotherapy agents.
O07
A RETROSPECTIVE ANALYSIS OF MULTIMODALITY
TREATMENT FOR CANINE ORAL MELANOMA: 126
CASES. Michelle Turek1, Tracy LaDue2, Jayme Looper3, Koichi
Nagata4, Keijiro Shiomitsu5, Michele Keyerleber6, Julia Buchholz7,
Tracy Gieger5, David Vail1. 1University of Wisconsin-Madison,
School of Veterinary Medicine, Madison, WI, USA, 2Southeast
Veterinary Oncology and Internal Medicine, Orange Park, FL,
USA, 3Chicago Veterinary Specialty Group, Chicago, IL, USA,
4University of Georgia, College of Veterinary Medicine, Athens,
GA, USA, 5Louisiana State University, School of Veterinary Med-
icine, Baton Rouge, LA, USA, 6Tufts University Cummings
School of Veterinary Medicine, North Grafton, MA, USA,
7Animal Oncology and Imaging Center, Hunenberg, Switzerland
Oral melanoma (OM) has a high propensity to metastasize to
regional lymph nodes (LN) and lungs. Surgery and/or radiother-
apy (RT) are eﬀective local treatments, however most dogs suc-
cumb to distant metastasis. Immunotherapy represents an
attractive strategy for this potentially immunogenic tumor. The
objective of this multi-institutional retrospective study was to
examine the clinical outcome of dogs with OM treated with
ONCEPTTM melanoma vaccine, +/- surgery and/or RT.
Medical records of dogs with OM treated with ONCEPTTM
were reviewed from seven veterinary radiotherapy facilities. Many
dogs underwent concurrent surgery and/or RT (8 Gray X 4 weekly
fractions). Dogs with distant metastasis and those receiving con-
current chemotherapy were excluded.
One hundred and twenty six dogs were included. All received
ONCEPTTM. Sixty had adequate local control (ALC; complete
excision or irradiation of microscopic disease). Fifteen were treated
in the microscopic setting. Fifty-one were treated in the gross dis-
ease setting, of which 39 underwent RT. Median time to progres-
sion, median progression-free survival and median overall survival
were 304, 244 and 617 days, respectively. Dogs with ALC had
improved clinical outcomes. The following also correlated with
favorable clinical outcomes: rostral location, stage 1, absence of
LN metastasis, low mitotic index, absence of bony lysis, absence
of gross disease.
This is the largest reported series of dogs with OM treated with
ONCEPTTM. Clinical outcomes are similar to those reported
recently for dogs treated with surgery and/or RT alone. Several
prognostic indicators were conﬁrmed. A prospective, randomized,
controlled study is needed to determine the clinical beneﬁt of
ONCEPTTM.
O08
ENHANCEMENT OF DOXORUBICIN EFFECTIVENESS
WHEN COMBINED WITH SALINOMYCIN IN FISS CELL
LINES. Lucia Borlle1, Brittany Zumbo2, Kelly R. Hume1.
1Cornell University, Ithaca, NY, USA, 2Michigan State Univer-
sity, MI, USA
Feline injection site sarcoma (FISS) is an aggressive neoplasia
that remains a challenge for clinicians. Radical surgery is the ﬁrst
choice treatment but is not always feasible. Chemotherapeutic
responses have been documented but are generally of short dura-
tion; tumors often develop resistance quickly. Salinomycin is an
ionophore that has been shown to inhibit cancer stem cells and to
increase the sensitivity of human soft tissue sarcoma cells to dox-
orubicin chemotherapy. The aim of our study was to determine if
salinomycin could be used to increase the sensitivity of FISS cell
lines to doxorubicin. Two primary cell lines cultured from feline
patients with histologically conﬁrmed FISS were used for this pur-
pose. Since the threshold response to doxorubicin diﬀers, we
ranked the cells according to the sensitivity to doxorubicin and
used one sensitive line (C10) and one resistant line (B4). Cell via-
bility assays (MTT) were used to determine the response to single
agent and combination therapy. Three independent assays were
performed, with samples evaluated in triplicate in each assay. Stu-
dent’s t-tests were employed to compare the results of individual
doxorubicin concentrations with and without salinomycin combi-
nation therapy. Addition of 5 uM salinomycin resulted in a statis-
tically signiﬁcant (P < 0.05) reduction in cell viability compared to
single agent doxorubicin at multiple concentrations for both cell
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lines. Our results highlight a potential chemotherapy protocol for
the treatment of FISS. Further investigations need to be pursued
to deﬁne the eﬀect of this novel therapeutic combination and to
validate our results in vivo.
O09
CLINICAL ADVANCEMENT OF A RNA-TRANSFECTED
CD40-B CELL VACCINE FOR THE TREATMENT OF
CANINE NON-HODGKIN’S LYMPHOMA. Nicola Mason,
Martha MaloneyHuss, Josephine Gnanandarajah. University of
Pennsylvania, Philadelphia, PA, USA
Canine Non-Hodgkin’s lymphoma (NHL) occurs in approxi-
mately 30–100/100,000 dogs per year and accounts for up to 83%
of canine hematopoietic cancers. Standard–of-care treatment for
canine NHL comprises multi-drug chemotherapeutic protocols.
60–85% of dogs enter a complete clinical remission following
induction chemotherapy, and median ﬁrst-remission durations
range from 140 to 385 days. Resistance to chemotherapy increases
with each subsequent relapse and less than 10% of patients survive
longer than 2 years from diagnosis. To prolong overall survival,
more eﬀective therapies are required to prevent relapse following
successful induction chemotherapy.
Directing the immune system to speciﬁcally target malignant
cells is a powerful strategy in the treatment of cancer. We have
previously developed a vaccine strategy that utilizes autologous
CD40-activated B cells as antigen-presenting cells electroporated
with autologous tumor RNA as the antigenic payload to stimulate
anti-tumor immunity in dogs with NHL. In our ﬁrst clinical trial,
we showed that dogs vaccinated three times at three week intervals
following successful induction chemotherapy had a tendency
towards prolonged remission times and overall survival when com-
pared to historical controls. Furthermore, vaccinated dogs that did
relapse showed a statistically signiﬁcant increase in overall survival
following rescue chemotherapy. These results coupled with
immune analysis from vaccinated patients suggested that while
RNA loaded CD40-activated B cells primed an anti-tumor
immune response, it was insuﬃcient to maintain remission. Fur-
thermore, we hypothesized that rescue chemotherapy boosted vac-
cine primed tumor-speciﬁc immunity and lead to prolonged second
remission times. We therefore hypothesized that repeat administra-
tions of RNA-loaded CD40-activated B cells given every 2 months
following an initial priming course would maintain anti-tumor
immunity and prevent relapse.
To investigate this hypothesis we are currently performing a sec-
ond phase I/II clinical trial using RNA-loaded CD40-activated B
cells. Fifteen dogs will be recruited to this study. Eligibility criteria
include a recent diagnosis of NHL, no prior treatment with
chemotherapy or steroids, and no evidence of circulating blasts.
At the time of diagnosis, peripheral blood mononuclear cells and
malignant lymph node tissue are harvested to generate CD40-acti-
vated B cells and whole tumor RNA respectively. Dogs then
undergo a 19-week CHOP-based chemotherapy protocol. Only
dogs in complete clinical remission following induction chemother-
apy are eligible to receive the autologous vaccine. Dogs are vacci-
nated every three weeks for three doses, and then every two
months until clinical relapse. Induction and maintenance of anti-
tumor immunity is being determined using an IFN-c ELISpot
assay. The primary endpoint of this trial is time to progression,
and the secondary endpoints include duration of anti-tumor immu-
nity, overall survival and lymphoma-speciﬁc survival.
To date, ten dogs have been recruited and CD40-activated B
cells have been successfully generated for nine dogs. Brieﬂy,
PBMCs are co-cultured with feeder cells consisting of irradiated
K562 cells transfected with human CD40L (KtCD40L) in the pres-
ence of cyclosporine and IL-4, to generate CD40-activated B cells.
CD40-B cells are then electroporated with RNA extracted from
autologous malignant lymph node tissue or with canine distemper
virus Hemagglutinin antigen (CDV-HA) mRNA as a control vac-
cine. At the time of writing, 2/10 dogs have completed their induc-
tion chemotherapy and have received their initial priming
vaccinations. No adverse events have occurred following vaccine
administration, and neither dog has yet relapsed. The trial is ongo-
ing and the preliminary data conﬁrm the feasibility of autologous
CD40-B cell vaccine generation and safety of administration.
ELISpot analysis at baseline and at each vaccine time point are
being performed to elucidate whether repeat vaccinations eﬀec-
tively maintain anti-tumor immunity.
O10
VITAMIN D STATUS AND ACUTE PHASE PROTEIN
CONCENTRATIONS IN CANINE CANCER PATIENTS.
Nicole Weidner1, J. Paul Woods2, Anthony J. Mutsaers2, Julie
Bayle3, Adronie Verbrugghe2. 1Department of Biomedical
Sciences, Ontario Veterinary College, University of Guelph,
Guelph, ON, Canada, 2Department of Clinical Studies, Ontario
Veterinary College, University of Guelph, Guelph, ON, Canada,
3Royal Canin Research Center, Aimargues, France
Circulating concentrations of acute phase proteins (APP) have
been used as biomarkers in canine oncology. Increased concentra-
tions have been observed in cancer patients and decreased concen-
trations are linked to patient remission. In humans, increased APP
concentrations have been linked with low vitamin D status in sev-
eral disease states. Low vitamin D status has also been observed in
human and canine cancer patients. Therefore, there is the possibil-
ity that increased APP concentrations will be linked with decreased
vitamin D status in canine cancer patients. The objective of this
study was to examine the relationship between blood vitamin D
and APP concentrations in healthy dogs and dogs with cancer.
Dogs with lymphoma (n = 34), osteosarcoma (n = 21) and mast
cell tumors (n = 26) diagnosed by cytology and/or histology pre-
senting to one referral hospital for treatment, as well as client-
owned healthy control dogs (n = 25), were enrolled. Blood samples
were collected from all dogs prior to any treatment and analyzed
for plasma 25-hydroxyvitamin D (25(OH)D) using radioim-
munoassays, and haptoglobin (Hp), alpha-1-acid glycoprotein
(AAG) and serum amyloid A (SAA) using ELISA kits. Statistical
analyses were completed with SAS 9.3. Vitamin D and APP con-
centrations were compared between groups using ANOVAs fol-
lowed by Tukey-Kramer post-hoc analyses. Pearson correlation
coeﬃcients were performed to determine relationships between
vitamin D and APP concentrations within each group.
MeanSD plasma 25(OH)D concentrations were signiﬁcantly
lower in dogs with lymphoma (102  33 nmol/L) than in healthy
dogs (129  41 nmol/L, P = 0.007). MeanSD plasma Hp and
AAG concentrations were signiﬁcantly higher in dogs with lym-
phoma (9.6  7.3 ng/mL and 92.4  71.0 ng/mL, respectively)
than in healthy dogs (3.0  1.7 ng/mL, P < 0.001 and
43.7  30.8 ng/mL, P < 0.001, respectively). There were no signiﬁ-
cant diﬀerences in blood SAA levels among groups. Pearson corre-
lation coeﬃcients revealed a moderate inverse relationship between
plasma AAG and 25(OH)D concentrations (R = 0.39, P = 0.024)
in lymphoma patients only.
The lower plasma 25(OH)D and higher Hp and AAG concen-
trations in canine lymphoma patients compared to healthy dogs is
consistent with previous reports. However, this study is the ﬁrst to
report these observations within the same population. Further
research is needed to investigate whether decreased plasma 25(OH)
D concentration is a factor in cancer development, or a conse-
quence of cancer, and to determine the clinical relevance of these
ﬁndings.
O11
RETROSPECTIVE EVALUATION OF METRONOMIC
CYCLOPHOSPHAMIDE IN EPITHELIAL AND MESENCHY-
MAL MALIGNANT TUMOURS. J Ellis, RD Foale. Dick White
Referrals, Six Mile Bottom, Cambridgeshire, UK
Continuous low dose chemotherapy administration has been
reported to have anti-angiogenic eﬀects with eﬃcacy against multi-
ple tumour types. This study aimed to retrospectively assess the
use of metronomic cyclophosphamide for histopathologically con-
ﬁrmed solid malignant canine tumours.
Patient records from 2009 to 2014 were reviewed at a multi-
disciplinary referral hospital. Dogs without histological
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conﬁrmation of diagnosis were excluded. Thirty-seven cases of
epithelial or mesenchymal malignancy in dogs treated with 10 mg
cyclophosphamide daily/every other day were identiﬁed. This
included 14 high grade soft tissue sarcomas, 5 soft tissue sarcomas
of undeﬁned grade, 4 intermediate grade soft tissue sarcomas, 3
splenic haemangiosarcomas, 3 incompletely excised low grade soft
tissue sarcomas, 2 thyroid carcinomas, and 1 each of adenocarci-
noma, bladder haemangiosarcoma, splenic ﬁbrosarcoma, apocrine
gland carcinoma, metastatic prostate carcinoma, and metastatic
carcinoma of unknown origin. Two were lost to follow up.
Twenty-two had at least one attempt at surgical excision and three
underwent radiotherapy prior to initiation of chemotherapy.
Three of the dogs (8.6%) developed haematuria, but no other
adverse eﬀects were reported. The haematuria resolved in all three
dogs after cessation of cyclophosphamide.
74% of dogs had stable disease or partial/complete remission
>100 days with cyclophosphamide, including two dogs that had
failed previous chemotherapy protocols and one that had received
radiotherapy. Four dogs did not have resection of the primary
tumour, and three of these remained clinically well for >100 days.
20 of 35 dogs (57%) had DFI >6 months with 13 (37%) still alive
over one year later.
Of the dogs with intermediate/high grade sarcomas (n = 18) the
median survival time (MST) was 362 days, with one dog lost to
follow up and four still alive.
Of the dogs with carcinomas (n = 6) one was lost to follow up
and two are still alive >1 year later with no clinical signs. One dog
had a reduced rate of progression and stable disease for >100 days
with no clinical signs of disease. Two dogs with thyroid carcinoma
were still alive three years later. This is in contrast to the reported
MST for invasive thyroid carcinoma treated with cisplatin of
98 days.
This study adds to the evidence that metronomic cyclophos-
phamide may have some use in the treatment of malignant mes-
enchymal and epithelial tumours. However, it is important to note
that even at low doses side eﬀects may occur.
O12
EVALUATION OF TOCERANIB PHOSPHATE (PALLADIA)
IN THE TREATMENT OF FELINE MAST CELL NEO-
PLASIA: 53 CASES. Erika Berger1, Chad Johannes1, Gerald
Post2, Gillian Rothchild2, Kai-Biu Shiu3, Sarah Wetzel3, Chelsea
Tripp4, Theresa Arteaga5, Martin Crawford-Jukubiak6, Anna Rita
Serras7, Sarah Gillings8, Christine Swanson9, Shawna Greene10,
Kelly O’Neill11, Michelle Pressel12. 1Iowa State University College
of Veterinary Medicine, Ames, IA, USA, 2The Veterinary Cancer
Center, Norwalk, CT, USA, 3Veterinary Specialty Center, Madi-
son, WI, USA, 4Veterinary Cancer Specialty Center, Seattle, WA,
USA, 5Animal Cancer Center, Monterey, CA, USA, 6Sage Centers
for Veterinary Specialty and Emergency Care, Concord, CA,
USA, 7Animal Health Trust, Newmarket, Suﬀolk, UK, 8Summit
Veterinary Referral Center, Tacoma, WA, USA, 9Blue Pearl Spe-
cialty and Emergency Medicine for Pets, Grand Rapids, MI, USA,
10Iowa Veterinary Specialties, Des Moines, IA, USA, 11Saint Fran-
cis Veterinary Specialists, Decatur, GA, USA, 12Paciﬁc Veterinary
Specialists, Capitola, CA, USA
The purpose of this study was to solicit and compile data from
practicing veterinary specialists regarding their use of toceranib in
cats with mast cell neoplasia and to provide initial assessment of
possible clinical beneﬁt and toxicity.
The American College of Veterinary Internal Medicine Oncol-
ogy and Small Animal Internal Medicine listserves were used to
solicit data pertaining to cases in which toceranib was used in the
treatment of feline mast cell neoplasia. Cases were included if the
following data were received: signalment (age, gender, breed), ana-
tomic classiﬁcation of disease (cutaneous or visceral), previous and
concurrent treatment, toceranib dose (mg/kg) and schedule, dura-
tion of therapy, best response, and documentation of adverse
events.
Case data from 53 cats with cutaneous (n = 25) or visceral
(n = 28) mast cell neoplasia were received. Clinical beneﬁt (CB)
was seen in 81% (43/53), including 88% (22/25) with cutaneous
(8CR, 12PR, 2SD) and 75% (21/28) with visceral (5CR, 13PR,
3SD) involvement. Most cats (n = 49) did not receive
concurrent radiation or chemotherapy, though a majority
(n = 38) received glucocorticoids during toceranib treatment.
Mean duration of toceranib treatment in cats experiencing CB
was 37 weeks (4–106) and 48 weeks (10–199) for cutaneous and
visceral cases, respectively. Toceranib was administered at a
median dose of 2.5 mg/kg in cats with CB; in 91% (39/43) the
drug was given 3 times per week. Treatment was generally well
tolerated with 57% (30/53) cats experiencing adverse eﬀects at
some point during toceranib treatment. The majority of these
signs were low-grade (Grade 1 or 2) gastrointestinal or hemato-
logic toxicities that resolved with treatment break and/or dose
adjustment.
Toceranib appears to be well-tolerated in feline patients with
mast cell neoplasia. Biologic activity of this drug is evident in the
studied cats, however further prospective studies are needed to
fully elucidate its role in treatment of this condition.
O13
EXPRESSION OF P GLYCOPROTEIN (ABCB1) IN CATS
WITH T-CELL LYMPHOCYTIC GASTROINTESTINAL
LYMPHOMA. Valter de Medeiros Winkel, Bruno Cogliati,
Archivaldo Reche Jr, Ana Luiza Nairismagi Alves, Sılvia Regina
Ricci Lucas. University of Sao Paulo, Sao Paulo, SP, Brazil
Gastrointestinal is the most common anatomical form of lym-
phoma in cats and systemic chemotherapy is indicated for the
treatment. Although most of cats can achieve a complete remission
with chemotherapy, relapse can occurs and may be associated to
the multidrug resistance (MDR). Cell mechanisms of MDR
include activation of transmembrane proteins, that reduce intracel-
lular concentrations of diﬀerent chemical compounds, and alter-
ations in drug target. The main protein related to MDR
phenotype is P-glycoprotein. Its overexpression results in reduced
concentration of certain drugs within the cell, which is linked to
the resistance. The aim of this study was to investigate P glycopro-
tein (P-gp) expression in cats with T-cell lymphocytic gastrointesti-
nal lymphoma. Immunohistochemistry was performed in 40
samples using the monoclonal antibodies mouse anti-PAX-5
(PAX5-Invitrogen), polyclonal rabbit anti-CD3 (DAKO) and
mouse anti-P-glycoprotein (clone C494-Enzo Life Sciences). P-gp
immunoreactivity was analysed by degree of staining intensity,
between 0 (no expression) to 3 (strong expression). Lymphoma
was considered to be positive for P-gp when more than 10% of
the neoplastic population expressed the protein. Three cats had a
strong and 7 had a moderate expression, comprising 25% of the
cases. The median of overall survival time was 24 months for these
10 cats; 60% had complete and 40% partial response to the treat-
ment, and it was the same median observed for all cats studied. In
conclusion, the expression of P-gp was observed in 25% of the
cats with T-cell lymphocytic gastrointestinal lymphoma and this
expression was not related to the treatment response or overall
survival time.
O14
EARLY EXPERIENCES WITH STEREOTACTIC RADIATION
THERAPY FOR THE TREATMENT OF CANINE NON-
LYMPHOMATOUS NASAL TUMORS. Tracy Gieger, Michael
Nolan. Department of Clinical Sciences (College of Veterinary
Medicine), and Comparative Medicine Institute, Raleigh, NC,
USA
The purpose of this study was to describe initial experiences
with a stereotactic radiation therapy (SRT) protocol (10 Gy x 3
daily fractions delivered with 6 MV photons via a linear accelera-
tor) used as treatment for non-lymphomatous nasal tumors in
dogs. A retrospective analysis of cases treated from August 2013
to October 2015 at NC State Veterinary Hospital was per-
formed. Dogs were included if they had biopsy-conﬁrmed non-
lymphomatous nasal tumors. Dogs treated with chemotherapy
were excluded. The gross tumor volume (GTV) was contoured
using pre- and post-contrast 1–2 mm slice thickness CT image sets.
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A clinical target volume (CTV) expansion was used to include the
ipsilateral nasal cavity and sinuses as well as 0.5–1 cm of the con-
tralateral nasal cavity. A PTV expansion was not used (CTV =
PTV). Thirty Gray (Gy) was prescribed to 99% of the GTV and >
95% of the PTV with a planned simultaneous boost to the center
of the GTV. Cone beam CT, indexed bite-block system, and a
treatment couch with 6 degrees of freedom were used for set up
and delivery. Cases were reviewed and information related to
patient demographics, tumor characteristics, and radiation plan
dosimetry was collected.
Twenty-ﬁve cases were included. Stages included T1 (n = 1), T2
(n = 10), T3 (n = 2), T4 (n = 12). None had evidence of distant
metastasis. Nineteen had regional lymph node aspirates and metas-
tasis was present in one. Tumor types included adenocarcinomas
(n = 15), chondrosarcomas (n = 5), transitional nasal carcinomas
(n = 3), intranasal squamous cell carcinoma (n = 1), and neuroes-
thesioblastoma (n = 1). Clinical signs improved in all cases. Twelve
cases had recheck CT scans 3–4 months post-SRT and partial or
complete tumor response was seen in all cases. Minimal acute toxi-
city was detected. The only late eﬀect noted to date is oronasal ﬁs-
tula development in one dog 4 months post-SRT (this was
anticipated due to tumor invasion into the palate at diagnosis).
The median disease progression-free survival time has not been
reached, and 52% of dogs are progression-free at 1 year. Nine
dogs are deceased (median survival time 375 days) and 40% are
alive 600 days post SRT.
Three fraction SRT has been used to treat non-lymphomatous
nasal tumors in 25 dogs with limited adverse events. Continued
accrual and follow-up will be necessary to conﬁrm low toxicity,
further elucidate eﬀects of stage on outcome, and characterize clin-
ical eﬃcacy.
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TREATMENT OF CANINE APPENDICULAR OSTEOSAR-
COMA WITH AMPUTATION, CARBOPLATIN, AND
TOCERANIB PHOSPHATE. Tracy Gieger1, Dawn Clarke2, Julie
Nettifee-Osborne1, Chad Johannes3, Brianna Hallman1, Michael
Nolan1, Laurel Williams4. 1North Carolina State University,
Raleigh, NC, USA, 2University of Georgia College of Veterinary
Medicine, Athens, GA, USA, 3Iowa State University, Ames, IA,
USA, 4Veterinary Specialty Hospital of the Carolinas, Cary, NC,
USA
Osteosarcoma (OSA) is locally invasive and highly metastatic.
We hypothesize that standard-of-care carboplatin chemotherapy
followed by continued administration of toceranib phosphate (TP)
will result in improved survival in dogs with OSA as compared to
historical controls that did not receive TP. In addition, we hypoth-
esize that TP will decrease circulating levels of pro-angiogenic
MMP-9, a downstream factor and surrogate marker for VEGF
receptor inhibition.
Ten dogs with histologically conﬁrmed OSA with no evidence
of thoracic metastasis at diagnosis were treated with amputation
followed by 4 doses of carboplatin chemotherapy (300 mg/m2 IV
q 3 weeks). Fourteen days after chemotherapy was completed, TP
was initiated at a dose of 2.75 mg/kg PO q 48 hours. Serum sam-
ples for VEGF and MMP-9, bloodwork to evaluate toxicity,
screening for metastasis with thoracic radiographs, and quality-of-
life (QOL) scores monitored via owner surveys were performed
monthly. The Kaplan-Meier method was used to calculate OSA-
free survival and overall survival (OS). A Friedman’s test was
used to compare VEGF and MMP values at baseline, pre-TP, and
end of study. A Kruskal-Wallis test of repeated measures was
used to compare platelet-corrected VEGF values at baseline,
pre-TP, and end of study. P values of <0.1 were considered
signiﬁcant.
Three dogs required dose reductions of carboplatin secondary
to neutropenia, and two required drug holidays during TP treat-
ment. No dogs were withdrawn from the study due to toxicity.
Seven dogs developed local recurrence or metastasis as the ﬁrst
event. One dog was withdrawn from the study due to owner
wishes, one was euthanized due to osteoarthritis, and one devel-
oped lymphoma with no evidence of OSA metastasis. There
was no signiﬁcant diﬀerence in MMP or VEGF (absolute or plate-
let-corrected) at any time point, and there was no correlation of
these values with OSA-free survival or OS. Median OSA-free sur-
vival was 183 days (range, 55–576) and OS was 250 days (range,
80–882).
Although the combination of carboplatin followed by TP was
well-tolerated in dogs with appendicular OSA, survival times did
not exceed previously published data from dogs treated with
amputation followed by chemotherapy. Serum VEGF and MMP-9
levels remained unchanged from baseline despite the continued
administration of TP. The results of this study do not support
ongoing TP administration post amputation and standard-of care
chemotherapy in dogs with appendicular OSA.
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SAFETY ASSESSMENT OF A NOVEL ONCOLYTIC
MARABA VIRUS IN CATS. J. Paul Woods1, Byram Bridle1,
Dorothee Bienzle1, Josepha Delay2, Annette Morrison3, Michelle
Cieplak3, Jeﬀ Hummel4, Brian Lichty4. 1Ontario Veterinary
College, University of Guelph, Guelph, ON, Canada, 2Animal
Health Laboratory, University of Guelph, Guelph, ON, Canada,
3Campus Animal Facilities, University of Guelph, Guelph, ON,
Canada, 4McMaster Immunology Research Centre, McMaster
University, Hamilton, ON, Canada
Oncolytic viruses are viruses whose replication is restricted to
tumour cells leading to cytolysis. A growing number of viruses are
being developed as oncolytic viruses and various strategies have
been utilized to target tumour cells. Our group developed a bio-
therapeutic that combines two emerging cancer treatment modali-
ties, tumour vaccination and oncolytic viruses. We recently
determined that oncolytic viruses expressing tumour antigen trans-
genes are an excellent means to boost and enhance tumour vacci-
nation. In this preliminary study, cats were ﬁrst vaccinated with
an adenovirus expressing a cancer gene, and then boosted with
another virus (Maraba) also expressing this cancer gene. This vac-
cination protocol should elicit strong immunity to cancer cells, but
should not cause any ill eﬀects to the cats. The purpose of this
study was to determine the safety (or toxicity) of a genetically
altered oncolytic Maraba virus in cats.
Five young male (6–12 months old) purpose-bred cats were vac-
cinated intramuscularly with 9 x 109 PFU of a non-replicating
human serotype 5 adenoviral vaccine vector (prime). Three weeks
later the cats were administered 2.64 x 1011 PFU of MG1 Maraba
virus intravenously (boost). Cats were monitored with physical
exams observing for clinical signs, and by complete blood counts
(CBC). Peripheral blood, saliva, urine, and feces were collected for
virus isolation on days 1, 2, 3, 4 and 7 post- Maraba virus
infusion.
There were no severe adverse events. Two cats had mild tran-
sient pyrexia (40 - 41.4 C) between 2 and 5 hours post Maraba
virus infusion (typical of cytokine induction). The CBCs revealed
a transient mild neutrophilia in 2 cats one day after Maraba virus
infusion (14.92 and 8.73; reference interval 2.1–8.3 x 109 /L).
Thrombocytopenia of 27 x 109/L (reference range 93–514 x 109/L)
was noted in one cat 2 days post Maraba virus infusion, and in
another cat thrombocytopenia of 9 x 109/L and 33 x 109/L on
days 3 and 7, respectively, post Maraba virus infusion.
Viral genomes but not replication-competent viruses were
detected in secondary lymphoid tissues (i.e. spleen) on day 39.
Replication-competent virus was not detected in peripheral blood,
saliva, urine, or feces.
Viral genomes in secondary lymphoid tissues without concur-
rent replication-competent virus is a ﬁnding similar to that in mice
and primates, and reﬂects the propensity of Maraba virus to be
taken up by antigen-presenting cells when delivered systemically,
making it an ideal vector for boosting immune responses.
The lack of replication-competent virus in saliva, urine, feces or
peripheral blood satisﬁed Canadian Food Inspection Agency
(CFIA) concerns regarding potential shedding, and enabled initia-
tion of a clinical trial utilizing Maraba virus to treat cats with
mammary cancer. In this trial a heterologous prime:boost strategy
targeting tumour antigens will be tested.
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ROLE OF MONOCYTE RECRUITMENT IN
HEMANGIOSARCOMA METASTASIS IN DOGS (VCS
AWARD WINNER). Daniel Regan1, Andrea Escaﬃ1, Jonathan
Coy1, Jade Kurihara1, Steven Dow1. 1Department of Clinical
Sciences, Flint Animal Cancer Center, Colorado State University,
Fort Collins, CO, USA
Introduction: Canine hemangiosarcoma is a highly malignant
tumor, which is associated with poor long-term survival due to the
development of early and widespread metastatic disease. Currently,
little is known regarding the biology of canine hemangiosarcoma,
and the mechanisms accounting for the highly metastatic nature of
the tumor are poorly understood. In humans and rodents, mono-
cytes have been shown to play key roles in metastasis through pro-
motion of tumor cell extravasation, seeding, growth, and
angiogenesis, as well as suppression of anti-tumor immunity. How-
ever, there has been little investigation into the role of monocytes
in canine tumor metastasis. Therefore, we investigated the poten-
tial role of monocyte inﬁltration in the regulation of tumor metas-
tasis in dogs.
Methods: To address this question, we initially performed
immunohistochemistry for CD18 to determine the degree of mono-
cyte inﬁltration in necropsy samples obtained from several com-
mon metastatic tumors of dogs, including hemangiosarcoma,
osteosarcoma, and various carcinomas.
Results: We found that compared to other tumor types, heman-
giosarcoma metastases had signiﬁcantly greater inﬁltration of
CD18+ monocytes. Next, migration assays were used to compare
the ability of tumor cell lines to stimulate monocyte migration
in vitro. Hemangiosarcoma cell lines were among the strongest at
stimulating monocyte migration, and were also found to be the
highest producers of the monocyte chemoattractant CCL2. In addi-
tion, hemangiosarcoma metastases in vivo were found to produce
large amounts of CCL2, compared to other tumor metastases.
Conclusion: These results are consistent therefore with the
hypothesis that overexpression of CCL2 and recruitment of large
numbers of monocytes may explain in part the aggressive metastatic
nature of canine hemangiosarcoma. Moreover, these ﬁndings suggest
that immunotherapeutic interventions designed to block monocyte
recruitment or mobilization may be an eﬀective adjuvant strategy for
suppressing tumor metastasis in dogs with hemangiosarcoma.
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PHASE I CLINICAL TRIAL OF THE TARGETED
CHEMOTHERAPEUTIC DRUG, FOLATE-TUBULYSIN, IN
DOGS WITH URINARY TRACT TRANSITIONAL CELL
CARCINOMA (VCS AWARD WINNER). Nicholas Szigetvari1,
Deepika Dhawan1, Jose A. Ramos-Vara1, Christopher P. Leamon2,
Patrick J. Klein2, Hock Gan Heng1, Iontcho R. Vlahov2, Philip S.
Low2, Lindsey M. Fourez1, Deborah W. Knapp1. 1Purdue
University College of Veterinary Medicine, West Lafayette, IN,
USA, 2Purdue University College of Chemistry, West Lafayette, IN,
USA
Introduction: Targeted chemotherapy can include repurposing
drugs previously considered clinically irrelevant due to marked
toxicity and low therapeutic index. Tubulysin is one such drug
with compelling antiproliferative activity in vitro, but poor tolera-
bility in vivo. High aﬃnity folate receptor (FR) expression has pre-
viously been found in canine transitional cell carcinoma (TCC)
and serve as a druggable target. A phase I clinical trial of Folate-
Tubulysin was conducted in dogs with urinary tract TCC.
Methods: With PACUC approval, eligible dogs were enrolled in
a 3 + 3 dose escalating cohort study of Folate-Tubulysin (Endocyte,
West Lafayette, IN). Inclusion criteria were histologic diagnosis of
TCC, presence of FRs on the TCC cells detected by immunohisto-
chemistry and/or folate uptake in the TCC detected by nuclear
scintigraphy, and informed pet owner consent. The initial dose was
0.2 mg/kg given intravenously every two weeks, with intra- and
inter-cohort escalation by 0.02 mg/kg after at least two consecutive
treatments. Escalation continued until dose limiting toxicity (DLT)
was observed and the maximum tolerated dose (MTD) determined.
Results: Eleven dogs were enrolled to obtain the maximum tol-
erated dose (MTD). A total of twenty seven dogs were enrolled to
further investigate toxicity and tumor response. The Folate-Tubu-
lysin MTD was 0.26 mg/kg administered every two weeks. The
most common DLTs were neutropenia, anorexia, and/or lethargy.
Resolution of side eﬀects occurred with minimal supportive care
and in some dogs treatment delay. Early categorical tumor
responses have included 3 partial remissions, 16 stable disease, 8
progressive disease.
Conclusion: Folate-Tubulysin was generally well tolerated when
given at or below the MTD. Conjugation of Tubulysin to folate
allows use of this compound that otherwise would not be possible
due to toxicity.
This work was supported by the Animal Cancer Foundation and
Endocyte.
EN01
GLUCOSE HOMEOSTASIS DETERIORATES MORE
RAPIDLY WITH AGE IN BURMESE CATS COMPARED TO
NON-BURMESE. Margareth Rose Lederer1, Jacquie Rand2,
Nubia Lopes2, John Morton3, Nick Jonsson1. 1University of Glas-
gow, Glasgow, Scotland, UK, 2University of Queensland, Gatton,
Qld, Australia, 3Jemora Pty Ltd., Geelong, Vic., Australia
Burmese cats are predisposed to diabetes mellitus in Australia,
New Zealand and United Kingdom, and the disease is 3 to 4 times
more prevalent in this breed compared to domestic cats. Mecha-
nisms predisposing Burmese cats to diabetes remain unclear. This
study compared hormonal and biochemical variables associated
with glucose and lipid metabolism between mixed-age, lean to
overweight, clinically healthy Burmese and non-Burmese cats. Bur-
mese cats older than 3.5 years had higher fasting glucose com-
pared to non-Burmese (P = 0.02), with 1.3 mmol/L higher at
3.5 years and 3.5 mmol/L higher at 10 years of age (P < 0.001),
but not at 2 years of age. Mean and 2-hr glucose concentrations
during a glucose tolerance test were higher in Burmese than non-
Burmese cats (P < 0.006 to 0.031), indicating relative glucose intol-
erance. Lean Burmese cats had 4.8 lU/mL higher fasting insulin
concentrations than non-Burmese, suggesting they are insulin resis-
tant (P = 0.031). At time 10 minutes during the GTT, Burmese
cats had lower insulin concentration compared to non-Burmese,
but were higher at 120 minutes (P = 0.066 and P = 0.046). This is
consistent with diminished ﬁrst phase, and increased and
prolonged second phase insulin release, a pattern of insulin
secretion described in prediabetic, diabetic, obese humans and obese
cats. Fasting triglyceride concentration was 0.2 mmol/L higher
(P = 0.015) and fasting NEFA concentration was 0.18 mmol/L
higher (P = 0.016) in Burmese compared to non-Burmese. These
results demonstrate that Burmese cats have more rapid deterioration
of b-cell function with age, and impaired glucose homeostasis and
lipid metabolism occur concurrently in these cats.
EN02
PERTURBATIONS IN SERUM FRUCTOSAMINE LEVEL IN
DIABETIC HYPERTHYROID CATS – A RETROSPECTIVE
STUDY. Arnon Gal1, Brie Trusiano2, Adrienne French3, Nicolas
Lopez-Villalobos1, Amy MacNeill2. 1Institute of Veterinary,
Animal and Biomedical Sciences, Palmerston North, New Zealand,
2Colorado State University, Ft. Collins, USA, 3New Zealand
Veterinary Pathology, Palmerston North, New Zealand
Previous studies indicated that serum fructosamine level is
decreased in hyperthyroid cats; however, its clinical utility in dia-
betic hyperthyroid cats was not reported. We hypothesized that
hyperthyroidism in diabetic cats will result in a clinically signiﬁ-
cant decrease in serum fructosamine level compared to euthyroid
diabetic cats. Data of serum total thyroxine (TT4) and fruc-
tosamine of hyperthyroid/euthyroid diabetic/nondiabetic cats from
the New Zealand Veterinary Pathology and Colorado State
University were retrieved and statistically analyzed. Serum fruc-
tosamine was signiﬁcantly lower in hyperthyroid diabetic than
euthyroid diabetic cats (mean 332 µmol/L 95% CI 291–379,
n = 18 versus mean 527 µmol/L 95% CI 515–553, n = 186) while
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not diﬀerent between hyperthyroid diabetic and euthyroid nondia-
betic cats (mean 332 µmol/L 95% CI 291–379, n = 18 versus mean
321 µmol/L 95% CI 296–345, n = 128). There was a signiﬁcant
negative correlation between serum TT4 concentration and serum
fructosamine and glucose concentrations (n = 659, P < 0.01, and
n = 297, P < 0.01, respectively). Hyperthyroid cats (diabetic or
not) had signiﬁcantly (P < 0.05) lower serum glucose than euthy-
roid cats (diabetic or not). Diabetes and random variability
accounted for 49.7% and 45.4% of the change in serum
fructosamine; whereas, age (3.1%) and population (1.8%) had
minimal impact on serum fructosamine. In conclusion, in the
current study, serum fructosamine concentration was signiﬁcantly
decreased in diabetic hyperthyroid cats and was similar to the
fructosamine concentration in euthyroid nondiabetic cats. In addi-
tion, approximately 45% of the change in serum fructosamine was
independent of diabetes. Future studies should be undertaken to
explore speciﬁc factors that have an impact on fructosamine level.
EN03
PHARMACODYNAMIC AND PHARMACOKINETIC
PROPERTIES OF INSULIN ASPART FOLLOWING
SUBCUTANEOUS AND INTRAMUSCULAR INJECTION IN
CATS. Hannah Pipe-Martin1, Jon Fletcher1, Chen Gilor2, Michael
Kearney3. 1Department of Veterinary Clinical Sciences, School of
Veterinary Medicine, Louisiana State University, Baton Rouge,
LA, USA, 2Department of Veterinary Clinical Sciences, College of
Veterinary Medicine, The Ohio State University, Columbus, OH,
USA, 3Department of Pathobiological Sciences, School of Veteri-
nary Medicine, Louisiana State University, Baton Rouge, LA,
USA
Insulin aspart (Aspart) is a rapid-acting insulin analog that has
been shown to be an eﬀective treatment for diabetic ketoacidosis
(DKA) when administered by intermittent subcutaneous (SC)
injection in humans. In cats, rapid-acting insulin analogs have not
yet been evaluated, and the most commonly used protocols for
DKA involve delivery of regular insulin via constant intravenous
infusion, which can be technically challenging. The aim of this
study was to determine the pharmacodynamics (PD) and pharma-
cokinetics (PK) of Aspart following SC and intramuscular (IM)
injections in healthy cats.
Using the isoglycemic clamp method, time-action proﬁles were
generated in eight healthy cats to determine pharmacodynamics of
Aspart following SC and IM injection. Pharmacokinetics were
determined by measuring the plasma Aspart concentration every
15 minutes during the clamp using the Mercodia Iso-insulin
ELISA kit.
Mean  SEM time to onset of action and duration of action
did not diﬀer signiﬁcantly between SC (11.12  0.97 minutes and
154  14.8 minutes) and IM injection (13.75  3.1 minutes and
176  19.8 minutes), and both methods of administration resulted
in acceptable plasma concentrations and blood glucose lowering
eﬀect. Subcutaneous injection resulted in greater plasma Aspart
concentration at 15 and 30 minutes and greater peak concentra-
tions when compared to IM injection (P < 0.0001 and P = 0.0005
respectively).
Aspart is rapidly absorbed following SC and IM injection in
healthy cats. The eﬀective and predictable glucose lowering eﬀect
of insulin aspart may be advantageous in the treatment of DKA
in cats.
EN04
THE EFFECT OF TETRA-HYDROXYLATED BILE ACID ON
ADIPOCYTE SIZE AND INSULIN SENSITIVITY IN
HEALTHY CATS. Isabelle Rast1, Elena Salesov1, Thomas Lutz2,
Eric Zini1, Christian Wolfrum3, Claudia Reusch1. 1Clinic for Small
Animal Internal Medicine, Vetsuisse Faculty, University of Zurich,
Zurich, Switzerland, 2Institute of Veterinary Physiology, Vetsuisse
Faculty, University of Zurich, Zurich, Switzerland, 3Laboratory of
Translational Nutrition Biology, Swiss Federal Institute of Tech-
nology Zurich, Schwerzenbach, Switzerland
Obesity is a major risk factor for the development of diabetes in
cats. Recently, retinoid-related orphan receptor gamma (RORc)
has been identiﬁed as an important transcription factor in the
development of large insulin-resistant adipocytes. RORc can be
inhibited by its ligand tetra-hydroxylated bile acid (THBA). Oral
supplementation of THBA reduces adipocyte size, improves insulin
sensitivity and prevents hyperglycemia in obese mice. The purposes
of this study were to investigate palatability and possible side
eﬀects of THBA, and the eﬀects of THBA supplementation on
adipocyte size and insulin sensitivity in healthy cats.
Six healthy purpose-bred cats were fed 5 mg/kg/day of THBA
for 8 weeks. THBA was given in a small amount of food to each
cat individually before the daily ration was oﬀered. Complete
blood count, biochemical proﬁle and insulin tolerance test (ITT;
0.1 IU/kg insulin aspart IV) were performed at weeks 0 and 8.
After 12–18 hours of fasting blood glucose concentration was
recorded and the rate constant for the disappearance of glucose
(KITT) was calculated. Subcutaneous fat tissue samples were taken
in the umbilical area by a 4 mm biopsy punch, and adipocyte size
was determined by histological and image based analysis of at
least 10 sections per animal. Data were analyzed by parametric
tests (P < 0.05).
Oral supplementation of THBA was well accepted in all cats,
and no side eﬀects were noted. None of the cats displayed abnor-
malities on complete blood count and serum biochemical proﬁle.
Fasting blood glucose concentration and average size of white sub-
cutaneous adipocytes were signiﬁcantly lower after 8 weeks of
THBA administration, whereas KITT did not diﬀer.
The reduction of adipocyte size in response to THBA treatment
is in accordance with data from mice and underscores the possible
role of RORc signaling in the control of adipose tissue metabo-
lism. While we observed a signiﬁcant reduction in fasting glucose,
overall insulin sensitivity did not improve. These ﬁndings might be
explained by the fact that insulin sensitivity in normal weight sub-
jects is mainly determined by liver and muscle cell function, while
altered adipocyte size would not contribute signiﬁcantly to the
ITT. Future studies in obese cats and altered dosing regimes are
required to assess whether THBA improves insulin resistance in
cats, in addition to direct eﬀects on adipocyte size.
EN05
THE EFFECT OF ADIPOSITY AND DIET ON SECRETION
OF INCRETIN HORMONES IN CATS. Chen Gilor, Katie
McCool, Adam Rudinsky, Valerie Parker, Prosper Boyaka. The
Ohio State University, Columbus, OH, USA
Degree of adiposity and dietary macronutrient composition
aﬀect the secretion of incretin hormones but little is known about
their eﬀect in cats.
In this study, 8 overweight cats were fed a maintenance diet
(MD) for 3 weeks followed by a weight control diet (WCD, lower
fat, higher in carbohydrates and ﬁber). Cats were fed ad libitum
initially and then food was restricted to achieve 1–2% loss of body
weight weekly (11 weeks). When lean, cats were fed MD for 2
additional weeks. A standardized meal test (SMT) using a third
diet was performed after at least 7 days on each diet, before and
after weight loss (4 SMT’s total). Glucose, insulin, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP) concentrations were measured immediately before and over
6 hours after feeding the SMT. Area under the concentrations
curve (AUC) was compared using non-parametric tests.
Glucose, insulin and GLP-1 concentrations did not diﬀer
between SMT’s at the 4 time points. Fasting GIP concentrations
also did not diﬀer but post-prandial GIP secretion was aﬀected by
degree of adiposity (P = 0.025) with a trend towards an eﬀect of
diet (P = 0.085). GIP secretion in lean cats fed WCD was higher
than in obese fed MD (P = 0.0062).
In conclusion, compared to the overweight state, GIP secretion
was increased in cats in response to SMT in the lean state.
On-going exposure to WCD increased GIP responses to SMT,
suggesting that dietary macronutrient content is important in
determining GIP responses not only acutely but also on a long-
term basis.
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BREED, COAT COLOUR AND HAIR LENGTH AS RISK
FACTORS FOR FELINE HYPERTHYROIDISM. Victoria J.
Crossley, Yu-Mei Chang, Robert C. Fowkes, Jonathan Elliott,
Harriet M. Syme. Royal Veterinary College, London, UK
Hyperthyroidism commonly aﬀects geriatric cats, but its aetiol-
ogy is poorly understood. Previous studies have shown Siamese,
Himalayan and Burmese cats to have reduced risk of developing
hyperthyroidism. These breeds have colourpoint coats as a result
of temperature-sensitive mutations in the tyrosinase gene, which
limit conversion of tyrosine to melanin pigment. Tyrosine is essen-
tial for synthesis of both melanin and thyroid hormones and, as
such, coat pigmentation may impact relative tyrosine availability
for thyroid hormone production. This study aimed to identify
potential associations between coat phenotype and development of
hyperthyroidism, by investigation of breed, coat colour and hair
length as risk factors for feline hyperthyroidism.
This retrospective study of cats aged ≥10 years, referred to a
single UK veterinary teaching hospital (2006–2014), used elec-
tronic patient records to obtain owner-reported data regarding
breed, coat colour, age and sex, and clinical data to classify cats
as hyperthyroid/euthyroid. Bayesian multivariable logistic regres-
sion was used to evaluate breed, age and sex as risk factors for
hyperthyroid status in all the cats (purebred and non-purebred).
To avoid interactions with coat length or colour in purebreds, the
eﬀect of coat colour/pattern, colour dilution, base pigment, white
markings and hair length were assessed only in non-purebred cats
in a separate analysis. Variables with P < 0.2 in univariate analy-
ses were evaluated in multivariable models, with ﬁnal variables sig-
niﬁcant at P ≤ 0.05. Risk factors are quantiﬁed as odds ratio
((OR) P-value).
Of 3934 cats included in the ﬁnal analysis, 885 were hyperthy-
roid and 3049 euthyroid. Multivariable results showed Burmese
(OR 0.01, P = 0.005), Persians (OR 0.20, P < 0.001), Siamese (OR
0.32, P = 0.006), Abyssinians (OR 0.04, P = 0.035) and British
shorthairs (OR 0.52, P = 0.014) had reduced risk of hyperthy-
roidism compared to domestic shorthairs. Domestic longhairs (OR
1.34, P = 0.015) showed increased risk of hyperthyroidism com-
pared to domestic shorthairs, but coat colour, colour dilution,
base pigment and white markings did not have a signiﬁcant eﬀect.
Overall, females (OR 1.39, P < 0.001) had increased risk of hyper-
thyroidism compared to males, and, compared to 10 year olds,
increased risk was found in cats aged 11–12 years (OR 1.45,
P = 0.007), 13–14 years (1.83, P < 0.001) and 15–17 years (OR
1.50, P = 0.004).
To authors’ knowledge this is the ﬁrst study to report increased
risk of hyperthyroidism in long haired, non-purebred, domestic
cats. Consistent with a number of previous studies, increased risk
of hyperthyroidism was found with increased age and female sex,
and reduced risk in Burmese, Siamese and Persian breeds. How-
ever, this study also newly identiﬁed two further purebreds, Abys-
sinian and British shorthair, at reduced risk of hyperthyroidism,
neither of which were exclusively colourpoint. Coat colouration
was not found to be associated with risk of hyperthyroidism in the
analysis of domestic cats, however, reliance on secondary data
may have resulted in misclassiﬁcation errors and coat phenotype
may be a poor surrogate marker for melanin concentrations. Fur-
ther studies are required to evaluate tyrosine availability as a
potential factor in the aetiology of feline hyperthyroidism, and to
investigate the apparent protective eﬀect in certain purebreds and
associations between hyperthyroidism and hair length.
EN07
DOES A LIMITED IODINE DIET AFFECT THE RESPONSE
TO RADIOACTIVE IODINE THERAPY IN HYPERTHYROID
CATS?. Allison Rowland, Karyn Harrell, Katharine Lunn. North
Carolina State University, Raleigh, NC, USA
A retrospective study was performed to determine the outcome
of radioactive iodine (131-I) therapy in cats previously treated with
a limited iodine diet (Hill’s Prescription Diet y/d).
Medical records were searched for cats receiving 131-I therapy
after documented feeding of the prescription diet for at least
14 days. Cats were excluded if the prescription diet had been
supplemented with other foods, or if methimazole had been
administered concurrently with, or subsequent to, the prescription
diet. Owners were contacted directly to provide missing dietary
information.
Nine cats fulﬁlled the study criteria. The prescription diet was
fed for a median of 91 days (range: 19–371). The interval between
discontinuing the diet and administering 131-I was 0 days in 3
cats, 4–5 days in 3 cats and 16–24 days in 3 cats. Highest serum
total thyroxine (T4) without therapy was used in calculating 131-I
dose; median highest T4 was 10.3 mcg/dl (range: 4.3–23.8 mcg/dl;
reference range: 0.78–4.27 mcg/dl). The median dose of 131-I
administered was 3.64 mCi (range: 3.06–5.26 mCi). The cats were
initially evaluated 22–57 days after 131-I therapy and hyperthy-
roidism had resolved in all 9 cats, with a median post-therapy
total T4 of 1.3 mcg/dl (range: 0.5–1.8 mcg/dl). Total T4 was below
the reference range in 2 cats (0.5 and 0.55 mcg/dl) at the initial
post-therapy evaluation, but was normal 22 and 34 days later (0.9
and 1.6 mcg/dl respectively).
In this small group of cats, pre-treatment with a limited iodine
diet did not adversely aﬀect the response to 131-I therapy.
EN08
EFFECTS OF LEVOTHYROXINE ADMINSTRATION AND
WITHDRAWAL ON THE HYPOTHALAMIC-PITUITARY-
THYROID AXIS IN EUTHYROID DOGS. Vincent Ziglioli,
David Panciera, Edward Monroe, Gregory Troy, Katie Boes. Vir-
ginia Maryland College of Veterinary Medicine, Blacksburg, VA,
USA
Many dogs are misdiagnosed with hypothyroidism because of
the vague presenting signs and limitations of thyroid function
tests, leading to inappropriate treatment with levothyroxine. Dur-
ing chronic supplementation, the hypothalamic-pituitary-thyroid
axis (HPTA) is suppressed and may make it diﬃcult to accurately
determine thyroid function following withdrawal of levothyroxine.
We sought to determine if the HPTA is suppressed following
levothyroxine administration in euthyroid dogs and the time
required for resolution of any suppression. We hypothesized that
levothyroxine administration would suppress the HPTA in euthy-
roid dogs and that the HPTA would recover within 8 weeks in all
dogs, regardless of the duration of treatment.
Twenty-eight healthy euthyroid dogs were administered levothy-
roxine (mean dose 0.024 mg/kg every 24 hours) for either 8 weeks
(Group 1) or 16 weeks (Group 2). The dose of levothyroxine was
adjusted weekly until a target total thyroxine (T4) serum concen-
tration of 40–70 nmol/L was obtained 4–6 hours post pill. Serum
concentrations of T4, free thyroxine (fT4) by equilibrium dialysis,
thyrotropin (TSH), and 3,5,30-triiodothyronine (T3) were measured
every 4 weeks during supplementation and for 4 months after
levothyroxine was discontinued. A mixed model ANOVA followed
by Tukey’s procedure for multiple comparisons was used to com-
pare thyroid function tests both within and between groups. The
level of signiﬁcance was set at <0.05.
Mean serum concentrations of T4 and fT4 were signiﬁcantly
higher and TSH was signiﬁcantly lower during levothyroxine
administration compared to baseline in both groups. Mean serum
concentrations of T4, fT4 and TSH beginning 1 week after levothy-
roxine was discontinued were signiﬁcantly diﬀerent compared to
values during levothyroxine administration but not compared to
baseline values. When groups 1 and 2 were compared, there was
no diﬀerence in mean T4, fT4, and T3 concentrations between
groups during or after levothyroxine supplementation. Suppression
of the HPTA occurred during levothyroxine supplementation, with
mean serum T4, fT4 and TSH concentrations returning to the ref-
erence interval by 1 week after discontinuation in both groups. It
appears that assessing thyroid function tests 1 week after long-
term levothyroxine supplementation may reliably establish dogs as
being euthyroid.
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VARIABILITY OF P450SCC AUTOANTIBODY PERSISTENCE
IN DOGS AFFECTED WITH HYPOADRENOCORTICISM.
Alisdair Boag1, Michael Christie2, Kerry McLaughlin3, Peter
Graham4, Harriet Syme5, Brian Catchpole5. 1Royal (Dick) School
of Veterinary Studies, Edinburgh, UK, 2University of Lincoln,
Lincoln, UK, 3King’s College, London, UK, 4University of
Nottingham, Nottingham, UK, 5Royal Veterinary College,
London, UK
Autoantibodies directed against the P450 side chain cleavage
enzyme (P450scc) have been recently described in a proportion of
dogs aﬀected with hypoadrenocorticism, consistent with an
immune-mediated disease process. In humans aﬀected with Addi-
son’s disease, autoantibodies can have a predictive value, being
detected prior to clinical signs developing, and have been shown
to persist post-diagnosis. Furthermore, an autoantibody positive
status post-diagnosis has been associated with successful remission
of Addison’s disease following B-cell depletion with rituximab,
suggesting active pathology in these cases.
The current study explored changes in serum P450scc autoanti-
body status over time in dogs diagnosed with spontaneous
hypoadrenocorticism. P450scc autoantibodies were measured by
radioimmunoassay in an initial cohort of 213 dogs, indicating a
prevalence of 24%. Thirty two of these dogs had repeat samples
(n = 80 in total) available for analysis. Between two and six sam-
ples were available for each dog, obtained between two and
787 days apart.
Five dogs were consistently autoantibody positive in all sam-
ples, up to 425 days between sampling times, these comprised one
male and four female dogs, with three crossbreeds, a Dogo
Argentino and an English springer spaniel. Three dogs were ini-
tially autoantibody positive, then became negative at later time
points, a 3 y 11 month old male entire bull terrier, a 4 y 5 month
old female neutered beagle and a 2 y female entire crossbreed
dog. One dog, a 1 y 8 month old female entire standard poodle,
initially negative for P450scc autoantibodies, seroconverted 18
months after diagnosis. The remaining 23 dogs with multiple sam-
ples available were consistently autoantibody negative. Persistence
was not associated with sex (P = 0.673).
This study demonstrates persistence of P450scc autoantibodies
in a subset of dogs aﬀected with hypoadrenocorticism and sero-
conversion over one year post-diagnosis. Whilst P450scc autoanti-
body positivity has been associated with sex, with females having
a higher prevalence, there was no sex diﬀerence in persistence
demonstrated. P450scc expression in the ovary may act as an addi-
tional source of antigenic stimulation in female dogs, explaining
the later seroconversion observed in one individual. However, par-
alleling humans with Addison’s disease, antibody persistence in
dogs with hypoadrenocorticism might represent persistent pathol-
ogy, due to residual antigenic stimulation and autoimmune inﬂam-
mation in the adrenal gland.
EN10
JUVENILE HYPOADRENOCORTICISM IN THE NOVA
SCOTIA DUCK TOLLING RETRIEVER: A RECESSIVE
MONOGENIC AUTOIMMUNE DISEASE. Emily Brown1, Amy
Young2, Zena Wolf3, Claire Wade4, Angela Hughes5, Oded
Foreman6, Kartika Jayashankar1, Anita Oberbauer2, Noa Safra1,
Kirstin Linblad-Toh7, Shelley Burton8, Danika Bannasch1.
1University of California, Davis School of Veterinary Medicine,
Davis, CA, USA, 2University of California, Davis, Davis, CA,
USA, 3Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA, USA, 4University of Sydney, Sydney, NSW,
Australia, 5Mars Veterinary, Germantown, MD, USA, 6Genen-
tech, Inc., South San Francisco, CA, USA, 7Broad Institute of
Harvard and Massachusetts Institute of Technology, Cambridge,
MA, USA, 8Atlantic Veterinary College, University of Prince
Edward Island, Charlottetown, PE, Canada
While hypoadrenocorticism, or Addison’s disease, can occur in
a dog of any breed at any age, certain breeds, including Nova Sco-
tia Duck Tolling Retrievers (NSDTRs), have an increased inci-
dence of the disease. Speciﬁcally in the NSDTR, there appears to
be at least two forms of Addison’s disease in the breed: a juvenile
onset form (JADD) occurring in dogs under 1 year of age, and an
adult onset form occurring in dogs at 4.5 years of age on average.
JADD diﬀers from adult onset Addison’s disease, as it can be a
multisystemic illness and appears to involve an autoimmune com-
ponent. This is supported by the identiﬁcation of a CD3+ T cell
inﬁltrate in histologic sections of a JADD aﬀected adrenal gland
sample and that many cases are often aﬀected with other autoim-
mune diseases, including immune-mediated hemolytic anemia and
thrombocytopenia, immune-mediated polyarthritis, and hypothy-
roidism. To identify a genetic basis of JADD, a genome-wide asso-
ciation study was performed using the Illumina Canine HD
173,000 SNP array with 14 NSDTRs diagnosed with Addison’s
disease less than 1 year of age and 33 healthy control NSDTRs
over 6 years of age. All cases were deﬁnitively diagnosed through
an adrenocorticotrophic hormone stimulation test. Genome-wide
association analysis identiﬁed a 1.7 Mb associated haplotype on
chromosome 27. Whole genome sequencing was performed on 2
NSDTRs with the associated haplotype, as well as 6 unaﬀected
NSDTRs and 11 other dogs from 5 diﬀerent breeds. Analysis of
variants yielded 5 segregating SNPs in the associated region: 1
intergenic, 2 intronic, 1 coding, and 1 in the 30 untranslated region
of a gene. The only coding variant, a missense mutation causing
an amino acid change from a proline to a leucine, occurs in a cur-
rently uncharacterized gene, but is predicted to be damaging and
deleterious based on sequence conservation. In summary,
genome-wide association and whole genome sequencing analysis has
identiﬁed a novel gene and mutation implicated in multi-organ
autoimmunity and juvenile onset Addison’s disease in the NSDTR.
EN11
VARIABILITY IN POST ACTH STIMULATION SERUM
CORTISOL FOLLOWING ADMINISTRATION OF CORTI-
SONE ACETATE IN HEALTHY DOGS. Arnon Gal, Karin
Weidgraaf, James Bowden, Nicolas Lopez-Villalobos, Nick Cave.
Institute of Veterinary, Animal and Biomedical Sciences, Massey
University, Palmerston North, New Zealand
The adrenocorticotropic hormone stimulation test (AST), often
used for the diagnosis of canine hyperadrenocorticism, has a wide
range of sensitivity and speciﬁcity. Thus, we hypothesized that stan-
dardized negative feedback on the hypothalamic-pituitary-adrenal-
axis will result in large variability in the post AST serum cortisol
concentrations. Therefore, this study aimed to evaluate the variabil-
ity in the post AST serum cortisol in healthy dogs and to statisti-
cally examine parameters that may inﬂuence cortisol responses.
Fourteen healthy Harrier Hound dogs (mean age 7.1y3.2;
mean body weight 26.5 kg2.7) were randomized by a Latin
square design to receive 5 treatments [placebo, 50 mg, 37.5 mg,
25 mg, and 12.5 mg of cortisone acetate (CA)] in each of the ﬁve
7-day treatment periods, which were separated by 14-day washout
periods. An AST was performed 24 hours after the last dose of
CA for each of the 5 treatments and serum cortisol was analyzed
by an electrochemiluminescence immunoassay.
A signiﬁcant dose dependent decrease in the mean (SEM) post
AST serum cortisol was observed (placebo 365  13 nmol/L, CA
12.5 mg 347  13 nmol/L, CA 25 mg 335  13 nmol/L, CA
37.5 mg 326  13 nmol/L, CA 50 mg 308  13 nmol/L). There
was a signiﬁcant (P < 0.05) between-week variability in post AST
serum cortisol in the placebo and 25 mg and 37.5 mg CA groups.
The overall variability in the post AST serum cortisol concentra-
tions was attributed to the individual dog (31%), random unex-
plained variability (31%), dose of CA (16%), age (15%), body
weight (4%), and timing of treatment (3%).
The wide range in the published speciﬁcity of the AST may be
related to large variations in cortisol responses.
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EN12
IONIZED HYPERCALCEMIA IN CATS: ETIOLOGIES AND
ASSOCIATED CLINICAL SIGNS. Muzzammil Sayyid, Chen
Gilor, Valerie Parker, Adam Rudinsky, Dennis Chew. The Ohio
State University, Columbus, OH, USA
The etiologies, concurrent diseases, and clinical signs associated
with hypercalcemia in cats have been reported in the past based
only on measurement of total calcium and excluding cases of idio-
pathic hypercalcemia (IHC). Here we report on the relative fre-
quency of various diagnoses and concurrent clinical signs
associated with ionized hypercalcemia in cats. The medical records
of an academic institution that treats primary and secondary cases
was searched for cases treated between the years 2003–2013. Cases
were included if serum or plasma ionized calcium concentrations
were above the upper limit of the reference interval at least twice.
Cats were excluded if ionized hypercalcemia was not present on
follow-up examination or if a ﬁnal diagnosis was not made.
Sixty-nine cases were identiﬁed. The most common diagnoses
were IHC (48%) and chronic kidney disease (35%). Urolithiasis was
diagnosed in 14% (43% calcium oxalate), neoplasia in 13% (46%
lymphoma) and primary hyperparathyroidism in 3%. Other diag-
noses included hyperthyroidism (8%), hypertrophic cardiomyopathy
(4%), feline idiopathic cystitis (2%), and diabetes mellitus (2%). The
average age at diagnosis of hypercalcemia was 10.0  4.61 years.
Most common clinical signs reported in the IHC group versus other
diagnoses (in which clinical signs could be related to the primary dis-
ease, and not necessarily to hypercalcemia), were anorexia (21.7%
versus 31.9%), vomiting (14.5% versus 26.1%), lethargy (10.1% ver-
sus 7.2%), and constipation (10.1% versus 1.4%).
In conclusion, ionized hypercalcemia in cats is frequently idio-
pathic. The association between feline ionized hypercalcemia and
its etiologies and clinical signs should be further explored in case-
controlled studies.
EN13
EVALUATION OF BASAL CORTISOL CONCENTRATIONS
FOR THE DIAGNOSIS OF HYPOADRENOCORTICISM IN
DOGS. Ashley Gold, Joe Hauptman, Daniel Langlois. College of
Veterinary Medicine, Michigan State University, East Lansing,
MI, USA
Canine hypoadrenocorticism is a potentially life-threatening
endocrine disorder characterized by glucocorticoid deﬁciency, with
or without concurrent mineralocorticoid deﬁciency. The current
standard for diagnosing hypoadrenocorticism is the ACTH stimula-
tion test, but a simpler and less expensive test with similar accuracy
would be desirable. Previous studies regarding the diagnostic utility
of basal plasma or serum cortisol concentrations are limited by low
numbers of aﬀected dogs, and receiver operating characteristics
(ROC) methods were not utilized to identify optimal cut-oﬀ points.
The purpose of our study was to evaluate the diagnostic utility of
basal cortisol concentrations for the diagnosis of hypoadrenocorti-
cism in a large number of dogs by constructing an ROC curve to
identify optimal cut-oﬀs for sensitivity and speciﬁcity. Furthermore,
the diagnostic utility was evaluated in two sub-populations of dogs:
those with electrolyte abnormalities (Na:K ratio ≤28) and those
without electrolyte abnormalities (Na:K ratio >28).
Medical records for dogs in which an ACTH stimulation test
had been performed for a clinical suspicion of hypoadrenocorti-
cism between 2005 and 2015 were retrospectively reviewed. Dogs
that had received treatment for hyperadrenocorticism or recent
glucocorticoid therapy were excluded. Five hundred and fourteen
dogs met inclusion criteria, including 163 dogs with hypoadreno-
corticism (post-ACTH stimulated cortisol concentration ≤55 nmol/
L). An ROC curve was constructed for basal cortisol concentra-
tions using commercially available software. The area under the
ROC curve was 0.991. The ROC curves were nearly identical when
evaluating dogs with and without electrolyte abnormalities. Accu-
racy was optimal at 22 nmol/L, which provided a sensitivity and
speciﬁcity of 96.9% and 95.7%, respectively. At cut-oﬀs of
55 nmol/L and 4 nmol/L, sensitivity and speciﬁcity were 99.4%
and 99.7%, respectively. Using a previously estimated prevalence
of 15%, cut points of 55 nmol/L and 4 nmol/L resulted in nega-
tive and positive predictive values of 99.8% and 97.9%,
respectively. Even at lower prevalence rates, positive predictive val-
ues remained high at low cut points. Results of this study reaﬃrm
the high sensitivity and negative predictive value of basal cortisol
concentrations for the diagnosis of hypoadrenocorticism. However,
the high speciﬁcity and positive predictive values at low cut points
could be of major importance for veterinary practitioners.
Prospective studies are needed to further substantiate these
ﬁndings.
EN14
THYROID PROFILES IN HEALTHY KITTENS AGED TWO
TO SIXTEEN WEEKS OF AGE. Christina Marino, Margret
Casal. University of Pennsylvania, Matthew J. Ryan Veterinary
Hospital, Philadelphia, PA, USA
Congenital hypothyroidism (CH) is associated with signiﬁcant
morbidity and mortality in pediatric felines. Thyroid hormones
(TH) are essential for normal development of the nervous and
skeletal systems. The paucity of information on TH levels and the
inability to identify early histopathologic changes has led to CH
underdiagnosis. The literature on TH levels in kittens is sparse
and incongruent, comprised of mostly case reports. References
state kitten total thyroxine (TT4) levels are 2 to 3 times higher
than the adult cat TT4 level. They also make the assumption free
thyroxine (fT4) levels are higher than the adult cat. An abstract
was previously presented showing kitten TH levels did not exceed
the adult cat normals. These values were measured with assays
that are no longer used. The normal pediatric TH levels must be
evaluated with the newer and currently available assays. The
purpose of this study was to determine the TT4, fT4, total
tri-idiothyronine (T3), free tri-idiothyronine (fT3) and thyroid
stimulating hormone (TSH) levels in healthy kittens aged 2
through 16 weeks measuring levels at weekly intervals using the
current available diagnostic methods.
Normal, healthy kittens from a research colony in an approved
facility at the University of Pennsylvania, School of Veterinary
Medicine were used. One half to one milliliter of whole blood
based on body weight was drawn by jugular venipuncture each
week. Serum was immediately obtained and frozen until analysis.
The samples were submitted to the Michigan State University
Diagnostic Laboratory for Animal and Population Health. All TH
measurements were performed on serum. The TSH was measured
using a canine chemiluminescent assay. The TT4, TT3 and fT3
were measured with radioimmunoassays and the fT4 was mea-
sured using equilibrium dialysis. All assays have been previously
validated in cats.
Samples were collected at the same time in the morning at
weekly intervals. All values are reported as the mean. The TT4
was initially above the adult cat reference range (ACRR;
10–47 nmol/L) at 2 weeks and peaked at 6 weeks (50.9 nmol/L
and 64.6 nmol/L, respectively). The TT4 returned to within the
ACRR at 8 weeks, was elevated again at 10 weeks (50.0 nmol/L),
returned within the ACRR at 13 weeks and remained stable
through 16 weeks. The fT4 remained within the ACRR
(10–53 pmol/L) through all 16 weeks, but showed a similar peak
at 6 and 10 weeks (50 pmol/L and 39.8 pmol/L, respectively). The
TSH was within the ACRR (0–0.38 ng/mL) throughout the
16 weeks. The TSH remained stable at 0.16 ng/mL from 2 through
4 weeks, decreased within the ACRR at 8 weeks, peaked at
10 weeks (0.18 ng/mL) and then continuously decreased to
0.06 ng/mL at 16 weeks. The TT3 and fT3 remained within the
ACRR through all 16 weeks. Both hormones peaked at 6 weeks
and remained at that level through 16 weeks.
The TH levels in pediatric kittens were measured with the newer
assays and with the exception of TT4, all TH levels were within
the ACRR. The TT4 did not elevate more than twice the upper
limit of the ACRR at any time point and was consistently within
the ACRR after 12 weeks of age. A peak in TT4, fT4, TT3 and
fT3 was seen at 6 weeks and a peak in TT4 and fT4 was also seen
at 10 weeks. TSH levels using the canine TSH assay have been
validated for use in adult cats, but these values have not yet been
reported in kittens. The TSH levels remained within the ACRR
and it showed a similar peak at 10 weeks. These patterns likely
occur due to an increased growth and development at 6 and
10 weeks.
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SPECTROPHOTOMETRY AND ULTRACENTRIFUGATION
FOR MEASUREMENT OF PLASMA LIPIDS IN DOGS WITH
DIABETES MELLITUS. Eileen Seage, Kenneth Drobatz,
Rebecka Hess. Matthew J. Ryan Veterinary Hospital of the
University of Pennsylvania, Philadelphia, PA, USA
Conﬂicting results have been reported regarding lipid concentra-
tions in dogs with diabetes mellitus (DM). Some studies have
reported that low-density lipoprotein-cholesterol (LDL-C) is not
signiﬁcantly diﬀerent in dogs with and without DM. The goal of
this study was to report total cholesterol (TC), total triglycerides
(TG), high-density lipoprotein-cholesterol (HDL-C), very low-
density lipoprotein-cholesterol (VLDL-C), and LDL-C in fasted
dogs with and without DM.
Twenty-two dogs with DM and nine healthy control dogs with
normocholesterolemia were prospectively enrolled following a min-
imum eight-hour fast. Plasma lipid fractions were measured by
ultracentrifugation (TC, HDL-C, VLDL-C, and LDL-C) or direct
sample analysis (TG) coupled with enzymatic reactions and spec-
trophotometric end points (Roche COBAS c311). Median lipid
concentrations in dogs with and without DM were compared using
a two-sample Wilcoxon rank-sum test. A P-value <0.05 was con-
sidered signiﬁcant.
In dogs with DM, median TC (343 mg/dl), TG (98 mg/dl),
HDL-C (196 mg/dl), VLDL-C (39.5 mg/dl), and LDL-C (67.5 mg/
dl) concentrations were signiﬁcantly higher than concentrations in
healthy dogs (197 mg/dl, 57 mg/dl, 168 mg/dl, 12 mg/dl, 16 mg/dl,
respectively, P < .05 for all comparisons). The greatest diﬀerence
was measured in LDL-C concentration, which was 4.2 times
higher in dogs with DM compared to controls. VLDL-C, TC, and
TG concentrations were 3.3, 1.7, and 1.7 times higher, respectively,
in dogs with DM compared to healthy dogs. The smallest diﬀer-
ence was noted in HDL-C concentrations.
It is concluded that the increase in LDL-C is an important com-
ponent of dyslipidemia in dogs with DM. Future studies of thera-
peutics focused at decreasing LDL-C in dogs with DM may be
warranted.
EN16
EFFECT OF HYDROCORTISONE ADMINISTRATION ON
LEPTIN AND ADIPONECTIN SYNTHESIS IN HEALTHY
DOGS. Hye-Ryung Choo, Changhwan Ahn, Woon-Bum Baek,
Bohye Shin, Hakhyun Kim, Ji-Houn Kang, Eui-Bae Jeung, Mhan-
Pyo Yang. Chungbuk National University College of Veterinary
Medicine, Cheongju, Chungbuk, Republic of Korea
The objective of the present study was to examine whether cir-
culating concentrations of leptin and adiponectin, distribution of
abdominal fat, and mRNA expressions of leptin and adiponectin
in abdominal adipose tissue were aﬀected by hydrocortisone
administration. Six laboratory dogs each received hydrocortisone
(8.5 mg/kg) orally every 12 hours for 90 days. We measured the
serum concentrations of leptin and adiponectin using canine-
speciﬁc ELISA kits. We quantiﬁed visceral fat using CT scanning,
and we analyzed the mRNA expressions of leptin and adiponectin
in abdominal fat using real-time PCR.
Hydrocortisone administration resulted in increased abdominal
visceral fat mass on days 30, 60, and 90 compared with fat mass
before administration (day 0). Additionally, visceral fat area at
the L3 level also was increased during hydrocortisone administra-
tion. Serum leptin concentrations began to increase on day 1 of
hydrocortisone administration and were signiﬁcantly increased on
days 1, 3, 7, 30, 60, and 90 compared with concentrations on
day 0. Serum adiponectin concentrations on days 1, 3, 7, 30, 60,
and 90 were decreased compared with concentrations on day 0.
The mRNA expressions of leptin and adiponectin in the abdomi-
nal fat were increased on day 30 compared with expressions on
day 0, but the expressions were decreased on days 60 and 90
compared with those on day 30. We identiﬁed a correlation
between serum leptin and adiponectin concentrations and visceral
fat distribution. This study showed that hydrocortisone adminis-
tration aﬀected visceral fat distribution and serum concentrations
of leptin and adiponectin by dysregulating leptin and adiponectin
expression.
EN17
USING PURIFIED FELINE INSULIN TO EVALUATE
CROSS-REACTIVITY WITH A HUMAN INSULIN ANALOG
ELISA. Jon Fletcher, Hannah Pipe-Martin, Chin-chi Liu. Depart-
ment of Veterinary Clinical Sciences, School of Veterinary Medi-
cine, Louisiana State University, Baton Rouge, LA, USA
Recombinant DNA technology has been used to modify the
structure of human insulin to yield analogs that are more rapidly-
acting than regular insulin or have a longer duration of action
than NPH insulin. The long-acting insulin analogs have been stud-
ied in cats and are routinely used to manage feline diabetics. More
recently, the isoglycemic clamp method has been used to study the
metabolic eﬀect of a rapid-acting insulin analog in healthy cats.
Generating time-action proﬁles to study the pharmacodynamic
properties of insulin formulations does not require measurement
of plasma insulin concentrations, but if measured, they provide
useful pharmacokinetic data that can be used to validate the time-
action proﬁles. The Iso-Insulin ELISA (Mercodia AB, Uppsala,
Sweden) is used to measure the concentration of insulin analogs in
plasma. A previous study using actual feline serum samples with a
wide range of insulin concentrations measured by a commercial
ELISA failed to detect cross-reactivity of feline insulin with the
Iso-Insulin ELISA.
The purpose of this study was to evaluate the cross-reactivity of
feline insulin with the Iso-Insulin ELISA using puriﬁed feline insu-
lin standards. Five puriﬁed feline insulin standards with known
concentrations ranging from 9.13 ng/L to 702 ng/L that are used
as calibrators for the commercial feline insulin ELISA (Mercodia
AB, Uppsala, Sweden) were used. The ELISAs were performed in
duplicate according to the manufacturer’s recommendations. The
mean absorbance values of the feline insulin ELISA calibrators
were below the mean absorbance value of the lowest Iso-Insulin
calibrator (0.087) except for the ﬁrst calibrator, which had a
slightly higher mean absorbance of 0.099. The slightly higher
absorbance for the ﬁrst calibrator was likely the result of a minor
technical issue with this very sensitive ELISA since all calibrators
with higher insulin concentrations consistently had absorbances at
or below the lowest Iso-insulin calibrator.
These results demonstrate that puriﬁed feline insulin concentra-
tions up to 702 ng/L are not detected by the Iso-Insulin ELISA,
and therefore will not interfere with insulin analog measurements
in feline plasma.
EN18
STEROID HORMONE PANEL TEST AND TRILOSTANE
AND MELATONIN THERAPY IN POMERANIAN DOGS
WITH ALOPECIA X. Melissa Sanches1, Marcia Jerico2, Eric
Januario1. 1Pet Care Centro Veterinario, Sao Paulo, SP, Brazil,
2Universidade Anhembi Morumbi and Clinica Veterinaria Alto da
Lapa Sao Paulo, SP, Brazil
Alopecia X is a skin disease of unknown etiology characterized
by non-inﬂammatory, bilateral and symmetric alopecia, with
hyperpigmentation and absence of pruritus. This condition is most
frequently observed in young dogs of Nordic breeds, and is
thought to be related to abnormal adrenal gland function, with tri-
lostane and melatonin having been proposed as possible treatment
alternatives. This study aims to evaluate the comprehensive steroid
panel and therapeutic response of Pomeranian dogs diagnosed
with Alopecia X. Eighteen Pomeranian dogs admitted at veteri-
nary clinics (S~ao Paulo, Brazil) with a chief complaint of symmet-
ric and bilateral alopecia were studied. These included 12 males
and 6 females, 16 of which were neutered, aging from 2 to 5 years.
All animals were subjected to thorough laboratory screening:
complete blood count with diﬀerential leukocyte count, liver
function enzymes, urea, creatinine, triglycerides, cholesterol, blood
glucose, and thyroid panel, as well as urinalysis and abdominal
ultrasonography; all exam results were within the reference
values. Subsequently, blood samples were collected to quantify
by radioimmunoassay at Provet Laboratories (Brazil) and
Tennessee University the following hormones, both before and
after synthetic ACTH stimulation (single dose 0.05 mg/kg/EV):
17-hydroxiprogesterone, aldosterone, androstenedione, cortisol,
estradiol, progesterone and testosterone. Eight dogs were then
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subjected treatment A (trilostane 1 mg/kg PO BID), seven dogs
were subjected to treatment B (trilostane 1 mg/kg PO BID and
melatonin 3 mg/dog PO BID) and two dogs received treatment C
(melatonin 3 mg/dog PO BID); three animals were lost to follow-
up. In comparison to reference values established by the laborato-
ries for both neutered and non-neutered dogs, the animals with
Alopecia X presented higher levels in three of the seven hormones
both before and after the ACTH stimulation test. Abnormally ele-
vated hormone levels were observed prior to and following ACTH
stimulation in respectively: 3 (17%) and 16 dogs (89%) for 17-
hydroxiprogesterone, 9 (50%) and 10 dogs (55%) for androstene-
dione, and 2 (11%) and 16 dogs (89%) for progesterone. Also, the
abnormally elevated testosterone levels were observed in 6 dogs
(33%) prior to ACTH stimulation and 8 dogs (44%) following
ACTH stimulation. Two dogs presented abnormally decreased
estradiol levels, both prior to and following ACTH stimulation.
On the other hand, abnormally elevated cortisol levels were
observed in 3 dogs (17%) prior to ACTH stimulation, and these
elevated levels were maintained by only one dog (6%) following
ACTH administration. In contrast, all dogs had aldosterone levels
within reference ranges, with the exception of one dog with slightly
elevated aldosterone levels prior to ACTH stimulation. Of the
dogs subjected to treatment A, four (50%) had complete hair
regrowth and three (37.5%) had partial regrowth after three
months of treatment. Of the dogs subjected to treatment B, one
(14%) had complete hair regrowth, four (57%) had partial
regrowth, and one (14%) did not show signs of regrowth. Treat-
ment for one of the two dogs subjected to treatment C had to be
withdrawn due to emesis. Pomeranian dogs aﬀected by Alopecia
X presented increased levels of 17-hydroxiprogesterone,
androstenedione, testosterone and progesterone, both prior to and
following stimulation with synthetic ACTH, suggesting an adrenal
gland increased function in the sex hormones production. Due
this, trilostane, as a steroidogenesis blocker, was found to be a
positive therapeutic option for Alopecia X, with or without the
association of melatonin.
EN19
METABOLITE DIFFERENCES BETWEEN HEALTHY
SENIOR BURMESE AND NON-BURMESE CATS, AND
ASSOCIATIONS BETWEEN METABOLITES AND
MEASURES OF GLUCOSE METABOLISM. Mia Reeve-
Johnson1, Jacquie Rand1, Stephen Anderson2, Diane Vankan1,
Daniel Dias3, Berin Boughton3, Alysha De Livera3, Katsumi
Ishioka4, Ute Roessner4. 1School of Veterinary Science, University
of Queensland, Brisbane, Australia, 2School of Biomedical
Sciences, University of Queensland, Brisbane, Australia, 3Centre
for Molecular, Environmental, Genetic and Analytic (MEGA)
Epidemiology, Melbourne School of Population and Global
Health, The University of Melbourne, Melbourne, Australia,
4School of Veterinary Nursing & Technology, Faculty of Veterinary
Science, Nippon Veterinary and Life Science University, Tokyo,
Japan
Phenotypic identiﬁcation of cats at risk of developing diabetes
has yet to be deﬁned. Burmese cats are reported to have a dyslipi-
demia and are 3 to 4 times more likely to develop diabetes than
other breeds.
To identify plasma metabolite diﬀerences between healthy
senior Burmese and matched non-Burmese cats ranging from lean
to obese, and to determine if signiﬁcant correlations exist between
these metabolites and measures of glucose metabolism, hormonal
and biochemical related to diabetes.
Of the 69 cats tested, 49 non-Burmese; 20 lean (BCS 4-5/9), 12
overweight (BCS 6-7/9) and 17 obese (BCS 8-9/9) and 20 were
Burmese (6 lean, 12 overweight and 2 obese).
Food was withheld 18 - 24 hours, and a cephalic vein catheter
implanted. A venous blood sample was collected and the serum
and plasma separated and frozen at 80°C. A glucose tolerance
test (glucose 0.5 g/kg) was performed. Biochemical (screening, fast-
ing and 2-hr blood glucose in the glucose tolerance test, triglyc-
eride), hormonal (leptin, adiponectin, leptin:adiponectin ratio,
insulin, glucose:insulin ratio) and enzymatic (fPLI, MCP-1) analy-
ses were performed on plasma and serum samples. After extraction,
analyses using GC-MS was performed. Linear modeling was used
to identify statistically signiﬁcant (adjusted P-value<0.05) metabo-
lites associated with obesity and whether these responses were
aﬀected by sex and age. Pearson correlations were used to identify
relationships between metabolites and other parameters.
GC-MS analyses identiﬁed 25 metabolites signiﬁcantly
(P < 0.05) diﬀerent between Burmese and non-Burmese cats. In
Burmese cats, metabolites that are involved in amino acid metabo-
lism were either increased (phenylalanine, tyrosine, valine, serine,
threonine, cysteine, proline and arginine) or decreased (cysteine,
alanine and b-alanine) compared to non-Burmese cats. Some
metabolites in carbohydrate metabolism were decreased (glucose,
fructose, lactic acid), as were some involved in lipid metabolism
(glucose 3 phosphate, phosphoric acid, stearic acid, cholesterol).
When these metabolites were correlated with known measures of
glucose metabolism, numerous amino acids were positively corre-
lated with insulin and triglyceride (tyrosine, phenylalanine cysteine,
proline, glutamine and arginine were all positively correlated with
insulin, and tyrosine and phenylalanine were also correlated with
triglyceride). These results agreed with human studies where future
risk of developing diabetes was found to be associated with these
changes in metabolites. The amino acid metabolites alanine, thre-
onine and tyrosine were negatively correlated with adiponectin
and glucose and fructose were positively associated with 2-hr
blood glucose following a glucose tolerance test. However, some
metabolites considered discriminators of impaired fasting glucose
and increased in humans at risk of diabetes (phosphoric acid, ala-
nine and stearic acid) were decreased in Burmese cats, as were
metabolites of glycerolipid metabolism (glycerate, glycerol 3 phos-
phate, glucose and fructose).
This study is the ﬁrst to report metabolite diﬀerences between
healthy non-Burmese and Burmese cats and identiﬁes some
biomarkers involved in amino acid, carbohydrate and lipid meta-
bolism that are altered in Burmese cats in a similar pattern to
those identiﬁed in humans at risk of diabetes. Further research is
required to determine if these are useful as markers of metabolic
dysfunction in cats at risk of developing diabetes.
EN20
A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES
NOVEL CANDIDATE GENES FOR SUSCEPTIBILITY TO
DIABETES MELLITUS IN DSH CATS (ESVE AWARD
WINNER). Y Forcada1, M Boursnell2, B Catchpole1, DB Church1.
1The Royal Veterinary College, North Mymms, UK, 2Animal
Health Trust, Newmarket, UK
Diabetes mellitus (DM) is a common feline endocrinopathy and
pathophysiologically similar to human type 2 diabetes (T2DM).
T2DM occurs due to a combination of insulin resistance and b-cell
dysfunction. Several studies have identiﬁed environmental and
genetic susceptibility factors for T2DM. In cats, environmental
factors such as obesity and physical inactivity have been linked
with DM; however, identiﬁcation of genetic factors has been chal-
lenging. To date, MC4R is the only gene shown to be associated
with increased susceptibility to DM in overweight domestic short
hair (DSH) cats. The aim of the present study was to perform a
genome-wide association study (GWAS) to identify loci associated
with DM in lean DSH cats.
Illumina Inﬁnium 63k iSelect DNA arrays were used to interro-
gate genomic DNA samples from 200 lean diabetic DSH cats from
the Royal Veterinary College Feline DM Archive and 400 control
DSH cats. The data was analysed using PLINK whole genome
data analysis toolset. Signiﬁcance was established at P < 1 x 105.
SNPs with a minor allele frequency below 0.05 and a call rate
below 95% and individuals with a genotyping rate < 90% were
excluded from analysis.
A total of 49,930 SNPs were available for analysis. After
excluding cats with low genotypic rate, 389 control DSH and 192
lean diabetic DSH cats were evaluated. Diabetic cats had a mean
(SD) age of 11.62 (3.44) years; 123 (63%) were male, 71 (37%)
female. Nondiabetic cats had a mean (SD) age of 14.83 (2.06)
years; 216 (54%) were female, 183 (46%) male. Control cats were
signiﬁcantly older than diabetic cats (P < 0.0001; t-test). Five sig-
niﬁcant SNPs were identiﬁed: chrA2.4150731 (P = 1.4 x 107);
1452 2016 ACVIM Abstracts
chrUn17.115508 (P = 7 x 107); chrUn17.394136 (P = 3 x 107);
chrUn17.314128 (P = 3 x 107) and chrUn17.7283 (P = 9 x 106).
The ﬁrst SNP is located within chromosome A2; the others are
located within a 0.8 Mb region towards the end of chromosome
A3. The SNP in chromosome A2 is located 3 kb upstream of
dipeptidyl-peptidase-9 (DPP9), a peptidase similar to DPP-4,
involved in incretin inactivation. Within the identiﬁed region of
chromosome A3, genes of interest include TMEM18 and ACP1;
both have been associated with T2DM in humans, most likely
causing insulin resistance. This is the ﬁrst GWAS of DM in cats.
A number of signiﬁcant SNPs have been identiﬁed, some of which
are located in proximity to genes that have been associated with
T2DM in humans; others could be involved in pathophysiology
related to DM. Further investigation of these candidate genes is
warranted.
Disclosures: Disclosures to report.
SNP chips for the GWAS were provided by the Morris Animal
Foundation.
GI01
SERUM PANCREATIC LIPASE IMMUNOREACTIVITY
CONCENTRATIONS IN DOGS WITH GASTROINTESTINAL
FOREIGN BODIES. Lauren Cochran1, Steve Hill1, Jan Suchodol-
ski2, Jonathan Lidbury2, Joerg Steiner2. 1Veterinary Specialty
Hospital of San Diego, San Diego, CA, USA, 2College of Veteri-
nary Medicine, Texas A&M University, College Station, TX, USA
Elevated serum canine pancreatic lipase immunoreactivity
(cPLI) concentrations are highly speciﬁc for pancreatitis. Addition-
ally, some studies in dogs with primary gastrointestinal (GI) dis-
ease have suggested a negative outcome in dogs with increased
serum cPLI concentrations. GI disease, including foreign bodies
(FBs) can mimic clinical signs of pancreatitis. GI FBs have also
been proposed as a risk factor for the development of pancreatitis
in dogs. To date the prevalence of pancreatitis in dogs with GI
FBs is unknown. The primary aim of this study was to determine
the prevalence of elevated cPLI concentrations (as measured by
Spec cPL) in dogs with GI FBs, and to correlate Spec cPL con-
centrations with patient survival. A secondary aim was to compare
Spec cPL concentrations among dogs based on age, FB type, FB
location, and type of removal procedure.
Serum Spec cPL was measured in 49 dogs prospectively enrolled
with endoscopically or surgically conﬁrmed GI FBs from May
2014 to May 2015. Samples were obtained the day of the proce-
dure prior to anesthetic induction. Dogs were retrospectively
grouped based on age (≤4 years, n = 22; 5–8 years, n = 11;
≥9 years, n = 16), FB type (linear, n = 14; discrete, n = 35), FB
location (stomach, n = 21; duodenum, n = 3; jejunum, n = 12;
involving multiple segments, n = 13) and type of removal proce-
dure (endoscopy, n = 19; surgery, n = 30). The prevalence of a
serum Spec cPL above the upper limit of the reference interval (≥
200 µg/L) or the suggested cut-oﬀ value for pancreatitis (≥ 400 µg/
L) was determined in all dogs. Serum Spec cPL concentrations
were compared amongst groups using Kruskal-Wallis or Mann-
Whitney U tests, as appropriate. Statistical signiﬁcance was set at
P < 0.05.
A Spec cPL≥ 200 µg/L was identiﬁed in 12/49 dogs (24.5%), 9
of which (18.4%) had a Spec cPL≥ 400 µg/L. Spec cPL (median,
range) was higher in dogs 5–8 years (125 ug/L, <30–2885 µg/L)
and ≥9 years (233 µg/L, 43–2816 µg/L) of age than in dogs
≤4 years (59 µg/L, <30–246 µg/L; P < 0.0001) of age. Spec cPL
was higher in dogs with linear FBs (376 µg/L, <30–2885 µg/L)
than in dogs with discrete FBs (68 µg/L, <30–837 µg/L;
P = 0.0038). Spec cPL was higher in dogs with FBs aﬀecting mul-
tiple GI segments (569 µg/L, <30–2885 µg/L) than in dogs with
gastric FBs (60 µg/L, <30–185 µg/L; P = 0.0159). Spec cPL was
higher in dogs undergoing surgery (108.5 µg/L, <30–2885 µg/L)
than in dogs undergoing endoscopy (63 µg/L, <30–185 µg/L;
P = 0.0322). Two of 49 dogs (4%) were euthanized during the
course of the study. Both dogs had evidence of septic peritonitis at
the time of euthanasia. In both dogs, Spec cPL concentrations
were elevated (1292 µg/L and 2816 µg/L, respectively).
The overall prevalence of Spec cPL ≥ 200 µg/L and ≥ 400 µg/L
in dogs with GI FBs was relatively low (24.5% and 18.4%, respec-
tively). Spec cPL was higher in middle aged and older dogs, dogs
with linear FBs, and dogs that needed to undergo surgery for FB
removal. A Spec cPL≥ 400 µg/L was noted in both dogs that were
euthanized. Due to this small number, additional studies would be
needed to conﬁrm if an elevated Spec cPL is associated with a neg-
ative outcome in dogs with GI FBs.
GI02
SERUM PANCREATIC LIPASE IMMUNOREACTIVITY
CONCENTRATIONS AFTER CHRONIC ADMINISTRATION
OF SUPRAPHYSIOLOGIC DOSES OF GLUCOCORTICOIDS
TO DOGS. Sarah Cocker1, Keith Richter1, Joerg Steiner2,
Jonathan Lidbury2, Jan Suchodolski2. 1Veterinary Specialty Hospi-
tal, San Diego, CA, USA, 2Gastrointestinal Laboratory, Depart-
ment of Small Animal Medicine and Surgery, College of
Veterinary Medicine, Texas A&M University, College Station, TX,
USA
Prednisone and other glucocorticoids (GCs) are commonly used
as long-term medications to treat a multitude of immune medi-
ated, inﬂammatory, and neoplastic diseases in dogs. Patients with
many of these diseases may have clinical signs that overlap with
those of patients with pancreatitis. The eﬀect of long-term GC
administration on canine serum Spec cPL concentrations has not
been adequately assessed. Therefore, the aim of this study was to
determine if long-term administration of GCs at supraphysiologic
doses aﬀects serum concentrations of Spec cPL in dogs with a
variety of diﬀerent diseases.
Dogs were prospectively enrolled at the Veterinary Specialty
Hospital of San Diego between February 2015 and October 2015.
Inclusion criteria for enrollment included prescribed long-term (≥
3 weeks) administration of at least 0.5 mg/kg/day prednisone-
equivalent of GCs. Serum Spec cPL concentration was measured
prior to initiation of GC therapy so each dog served as its own
control. A second measurement of serum Spec cPL concentration
was obtained in all dogs after at least 3 weeks of treatment with
GCs. Only dogs that had no dosage change within one week of
sampling were evaluated. The dose of GCs recorded was the dose
that was being administered at the time that the second serum
sample was collected. Cases were excluded if there was poor owner
compliance with GC administration (deﬁned as missing more than
two consecutive doses of GCs) or if there was administration of
other medications known or suspected to increase serum Spec cPL
concentrations (e.g. potassium bromide or phenobarbital) or GC
administration within the 3 months prior to enrollment. Compar-
ison of serum Spec cPL between pre GC administration and ≥
3 weeks post GC administration was performed using Wilcoxon
matched-pairs signed rank test. Statistical signiﬁcance was set as
P < 0.05.
A total of 23 dogs were enrolled. Eight cases were excluded due
to euthanasia (n = 3), lack of follow up for second sample (n = 3),
GC dose <0.5 mg/kg/day at time of second sample collection
(n = 1), and change in GC dose < 1 week before second sample
collection (n = 1). Fifteen cases met the inclusion criteria. Of the
15 cases enrolled reasons for chronic GC administration included:
immune mediated thrombocytopenia (n = 4), immune mediated
hemolytic anemia (n = 4), protein losing enteropathy (n = 3), histi-
ocytic sarcoma (n = 1), suspected immune mediated pancytopenia
(n = 1), myeloﬁbrosis (n = 1), and mast cell tumor (n = 1). The
median Spec cPL concentrations for pre and post GC administra-
tion were 68 lg/L (30 – 1,997 lg/L) and 165 lg/L (30 – 1,628 lg/
L), respectively. There was no statistically signiﬁcant diﬀerence of
serum Spec cPL concentrations between baseline and post GC
therapy of ≥ 3 weeks in this group of patients (P = 0.19; Figure 1).
The results of this study did not reveal a statistically signiﬁcant
diﬀerence in SPEC cPL concentrations in dogs prior to adminis-
tration of GC and ≥ 3 weeks after administration of supraphysio-
logic doses of GCs. Thus, the administration of GCs should not
compromise the clinician’s ability to interpret results of SPEC cPL
concentrations.
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SERUM IL-2, IL-6, IL-8, AND TNF-Α CONCENTRATIONS IN
DOGS WITH INCREASED SERUM SPEC CPL CONCEN-
TRATIONS. Agostino Buono1, Andrea Petrelli2, Jonathan
Lidbury1, Jan Suchodolski1, Joerg Steiner1. 1Gastrointestinal
Laboratory, Department of Small Animal Clinical Sciences, Texas
A&M University, College Station, TX, USA, 2Department of
Veterinary Medical Sciences, University of Bologna, Ozzano
dell’Emilia, Italy
The role of cytokines in pancreatitis is well characterized in
human medicine. However, limited information is available about
their role in dogs with pancreatitis. The aim of this study was to
describe serum concentrations of interleukin (IL) -2, IL-6, IL-8,
and tumor necrosis factor-alpha (TNF-a) in dogs with increased
serum concentrations of pancreatic lipase immunoreactivity (cPLI;
as measured as Spec cPL).
Forty-nine surplus serum samples from dogs with a serum cPLI
concentration >1000 µg/L were used for this study. Ten healthy dogs
with serum cPLI concentration <200 µg/L were used as controls.
Serum cytokine concentrations were measured using previously ana-
lytically validated electrochemiluminescence immunoassays. Data
were analyzed using nonparametric statistics. Signiﬁcance was set at
P < 0.05.
The cytokine concentrations were signiﬁcantly increased in dogs
with serum cPLI concentrations >1000 µg/L when compared to
healthy controls, (increased cPLI group median [minimum-maxi-
mum] versus healthy group median [minimum-maximum]): IL-2
(18.9 pg/mL [0–559.2] versus 7.4 [1.7–56.8], P = 0.0167); IL-6
(17.0 pg/mL [0–1085] versus 4.5 [0.6–88] P = 0.0003); IL-8
(6054.4 pg/mL [667.9–19664.9] versus 2849.8 [1538.5–4247.5],
P = 0.0029); TNF-a (1.2 pg/mL [0–115.1 pg/mL] versus 0.3 [0.1–
0.6], P = 0.0014). No correlation was found between age, sex, or
serum cPLI concentration and any of the serum cytokine concen-
trations.
In conclusion, serum IL-2, IL-6, IL-8, and TNF-a concentra-
tions were signiﬁcantly increased in dogs with serum cPLI concen-
trations >1,000 µg/L. Prospective studies are needed to assess the
utility of these cytokines as early diagnostic markers or prognostic
markers in dogs with pancreatitis.
GI04
FISHHOOK FOREIGN BODIES IN DOGS AND CATS: 107
CASES (2004–2015). Austin Hardegree1, James Barr1, Micah
Bishop2, Medora Pashmakova1. 1Texas A&M University, College
Station, TX, USA, 2Animal Specialty Hospital, Naples, FL, USA
Fishhook foreign bodies are a common presentation in certain
geographic areas and often require emergent removal from the
gastrointestinal tract or skin. In the authors’ institution, endo-
scopic retrieval is considered highly successful in contrast to previ-
ous literature. The objective of this study was to describe location,
retrieval, complications, and outcomes associated with ﬁshhooks.
Electronic medical records of cats and dogs admitted between
2004 and 2015 for ﬁshhook foreign bodies were searched for
radiographic location of ﬁshhook, retrieval method, and documen-
tation of complications and outcome. Data was tested for normal-
ity. A Mann-Whitney test or odds ratios were constructed to
compare association between diﬀerent variables.
One hundred and seven cases (5 cats and 102 dogs) with a total
of 111 ﬁshhooks were included. Single shanked hooks comprised
52/111 (46.85%) and multiple shanked hooks comprised 59/111
(53.15%) of cases. Most common locations were the pharyngeal/
oral region 38/111 (34.26%)), cervical esophagus (25/111
(22.52%)), and stomach (27/111 (24.32 %)). Three hooks were
cutaneously embedded. Hooks with multiple shanks were 2.314
times more likely to be associated with esophageal damage than
single shanked hooks (95% CI: 1.038–5.159; P = 0.0478). Endo-
scopic retrieval was successful in 60/69 (87.0%) cases in which it
was attempted. Esophageal perforation occurred in 2 endoscopic
cases and a total of 9 cases necessitated surgery. Survival was
100%.
Our study supports that endoscopic retrieval is highly successful
and survival is 100%, even in cases requiring surgery. While multi-
ple shanked ﬁshhooks are more likely to cause esophageal damage,
neither type of hook nor location aﬀected outcome.
GI05
PERTURBATIONS OF THE INTESTINAL MICROBIOTA
AND BILE ACID METABOLISM IN DOGS WITH DIABETES
MELLITUS. Alana Redfern-Allen1, Blake Guard2, Jan
Suchodolski2, Joerg Steiner2, Jonathan Lidbury2, Albert Jergens1.
1Iowa State University, Ames, IA, USA, 2Texas A&M University,
College Station, TX, USA
The intestinal microbiota has been recently linked to the devel-
opment of human metabolic diseases including diabetes mellitus
(DM), due to its role in energy balance, gut permeability, and host
inﬂammatory state. Microbial imbalances may also aﬀect bile acid
(BA) metabolism through altered proﬁles of primary and sec-
ondary BA, which modulate signaling pathways involved in insulin
resistance via GLP-1 induction. Characterization of the intestinal
microbiota and BA in dogs with DM has not been systematically
evaluated. Therefore, the aim of this study was to investigate the
fecal microbiota and BA composition of healthy dogs and dogs
with DM.
Fecal samples were collected from 27 heathy control dogs and
23 diabetic dogs. The fecal microbiota was evaluated prior to
intervention using quantitative polymerase chain reaction (qPCR)
for E. coli, Streptococcus, Turicibacter, Faecalibacterium, Fusobac-
terium, and Blautia. The fecal concentrations of primary (i.e.,
cholic and chenodeoxycholic acid) and secondary (i.e., litho-,
deoxy-, and ursodeoxycholic acid) BA were measured using gas
chromatography with mass spectrometry. Non-parametric Mann-
Whitney U tests were used to compare these parameters between
healthy dogs and dogs with DM. Statistical signiﬁcance was set at
P < 0.05.
Results indicate that DM dogs exhibit imbalances in their fecal
microbiota characterized by decreased numbers of Turicibacter
(P = 0.026) and Faecalibacterium (P = 0.002) as compared to
healthy dogs. Perturbations in BA metabolism were observed in
the DM cohort and involved an increase in primary BAs and a
decrease in secondary BAs (P < 0.001 for both).
We conclude that dogs with DM have signiﬁcant imbalances in
intestinal microbiota and also altered bile acid metabolism, which
may contribute to disease pathogenesis and morbidity. Further
studies are warranted to elucidate mechanisms behind these alter-
ations, and whether they are primarily due to disease or secondary
to environmental factors including diet and antibiotics.
GI06
VARIATION OF THE MICROBIOME AND METABOLOME
ALONG THE CANINE GASTROINTESTINAL TRACT.
JB Honneﬀer, JM Steiner, JA Lidbury, JS Suchodolski. Gastroin-
testinal Laboratory, Texas A&M University, College Station, TX,
USA
The gastrointestinal tract (GIT) of the dog is a complex ecosys-
tem and its biological and biochemical compositions vary along
the length of the GIT. The analysis of fecal samples is frequently
used as a surrogate indicator for gastrointestinal disease occurring
in more proximal intestinal sections. While the canine gastroin-
testinal biogeography of the microbiome has previously been
described, corresponding metabolite proﬁles at various points
along the GIT of healthy dogs have not been characterized to our
knowledge. Therefore, the aim of this study was to perform 16s
rRNA gene sequencing and untargeted metabolomics on samples
from multiple sites to characterize the metabolome and micro-
biome along the GIT of healthy dogs.
Samples of the duodenal, ileal, colonic, and rectal contents were
collected from six adult dogs immediately after humane euthanasia
for another study. The microbiota was characterized using Illu-
mina sequencing of the 16S rRNA gene. The metabolome was
characterized by untargeted mass spectrometry-based methods.
Inter-animal variation was statistically addressed by blocking in
the software JMP, with subsequent Wilcoxon tests and Benjamini-
Hochberg correction for multiple comparisons. Statistical signiﬁ-
cance was set at P < 0.05.
Predominant phyla throughout the samples were Proteobacteria,
Firmicutes, Fusobacteria, and Bacteroidetes. Percentages of reads
identiﬁed as Proteobacteria decreased aborally (P = 0.017;
1454 2016 ACVIM Abstracts
duodenum, 62%; ileum, 48%; colon, 9%; rectum, 6%), while
those of Firmicutes increased (P = 0.032; 20%, 43%, 68%, 69%).
On the gas chromatography platform, 530 unique compounds
were detected, and 199 of these were assigned to named metabo-
lites. 134 named metabolites had at least one site-pair comparison
reaching statistical signiﬁcance. Key fermentation compounds such
as sugars and amino acids had varied site distributions: glucose
increased progressively along the GIT along with 6-deoxyglucose
(P = 0.047 and 0.034, respectively). Nearly all amino acids exhib-
ited a decrease between the ileum and colon (e.g., alanine, citrul-
line, glutamine, glycine, lysine, methionine, tryptophan, and
valine, all P < 0.03).
In conclusion, the metabolome and microbiome vary along the
canine GIT and further studies are needed to explore the eﬀect of
local disease at speciﬁc sites, to determine the host versus micro-
bial origin of these metabolites, and possibly to enhance extrapola-
tion from fecal assay results to improve our understanding of GI
diseases.
GI07
EFFECTS OF A HYDROLYZED PROTEIN DIET AND
METRONIDAZOLE ON THE FECAL MICROBIOME AND
METABOLOME IN HEALTHY DOGS. Jan Suchodolski1, Erin
Olson2, Julia Honneﬀer1, Blake Guard1, Amanda Blake1,
AlShawaqfeh Mustafa1, J€org Steiner1, James Barr1, Frederic
Gaschen2. 1Gastrointestinal Laboratory, Texas A&M University,
College Station, TX, USA, 2Louisiana State University, Baton
Rouge, LA, USA
The abnormal interaction between the GI microbiome and the
immune system is a major contributing factor to IBD. Treatment
often includes the use of antimicrobials like metronidazole or the
use of an elimination diet (i.e., hydrolyzed protein diet), but their
eﬀects on the intestinal microbiota are not well studied. Recent
epidemiological studies in humans have linked gut dysbiosis due to
antibiotics as risk factor for various chronic diseases, such as obe-
sity, diabetes, and asthma. A better understanding of the func-
tional eﬀects of antibiotics and diets on the microbiome is needed.
The aim of this study was to prospectively evaluate the impact of
metronidazole administration versus hydrolyzed protein diet on
the metabolome of healthy dogs.
Twenty-four healthy pet dogs were assigned to one of 3 groups
(8 dogs each): control dogs with no intervention (group 1, G1),
dogs treated with a soy-based hydrolyzed diet (Purina HA) for
12 weeks with administration of metronidazole 15 mg/kg PO
q12 h during weeks 6 to 8 (G2), and dogs maintained on their
usual diet and administered the same dose of metronidazole for
2 weeks (G3). Feces and blood were collected at day (D) 0, 21 and
42 in G1; and D0, 14, 28 and 42 days in G2 and G3. Microbial
communities were analyzed by Illumina sequencing of 16S rRNA
genes, and the software PICRUSt was used to predict functional
gene families. The serum and fecal metabolome was assessed by
an untargeted approach combining various mass spectrometry
platforms. All assessed parameters were adjusted for multiple com-
parisons using the Benjamin Hochberg adjustment, and an
adjusted P < 0.05 was considered signiﬁcant.
No signiﬁcant diﬀerences in any of the evaluated parameters
were observed in G1 (control group). Also, in G2, the dietary
switch to the hydrolyzed diet (between baseline and week 6) did
not lead to any signiﬁcant changes in any of the evaluated param-
eters. However, when dogs in G2 and the dogs in G3 received
metronidazole, signiﬁcant changes were observed. Because the
responses in these 2 groups were similar, they were combined for
statistical analysis. Microbiome structure and diversity were signiﬁ-
cantly altered between baseline and time of completion of metron-
idazole treatment, and also 4 weeks after end of metronidazole
treatment (ANOSIM: P = 0.002). The most signiﬁcant changes
were increases in E. coli and decreases in Firmicutes. Functional
gene families found to be signiﬁcantly more abundant during
antibiotic administration included: lipopolysaccharide biosynthesis,
glutathione metabolism, recombination and repair proteins, trypto-
phan metabolism, and fatty acid metabolism (P < 0.0001 for all).
At cessation of antibiotic administration (D14), functional gene
families found to be signiﬁcantly more abundant included: bile
secretion, xylene degradation, dioxin degradation, and signal
transduction mechanisms (P < 0.0001 for all). Metronidazole lead
to alteration in 98 out of 469 measured fecal metabolites. Major
changes observed were reduction in secondary bile acids
(P < 0.001), increases in oxidative stress pathways (P < 0.0001),
and changes in tryptophan-indole pathways (P < 0.001). While
most of the changes were reversed 14 days after the end of antibi-
otic administration, some of the evaluated bacterial taxa and
metabolites remained signiﬁcantly altered up to 4 weeks after end
of administration (end of study).
In conclusion, metronidazole has a profound eﬀect on the fecal
microbiome and metabolome, which only partially resolves after
4 weeks. Further studies are warranted to assess whether the dys-
biosis and these disrupted metabolic pathways due to metronida-
zole may pose a risk factor for development of some chronic
diseases. In contrast, the hydrolyzed diet had no noticeable eﬀect
on the microbiome and metabolome of healthy dogs.
GI08
ALTERED FECAL BILE ACID METABOLISM IN DOGS
WITH CHRONIC ENTEROPATHY. Blake Guard1, Linda
Toresson2,3, Julia Honneﬀer1, Amanda Blake1, Yuri Lawrence1,
Jonathan Lidbury1, Joerg Steiner1, Jan Suchodolski1. 1Texas
A&M University, College Station, TX, USA, 2Evidensia Specialist
Animal Hospital, Helsingborg, Sweden, 3Helsinki University,
Helsinki, Finland
Chronic enteropathy in dogs has been characterized as a multi-
factorial disease that is thought to involve inappropriate and
ongoing activation of the mucosal immune system in addition to a
microbial dysbiosis. Recently, studies in humans have suggested
that in some patients with inﬂammatory bowel disease, microbial
dysbiosis drives bile acid (BA) dysmetabolism. Primary BAs are
synthesized by the liver and secreted into the intestinal lumen,
where enzymatic reactions catalyzed by bacteria lead to BA bio-
transformation. Additionally, BAs participate in gastrointestinal
mucosal defense. For example, secondary BAs have been shown to
be anti-inﬂammatory as they have the potential to decrease the
synthesis of proinﬂammatory cytokines such as TNF-a. Therefore,
the aim of this study was to investigate the fecal BA proﬁles of
dogs with chronic enteropathy.
Fecal samples were collected from healthy dogs (n = 13) and
dogs with chronic enteropathy with histologically conﬁrmed
inﬂammation (n = 13). Fecal bile acids were analyzed by gas chro-
matography coupled with mass spectrometry. A Mann-Whitney U
test was used to compare concentrations of BAs between groups.
Cholic acid and chenodeoxycholic acid were among the primary
bile acids measured, while deoxycholic acid, lithocholic acid, and
ursodeoxycholic acid were among the secondary bile acids mea-
sured. Statistical signiﬁcance was set at P < 0.05.
No signiﬁcant diﬀerences in fecal concentrations of primary bile
acids were found between healthy dogs and dogs with chronic
enteropathy. Deoxycholic acid was signiﬁcantly decreased in dogs
with chronic enteropathy (median [min-max]: 0.26 µg/mg [0.11–
13.18 µg/mg]) compared to healthy dogs (median [min-max]:
4.64 µg/mg [0.11–18.94 µg/mg]; P = 0.0240). Lithocholic acid was
also signiﬁcantly decreased in the dogs with chronic enteropathy
(median [min-max]: 0.07 µg/mg [0.01–2.94 µg/mg]) compared to
healthy dogs (median [min-max]: 1.05 µg/mg [0.03–3.21 µg/mg];
P = 0.0159).
In conclusion, this study revealed a decrease in fecal secondary
bile acids in dogs with chronic enteropathy. Further studies
are needed to investigate the interplay between speciﬁc bacte-
rial groups and altered bile acid metabolism as well as their
relationship with intestinal inﬂammation in dogs with chronic
enteropathy.
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ALTERED FECAL STEROL PROFILES IN DOGS WITH
CHRONIC INFLAMMATORY ENTEROPATHY. JB Honneﬀer1,
L Toresson2,3, BC Guard1, R Lopes1, AB Blake1, JA Lidbury1,
JM Steiner1, JS Suchodolski1. 1Gastrointestinal Laboratory, Texas
A&M University, College Station, TX, USA, 2Evidensia Specialist
Animal Hospital, Helsingborg, Sweden, 3University of Helsinki,
Finland
Diseases of chronic inﬂammation of the gastrointestinal tract,
including idiopathic inﬂammatory bowel disease (IBD), are
thought to be perpetuated by bacterial dysbiosis and dysregulation
of the mucosal immune system in both humans and animals. Gas-
trointestinal (GI) absorption of metabolites is altered by inﬂamma-
tion, with concurrent changes in microbial metabolism within the
GI tract. Cholesterol is the primary sterol in mammals; it is incor-
porated into cell membranes throughout the body and used as a
building block for endogenous hormones, steroids, and bile acids.
Some phytosterols have shown anti-inﬂammatory properties and
have been shown to decrease disease severity in a murine colitis
model. Therefore, the aim of this study was to compare fecal
sterol proﬁles of dogs with chronic enteropathy to those of healthy
dogs.
Fecal samples were collected from healthy dogs (n = 13) and
dogs with chronic enteropathy (n = 13) with biopsy-conﬁrmed
inﬂammation. Sterols in lyophilized feces were subjected to
trimethylsilyl ether derivatization and analyzed by gas chromatog-
raphy-mass spectrometry (GC/MS) operating in Single Ion Moni-
toring (SIM) mode. Target analytes included cholesterol,
cholestanol, b-sitosterol, sitostanol, fucosterol, stigmaterol, and
campesterol. Fecal concentrations of sterols were expressed as
lg/mg of lyophilized feces. A Mann-Whitney U test was used for
comparison between animal groups with statistical signiﬁcance set
at P < 0.05.
Fecal cholesterol and cholestanol were not signiﬁcantly altered
between healthy dogs and dogs with chronic enteropathy. How-
ever, phytosterols were signiﬁcantly decreased in dogs with chronic
enteropathy (healthy group median [min-max] versus chronic
enteropathy group median [min-max]): b-sitosterol (P = 0.0066,
2.53 µg/mg [1.41–4.62] versus 1.34 [0.084–3.70]); sitostanol
(P = 0.0001, 0.54 µg/mg [0.17–1.14] versus 0.08 [0.01–0.45]); fucos-
terol (P = 0.0138, 0.23 µg/mg [0.10–0.33] versus 0.09 [0.01–0.80]);
stigmasterol (P = 0.0138, 0.46 µg/mg [0.23–0.66] versus 0.30 [0.01–
0.52]); and campesterol (P = 0.0313, 0.84 µg/mg [0.45–1.76] versus
0.53 [0.14–1.79]).
In conclusion, this study suggests that the fecal sterol proﬁle in
dogs with chronic enteropathy is characterized by decreased phy-
tosterols. Additional studies are required to explore the eﬀect of
dietary supplementation of phytosterols and to investigate how
these sterols are related to speciﬁc bacterial groups that digest diet-
ary plant material in these patients.
GI10
THE FECAL MICROBIOME OF DOGS WITH EXOCRINE
PANCREATIC INSUFFICIENCY. Anitha Isaiah, Joseph Cyrus
Parambeth, Jonathan A Lidbury, Joerg M Steiner, Jan S
Suchodolski. Gastrointestinal Laboratory, Texas A&M University,
College Station, TX, USA
Exocrine pancreatic insuﬃciency (EPI) in dogs is a syndrome of
inadequate synthesis and secretion of pancreatic enzymes, which
leads to clinical signs of maldigestion. Previous reports show that
small intestinal bacterial dysbiosis occurs in dogs with EPI and is
reversed with pancreatic enzyme therapy. However, there are no
studies evaluating the fecal microbiome of dogs with EPI. The
objective of this study was to compare the fecal microbiome of
healthy dogs (n = 18), untreated (n = 7) dogs with EPI, and dogs
with EPI treated with enzyme replacement therapy (n = 19).
To be included into the study, the dogs had to be at least 1 year
of age, have clinical signs of EPI, a serum cTLI concentration
≤2.5 lg/L, and be free from any other concurrent disease. Three
naturally voided fecal samples collected over three consecutive
days were frozen immediately after collection and pooled. Fecal
samples were collected in a similar manner from healthy dogs
without any clinical signs of gastrointestinal disease. Extracted
DNA from fecal samples was used for Illumina sequencing of the
bacterial 16S rRNA gene and analyzed using Quantitative Insights
Into Microbial Ecology (QIIME). The analysis of similarities
(ANOSIM) function in the statistical software package PRIMER
6 (PRIMER-E Ltd., Luton, UK) was used on the unweighted
UniFrac distance matrix to determine if any groups of samples
contained signiﬁcantly diﬀerent bacterial communities. There was
a signiﬁcant diﬀerence in fecal microbial communities when
healthy dogs were compared to treated (P = 0.001) and untreated
(P = 0.001) dogs with EPI. Quantitative Insights Into Microbial
Ecology (QIIME). The analysis of similarities (ANOSIM) function
in the statistical software package PRIMER 6 (PRIMER-E Ltd.,
Luton, UK) was used on the unweighted UniFrac distance matrix
to determine if any groups of samples contained signiﬁcantly dif-
ferent bacterial communities. There was a signiﬁcant diﬀerence in
fecal microbial communities when healthy dogs were compared to
treated (P = 0.001) and untreated (P = 0.001) dogs with EPI.
Alpha diversity was signiﬁcantly decreased in untreated and trea-
ted EPI dogs when compared to the healthy dogs (P < 0.01). The
families Biﬁdobacteriaceae (P = 0.006), Enterococcaceae
(P = 0.035), and Lactobacillaceae (P = 0.001) were signiﬁcantly
increased in the untreated and treated dogs with EPI when com-
pared to healthy dogs. In contrast, Lachnospiraceae (P < 0.001),
and Blautia (P < 0.001) were signiﬁcantly decreased in dogs with
EPI.
In conclusion, this study suggests that the fecal microbiome of
dogs with EPI (both treated and untreated) is diﬀerent from that
of healthy dogs.
GI11
EFFECT OF WEIGHT LOSS AND DIET ON FECAL MICRO-
BIOTA AND FECAL METABOLOMICS IN CATS. Adam
Rudinsky1, Katie McCool1, Valerie Parker1, Prosper Boyaka1,
Josh Daniels1, Rosana Lopes2, Joerg Steiner2, Jan Suchodolski2,
Chen Gilor1. 1The Ohio State University College of Veterinary
Medicine, Columbus, OH, USA, 2Texas A&M University College
of Veterinary Medicine, College Station, TX, USA
Intestinal microbiota and short chain fatty acids (SCFA) are
important in a variety of metabolic disorders. We hypothesized
that obesity and diet aﬀect intestinal microbiota and SCFA in cats.
Eight cats were used in a repeated-measures study. Cats were
fed a maintenance diet (M-diet) from study days -21-0 then
switched to a weight-loss diet (WL-diet) on day 0 without calorie
restriction until day 7. On days 8–84, daily intake was restricted to
achieve 1–2% weight-loss per week. On days 84–98, feeding the
M-diet resumed while maintaining stable body condition score
(BCS). Fecal samples were collected and stored at 80°C until
analysis. Samples were collected on day 7 and 0 (Obese/M-diet),
5 and 7 (Obese/WL-diet), 77 and 84 (Lean/WL-diet) and 86, 89,
91 and 98 (Lean/M-diet) for microbiota and SCFA proﬁles. Body
weight, BCS, muscle condition score, and body fat percentage
were assessed throughout the study.
Microbiota and SCFA proﬁles revealed changes associated with
diet and BCS. Microbiota diversity and species richness alterations
were noted. Acetic and butyric acid production was signiﬁcantly
diﬀerent between obese and lean cats. Diet and BCS had signiﬁ-
cant interaction in the statistical model for remaining SCFA. On
post-hoc analysis, isobutyric, valeric and isovaleric acids were
signiﬁcantly diﬀerent between obese and lean cats on the mainte-
nance diet. Valeric and isovaleric were diﬀerent between the
M-diet and WL-diet in obese cats.
Microbiota and SCFA proﬁle alterations were noted based on
body condition. Further study is warranted to determine the
impact of these changes on inﬂammation and metabolic disorders.
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PROBIOTIC MIXTURE VSL#3 INCREASES BENEFICIAL
FECAL AND MUCOSAL MICROBIOTA IN CANINE
INFLAMMATORY BOWEL DISEASE. Jan Suchodolski1, Robin
White2, Blake Guard1, Todd Atherly3, Peter Sciabarra1, Steve
Hill4, Craig Webb5, Curtis Mosher1, Giacomo Rossi6, Albert
Jergens1. 1Texas A&M University, College Station, TX, USA,
2Iowa State University, Ames, IA, USA, 3USDA-ARS, Ames, IA,
USA, 4Veterinary Specialty Hospital, San Diego, CA, USA,
5Colorado State University, Fort Collins, CO, USA, 6University
of Camerino, Camerino, Italy
Canine inﬂammatory bowel disease (IBD) is an immune-
mediated enteropathy likely triggered by environmental and
immunoregulatory factors in genetically susceptible dogs. Previous
studies suggest a pivotal role for intestinal bacteria in disease
pathogenesis since luminal microbial composition is markedly
altered at diagnosis. It has been suggested that probiotic bacteria
are eﬀective and promising agents for the treatment of IBD in
humans and animals. However, the eﬀects of probiotic bacteria
that directly interact with the host’s resident intestinal microbiota
are poorly understood. The aim of the present study was to inves-
tigate the impact of multi-strain probiotic VSL#3 supplementation
(Visbiome; Exegi Pharma) at a dose of 50 billion bacteria/kg/day
on the fecal and intestinal mucosal microbiota in dogs with IBD.
Nineteen dogs diagnosed with moderate-to-severe IBD (CIBDAI ≥
6) were randomized to receive standard IBD therapy (ie, elimina-
tion diet and prednisone) with or without probiotic VSL#3 for
8 weeks. Dogs were evaluated clinically at 0, 3, and 8 weeks and
endoscopically and histopathologically at 0 and 8 weeks. The fecal
and mucosal microbiota were investigated before and during treat-
ment using 16S rRNA based quantitative polymerase chain reac-
tion (qPCR) and ﬂuorescence in situ hybridization (FISH),
respectively. Both cohorts of IBD dogs showed a reduction in GI
signs after 8 weeks of therapy compared to baseline CIBDAI
scores (P < 0.05). Using qPCR, the placebo group failed to show
signiﬁcant changes in any of the bacterial groups analyzed. In con-
trast, VSL#3 treated dogs showed a signiﬁcant (P = 0.001)
increase in total lactic acid bacteria (Biﬁdobacteria, Streptococci,
Lactobacilli) at treatment weeks 3 and 8 versus baseline values.
Biﬁdobacteria were also signiﬁcantly (P = 0.018) increased at 3
and 8 weeks post-VSL#3 treatment. FISH analysis showed that
VSL#3 altered the number and spatial distribution of most colonic
mucosal bacterial groups including total bacteria and the number
of Biﬁdobacteria, Fecalibacteria, Lactobacilli, Streptococci, and
Enterobacteriaceae (P < 0.05 for each). The number of mucus-
laden and attaching Biﬁdobacteria and Streptococci were also sig-
niﬁcantly (P < 0.05) increased in dogs receiving VSL#3. In conclu-
sion, probiotic therapy of IBD dogs with VSL#3 increases the
number of fecal and mucosal probiotic genera, especially the lactic
acid bacteria. IBD dogs receiving standard therapy (placebo)
showed little change in the composition of microbial communities
despite exhibiting clinical improvement.
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CHANGES IN INTESTINAL MACROPHAGE POPULATIONS
FOLLOWING CLINICAL RESOLUTION IN DOGS WITH
CHRONIC ENTEROPATHY. Julien R.S. Dandrieux1, Wayne
Kimpton1, Barbara Bacci2, Karin Allenspach3, Albert E. Jergens4,
Caroline Mansﬁeld1. 1University of Melbourne, Werribee, Vic.,
Australia, 2University of Surrey, Guildford, Surrey, UK, 3Royal
Veterinary College, London, UK, 4Iowa State University, Ames,
IA, USA
Chronic enteropathy (CE) is a multi-factorial disease, which
involves aberrant immune responses to commensal bacteria or
dietary antigens. Although macrophages have been shown to play
an important role in human disease very little information is avail-
able in dogs. CD163 is a scavenger receptor speciﬁc for macro-
phages, and has been detected in canine duodenum. The aim of
this study was to determine if intestinal CD163 positive cell
(CD163+) populations alter after successful treatment of CE.
Calprotectin was used as an additional marker for macrophages.
Dogs were prospectively enrolled and underwent standard diag-
nosis and treatment trial for CE. Duodenal biopsies were taken
before and after long-term resolution of clinical signs (≥2 months).
Serial histologic sections were stained for CD163 (using AM-3K)
and calprotectin. Positively stained cells in ﬁve villous and crypt
regions were manually counted. The percentages of positively
stained cells from the total nucleated cells per 10,000 lm2 before
and after treatment were compared with repeated-measure
ANOVA.
Five dogs had dietary-responsive and three steroid-responsive
CE. CD163+ signiﬁcantly increased following treatment in the villi
(from 4.8% [0–12.6] to 6.2% [0.0–12.4], P = 0.043), whereas cal-
protectin+ signiﬁcantly decreased (from 3.7 [0.0–11.7] to 2.0 [0.0–
9.7]). Increased CD163+ (5.3 [1.0–9.7] to 6.2 [0.8–12.5]) and
decreased calprotectin+ (1.3 [0.0–4.2] to 0.9 [0.0–4.5]) was also
observed following treatment in the crypts, although this was not
signiﬁcant. Similar changes were seen in food and steroid respon-
sive dogs.
These results suggest that macrophages may play a role in
canine CE. Further characterization of macrophages is warranted
to understand their role in CE.
GI14
HISTOPATHOLOGIC CHARACTERISTICS OF INTESTINAL
BIOPSIES FROM DOGS WITH CHRONIC ENTEROPATHY
WITH AND WITHOUT HYPOALBUMINEMIA. Sara
Wennogle1, Craig Webb1, Simon Priestnall2. 1Colorado State
University, Fort Collins, CO, USA, 2Royal Veterinary College,
Hertfordshire, UK
The term protein-losing enteropathy (PLE) is often applied to
cases of chronic enteropathy (CE) when the disease process results
in hypoalbuminemia. Multiple previous studies have identiﬁed
hypoalbuminemia as a risk factor for a negative outcome in dogs
with chronic enteropathy, yet it has not been determined whether
the histopathology diﬀers between CE dogs with and without
hypoalbuminemia. The goal of this retrospective study was to com-
pare histopathologic ﬁndings (as determined by the WSAVA scor-
ing system) in dogs with CE with and without hypoalbuminemia.
Electronic medical records at Colorado State University were
reviewed for dogs having intestinal biopsy performed between Jan-
uary 2010–July 2015. Included dogs had clinical signs compatible
with CE of at least 3 weeks duration. Dogs with signiﬁcant con-
current disease, potential non-GI causes of hypoalbuminemia,
intestinal lymphoma, or for which a complete medical record
could not be obtained were excluded. 83 cases were suitable
for inclusion. Dogs were placed in either the CE (albumin
≥ 3.0 gm/dL), or CE w/ PLE (albumin <3.0 gm/dL) group.
Recorded data included signalment, presenting complaint, clinical
signs, additional clinicopathologic abnormalities, tissue types avail-
able, and method of biopsy procurement. A blinded pathologist
(SLP) was asked to review all biopsies and apply the WSAVA
scoring system to each intestinal biopsy. In cases where more than
one tissue type was available (13/83), the tissue type with the high-
est total WSAVA score was used in the analysis.
Results are summarized in the table below. The most notable
discrepancies between groups occurred in the categories of crypt
distension (CD), lacteal dilation (LD), villous stunting (VS), and
lamina propria neutrophils (LP N), with a greater proportion of
dogs in the CE w/ PLE exhibiting those changes on histopathol-
ogy. Villous epithelial injury (VEI) and intraepithelial lymphocytes
(IEL) were also appreciably more common in dogs in the CE w/
PLE group. Lamina propria lymphocytes and plasma cells (LP L/
PC) and lamina propria eosinophils (LP E) were observed in both
groups. Mucosal ﬁbrosis (MF) was uncommon in both groups.
Dogs with PLE secondary to CE had a greater percentage of
lacteal dilation, injury to the villi, crypt distension, and lamina
propria neutrophils than dogs with CE that had normal albumin.
Furthermore, although lacteal dilation was noted in 76% of
PLE cases, it was listed as a primary diagnosis in only 5 cases.
Further investigation is required to determine if these diﬀerences
represent a diﬀerence in underlying etiology, or should alter treat-
ment strategy in speciﬁc cases.
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HUMAN GRANULOCYTE IMMUNOFLUORESCENCE
ASSAY FOR ANTI-NEUTROPHIL ANTIBODIES SHOWS
STRONG ASSOCIATION WITH CANINE FOOD
RESPONSIVE DIARRHEA. Karin Allenspach1, Shayna Streu2,
Valerie DiMuro3, Anna Riddle1, Joseph Kirk1, Lucrezia Peraz-
zotti4, Regina Wagner5, Elisbabeth Mueller5, Jessica Florey1.
1Royal Veterinary College, London, UK, 2Michigan State Univer-
sity, East Lansing, MI, USA, 3Arcadia University, Philadelphia,
PA, USA, 4Euroimmun UK Ltd, Wimbledon, UK, 5Laboklin AG,
Bad Kissingen, Germany
Perinuclear anti-neutrophilic antibodies (pANCA) have previ-
ously been shown to be serum markers in canine IBD, and more
likely to be associated with food responsive diarrhea (FRD) cases
than steroid responsive disease (SRD). The indirect immunoﬂuo-
rescence assay used in previous publications is based on isolation
of canine granulocytes from donor dogs, which are subsequently
ﬁxed in ethanol on microscope slides, and then incubated with the
patient serum and secondary antibody. This assay is time consum-
ing and has been shown to have low inter-observer agreement. In
this pilot study we therefore sought to investigate whether a com-
mercially available human granulocyte indirect immunoﬂuores-
cence assay could be used to detect pANCA in dogs and to
evaluate preliminary sensitivity and speciﬁcity of the assay for
groups of dogs with FRD versus SRD.
Forty-four dogs with FRD and 20 dogs with SRD were
included in the study. Granulocyte Mosaic Biochip slides (EURO-
IMMUN AG) containing human granulocytes ﬁxed in ethanol,
human granulocytes ﬁxed in formalin, puriﬁed myeloperoxidase
protein (MPO), puriﬁed proteinase-3 protein (PR-3), and HEp-2
cells were used for the assay. These biochips allow detection of
pANCA, cytoplasmic antineutrophil antibodies (cANCA), as well
as anti-nuclear antibodies (ANA) on the same slide. The assay was
performed according to manufacturer’s instructions. Brieﬂy, bio-
chips were incubated with 30ul of 1:10 and 1:100 diluted serum
samples for 30 Min, then washed and incubated with secondary
anti-dog IgG FITC-labeled antibody for 30 Min. After washing,
the slides were embedded in medium, covered and evaluated under
ﬂuorescence light at 20–409 magniﬁcation by two independent
observers.
The number of pANCA or cANCA positive results in the group
of FRD dogs was 27/44 (61%). To the contrary, none of the dogs
in the SRD group had evidence of pANCA or cANCA seroreac-
tivity (0/20). Consequently, sensitivity of the new assay to predict
FRD amongst a group of dogs with chronic enteropathies was
0.61 (95% CI 0.45–0.75); and speciﬁcity was 1.0 (95% CI 0.89–
1.0). This is comparable to previous studies using the canine gran-
ulocyte method (sensitivity 0.51; speciﬁcity 0.95). Fishers exact test
revealed a statistically signiﬁcant association of a positive pANCA
or cANCA test with FRD (P < 0.0001). Inter-observer agreement
for the assay was good (kappa 0.75). Furthermore, in 8 of the
ANCA positive cases, it was possible to identify either MPO or
PR-3 as antigens on the biochips.
In conclusion, the human granulocyte immunoﬂuorescence
assay used in this study was able to identify sero-positivity for
ANCA in a high percentage of dogs with FRD. The data suggests
that this assay could be used as an alternative to the canine assay
for detection of ANCA in dogs.
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SERUM CITRULLINE CONCENTRATIONS IN DOGS WITH
CHRONIC ENTEROPATHY. Rosana Lopes, Yuri Lawrence,
Robert K. Phillips, Jonathan A. Lidbury, Jan S. Suchodolski, J€org
M. Steiner. Gastrointestinal Laboratory, Texas A&M University,
College Station, TX, USA
Citrulline, a non-proteinogenic amino acid, has recently been
described as a biomarker of enterocyte function in humans.
Decreased concentrations of plasma citrulline have been reported
in patients with short bowel syndrome, Crohn’s disease, viral
enteritis, or in critically ill patients. In dogs, the relationship
between serum citrulline concentration and small intestinal dys-
function has not been well characterized. Citrulline is mainly syn-
thesized from glutamine in enterocytes and is metabolized in the
duodenum and jejunum. Therefore, intestinal injury can lead to
decreased serum citrulline concentrations. The aims of this study
were to analytically validate a GC/MS method for the measure-
ment of citrulline in canine serum and to assess the concentration
of this amino acid in dogs with chronic enteropathy.
Surplus serum samples from 40 dogs were used for analytical
validation of the citrulline assay. Thirty-one surplus serum samples
from healthy dogs and dogs with chronic enteropathy were used
to evaluate possible alterations in serum citrulline concentrations
in dogs with chronic enteropathy. Validation variables included
the lower limit of detection, linearity, spiking recovery, and preci-
sion. Serum citrulline concentrations from 19 dogs with chronic
enteropathy were compared to those from 12 healthy dogs. A
Mann-Whitney U test was performed to compare serum citrulline
concentrations between healthy and diseased dogs. Statistical sig-
niﬁcance was set as P < 0.05.
The lower limit of detection for citrulline in serum was
4.9 µmol/L. Observed-to-expected ratios for citrulline dilutional
parallelism (n = 6) were 83.2% to 116.7%. Recoveries for spiking
concentrations of citrulline in serum samples (n = 5) were between
84.9% to 119.4%. Mean intra- and inter-assay coeﬃcients of vari-
ation (%CVs) for the citrulline assay were 5.4% and 10.9%,
respectively. Dogs with chronic enteropathy had signiﬁcantly lower
serum citrulline concentrations (median [minimum - maximum]:
10.5 µmol/L [2.8 - 46.0]) than healthy dogs (median [minimum -
maximum] 32.5 µmol/L [20.0 - 44.0]; P < 0.0001).
The assay evaluated here was shown to be linear, precise, accu-
rate, and reproducible. Dogs with chronic enteropathy had signiﬁ-
cantly lower serum citrulline concentrations than healthy dogs.
Further studies are warranted to assess the clinical utility of the
serum citrulline as a biomarker for enterocyte function in dogs.
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ORAL VERSUS PARENTERAL COBALAMIN
SUPPLEMENTATION IN DOGS WITH CHRONIC
ENTEROPATHIES AND HYPOCOBALAMINEMIA.
Linda Toresson1, Joerg Steiner3, Jan Suchodolski3, Thomas
Spillmann2. 1Evidensia Specialist Animal Hospital, Helsingborg,
Sweden, 2Helsinki University, Helsinki, Finland, 3Gastrointestinal
Laboratory, Texas A&M University, College Station, TX, USA
Hypocobalaminemia is a common sequel to chronic enteropa-
thies (CE) in dogs and has been reported to be associated with
a negative outcome. Current supplementation protocols for
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cobalamin (cbl) in dogs call for parenteral (PE) supplementation,
although no protocol has been validated. In humans, several stud-
ies have reported equal eﬃcacy of per oral (PO) and PE adminis-
tration of cbl. Further, this group has previously reported about
successful PO cbl supplementation in dogs with CE and
hypocobalaminemia in a retrospective study. Thus, the purpose of
this prospective randomized study was to validate the current PE
and a new PO cbl supplementation protocol and compare the eﬃ-
cacy of PO versus PE cbl supplementation in dogs with
hypocobalaminemia.
Dogs with symptoms of CE and a serum cbl below 285 ng/L
(reference interval: 244–959 ng/L) were included from Evidensia
Specialist Animal Hospital, Helsingborg, Sweden, Helsinki Univer-
sity Hospital, Finland, and from two other Swedish Veterinary
Clinics. Dogs were randomized to treatment with either daily PO
cbl tablets during the whole study period (cyanocobalamin (Behe-
pan) 1 mg/tablet; dogs up to 10 kg received ¼ tablet, dogs 10 to
20 kg ½ tablet and dogs ≥ 20 kg 1 tablet/day) or PE cbl according
to a protocol currently suggested by a diagnostic laboratory
(http://vetmed.tamu.edu/gilab/research/cobalamin-information#-
dosing). A block-randomized schedule was performed by an exter-
nal statistician prior to the start of the study in March 2014. The
study was approved by the Swedish Board of Agriculture and the
Viikki Campus Research Ethics Committee, Finland. Serum cbl
for follow-up was analyzed 28  5 days and 90  15 days after
initiation of supplementation using an automated chemilumines-
cence immunoassay (Immulite 2000, Siemens Healthcare
Diagnostics).
41 dogs of 22 breeds were included with a median age of 6.2
(range 1.7–13.1) All of the dogs had symptoms of CE. Concurrent
medical treatment and diet was given based on clinical judgement.
Intestinal biopsies from the small and large intestine conﬁrming
chronic inﬂammation were available from 25/41 dogs. There was
no statistically signiﬁcant diﬀerence in serum cbl concentrations at
baseline between the two groups (P = 0.25, Mann Whitney test).
Serum cbl increased in all dogs after supplementation. In the
group receiving PO supplementation, median serum cbl concentra-
tions was 245 ng/l (150–285) at inclusion (n = 22), 970 ng/L (564–
2026) after 28 days (n = 22), and 1334 ng/L (768–3921) after
3 months (n = 20). The diﬀerence between baseline and 28 days
was statistically signiﬁcant (P < 0.0001; Wilcoxon matched-pairs
signed rank test) as well as the diﬀerence between 28 days and
3 months (<0.006; Wilcoxon matched-pairs signed rank test). In
the group receiving PE cbl, mean cbl concentration was
221  43 ng/L at inclusion (n = 19), 1686  757 ng/L after
28 days (n = 19), and 803  275 ng/L (n = 13) after 3 months.
The diﬀerence between baseline and 28 days was statistically sig-
niﬁcant (P < 0.0001; paired t-test) as well as the diﬀerence between
28 days and 3 months (P = 0.0003, paired t-test). Comparing the
increase in serum cbl concentrations at 28 days to baseline, the
increase was signiﬁcantly higher in the PE group than the PO
group (mean increase 1465  745 ng/L and 888  449 ng/L,
respectively, P = 0.004, unpaired t-test). However, after 3 months,
the median (range) increase in serum cbl concentrations compared
to baseline group were signiﬁcantly higher in the PO than the PE
group (970 ng/L (538–3663) and 608 ng/L (38–997), respectively,
p = 0.0001, Mann Whitney test).
We conclude that both PO and PE cbl supplementation appears
to eﬀectively increase serum cbl concentrations in dogs with CE
and hypocobalaminemia. Further studies comparing cellular cobal-
amin status after PO or PE supplementation are warranted.
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PLASMA ESSENTIAL TRACE ELEMENT
CONCENTRATIONS IN DOGS WITH CHRONIC
ENTEROPATHY. Nozomu Yokoyama, Hiroshi Ohta, Hazuki
Mizukawa, Yumiko Kagawa, Shouta Nakayama, Noboru Sasaki,
Keitaro Morishita, Kensuke Nakamura, Yoshinori Ikenaka,
Mayumi Ishizuka, Mistuyoshi Takiguchi. Department of
Veterinary Clinical Sciences, Graduate School of Veterinary
Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Chronic enteropathy (CE) is a common cause of malnutrition in
dogs. Essential trace elements (ETE) are deﬁned as micronutrients
that are required for proper biochemical processes in the body. To
date, little is known about plasma ETE status in dogs with CE.
The aim of this study was to determine whether ETE deﬁciency
occurred in dogs with CE.
Dogs with CE that were presented to Hokkaido University
Veterinary Teaching Hospital between July 2014 and June 2015
were recruited. Fourteen laboratory beagles were used as controls.
Plasma ETE concentrations (Chromium, manganese, iron, cobalt,
copper, zinc, selenium, molybdenum) were measured by induc-
tively coupled plasma-mass spectrometry. Plasma ETE concentra-
tions in CE dogs were compared with those of controls. In CE
dogs, correlation between plasma ETE concentrations and canine
chronic enteropathy activity index (CCECAI), plasma albumin
concentration and histopathologic score calculated according to
the World Small Animal Veterinary Association (WSAVA)
criteria.
Twenty-two dogs with CE were enrolled in this study. There
were no signiﬁcant diﬀerences between plasma ETE concentrations
of CE dogs and those of controls, except for molybdenum. Plasma
molybdenum concentration in CE dogs (median 6.9 ng/mL, range
0.38–60 ng/mL) was higher than that of controls (median 3.2 ng/
mL, range 0.72–4.7 ng/mL) (P = .015). However, plasma molybde-
num concentration didn’t correlate with CCECAI, albumin con-
centration and histopathologic score.
These results indicate that there might be no obvious plasma
ETE deﬁciency in dogs with CE. Further study is necessary to
clarify the reason for increased plasma molybdenum concentration
in dogs with CE.
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VALIDATION OF ULTRASONOGRAPHIC MEASUREMENT
OF GASTRIC EMPTYING TIME IN HEALTHY CATS USING
RADIONUCLIDE SCINTIGRAPHY. Roman Husnik, Jon
Fletcher, Lorrie Gaschen, Frederic Gaschen. Department of
Veterinary Clinical Sciences, School of Veterinary Medicine,
Louisiana State University, Baton Rouge, LA, USA
The prevalence of gastric emptying (GE) disorders in cats is
unknown due to lack of clinically applicable diagnostic test. This
study assesses agreement for GE times between ultrasonography
and the gold standard in 7 healthy cats.
For scintigraphy, 60-second static acquisitions were performed
in right and left lateral recumbency at 0, 5, 15, 30, 45, and 60 min-
utes following a 4 mCi Tc99M-mebrofenin solid test meal (20% of
daily energy requirements), and at 30-minute intervals thereafter.
Mean total counts from a gastric region of interest were measured
from both images. Geometric means of the decay-corrected counts
were calculated, and the amount of gastric radioactivity was
expressed as a percentage of the initial count. Using nonlinear
regression analysis, 25%, 50%, 75% and 90% GE times were
determined. Sonographic assessment of GE was repeated three
times after the same meal (non-labeled). Using the same time
points, mean cross-sectional area of transverse images of the
relaxed antrum was obtained and expressed as a percentage of the
maximal area. The area under the curve was calculated and 25%,
50%, 75% and 90% GE times determined.
Good correlation was found between scintigraphy and sonogra-
phy for the 75% (287  67 [mean  SD] and 306  28 minutes
respectively, r = 0.85, P < 0.02) and 90% GE times (340  77 and
381  29 minutes respectively, r = 0.85; P < 0.02). Ultrasound
evaluation of antral cross-sectional area is a valid alternative to
scintigraphy in the late phase of GE in healthy cats.
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EFFECT OF MOSAPRIDE ON POSTPRANDIAL
GALLBLADDER MOTILITY AND PLASMA LEVELS OF
MOTILIN IN DOGS. Toshiaki Kakimoto, Hideyuki Kanemoto,
Kenjiro Fukushima, Koichi Ohno, Hajime Tsujimoto. The Univer-
sity of Tokyo, Tokyo, Japan
Impairment of gallbladder motility might be responsible for the
pathogenesis of gallbladder mucocele and biliary sludge in dogs
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and the improvement of the gallbladder motility has a possibility
to exert the preventive eﬀects on the progression of the gallbladder
diseases. However, little has been studied on the treatments to
enhance the gallbladder motility in dogs. It was reported that 5-
HT4 receptor agonist improves gallbladder emptying in human
gallstone patients, and that mosapride, which is a selective 5-HT4
receptor agonist practically used for prokinetics of canine gastroin-
testinal disease, induces the increase of motilin, which is a
physiological inducer of gallbladder motor activity. In this study,
we investigated the eﬀects of mosapride on the postprandial gall-
bladder motility and the plasma levels of motilin in dogs with or
without biliary sludge. Furthermore, we examined the expression
of 5-HT4 receptor using gallbladder tissue of a normal dog.
Nine apparently healthy beagles, owned by the University of
Tokyo, were enrolled in this study. Of these, 5 did not have any
gallbladder abnormality (group N), and 4 had biliary sludge
(group S) based on the assessment by ultrasonography. Gallblad-
der ejection fractions (EF) were compared between dogs that
were given diet with and without simultaneous single oral admin-
istration of mosapride 1 mg/kg. EF was estimated by ultrasonog-
raphy, as described in the previous study. Brieﬂy, dogs were
fasted at least 12 hours before examination. Once the fasting
gallbladder volume was ultrasonographically measured, they were
given a test diet with and without mosapride. Postprandial gall-
bladder volume was recorded at an hour after the feeding. Before
each ultrasonography, blood was collected for the measurement
of plasma motilin levels. Experiments and animal care complied
with the policies outlined in the Guide to Animal Use and Care
of the University of Tokyo. The expression of 5-HT4 receptor
was evaluated by Western blotting using an archived canine
gallbladder.
In the group N, median EF of the dogs treated with mosapride
was signiﬁcantly higher than those without the treatment [46.1%
(range: 44.1 to 60.6) versus 38.1% (24.2 to 43.5%), respectively,
P < 0.05]. Such tendency was also observed in the group S,
although the diﬀerence was not signiﬁcant [treatment: 43.3% (33.9
to 63.2%) versus without treatment: 34.8% (23.6 to 37.7%),
P = 0.06]. However, the median degree of the increase of the
plasma motilin concentrations after feeding was not signiﬁcantly
diﬀerent between the dogs with and without mosapride in either
group [Group N: mosaporide: 1.6 pg/mL (range: - 123.3 to
168.3 pg/mL) versus feeding only: 65.0 pg/mL (- 25.0 to 415.0 pg/
mL), Group S: mosaporide: 37.0 pg/mL (range: - 273.0 to 95.0 pg/
mL) versus feeding only: 173.3 pg/mL (5.0 to 363.3 pg/mL)]. In
Western blotting, an immunoreactive band was observed at the
position of 45 kDa using the protein puriﬁed from the archived
gallbladder, suggesting that 5-HT4 is expressed in the canine gall-
bladder.
These results suggested that mosapride enhances postprandial
gallbladder motility. Although the mechanisms of this eﬀect are
still to be clariﬁed, our results suggested that mosapride enhances
gallbladder motility possibly via gallbladder 5-HT4 receptor and
motilin does not play a role in this eﬀect. Further studies are
needed to support our results.
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EVALUATION OF THE PRESENCE AND ROLE OF CYS-
TEINE PROTEASE 30 IN FELINE T. FOETUS. M. Katherine
Tolbert, Emily Gould, Mabre Brand, Stephen Kania. University
of Tennessee, Knoxville, TN, USA
Tritrichomonas foetus (Tf) is a ﬂagellated protozoan parasite
that is recognized as a signiﬁcant cause of diarrhea in domestic
cats with a prevalence rate as high as 30%. No drugs have been
shown to consistently eliminate Tf infection in all cats. Cysteine
proteases (CPs) have been identiﬁed as mediators of Tf-induced
adhesion-dependent cytotoxicity to the intestinal epithelium. Thus,
CPs represent novel targets for the treatment of feline trichomono-
sis. However, cats also produce CPs that are part of life-critical
systems. Thus, parasitic CPs need to be selectively targeted to
reduce the potential for host toxicity. Previous studies have
demonstrated the importance of a speciﬁc CP, CP30, in mediating
bovine and human trichomonad cytopathogenicity. Thus, the aims
of this study were to characterize the presence of CP30 in feline Tf
isolates and to evaluate the eﬀect of targeted inhibition of CP30
on feline Tf-induced adhesion dependent cytotoxicity.
The presence of CP30 in 4 diﬀerent feline Tf isolates was evalu-
ated by indirect immunoﬂuorescence and ﬂow cytometry using a
rabbit polyclonal antibody that targets bovine Tf CP30 (a-CP30).
Feline Tf treated with rabbit IgG and/or secondary Ab in the
absence of a-CP30 Ab and bovine Tf were used as negative and
positive controls, respectively. The eﬀect of inhibition of CP30
activity on Tf adhesion-dependent cytopathogenicity was deter-
mined using CFSE-labeled feline Tf that were allowed to adhere
to monolayers of porcine intestinal epithelial cells (IPEC) in co-
culture. The eﬀect of CP30 inhibition on feline Tf adhesion and
cytotoxicity was evaluated by immunoﬂuorescence quantiﬁcation
assays and crystal violet spectrophotometric analysis. A minimum
of 6 replicates were performed for each co-culture experiment.
Data were analyzed using Systat software (P < 0.05).
CP30 expression was identiﬁed in all feline Tf isolates tested by
indirect immunoﬂuorescence and ﬂow cytometry. Treatment of
feline isolates with a-CP30 Ab resulted in signiﬁcantly decreased
Tf adhesion to and cytotoxicity towards IPEC-J2 monolayers com-
pared to rabbit IgG-treated Tf isolates.
These studies establish that CP30 is expressed by feline Tf isolates
and may be an important virulence factor in the cytopathogenicity
of feline Tf. The results of these studies provide strong evidence-
based justiﬁcation for investigation of CP30 as a novel target for the
prevention and/or treatment of feline trichomonosis.
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EVALUATION OF THE EFFECT OF OMEPRAZOLE ON
SERUM CALCIUM, MAGNESIUM, GASTRIN AND BONE IN
CATS. Emily Gould1, Casey Clements1, Ann Reed1, Luca Giori1,
Joerg M. Steiner2, Jonathan A. Lidbury2, Jan S. Suchodolski2,
Mabre Brand1, Tamberlyn Moyers1, Lee Emery1, M. Katherine
Tolbert1. 1University of Tennessee College of Veterinary Medicine,
Knoxville, TN, USA, 2Texas A&M University College of
Veterinary Medicine & Diagnostic Sciences, College Station, TX,
USA
Chronic proton pump inhibitor administration has been associ-
ated with electrolyte imbalances and cobalamin deﬁciency, dis-
rupted bone homeostasis, serum hypergastrinemia and rebound
acid hypersecretion in humans. These side eﬀects could have
important clinical implications in cats. However, no studies have
explored if cats receiving prolonged oral omeprazole (e.g., >
4 weeks in duration) experience similar side eﬀects. We hypothe-
sized that prolonged oral omeprazole administration would result
in altered bone homeostasis and/or serum calcium, magnesium,
cobalamin and/or gastrin concentrations in healthy cats.
In a within subjects, pre to post design, 6 adult healthy colony
cats received either omeprazole (0.83–1.6 mg/kg PO q12 h) or pla-
cebo (250 mg lactulose PO q12 h) for 60 days. Analyses of serum
calcium, magnesium, cobalamin and gastrin concentrations were
performed on days 0, 30, and 60, with dual energy x-ray absorp-
tiometry performed at days 0 and 60 for each treatment. On day
60 of omeprazole treatment, intragastric pH capsules were placed
in two of the cats to measure the eﬀects of rapid omeprazole ces-
sation. Continuous data were analysed using a two-way ANOVA
and tested to account for the eﬀects of phase of treatment, time of
measurement and the interaction of phase and time. Log transfor-
mation of serum gastrin, bone mineral density (BMD) and bone
mineral content (BMC) were required for the data to meet
ANOVA normality assumptions. To reduce the possibility of a
Type I error due to analysis of multiple study variables, the Bon-
ferroni correction was applied (a = 0.006). SAS 9.4 was used to
perform all data analyses and generate all descriptive statistics.
No signiﬁcant changes were observed between treatment and
placebo for any parameters, except serum gastrin, which was sig-
niﬁcantly higher during omeprazole treatment in comparison to
placebo (P < 0.002). Although the change was not signiﬁcant, all
cats experienced a decrease in BMC by the end of the omeprazole
treatment arm. Evidence of gastric hyperacidity was seen in both
cats following cessation of omeprazole.
In conclusion, the results of this study provide evidence that
omeprazole may be relatively safe when administered to cats for
60 days or less, but slow withdrawal of the medication is recom-
mended based on the hypergastrinemia and rebound hyperacidity
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demonstrated in this pilot trial. However, further studies involving
more cats are needed to conﬁrm these results.
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GRAVITY-ASSISTED ESOPHAGEAL TRANSIT
CHARACTERISTICS IN DOGS WITH MEGAESOPHAGUS.
Jillian Haines1, Alison Khoo2, John Thomason3, Erin Brinkman3,
Andrew Mackin3. 1Washington State University, Pullman, WA,
USA, 2Western College of Veterinary Medicine, Saskatoon,
Saskatchewan, Canada, 3Mississippi State University, Mississippi
State, MS, USA
Treatment of megaesophagus (ME) often relies on feedings in a
vertical position. Little is known about the behavior of food mate-
rial in the esophagus during transit to the stomach in dogs with
ME. The aims of our project were to standardize a contrast video
ﬂuoroscopy technique to evaluate esophageal transit time in dogs
with ME while sitting in a vertical position, and to use this infor-
mation to determine an appropriate duration an individual patient
with ME should remain vertical after drinking and feeding.
Twelve dogs with ME were included in the study. Six dogs had
congenital ME, 4 dogs had idiopathic acquired ME, and 2 dogs
had ME secondary to myasthenia gravis. All dogs were placed in a
vertical position using adjustable size-appropriate Bailey chairs.
Bailey chairs were constructed from thin wood which allowed them
to be radiolucent. In three diﬀerent feeding sessions, dogs were
given standardized amounts of liquid barium, canned food meat-
balls mixed with barium, or their normal diet also mixed with bar-
ium (if the diet was a diﬀerent consistency than meatballs, generally
a slurry). Fluoroscopy was performed in 5 minute increments to
visualize transit of food or barium from time to ingestion until full
clearance of material from the esophagus, or for a maximum of
20 minutes for liquid barium and 30 minutes for food material.
In dogs that were accustomed to the Bailey chair, performance
of contrast video ﬂuoroscopy was technically straightforward. Sig-
niﬁcant individual variation was seen between dogs for transit time
of all three ingesta types. Ingesta consistency aﬀected transit time,
but the consistency that allowed the most rapid transit time varied
by individual. Mean transit time for liquid was 15.4 mins with
58% (7/12) of dogs having no clearance of liquid by 20 mins.
Mean transit time for meatballs was 24.6 mins with 67% (8/12)
having incomplete clearance of meatballs at 30 minutes. Mean
transit time for the slurry consistency was 26.3 mins with 75% (6/
8) of tested dogs having incomplete clearance of food at 30 mins.
Three dogs were identiﬁed as having gastroesophageal reﬂux and
one dog was found to have a concurrent swallowing disorder.
Based on individual imaging results, recommendations were made
to alter management strategies for 8/12 dogs; change food consis-
tency in 50%, change time kept upright in 25% of dogs, and alter
pharmacologic therapy in 17%.
Fluoroscopy performed utilizing vertical positioning in modiﬁed
Bailey chairs in dogs with ME provided clear information that
allowed for individual evaluation of the most ideal food consis-
tency, anticipated behavior of ingested water, and overall esopha-
geal transit time for ingested food material. This information
permitted informed decision-making with regards to what food type
appeared to be best for individual dogs, whether providing drinking
water at times separate to feeding was likely to be well tolerated,
and how long the dog would need to remain in a vertical position
after eating or drinking. The imaging also allowed for identiﬁcation
of concurrent disorders aﬀecting food tolerance and allowed for
more speciﬁc management strategies in the majority of dogs.
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FEASIBILITY OF MEASURING GASTROINTESTINAL
TRANSIT TIME IN HEALTHY DOGS USING ALICAM. Jill S.
Pomrantz1, Jonathan A. Lidbury2, Brian T. Hardy3, J€org M.
Steiner2, Jan S. Suchodolski2, Brigitte B. Mcatee2, Jeﬀrey A.
Solomon1. 1Inﬁniti Medical, LLC, Menlo Park, CA, USA, 2Texas
A&M University, College Station, TX, USA, 3University of
California, Davis, Davis, CA, USA
The lack of a simple and widely available test for assessing gas-
trointestinal motility in dogs can make diagnosing disorders diﬃ-
cult. Ambulatory light-based imaging is an easy to use, novel
gastrointestinal imaging technique performed by oral administra-
tion of a fully automated capsule-sized camera device (ALICAM)
that is propelled by natural peristalsis. The time required for pas-
sage of the capsule through the stomach and small intestine can be
determined based on correlation of images with an internal clock.
The aim of this study was to evaluate the feasibility of using ALI-
CAM to measure gastric transit time (GTT) and small intestinal
transit time (STT) in healthy dogs.
The study subjects were 10 clinically healthy dogs between 3
and 8 years of age that weighed 17–32 kg. Dogs were fasted for
16–24 hours before and 8 hours after capsule administration.
Images were downloaded and independently reviewed by 3 board-
certiﬁed internists. Each reviewer determined GTT and STT. The
reproducibility of the results was compared between reviewers.
The median (min-max) GTT was 86 (13–218) minutes. The
median (min-max) STT was 124 (34–168) minutes. There was
agreement among the reviewers with an intra-class correlation
coeﬃcient of >0.999 and 0.969 for GTT and STT respectively.
The upper limits of the 95% conﬁdence intervals for GTT and
STT in healthy dogs were 243 and 179 minutes, respectively.
Ambulatory light-based imaging can be used to assess gastroin-
testinal transit time in healthy dogs. Further studies are needed to
determine its role in dogs with gastrointestinal disease.
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COMPARISON OF GASTRIC TRANSIT TIME IN HEALTHY
DOGS AND DOGS WITH SIGNS OF GASTRIC
HYPOMOTILITY. Jill S. Pomrantz1, Jonathan A. Lidbury2,
Brian T. Hardy3, J€org M. Steiner2, Jan S. Suchodolski2, Brigitte
B. Mcatee2, Jeﬀrey A. Solomon1. 1Inﬁniti Medical, LLC, Menlo
Park, CA, USA, 2Texas A&M University, College Station, TX,
USA, 3University of California, Davis, Davis, CA, USA
Ambulatory light-based imaging is a gastrointestinal imaging
technique performed by oral administration of a fully automated
camera device contained in a capsule (ALICAM) that is propelled
by natural peristalsis. Gastric transit time (GTT) can be
determined by visualization of the capsule’s passage from the
stomach into the duodenum and correlating images with the clock
function of the device. The aim of this study was to use the ALI-
CAM system to compare the GTT in healthy dogs with the GTT
in sick dogs with clinical signs that could be consistent with gastric
hypomotility.
The study population consisted of a group of 10 clinically
healthy dogs and a group of 26 dogs with retching, regurgitation,
and/or vomiting. All dogs were fasted for 16–24 hours before and
8 hours after capsule administration. Studies were reviewed by a
board-certiﬁed internist. For each case, GTT was determined. A
Wilcoxin rank sum test was used to compare the two groups.
The median GTT (min-max) in healthy dogs was 86 (13–218)
minutes. The median (min-max) GTT in sick dogs was 187
(2–1405) minutes. In 7 sick dogs, the capsule remained in the
stomach for the duration of the study (435–1405 minutes) and the
recorded time represented the minimum GTT. The GTT for sick
dogs was signiﬁcantly longer than for healthy dogs (P = 0.046).
The results of this study suggest that gastric hypomotility occurs
in a subset of dogs presenting with retching, regurgitation, and/or
vomiting. Further studies are needed to determine if these dogs
would beneﬁt from prokinetic therapy.
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FEASIBILITY OF A NOVEL GASTROINTESTINAL IMAGING
DEVICE FOR USE IN DOGS. Jill S. Pomrantz1, Brian T. Hardy2,
Ajay Sharma3, Jeﬀrey A. Solomon1. 1inﬁniti Medical, Llc, Menlo
Park, CA, USA, 2University of California, Davis, Davis, CA, USA,
3University of Georgia, Athens, GA, USA
The purpose of this study was to test the safety and feasibility
of a disposable and fully automated ingestible camera system that
images the gastrointestinal tract in ambulatory dogs.
Five ambulatory light-based imaging (ALI) devices were con-
structed and contained within a translucent 11x31 mm capsule.
The key components were a battery, a light source, 4 auto-focus-
ing cameras, an internal memory system, and a microprocessor
with an accelerometer that synchronized camera activity with
device motion.
Five client-owned dogs were food restricted for 24 hours before
and 8 hours after capsule administration. Capsules were adminis-
tered using a direct pilling technique. Normal activity and access
to water were permitted throughout the study. After recovery, cap-
sules were inspected for damage. Images were then downloaded
and independently reviewed by three board-certiﬁed internists.
Capsules were successfully administered to 5/5 dogs and were
recovered within 24 to 36 hours. There were no adverse events.
Median (min-max) study duration was 16 (8–18) hours. Capsules
recorded a median (min-max) of 19,713 (8572–51,683) images.
Median (min-max) gastric and small intestinal transit times were
89 (10–110) minutes and 134 (68–177) minutes respectively. Visual-
ization of the mucosa and image quality were described as excel-
lent for the stomach and small bowel. The colon was poorly
imaged due to retained feces.
ALI is safe and feasible in dogs. It produced high quality
images throughout the majority of the gastrointestinal tract. Visu-
alization of the colon might be feasible with additional prepara-
tion. This non-invasive technique may expand the role of imaging
in dogs with gastrointestinal signs.
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CORRELATION BETWEEN NOVEL IMMUNOHISTOCHEM-
ICAL MARKERS, HISTOPATHOLOGY AND CLINICAL
SCORES IN CATS WITH CHRONIC ENTEROPATHY.
Giacomo Rossi1, Alison Manchester2, Jan Suchodolski3, Craig
Webb2. 1University of Camerino, Matelica, Italy, 2Colorado State
University, Fort Collins, CO, USA, 3Texas A&M University,
College Station, TX, USA
A number of studies have demonstrated a poor correlation
between histopathology and the clinical severity of chronic
enteropathy in dogs, as well as the potential contribution of vari-
ous immunohistochemical (IHC) markers to enhance interpreta-
tion of intestinal biopsies. Although a standardized scoring system
has been developed for feline enteropathy using clinical parameters
and histopathologic severity, a similar investigation, including the
utility of IHC markers, has not yet been performed in cats. The
purpose of this study was to identify correlations between
histopathologic severity, immuno-histochemical markers, and clini-
cal scoring of cats with chronic enteropathy.
A modiﬁed feline chronic enteropathy activity index score
(FCEAI), a standard panel of gastrointestinal serum parameters, a
standardized quantiﬁcation of histopathology, a quantitative fecal
score, and a group of immunohistochemical (IHC) markers were
determined in 29 cats presented for signs consistent with chronic
enteropathy. Study participants were from a client-owned popula-
tion of cats experiencing diarrhea and/or vomiting of at least 3-
weeks duration; had no evidence of a non-gastrointestinal disease
based on history, physical examination, biochemical proﬁle, com-
plete blood count, urinalysis, total T4, and fPLI and fTLI; and
had endoscopy with biopsies and histopathology of the small intes-
tine as part of their diagnostic work-up. Serum cobalamin and
folate concentrations were also determined. Histopathologic grad-
ing and IHC quantiﬁcation was performed by a single, board certi-
ﬁed pathologist blinded to any additional information regarding
the case. Immunohistochemistry was performed to identify the
prevalence of cellular staining for TGF-b, CD3, Foxp3, and
MAC387. The degree of cellular staining was measured at 3
random and separate areas and those 3 values were averaged to
give the ﬁnal immunohistochemical score for each particular mar-
ker. Biochemical parameters, FCEAI scores, and histopathologic
grading scores were tested for normality using the Kolmogorov-
Smirnov test, and since the vast majority of data was not normally
distributed, non-parametric statistics were used for analysis.
Nonlinear regression analysis demonstrated a signiﬁcant positive
correlation between the FCEAI score and all 4 IHC markers:
TGF-beta (r2 0.24, P = 0.008), CD3 (r2 0.24, P = 0.011), Foxp3
(r2 0.17, P = 0.026), and MAC 387 (r2 0.25, P = .006). The
histopathologic severity score was found to have a signiﬁcant neg-
ative correlation with the IHC for TGF-beta (r2 0.29, P = 0.004)
and Fox p3 (r2 0.25, P = 0.007) and a signiﬁcant positive correla-
tion with CD3 (r2 0.40, P = 0.0007), but not MAC 387. This study
failed to demonstrate a signiﬁcant correlation between the
histopathologic severity score and either the fecal score or the
modiﬁed FCEAI scoring index.
As with dogs, there appears to be an absence of a signiﬁcant
correlation between histologic severity and clinical scorings such as
a clinical severity index or fecal score in cats with chronic
enteropathy. A signiﬁcant correlation was, however, identiﬁed
between a novel set of IHC markers and both the histopathology
and clinical severity scores. The pathophysiologic relevance and
clinical utility of these markers remains to be determined.
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FECAL D-/L-LACTATE CONCENTRATIONS AND
ABUNDANCE OF LACTIC ACID BACTERIA IN DOGS WITH
EXOCRINE PANCREATIC INSUFFICIENCY. Amanda Blake,
Joseph Cyrus Parambeth, Anitha Isaiah, Blake Guard, Jonathan
Lidbury, Jorg Steiner, Jan Suchodolski. Gastrointestinal Labora-
tory, Texas A&M University, College Station, TX, USA
Exocrine pancreatic insuﬃciency (EPI) in dogs is characterized
by maldigestion as a result of inadequate synthesis and secretion
of pancreatic enzymes. Previous studies have shown that dogs
with EPI have small intestinal dysbiosis (SID) and may require
concurrent antibiotic therapy in addition to pancreatic enzyme
replacement therapy. In humans, patients with short bowel syn-
drome, which is also characterized by maldigestion and SID, have
been reported to have increased fecal lactate concentrations.
Therefore, the aim of this study was to compare the abundance
of lactic acid-producing bacteria and D- and L-lactate concentra-
tions in feces from healthy dogs (n = 18), dogs undergoing
enzyme replacement therapy for EPI (n = 17), and untreated dogs
with EPI (n = 5).
Inclusion criteria for dogs with EPI were: a serum cTLI concen-
tration ≤ 2.5 µg/L, age ≥ 1 year, clinical signs of EPI, and no
other concurrent disease. Healthy dogs had no clinical signs of
gastrointestinal disease. Fecal samples were obtained for three con-
secutive days, pooled, and DNA was extracted using the Power-
SoilDNA Isolation Kit (MoBio Laboratories) for analysis of
lactic acid producing bacteria by quantitative PCR. Fecal samples
were deproteinized and fecal D- and L-lactate were measured by
enzymatic methods (R-Biopharm, D-/L-lactic acid kit). A Krus-
kal-Wallis test followed by Dunn’s post-test was used to compare
lactate concentrations and bacterial abundances between groups.
Statistical signiﬁcance was set at P < 0.05.
D-lactate was signiﬁcantly increased in both the treated (median
[min-max]: 4.34 mM [0.16–20.77 mM]; P = 0.0081) and untreated
(11.45 mM [5.65–26.49 mM]; P = 0.0013) dogs with EPI when
compared to the healthy controls (0.35 mM [0.13–0.74 mM]).
L-lactate was signiﬁcantly increased in both the treated (median
[min-max]: 18.25 mM [0.29–32.61 mM]; P = 0.0023) and untreated
(23.31 mM [13.28–24.76 mM]; P = 0.0019) dogs with EPI when
compared to the healthy controls (0.47 mM [0.18–2.79 mM]). Lac-
tobacillus and Biﬁdobacterium were signiﬁcantly increased in both
treated (P = 0.0007and P = 0.0019, respectively) and untreated
dogs (P = 0.0120 and P = 0.0076, respectively) with EPI when
compared to healthy controls.
In conclusion, this study suggests that fecal D- and L-lactate
are increased in dogs with exocrine pancreatic insuﬃciency,
regardless of enzyme replacement treatment status. Also, lactate-
producing bacterial groups were altered in dogs with EPI when
compared to healthy control dogs.
1462 2016 ACVIM Abstracts
GI29
EVALUATION OF SERUM BETA-HYDROXYBUTYRATE
CONCENTRATIONS IN DOGS WITH CHRONIC ENTERO-
PATHIES. G Esposito1, K Allenspach2, JM Steiner1, JA
Lidbury1, JS Suchodolski1. 1Gastrointestinal Laboratory, College
of Veterinary Medicine Texas A&M University, College Station,
TX, USA, 2Royal Veterinary College, London, UK
Beta-hydroxybutyrate (BHB), a ketone body, is synthesized in
the liver from acetyl CoA and is utilized as an energy source when
glucose supplies are limited. BHB has been demonstrated to play a
role in the oxidative stress response by the binding of histone
deacetylase and in the suppression of inﬂammatory disease by
antagonizing the cryopyrin inﬂammasome (NALP3). Previous
untargeted metabolomics studies of both human and canine
patients with idiopathic inﬂammatory bowel disease have shown
signiﬁcantly higher serum concentrations of BHB in diseased
patients than in healthy controls, suggesting that BHB may be use-
ful as a biomarker for inﬂammatory bowel disease. In this study,
we investigated serum BHB concentrations in healthy dogs and
dogs with two types of chronic enteropathy: food responsive diar-
rhea and steroid-responsive diarrhea.
Serum samples from dogs with food responsive diarrhea (FRD,
n = 30), steroid responsive diarrhea (SRD, n = 14), and a group of
healthy control dogs (n = 30) were used. All samples were surplus
material from a previous study. Dogs were diagnosed as having
food responsive or steroid responsive diarrhea based on response
to treatment. Serum concentrations of BHB were measured in
serum samples using a colorimetric assay kit (beta-hydroxybutyrate
colorimetric assay kit, Cayman Chemicals). A Kruskal-Wallis was
performed to compare serum concentrations between groups.
Median serum BHB concentrations were (minimum – maxi-
mum): 0.45 mmol/L (0.02 – 0.11) for healthy dogs, 0.45 mmol/L
(0.00 – 0.27) for dogs with SRD, and 0.03 mmol/L (0.01 – 0.13)
for dogs with FRD. There was no signiﬁcant diﬀerent between the
three groups (P = 0.328).
These results suggest that serum concentrations of BHB are not
signiﬁcantly increased in dogs with chronic enteropathies com-
pared to healthy dogs.
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EFFECT OF SERUM CREATININE ON FELINE SERUM
DGGR-LIPASE AND SERUM PANCREATIC LIPASE
IMMUNOREACTIVITY. Ellen Everson, Anthony Abrams-Ogg,
Helen Kocmarek, Kristiina Ruotsalo. University of Guelph,
Guelph, ON, Canada
The objective of this study was to examine the inﬂuence of kidney
function (indicated by serum creatinine level) on serum
1,2-o-dilauryl-rac-glycero-3-glutaric acid-(60methylresoruﬁn) ester
(DGGR) lipase and pancreatic lipase immunoreactivity (PLI) in cats.
Using electronic record searches, all cats were identiﬁed that had
had a serum biochemistry proﬁle ordered at the Ontario Veterinary
College between January 1, 2010 and April 14, 2015. Serum crea-
tinine had been measured at the Animal Health Laboratory
(AHL), University of Guelph, by enzymatic UV method (Randox)
on a Cobas 6000 c501 analyzer (Roche Diagnostics). Serum lipase
had been measured at AHL by the DGGR colorimetric assay
(Cobas) on the same analyzer. In some cases, an aliquot of the
same serum sample had been submitted for Spec fPL at IDEXX
laboratories, Markham, ON. Laboratory results were retrieved and
corresponding medical records reviewed. Data obtained from the
records included, when available, hydration status and body condi-
tion score as assessed by the attending clinician.
Data were ﬁrst assessed as independent events by analyzing only
the results of the ﬁrst serum biochemistry proﬁle obtained for each
cat (n = 1314). The median lipase value in the group of cats with
creatinine values above reference interval (>190 µmol/L, n = 162)
was 18.5 U/L (range 7–594 U/L), which was higher (P < 0.001)
than the median lipase value of 14 U/L (range 5–747 U/L) in the
group of cats with creatinine values ≤190 (n = 1152), although
ranges overlapped substantially. The same trend (P = 0.06) was
observed for PLI in these respective groups: median was 16.6 µg/L
(range 1.5–50 µg/L) for cats with creatinine >190 µmol/L (n = 9);
median was 3.85 µg/L (range 0.5–50 µg/L) for cats with creatinine
≤190 µm/L (n = 55). There was a signiﬁcant, but weak, correlation
between creatinine and lipase values across all cats (rho=0.2,
P < 0.001, n = 1314), but no correlation was present for the group
of cats with creatinine values >190 µmol/L (n = 162). There was
no correlation between creatinine and PLI. Multivariate linear
regression was used to assess the inﬂuence of creatinine, hydration,
and body condition on lipase over all cats for which this informa-
tion was available (n = 313); none of these variables demonstrated
a signiﬁcant eﬀect (P = 0.09, 0.22, and 0.97, for creatinine, hydra-
tion, and body condition, respectively). The data were next
assessed by MANOVA for variation over time within individual
cats for which repeat serum biochemistries and medical record
data were available (n = 279). Hydration demonstrated a signiﬁ-
cant eﬀect on creatinine (P < 0.001), and a trend towards eﬀect on
lipase (P = 0.07). Creatinine did not demonstrate any further rela-
tionship with lipase (P = 0.39). PLI was repeated in 15 cats; values
moved in the same direction as creatinine in only 4 cases.
The data indicate that kidney function has a mild eﬀect on
DGGR-lipase level in cats, which may in part be due to hydration
status. The study may be underpowered to show this eﬀect in all
analyses and on PLI. Creatinine may underestimate decreased kid-
ney function in underweight cats, aﬀecting results, but the overall
weak associations between creatinine and lipase, and creatinine and
PLI, suggest that elevated lipase or PLI should not be attributed
solely to decreased kidney function in azotemic cats. This may be
because the magnitude of increases in lipase and PLI in pancreatic
disorders overwhelms the magnitude of eﬀect of kidney function.
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PREVALENCE OF HELICOBACTER SPECIES AND THEIR
ASSOCIATION WITH GASTRIC PATHOLOGY IN DOGS
WITH GASTROINTESTINAL DISEASE. Roman Husnik1, Jiri
Klimes2, Simona Kralova-Kovarikova3, Petr Fictum4, Michal
Kolorz5, Frederic Gaschen1. 1Department of Veterinary Clinical
Sciences, School of Veterinary Medicine, Louisiana State Univer-
sity, Baton Rouge, LA, USA, 2Department of Biology and Wild-
life Diseases, Faculty of Veterinary Hygiene and Ecology,
University of Veterinary and Pharmaceutical Sciences Brno, Brno,
Czech Republic, 3Department of Small Animal Internal Medicine,
Faculty of Veterinary Medicine, University of Veterinary and
Pharmaceutical Sciences Brno, Brno, Czech Republic, 4Depart-
ment of Pathological Morphology And Parasitology, Faculty of
Veterinary Medicine, University of Veterinary and Pharmaceutical
Sciences Brno, Brno, Czech Republic, 5Department of Human
Pharmacology and Toxicology, Faculty of Pharmacy, University
of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech
Republic
The prevalence and pathogenic role of diﬀerent species of Heli-
cobacter in the dog have not been deﬁnitely documented to date.
This prospective study included 84 privately owned dogs for which
the prevalence of gastric Helicobacter species and associated gas-
tric lesions was determined, and the accuracy of diﬀerent diagnos-
tic techniques was compared.
Inclusion criteria consisted of chronic GI clinical signs (vomit-
ing, diarrhea, anorexia, weight loss), exclusion of non-GI diseases
and discontinuation of all medications for at least 2 weeks. Biopsy
specimens were obtained by gastroduodenoscopy. The presence of
Helicobacter spp. was detected using genus- and species-speciﬁc
PCR (investigated species were H. heilmannii sensu stricto [HH
s.s.], H. bizzozeronii [HB], H. felis [HF], H. salomonis [HS] and
H. pylori [HP]), cytology, rapid urease test, and histologic exami-
nation with hematoxylin-eosin and silver staining of gastric biopsy
samples.
PCR detected Helicobacter DNA in 60 dogs (71.4%). Compar-
ing the diagnostic value of cytology, rapid urease test and histol-
ogy to PCR, cytology yielded a sensitivity of 88.3% and a
speciﬁcity of 91.7%. The rapid urease test had a sensitivity of
85% and a speciﬁcity of 91.7% and histology had a sensitivity of
81.7% and a speciﬁcity of 83.3%. Using a combination of diag-
nostic tests for Helicobacter spp. including rapid urease test, cytol-
ogy, histology and PCR, 65 dogs (77.4%) had one or more
positive result. For 61 dogs (72.6%) diagnostic tests were concor-
dant. Single infections with HH s.s. was detected by PCR in
23.3%, HB in 15%, HS in 6.7% and HF in 1.7% of 60 PCR
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positive dogs. Mixed infection of HH s.s. and HB was found in
38.3% and combination of HH s.s. and HF was detected in 1.7%
of the dogs. Helicobacter species remained undetermined in 13.3%
of the patients. No HP was found in animals examined. In most
dogs, the endoscopic appearance of the gastric mucosa was nor-
mal. Overall, the most common endoscopic lesions were erosions
or ulcers and increased granularity of gastric mucosa. Gastritis
was diagnosed histologically in 36.7% of dogs positive for Heli-
cobacter spp. and in 41.7% of dogs without evidence of Helicobac-
ter colonization. Severe lymphocytic-plasmacytic gastritis (11.1%)
and acute purulent-necrotic gastritis (1.5%) were found in single
HB infections and moderate lymphocytic-plasmacytic gastritis
(14.3%) in single HH s.s. infections. An association between the
presence of mixed infection (including HH s.s. and HB) and the
lower severity of gastric inﬂammation was detected when com-
pared to single Helicobacter species infection.
This is a large study evaluating association of the individual
Helicobacter species with histologically conﬁrmed gastritis in dogs.
Dogs are frequently colonized by Helicobacter spp. other than HP,
and may represent a reservoir for human infection with non-HP
Helicobacter spp. The combination of cytology and rapid urease
test performed on gastric biopsy samples represents a reliable diag-
nostic method suitable for clinical practice. Competitive inhibition
may occur when 2 Helicobacter species are simultaneously detected
in gastric biopsies, and the presence of one Helicobacter species
may interfere with the virulence of other Helicobacter species.
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NORMAL AND ABNORMAL FINDINGS IN THE CANINE
GASTROINTESTINAL TRACT USING AMBULATORY
LIGHT-BASED IMAGING. Jill S. Pomrantz1, Brian T. Hardy2,
Jeﬀrey A. Solomon1. 1Inﬁniti Medical, LLC, Menlo Park, CA,
USA, 2University of California, Davis, Davis, CA, USA
Ambulatory light-based imaging (ALI) is a new imaging modality
that allows for non-invasive endoluminal visualization of the gas-
trointestinal mucosa. ALI is performed by oral administration of a
capsule containing a fully automated camera (ALICAM) that is pro-
pelled by natural peristalsis. The capsule is retrieved from the dogs’
feces and images are downloaded. Familiarity with normal and
abnormal ﬁndings is essential to accurate interpretation of these
studies, but these have yet to be documented in veterinary patients.
The aim of this study was to present a gallery of normal and abnor-
mal images of the canine gastrointestinal tract using ALICAM.
ALICAM studies from 65 dogs were evaluated retrospectively
by a board-certiﬁed internist. The average study consisted of
21,003 images obtained over 16 hours. Patients evaluated included
55 dogs with clinical signs of gastrointestinal disease and 10 asymp-
tomatic dogs. The patients ranged in age from 4.5 months to
13.7 years old and in weight from 7.8 to 72 kg. Images representa-
tive of normal mucosa and common lesions were saved and logged.
The most common reasons for ALICAM administration were
vomiting, diarrhea, signs of gastrointestinal bleeding, or a combi-
nation of several gastrointestinal signs. Gastric lesions identiﬁed in
dogs with gastrointestinal signs included irregular mucosa, polyps,
ulcers, erosions, masses and foreign material. Small intestinal
lesions identiﬁed included irregular mucosa, dilated lacteals, ulcers,
erosions, masses, and parasites (tapeworms and hookworms).
Colonic lesions included masses and erosions.
Establishing characteristics of normal and abnormal ﬁndings is
an important step in the evolution of ALI as a diagnostic test.
GI33
FECAL a1-PROTEINASE INHIBITOR CONCENTRATIONS
IN DOGS WITH CARDIAC DISEASE. Joseph Cyrus Param-
beth, Jordon P. Vitt, Jan S. Suchodolski, Jonathan A. Lidbury,
Ashley B. Saunders, Joerg M. Steiner. Department of Small
Animal Clinical Sciences, College Station, TX, USA
Protein-losing enteropathy (PLE) has been documented in vari-
ous cardiac diseases (i.e., congestive heart failure, constrictive
pericarditis, and congenital heart diseases) typically related to
increased interstitial pressure and intestinal lymphangiectasia in
humans. Fecal a1-proteinase inhibitor (fa1-PI) is a stable protein
lost into the gastrointestinal tract at a rate comparable to that of
albumin and therefore serves as an endogenous marker of gas-
trointestinal protein loss. While PLE has been suspected in dogs
with cardiac disease, no published studies are available. The aim
of this study was to evaluate fa1-PI concentrations in dogs with
variety of cardiac diseases.
Single, naturally voided fecal samples from 27 adult dogs
(≥1 year of age) and 15 puppies (<1 year of age) were collected
from dogs with congenital and acquired cardiac diseases. Two
dogs, one puppy and one adult, had serial fecal evaluations (i.e.,
before and after occlusion of their patent ductus arteriosus (PDA)
with an Amplatz canine ductal occluder (ACDO) device). Each
dog in the study had an echocardiogram performed by a board
certiﬁed cardiologist or a resident under the supervision of a board
certiﬁed cardiologist. Fecal samples were frozen upon collection
and fa1-PI concentration was measured using an in-house radioim-
munoassay and was compared with an established reference inter-
val for healthy adult dogs. A fa1-PI concentration of ≥21.0 lg/g
feces was considered abnormal.
Three of 27 adult dogs (11%) all with congenital cardiac disease
had an increased fa1-PI concentration (median [minimum - maxi-
mum]: 10.1 lg/g feces [1.8 - 45.6]). Also, nine of 15 (60%) of the
puppies, all with congenital heart diease, had an increased fa1-PI
concentration (median [minimum - maximum]: 24.8 lg/g feces [6.6
- 79.1]). Some of the dogs had multiple congenital heart defects on
echocardiographic evaluation. Also, the severity of cardiac disease
varied in each patient. For the two PDA dogs for which samples
from two time points were available, there was a reduction in fa1-
PI concentration post coil embolization; from 79.1 to 21.5 lg/g
feces in the puppy, and from 36.5 to 14.1 lg/g feces in the adult.
The increased fa1-PI concentrations in puppies have to be inter-
preted with caution as higher fa1-PI concentrations have been
reported previously in puppies and a speciﬁc reference interval for
puppies has not been established.
Limitations of this study include the small number of dogs, the
lack of intestinal biopsies to rule out any other causes of increased
gastrointestinal protein loss, the lack of multiple fecal samples to
account for day to day variability in fa1-PI concentrations
reported earlier, the variety of cardiac diseases, and lack of com-
plete serum chemistry proﬁles for all dogs. However, this study
shows that fa1-PI concentrations may be increased in a subset of
dogs with cardiac disease. Prospective studies are needed to estab-
lish if increased fa1-PI concentrations in dogs occur consistently
with congenital heart diseases, are increased in dogs with acquired
heart diseases that increase interstitial pressure, and if elevations
have any inﬂuence on treatment or prognosis.
GI34
EVALUATION OF THE EFFECTS OF PRE-CONDITIONING
ON FEMALE CANINE ADIPOSE-DERIVED MESENCHYMAL
STEM CELL CYTOKINE PRODUCTION. Rebecca Timmons,
Stephanie Smith, Craig Webb, Tracy Webb. Colorado State
University, Fort Collins, CO, USA
Clinical use of mesenchymal stem cell (MSC) therapy may be
optimized through pre-conditioning methods that would enhance
their immunomodulatory functions. We investigated the eﬀects of
pre-conditioning strategies on cytokine production of female
canine adipose-derived MSC that may optimize clinical eﬀects of
MSC application in this species. Adipose-derived MSC were gener-
ated from healthy adult female dogs and subjected to 6 conditions.
Supernatants were harvested after 1, 6, 12, 18, and 24 hours, and
levels of cytokines present in the supernatants were determined by
ELISA. IL-10 and TGFb were not released in measurable
levels within a 24 hour period under any of the tested culture
conditions. Large amounts of MCP-1 (mean=10.2 ng/mL) and
VEGF (mean=2.9 ng/mL) and very small amounts of IL-8
(mean=40.9 pg/mL) were constitutively produced by the cells at
24 hours. All of the pre-conditioning strategies except TGFb
altered measured cytokine production in the MSC from control
levels at 24 hours: poly I:C increased IL-8 and MCP-1 secretion;
IFNc increased MCP-1 and decreased VEGF and IL-8 secretion;
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serum-free decreased IL-8, MCP-1, and VEGF secretion; and the
mixed hypoxic environment inhibited MCP-1, VEGF, and IL-8
secretion. All changes in cytokine secretion were evident at the
6 hour time point with most at maximal levels by 12 hours sug-
gesting that 12 hour culture periods are suﬃcient to induce rele-
vant changes in MSC cytokine secretion. This initial study shows
that speciﬁc pre-conditioning methods hold promise for tailoring
and augmenting canine MSC immunomodulatory properties to
treat speciﬁc diseases, although further study is necessary and cur-
rently on going.
HM01
REPRODUCIBILITY, STABILITY AND BIOLOGICAL
VARIABILITY OF THROMBIN GENERATION USING
CALIBRATED AUTOMATED THROMBOGRAPHY IN
HEALTHY DOGS. Beno^ıt Cuq1, Shauna Blois1, Darren Wood1,
Anthony Abrams-Ogg1, Christian Bedard2. 1Ontatio Veterinary
College, University of Guelph, Guelph, ON, Canada, 2Faculte de
Medecine Veterinaire, Universite de Montreal, St Hyacinthe, QC,
Canada
Thrombin plays a central role in hemostasis and thrombosis,
and is involved in all in vivo hemostatic pathways. Calibrated
automated thrombography (CAT), a thrombin generation assay,
may therefore be a valid physiological test for hemostatic disorders
in dogs. Our objectives were to establish reference intervals for
CAT thrombin generation, and assess the eﬀects of pre-analytical
and biological variability on this assay in healthy dogs.
Lag time (lag), time to peak (ttpeak), peak thrombin generation
(peak), and endogenous thrombin potential (ETP) were measured
in 41 clinically healthy dogs. Both direct jugular venipuncture and
winged-needle catheter-assisted saphenous venipuncture were used
to collect samples from each dog. Storage stability at 80°C was
assessed over 2 months in a subset of samples. Biological variabil-
ity of CAT was assessed via nested ANOVA using samples
obtained weekly from 9 dogs for 4 consecutive weeks.
Samples for CAT analysis were stable at 80°C for up to
2 months. Samples collected via winged-needle catheter venipunc-
ture showed poor repeatability compared to direct venipuncture
samples; there was also poor agreement between the two sampling
methods. Intra-individual variability of CAT variables was low
(≤7.8%); inter-individual variability ranged from 4.8–76.8%. Ana-
lytic precision goals were met for ttpeak, peak and ETP. Indices
of individuality ranged from 0 to 0.12.
In conclusions, thrombin generation seems to be stable and
repeatable in healthy dogs. Direct venipuncture sampling is recom-
mended for CAT. Indices of individuality were low for all CAT
variables, suggesting limited utility of population-based reference
intervals for this assay.
HM02
DEVELOPMENT AND VALIDATION OF A NOVEL CANINE
IMMUNE THROMBOCYTOPENIA BLEEDING SCORE. Kelly
Makielski1, Marjory Brooks2, Chong Wang1, Jonah Cullen1, Ann-
ette O’Connor1, Dana LeVine1. 1Iowa State University, College of
Veterinary Medicine, Ames, IA, USA, 2Cornell University, College
of Veterinary Medicine, Ithaca, NY, USA
A method of objective quantiﬁcation of clinical bleeding in
canine immune-mediated thrombocytopenia (ITP) is needed
because ITP patients have variable bleeding tendencies that do not
directly relate to severity of thrombocytopenia. A consistent
description of their bleeding would allow more direct comparisons
of this bleeding heterogeneity in multi-institution studies. Applica-
tion of a standardized bleeding assessment tool would help stratify
ITP patients in clinical trials based on their bleeding severity to
provide an objective comparison of patient outcomes among treat-
ment protocols. In this study we aimed to develop and validate a
daily canine ITP bleeding assessment tool (DOGiBAT) and to
evaluate the utility of a training course for improving accurate
implementation of the DOGiBAT.
A novel bleeding assessment tool, DOGiBAT, was developed
for canine ITP comprising nine diﬀerent anatomic site-speciﬁc
bleeding grades ranging from 0 (none) to 2 (severe). An online
training course was developed for application of the DOGiBAT to
score clinical cases. A case-based quiz set of still images was used
to assess the trainees’ ability to apply the DOGiBAT tool. Addi-
tionally, to assess the eﬃcacy of the training course, 70 veterinary
student volunteers were randomized to take the quiz with (n = 35)
or without (n = 35) the training. All students scored all sites from
all cases and site scores were considered correct if they agreed with
the investigators’ pre-speciﬁed classiﬁcation. The frequency of cor-
rect scores was compared between trained and untrained students.
A logistic regression model was used to assess the association
between training and score, while adjusting for correlated
responses from sites within cases.
Clinicians (n = 13) and technicians (n = 3) taking the quiz fol-
lowing training were able to correctly apply the DOGiBAT, scoring
100% of responses correctly. 86.1% of responses from students
that received training were correctly scored, compared to only
78.2% of responses from students that did not receive training. The
odds of trained students giving correct answers were higher than
untrained students (P < 0.0001). The anatomic site for which train-
ing was most important for correct scoring was oral bleeding
(82.9% with training, 47.6% without; P < 0.0001). Similarly, scor-
ing of ocular (75.2% with training, 58.1% without; P = 0.0097)
and cutaneous bleeding (84.8% with training, 66.7% without;
P = 0.003) were improved by the training course. Students with
more clinical experience were better able to apply the DOGiBAT
correctly (fourth years, 84.2%; third years, 80.1%; P < 0.0149).
Our study suggests that the DOGiBAT is simple scoring tool
for classiﬁcation of bleeding severity in dogs with ITP. A short
online training course was shown to improve the accuracy and
consistency of DOGiBAT scoring. Adoption of the DOGiBAT
scoring system for future clinical trials of canine ITP patients will
facilitate more rigorous assessment of treatment-eﬀect based on
standardized bleeding outcomes.
HM03
EFFECTS OF ASPIRIN DOSE ESCALATION ON CANINE
PLATELET FUNCTION AND URINARY THROMBOXANE
AND PROSTACYCLIN LEVELS. Natalie McLewee, Todd
Archer, Robert Wills, Andrew Mackin, John Thomason.
Mississippi State University, MS, USA
Aspirin is commonly used in an eﬀort to prevent thrombus for-
mation in dogs. High-dose aspirin (10 mg/kg, PO, q 12 h) reliably
inhibits platelet function and thromboxane A2 (TXA2) synthesis,
but can be associated with unacceptable side eﬀects, including
inhibition of prostacyclin synthesis, which counteracts the eﬀects
of inhibition of TXA2. Lower doses of aspirin, in contrast, inhibit
platelet function and TXA2 synthesis, have few side eﬀects, and
allow ongoing prostacyclin synthesis. However, low-dose aspirin
therapy at standard dosage (0.5–1 mg/kg, PO, q 24 h), does not
reliably inhibit platelet function, a phenomenon known as “aspirin
resistance”. Aspirin-associated platelet dysfunction has been shown
to be highly dose-dependent, suggesting that traditional “low-
doses” of aspirin may be under-dosing canine patients. Our study
used incremental increases in dosages to determine the dose of
aspirin that consistently inhibited platelet function and TXA2 syn-
thesis without inhibiting prostacyclin synthesis.
Eight healthy adult research dogs were separated into one of 5
groups, with each group given diﬀerent oral doses of aspirin: Dose
A, 0.5 mg/kg, q24 h; Dose B, 1 mg/kg, q24 h; Dose C, 2 mg/kg,
q24 h; Dose D, 4 mg/kg, q24 h or Dose E, 10 mg/kg, q12 h. Prior
to aspirin therapy (Day 0) and again after one week (Day 7) of
drug administration, blood and urine were collected to assess pla-
telet function (turbidimetric aggregometry and PFA-100 (closure
time)) and urine 11-dehydro-thromboxane B2 (11-dTXB2, a stable
metabolite of TXA2) and 6-keto-prostaglandin F1a (6-keto-PGF1a,
a stable metabolite of prostacyclin) synthesis. A dog was consid-
ered to be an aspirin responder if there was >25% reduction in
maximal amplitude on aggregometry, or the Day 7 PFA-100
closure time was >300 seconds.
On aggregometry, for Doses A-E, there was a mean decrease in
maximum amplitude of 3.8%, 41.3%, 81.3%, 75.9%, and 87.8%,
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respectively. Compared to Day 0, there was a signiﬁcant decrease
on Day 7 for Doses B-E. The maximum amplitude was decreased
>25% (indicating aspirin responsiveness) in all dogs receiving Dose
C or greater. Similar to aggregometry, when the PFA-100 closure
times on Day 0 were compared to Day 7, there was a signiﬁcant
increase for Doses B-E. On Day 7, for Doses A-E, mean PFA-
100 closure time was >300 seconds (indicating aspirin responsive-
ness) in 0%, 25%, 62.5%, 87.5%, and 87.5%, respectively. Com-
pared to Day 0, there was a signiﬁcant decrease on Day 7 for the
concentrations of 11-dTXB2 (P = 0.0003) and 6-keto-PGF1a
(P = 0.0075). However, the changes in 11-dTXB2 and 6-keto-
PGF1a were not dependent on aspirin dose.
The results of our study suggest that an aspirin dose of 2 mg/
kg, PO, q24 h reliably inhibits platelet function in normal dogs
based on the established “gold standard” assay, platelet aggregom-
etry. Additionally, even though all aspirin doses inhibited prosta-
cyclin synthesis to some degree, there was no diﬀerence in
prostacyclin concentration between a dose of 2 mg/kg, PO, q24 h
and the traditionally used lower doses. Based on our results, an
increased standard aspirin “low-dose” of 2 mg/kg, PO, q24 h may
minimize the risk of aspirin resistance in dogs.
HM04
B CELL ACTIVATING FACTOR AS A BIOMARKER IN
DOGS WITH PRIMARY IMMUNE MEDIATED THROMBO-
CYTOPENIA. Jessica Pritchard1, Michael Wood2, Adam Birken-
heuer1, Henry Marr1. 1Department of Clinical Sciences, College of
Veterinary Medicine, North Carolina State University, Raleigh,
NC, USA, 2Department of Medical Sciences, School of Veterinary
Medicine, University of Wisconsin – Madison, Madison, WI, USA
There is a critical need for a biomarker that diﬀerentiates active
primary immune mediated thrombocytopenia (pITP) from sec-
ondary causes of thrombocytopenia, and the concentration of
which correlates with disease status in dogs. Such a biomarker
would provide a valuable diagnostic tool to modulate therapy,
evaluate risk of relapse, and reduce patient exposure to potentially
harmful immunosuppressive medications. B cell activating factor
(BAFF) is a cytokine within the tumor necrosis factor family that
plays a crucial role in B cell maturation, survival, and class switch-
ing. Increased concentrations of BAFF in mice and people have
been linked to immune-mediated diseases such as systemic lupus
erythematosus, rheumatoid arthritis, and ITP. Our central hypoth-
esis is that BAFF production will be signiﬁcantly and speciﬁcally
increased in dogs with untreated pITP.
The purpose of this pilot study was to quantify and compare the
transcription of BAFF in the blood of dogs with untreated pITP,
dogs with secondary thrombocytopenia, and healthy control dogs.
Quantitative real-time PCR (qRT-PCR) was used to assess BAFF
mRNA expression. Total RNA was isolated from 6 dogs with
untreated pITP, 5 healthy dogs, and 15 dogs with secondary throm-
bocytopenia. pITP was deﬁned as dogs that had platelet counts
<20,000 cells/mL, were PCR and serology negative for Babesia, Ehr-
lichia, and Anaplasma, had no evidence of neoplasia on abdominal
and thoracic imaging, and no history of drug administration (antibi-
otics, corticosteroids, vaccines, or chemotherapeutics). Secondary
thrombocytopenic control dogs had platelet counts below the refer-
ence interval due to diagnoses other than pITP, and healthy dogs
presented for wellness exams and had normal platelet counts. qRT-
PCR was performed using intron-spanning primers to amplify a 129
base pair region of the mRNA. b-actin was used as a reference gene.
The relative mRNA expression of BAFF in pITP dogs was
increased 12.13-fold and 3.25-fold compared to healthy control
dogs and dogs with secondary thrombocytopenia, respectively
(P < 0.01) (Figure 1).
These results indicate that relative expression of BAFF mRNA
is increased signiﬁcantly and speciﬁcally in dogs with pITP com-
pared to both healthy dogs and dogs with other causes of throm-
bocytopenia, similar to previous ﬁndings in people. Thus, BAFF
may be a useful biomarker to distinguish dogs with pITP from
those with other causes of thrombocytopenia. Using these primers
our group has also identiﬁed a canine macrophage cell line (030-
D) that expresses BAFF and is utilizing them for protein identiﬁ-
cation and quantitation as well as further characterization of
BAFF mRNA splice variants.
HM05
COMPARISON OF MULTIPLATE, PLATELET FUNCTION
ANALYZER-200, AND PLATELETWORKS IN DOGS TREA-
TED WITH ASPIRIN AND CLOPIDOGREL. Sophie Saati,
Anthony Abrams-Ogg, Shauna Blois, Darren Wood. University of
Guelph, Guelph, ON, Canada
In dogs, the antiplatelet drugs aspirin (ASA) and clopidogrel
may be used in an eﬀort to prevent thromboembolism. Response
to these drugs might be variable as in humans, therefore platelet
function testing may be warranted to monitor treatment eﬀect.
This study aimed to evaluate the eﬀects of ASA, clopidogrel, or
combination therapy, in healthy laboratory Beagles using three
platelet function tests: Multiplate Analyzer (MP), Platelet Func-
tion Analyzer-200 (PFA), and Plateletworks (PW). Secondary
goals were comparison of PW using two hematology analyzers:
Vetscan HM5 (using impedance) and ADVIA 2120 (using ﬂow
cytometry); and evaluation of the novel INNOVANCE P2Y car-
tridge for PFA to evaluate clopidogrel-induced platelet inhibition.
Six dogs were given ASA 1 mg/kg/day and placebo, clopidogrel
2 mg/kg/day and placebo, or a combination of both drugs, for
1 week each. Drugs were given in a randomized crossover design
(Latin square). Each dog was randomized to one of the three
treatments in three diﬀerent phases such that each dog received
each treatment. Investigators were blinded to the treatments. A
washout period of 2 weeks occurred between phases. Blood sam-
ples were collected on days 0 and 7 of each phase, and analyzed
using MP (adenosine diphosphate [ADP], arachidonic acid [AA],
collagen [COL] agonists), PFA (P2Y, COL-ADP, COL-Epinephr-
ine [EPI] cartridges), and PW (ADP, AA, COL agonist tubes)
using the two hematology analyzers.
Signiﬁcant (P < 0.05) changes in mean values pre and post
treatments were: For MP - Area under the curve (AUC) units (U)
was decreased with COL only with combination therapy (pre 19
U, post 6 U). AUC was decreased with AA with either clopido-
grel (pre 41 U, post 19 U) or combination therapy (pre 44 U, post
9 U). AUC was decreased with ADP with all treatments (ASA
pre 62 U, post 52 U; clopidogrel pre 59 U, post 13 U; combina-
tion pre 58 U, post 12 U). For PFA – closure time (CT) was
increased with the P2Y cartridge with clopidogrel (pre 95 seconds,
post >300 seconds) and combination therapy (pre 119 seconds,
post >300 seconds). CT was increased with the COL-ADP car-
tridge with clopidogrel (pre 65 seconds, post 185 seconds) and
combination therapy (pre 68 seconds, post 215 seconds). CT was
increased with the COL-EPI cartridge only with ASA (pre 167
seconds, post 235 seconds). For PW using the HM5 analyzer - %
aggregation (% Agg) with AA was decreased for all treatments
(ASA pre 80%, post 7%; clopidogrel pre 90%, post 4%; combi-
nation pre 78%, post 12%). With ADP, % Agg was decreased for
Levels of plasma BAFF mRNA in healthy dogs (control), dogs
with secondary thrombocytopenia (other TP), and dogs with ITP.
The ratios of BAFF mRNA in dogs with ITP compared to those
with secondary thrombocytopenia and healthy dogs are 3.25 and
12.13, respectively.
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clopidogrel (pre 45%, post 9%) and combination therapy (pre
47%, post 9%). PW results for HM5 and ADVIA 2120 showed
almost perfect agreement (kappa 0.83–0.98). Although the results
above revealed changes in mean values with treatments, results
were variable for individual dogs. The only tests for which every
dog’s individual values followed the changes in mean values were:
MP with COL with combination therapy; PFA with the P2Y car-
tridge with clopidogrel or combination therapy; PW with ADP for
clopidogrel or combination therapy, and PW with AA for all
treatments.
All three platelet function tests detected ASA and clopidogrel
eﬀects in some dogs and may have utility for monitoring antiplate-
let therapy. The P2Y cartridge was superior to the COL-ADP car-
tridge for detection of clopidogrel eﬀect with PFA. PW can be
performed with either Vetscan HM5 or ADVIA 2120, and PW
using AA was the only test that detected all drug eﬀects.
HM06
EVALUATION OF THE RISK OF RELAPSE OF CANINE
IMMUNE-MEDIATED THROMBOCYTOPENIA AFTER
ROUTINE VACCINATION. Jenny Ellis, Patricia M. Ward,
Robert D. Foale. Dick White Referrals, Six Mile Bottom,
Cambridgeshire, UK
Vaccination has been suggested as a cause of initial develop-
ment and relapse of immune-mediated thrombocytopenia (ITP),
although this relationship has not been deﬁnitively established in
dogs. This study aimed to identify cases of canine primary ITP
that had been vaccinated after cessation of treatment and to assess
if any of these vaccinated cases showed signs of relapse.
Records of animals diagnosed with ITP between 2004 and 2014
were retrospectively reviewed at a multi-disciplinary hospital.
Cases were included if a diagnosis of presumptive primary ITP
had been made with a platelet count of below 50x109/l (ref 200 –
500). Dogs diagnosed with secondary ITP were excluded, as were
cases that did not have assessment for underlying disease, with
minimum investigation required comprising full haematological
and biochemical assessment including blood ﬁlm evaluation,
abdominal ultrasonography and thoracic radiography. Infectious
disease PCR tests were also performed in some cases at the discre-
tion of the clinician involved. Referring veterinary practices were
contacted for follow-up information regarding length of treatment,
ongoing vaccination protocols including dates and vaccination
administered, and survival data as required.
One hundred and forty-six thrombocytopenic dogs were identi-
ﬁed, with 32 dogs not surviving to discharge. Sixty-eight dogs were
excluded due to detection of an underlying infectious or neoplastic
disease. Of the dogs with presumptive ITP, 11 were lost to follow-
up and 14 dogs were still receiving prednisolone or other immuno-
suppressive agents. Four of these dogs remained on long-term
prednisolone due to relapse when the dose was tapered.
Of the 21 dogs that were in remission with all immunosuppres-
sive treatment withdrawn, 9 did not receive any vaccinations after
diagnosis. None of these dogs showed signs of relapse during the
follow-up period. The remaining 12 dogs received at least one vac-
cination a minimum of one month after discontinuing all immuno-
suppressive treatments. One of these dogs had initially relapsed
early in the treatment course, prompting a longer treatment proto-
col before withdrawal of treatment. None of the dogs receiving
vaccinations once immunosuppressive treatment was withdrawn
showed signs of relapse, including those receiving multiple vaccina-
tions over several years. Vaccinations administered included a
combination of core boosters, intranasal vaccination for Bordetella
bronchiseptica, and one dog received a Rabies booster for travel.
These results failed to show an association between relapse of
presumptive primary ITP in dogs and vaccination, although the
possibility cannot be excluded. Future studies assessing higher
numbers of dogs would be required to further assess a potential
association.
HM07
PREDICTING IN VIVO RESPONSE TO LOW-DOSE
ASPIRIN IN HEALTHY DOGS USING IN VITRO PLATELET
AGGREGOMETRY. Rachel Hegedus, Pamela Lee, Michael
Court, Jillian Haines. Washington State University, Pullman, WA,
USA
Aspirin, or acetylsalicylic acid (ASA), is a cyclooxygenase inhi-
bitor that prevents the synthesis of hemostatically active prosta-
glandins. At low doses aspirin is used to inhibit platelet function
and ultimately thrombus formation. Some human patients appear
non-responsive to these antiplatelet eﬀects, termed “aspirin resis-
tance.” This same phenomenon has been identiﬁed in dogs and
could be a contributing factor to the formation of thromboemboli
in some at risk patients. Accurately predicting aspirin response
prior to treatment could prevent inappropriate drug therapy and
devastating thrombus formation in otherwise manageable diseases.
The objective of our study was to determine whether the ASA
concentration needed to cause 50% inhibition of platelet aggrega-
tion (EC50) measured using dog blood collected before ASA treat-
ment (i.e. the in vitro EC50) could be used to predict the EC50
value measured in the same dogs after administration of low-dose
oral aspirin (i.e. the in vivo EC50).
Twenty client-owned healthy dogs were utilized for this study.
In vitro testing was performed on two separate occasions at least
1 week apart to determine individual repeatability. Blood was
incubated with six concentrations of aspirin and aggregation was
measured using a multiple electrode impedance aggregometer
(Multiplate instrument). In vivo testing was performed at least
1 week after in vitro testing. The same dogs received a single
dose of 1 mg/kg aspirin orally and aggregation was assessed at
baseline prior to administration, then 20 minutes, 40 minutes,
and 180 minutes after administration. Additionally, plasma con-
centrations of ASA and salicylic acid (SA) were measured at each
time point using liquid chromatography–mass spectrometry (LC-
MS). SA is the major ASA metabolite and may be a better indica-
tor of ASA exposure (bioavailability) than ASA.
Calculation of an in vitro EC50 allowed dogs to be separated
into four diﬀerent response groups. Sixteen of the 20 dogs (80%)
had in vitro EC50 values below 250 umol/L consistent with an
appropriate aspirin response with mean  SD (range) values of
84.5  36.0 (34.8–151.4) umol/L. When these values were evalu-
ated for repeatability a mean diﬀerence of 44.9% was found with
the highest diﬀerence between independent measurements for each
dog of 95.1%. One dog showed a consistently poor response with
in vitro EC50 values between 250–500 umol/L at both times mea-
sured. Two dogs had substantial variation in their in vitro EC50
values between the two time points and were classiﬁed as variable
responders. One additional dog showed no signiﬁcant inhibition of
platelet aggregation at any time up to an ASA concentration of
3300 umol/L and was classiﬁed as a non-responder. In vivo aspirin
dosing at 1 mg/kg did not cause measureable inhibition of platelet
aggregation in any of the dogs after a single dose at any time
point. An in vivo EC50 could not be established based on these
ﬁndings as 50% inhibition was never achieved at this dose. Plasma
ASA and SA concentrations were available for 18 of 20 dogs. The
mean  SD (range) maximum plasma concentrations (Cmax) for
ASA were 0.23  0.21 (0 - 0.77) umol/L and for SA were 21  5
(14 - 34) umol/L. Two dogs did not have ASA concentrations
above the detection limit (0.03 umol/L).
This study suggests individual variation in aspirin response does
exist in dogs as assessed by multiple electrode aggregometry. A
single low dose (1 mg/kg) of aspirin was not suﬃcient to cause
measurable inhibition of platelet aggregation in healthy dogs and
resulted in ASA and SA concentrations that were substantially less
than the in vitro EC50. Low-dose (1 mg/kg) aspirin therapy may
not be a reliable antithrombotic therapy after only a single dose
thus necessitating the potential need for additional therapies dur-
ing the ﬁrst 24 hours. Further research looking at higher oral
aspirin doses or multiple day dosing is warranted to better estab-
lish an in vivo EC50 and determine the predictive value of in vitro
EC50 determination prior to commencement of therapy.
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RETROSPECTIVE EVALUATION OF ANEMIA AND ERY-
THROCYTE MORPHOLOGY IN DOGS WITH LYMPHOMA
AND INFLAMMATORY BOWEL DISEASE. Cyril Parachini-
Winter, Lisa Carioto, Carolyn Gara-Boivin. School of Veterinary
Medicine of the University of Montreal, Saint-Hyacinthe, Canada
The diﬀerentiation between intestinal lymphoma and inﬂamma-
tory bowel disease (IBD) can be diagnostically challenging. Ane-
mia is a frequent paraneoplastic syndrome in dogs with
lymphoma, and eccentrocytes have also been reported in canine
lymphoma. The purpose of this study was to assess the prevalence
of anemia and various RBC morphologic anomalies in the periph-
eral blood of dogs with a diagnosis of lymphoma or IBD, to deter-
mine if there is an association with the speciﬁc disease and with
the severity of lymphoma.
Medical records of 32 dogs diagnosed with all forms of lym-
phoma, 23 dogs diagnosed with IBD and 28 control dogs, pre-
sented to the Centre Hospitalier Universitaire Veterinaire between
2006 and 2014 were retrospectively reviewed. Each blood smear
was blindly re-assessed by a board-certiﬁed pathologist. A compar-
ison between the following 3 groups: healthy dogs, dogs with IBD
and dogs with lymphoma, as well as within the lymphoma group
(stages 1,2,3 versus 4/5, sub-stage a versus b, and small versus
intermediate/large cells) was performed for the following hemato-
logic parameters: hematocrit, hemoglobin, erythrocyte count, mean
corpuscular volume, and mean corpuscular hemoglobin concentra-
tion. The total numbers and each speciﬁc RBC anomaly were
compared between these 3 groups. RBC morphologic anomalies
were also categorized by the underlying pathologic process (regen-
erative anemia, oxidative stress, or other morphologic changes)
and compared between the 3 groups.
Prevalence of anemia was signiﬁcantly higher in dogs with lym-
phoma than dogs with IBD (P = 0.02) and healthy dogs
(P = 0.0001), and signiﬁcantly higher in stages 4 and 5 lymphoma
as compared to stage 1, 2 or 3 (P = 0.045). There was a signiﬁ-
cantly higher total number of RBC morphological anomalies in
the peripheral blood of dogs with lymphoma as compared to dogs
with IBD (P = 0.02) and healthy dogs (P < 0.0001). Dogs with
sub-stage b lymphoma also had a higher prevalence of total RBC
morphologic anomalies as compared to sub-stage a (P = 0.04).
When categorized by pathologic etiology, dogs with lymphoma
had a signiﬁcantly higher number of RBC anomalies associated
with regenerative anemia (P < 0.0001), oxidative stress
(P = 0.002), and other RBC anomalies (P < 0.0001) when com-
pared to healthy dogs, but no signiﬁcant diﬀerence when com-
pared to dogs with IBD. The prevalence of eccentrocytes was
signiﬁcantly higher in dogs with lymphoma compared to IBD
(P = 0.03), as well as healthy dogs (P = 0.002). No diﬀerences
were noted between small, intermediate and large cell lymphoma
for all parameters studied.
In conclusion, observation of anemia, of an increased total
number of RBC morphological anomalies on blood smear, and
speciﬁcally the presence of eccentrocytes could increase the clinical
suspicion of lymphoma when compared to IBD in dogs with a
suggestive clinical presentation.
HM09
AN IN-VITRO ASSESSMENT OF CANINE TO FELINE RED
BLOOD CELL XENOTRANSFUSION. Michele Wilkinson, Ian
McClure, Patricia Kaufman. Animal Blood Resources Interna-
tional, Stockbridge, MI, USA
Canine to feline xenotransfusions are increasingly reported in
the veterinary literature as a temporary but questionably eﬀective
means of addressing life threatening anemia in recipient cats. This
study was conducted to determine the in-vitro compatibility of
feline red blood cells (RBCs) with canine sera and conversely
canine RBCs with feline sera. Each cat and dog had a saline
assessment initially conducted to determine if pre-existing auto-
agglutination existed. Both major and minor cross matches were
performed, with major deﬁned as feline sera against canine RBCs
and minor deﬁned as feline RBCs against canine sera. All cross
matches were performed via manual technique at 4, 25 and 37
degrees Centigrade. The end assessment of incompatibility was
based on scored assessments of macroscopic or microscopic agglu-
tination and/or hemolysis of RBCs. The ﬁrst group of cross
matches consisted of 19 blood Type A cats against ﬁve dogs. The
dogs were selected to comprise a broad spectrum of the Dog Ery-
throcyte Antigen (DEA) possibilities. Each of the 19 cats had a
major and minor cross match with each of the ﬁve dogs at all
three temperatures for a total of 570 data points. None of the
cross matches were compatible (100% incompatibility). To expand
the database of canine bloodtypes, a second novel group of seven
blood Type A cats were major and minor cross matched against
ten dogs, ﬁve dogs of which were cohorts from the ﬁrst set of
cross match data. This yielded 420 data points for assessment of
compatibility. Similar to the ﬁrst data set, none of the cross
matches were compatible (100% incompatibility). This data sug-
gests there is an inherent incompatibility between dog and cat
blood regardless of components tested. Clinicians contemplating
canine to feline xenotransfusions should be cautious of utilizing
this technique even in the presence of life threatening anemia.
HM10
CHARACTERIZATION OF THE IMMUNOPHENOTYPE OF
DOGS WITH IMMUNE-MEDIATED HEMOLYTIC ANEMIA.
James Swann, Julia Wu, Barbara Glanemann, Oliver Garden.
Royal Veterinary College, London, UK
Whereas the clinical features of immune-mediated hemolytic
anemia (IMHA) have been described extensively in dogs, the
immunologic phenotype of this disease has yet to be fully charac-
terized. We hypothesized that this phenotype would diﬀer between
dogs with primary IMHA and dogs with inﬂammatory diseases
that did not have an immune-mediated etiology.
Serum and EDTA-anticoagulated blood samples were collected
from healthy control dogs (HC), dogs with primary IMHA
(IMHA), and dogs with inﬂammatory diseases (INF). Dogs were
considered to have primary IMHA if they were anemic (with
hematocrit less than 35%) and fulﬁlled one of the following crite-
ria: signiﬁcant spherocytosis on fresh blood smear, persistent
agglutination of erythrocytes after dilution in saline, or a titer of
greater than 1:16 in a direct antiglobulin test. Dogs were excluded
if any underlying cause of disease was detected by serum biochem-
ical testing, imaging of the thorax and abdomen and testing for
infectious agents. Dogs in the INF group had diseases that were
not considered to have an immune-mediated etiology and had no
previous history of autoimmune disease. Dogs in the HC group
had no previous history of autoimmune disease and had unre-
markable physical examinations. Owners of dogs consented for
collection and use of samples, and the study was approved by an
institutional ethical review committee.
After lysis of red blood cells, peripheral blood mononuclear
cells (PBMCs) were stained with ﬂuorophore-conjugated antibod-
ies speciﬁc for CD4, CD5, CD8, CD79b and FoxP3 and analyzed
by ﬂow cytometry to identify major lymphocyte subsets. Total
RNA was extracted from PBMCs for quantitative reverse tran-
scriptase polymerase chain reactions using primers for three
reference genes and for interferon gamma (IFNc) and interleukin
(IL)-10. The serum concentrations of ﬁve cytokines (IL-2, IL-6,
IL-8, IL-10 and TNFa) were measured using enhanced chemilumi-
nescent assays. Results of complete blood cell counts and serum
biochemical proﬁles were recorded for all INF and IMHA cases.
Samples were obtained from 25 IMHA dogs, in addition to 20
HC and 11 INF dogs; these groups had similar age and sex dis-
tributions. There was no diﬀerence in the proportion of regula-
tory T cells, helper T cells or cytotoxic T cells between groups
(P = 0.226), but the serum concentrations of IL-2 (P < 0.001)
and TNFa (P < 0.001) were signiﬁcantly greater in IMHA dogs
compared to either of the other groups. The serum concentra-
tions of IL-6 (P = 0.001) and IL-8 (P = 0.001) were signiﬁcantly
greater in IMHA dogs compared to HC, but there was no diﬀer-
ence compared to the INF group. There was no diﬀerence
between groups in the serum concentration of IL-10 (P = 0.731),
nor in the relative expression of IL-10 (P = 0.805) or IFNc
(P = 0.670). Principal component analysis revealed three major
factors underlying the variability in the dataset, of which one,
positively correlated with IL-2, IL-8, TNFa, blood monocyte
count, serum total bilirubin concentration and negatively
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correlated with hematocrit, diﬀered between IMHA and INF
dogs (P = 0.001).
Immunophenotyping of dogs with IMHA revealed increased
concentrations of some pro-inﬂammatory cytokines compared to
HC and INF dogs. Characterization of factors explaining variabil-
ity in all parameters suggested development of diﬀerent underlying
inﬂammatory processes in IMHA and INF groups. Further work
is required to determine whether these changes are associated with
survival and whether interventions that ameliorate the eﬀects of
IL-2 and TNFa might improve outcome in dogs with IMHA.
HM11
A RETROSPECTIVE STUDY ON USE OF LEFLUNOMIDE
IN DOGS WITH IMMUNE MEDIATED DISEASES. Masahiko
Sato, Julia Veir, Marie Legare, Michael Lappin. Colorado State
University, Fort Collins, CO, USA
Leﬂunomide is an immunomodulating agent labeled for the
treatment of rheumatoid arthritis and psoriatic arthritis in
humans. The drug inhibits the synthesis of ribonucleotide uridine
monophosphate pyrimidine which ultimately lessens lymphocyte
replication. This eﬀect could be of beneﬁt in the treatment of a
variety of immune mediated diseases in dogs. The pharmacokinet-
ics of leﬂunomide are known in dogs and the drug can suppress
lymphocyte proliferation in this species. However, little clinical
information concerning use of the drug in dogs is available. The
purpose of this retrospective study was to report safety and eﬃ-
cacy of leﬂunomide for the treatment of naturally occurring
immune mediated diseases in dogs.
Medical records from 1995–2014 at a USA Veterinary Teaching
Hospital were retrospectively searched for dogs with immune
mediated diseases administered leﬂunomide. Data that were
extracted from the medical records included signalment, body-
weight, underlying indication for leﬂunomide, dose of leﬂunomide,
treatment duration, concurrent medications, treatment response,
and adverse events. Dogs with immune mediated polyarthritis
(IMPA) were assessed for response to treatment on the basis of
clinical signs of IMPA and physical examination ﬁndings. Dogs
with immune mediated thrombocytopenia (IMTP) were assessed
for response to treatment based on platelet count. A dog with
cutaneous histiocytosis (CH) was assessed for treatment response
on the basis of gross appearance of the skin lesion.
A total of 92 cases were included. The mean dose of leﬂuno-
mide was 1.79  0.8 mg/kg/day. The median duration of the use
of leﬂunomide was 23.5 weeks. Adverse events which could be
related to leﬂunomide administration included diarrhea (3 of 92,
3.3%), lethargy (2 of 92, 2.2%), suspect blood dyscrasia (3 of 92,
3.3%), thrombocytopenia (2 of 31, 6.5%) and increased liver
enzyme activities (1 of 16, 6.3%). Leﬂunomide was discontinued
due to the possible adverse events in 6 dogs (6.5%). Signiﬁcant
dose diﬀerences between dogs with adverse events (n = 11,
2.6  0.8 mg/kg/day) and dogs without adverse events (n = 81,
1.7  0.8 mg/kg/day) were found (P < 0.001). The treatment
response could be evaluated in 9 dogs with suspected IMPA, 7
dogs with IMTP, and 1 dog with CH. All of the 9 dogs with
IMPA, 1 dog with IMTP and 1 dog with CH received leﬂunomide
without administration of concurrent immunosuppressant drugs.
Six of the dogs with IMTP received leﬂunomide with concurrent
immunosuppressant drugs, the doses of which were unchanged
when leﬂunomide was added to the treatment. Of these 17 dogs,
12 dogs (70.5%; 7 dogs with IMPA, 4 dogs with IMTP, 1 dog
with CH) had an apparent positive response to the use of leﬂuno-
mide. There was no signiﬁcant diﬀerence (P = 0.18) in doses
between dogs that responded to leﬂunomide (2.0  0.8 mg/kg/
day) and those that did not respond (1.5  0.4 mg/kg/day).
A lower starting dose of leﬂunomide of 2 mg/kg/day than the
current suggested dose of leﬂunomide of 3–4 mg/kg/day is recom-
mended based on the ﬁndings in this study.
HM12
EFFECTS OF LEUKOREDUCTION AND STORAGE ON
EICOSANOID CONCENTRATIONS IN UNITS OF CANINE
PACKED RED CELLS. Samantha Muro, Jung Hwa Lee,
Matthew Ross, Robert Wills, Todd Archer, Andrew Mackin, John
Thomason. Mississippi State University College of Veterinary
Medicine, Starkville, MS, USA
Storage of blood products creates an unnatural environment
that can accelerate product degradation and pose risk to the recip-
ient. Eicosanoids are arachidonic acid-derived bioactive molecules
that are involved in inﬂammation and can accumulate inside units
of packed red blood cells (pRBCs). Since leukocytes and platelets
are the primary sources of eicosanoid synthesis within units of
pRBCs, removal of these cells via leukoreduction may decrease
eicosanoid synthesis and potentially reduce the risk of transfusion-
related complications.
In this crossover study, units of blood were collected from 8
healthy dogs. In half of the units, leukocytes and platelets were
removed via leukoreduction. Units of pRBCs were then created
via centrifugation and stored for 10 or 21 days. Initial baseline
plasma samples were collected after processing and before storage
(Day 0). Additional samples were collected following storage for
10 or 21 days, both after removal from refrigeration and again
after 5 hours at room temperature (to simulate transfusion condi-
tions). Concentrations (ng/mL) of arachidonic acid (AA), prosta-
glandin E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin F2a
(PGF2a), thromboxane B2 (TXB2, stable metabolite of TXA2),
6-keto-prostaglandin F1a (6-keto-PGF1a, stable metabolite of
prostacyclin) and leukotriene B4 (LTB4) were quantiﬁed by liquid
chromatography-mass spectrometry.
There was no diﬀerence in AA, PGE2, PGD2, and LTB4 con-
centrations at any time point, and there was no diﬀerence in the
concentrations between leukoreduced and non-leukoreduced units.
Prior to storage (Day 0), there were signiﬁcantly greater concen-
trations of TXB2 in units of leukoreduced pRBCs compared to
non-leukoreduced units. In all leukoreduced samples, except for
Day 10 post-transfusion, the TXB2 concentrations decreased com-
pared to Day 0. Except for the pre-storage samples, there was no
diﬀerence in TXB2 concentrations between leukoreduced and
non-leukoreduced units. On both Days 10 and 21, there was a
signiﬁcant increase in 6-keto-PGF1a concentrations for both leuko-
reduced and non-leukoreduced units. There was no diﬀerence in
the 6-keto-PGF1a concentrations between leukoreduced and non-
leukoreduced units, except for the Day 10 post transfusion sam-
ples, in which the leukoreduced units were increased compared to
the non-leukoreduced units.
Prior to storage, the PGF2a concentrations were signiﬁcantly
greater in units of leukoreduced pRBCs compared to non-leukore-
duced units. However, for the remaining time points, the PGF2a
concentrations decreased compared to Day 0, and there was no
diﬀerence between leukoreduced and non-leukoreduced units.
In units of pRBCs, leukoreduction markedly inﬂuenced some
eicosanoid concentrations. In general, removal of platelets and
white cells tended to decrease production of most eicosanoids dur-
ing storage. For some eicosanoids, however, this eﬀect was coun-
teracted by the passage of blood through the leukoreduction ﬁlter,
which lead to marked increases in eicosanoid levels in units of
pRBCs prior to storage. Further studies will be needed to deter-
mine what impact the complex eﬀects of leukoreduction on eicosa-
noids in stored pRBCs will have on the incidence of transfusion
reactions.
HM13
INCIDENCE OF DEA 5 IN CANINE POPULATION USING
NOVEL CANINE ANTISERA. Ian McClure, Michele Wilkinson,
Patricia Kaufman. Animal Blood Resources International, Dixon,
CA, USA
Dog Erythrocyte Antigen (DEA) 5 is a red cell membrane
receptor, and is one of the six blood groups that have been
described having clinical implications1,2. Up until recently, blood
typing was unavailable for this antigen. Previous supplies of the
DEA 5 antisera had been exhausted, and the ability to create more
was seriously hindered. A novel antisera was recently discovered,
bringing back the ability to accurately blood type for the DEA 5
antigen.
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A proprietary testing methodology was developed for this antis-
era using known facts about the DEA 5 antigen. The antisera was
tested against canines previously known to be positive for the
DEA 5 antigen. The antisera proved to identify the DEA 5 anti-
gen with 100 percent positivity. Blinded in-house trials were per-
formed as well, and technicians could correctly identify canines
with the DEA 5 antigen.
Once the testing methodology was codiﬁed, and a Standard
Operating Procedure (SOP) written, testing for the DEA 5 antigen
moved into phase two, blind clinical testing. Two closed canine
colonies were tested for the DEA 5 antigen, one comprised entirely
of unrelated greyhounds, the other of mixed canines. Previously, a
portion of these mixed canines had been typed for the DEA 5
antigen, so the sample set had known positives mixed with
unknowns. Samples were blinded via identiﬁcation number. All
canines were infectious disease screened, up to date on vaccina-
tions and physical examinations. Testing on the two canine colo-
nies revealed an interesting ﬁnd. Previously, it was thought that
greyhounds had up to a 30% incidence rate of the DEA 5 anti-
gen3. However, in testing of the closed greyhound colony, the inci-
dence rate proved to be zero. In a mixed breed closed canine
colony, the incidence of the DEA 5 antigen proved to be 21.6%.
All previously known DEA 5 antigen positive mixed canines were
correctly identiﬁed by laboratory technicians.
In phase three of the testing methodology, clinical samples sent
to the laboratory were typed for the DEA 5 antigen to establish
an incidence rate. Over a period of two months, the laboratory
used convenience sampling to test for the DEA 5 antigen. At the
closing of phase three, a total of 777 random canine samples were
tested, with a total of 63 canines testing positive for the DEA 5
antigen, resulting in an incidence rate of 8.1 %, consistent with
previously known incidence rates. Therefore, at the conclusion of
phase three, it was determined the novel antisera was valid for the
detection of the DEA 5 antigen.
With the re-introduction of a novel anti-DEA 5 reagent, a more
complete proﬁle of canine blood types can be achieved. This can
result in better clinical decision making regarding transfusion in
the canine patient, and therefore better outcomes, including the
avoidance of delayed transfusion reactions when a DEA 5 incom-
patibility exists.
1. Colling, DT, Saison R: Canine Blood Groups: II. Description
of a new allele in the Tr Blood Group System. Animal Genetics
11:13–20, 1980.
2. Symons M, Bell K: Canine blood groups: Descriptions of 20
speciﬁcities. Animal Genetics 23:509–515, 1992.
3. Hale, Anne: Canine Blood Groups and Their Importance.
Transfusion Medicine25:6 1995.
HM14
PROSPECTIVE STUDY IN THE TREATMENT OF NONRE-
GENERATIVE IMMUNE-MEDIATED ANEMIA IN 8 DOGS.
Keitaro Morishita, Kyosuke Takeuchi, Shunsuke Mori, Sayuri
Hayakawa, Kensuke Nakamura, Noboru Sasaki, Hiroshi Ohta,
Mitsuyoshi Takiguchi. Hokkaido University, Sapporo, Japan
Nonregenerative immune-mediated anemia (NRIMA) is a com-
mon hematologic disorder in dogs. Because the bone marrow of
the aﬀected dogs shows erythroid hyperplasia and/or erythroid
maturation arrest, it has been recognized as immune-mediated
destruction of erythroid precursor cells. A variety of immunosup-
pressive agents have been used in the treatment of this disease, but
information regarding the therapeutic eﬃcacy is limited due to the
lack of prospective research. The aim of this pilot study was to
assess the treatment outcome to the pre designed immunosuppres-
sive regimen including corticosteroids, cyclosporine and mycophe-
nolate mofetil.
8 dogs with NRIMA referred to Hokkaido university teaching
hospital between 2012 and 2015 were included. Inclusion criteria in
this research were a minimum 5-day history of anemia, a severe
nonregenerative anemia (Hct < 20%) with absolute reticulocyte
count < 60 9 103/ll, and absence of any identiﬁable underlying
disease which could induce severe anemia. The following data were
collected for each dog: age, breed, sex, results of hematological
analyses performed on admission, results of bone marrow examina-
tion. First treatment regimen included prednisolone (2 mg/kg/day)
and cyclosporine (10 mg/kg/day) for 8 weeks. Good response were
deﬁned as an absolute reticulocyte count > 60 9 103/ll or increas-
ing Hct. Dogs that responded within 8 weeks continued to be trea-
ted with gradual tapering of dose, and re-evaluated after 6 month.
Dogs that did not respond to the ﬁrst regimen proceeded to second
regimen including prednisolone and mycophenolate mofetil
(15 mg/kg, twice a day). Similarly, good response for second regi-
men was determined as explained above and dogs that did not
respond to both regimens were deﬁned as poor response.
Dogs ranged 5 to 9 years old (median age, 9.5 years), and
included 5 castrated males, 2 intact females and 1 spayed female.
There were 6 miniature dachshunds, 1 Shih-tzu and 1 Papillon.
Median Hct and absolute reticulocyte count were 16.3% and
59,640/ll, respectively. Bone marrow erythroid series were evalu-
ated as hyperplasia in 5 dogs, euplasia in 2 dogs and hypoplasia in
1 dog. Erythroid maturation arrest was observed in all dogs. 6 of
8 dogs underwent core biopsy and 2 dogs showed myeloﬁbrosis. 5
of 8 dogs responded to the ﬁrst regimen and time to response was
between 28 and 52 days. 3 dogs stopped receiving the ﬁrst regimen
due to anorexia that might be induced by Cyclosporine. 6 month
prognoses of the other 2 dogs were complete remission (CR: Hct
increased to reference range) and partial remission (PR: Hct did
not reach the reference range), respectively. 3 dogs that did not
respond to ﬁrst regimen were proceeded to the second regimen. 1
of 3 dogs showed response after 29 days and 6 month prognosis
was PR. The other 3 dogs that discontinued receiving Cyclospor-
ine were also proceeded to the second regimen, and 6 month prog-
noses were CR in 2 dogs and PR in 1 dog. 2 dogs that did not
show any response to both treatments had myeloﬁbrosis.
In this research, response to both regimens could be evaluated
in 6 dogs and median response time was 35 days (range 28–52).
These results may be valuable for practitioners in consideration of
changing immunosuppressive agent.
HM15
VALIDATION OF RAPID THROMBOELASTOGRAPHIC
ANALYSIS ON CITRATED AND NATIVE WHOLE BLOOD
FROM HEALTHY DOGS. Hye-Bin Wang1, Hyeri Shin1,
Jin-Young Chung2, Kun-Ho Song1, Kyoung-Won Seo1. 1Chungnam
National University, Daejeon, Korea, 2Kangwon National
University, Chuncheon, Korea
Thromboelastography (TEG) is rapid and non-invasive diagnos-
tic instrument that has been used in veterinary medicine for evalu-
ation of haemostatic function in whole blood (WB). Recently,
rapid thromboelastography (r-TEG) has been recognized as an
overall evaluation of coagulation abnormalities in human medicine
and become available faster than conventional coagulation tests
(CCTs). Although r-TEG is becoming more generally used in
human medicine, there are no studies describing the use of r-TEG
in veterinary medicine. The objectives of this study were to 1) vali-
dation of r-TEG values with native and citrated WB samples from
healthy dogs, and to compare stability and repeatability between
two types of samples, and 2) examine whether the use of r-TEG
could accelerate the coagulation pathway and decrease in taken
time in comparison to kaolin activated TEG. Blood was collected
from 16 clinically healthy Beagle dogs. TEG analysis was per-
formed on kaolin-activated, citrated r-TEG, and native r-TEG
blood samples. TEG activated clotting time (ACT), kappa value
(k), alpha angle (a), and maximum amplitude (MA) were
recorded. Coeﬃcients of variation (CV) of native r-TEG and
citrate r-TEG for TEG ACT, K, a angle, and MA were 13.4/
18.8%, 11.1/16.6%, 4.2/5.1% and 10.0/10/0%, respectively. The
mean time for the citrated and native r-TEG were 1313.9  250.9/
1351.3  264.6 seconds (mean  SD) respectively, in comparison
with 1779.9  197.0 seconds for kaolin activated TEG.
The native and citrated r-TEG tests were taken signiﬁcantly less
time than the kaolin activated TEG test (P < 0.05). Based on the
results of this study, the r-TEG can evaluate haemostatic status
rapidly than other coagulation tests and it is expected to be use-
fully used in critical setting in veterinary medicine.
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SERIAL EVALUATION OF THROMBOELASTOGRAPHY
AND PLATELET AGGREGOMETRY IN HEALTHY DOGS.
Sarah Shropshire, Christine Olver, Michael Lappin. Colorado
State University, Fort Collins, CO, USA
The coagulation system is comprised of many complex interac-
tions where a balance between the pro-thrombotic and ﬁbrinolytic
arms is necessary to maintain normal hemostatic function. Throm-
boelastography (TEG) and platelet aggregometry are specialized
assays that help to evaluate the viscoelastic properties of blood
clotting and platelet function, respectively. If interindividual vari-
ability is high, serial evaluation within an individual rather than
single measurements may provide greater sensitivity to detect clini-
cally signiﬁcant changes. If the intraindividual variability is greater
than the interindividual variability however, then serial evaluation
would not oﬀer increased sensitivity. The purpose of this study
was to compare interindividual and intraindividual variability over
time for TEG and platelet aggregometry variables in healthy dogs.
Tissue factor activated TEG was performed in six speciﬁc
pathogen free (SPF) sex and age-matched healthy Beagles at three
diﬀerent time points where the variables reaction time (R), clotting
time (K), rate of clot formation (a), and maximum amplitude
(MA) were recorded. Adenosine diphosphate (ADP)-induced and
arachidonic acid (AA)-induced platelet aggregometry in addition
to platelet count, hematocrit, and ﬁbrinogen were also performed
concurrently. APTT, OSPT, antithrombin activity, and D-dimer
concentrations were measured on the ﬁrst day of the study. A one-
way random eﬀects model was used to analyze the following vari-
ables; R, K, a, MA, area under the curve for ADP (AUCADP),
and area under the curve for AA (AUCAA). Variance components
were created from the random eﬀects model and used to calculate
coeﬃcients of variation for interindividual variability (CVG) and
intraindividual variability (CVI). A repeated measures ANOVA
was performed on the platelet count, hematocrit, and ﬁbrinogen
over the three time points with P < 0.05 considered signiﬁcant.
The intraindividual variability was lower than the interindivid-
ual variability over time for MA, AUCADP, and AUCAA however
the intraindividual variability was higher than the interindividual
variability for the TEG variables R, K, and a. There were no sta-
tistical diﬀerences in the platelet count, hematocrit, and ﬁbrinogen
measurements over time.
Based on the results of this study, serial measurements for ADP
and AA-induced platelet aggregometry and the TEG variable MA
may provide a more sensitive method to detect relevant changes
when monitoring patients. However, due to the high intraindivid-
ual variability for the TEG variables R, K, and a, serial measure-
ments may not be more beneﬁcial than a single measurement and
comparing it to population based reference intervals.
HP01
FLUORESCENCE IN SITU HYBRIDIZATION IDENTIFIES
OCCULT BACTERIAL INFECTION IN GALLBLADDER
MUCOCELES. Sara Wennogle1, David Twedt1, Kenneth Simp-
son2. 1Colorado State University, Fort Collins CO, USA, 2Cornell
University, Ithaca NY, USA
Gallbladder mucocele is a commonly recognized form of gall-
bladder disease in the dog that is characterized by cystic mucinous
hyperplasia and insidious accumulation of viscous bile and mucus
within the gallbladder. Although several predisposing factors have
been proposed, the underlying etiology of gallbladder mucocele
formation is unknown. Previous studies have found limited associ-
ations with cholecystitis or bacterial infection. The aim of this
study was to utilize culture-independent, ﬂuorescence in situ
hybridization (FISH) to determine the presence of bacteria in gall-
bladder mucoceles with and without concurrent cholecystitis.
Electronic medical records at Colorado State University were
reviewed for cases of histopathologically conﬁrmed gallbladder
mucocele between December 2010 and January 2015. 29 cases were
available and suitable for evaluation. Case data included patient
signalment, clinical signs, clinicopathological abnormalities, ultra-
sonographic ﬁndings, histopathology, and bacterial culture of bile
and liver. Formalin-ﬁxed, paraﬃn-embedded gallbladder sections
were mounted on charged glass slides and evaluated by FISH
using a eubacterial probe (5Cy3-EUB-338) concurrently with a
control probe (56 FAM-Non-EUB-338). Sections were examined
on a BX51 epiﬂuorescence microscope, and images were captured
with an Olympus DP-7 camera.
Dogs undergoing cholecystectomy for treatment of gallbladder
mucocele ranged in age from 6–14 years old. The most common
breeds were mixed (n = 10), Shetland Sheepdog (n = 3), Miniature
Schnauzer (n = 2), Pomeranian (n = 2), and Miniature Dachshund
(n = 2). Ultrasound was performed in all 29 cases, with 22/29
(76%) exams concluding the appearance of the gallbladder was
consistent with a mucocele. Histopathology revealed cystic muci-
nous hyperplasia in all cases, with associated cholecystitis noted in
13/29(45%) cases. Bacteria were detected by eubacterial FISH in
8/29 (28%) cases. Bacteria were visualized as multifocal clusters of
short rods within the mucus (n = 1), adherent to the wall (n = 1),
or within the parenchyma (n = 4) in 6/29 (21%) gallbladders. In 2
cases, a single bacterium was observed within the gallbladder par-
enchyma. Of the 6 cases with multifocal bacteria, 4 had concurrent
cholecystitis. Bacterial culture of mucocele contents was positive in
only 1/24 cases, yielding moderate growth of Escherichia coli.
FISH analysis of this case showed diﬀuse colonization of mucocele
contents and mucosa by E. coli.
FISH detected the presence of bacteria in 28% of mucoceles
evaluated. FISH was more sensitive than bacterial culture, which
was positive in only 1/8 cases with visible bacteria. Our results
reveal that bacterial infection is more common than previously
thought, and support the need for further studies to examine the
relationship between gallbladder mucoceles, cholecystitis, and bac-
terial infection.
HP02
ASSOCIATION OF GALLBLADDER MUCOCELE FORMA-
TION WITH OCCULT HYPOTHYROIDISM IN DOGS: A
MATCHED CASE-CONTROLLED STUDY. Kathleen Aicher,
John Cullen, Gabriela Seiler, Katharine Lunn, Kyle Mathews,
Maria Correa, Jody Gookin. North Carolina State University,
Raleigh, NC, USA
Gallbladder mucocele (GBM) formation results from accumula-
tion of viscous bile that obstructs or ruptures the gallbladder.
After cholecystectomy a median of 27% of dogs die before hospi-
tal discharge. The cause of GBM formation is unknown. Retro-
spective studies identify 14–17% of dogs with GBM have a
diagnosis of hypothyroidism compared to 5–9% of normal dogs.
Whether hypothyroidism is an independent risk factor for GBM
formation or the consequence of an underlying metabolic syn-
drome is unknown. This distinction has important implications
regarding the cause of GBM formation and may establish a ratio-
nale for diagnosis or treatment of hypothyroidism in these dogs.
We undertook a prospective case controlled study of dogs newly
diagnosed with GBM formation and lacking clinical signs of
hypothyroidism to test a hypothesis that occult hypothyroidism
exists at a high prevalence in these dogs and that the cause may
diﬀer from classic lymphocytic thyroiditis. Dogs diagnosed with
GBM by ultrasound and healthy, age, breed and sex-matched dogs
with normal gallbladder ultrasound were enrolled. Exclusion crite-
ria included clinical evidence, prior diagnosis or treatment for
hypothyroidism; drugs interfering with thyroid function, intact
reproductive status, or emergent disease. Testing included a CBC,
chem panel, UA, thyroid function testing including serum total
T4, total T3, free thyroxine by equilibrium dialysis (FT4), free tri-
iodothyronine (FT3), thyrotropin (TSH) and autoantibodies to
T4AA, T3AA and TGAA. Dogs were stratiﬁed by disease severity
into 1) no clinical signs, 2) mild clinical disease, 3) moderate to
require hospitalization, and 4) severe requiring intensive care (incl.
emergent surgery). Thyroid histology of GBM dogs and controls
was examined by a pathologist blinded to the diagnosis. Paramet-
ric data were analyzed by t-test and non-parametric data by
Mann-Whitney U test. P < 0.05 was considered signiﬁcant. Of 106
screened dogs, 38 with GBM met study inclusion criteria and ran-
ged in age from 6–16 years (median 10.5 yrs). Breeds included 11
Shetland sheepdogs, 4 Cocker Spaniels, 3 Chihuahuas, 3 Beagles,
and 16 other pure breeds. Illness severity scores were: 37% absent;
21% mild; 21% moderate; and 21% severe. Of 18 healthy dogs
screened, 12 were enrolled. Dogs with GBM had signiﬁcantly
2016 ACVIM Abstracts 1471
lower serum T4 (median 11, range 0–44 nM), T3 (median 0.7,
range 0–1.7 nM), FT4 (median 15, range 1–27 pM), and FT3 (me-
dian 3, range 0–10.5 pM) compared to control dogs. Relative to
control dogs, dogs with GBM frequently had severely low individ-
ual thyroid hormone concentrations. Serum T4 was below refer-
ence range (RR) in 50% of GBM dogs compared to 8% controls.
Four (10.5%) GBM dogs had a T4 = 0. Serum T3 was below RR
in 47% of GBM dogs compared to 25% controls. Three (8%)
GBM dogs had a T3 = 0. Serum FT4 was below RR in 12% of
GBM dogs compared to 0% controls. Serum FT3 was below RR
in 17% of GBM dogs compared to 0% controls. Signiﬁcant diﬀer-
ences in T4AA, T3AA or mean TSH were not identiﬁed. However
23.5% of GBM dogs and only 8% control dogs had an elevated
TSH. Serum TGAA was elevated in 17% of control dogs and 0%
of GBM dogs. No inﬂammation was detected in the thyroids of
any of 12 dogs with GBM undergoing autopsy. These results iden-
tify a high prevalence of occult, often severe, decreases in individ-
ual serum thyroid hormone concentrations in GBM dogs.
Inﬂuence of non-thyroidal illness must be considered for some of
these abnormalities. Lack of serum TGAA and absent histologic
inﬂammation in thyroids of GBM dogs is noteworthy. These ﬁnd-
ings suggest that an alternative mechanism for abnormal thyroid
function in dogs with GBM should be considered.
HP03
INTEROBSERVER AGREEMENT FOR HISTOLOGICAL
SCORING OF CANINE HEPATIC FIBROSIS. Jonathan Lid-
bury1, Aline Rodrigues Hoﬀmann1, Fabiano Olivera2, Brian Por-
ter1, Thomas Van Winkle3, Jan Suchodolski1, Guy Grinwis4,
Renata Ivanek1, John Cullen5, Joerg Steiner1. 1Texas A&M
University, College Station, TX, USA, 2Antech Diagnostics,
College Station, TX, USA, 3University of Pennsylvania, Philadel-
phia, PA, USA, 4Utrecht University, Utrecht, The Netherlands,
5North Carolina State University, Raleigh, NC, USA
Hepatic ﬁbrosis is an important complication of canine chronic
hepatitis. To the authors’ knowledge, the interobserver agreement
associated with the histological scoring of ﬁbrosis from canine
hepatic biopsy specimens has not previously been reported. There-
fore, the aim of this study was to evaluate the interobserver agree-
ment for the histological scoring of canine hepatic ﬁbrosis.
Paraﬃn-embedded liver specimens from 50 dogs were selected
from the tissue archives at Texas A&M University and North Car-
olina State University. Two contiguous sections were cut from
each specimen, one was stained with hematoxylin and eosin
(H&E) and one with picrosirius red (PR). Six board-certiﬁed vet-
erinary pathologists assigned a ﬁbrosis score (0: absent, 1: mild, 2:
moderate, 3: marked, or 4: very marked) to each section using a
scoring system adapted from the Ishak scoring system that is used
in humans. Interobserver agreement for the H&E and PR stained
sections was evaluated using the kappa and weighted-kappa statis-
tics. The median ﬁbrosis score assigned to H&E and PR stained
sections from each dog were compared using the Wilcoxon signed-
rank test.
Multiuser kappa (95% CI) for H&E stained sections was 0.35
(0.26  0.44) and multiuser weighted-kappa was 0.59 (0.50 
0.70). Pathologists were in complete agreement 49% of the time,
diﬀered by one score level 41% of the time, and diﬀered by more
than 1 score level 11% of the time. Multiuser kappa (95% CI) for
PR stained sections was 0.39 (0.30  0.49) and multiuser
weighted-kappa was 0.64 (0.55  0.73). Pathologists were in com-
plete agreement 53% of the time, diﬀered by one score level 42%
of the time, and diﬀered by more than one score level 5% of the
time. There was no signiﬁcant diﬀerence in the median ﬁbrosis
scores assigned by the 6 pathologists between H&E and PR
stained sections (both medians were 2; P = 0.248).
There was only fair interobserver agreement when veterinary
pathologists assessed canine hepatic ﬁbrosis from H&E or PR
stained sections. However, because there was frequent partial
agreement between pathologists, this scoring system may be
acceptable for clinical use. A clear beneﬁt of the routine staining
with PR for the assessment of hepatic ﬁbrosis was not demon-
strated in this study.
HP04
EMBOLIZATION OF INTRATRAHEPATIC PORTOSYS-
TEMIC SHUNTS IN DOGS WITH A PROTOTYPE COIL.
Matthias Schneider, Andreas Stosic, Stephan Bayer. Small Animal
Clinic, Giessen, Germany
Surgical treatment of intrahepatic portosystemic shunts (iPSS) is
challenging. Frequently, multiple interventions are needed to avoid
portal hypertension and to achieve a complete closure. Complica-
tions seen in catheter-assisted embolization with commercial coils
include coil migration, portal hypertension (rapid thrombotic
occlusion), and incomplete occlusion. Attenuation of hepatic vein
by means of stent-supported coil embolization may lead to the
development of intrahepatic venous collaterals. In the present
study we postulated that implantation of a single prototype coil
combined with immediate unfractionated heparin therapy (UHT)
is an eﬀective treatment for iPSS in dogs and has fewer complica-
tions than reported with open surgery.
Dogs with single iPSS with or without intrahepatic venous col-
laterals were included. A percutaneous access to the right jugular
vein was used for retrograde portal vein catheterization. Portal
vein pressure and iPSS diameter were measured unblocked and
blocked (balloon catheter: 8F wedge catheter or 20/27 mm occlu-
sion catheter). The prototype coil with polyester ﬁbers was selected
to be either at least 1 mm larger in diameter than the blocked iPSS
or twice the diameter of the unblocked iPSS, and was implanted
using an 8F guiding catheter. Coagulation times were assessed by
activated coagulation time (ACT) at baseline and during UHT.
Heparin was started before coil implantation with a bolus of
100 IU/kg (injected into the portal vein), followed by continuous
rate infusion (25 IU/kg/h). Postoperatively, UHT was adminis-
tered 150 IU/kg q6 h subcutaneously and intermittent 50 IU/kg
intravenously to achieve an ACT of 150 to 200 seconds, and then
adjusted based on sonographic proven development/resolution of
ascites. Functional closure was judged according to the result of
the oral ammonia tolerance test. Descriptive statistics and Kaplan-
Meier analysis was used.
The prototype coil was implanted in a total of 25 dogs. Most
common breeds were Hovawart (n = 8) and Golden Retriever
(n = 5). Median age was 10 months (range 6 – 35) and median
body weight 26 kg (range 12 – 48). iPSS originated from the right
lateral (n = 1), right medial (n = 7) or left portal vein branch
(n = 17). 19/25 dogs showed portal hypertension during shunt
blocking. Unblocked and blocked shunt diameter were
5.2 - 13.0 mm (median 8.3; n = 25) and 9.0 - 21.0 (median 13.3;
n = 24), respectively. Intervention was successful at the ﬁrst
(n = 24) or second (n = 1) intervention. Major complications devel-
oped in 5 dogs leading to death in 2 dogs. Minor complications
were common and were mostly associated with bleeding problems.
One dog was lost to follow-up after three months. Of the remaining
22 dogs, 5 experienced complications associated with change to a
non-protein restricted diet: severe neurological abnormalities lead-
ing to euthanasia (n = 1), moderate symptoms leading to re-inter-
vention (n = 2), mild symptoms which could be treated successfully
by changing to a moderately protein restricted diet (n = 2). All dogs
without portal hypertension showed functional closure at 3 months
follow-up. In dogs with portal hypertension the cumulative propor-
tion of functional closure reached 81% at 24 months follow-up.
In conclusion, stiﬀness and size of the prototype coil were
responsible for the high procedural success and functional closure
rates. Unfractionated heparin treatment needs optimization to
reduce complications, but the general treatment regimen seems
promising.
HP05
INVESTIGATION OF HEPATIC COPPER ACCUMULATION
IN DOGS FROM TWO TIME PERIODS (1982–1988 AND
2009–2015). Ryan Schultz, Rebecca Smedley, John Buchweitz,
Katie Barnes, Sarah Abood, Daniel Langlois. Michigan State
University College of Veterinary Medicine, East Lansing, MI,
USA
Canine copper-associated hepatitis (CCAH) has become an
increasingly recognized cause of progressive and potentially fatal
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liver disease in dogs; however, the exact etiology remains unclear.
To date, no broad epidemiologic investigations quantifying hepatic
copper concentrations over time in both predisposed (to CCAH)
and non-predisposed breeds have been conducted. The purpose of
our study was to determine and compare quantitative hepatic cop-
per concentrations in breeds that are, or are not, predisposed to
CCAH from two study periods. We hypothesized that hepatic cop-
per concentrations have increased for all dogs over time, but the
relative increase will be greater in predisposed breeds. A retrospec-
tive search of the histopathology database at the Michigan State
University Diagnostic Center for Population and Animal Health
was conducted for two study periods: 1982 through 1988, and
2009 through 2015. Doberman Pinschers, Labrador Retrievers,
and West Highland White Terriers were considered predisposed to
CCAH. Dalmatians, Skye Terriers, and Bedlington Terriers were
excluded from analysis due to a rarity of cases, limited informa-
tion on predisposition, or a known genetic etiology, respectively.
Cases with archived liver tissue available were randomly selected,
reviewed, and then classiﬁed by breed and presence or absence of
inﬂammatory liver disease. Hepatic copper concentrations (parts
per million, dry weight basis) were measured in all specimens using
inductively coupled plasma mass spectrometry. Comparisons were
made within and across groupings using commercially available
statistical software.
A total of 373 cases were evaluated, including 207 dogs predis-
posed to CCAH and 166 non-predisposed dogs. Independent of
breeds groupings and inﬂammatory activity, mean hepatic copper
concentrations in the recent time period were 225 ppm greater
than those in the historical time period (P < 0.05). This eﬀect was
predominantly due an increase of 386 ppm over time in predis-
posed breeds (P < 0.001). The mean hepatic copper concentration
of 338 ppm in non-predisposed breeds in recent years was greater
than the mean hepatic copper concentration of 271 ppm in non-
predisposed breeds in the historical period, but this trend did not
reach signiﬁcance (P = 0.08). In the recent period, the mean hep-
atic copper concentration of 519 ppm in predisposed breeds with
non-inﬂammatory liver histology was greater than the mean hep-
atic copper concentration of 297 ppm in non-predisposed breeds
with non-inﬂammatory liver histology (P < 0.001). This diﬀerence
was not observed in the historical time period. In both periods,
dogs with hepatitis had higher hepatic copper concentrations than
those without hepatitis, but this diﬀerence was magniﬁed in recent
years. In the aggregate, these ﬁndings conﬁrm that hepatic copper
concentrations have changed over time. The etiology of these
changes is unknown, but suggestive of changes in environmental
copper exposure. Detailed investigations of potential sources of
copper exposure, namely drinking water and diet, are needed to
further elucidate a potential environmental etiology. Additional
investigations also are needed to determine if these changes are
important for all breeds of dog.
ID01
EVIDENCE FOR GENETIC PREDISPOSITON TO BORRE-
LIA BURGDORFERI INFECTION IN PURPOSE BRED
BEAGLES. Elena Contreras1, Scott Moroﬀ2, Michael Lappin1.
1Department of Clinical Sciences, Colorado State University
Veterinary Teaching Hospital, Fort Collins, CO, USA, 2Antech
Diagnostics, Lake Success, NY, USA
Borrelia burgdorferi (BB) and Anaplasma phagocytophilum (AP)
are transmitted by Ixodes spp., and seroprevalence rates in ende-
mic areas can be greater than 15% in dogs. A genetic predisposi-
tion to infection (Bernese mountain dogs) or clinical illness
associated with BB has been suggested, particularly in people and
dogs with Lyme nephritis (Retriever breeds). In vaccine studies,
wild caught I. scapularis adults placed in feeding chambers and
allowed to feed for seven days usually results in at least a 75% BB
infection rate. Recently, an I. scapularis infestation study using a
previously reported model and ticks with a similar BB carriage
rate from the same collection area previously used, resulted in only
a 29.2% infection rate. The purpose of this report is to describe
the genetic relatedness of the dogs used in that study.
A total of 10 female and 14 male purpose-bred beagles,
9–12 months of age, and negative for antibodies against A. phago-
cytophilum, B. burgdorferi, and E. canis (Accuplex 4 BioCD
system; Antech Diagnostics), were infested for 7 days with 13
female and 12 male wild-caught I. scapularis with an estimated 48%
BB infection rate and a 15% AP infection rate. Blood was collected
from all dogs prior to tick attachment and then on Weeks 1–12 and
Week 18 after tick attachment and screened for BB and AP anti-
bodies as described. Dogs that seroconverted were assumed to have
been infected. Statistical analyses were performed with commercial
software; P ≤ 0.05 was considered statistically signiﬁcant.
Antibodies against BB were detected in 7 of 24 dogs (29.2%)
between 4–8 weeks post-infestation; all positive dogs were females
(P = 0.0003). When positive and negative dogs were compared,
there were no signiﬁcant diﬀerences in the ages, number of ticks
recovered, or number of fed ticks. Antibodies against AP were
detected in the serum of 10 of 24 dogs (41.7%). Results using the
same source of dogs, ticks, and model in previous publications were
77.8% and 55.5%% for BB and AP, respectively. The diﬀerences in
infection rates between the current and historical studies were simi-
lar for AP but signiﬁcantly lower in the current study for BB
(P = 0.004). The most recent common ancestor (MRCA) for 6 of
the 7 (86%) BB-positive dogs was either a sibling or parent. Dogs A
and B were siblings and had the same father as Dog C. The mother
of Dog D was the maternal grandmother of Dogs A and B. The
father of Dog E was the paternal great grandfather of Dogs A, B, C.
The mother of Dog F was the maternal grandmother of Dog E. The
MRCA for 8 of the 17 (47.1%) BB-negative dogs was either a sibling
or parent. None of the BB positive dogs had a MRCA sibling or
parent in common with any of the BB negative dogs.
These ﬁndings provide further evidence that a genetic predispo-
sition to B. burgdorferi infection exists. As studies have investi-
gated common genotypes and alleles among humans with Lyme
borreliosis and arthritis, this should also be considered in future
studies of canine Lyme borreliosis.
ID02
RAPID DIAGNOSIS OF BABESIA GIBSONI USING POINT-
OF-CARE INSULATED ISOTHERMIC POLYMERASE
CHAIN REACTION ASSAY. Kirsten Cooke1, Patrick Frenzer1,
Julie K. Levy1, Sylvia Tucker1, P. Cynda Crawford1, Sarah Kirk2.
1University of Florida, Gainesville, FL, USA, 2The American
Society for the Prevention of Cruelty to Animals, New York, NY,
USA
Babesia gibsoni is commonly identiﬁed in pit bull-type dogs,
particularly those involved in dogﬁghts. Dogs seized from ﬁghting
operations undergo health and behavior evaluations to assess suit-
ability for adoption. Adoption carries the risk for sending dogs
harboring infectious diseases to unsuspecting owners or to regions
where the infections are not endemic. Screening large numbers of
dogs for infectious diseases is expensive and it may be days before
results are available. A more rapid and cost-eﬀective diagnostic
test would make identiﬁcation and treatment of B. gibsoni infected
dogs more feasible for rescue organizations. Recently, the develop-
ment of insulated isothermic PCR (iiPCR) has made mobile PCR
a reality. The purpose of this study was to determine performance
of the POCKIT iiPCR system for diagnosis of B. gibsoni in dogs
rescued from ﬁghting organizations.
Whole blood was collected from 260 pit bull-type dogs rescued
during a federal dogﬁghting investigation. Real-time PCR was per-
formed for Babesia species, and positive samples underwent a sec-
ond round of species-speciﬁc PCR in a commercial diagnostic
laboratory (IDEXX Laboratories, Inc.). Residual whole blood
samples were frozen and stored at -80 C pending subsequent anal-
ysis. POCKIT iiPCR was performed twice on each sample, once
with a kit speciﬁc for B. gibsoni and once with a kit that detects
both B. gibsoni and Babesia canis (Babesiosis). The sensitivity and
speciﬁcity of each test were calculated using the commercial test as
the gold standard. Positive (PPV) and negative (NPV) predictive
values were calculated for theoretical 5%, 15%, and 30% preva-
lences. The study was approved by the UF IACUC.
A total of 80 dogs (31%) were positive for B. gibsoni by the gold
standard commercial PCR test. Of these, 72 were identiﬁed as posi-
tive by the POCKIT iiPCR B. gibsoni kit, and 70 were identiﬁed
as positive by the POCKIT iiPCR Babesiosis kit. Sensitivity and
speciﬁcity of the B. gibsoni kit were 90% and 99%, respectively.
Sensitivity and speciﬁcity of the Babesiosis kit were 88% and 98%,
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respectively. The PPVs of the B. gibsoni kit at 5%, 15%, and 30%
prevalence were 82%, 94%, and 97% respectively. The NPVs of
the B. gibsoni kit were 99%, 98%, and 96% respectively. The PPVs
of the Babesiosis kit were 70%, 89%, and 96% respectively. The
NPVs of the Babesiosis kit were 99%, 98%, and 95% respectively.
The POCKIT iiPCR system was quick to learn, portable, and
had a short run time of approximately 1 hour. There were few
false-positive results, indicating that positive results are likely to
represent true infections when tested in high-risk animals. Approx-
imately 10–15% of infected dogs would be missed by the
POCKIT iiPCR system. However, the portability and speed with
which results can be obtained may result in more infected dogs
being diagnosed than in the current situation in which testing is
rarely performed in dog-ﬁghting cases due to cost and logistics of
sending samples to outside laboratories. This system may also be
used for B. gibsoni treatment monitoring using a hybrid approach.
For example, following initial diagnosis with either the POCKIT
system or a commercial laboratory, the POCKIT system could
be used for testing during treatment. Once a negative result was
obtained, a sample could be submitted to a commercial laboratory
to conﬁrm treatment eﬃcacy. Although this study focused on mass
screening for B. gibsoni, the portable iiPCR platform has potential
to aid in rapid detection of a variety of infections under ﬁeld
conditions.
ID03
PREVENTION OF BORRELIA BURGDORFERI AND ANA-
PLASMA PHAGOCYTOPHILUM TRANSMISSION FROM
IXODES SCAPULARIS TO DOGS BY SAROLANER. Nicole
Honsberger, Robert Six, Thomas Heinz, Angela Weber, Sean
Mahabir, Thomas Berg. Zoetis, Kalamazoo, MI, USA
The eﬃcacy of sarolaner (SimparicaTM, Zoetis) to prevent trans-
mission of Borrelia burgdorferi and Anaplasma phagocytophilum
from infected wild-caught Ixodes scapularis to dogs was evaluated
in a well-controlled laboratory study. Twenty-four purpose-bred
laboratory Beagle dogs seronegative for B. burgdorferi and A.
phagocytophilum antibody were allocated randomly to one of three
oral treatment groups: placebo administered on Days 0 and 7, sar-
olaner administered on Day 0 (28 days prior to tick infestation),
or sarolaner administered on Day 7 (21 days prior to tick infesta-
tion). Sarolaner tablets were shaved and/or sanded based on each
dog’s individual bodyweight to provide a dosage of 2 mg/kg. On
Day 28 each dog was infested with approximately 25 female and
25 male wild caught adult I. scapularis that were determined by
random sampling to have infection rates of 57% for B. burgdorferi
and 6.7% for A. phagocytophilum by PCR. In situ tick counts were
conducted on Days 29 and 30. On Day 33, all ticks were counted
and removed. Blood samples collected from each dog on Days 27,
49, 63, 77, 91 and 104 were tested for the presence of B. burgdor-
feri and A. phagocytophilum antibodies using the SNAP 4Dx
Plus Test, and quantitatively assayed for B. burgdorferi antibodies
using an ELISA test. Skin biopsies collected on Day 104 were
tested for the presence of B. burgdorferi by bacterial culture and
PCR. Acaricidal eﬃcacy was calculated based on the reduction of
geometric mean live tick counts in the sarolaner-treated groups
compared to the placebo-treated group for each tick count.
Geometric mean live tick counts for placebo-treated dogs were
14.8, 12.8 and 19.1 on Days 29, 30 and 33, respectively. For the
group treated with sarolaner 21 days prior to infestation, the per-
cent reductions in mean live tick counts on Days 29, 30, and 33
were 86.3%, 100%, and 100%, and for the group treated with sar-
olaner 28 days prior to infestation were 90.9%, 97.1%, and 100%.
Geometric mean live tick counts for both sarolaner-treated groups
were signiﬁcantly lower than those for the placebo group on all
count days (P < 0.0001).
Successful transmission of B. burgdorferi to all eight placebo-
treated dogs was conﬁrmed by positive antibody (6 of 8 dogs),
PCR (7 of 8 dogs), and/or culture result (7 of 8 dogs). Similarly,
transmission of A. phagocytophilum was conﬁrmed by the presence
of antibodies in four placebo-treated dogs. In contrast, a single
oral dose of sarolaner prevented transmission of B. burgdorferi
from infected ticks to dogs infested 21 or 28 days after treatment
as demonstrated by negative antibody, PCR, and culture results.
Prevention of A. phagocytophilum transmission was also
demonstrated by negative antibody in all sarolaner-treated dogs.
There were no adverse reactions to treatment with sarolaner.
ID04
MOLECULAR ANALYSIS ON CANINE BABESIA PREVA-
LENCES AND EXPOSURE TO ANAPLASMA, EHRLICHIA,
BORRELIA AND DIROFILARIA IN MOST POPULATED
SERBIAN REGION – BELGRADE AREA. Milica Kovacevic
Filipovic1, Anja Ilic1, Zorana Milanovic1, Dragan Bogdanovic2,
Vladimir Radonjic3, Jelena Francuski Andric1, Nenad Andric1,
Brendon Thatcher4, Christian Leutenegger4, Phyllis Tyrrell4,
Antony Mestek4, Chandrashekar Ramaswamy4. 1Faculty of
Veterinary Medicine, University of Belgrade, Belgrade, Serbia,
2State University of Novi Pazar, Novi Pazar, Serbia, 3Private
Veterinary Practice Petrovac”, Belgrade, Serbia, 4IDEXX
Laboratories, Westbrook, Maine, USA
Babesiosis is endemic in many parts of Serbia. Other tick borne
diseases are less commonly diagnosed because their clinical signs
are nonspeciﬁc and there is no published data indicating their
prevalence. The aim of this study was to determine molecular
prevalence of Babesia canis canis and B. gibsoni, molecular and
seroprevalence of Anaplasma phagocytophilum, A. platys, Ehrlichia
canis, E. ewingii, E. chaﬀeensis and Borrelia burgdorferi and Diroﬁ-
laria sp. microﬁlariae in diﬀerent outdoor canine populations.
Blood samples from apparently healthy stray (n = 38), shelter
(n = 39) and hunting dogs (n = 35) and outdoor pet dogs sus-
pected to have tick borne diseases (n = 50) were tested using real
time PCR and serological assays. Real-Time PCR assays were
used to amplify Babesia, Anaplasma and Ehrlichia DNA from
blood samples. An experimental SNAP Multi-Analyte Assay
(SNAP M-A) (IDEXX Laboratories, Inc. Westbrook, Maine,
USA) was used to screen all sera for antibodies to Anaplasma and
Ehrlichia genus peptides and A. phagocytophilum, A. platys, B.
burgdorferi, E. canis, E. ewingii, and E. chaﬀeensis species-speciﬁc
peptides. Modiﬁed Knott test was used to identify dogs with Diro-
ﬁlaria sp. microﬁlaria presence.
In total, prevalence of Babesia sp. infections among apparently
healthy dogs was 16% and among sick pet dogs, was 65%. Preva-
lence of B. canis was the highest in shelter (25%) and the lowest in
stray dogs (8%). B. gibsoni was rare among shelter, stray and pet
dogs, while it was not detected among hunting dogs. Molecular
analysis did not reveal the presence of dogs with active anaplasmo-
sis, ehrlichiosis or borreliosis. However, 32% of stray and shelter
dogs, 12% of hunting dogs and 4% of sick pet dogs had antibod-
ies to A. phagocytophilum. Only one dog (hunting group) was
seropositive to A. platys, one dog to E. ewingii (stray group) and
two dogs to B. burgdorferi (stray group). None of the dogs was
seropositive to E. canis and E. chaﬀeensis. Also, 33% of pet, 18%
of hunting, 11% of stray and 3% of shelter dogs had microﬁlariae
in the blood. Number of dogs exposed to two and three pathogens
was the highest among shelter dogs (31% and 10%, respectively),
and number of dogs exposed to four pathogens was the highest
among stray dogs (5%).
In Belgrade area, B. canis and A. phagocytophilum are the most
prevalent vector-borne pathogens in apparently healthy outdoor
dog population, while B. canis and Diroﬁlaria sp. are the most
important pathogens among sick pet dogs.
ID05
ENHANCED SEROLOGIC SURVEILLANCE TO DETECT
PREVALENCE OF CANINE VECTOR-BORNE INFECTIONS
ON THE ISLAND OF ST. KITTS, WEST INDIES. Diana
Scorpio1, Jennifer Ketzis1, Linda Shell1, Brendon Thatcher2,
Ramaswamy Chandrashekar2. 1Ross University School of
Veterinary Medicine, Basseterre, Saint Kitts and Nevis, 2Idexx
Laboratories, Westbrook, Maine, USA
The island of St. Kitts (West Indies) has a large feral and semi-
feral dog population. Semi-feral dogs present a unique opportunity
for study since they are mostly outdoors but are comparatively well
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taken care of compared to feral dogs. Care tends to range from
minimal to adequate, though many owners use the Ministry of
Agriculture Veterinary Services for preventative medicine rather
than a veterinary hospital setting. Historically, dogs on the island
are endemically infected and infested with internal and ectopara-
sites, which are also associated with a number of vector-borne dis-
eases. Due to the high prevalence of the vector Rhipicephalus
sanguineus, it is not unusual to see high prevalence of Ehrlichia
canis and Anaplasma platys. Samples collected from an island-wide
ﬁeld study from last year revealed an abundance of serologic data.
These samples have been further tested utilizing a research-based
serology platform (IDEXX Laboratories) and additional canine
vector-borne infections data has been collected from these analyses.
Over a period of 3 months, veterinarians and students from
RUSVM visited all 9 parishes of St. Kitts, covering a diverse geo-
graphic area with a wide diversity in ecosystem landscape. One hun-
dred and eleven dogs were identiﬁed and visited, and were given a
complete physical exam, then blood and feces were collected.
Demographic data was collected, including breed, age, housing,
other animals in household, evidence of ticks or ﬂeas, deworming
and vaccine administration. Blood was analyzed using a research-
based broader canine vector-borne infection serologic platform
(SNAP M-A, IDEXX Laboratories), which tests for speciﬁc anti-
bodies against E. ewingii, E. canis, E. chaﬀeensis, Anaplasma platys,
A. phagocytophilum, and Borrelia burgdorferi. This testing platform
is also based on a rapid ELISA SNAP technology.
Analyses using the new SNAP M-A serologic platform
revealed no evidence of exposure to E. ewingii, E. chaﬀeensis, or
Borrelia burgdorferi. However, as expected due to the endemic nat-
ure of the tick vector, the platform identiﬁed A. platys exposures
of approximately 20.7%. E. canis exposures were detected at a
prevalence of approximately 32%. Of interest is that the SNAP
M-A test also identiﬁed 19 dogs (17%) with antibodies to A.
phagocytophilum, not previously described on St. Kitts due to the
absence of Ixodes tick vectors.
Using the SNAP M-A serologic platform, there was a robust
capacity to detect up to 2 Anaplasma species, in addition to having
a sensitivity which corroborates previously published prevalence
rates of E. canis. Of note is the presence of A. phagocytophilum
exposures, and additional studies are warranted to understand and
explain these ﬁndings. The data collected in this study supports
the importance of including an exhaustive list of diﬀerentials when
suspecting canine vector-borne infections, in addition to aggressive
and consistent use of environmental and topical parasiticides for
tick control.
ID06
PERFORMANCE OF POINT-OF-CARE ASSAYS FOR FELV
AND FIV. Julie Levy. Maddie’s Shelter Medicine Program,
University of Florida, Gainesville, FL, USA
At least 5% of cats in the US are infected with FeLV or FIV,
contagious retroviruses that predispose to bone marrow suppres-
sion, cancer, chronic inﬂammatory conditions, immune dysfunc-
tion, and wasting syndromes. This equates to more than 5 million
cats aﬀected by these preventable viruses and at risk for disease
and premature death. Although vaccination plays a role in preven-
tion, the cornerstone of control is identiﬁcation and segregation of
infected cats. Recently, new point-of-care screening tests have
become available, but independent comparison of test performance
is needed. The purpose of this study was to determine the perfor-
mance of currently available FeLV antigen/FIV antibody combi-
nation test kits.
For assessment of FeLV tests, serum or EDTA whole blood
samples were collected from animal shelters or reference labora-
tory and tested with two microtiter plate ELISAs for the detection
of FeLV p27 antigen (ViraCHEK/FeLV and PetChek FeLV
Antigen Test) to establish a gold standard. Only samples with con-
cordant results were included in the study. For assessment of FIV
tests, plasma samples previously collected from naturally or experi-
mentally infected cats and veriﬁed by virus culture and from unin-
fected SPF cats were included. None of the cats had been
vaccinated against FIV. The ﬁnal study set included 146 FeLV+,
154 FeLV-, 94 FIV+, and 97 FIV- samples. Point-of-care tests
evaluated in this study included SNAP Combo FeLV Ag/ FIV
Ab Test, WITNESS FeLV-FIV Test Kit, Anigen Rapid FIV
Ab/FeLV Ag Test Kit, VetScan Feline FeLV/FIV Rapid Test.
All test results were visually read by two blinded observers.
The SNAP test had the overall best performance. In high-
stakes testing, test kits should be selected for both high sensitivity
and speciﬁcity. When tests lack sensitivity, infected cats may
escape detection and remain at risk for infecting other cats. When
speciﬁcity falls, uninfected cats may be unnecessarily segregated or
even euthanized. In low infection prevalence, such as observed in
FeLV and FIV, decreased speciﬁcity has the largest impact on
erroneous test results, leading to decreased positive predictive
value (increased false-positives).
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DOES A DIVA TEST EXIST FOR DIFFERENTIATING FIV
INFECTION FROM FIV VACCINATION?. Cynda Crawford.
Maddie’s Shelter Medicine Program, University of Florida,
Gainesville, FL, USA
Diagnosis of FIV infection is based on detection of circulating
FIV antibodies. Introduction of FIV vaccines created a diagnostic
dilemma because vaccine antibodies were indistinguishable from
those induced by infection using existing serological assays. New
point-of-care tests for FIV antibody are now available to practi-
tioners. The purpose of this study was to determine the accuracy
of FIV diagnostic tests in FIV-vaccinated cats and whether any of
the tests could serve as a DIVA test to diﬀerentiate infected from
vaccinated animals.
Plasma samples were collected from 104 uninfected SPF
cats vaccinated 3 times with a killed dual-subtype FIV vaccine
(Fel-O-Vax, Boehringer Ingelheim) according to manufacturer
instructions. Age at vaccination ranged from 2.5 to 13 months.
The interval between vaccination and sample collection ranged
from 1.75 to 14 months. The FIV-free infection status of all cats
was conﬁrmed by virus culture. Three FIV-infected cats were simi-
larly vaccinated and tested. The plasma samples were tested in 4
commercial point-of-care assays: SNAP Feline Combo FeLV
Ag/FIV Ab Test, WITNESS FeLV-FIV Test, Anigen Rapid
FIV Ab/FeLV Ag Test Kit, and VetScan Feline FeLV/FIV Rapid
Test. All testing was performed by personnel blinded to sample sta-
tus. Each test result was independently interpreted by 2 personnel.
The SNAP and VetScan tests detected FIV antibodies in 102/
104 and 88/104 uninfected vaccinated cats, respectively. This
would lead to misclassiﬁcation of most of the vaccinated cats as
infected. The WITNESS and Anigen tests had very high speci-
ﬁcity, indicating that nearly all vaccinated cats were correctly
identiﬁed as uninfected. All 4 tests correctly identiﬁed the 3
FIV-infected cats that were vaccinated against FIV.
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Accurate detection of FIV-infected cats is essential to providing
appropriate care and segregation from uninfected cats. Since
euthanasia is a tool employed in the control of FIV, especially in
animal shelters where the previous vaccination history of cats is
usually unknown, misidentiﬁcation of vaccinated cats as being
infected may have unwarranted fatal consequences. Based on this
study, the WITNESS FeLV-FIV Test and the Anigen FIV Ab/
FeLV Ag Test are the most accurate for diﬀerentiating FIV-
infected from FIV-vaccinated cats and meet the criteria for DIVA
tests.
ID08
AN EPIDEMIOLOGICAL STUDY OF GAMMAHER-
PESVIRUSES IN DOMESTIC CATS IN JAPAN. Morihiro
Tateno, Yasuyuki Endo, Masashi Takahashi. Kagoshima
University, Kagoshima, Japan
Gammaherpesviruses (GHVs) are members of an emerging sub-
family of the Herpesvividae. The two major human GHVs,
Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated her-
pesvirus (KSHV) are clinically important pathogens because those
viruses possess tumorigenesis potential especially in immune-com-
promised patients. In feline practice, we often experience tumor
cases, especially lymphomas. Feline leukemia virus (FeLV) was a
major cause for the development of lymphoma in the past days,
however, the majority of lymphoma cases are shifting to FeLV-
free cats. But the mechanism of tumorigenesis in these “sponta-
neously” developed lymphomas has not been well understood.
Under this situation, GHV became a candidate which explains the
lymphomagenesis in domestic cats. Recent study identiﬁed a novel
GHV in domestic cats (Felis catus GHV, FcaGHV), and epidemi-
ological surveys found that FcaGHVs are distributing in several
countries including the United States, Australia, Singapore, Ger-
many and Austria. In the present study, a molecular epidemiologi-
cal study was conducted to investigate the prevalence of GHVs in
Japan using large numbers of samples which were previously used
to a nation-wide epidemiological survey for two feline retroviruses
in Japan (Nakamura Y et al., J Vet Med Sci, 72:1051–1056, 2010).
GHV-derived DNA in blood samples was detected by degener-
ate nested pan-GHV PCR targeting gB gene as previously
reported. Nucleotide sequences of obtained DNA fragments were
determined and BLAST analysis was carried out. Phylogenic anal-
ysis was also conducted. Risk factors relating to GHV infection
on clinical parameters, including age, sex, status of retrovirus
infections, bite wound history and clinical signs, were statistically
analyzed using univariable (Fisher’s exact test) and multivariable
(Logistic regression model) analyses.
GHV-derived DNA was detected in 2.6% of Japanese domestic
cats. BLAST analysis revealed that all of them showed high simi-
larity with FcaGHVs which were isolated from domestic cats in
the United States. Phylogenic analysis also revealed that all Japa-
nese isolates formed one cluster with FcaGHV. Age (> 2 years
old) (Odds ratio [OR], 6.02; 95% conﬁdential interval [CI], 0.79–
46.0; P = 0.05) and feline immunodeﬁciency virus (FIV) infection
(OR, 5.41; 95% CI, 1.93–15.1; P < 0.01) were found to be a risk
factor in univariable analysis. In multivariable analysis, only FIV
infection (OR, 3.74; 95% CI, 1.28–10.94; P = 0.016) was a signiﬁ-
cant risk factor.
In this study, the prevalence of GHVs in Japanese domestic cats
was surveyed and risk factor for GHV infection was determined.
FcaGHV prevalence in Japan (2.6%) was lower than previously
reported prevalence in other countries and areas (US, 16%; Eur-
ope, 16.2%). It was unable to determine the cause of this diﬀer-
ence. However, Japanese isolates were identiﬁed to have close
genetic relationship to domestic cat derived FcaGHV. This ﬁnding
suggested that the virus is highly conserved in each animal species
and GHV is harboring in host speciﬁc manner as well as other
herpesviruses. The risk factor for GHV infection in Japanese cats
was FIV infection and it was same as previously reported. But we
have to clarify how FIV enhances the GHV infection and/or vire-
mia. The clinical importance of GHVs infection in feline practice
is still unknown. Further investigation will be necessary to identify
the pathogenicity of GHVs in domestic cats.
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CANINE INFLUENZA H3N2 INFECTION IN FOUR DOGS.
Anne Cohen1, Jill Richardson2, Amy Glaser3, Edward Dubovi3,
Nyssa Reine-Salz2. 1Chicago Veterinary Emergency and Specialty,
Chicago, USA, 2Merck Animal Health, Madison, USA, 3Cornell
University, Ithaca, USA
The H3N2 inﬂuenza virus is of avian origin and was ﬁrst iso-
lated from clinically ill dogs in China in 2006 and South Korea in
2007.1 Canine H3N2 inﬂuenza virus has been associated with sev-
ere respiratory signs and other clinical signs such as fever, reduced
body weight, and interstitial pneumonia.1 This case report presents
four conﬁrmed, naturally infected clinical cases of Canine Inﬂu-
enza H3N2 in the United States. The cases presented were all pet
dogs that had histories of recent exposure to other dogs in a social
setting including dog parks and doggie day cares. None of the
dogs originated from, or had traveled to, typical regions endemic
for this viral disease. All dogs were presented at diﬀerent stages of
illness attributed to infectious respiratory disease.
One dog , a 1.5 year old Corgi, was evaluated for lethargy,
anorexia, and loose stool for 2 days. He had also developed a
cough on the day of presentation and had mild increases in respira-
tory rate. On physical examination, he had a fever with mildly
increased respiratory sounds. The patient was re-presented the next
day for worsened signs of coughing, lethargy and hyporexia. Tho-
racic radiographs were performed which showed severe bilateral
bronchopneumonia. Based on his poor response to supportive care,
the owners elected humane euthanasia. Necropsy was performed at
the New York State Veterinary Diagnostic Laboratory at Cornell
University. Necropsy revealed Severe, acute, locally extensive
necrohemorrhagic interstitial pneumonia with epithelial necrosis.
Another dog, a 8 year 10 month old Miniature Pincher, was eval-
uated after a 9 day history of coughing, wheezing, weakness, ataxia,
hyporexia and one day of clear nasal discharge. On physical exami-
nation, the patient was weak, ~7% dehydrated, had serous nasal dis-
charge, muﬄed heart sounds, poor peripheral femoral pulses, and
harsh bilateral thoracic sounds with crackles and wheezes. Thoracic
radiographs were performed which showed right caudodorsal and
left cranial bronchoalveolar bronchopneumonia. The patient experi-
enced cardiopulmonary arrest and upon return of spontaneous cir-
culation the owners elected humane euthanasia. Necropsy results
were severe, acute, multifocal to coalescing necrohemorrhagic pneu-
monia with hyaline membrane formation and epithelial necrosis.
Enteric lesions were also noted with moderate, diﬀuse, chronic lym-
phoplasmacytic enteritis with multifocal crypt necrosis.
Another dog, a 4 year old Greater Swiss Mountain dog, was
referred for hospitalization due to right cranial and middle lung
lobe consolidation, fever, dyspnea, gagging with phlegm produc-
tion, exercise intolerance and hyporexia. On physical examination,
he was quiet, febrile at 105.1 degrees Fahrenheit, had an increased
respiratory rate of 60 breaths per minute with harsh bronchovesic-
ular lung sounds. He became oxygen dependent with a pulse
oximetry of 89–91%. Recheck thoracic radiographs were per-
formed on the fourth day of hospitalization which showed a wors-
ened alveolar pattern in the right and left cranial thorax. He was
hospitalized for 7 days, making gradual improvements until dis-
charge. H3N2 was conﬁrmed via PCR at Cornell University.
The fourth case, a 10 year old terrier mix breed, was presented
for evaluation of a productive cough for two days and one day of
lethargy, anorexia and weakness. On physical examination, harsh
lung sounds with mild increased respiratory rate was appreciated.
The patient vomited a large volume of bile material after examina-
tion. A severe fever of 107.1 degrees Fahrenheit was appreciated
with a respiratory rate of 48 breaths per minute and ~5% dehy-
dration. Thoracic radiographs were performed which showed a
mild to moderate bronchointerstitial pattern most concentrated in
the caudodorsal lung ﬁelds. The patient was hospitalized for
4 days and was eventually tapered oﬀ of oxygen and sent home
on oral antibiotic therapy. A respiratory panel was sent to IDEXX
Reference Laboratory. The patient was positive for an Inﬂuenza A
Assay, negative for an H3N8 PCR and positive for H3N2 PCR.
All four of the dogs were diagnosed with Canine Inﬂuenza
H3N2 through PCR, three through the New York State Veteri-
nary Diagnostic Laboratory and one through Idexx Diagnostic
Laboratory. In patients with characteristic clinical features, Canine
Inﬂuenza H3N2 virus infection should still be considered as diﬀer-
ential diagnosis.
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DEMONSTRATION OF PROTECTION AGAINST CANINE
INFLUENZA VIRUS H3N2 INFECTION FOLLOWING
VACCINATION WITH INACTIVATED CIV H3N2. Rhonda
LaFleur1, Tamara Davis1, Patrick Tuma1, Huchappa Jayappa1,
Mike Francis2, Ian Tarpey2. 1Merck Animal Health, Elkhorn, NE,
USA, 2MSD Animal Health, Milton Keynes, UK
A study was conducted in dogs to evaluate the eﬃcacy of an
inactivated Canine Inﬂuenza Virus (CIV) H3N2 vaccine following
experimental challenge with a virulent heterologous strain of CIV
H3N2, isolated from the recent CIV H3N2 outbreak in the United
States. Eleven dogs, 7–8 weeks of age, were vaccinated with 2
doses of an inactivated CIV H3N2 vaccine, 3 weeks apart, and 19
dogs were vaccinated with a placebo. Two weeks after the second
vaccination, all dogs were challenged intranasally with virulent
CIV H3N2 and then monitored daily for 10 days for clinical signs
including fever, nasal discharge, sneezing, coughing, depression,
and dyspnea. Nasal swabs were collected to evaluate viral shed-
ding, and serum samples were collected at various time points to
determine antibody titers. At necropsy, lungs were scored for con-
solidation. Following the booster vaccination, the placebo-vacci-
nated control dogs remained seronegative (<10) to CIV H3N2,
while 10 of the 11 vaccinated dogs developed an antibody titer to
CIV H3N2 (GMT = <80; Range = <10 - 320). Antibody titers in
dogs from both treatment groups increased following challenge,
but the increase was greater in the vaccinated dogs
(GMT = >1452; Range = 40 - >10,240). Following challenge, 8
(42%) of the 19 placebo-vaccinated control dogs were euthanized
prior to the 10-day post-challenge observation period due to severe
clinical signs, including diﬃculty breathing, depression, fever, and
severe coughing with retching; whereas, none (0%) of the vacci-
nates had to be euthanized (P = 0.014). Clinical signs were evalu-
ated based on a weighted scoring system. The mean clinical score
for the placebo-vaccinated control group was 24.9, compared to
only 8.7 for the vaccinated group (P = 0.036). The placebo-
vaccinated control group shed CIV H3N2 virus for a mean of
1.9 days, compared to 1.4 days for the vaccinated group
(P = 0.507). The median lung consolidation score for the placebo-
vaccinated control group was 7.4, compared to 0.0 for the vacci-
nated group (P = 0.026). Results of this study demonstrate that
this inactivated CIV H3N2 vaccine signiﬁcantly protects dogs
against severe clinical disease and lung consolidation associated
with a virulent CIV H3N2 infection.
ID11
PREVALENCE OF CANINE INFECTIOUS RESPIRATORY
DISEASE COMPLEX PATHOGENS IN DOGS IN GEORGIA
AND NORTH CAROLINA. Jill Richardson1, Amy Glaser2,
Edward Dubovi2, Nyssa Reine-Salz1. 1Merck Animal Health,
Madison, NJ, USA, 2Cornell University, Ithaca, NY, USA
Canine infectious respiratory disease complex (CIRDC) is
caused by many diﬀerent viruses and bacteria. In June 2015, vet-
erinarians around Atlanta, Georgia and also western areas of
North Carolina began to notice an unusual increase in dogs pre-
senting to their clinics with signs of infectious respiratory disease.
Nasal and pharyngeal swabs from dogs exhibiting clinical signs
were submitted to the Animal Health Diagnostic Center (AHDC)
at Cornell University. A canine respiratory polymerase chain reac-
tion (PCR) screening panel was utilized which allows identiﬁcation
of the following CIRDC pathogens: Bordetella bronchiseptica,
Mycoplasma cynos, canine adenovirus 1 and 2, canine distemper,
canine inﬂuenza A, H3N8 and H3N2, parainﬂuenza virus 5, pneu-
movirus and respiratory coronavirus.
Between June 1 and August 7, 2015, Merck Animal Health’s
Diagnostic Support Program tested over 175 samples from dogs
with clinical signs of respiratory disease from Georgia and North
Carolina. Of those dogs, 51 tested positive for Canine Inﬂuenza
virus H3N2 - 29 of these cases were identiﬁed from Georgia and
22 cases were from North Carolina. None of the tested dogs were
conﬁrmed to have the H3N8 canine inﬂuenza strain.
Results of the testing in these regions also identiﬁed 38 cases of
parainﬂuenza virus, 10 cases of B. bronchiseptica, four cases of
adenovirus type 2, 29 cases of pneumovirus, 33 cases of
respiratory coronavirus, and one case of canine distemper. Further
evaluation of the positive cases of parainﬂuenza showed that 34 of
the 38 had received parainﬂuenza vaccination with the injectable
distemper, adenovirus type 2, parvovirus and parainﬂuenza virus
combination vaccine. Also, of the 38 parainﬂuenza positive dogs,
21 had been vaccinated with a monovalent B. bronchiseptica vac-
cine (oral, injectable or intranasal). Seven of these dogs had been
vaccinated with a B. bronchiseptica and parainﬂuenza combination
intranasal product, of which two had been recently vaccinated and
the parainﬂuenza sampled may have been of vaccine origin.
The information gathered from this testing program documents
the spread of Canine Inﬂuenza virus H3N2 to two new locations in
the US. In addition, data collected supports the role of parain-
ﬂuenza virus as a major preventable pathogen in CIRDC and route
of vaccination should be considered in vaccination protocols.
ID12
FREQUENCY, BENEFITS AND HEALTH RISKS OF
ANIMALS IN NURSING HOMES: CROSS-SECTIONAL
STUDY OF OHIO FACILITIES. Jason Stull, Timothy Landers.
The Ohio State University, Columbus, OH, USA
Animals are argued to play an important role in nursing homes,
providing health beneﬁts, but may also be a source of infections
and injuries for animals and patients. To-date little is known of
the involvement of animals in nursing homes, practices in place to
protect pet and resident health, or speciﬁc health beneﬁts and
risks. The objective of this study was to determine the frequency
and avenues in which animals are utilized in the nursing home
environment, practices to safeguard health, and beneﬁts and risks
of resident-animal interactions. An anonymous 15-minute online
questionnaire was developed and delivered to a convenience sam-
ple of nursing home administrators in Ohio, USA from November
2014 through March 2015.
Responses from 95 facilities (approximately 5% of all registered
facilities in OH) of varying sizes and geographic locations were
received and adequately completed to allow for analysis. Nearly
all respondents (94; 99%) allowed animals in their facilities (live-
in, visiting, or both), with dogs being the most frequent animal
involved with facility activities (99%), followed by cats (89%),
birds (74%), ﬁsh (57%), and rodents (28%). High-risk species such
as reptiles/amphibians and “petting zoo farm animals (e.g., pigs,
goats, chickens)” were often permitted in facilities (27% and 12%,
respectively). Few facilities had restrictions targeting particular
species (n = 9) or age (n = 1) of animals. Animals were reported
to visit most (71%) facilities weekly or more often. One respon-
dent (1%) reported an animal (cat) was mistreated by a resident
or staﬀ in the preceding 12 months. No known or suspected ani-
mal-associated infections were reported for the preceding
12 months. Perceived beneﬁts of animals in facilities were high
(e.g., all participants agreed/strongly agreed that “residents
appeared to be happier after interacting with an animal” and “ani-
mals were useful for calming agitated residents”).
These results highlight the frequent use and perceived beneﬁts
of involving animals in nursing homes, but also common gaps in
established policies and best practices important for reducing resi-
dent and animal health risks. Findings can assist in the develop-
ment of directed guidance documents for nursing homes to better
facilitate safe interactions between residents and animals.
ID13
EFFECTOFQUORUMQUENCHINGWITHAZITHROMYCIN
ON PSEUDOMONAS AERUGINOSA ASSOCIATED OTITIS
EXTERNA/MEDIA IN DOGS. Modest Vengust1, Javid
Hosseini1, Darja Kusar1, Gabrijela Tavcar Kalcher1, Irena Zdovc1,
Rok Blagus2, Tina Kotnik1. 1Veterinary Faculty, University of
Ljubljana, Ljubljana, Slovenia, 2Medical Faculty, University of
Ljubljana, Ljubljana, Slovenia
Many bacteria can express their virulence via quorum sensing
(QS); in Pseudomonas aeruginosa (PA) the QS signal molecules are
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N-acyl-homoserine lactones (PA-AHLs). The use of QS blockers
or quorum quenching (QQ) to attenuate bacterial growth and vir-
ulence is a new strategy for treatment of resistant bacterial patho-
gens. Azithromycin (AZ) expresses in-vitro and in-vivo QQ eﬀect,
and is used clinically to reduce PA virulence. Hypotheses were
tested that topical treatment with AZ will: 1) Attenuate the forma-
tion of most common PA-AHLs: N-butyryl-L-homoserine lactone
(BHL), N-decanoyl-L- homoserine lactone (HHL) and N-(3-oxo-
dodecanoyl)-L-homoserine-lactone (OdDHL); 2) Enhance PA
clearance from the ear canal; 3) Have a positive eﬀect on ear canal
sample cytology; and 4) Reduce the severity of clinical signs
related to PA associated otitis externa/media (PAOEM) in dogs.
This was a randomized double blind placebo controlled study.
Samples were collected from 21 dogs with PAOEM, which were
treated with topical AZ (1 mL AZ solution at the concentration of
50 µg/mL, SID) or placebo (1 mL sterile 0.9% saline) for 56 days.
All dogs were prescribed standard PAOEM treatment and regu-
larly evaluated by their veterinarians. For the purpose of this
study dogs were clinically evaluated and ear canal samples taken
on days 0, 7, 14, 21, 28, 42 and 56. Samples were obtained by rins-
ing ear canals with 30 mL of sterile saline. The concentration of
BHL, HHL and OdDHL in ng/mL was determined by liquid chro-
matography coupled with tandem mass spectrometry. Bacteriologi-
cal and cytological analyses were performed. Clinical signs (ear
canal edema, pain, stenosis and erythema) were graded from 0–4;
grades were then summarized to form a single clinical sign grade.
Data were analyzed using linear mixed eﬀects model for continu-
ous outcomes and general linear mixed eﬀects model for the bin-
ary outcomes; a P-value of <0.05 was considered signiﬁcant.
The concentration of BHL, HHL and OdDHL were not
aﬀected by time (P ≥ 0.1) or AZ (P ≥ 0.2). The presence of PA in
ear canal samples was aﬀected by time (P = 0.002) but not AZ
(P = 0.06). The presence of rod shaped bacteria, cocci and neu-
trophils in the sample were aﬀected by time (P ≤ 0.02) but not AZ
(P ≥ 0.08). Macrophages were not aﬀected by time or AZ. Clinical
signs and, therefore, the duration of the disease was inﬂuenced by
time (P < 0.0001). Azithromycin had no eﬀect on clinical signs
and the duration of the disease (P = 0.5).
Detection of PA-AHLs in this study showed that QS acts as a
promoter of PA virulence in otitis externa/media. PAOEM in dogs
is, therefore, an appropriate disease model to study the eﬀects of
QQ on PA. Neither of our hypotheses was veriﬁed. Azithromycin
had no eﬀect on PA-AHLs and the elimination of PA from the
ear canal, nor had any eﬀect on cytology of the sample or the out-
come of the disease. Only a weak tendency towards quicker elimi-
nation of PA from the ear canal was noted in this study.
ID14
COMPARATIVE EVALUATION OF FIVE IN-CLINIC
RAPID TESTS FOR FELINE LEUKEMIA VIRUS
INFECTION. Jiayou Liu1, Melissa Beall1, Tom O’Connor1,
Ramaswamy Chandrashekar1, Mike Lappin2. 1IDEXX Laborato-
ries, Westbrook, ME, USA, 2Colorado State University, Fort Col-
lins, CO, USA
The feline leukemia virus is a potentially life-threatening onco-
genic retrovirus that is transmitted horizontally by close contact or
vertically by in-utero transmission. The p27 viral core protein is
produced by the virus in infected cells and is found in the cyto-
plasm in several blood cells as well as free in the serum and
plasma of infected cats. Reference laboratories and veterinary clin-
ics commonly use some form of enzyme-linked immunoassay
(ELISA) or particle-based immunoassay to detect the presence of
the p27 protein antigen in samples obtained from blood. The
purpose of this study was to compare the performance of several
in-clinic tests: the SNAP Feline Triple Test (IDEXX), the
VetScan FeLV/FIV Rapid Test (Abaxis), the Witness
FeLV-FIV Test (Zoetis), Anigen Rapid FIV/FeLV Test
(BioNote), Speed Duo FeLV/FIV Test (Virbac).
The sample population (84 positive and 101 negative) consisted
of serum and plasma samples submitted to IDEXX’s worldwide
Reference Laboratory for feline retrovirus testing. Virus isolation
and reverse transcriptase polymerase chain reaction results were
not available and so samples were judged to be positive or nega-
tive based on the results of the ViraCHEK FeLV (Zoetis)
microtiter plate assay. ViraCHEK was used as the reference test
because it was reported in a published study to have high sensitiv-
ity and speciﬁcity (Hartmann et al. 2007) and it detects the same
FeLV antigen as does each of the in-clinic tests evaluated in this
study.
When compared to the ViraCHEK microtiter plate assay
results, the SNAP Feline Triple Test had the highest sensitivity
among all in-clinic tests evaluated (Table below).
These ﬁndings are important because in a clinical setting posi-
tive test results may be the only mechanism to identify infected
cats – false negative results could delay supportive care and result
in transmission to causal-contact na€ıve cats. Additional studies are
needed to determine the clinical sensitivity and speciﬁcity of these
tests using samples from cats characterized by PCR and/or viral
culture.
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DETECTION OF GIARDIASIS IN DOGS:COMPARISON OF
THREE RAPID DIAGNOSTIC TESTS. Hannah Bewsey, Jan
Drexel, Jiayou Liu, Brendon Thatcher, Tom O’Connor,
Ramaswamy Chandrashekar. IDEXX Laboratories, Westbrook,
ME, USA
Giardiasis is one of the most common intestinal parasitic infec-
tions aﬀecting both dogs and cats. Infections may be subclinical or
cause severe diarrhea. Dogs become infected by ingestion of Giar-
dia cysts in contaminated water or feces. A single fecal ﬂotation
has a diagnostic sensitivity of approximately 70% because cysts
can be few in number, are shed intermittently, and can be diﬃcult
to distinguish from other fecal matter by inexperienced observers.
Fecal ﬂotation combined with fecal antigen tests that detect sol-
uble cyst wall antigen results in a diagnostic sensitivity of approxi-
mately 97%. While new Giardia antigen assays are now available
for veterinary use, comparison studies are for the most part
lacking.
The present study compared the performance of three in-clinic
tests, the SNAP Giardia Test, the VetScan Canine Giardia
Rapid Test (Abaxis), and the Anigen Rapid CPV/CCV/Giardia
Antigen Test (BioNote). Canine fecal samples used were submitted
to IDEXX Reference Laboratories for ova and parasite testing by
centrifugal ﬂotation. After testing, the samples were stored at
20°C. The samples were then evaluated for soluble cyst wall anti-
gen using the Thermo ScientiﬁcTM ProSpecTTM Giardia Microplate
Assay. Positive samples were deﬁned as those testing positive by
both reference methods while negative samples were deﬁned as
those testing negative on both reference methods. A total of 95
positive samples and 81 negative samples were identiﬁed and tested
on all three in-clinic tests. Six samples were excluded from sensitiv-
ity/speciﬁcity analysis because they failed to produce positive con-
trol lines on the VetScan Test, despite producing valid results on
the other two in-clinic tests. Results were compared to the consen-
sus reference method results for calculation of sensitivity and
speciﬁcity.
In-clinic Test Comparative Sensitivity (95% CI) Comparative Specificity (95% CI)
SNAP® Feline Triple FeLV Test 97.6% (91.1-99.8) 100% (95.5-100)
WITNESS® FeLV Test 76.2% (66.0-84.0) 97.0% (91.2-99.3)
VetScan® FeLV Test 69.0% (58.5-77.9) 97.0% (91.2-99.3)
Anigen® FeLV Test 66.7% (56.0-75.8) 97.0% (91.2-99.3)
Speed Duo® FeLV Test 51.2% (40.7-61.6) 99.0% (94.0-100)
In-clinic Test
SNAP® Giardia Test
VetScan® Giardia Test
Anigen® Giardia Test
Comparative Sensitivity
(95% CI)
89.2% (81.1-94.2)
71.0% (61.0-79.2)
78.5% (69.0-85.7)
Comparative Specificity
(95% CI)
100.0% (94.2-100.0)
83.1% (73.0-89.9)
70.1% (59.1-79.2)
1478 2016 ACVIM Abstracts
Using these criteria, the SNAP Giardia Test had numerically
greater sensitivity and speciﬁcity than the other 2 tests. This study
used another antigen test in the deﬁnition of true positive and true
negative results since the samples were not fresh fecals; and not
tested using a diﬀerent test method like immunoﬂuorescent anti-
body assay.
ID16
SEROPREVALENCE OF ANTIBODIES TO ANAPLASMA
PHAGOCYTOPHILUM AND BORRELIA BURGDORFERI IN
DOMESTIC CATS. Jill Saucier1, Bryan Leonard1, Kristine
Hoyt2, Michael R. Lappin3, Ramaswamy Chandrashekar1, Jesse S.
Buch1. 1IDEXX Laboratories, Inc., Westbrook, Maine, USA,
2Cats on Call Clinic, Scarborough, Maine, USA, 3Colorado State
University, Fort Collins, CO, USA
Anaplasma phagocytophilum (Aph) and Borrelia burgdorferi (Bb)
are pathogenic bacteria vectored by Ixodes spp. and are known to
infect cats. While associations between Bb infections and feline
clinical syndromes are unclear, studies have demonstrated Aph
infection to be associated with fever, severe lethargy, and throm-
bocytopenia in cats. The present study aimed to evaluate the sero-
prevalence of antibodies to Aph and Bb in a large population of
domestic cats from across the United States to better understand
their risk of exposure to these agents.
A total of 5,416 samples submitted between September 2014
and February 2015 for Complete Blood Count (CBC)-inclusive
test proﬁles were obtained from IDEXX Reference Laboratories
located in Ixodes spp.-endemic areas. Samples originated from 26
states with California (24%), Illinois (19%), and Massachusetts
(13%) contributing most to the study population. The population
had a median age of 12.0 years (range: 1 month – 25 years) with
similar representation between males (51%) and females (49%).
All samples were screened by Aph-speciﬁc and Bb-speciﬁc peptide
immunoassays and the results were evaluated based on various test
and demographic parameters.
Overall, 9.7% of the feline sera tested in this study population
contained antibodies to Aph while 2.8% had antibodies to Bb.
Additionally, 1.2% of cats tested had antibodies to both Aph and
Bb. As observed in dogs and humans, antibody prevalence rates
among domestic cats varied by geography. The highest positive
rates for Aph and Bb were observed in Connecticut (20.2%,
n = 337) and Maine (14.0%, n = 50), respectively, while the lowest
seroprevalance for both Aph and Bb was observed in Nevada (Aph
= 2.1%, Bb = 0.0%, n = 47).
These results corroborate ﬁndings in previous studies which
indicate that cats can be infected with Aph and Bb and suggest
that tick prevention is an important consideration in cats as well
as dogs.
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VALIDATION OF A HIGH-THROUGHPUT SEROLOGICAL
ELISA METHOD FOR FELV P27 ANTIGEN DETECTION.
Genevieve Clark, Roberta Cahill, Brendon Thatcher, Peter F.
Smith, Thomas P. O’Connor, Ramaswamy Chandrashekar,
Melissa J. Beall, Jesse S. Buch. IDEXX Laboratories, Inc., West-
brook, Maine, USA
Feline leukemia virus (FeLV) is a globally-distributed oncogenic
retrovirus that can cause fatal disease in cats. Immunoassays that
detect FeLV p27 antigen and are readily used to aid in the diagno-
sis of FeLV have been commercially-available for more than two
decades. While single-sample rapid test formats are preferred for
in-clinic use, the microtiter plate format enzyme-linked
immunosorbent assay (ELISA) is the methodology most com-
monly employed in reference laboratory settings to facilitate batch
testing. However, current commercially-available microtiter plate
format ELISAs for FeLV are not well suited for this purpose
because they rely on manual wash steps, drop-wise addition of
reagents from reagent bottles, and visual interpretation of results.
The purpose of this study was to validate a microtiter plate format
ELISA designed speciﬁcally to maintain performance while
enhancing throughput in a reference laboratory setting.
The FeLV microtiter plate format ELISA method validated in
this study facilitates high throughput operation by combining par-
allel ﬂuid transfer processes with automated data acquisition and
results interpretation. The assay method is based on sequential
orthogonal screening and conﬁrmatory protocols. The screening
protocol utilizes two distinct anti-FeLV p27 mouse monoclonal
antibodies that produce a colorimetric response in samples con-
taining FeLV p27 antigen. The conﬁrmatory protocol requires
neutralization of positive samples in a separate set of controlled
assays using an anti-FeLV polyclonal antibody that blocks binding
of the mouse monoclonal antibodies to FeLV p27 antigen and
thereby inhibits color generation. The conﬁrmatory step oﬀers
increased assurance of speciﬁcity by enabling discrimination
between infected true positives and false positives associated with
several factors including anti-mouse heterophilic antibodies in
patient samples.
Precision of the screening assay was determined using 3 samples
(negative, low positive, and high positive). The intra-assay coeﬃ-
cient of variation (CV) ranged from 3.9% to 7.9% while the inter-
assay CV ranged from 6.0% to 8.6%. For the conﬁrmatory assay,
the same low positive and high positives samples were used
demonstrating an intra-assay CV which ranged from 3.0% to
4.7% and an inter-assay CV between 7.4% and 9.7%. No interfer-
ence was observed for either protocol at bilirubin, hemoglobin,
and lipid concentrations up to 14.4 mg/dl, 550 mg/dl, and 6.4
OD660 nm, respectively. The analytical sensitivity for FeLV p27
antigen was established at 1.7 ng/mL for inactivated whole FeLV
and at 1.0 ng/mL for puriﬁed recombinant FeLV p27. Discrimi-
nating analytical speciﬁcity was demonstrated based on the
absence of cross-reactivity to related retrovirus antigen from mur-
ine leukemia virus and Feline RD-114. Overall, the assay exhibited
100% diagnostic accuracy in 83 patient samples (n = 63 negative;
n = 20 positive) with FeLV status deﬁned on the combined basis
of PCR (FeLV RealPCR; IDEXX Laboratories, Inc.) and inde-
pendent ELISA (ViraCHEK FeLV; Zoetis, Inc.).
Results of this study validate that the new microtiter plate for-
mat ELISA is a highly speciﬁc, precise, and accurate method for
detection of FeLV p27 antigen in feline patient samples and is
appropriate for high-throughput applications in a reference labora-
tory setting.
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INVESTIGATION OF WHETHER LEPTOSPIRA VACCINAL
ANTIBODIES REACT WITH BORRELIA PEPTIDES USED
IN A COMMERCIAL ASSAY. Amber Caress1, Scott Moroﬀ2,
Michael Lappin1. 1Colorado State University, Fort Collins, CO,
USA, 2Antech Diagnostics, Lake Success, NY, USA
In small animal veterinary medicine, two of the most common
pathogenic spirochete genera are Borrelia spp. and Leptospira
spp.. While antibodies that develop against these organisms over
the course of infection in dogs are thought to be genus speciﬁc,
studies evaluating for cross-reactive antibodies against individual
Borrelia spp. or Leptospira spp. peptides are for the most part
lacking. The purpose of this study was to determine if Leptospira
spp. antibodies induced by administration of one of four commer-
cial vaccines would cross-react with the B. burgdorferi antigens
used in a commercially available assay.
Staﬀ and student owned dogs were recruited at a Veterinary
Teaching Hospital in a B. burgdorferi non-endemic area. Inclusion
criteria stipulated that dogs were apparently healthy, weighed at
least 10 kg, and had not been administered a Leptospira spp. vac-
cine within the past year. The dogs were randomized to be admin-
istered one of four commercially available Leptospira spp. vaccines
that all contained serovars Canicola, Gryppotyphosa, Icterohemor-
rhagiae, and Pomona. Blood was collected prior to vaccine admin-
istration on Week 0 and Week 3 and then again on Weeks 4, 8,
and 12. Leptospira spp. microagglutination titers (MAT) were
determined using a commercially available service. After conﬁrm-
ing the maximal Leptospira spp. titers occurred on Week 4, an ali-
quot of this sera was shipped to Antech Diagnostics for analysis
of B. burgdorferi antibodies against OspA, OspC, and OspF with
the Accuplex 4 BioCD system.
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The Week 4 sera from all 31 dogs had an MAT titer of 1:100
for at least 1 Leptospira spp. serovar. MAT titers of 1:800 or
greater were detected against serovar Gryppotyphosa and serovar
Pomona in 27 dogs. None of these 31 samples contained antibod-
ies against the B. burgdorferi OspA, OspC, and OspF peptides
used in the commercially available assay.
In conclusion, the B. burgdorferi peptides used in the Accuplex
4 BioCD system do not recognize antibodies induced by the com-
mercially available Leptospira spp. vaccines administered in this
study. However, lateral ﬂow device manufacturers and laboratories
providing B. burgdorferi serological assays have speciﬁc sources of
peptides that may vary antigenically from those used here and so
the results of this study may not be the same for all laboratories.
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CLINICAL AND LABORATORY FINDINGS IN DOGS WITH
IXODES-INDUCED CHRONIC ANAPLASMA PHAGOCY-
TOPHILUM INFECTION AFTER PREDNISOLONE ADMIN-
ISTRATION. Elena Contreras1, Kristy Dowers1, Scott Moroﬀ2,
Michael Lappin1. 1Department of Clinical Sciences, Colorado
State University Veterinary Teaching Hospital, Ft Collins, CO,
USA, 2Antech Diagnostics, Lake Success, NY, USA
Anaplasma phagocytophilum (AP) is transmitted by Ixodes spp.
and is the cause of granulocytic anaplasmosis in many species
including dogs, cats, horses, and people. In endemic areas, anti-
bodies against AP are detected in the serum of up to 40% of dogs
and some healthy dogs are AP PCR positive. The eﬀect of pred-
nisolone administration on dogs infected with AP after I. scapu-
laris infestation has not been determined.
A total of six young laboratory-reared beagles that were
infected by AP, but no other vector borne agents, as evidenced by
detection of AP DNA in blood by PCR assay (FastPanel, Antech
Diagnostics) and AP antibodies in serum (Accuplex 4 BioCD sys-
tem; Antech Diagnostics) after infestation with wild-caught I.
scapularis were selected for study. On Week 20 after I. scapularis
infestation, the dogs were placed into two Groups, each containing
one AP PCR positive, AP antibody positive dog and two AP PCR
negative, AP antibody positive dogs. Group 1 was administered
doxycycline at 5 mg/kg, PO, twice daily for 4 weeks. After sample
collection the morning of Week 24, all dogs were administered
prednisolone at 2 mg/kg, PO, daily for 2 weeks. The dogs were
evaluated daily for clinical abnormalities and by CBC, AP PCR
and AP antibody assay Weeks 24–28. Sera from 5 dogs was
assayed for AP antibodies on Week 48.
Clinical abnormalities were not detected over the course of the
study. The only CBC abnormalities noted were anemia, thrombo-
cytosis and neutropenia in one Group 1 dog and one Group 2 dog
on Week 24, prior to prednisolone administration. After Week 20,
only one dog was positive for AP DNA in blood (Group 2; Week
24 and Week 25). One Group 1 dog was negative for AP antibod-
ies in all samples collected after Week 20, and the other two
Group 1 dogs were negative for AP antibodies Week 48. In con-
trast, all dogs in Group 2 were AP antibody positive on Week 48.
The 2 dogs with anemia, thrombocytosis and neutropenia on
the day prednisolone was initiated were clinically normal, AP PCR
negative, and were normal in all other CBC evaluations, suggest-
ing these results were spurious. The one dog in Group 2 that was
positive for AP DNA on Week 25, was also positive on Week 24
prior to prednisolone administration. None of the other samples
assessed by CBC and AP PCR assay after initiation of pred-
nisolone administration showed evidence for activation of AP
infection, suggesting that this protocol is unlikely to adversely
aﬀect dogs with chronic AP infection in the ﬁeld. Whether other
immune suppressive protocols would activate chronic AP infection
remains to be proven. The only dogs that became AP seronegative
by Week 48 were administered doxycycline, suggesting treatment
may aid in the elimination of chronic AP infection, even after
prednisolone administration.
ID20
SERUM NEUTRALIZATION OF US FELINE CALICIVIRUS
ISOLATES FOLLOWING VACCINATION WITH A NON-
ADJUVANTED, KILLED, FCV-BIVALENT VACCINE. LeMac
Morris2, Jennifer Hess2, Michael Lappin1. 1Colorado State
University, Fort Collins, CO, USA, 2Boehringer Ingelheim, St.
Joseph, KS, USA
The objective of this study was to determine the proportion of
feline calicivirus (FCV) ﬁeld isolates that would be neutralized
in vitro by sera from cats that were routinely vaccinated with a
product containing two caliciviruses. Serum from cats hyperinocu-
lated against 2 feline caliciviruses (FCV) has been shown to cross
neutralize a greater proportion (90.2%) of 61 FCV ﬁeld isolates
from the United States when compared to serum from cats hyper-
inoculated with 1 FCV isolate (23.0%)
At 8 and 11 weeks of age, each of the 44 kittens was adminis-
tered an experimental vaccine containing modiﬁed-live pan-
leukopenia, modiﬁed-live feline herpesvirus 1, and non-adjuvanted
inactivated calicivirus strains FCV-255 and FCV-DD1. Serum was
collected from each kitten 7 and 14 days after the second dose of
vaccine and pooled by day.
The ability of the pooled sera to neutralize a total of 33 FCV
strains collected from cats in the USA was determined. The speci-
ﬁc FCV serum neutralization titer for each FCV was deﬁned as
the serum dilution causing a 50% inhibition of virus replication.
Using the Day 7 post-vaccine pooled sera, 24 of 33 (72.7%) FCV
isolates were neutralized. Using the Day 14 post-vaccine pooled
sera, 20 of 33 (60.6%) FCV isolates were neutralized. The placebo
serum pool had undetectable antibody titers against all 33 FCV
ﬁeld strains that were screened.
Cross-neutralization of USA ﬁeld strains of FCV was > 60%
using pooled sera from kittens that were only administered 2 doses
of an inactivated non-adjuvant vaccine containing FCV-DD1 and
FCV-255 strains. These results suggest that cats vaccinated with
products containing more than one FCV isolate will likely have
broad heterologous protection if exposed to ﬁeld strains of FCV.
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RISK FACTORS ASSOCIATED WITH GIARDIA AND CRYP-
TOSPORIDIUM IN PET DOGS AND CATS IN THE USA.
Hanaa Thigeel1, Francisco Olea-Popelka1, Valeria Scorza1, David
Aucoin2, Michael Lappin1. 1Colorado State University, Fort
Collins, CO, USA, 2Antech Diagnostics, Irvine, CA, USA
Giardia spp. and Cryptosporidium spp. are protozoans that colo-
nize and reproduce in the intestines of many domesticated animals,
including dogs and cats. Outcomes range from subclinical infection
to severe diarrhea. Cryptosporidium spp. infection rates in dogs
and cats are largely unknown as sensitive diagnostic procedures
were not previously available. Polymerase chain reaction (PCR)
assays are now available to amplify Giardia spp. and Cryptosporid-
ium spp. DNA from feces. The purpose of this study was to report
fecal PCR assay results for Giardia or Cryptosporidium in a sample
set of dogs and cats in the USA.
All fecal samples that were submitted to a commercial labora-
tory (ANTECH Diagnostics) between 2010 and 2015 for evalua-
tion with a PCR panel of assays that amply DNA of a select
group of infectious agents including Giardia spp. (dogs and cats),
Cryptosporidium spp. (dogs and cats), and Cryptosporidium felis
(cats only) were analyzed. Descriptive, univariable, and multivari-
able logistic regression analyses were conducted to assess associa-
tions amongst age, sex, region, and season and the probability of
testing positive to either Giardia spp. or Cryptosporidium spp. in
pet dogs and cats.
Giardia spp. and Cryptosporidium spp. fecal PCR assay results
were available for 23,042 dogs and 16,326 cats.
Cryptosporidium spp. DNA was ampliﬁed from feces of 336 of
1,762 Giardia spp. DNA positive dogs (19.1%) and 132 of 843 Giar-
dia spp. DNA positive cats (15.7%). Of the 843 Giardia spp. DNA
positive cats, 97 (11.8%) were positive for Cryptosporidium felis
DNA. Logistic regression models results showed that age (young)
and region were associated with presence of Giardia spp. DNA and
Cryptosporidium spp. DNA in feces of dogs and cats. In addition,
presence of Giardia spp. DNA in feces of dogs varied by season.
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The results indicate that Giardia spp. DNA, Cryptosporidium
spp. DNA, and Cryptosporidium felis DNA are commonly ampli-
ﬁed from feces of dogs and cats, coinfections are common, and
positive rates can vary by age, season, and region. Either of the
agents should be suspected more highly in young animals. Addi-
tional studies will be required to evaluate for associations of posi-
tive test results with clinical ﬁndings and to determine the
likelihood dogs or cats are carrying zoonotic Giardia spp. or Cryp-
tosporidium spp.
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CLINICALLY SIGNIFICANT DIFFERENCES IN SENSITIV-
ITY LEVELS OF IN-CLINIC RAPID TESTS FOR ANTIBOD-
IES TO ANAPLASMA SPP. IN DOGS. Jiayou Liu1,
Ramaswamy Chandrashekar1, Mathew Eberts2, Mary Menard3,
Katie Erswell4. 1IDEXX Laboratories, Westbrook, ME, USA,
2Lakeland Veterinary Clinic, Baxter, MN, USA, 3Borador Animal
Hospital, Salem, NY, USA, 4Pine Point Animal Hospital, Scarbor-
ough, ME, USA
Tick-borne diseases, including Lyme disease, ehrlichiosis, and
anaplasmosis, are becoming increasingly prevalent as tick distribu-
tions expand through climate change, wildlife migration, and
increased relocation of companion animals. Granulocytic anaplas-
mosis is caused by the obligate intracellular bacterium Anaplasma
phagocytophilum, which is transmitted by Ixodes spp. of ticks.
Both dogs and humans are susceptible to this infection. In dogs
common signs of the infection, such as lethargy, anorexia, lame-
ness and fever, are non-speciﬁc. Diﬀerential diagnosis is supported
by evidence of morulae or DNA, especially in acute cases, and by
detection of speciﬁc antibodies using IFA or ELISA-based tests.1
A related but distinct bacterium, A. platys, also infects dogs and
causes infectious cyclic thrombocytopenia.2
The present study compared the performance of two in-clinic
rapid tests, the SNAP 4Dx Plus Test (IDEXX), and the VetS-
can Canine Anaplasma Test (Abaxis). Random canine samples
sourced from endemic regions for A. phagocytophilum were charac-
terized by A. phagocytophilum Immunoﬂourescence assay (IFA)
which was performed by a commercial reference laboratory. A.
platys-speciﬁc samples were sourced from dogs living in the south-
west, an A. platys-endemic region. These samples were character-
ized using A. platys-speciﬁc peptide ELISA.3 The characterized
samples were then blinded and randomized before testing with the
two in-clinic rapid tests. Results are shown in the table below.
Notably, the VetScan Test failed to detect more than 60% of
the medium to high titer (1:400 and above) A. phagocytophilum
samples.
Independent evaluation of SNAP 4Dx Plus and VetScan Ana-
plasma Tests was performed in three diﬀerent veterinary practices
(Maine, New York and Minnesota) using samples obtained from
pet dogs. Similar results were obtained - the VetScan Test failed to
detect over half of the IFA positive dogs detected by the SNAP
4Dx Plus Test in each of the three clinics.
These results demonstrate the SNAP 4Dx Plus Test has better
sensitivity for the detection of antibodies to both A. phagocy-
tophilum and A. platys when compared to the Abaxis VetScan
Anaplasma Test.
1. Carrade et al. J Vet Intern Med. 2009, 23:1129.
2. Bowman DD, Topics in Companion Anim Med. 2011,
26:173.
3. Qurollo BA et al. Infect Ecol Epidemiol. 2014, 4: 24699.
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PREVALENCE OF SELECT INFECTIOUS DISEASE AGENTS
IN CLIENT OWNED CATS IN MOSCOW, RUSSIA. Katie
MacMillan1, Natalia Volgina2, Michael Lappin1. 1Colorado State
University, Fort Collins, Colorado, USA, 2Private Practice, Mos-
cow, Russia
Client-owned cats in Moscow, Russia can be exposed to ﬂeas
and ticks and some develop fever, hemolytic anemia, thrombocy-
topenia, gingivitis, and other clinical problems noted in cats of
other countries. However, limited data are available concerning
prevalence rates for infectious agents common to eastern and west-
ern Europe. The overall objective of this study was to determine
the estimated prevalence of select feline infectious disease agents in
a convenience sample population of cats from Moscow, Russia.
Remnant blood in EDTA and serum from client owned cats in
Moscow that were evaluated for reasons independent to the study
were collected with permission and stored a 4C until evaluated.
Using previously validated assays, sera were assayed for Toxo-
plasma gondii IgG (Toxo), Bartonella spp. IgG (Bart), FeLV anti-
gen (Ag), and FIV antibody (Ab). Total DNA was extracted from
blood samples and DNA of Anaplasma spp., Bartonella spp., Ehr-
lichia spp., and haemoplasmas were ampliﬁed by previously vali-
dated PCR assays with Mycoplasma hemofelis (Mhf) amplicons
conﬁrmed by sequencing.
None of the cats were positive for DNA of Anaplasma spp. or
Ehrlichia spp. but many of the cats showed evidence of exposure
or current infection with one of more of the other agents. Bar-
tonella spp. antibodies were most common in serum and Candida-
tus M. hemominutum (Mhm) DNA was most common in blood.
Toxoplasma gondii IgG and Bartonella spp. IgG titers ranged
from 1:64 to 1:2048. Of the 81 cat samples evaluated in all assays,
single, dual, triple, and quadruplicate infections were documented
in 31, 11, 2, and 2 samples, respectively. Using this subset of sam-
ples, 57.8% of the cats had evidence of infection or exposure to
one or more of the select agents.
The results from this sample population suggest cats in Moscow
are exposed to intermediate hosts or undercooked meat (T. gondii),
ﬂeas (Bartonella spp. and hemoplasmas), and come in direct con-
tact with infected cats (hemoplasmas, FeLV and FIV). These
infectious agents should be on appropriate clinical diﬀerential lists,
processed foods should be fed, ectoparasite control should be
maintained, and feline-feline contact should be avoided when
possible.
Species
Pathogen Percent 95% CI
Dog Giardia spp. 7.7 7.3-8.0
Cryptosporidium spp. 5.4 5.1-5.7
Cat Giardia spp. 5.2 4.9-5.5
Cryptosporidium spp. 7.4 7.0-7.9
Cryptosporidium felis 5.1 4.7-5.4
Organism Reference Test             
(sample size - pos/neg)
SNAP                   
4Dx Plus
Abaxis     
VetScan Test
SNAP                   
4Dx Plus
Abaxis     
VetScan Test
A. phagocytophilum       IFA (143/90) 86.0% 32.2% 96.7% 88.9%
A. platys       ELISA (68/147) 85.3% 63.2% 98.0% 89.1%
Relave Sensivity Relave Speciﬁcity
Toxo IgG Bart igG FeLV Ag FIV Ab Mhm alone Mhf alone Mhm/Mhf Bart PCR
24/96 (25%) 30/96 (30%) 4/93 (4.3%) 1/93 (1.1%) 14/100 (14%) 2/100 (2%) 1/100 (1%) 2/100 (2%)
Serology (positive/tested [%]) PCR (positive/tested [%])
2016 ACVIM Abstracts 1481
ID24
COXIELLA BURNETII DNA NOT IDENTIFIED IN FLEAS
FROM DOMESTIC CATS IN AUSTRALIA AND THE USA.
Alison Manchester1, Jennifer Hawley1, Julia Beatty2, Vanessa
Barrs2, Michael Lappin1. 1Colorado State University, Fort Collins,
CO, USA, 2Valentine Charlton Cat Centre, University of Sydney,
Sydney, Australia
Coxiella burnetii is a rickettsial pathogen with serious zoonotic
implications (Q fever) transmitted by direct contact and vectored
by numerous tick species. Cats infected C. burnetii have been
implicated in human infections in Australia and the United States
but minimal information exists concerning routes of feline infec-
tion. Recently, C. burnetii DNA was isolated from Ctenocephalides
felis collected from wildlife in Cyprus; this ﬂea commonly infests
cats. The purpose of this study was to evaluate select groups of
ﬂeas from cats in the Australia and United States for the presence
of C. burnetii DNA using a previously optimized PCR assay.
The DNA samples utilized in the study had been extracted from
ﬂeas infesting 96 cats in previously published Bartonella spp.,
hemoplasmas, and Rickettsia felis studies. They were maintained
at 80°C until the present study. The ﬂeas were collected from
cats in eastern Australia (86) and the southern United States (4
Alabama, 6 Florida) and pooled in groups comprised of a maxi-
mum of 5 ﬂeas before DNA extraction. A previously reported con-
ventional PCR assay utilizing primers pairs targeting the IS-1111
(IS-5, IS-9, IS-14 and IS-20) insertion sequences transposase ele-
ments in the C. burnetii genome was used. If positive amplicon
was detected, genetic sequencing would be performed to conﬁrm
the presence of the pathogen.
For this study, ﬂeas were not speciated before DNA extraction.
However, previous studies in both countries suggest C. felis was
most likely. The detection sensitivity of the assay was shown to be
3.14 ng total C. burnetii genomic DNA per PCR reaction utilized
in all 4 primer sets. While all positive and negative controls per-
formed as expected, none of the 96 pooled ﬂea extracts were posi-
tive for C. burnetii DNA.
Coxiella burnetii DNA was not recovered from ﬂeas collected
from cats in eastern Australia or the southern United States. The
results suggest that ﬂeas infesting domestic cats in these regions
are not important vectors for C. burnetii and are unlikely to play a
role in the transmission of the organism to humans with Q fever.
ID25
RISK OF HEARTWORM INFECTION IN DOMESTIC CANI-
NES OF NORTHWESTERN OREGON. Kirk Miller1, William
Rausch2. 1Oregon State University College of Veterinary
Medicine, Corvallis, OR, USA, 2Portland Veterinary Cardiology,
Portland, OR, USA
Canine infection with Diroﬁlaria immitis, the parasitic agent
responsible for causing heartworm disease, is easily and safely pre-
vented via the periodic administration of one of a number of pre-
ventative agents. Many veterinarians in Oregon do not routinely
recommend the use of heartworm prophylactics; therefore, dogs
are commonly not on a preventative. Confusion regarding the use
of heartworm preventatives in Oregon is understandable, given the
paucity of incidence data in our region. The decision between a
veterinarian and a client on whether or not to start a preventative
is often made based on a cost-beneﬁt analysis, where only the cost
is known. The purpose of this study was to evaluate the risk of
developing heartworm infection amongst unprotected dogs in
Northwestern Oregon. This information will enable veterinarians
and their clients to make more informed decisions regarding heart-
worm prevention.
Between March 2010 and August 2015 owners of all dogs sur-
rendered to the Oregon Humane Society ﬁlled out a short ques-
tionnaire relating to their dogs’ histories. This questionnaire was
used to determine the eligibility of each dog for this study. Criteria
for inclusion in the study included that the dogs: (1) had been in
the possession of the surrendering party since they were 6 months
of age or younger; (2) were at least 12 months of age; (3) had no
history of travel outside of the state of Oregon; and (4) were never
administered heartworm preventative. Dogs that did not meet all
four of these criteria were excluded from the study. Additional
information gathered from the records included breed, age, sex
and spay/neuter status, location (by zip code), and the average
number of hours the dog spent outdoors. If a dog did meet the
study criteria then blood was drawn and tested for the presence
of D. immitis using a commercially available ELISA test (IDEXX
Snap 4Dx Plus).
A total of 5,103 dogs were surrendered to the Oregon Humane
Society during this period. Of these, 298 met the inclusion criteria
and were included in the study. None of these 298 dogs tested pos-
itive for Diroﬁlaria immitis. The tested dogs had spent a median of
2 years with their previous owners (range 6 months to 16 years)
for a combined total of 1300.45 years of exposure. Using a likeli-
hood-based method, the maximum likelihood estimate (MLE) for
the risk is 0 (95% CI: [0, 0.0023]) per year.
The ﬁndings of this study suggest that the likelihood of unpro-
tected Northwestern Oregon dogs developing heartworm infection
is currently very low. Heartworm transmission prediction models
based on climate data (Knight/Lok) have shown that the climate
conditions in the area can support heartworm transmission. Data
compiled by the Companion Animal Parasite Council (Capcve-
t.org) conﬁrm that Diroﬁlaria immitis has been diagnosed within
the state of Oregon, although only 0.18% of all positive cases of
heartworm in the U.S. are in the state of Oregon. It is important
to consider that these data reﬂect a point in time. As the popula-
tion of Oregon continues to grow, more heartworm infected dogs
will invariably arrive. Changes in climate patterns will also inﬂu-
ence the transmission of this disease. Continued monitoring and
vigilance are recommended.
ID26
ECTOPARASITES AND VECTOR-BORNE PATHOGENS OF
DOGS IN BAJA CALIFORNIA SUR. Cody Minor, Dana Hill,
Danielle Straatmann, Michael Lappin. Colorado State University,
Fort Collins, CO, USA
In the last several years, clinical illness in a number of people in
Baja California Sur, Mexico, has been suspected to be associated
with rickettsial disease agents such as Rickettsia rickettsii, Rick-
ettsia felis, and/or Ehrlichia species. The objective of this study is
to determine the prevalence of select vectors and vector-borne dis-
ease agents carried by companion dogs of the region.
During planned community outreach sterilization and vaccina-
tion clinics for local dogs with consenting owners, samples of
ectoparasites were collected from infested dogs and preserved in
alcohol for identiﬁcation, and blood samples were collected in
EDTA and non-additive tubes retained for testing. Sera were
assayed for antigen of Diroﬁlaria immitis and antibodies against
Ehrlichia canis/E. ewingii, Anaplasma phagocytophilum/A. platys,
and Borrelia burgdorferi using a commercial kit (SNAP
4DXPlus, IDEXX Laboratories). Sera were also assayed for
antibodies against Rickettsia species by indirect ﬂuorescent anti-
body (IFA) testing (R. rickettsia antigen source). Total DNA was
extracted from blood and evaluated with conventional polymerase
chain reaction (PCR) assays to amplify DNA of Anaplasma spe-
cies, Babesia species, Bartonella species, Ehrlichia species, Rick-
ettsia species, and hemotropic Mycoplasma species
(Hemoplasmas). Positive amplicons were sequenced to ascertain
the species.
Samples from 67 dogs were available. From these, ectoparasites
Rhipicephalus sanguineus (33 dogs; 49.3%), Ctenocephalides felis
(11 dogs; 16.4%), and Pulex irritans/simulans (four dogs; 6.0%)
were identiﬁed. Diroﬁlaria immitis antigen (one dog; 1.5%) and
antibodies against A. phagocytophilum/A. platys (10 dogs; 14.9%)
and E. canis/E. ewingii (31 dogs; 46.3%) were detected in the
serum of some dogs. Two samples had probable antibodies against
R. rickettsii through IFA testing and are being conﬁrmed. Evalua-
tion of DNA from 41 dogs has been completed to date; E. canis
DNA was ampliﬁed from eight dogs (19.5%), A. platys DNA from
six dogs (14.6%), Babesia canis vogeli DNA from three dogs
(7.3%), and Mycoplasma haemocanis DNA from three dogs
(7.3%). Coinfections were conﬁrmed in four dogs (9.8%) and con-
sisted of D. immitis/E. canis (one dog), E. canis/A. platys (one
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dog), E. canis/M. haemocanis (one dog), and E. canis/A. platys/
M. haemocanis (one dog).
Vector-borne agents detected to date likely reﬂect common
exposure to R. sanguineus, as this tick vectors each of the PCR-
conﬁrmed agents. Further information will be gained by comple-
tion of the PCR assay analysis of the blood, ﬂeas, and ticks.
ID27
IDENTIFYING AGREEMENT AND BARRIERS TO
PROPOSED CANINE INFECTIOUS DISEASE GUIDELINES
FOR DOG GROUP SETTINGS. Jason Stull1, Michelle Evason2,
Jennifer Kasten1. 1Ohio State University, Columbus, OH, USA,
2Rayne Clinical Nutrition Canada, Burnaby, BC, Canada
Canine group settings, locations or events where dogs temporar-
ily come together in a shared environment (e.g., shows, sporting
events, dog parks) pose an increased risk for infectious disease
transmission. Despite this increased risk, few guidelines exist to
provide recommendations for reducing disease risk in these set-
tings. During 2014–2015 a panel of canine infectious disease
experts reviewed the current literature and drafted a set of 44 evi-
dence-based recommendations for prevention of infectious diseases
for dogs in group settings. In August 2015 a survey of attendees at
the AKC Canine Health Foundation Parent Organization confer-
ence was completed to determine agreement with and perceived
barriers to these recommendations. The 15-minute self-adminis-
tered survey was provided to 238 Conference attendees and con-
sisted of a series of Likert-type and open-ended questions (online
and paper format) seeking feedback on 22 of the recommenda-
tions. The survey was completed by 185 individuals (78%), and all
responses were reviewed, summarized, and open-ended comments
categorized by theme. Respondents self-identiﬁed as: participants,
judges, and breeders in a variety of local, national, and interna-
tional canine group events. Most respondents (> 40%) agreed with
all but three of the panel’s recommendations, yet a majority of
respondents stated the recommendations would be diﬃcult or very
diﬃcult to implement in their setting (primarily dog shows). Com-
mon survey result themes related to diﬃculty of implementation
included: administrative concerns (cost, human resources/man-
power), enforcement issues, ethical concerns, privacy concerns,
and strong need for oﬃcial outreach to promote awareness and
education related to canine infectious diseases. Survey responses
identiﬁed needs for: further reﬁnement of recommendations to aid
comprehension and clarity (especially around ecto- and endopara-
site control), and education to promote culture changes related to
disease risk prevention. In order to raise awareness of canine infec-
tious disease in group settings amoungst event participants, atten-
dees, and organizers; an online freely available canine infectious
disease risk calculator tool is being developed.
ID28
CORRELATION OF MYCOPLASMA QUANTITATIVE PCR
TO SEVERITY OF CONJUNCTIVITIS IN CATS. Alexis Dubin,
Jennifer Hawley, Cynthia Powell, Michael Lappin, Julia Veir.
Colorado State University, Center for Companion Animal Studies,
Fort Collins, CO, USA
Mycoplasma species are one of the most common infectious
causes of conjunctivitis in cats. Mycoplasma felis is commonly
implicated as a primary pathogen, but other Mycoplasma species
have also been detected in clinically ill cats. Findings from previ-
ous studies using conventional PCR (cPCR) to investigate the role
of Mycoplasma species in causation of feline conjunctivitis have
been mixed as Mycoplasma can be carried by apparently normal
cats. Therefore, the purpose of this study was to determine if
increasing severity of conjunctivitis in cats correlates with higher
Mycoplasma species copy numbers using qPCR.
A total of 77 conjunctival swabs collected from 29 shelter cats
with conjunctivitis and conﬁrmed to contain Mycoplasma species
DNA using cPCR were selected for study. The severity of conjunc-
tivitis at the time the samples were acquired was determined using
a grading scheme from 0 - 9. The samples were evaluated using a
previously validated qPCR to determine the Mycoplasma copy
number. Statistical methods consisted of using the Spearman’s rho
test to determine if severity of conjunctivitis was correlated to
qPCR Mycoplasma species copy number.
The results revealed the severity of conjunctivitis signiﬁcantly
correlated to qPCR Mycoplasma copy number (Spearman’s corre-
lation coeﬃcient 0.32, P = 0.0042), however, the strength of this
correlation was only mild to moderate.
Based on the results of this study, future investigation of the
impact of Mycoplasma species other than M. felis on the correla-
tion of qPCR and severity of conjunctivitis in cats should be
performed.
NM01
EFFECT OF THE HYPER-IMMUNE EGG YOLK SUPPLE-
MENTATION ON WEIGHT GAIN IN NEONATE PUPPIES.
Hanna Mila1, Alexandre Feugier2, Claire Mariani2, Aurelien Grel-
let2, Sylvie Chastant-Maillard1. 1Ecole nationale veterinaire de
Toulouse, UMR 1225 Interactions Ho^te-Pathogenes, INP, Tou-
louse, France, 2Royal Canin, Aimargues, France
Colostrum provides puppies with most of their passive immune
transfer, as in dogs only 5% of immunoglobulin G (IgG) is
acquired via transplacental transfer. Inadequate colostrum intake
during the ﬁrst day of life will deprive puppies not only of
immunoglobulins, but also from many hormones, growth factors
and nutrients. Hence, it increases the risk for neonatal morbidity
and mortality. Supplementation during the ﬁrst hours of life with
canine serum or plasma increased blood IgG concentration1 in
colostrum deprived puppies as well as improved their growth dur-
ing the entire neonatal period (0–3 weeks)2. This study aimed to
evaluate the eﬀect of exogenous speciﬁc antibodies administrated
via egg yolk before the intestinal barrier closure on growth in pre-
weaning puppies.
Speciﬁc antibodies against canine parvovirus type 2 (CPV2) and
E. coli were obtained in eggs from hens vaccinated separately
against one of the mentioned agents3. Egg yolk was ﬂash-dried
and tested for the presence of CPV2 and E. coli-speciﬁc antibodies.
Hyper-immune solution was then prepared by mixing egg powder
with a commercial milk replacer (Babydog Milk, Royal Canin,
Aimargues, France; 1 g of egg powder with CPV2 antibodies and
1 g of egg powder with E. coli antibodies with 12 mL of reconsti-
tuted milk). A total of 334 puppies from 16 diﬀerent breeds,
enrolled in one breeding kennel, were included in the study.
Depending on the expected adult body weight, puppies were classi-
ﬁed into small breed dogs (S; adult weight < 25 kg), and large
breed dogs (L; > 25 kg). Within each litter and taking into account
the birth weight, puppies were assigned into supplemented or con-
trol group. Each puppy from the supplemented group received
orally 1.5 mL/100 g bw of hyper-immune solution at once within
the ﬁrst 8 hours after birth. Puppies from the control group
received at the same dose (1.5 mL/100 g) and time after birth (<
8 h) the milk replacer only. All puppies were weighed at birth and
at 7, 14, and 21 days of life. Linear mixed models (MIXED proce-
dure; SAS Institute Inc., Cary, NC, USA) with litter modeled as a
random eﬀect were performed to determine the variables aﬀecting
birth weight and weight gain during the neonatal period: breed
size (small; large), age (0–7; 7–14; 14–21 days), supplementation
(supplemented or control group). All the interactions between
mentioned ﬁxed eﬀects were also tested.
L represent 38.3% (128/334) of the included puppies. Among L
and S, 65 (50.8%) and 104 (50.5%) were supplemented, respec-
tively. The weight at birth was signiﬁcantly higher in L compared
with S (median: 370 g [interquartile range: 325; 408 g] versus
200 g [156; 248 g]; P < 0.001). Birth weight was found not diﬀer-
ent between supplemented and control puppies whatever the breed
size (P = 0.14): supplemented L 366 g [330; 412 g] versus 375 g
[322; 405 g] in controls; supplemented S 199 g [155; 247 g] versus
201 g [159; 248 g] in controls. Weight gain during the neonatal
period was inﬂuenced by time (P < 0.001), supplementation
(P = 0.031) and the interactions between the breed size and sup-
plementation (P = 0.027) and time and breed size (P = 0.001). L
gained 176 g [67; 294 g] during the 1st week, 223 g [158; 324 g]
during the 2nd week and 260 g [160; 382 g] during the 3rd week
2016 ACVIM Abstracts 1483
of life, with signiﬁcantly greater weight gain compared with S only
during the 1st week (S = 116 g [66; 172 g]; P = 0.001). Whatever
the period concerned, supplemented L gained more weight during
the entire neonatal period than the controls (841 g [485; 1087 g]
versus 623 g [436; 858 g]; P = 0.048). No diﬀerence was evidenced
between supplemented and control S (P = 1).
In our study large breed puppies supplemented at birth with the
hyper-immune egg yolk had greater weight gain during the entire
neonatal period. Retarded growth at the early stage of life
increases the risk of morbidity and mortality in puppies4. Thus it
could be hypothesized that better growth in supplemented puppies
reﬂects a better health. Nevertheless, further studies are needed in
order to conﬁrm our ﬁndings in other breeding kennels and on
large number of individuals.
1Poﬀenbarger et al., 1991; 2“Canine health product containing
antibodies against canine parvovirus type 2” WO2015004181 A1.;
3Van Nguyen et al., 2006; 4Mila et al., 2012.
NM02
EFFECTS OF DIETARY MEDIUM CHAIN TRIGLYCERIDES
ON VOLUNTARY ACTIVITY IN DOGS AND CATS. Yuanlong
Pan, Hui Xu, Sandeep Bhatnagar, Janet Jackson. Nestle Purina
Research, St Louis, MO, USA
Decline in cerebral glucose metabolism is a common feature of
aging in people and animals including rats, dogs, and monkeys,
and it is closely associated with age-dependent cognitive decline.
We had conﬁrmed in a previous study that dietary medium chain
triglycerides (MCTs) can enhance cognitive functions in dogs by
providing the brain with an alternative energy source. In this
study, we investigated the eﬀects of dietary MCTs on voluntary
activity in dogs and cats.
In the cat study, sixteen middle-aged and senior cats were fed
100% of their maintenance energy requirements (MERs) with a
control diet for one week, and then were switched to the MCT-
containing diet for 28 days. Their daily activity was monitored
during the feeding trial with activity monitors. In the dog study,
twenty senior dogs were fed 100% of their MERs with a control
diet for 6 days, and then were assigned to one of 2 MCT-contain-
ing diets with 10 dogs per diet for 27 days. Then the dogs were
switched to the alternative MCT diet for 32 days. Daily activity
was recorded with activity monitors during the feeding trial. In
cats, the MCT-containing diet signiﬁcantly increased both daytime
(17381.23  2551.18 versus 22628.55  2790.61, P < 0.0001) and
night time activity (4415.56  654.71 versus 5926.66  786.88,
P = 0.002). Interestingly, in dogs, both MCT diets signiﬁcantly
increased only daytime activity (80349.46  9703.34 versus
99254.33  12163.83; 80349.46  9703.34 versus 105120.38 
11550.91, P < 0.05). The results show that both dogs and cats
became more active when fed a diet containing MCTs
NM03
EFFECTS OF DIETARY MACRONUTRIENT CONTENT AND
FEEDING PATTERN ON LEPTIN CONCENTRATIONS IN
LEAN HEALTHY CATS. Dagmar Tarkosova1, Jacquie Rand2,
Heidi Farrow2, Marcia Coradini2, John Morton3. 1University of
Veterinary and Pharmaceutical Sciences, Brno, Czech Republic,
2The University of Queensland, Brisbane, Australia, 3Jemora Pty
Ltd, Geelong, Australia
Excessive weight gain is associated with metabolic and hor-
monal changes that predispose cats to insulin resistance and other
disorders. The adipokine leptin is an important regulator of energy
metabolism, and circulating leptin concentrations correlate with
fat mass in cats and other species. In cats, leptin is associated with
insulin resistance, independent of bodyweight. Although dietary
factors such as energy density, fat content and feeding pattern
increase the risk of obesity, there is limited information on how
dietary factors such as feeding, fasting, and macronutrient content
inﬂuence leptin concentrations in cats. The aims of this study were
to compare leptin concentrations in lean, healthy cats fed diets
high in protein, fat and carbohydrate, to assess associations
between leptin concentrations and insulin, glucose, and NEFA
concentrations, and to determine the eﬀects of feeding pattern on
baseline and postprandial leptin concentrations.
A controlled trial was conducted with clinically healthy cats
(n = 24). Mean body weight was 4.9 kg and all cats had ideal
body condition score of 3 on a 5-point scale. All cats were fed a
“washout” diet (commercial feline diet) for ﬁve weeks, and were
then fed one of three test diets high in one of protein, fat or car-
bohydrate for ﬁve weeks. Diets were dry extruded formulations,
and each test diet provided approximately 50% of energy from the
test macronutrient, and 25% of energy from each of the other two
test macronutrients. Leptin concentrations were measured during
two feeding patterns: a meal-feeding test (once daily feeding) and
an ad libitum-feeding test, conducted 4 weeks after commencement
of the test diets. During the meal-feeding test, cats ate 90 - 100%
of the 12 hour ad libitum intake as a single meal in 0.5 hour.
Blood samples (4 mL), were collected over 24 hours in the meal
feeding test and 12 hours in the ad libitum test.
Distributions of leptin variables in the ad libitum and meal-
feeding tests were similar across dietary groups after consumption
of the washout diet for 5 weeks. Mean baseline concentrations (av-
erage of 30 and 5 minutes values), mean concentrations over
24 hours (mean 24-h), and peak leptin concentrations in the meal
feeding test varied signiﬁcantly by diet (overall P < 0.001 to
0.027). Baseline, mean 24-h and peak leptin concentrations for the
high fat diet were signiﬁcantly higher than for the high protein
diet, and for baseline and mean 24-h, for the high carbohydrate
diet. A similar pattern was observed in the ad libitum feeding test
with highest leptin concentrations in cats consuming the high fat
diet. In general, leptin concentrations after consuming the high
carbohydrate diet were not signiﬁcantly diﬀerent from the
high protein diet, but if they diﬀered, leptin concentration for the
high carbohydrate diet was higher compared to the high protein.
There was no signiﬁcant eﬀect of diet on the time to peak leptin
concentration in the meal-feeding test (overall P = 0.855), and
median times to peak leptin concentration were 15 hours for all
diets. In the meal-feeding test, only 3/8 cats signiﬁcantly exceeded
their baseline leptin concentration for each of the high protein and
high fat diets, but 7/8 did so for the high carbohydrate diet. In
general, leptin concentrations decreased signiﬁcantly approximately
2 hr after eating in the meal feeding test, but remained relatively
constant during ad libitum feeding. When data for all diets were
combined, leptin was signiﬁcantly positively correlated with insulin
concentrations during ad libitum feeding (P = 0.008 to 0.036), but
only at baseline and at 24 hours in the meal feeding test
(P = 0.025 and <0.001, respectively). There were no correlations
between leptin and either glucose or NEFA across all diets. Glu-
cose, insulin and NEFA did not account for the decline in leptin
soon after feeding in the meal feeding test.
In conclusion, independent of feeding pattern, leptin concentra-
tions tend to be highest in lean cats consuming a diet with 50% of
energy from fat, compared to diets high in protein or carbohy-
drate. Leptin concentrations vary minimally over 12 hours of ad li-
bitum feeding, whereas leptin decreases approximately 2 hours
after feeding following a fast, and this decrease is not accounted
for by changes in insulin, glucose or NEFA concentrations. Fur-
ther investigation is needed to understand the interactions between
hormones associated with satiety, dietary factors and weight gain
in cats.
NM04
EFFECT OF HIGH SODIUM DIET ON BLOOD PRESSURE
AND CARDIAC FUNCTION IN HEALTHY ADULT DOGS.
Hui Xu, Dottie Laﬂamme, Sandeep Bhatnagar, Xuemei Si, Grace
Long. Nestle Purina PetCare Research, St. Louis, MO, USA
Promoting water intake is recommended for managing dogs
with lower urinary tract disease. Increased dietary salt has been
used for this purpose in veterinary therapeutic diets. The objective
of this study was to evaluate potential adverse eﬀects of dietary
salt (sodium chloride) on blood pressure and cardiac function in
dogs.
Following a two week baseline period where dogs were fed a
Control Diet containing 0.13 g sodium/100 kcal ME, twenty
healthy dogs (6–10 years old) were allocated to two groups and fed
diets diﬀering only in total sodium chloride content: CONTROL
(CON) = 0.13 g sodium /100 kcal ME, or High Sodium Diet
(HNA) = 0.41 g sodium/100 kcal ME. Dogs were fed their
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respective diet for 6 months. During this period, indirect systolic
blood pressure was recorded monthly. Overall health, cardiac func-
tion evaluated by echocardiography (performed by boarded veteri-
nary cardiologist), plasma B-type natriuretic peptide (BNP), serum
biochemistry and urinalyses were assessed at 0 and 6 months on
test. Body composition was analyzed by dual energy X-ray absorp-
tiometry (DEXA) at 0, 3 and 6 months. Treatment eﬀects were
analyzed using t-test and Generalized Linear Mixed Models.
Overall, dietary sodium level had no signiﬁcant eﬀect on blood
pressure, cardiac function, plasma BNP, serum biochemical pro-
ﬁles or urinalyses. There were no dietary eﬀects or diet by time
interactions on bone mineral content or body composition. In con-
clusion, consumption of a diet containing 0.41 g sodium/100 kcal
ME had no adverse eﬀects on blood pressure or cardiac function
in healthy adult dogs over a 6-month period.
NM05
DETERMINING THE LACTATE AND GLUCOSE THRESH-
OLDS AND THE ACID-BASE IMBALANCES IN BEAGLES
DOGS. Alejandro Zamora Restan, Evandro Zacche, Jaislaine
Braz, Raphaela Marques Canola, Samara Beretta, Antonio
Queiroz-Neto, Guilherme Camargo Ferraz, Aparecido Antonio
Camacho. Universidade Estadual Paulista – UNESP, Jaboticabal,
Brazil
The determination of lactate and glucose threshold in dogs sub-
mitted to incremental exercise test (IET) is scarce. This study
aimed (1) to determine the lactate and glucose thresholds (2) to
investigate the acid-base responses of untrained dogs submitted to
incremental exercise test. Fourteen Beagle dogs, 1–2 years old,
healthy and untrained were used for determination of lactate and
glucose thresholds and submitted to IET using treadmill, with slop
from 5 to 7.5% and increasing speeds of 0.5 m/s every 5 minutes.
The test was concluded when dogs presented fatigue signals. Blood
samples were collected after 90 seconds of each eﬀort step, though
venous catheter placed in the jugular vein. The samples used for
determination of acid-base alterations were collected in the
moments before of IET, immediately and ﬁve minutes after the
fatigue. Data were submitted to Shapiro-Wilk test, and the Pear-
son was used to correlate the running velocities corresponding to
the lactate and glucose threshold and analysis between moments
of assessment was performed by using repeated measures one-way
ANOVA (P < 0.05). It was found high correlation between lactate
and glucose threshold velocities, r = 0.84 (P < 0.01), and for pH,
PCO2, HCO3
 strong ions diﬀerence (SID) were found moment
eﬀect (P < 0.001). The basal values of pH increased (P < 0.001) in
fatigue (7.341  0.02 to 7.390  0.04, respectively), and the PCO2
presented reduction (P < 0.001) in the fatigue and 5 minutes after
fatigue (31.74  5.9, and 37.01  5.8), in comparison with basal
value (41.4  2.2). The HCO3 decreased in fatigue and 5 minutes
after IET (18.2  2.3 and 19.1  2.5) when compared with basal
(21.9  1.1). The values of SID showed decreased in fatigue com-
pared to values before exercise (36,2  1,7 e 36,6  2.1) respec-
tively. Running velocities corresponding to the lactate and glucose
threshold showed accordance between them, what has been
already shown in horses and humans, besides results showed respi-
ratory alkalosis and metabolic acidosis, which is considered a
change due to hyperventilation and strenuous anaerobic activity,
decreasing PCO2 concentrations, which leads to increase pH
through the increase of the relation of HCO3
 and PCO2. SID
showed a metabolic acidosis possibly from lactate values increase.
Results of this study suggest that glucose threshold can be used as
a marker of aerobics capacity in dogs as it is used in humans and
horses, besides, maximum exercises in dogs cause acid basic
alterations.
NM06
WHEN FED FOODS WITH SIMILAR PALATABILITY, CATS
CHOOSE 30%, DOGS 23% OF CALORIES AS PROTEIN.
Dennis Jewell1, Jodi Vondran1, Melissa Vanchina1, Jean Hall2.
1Hill’s Pet Nutrition, Inc., Topeka, KS, USA, 2Oregon State
University, Corvallis, OR, USA
Dogs and cats have speciﬁc taste preferences that are inﬂuenced
by macronutrient composition and physical characteristics of food,
as well as presence or absence of speciﬁc taste imparting com-
pounds (palatability enhancers). This study investigated the rela-
tionship of food choice on macronutrient composition and that
choice on subsequent plasma amino acid concentrations. Experi-
mental foods for dogs and cats were individually prepared to have
similar palatability through manipulations of factors independent
of macronutrients. Foods with similar palatability preference for
their respective populations as a whole were then investigated for
intake choice using 20 dogs with varying body fat composition
(mean, 3.9 kg; SD, 0.9 kg; range, 2.4–6.2 kg;) and 27 cats (mean
body fat composition, 1.4 kg; SD, 0.9 kg; range 0.3–2.2 kg). Sub-
sequent eﬀects of food choice on serum amino acids were also
determined. Four completely balanced foods were available to
dogs and cats at all times. The four varied in macronutrient con-
tent: Food 1: high protein (33% of calories from protein for dogs;
42% for cats); Food 2: high fat (54% of calories from fat for
dogs; 44% for cats); Food 3: high carbohydrates (56% of calories
from carbohydrate for dogs; 52% for cats); and Food 4: blended
macronutrients. Dogs on average chose to consume 23.0% calories
from protein (SD, 1.5%; range 20–26%) whereas cats chose
30.3% of calories from protein (SD, 4%; range 24–38%). Body
composition inﬂuenced their choice of calories from protein. In
dogs, there was a positive relationship between body fat and per-
cent calories consumed as protein (r = 0.56; P = 0.02). There was
no relationship between lean body mass and percent calories con-
sumed as protein (r = 0.06; P = 0.82). Overall, dogs with high
body fat showed the highest preference for dietary calories from
protein. In cats, both body fat and lean body mass were negatively
associated with calories consumed as protein (P = 0.04; P = 0.02,
respectively), with a positive association for the interaction
(P = 0.02). Overall, cats with high body fat and high lean body
mass showed the highest preference for dietary calories from pro-
tein. Dogs had higher circulating amino acid concentrations of
threonine, methionine, isoleucine, and valine (P < 0.05) compared
with cats, the later which had higher circulating amino acid con-
centrations of isoleucine, valine, tyrosine, phenylalanine, and his-
tidine (P < 0.05). In both dogs and cats there was no eﬀect of
protein intake on circulating essential amino acid concentrations.
Increased intake of calories as protein was associated with increas-
ing plasma ornithine (dogs only) and citrulline (dogs and cats)
concentrations (P < 0.05). In summary, given the opportunity to
choose between foods with similar palatability, cats chose to con-
sume 30.3% and dogs 23.0% of their calories as protein. Although
there were species diﬀerences between circulating amino acid con-
centrations indicating metabolic shifts associated with protein
intake, there were no changes in circulating essential amino acid
concentrations.
NM07
A DOUBLE MASKED CLINICAL TRIAL OF A THERAPEU-
TIC FOOD IN THE MANAGEMENT OF CANINE ATOPY.
Jennifer Macleay, Heidi Schiefelbein, Kathy Gross. Hill’s Pet
Nutrition Inc., Topeka, KS, USA
The purpose of this double masked, controlled multicenter clini-
cal trial was to determine the impact of a food with ingredients
designed to have skin and coat health beneﬁts and immune modu-
lating eﬀects on clinical signs of seasonal atopic dermatitis versus
a control food. Dogs with a history of seasonal dermatitis, but
without current clinical signs consistent with atopy (CADESI and
pruritis scores = 0) were recruited in the spring from 11 general
practices in the United States. Dogs currently on foods designed
for adverse food reactions were excluded. Eligible dogs were ran-
domly assigned to Test or Control groups and evaluated by their
veterinarian at 0, 4, 8, 12 and 16 weeks. Consistent with accepted
standards of care, treatment was not withheld, therefore, pre-
scribed medications and dosing information was collected; only
oclacitinib which was not uniformly available to all practices was
disallowed. Veterinarians graded skin lesions using a modiﬁed
CADESI (0:absent - 4:severe for erythema, alopecia, excoriations
and licheniﬁcation for 27 body sites, max score of 432) and a pru-
ritis score (0:absent - 4:severe).
Forty-four adult dogs (22 Test, 22 Control) were enrolled and
completed the study. During the course of the study 18% of all
dogs had no reported dermatological clinical signs whereas 82%
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developed a positive CADESI and/or pruritis score. CADESI and
pruritis scores rose signiﬁcantly from 0 at all subsequent time
points but were generally low. Mean  SEM CADESI scores at
weeks 4, 8, 12 and 16 were; 2.6  0.98, 5.8  2.47, 8.6  3.31 and
6.6  1.91 respectively. Mean  SEM pruritis scores were
0.5  0.16 at week 4 and were highest at week 16; 1.2  0.16.
Incidence, location and types of clinical signs manifested were not
diﬀerent between groups. Medications were only dispensed to dogs
with a positive CADESI and/or pruritis score, which was 66% of
all dogs (73% of Control versus 59% of Test). Medications dis-
pensed were categorized as a topical containing a glucocorticoid, a
systemic antihistamine and/or a systemically administered gluco-
corticoid. An event history analysis revealed that time until pre-
scribing topical medications was highly similar between groups
(Test 98  7.0 versus Control 100  5.2 days) but was less so for
antihistamines (Test 62  4.1 versus Control 55  3.3 days) and
systemic glucocorticoids (Test 105  4.4 versus Control
90  6.4 days).
This study is the ﬁrst to describe the recurrence rate of seasonal
atopy in dogs from general practices as part of a grade 1, multi-
center clinical trial. Onset of clinical signs resulted in medical
intervention in the majority of dogs. Statistical power in this study
was likely inﬂuenced by the generally low CADESI and pruritis
scores combined with medical intervention. In addition, the inter-
val to medical intervention was likely inﬂuenced by the study
schedule which promoted frequent evaluations and case manage-
ment. This data suggests that dogs with seasonal atopy my beneﬁt
from frequent evaluations. This data also suggests altered manage-
ment of dogs fed the Test food as medication use was lower and
the interval prior to the onset of systemic antihistamines and/or
glucocorticoids was longer. A food designed for skin and coat
health beneﬁts and immune modulating eﬀects can be part of a
proactive atopy management program and may result in less medi-
cation needed.
NU01
LONGITUDINAL EVALUATION OF SERUM SYMMETRIC
DIMETHYLARGININE (SDMA) AND CREATININE (SCR) IN
DOGS WITH EARLY CKD. Sarah Guess1, Maha Yerramilli2,
Edward Obare2, Greg Grauer1,2. 1Kansas State University,
Manhattan, KS, USA, 2IDEXX Laboratories, Westbrook, ME,
USA
Retrospective feline studies have shown SDMA is more sensitive
than sCr for early CKD detection. Our objective was to compare
SDMA and sCr for detection of early CKD in a prospective, lon-
gitudinal study of older dogs.
SDMA and traditional serum and urine clinicopathologic tests
were measured biannually for four years in 43 dogs with an initial
median age of 8.9 years. Persistent increases in UPC, sCr, or
SDMA or decreases in USG triggered renal ultrasound (US) and
GFR (plasma iohexol clearance) evaluations. Necropsies were per-
formed whenever possible when dogs died or were euthanized.
CKD was documented in 23 dogs (53%) by US abnormalities
(n = 13), decreased GFR (> 40% reduction) (n = 13), persistent
renal proteinuria (UPC ≥ 0.5) (n = 6), or renal histology (n = 6)
(12 dogs had multiple abnormalities).
9 of 23 dogs had increased SDMA (≥ 14 µg/dl) without hypers-
thenuria concurrent or subsequent to CKD diagnosis. One dog
had a single (endpoint) increased SDMA and 8 had persistent/mul-
tiple SDMA increases. Conversely, only 2 of the 23 dogs had
increased sCr (> 1.8 mg/dl) at any point and both of these dogs
had concurrent/prior SDMA increases. In the 13 dogs with
decreased GFR, sCr and SDMA were increased in 1 and 7 dogs,
respectively. There were no persistent increases in SDMA without
hypersthenuria without CKD. Increased SDMA without hypers-
thenuria had 39% sensitivity and 100% speciﬁcity for CKD
whereas increased sCr without hypersthenuria had 9% sensitivity
but 100% speciﬁcity (P = 0.024).
SDMA is a sensitive biomarker for early canine CKD.
NU02
SDMA CORRELATES BETTER WITH CREATININE THAN
HIGH THROUGHPUT IMMUNOTURBIDOMETRIC CYS-
TATIN C ASSAY IN FELINE SERUM. Polina Prusevich, Julie
Cross. IDEXX Laboratories, Westbrook, ME, USA
The purpose of this study was to determine the correlation of
SDMA and Cystatin C with creatinine in felines, to assess the util-
ity of these markers together in diagnosing chronic kidney disease
(CKD).
Fifty-six feline serum samples were sourced from samples sub-
mitted to IDEXX Reference Laboratories for general chemistry
testing. Cystatin C, SDMA and creatinine were assayed using a
Beckman AU5800 clinical chemistry analyzer. All three methods
were calibrated appropriately on the day of assay, and QC was
performed prior to analysis of the feline serum samples. Fifty-six
feline serum samples were assayed in duplicate for all three ana-
lytes on the same day.
SDMA is validated in cats, with values above 14 µg/dL indicat-
ing that CKD is likely present. In this study, SDMA correlated
well with serum creatinine. All but one of the samples above the
feline creatinine cut-oﬀ of 2.5 mg/dL was also above the SDMA
cut-oﬀ (19 of the 20 elevated creatinine samples). This one sample
was very near the cut-oﬀs for both SDMA and creatinine. Samples
with normal creatinine values were distributed between normal
SDMA values (22 of 36 samples with normal creatinine values)
and elevated SDMA values (14 of 36 samples with normal crea-
tinine values) consistent with previous data showing that SDMA
can be elevated earlier than creatinine in some cases of CKD.
However, Cystatin C did not eﬀectively diﬀerentiate between
felines with normal or abnormal creatinine levels, with 25% (5 of
20 samples) of the feline samples with abnormal creatinine levels
showing normal Cystatin C, using the previously published Cys-
tatin C cut-oﬀ of 1.95 mg/dL, which was determined in cats. For
cats with normal creatinine levels, half of the Cystatin C results
were discrepant, with 50% (18 of 36 samples) having abnormal
Cystatin C levels.
In this study, there was no alternative cut-oﬀ value that could
be determined for this Cystatin C assay, which would signiﬁcantly
increase its diagnostic value.
SDMA has previously been shown to correlate well to GFR,
and can be elevated prior to creatinine in some animals, making it
an excellent marker for CKD in felines. However, this high-
throughput immunoturbidometric Cystatin C assay did not diﬀer-
entiate between animals with elevated creatinine, and cannot be
recommended for aid in diagnosing CKD in felines.
NU03
FIBROBLAST GROWTH FACTOR-23 IN CANINE CHRONIC
KIDNEY DISEASE. Laura Harjes1, Valerie Parker1, Katarzyna
Dembek1, Luciano Henrique Giovaninni2, Marcia Mery Kogika2,
Dennis Chew1, Ramiro Toribio1. 1The Ohio State University,
Columbus, OH, USA, 2University of S~ao Paulo, S~ao Paulo, Brazil
In humans and cats with chronic kidney disease (CKD), ﬁbrob-
last growth factor-23 (FGF-23) has been associated with disease
progression and development of renal secondary hyperparathy-
roidism (RHPT). In humans, elevations in FGF-23 often precede
hyperphosphatemia and RHPT. The objectives of this study were to
measure plasma FGF-23 concentrations in healthy dogs and dogs
with CKD and to determine its association with serum creatinine,
phosphorus, and parathyroid hormone (PTH) concentrations.
Thirty-four dogs with CKD and 10 healthy dogs were included.
Dogs with CKD were staged according to International Renal
Interest Society (IRIS) guidelines. A human FGF-23 ELISA was
validated for canine samples, showing linearity and intra- and
interassay coeﬃcients of variation <7%. Values are presented as
median (range). Plasma FGF-23 concentrations in healthy dogs
and dogs with IRIS stages 3 and 4 CKD were 315 pg/mL (211–
449), 2,302 (455–24,409) and 7,733 (2,520–41,265), respectively
(P < 0.01).
Plasma FGF-23 concentrations were positively correlated with
creatinine (r = 0.86, P < 0.01), phosphorus (r = 0.69, P < 0.01),
and PTH (r = 0.72, P < 0.01) concentrations in all study dogs.
Nineteen (56%) CKD dogs had FGF-23 concentrations above the
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upper range of normal dogs. Based on healthy dog phosphorus
concentrations, 11 (32%) CKD dogs had elevated phosphorus
concentrations. Only eight (24%) CKD dogs had hyperparathy-
roidism.
These ﬁndings suggest that FGF-23 concentrations rise in
canine CKD before other traditional markers of RHPT do. Conse-
quently, FGF-23 concentrations should be considered as an early
indicator of disease progression, RHPT, and potential target for
therapeutic intervention.
NU04
THE USE OF DARBEPOETIN ALFA TO STIMULATE
ERYTHROPOIESIS IN DOGS WITH CHRONIC KIDNEY
DISEASE. E. Hathaway Fiocchi1, Dorothy Brown1, Larry
Cowgill2, Samuel Tucker3, Jessica Markovich3, Mary Ann
Labato3, Mary Beth Callan1. 1University of Pennsylvania, School
of Veterinary Medicine, Philadelphia, PA, USA, 2University of
California, Davis School of Veterinary Medicine, Davis, CA,
USA, 3Tufts University School of Veterinary Medicine, North
Grafton, MA, USA
Erythropoiesis-stimulating agents are currently recommended
for veterinary patients with anemia secondary to chronic kidney
disease (CKD). Darbepoetin alfa (darbepoetin) has replaced epo-
etin due to a three-fold longer half-life allowing for less frequent
dosing. Also, darbepoetin is perceived to be less likely to elicit for-
mation of anti-erythropoietin antibodies resulting in pure red cell
aplasia (PRCA). A previous study examined the eﬃcacy of darbe-
poetin in cats with CKD; 14 of 25 cats responded, with adverse
events observed in 12 cats, including two with possible PRCA.
This retrospective study evaluated response to darbepoetin ther-
apy, protocols for administration, and potential adverse events in
dogs with CKD.
Thirty-four dogs with IRIS stage 3 or 4 CKD met the inclusion
criteria and their medical records were reviewed. Data recorded
included CBC, serum biochemistry panel, reticulocyte count,
serum iron parameters, systolic blood pressure, packed red blood
cell (pRBC) transfusion, iron supplementation, darbepoetin dose
and frequency of administration, comorbidities, adverse events,
and survival.
Starting HCT ranged from 9.6–28.9% (mean of 19.7%). The
starting dose of darbepoetin ranged from 0.4 - 2.08 mcg/kg (me-
dian 0.5 mcg/kg). The initial dosing frequency was every 7 days in
31/34 dogs. Nine of 34 dogs received a pRBC transfusion and 27/
34 dogs received iron supplementation in the form of a pRBC
transfusion, intramuscular iron dextran, oral supplementation, or
a combination thereof at the start of darbepoetin therapy. Sixteen
of 34 dogs received on-going iron supplementation throughout
treatment.
Survival following initiation of darbepoetin therapy ranged from
30 – 546 days (median 118 days). An estimated 442 doses of darbe-
poetin were administered over that course of treatment; the range
of doses administered per dog was 2 - 61 (median 11.5 doses per
dog). Dogs were considered responders if they achieved a HCT of
30% over the course of treatment. Twenty-nine of 34 dogs were
responders. Time to response ranged from 6 - 106 days (median
28 days). There was no association between starting HCT, dose or
frequency of administration of darbepoetin, or initial iron supple-
mentation between responders and non-responders. Dogs that
received a pRBC transfusion at the onset of treatment were more
likely to be non-responders (P = 0.013). Twenty-two dogs were
transitioned to an extended dosing interval following response, and
15 of those dogs subsequently required the dosing interval to be
shortened to maintain target HCT. No dog sustained a response at
a dosing interval greater than every 21 days. Potential adverse
events were documented in 19/34 dogs and included increased sys-
tolic blood pressure requiring treatment (n = 12), seizures (n = 5),
vomiting (n = 3), diarrhea (n = 3), hypersensitivity reaction to iron
injection (n = 1), and possible PRCA (1). Development of potential
adverse events resulted in discontinuation of darbepoetin only with
respect to possible PRCA; in all other cases, adverse events were
more likely attributed to underlying disease.
Darbepoetin is an eﬀective treatment for anemia secondary to
CKD. A dosing interval of >21 days is not eﬀective at maintaining
a response to therapy. Further studies are needed to deﬁne the
most eﬀective dose. PRCA was a possible adverse event in 1/34
dogs (2.9%).
NU05
VITAMIN D-BINDING PROTEIN – EARLY MARKER OF
TUBULAR INJURY IN DOGS WITH CHRONIC KIDNEY
DISEASE. Fernanda Chacar1, Marcia Kogika1, Talita Sanches2,
Douglas Caragelasco1, Cinthia Martorelli1, Camila Rodrigues2,
Jose Capcha2, Lucia Andrade2. 1School of Veterinary Medicine
and Animal Science, University of Sao Paulo, SP, Brazil, 2School
of Medicine, University of Sao Paulo, Sao Paulo, Sao Paulo,
Brazil
Vitamin D-binding protein (VDBP) is the main carrier of vita-
min D metabolites into circulation, and it is freely ﬁltrated
through glomerulus, and the complex VDBP-25-OH-vitamin D is
uptaken by megalin-cubilin receptors in proximal tubules. Once
the presence of VDBP in urine, it may indicate proximal tubular
dysfunction/injury as well as interstitial tubular ﬁbrosis. Also it
still remains to be proven whether loss of VDBP in urine may lead
to vitamin D deﬁciency and its contribution to the progression of
chronic kidney disease (CKD) in dogs. The hypothesis and the
aim of this study were to investigate whether VDBP could be pre-
viously detected in urine of dogs with CKD regardless of urinary-
to-protein ratio (UPC) values, and it will be an early and speciﬁc
marker of proximal tubular injury. Forty dogs according to IRIS
staging of CKD (stage 1 n = 10; stage 2 n = 10; stage 3 n = 10;
stage 4 n = 10) were enrolled, various breeds and age, and with no
proteinuric-associated disease. Nine clinically healthy dogs, diﬀer-
ent breeds and age, composed the control group. Dogs with CKD
were classiﬁed according to IRIS guidelines based on UPC as non-
proteinuric (UPC<0.2), borderline proteinuric (UPC= 0.2 to 0.5)
and proteinuric (UPC>0.5). Western blotting was performed to
investigate VDBP in canine urine (Anti-Vitamin D Binding Protein
antibody, ab95469, Abcam© 1:500). No urinary VDBP was
detected in control dogs and UPC was 0.14  0.04 (meanSEM)
and min= 0.028 and max= 0.41. In CKD dogs, urinary VDBP was
observed since the early stages of CKD, stages 1 and 2, and the
UPC was 0.39  0.29; 0.02–3.01 and 0.33  0.12; 0.14–1.14 (mean
SEM; min - max), respectively. In stage 1 CKD dogs, urinary
VDBP was detected in 7 out of 10 dogs and in 4 of those 7 dogs,
UPC was into the non-proteinuric range, 2 dogs in borderline
range and only one was proteinuric. In stage 2 CKD dogs, VDBP
in urine was noticed in 9 out of 10 CKD dogs and 5 of them had
UPC < 0.2, one dog was in borderline (UPC= 0.42) and 3 dogs
were slightly proteinuric (UPC of 0.67, 0.72 and 1.14). In CKD
dogs in stage 3, UPC was 1.51  0.54 (0.07–4.57) and VDBP in
urine was immunodetected in 8 out of 10 dogs and in 3 of those 8
dogs, UPC was ≤ 0.28 and the left 5 dogs were proteinuric. All
CKD dogs in stage 4 were proteinuric (UPC = 4.37  0.47; 1.4–
6.94) and showed VDBP in urine. In conclusion, the immunode-
tection of VDBP in urine noticed in the early stages of CKD in
dogs, mainly in stages 1 or 2, associated with UPC into non or
borderline proteinuric range, it reinforces that urinary VDBP
could be a potential early marker of kidney injury as well as to
detect the speciﬁc segment (proximal) of the nephron aﬀected.
NU06
ASSESSMENT OF REPEATED ADMINISTRATION OF A
FELINE FVRCP VACCINE AS A MODEL FOR INTERSTI-
TIAL NEPHRITIS. Stacie Summers, Shannon McLeland, Jennifer
Hawley, Jessica Quimby, Randall Basaraba, Catriona MacPhail,
Michael Lappin. Colorado State University, Fort Collins, CO,
USA
Progressive interstitial nephritis (IN) is the primary cause of
feline chronic kidney disease which is considered to be the leading
cause of death in adult cats. The Crandell Rees feline kidney
(CRFK) cell line is commonly used to grow feline herpesvirus 1
(FHV-1), calicivirus, and panleukopenia virus used in (FVRCP)
vaccine production. Previous studies have shown that cats
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administered FVRCP vaccines parenterally develop antibodies
against CRFK lysates and alpha enolase (glycolytic pathway
enzyme in all mammalian cells) and these antibodies can bind to
feline renal cell lysates. In addition, three of six cats that were
hyperinoculated (11 injections) with CRFK lysates over two years
had IN on renal biopsy collected two weeks after the last booster.
The primary objective of this study was to determine whether IN
could be induced over 16 weeks by repeatedly administering a
market leading parenteral FVRCP vaccine to potentially use as a
short term model to study biomarkers associated with IN in cats.
A total of six (three male; three female) one-year-old purpose
bred cats were included in the IACUC approved study. The cats
were previously maintained as unvaccinated controls in a FHV-1
study at ﬁve months of age and none of the cats had clinical signs
of FHV-1 when enrolled in the current study. On Week 0, blood,
serum, urine were collected for biomarker assays and a wedge kid-
ney biopsy for histopathological evaluation and alpha-enolase
immunohistochemistry was obtained. After sample collection on
Week 0 and again on Weeks 2, 4, 6, 8, 10, 12, and 14, all cats
were administered a commercially available FVRCP vaccine
shown previously to induce anti-CRFK and anti-enolase antibod-
ies and samples were collected for biomarker assays. After sample
collection on Week 16, similarly sized renal biopsies were made,
avoiding the previous biopsy sites. Haematoxylin and eosin stained
sections were provided to two board-certiﬁed pathologists that
were masked to the timing of the biopsies. Anti-CRFK and anti-
enolase antibodies levels in serum were determined by ELISAs.
All 6 cats developed progressively increasing anti-enolase and
anti-CRFK serum antibodies.
Histological evidence of interstitial nephritis was not detected
by light microscopy in any of the tissue biopsies. Signiﬁcant bio-
chemical or urinalysis changes during the study were not detected
and the cats were adopted to private homes for long term moni-
toring.
While anti-CRFK and anti-enolase antibodies were induced in
this model, biochemical or histopathology abnormalities were not
detected. Results of selected biomarkers and enolase immunohisto-
chemical staining will be used to further evaluate this potential IN
model.
NU07
COMPARISON OF VISUAL AND AUTOMATED INTERPRE-
TATION OF URINARY DIPSTICKS WITH GLUCOSE:CREA-
TININE RATIO AND GLUCOSE CONCENTRATION. Caroline
Aldridge1, Ellen N. Behrend1, Jo Smith2, Elizabeth G. Welles1,
Hollie P. Lee1. 1Auburn University, Auburn, AL, USA, 2Univer-
sity of Georgia, Athens, GA, USA
The accuracy of Bayer Multistix with visual reading for deter-
mination of the glucose concentration in canine urine is only 59%
(Behrend et al, J Vet Int Med, 2009). The correlation between
visual and automated assessment has not been investigated. Fur-
thermore, urine glucose:creatinine ratio (UGCR) may be a useful
method in quantifying glucosuria similar to urine protein:crea-
tinine ratio but has not been assessed. The purpose of this study
was to compare automated readings, visual readings and UGCR
for quantiﬁcation of glucosuria in canine urine.
Urine samples submitted to the Auburn University Clinical
Pathology Laboratory for urinalysis and that were naturally gluco-
suric (n = 39) were included. Multistix (Bayer) were used accord-
ing to manufacturer instructions and were read visually by a single
trained investigator (“visual reading”) and by the CLINITEK 50
analyzer (Bayer; “automated reading”). Urine glucose and urine
creatinine concentrations were measured using a Hitachi 911
Chemistry Analyzer (Boehringer Mannheim Corp.); the glucose
measurements were considered to be the true concentration (gold
standard). Spearman’s rank order correlation was used to evaluate
the relationship between: 1. glucose concentration and automated
readings; 2. glucose concentration and visual reading; 3. auto-
mated and visual readings; 4. automated readings and UGCR;
and 5. visual readings and UGCR. Signiﬁcance was set at
P < 0.05. Correlation was classiﬁed as excellent for r = 0.93–0.99,
good for r = 0.8–0.92, fair for r = 0.59–0.79 and poor for r < 0.59.
Reference intervals that correlated with the colors on the test strip
were devised based on the package insert (trace=76–175 mg/dL;
1 + = 176–375 mg/dL; 2 + = 376–750 mg/dL; 3 + = 751–
1500 mg/dL; 4 + = >1500 mg/dL).
Signiﬁcant correlation was detected between both automated
and visual readings and glucose concentration (P < 0.0001). The
correlation for automated readings was good (r = 0.834) but fair
for visual readings (r = 0.761). Overall, the underestimations and
overestimations of glucose concentration for the automated read-
ings was 56.4% and 15.4%, respectively. For the visual readings,
they were 13.2% and 36.8%, respectively. Signiﬁcant correlation
was detected between both automated and visual readings and
UGCR (P < 0.0001). However, correlation for automated readings
was classiﬁed as good (r = 0.801) but for visual readings was fair
(r = 0.719). Furthermore, automated and visual readings had a
signiﬁcant (P < 0.0001) and good correlation (r = 0.817).
Our results indicate that despite a good correlation between
automated and visual reading of Bayer Multistix, automated read-
ing may be better. Interestingly the automated readings tend to
underestimate glucose concentration while with visual reading,
overestimations are more common. The UGCR is a valid way to
assess urinary glucose excretion; however, it oﬀers no advantage
over measurement of glucose concentration in urine.
NU08
IMPACT OF CANINE PANCREAS-SPECIFIC LIPASE ON
THE OUTCOME OF DOGS WITH HEMODIALYSIS-DEPEN-
DENT ACUTE KIDNEY INJURY. Kanae Takada, Carrie Palm,
Steven Epstein, Larry Cowgill. University of California-Davis
Veterinary Medical Teaching Hospital, Davis, CA, USA
Acute pancreatitis (AP) and acute kidney injury (AKI) are com-
mon co-morbidities in both dogs and humans. In human patients
the presence of AP with AKI is a negative prognostic factor; how-
ever, a similar relationship has not been evaluated in dogs. When
considering hemodialysis for management of AKI in dogs, this
prognostic information could be important for therapeutic deci-
sions. Canine pancreas-speciﬁc lipase (SPEC) is used commonly to
support the diagnosis of AP in dogs. The purpose of this study
was to investigate elevated SPEC on the outcome of dogs with
AKI treated with hemodialysis.
Medical records were evaluated retrospectively from August
2011 to June 2015 to identify dogs presented to the UC Davis
VMTH that received intermittent hemodialysis for management of
AKI and also had a SPEC (Spec cPLTM, IDEXX Laboratories)
measured during the course of therapy. Outcome was assessed at
30 days from admission, and dogs were classiﬁed as died/eutha-
nized or alive. Surviving dogs were stratiﬁed further into non dial-
ysis-dependent or dialysis-dependent. An elevated SPEC was
deﬁned as ≥ 400 mcg/L. Median values of SPEC were compared
with a Mann-Whitney U test for each outcome category, above.
Categorical data were compared with a Fisher’s exact test. A P-
value of <0.05 was considered signiﬁcant. Data are presented as
median [range].
Forty-three client-owned dogs were included. Median initial
serum creatinine (iSCr) was 8.5 [3.6 - 16.6] mg/dl and median age
at presentation was 5.6 [0.70 - 13.5] years. Eighteen were male neu-
tered, 14 were female spayed, 4 were intact male, and 7 were intact
female dogs. At 30 days, 30/43 dogs (70%) were alive (iSCr, 8.6
[4.7 - 16.6] mg/dl) and 13/43 (30%) had died or been euthanized
(iSCr, 8.0 [3.6 - 15.3] mg/dl). Nine of 30 dogs (30%) were still dial-
ysis dependent at 30 days (iSCr, 10.9 [6.1 - 15.4] mg/dl), and 21/30
(70%) were non dialysis-dependent (iSCr, 8.3 [4.7 - 16.6] mg/dl).
SPEC was not signiﬁcantly diﬀerent between dogs alive at 30 days
and dogs that had died or were euthanized (SPEC 627.5 [29 -
Mean and SD of ELISA absorbance values of 6 cats administered an FVRCP 
vaccine
Antibody Week 0 Week 4 Week 8 Week 12 Week 16
Enolase 0.57 ± 0.16 2.00 ± 0.74 3.48 ± 0.72 3.82 ± 0.47 3.88 ± 0.43
CRFK 0.28 ± 0.03 0.66 ± 0.23 1.38 ± 0.39 1.63 ± 0.37 1.81 ± 0.4
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2001] mcg/L versus 455.0 [30 - 2001] mcg/L, P = 0.50). SPEC in
dialysis-dependent dogs was signiﬁcantly higher than non dialysis-
dependent dogs (SPEC 1001.0 [177 - 2001] mcg/L versus 379.0 [29
- 1001] mcg/L, P = 0.008). The proportion of dogs alive at 30 days
with SPEC ≥ 400 mcg/L during the treatment course was not dif-
ferent from alive dogs with SPEC < 400 mcg/L (71% versus 68%,
P = 1.0). In addition, the proportion of the non dialysis-dependent
dogs with SPEC ≥ 400 mcg/L during the treatment course was not
diﬀerent from non dialysis-dependent dogs with SPEC < 400 mcg/
L (42% versus 58%, P = 0.36).
These results suggest the presence of pancreatitis assessed as
SPEC ≥ 400 mcg/L did not aﬀect survival outcome at 30 days.
However, pancreatitis may be a more common co-morbidity in
dogs with more severe (dialysis-dependent) AKI and it may inﬂu-
ence renal recovery.
NU09
CHARACTERIZATION OF SUBCLINICAL BACTERIURIA,
URINARY TRACT INFECTION, AND PYELONEPHRITIS IN
DOGS WITH CHRONIC KIDNEY DISEASE. Jonathan Foster,
Harathi Krishnan, Stephen Cole. University of Pennsylvania,
School of Veterinary Medicine, Philadelphia, PA, USA
Bacterial urinary tract infection (UTI) is common in dogs, how-
ever the prevalence of subclinical bacteriuria (SBU) in healthy
dogs has recently been demonstrated to be substantially lower.
Following standards created by human infectious disease special-
ists, there has been more initiative put towards identifying and
characterizing SBU in dogs. Although it has been considered a
risk factor for UTI, the prevalence of UTI and SBU in dogs with
chronic kidney disease (CKD) is not known. The objectives of this
study were to retrospectively evaluate the prevalence of positive
urine cultures in dogs with CKD, and to further categorize these
patients as having SBU, clinical UTI, or pyelonephritis.
Medical records were reviewed retrospectively from 1/2010–7/
2015 for dogs with a diagnosis of CKD who had a urine culture
submitted. The diagnosis of CKD was based on International
Renal Interest Society (IRIS) guidelines. Patients were excluded if
they had another reason to develop UTI, namely endocrine disease
(hyperadrenocorticism, diabetes mellitus), urolithiasis, urinary
incontinence, urinary bladder neoplasia, had a nidus for infection
such as ureteral stent or subcutaneous ureteral bypass, or were
receiving systemic immunosuppression. Based on previously
reported deﬁnitions, patients were placed into one of the following
three categories based on the review of their medial record: SBU,
pyelonephritis, or UTI. The frequency of negative culture, SBU,
pyelonephritis, and UTI were compared across IRIS stages using
Fisher’s exact analysis. P < 0.05 was considered signiﬁcant for all
comparisons.
Two hundred and eighty-two cultures were submitted on 195
patients during the study time period. Forty-seven cultures per-
formed on 13 patients were excluded due to the presence of uret-
eral stents (5 patients), chemotherapy (2 patients), diabetes
mellitus (2 patients), transitional cell carcinoma (2 patients), uri-
nary incontinence and cystic calculi (1 patient each). A total of
235 cultures submitted on 182 patients were included in the ﬁnal
analysis. There were 8 intact males, 52 castrated males, 5 intact
females, and 117 spayed females. There were 40 positive urine cul-
tures (17.0% of all cultures) obtained on 33 patients (18.1% of all
dogs). Of all positive cultures, the most frequently determined
diagnosis was SBU (18 cultures, 45%), followed by pyelonephritis
(16 cultures, 40%), then UTI (6 cultures, 15%). There were no sta-
tistically signiﬁcant observed relationships between any IRIS stage
and diagnosis (P = 0.635). The number of positive cultures,
regardless of patient diagnosis, was not statistically signiﬁcant
between IRIS stages (P = 0.432). Escherichia coli was the most fre-
quently observed isolate (29/40 cultures, 72.5%).
In this population of dogs with CKD the prevalence of dogs
with positive urine culture was 18.1%. The most frequently
observed diagnosis associated with a positive culture was SBU.
Increasing IRIS stage of CKD was not found to be associated with
a higher frequency of any particular diagnosis. E. coli was the most
commonly observed isolate. Despite the rigorous criteria for deﬁn-
ing SBU, pyelonephritis, and UTI in the current study, it is possi-
ble that some patients were incorrectly categorized. Prospective
research is needed to determine if antibiotic therapy is indicated in
dogs with CKD and SBU. Additionally, renal biomarkers may
allow for better characterization of patients with SBU and occult
pyelonephritis and improve antibiotic stewardship.
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INITIAL OUTCOMES AND COMPLICATIONS OF THE
SUBCUTANEOUS URETERAL BYPASS PROCEDURE AT
TWO UNIVERSITY HOSPITALS (2012–2015). Ewan D.S.
Wolﬀ1, Roswitha Dorsch2, Julia Knebel2, Daniel J. Duﬀy1,
Lynetta J. Freeman1, Lynn Guptill1, Larry G. Adams1. 1Purdue
University, West Lafayette, IN, USA, 2Ludwig Maximilians
University Munchen, Munich, Bavaria, Germany
The aim of this study was to report combined experience of two
institutions placing subcutaneous ureteral bypass systems (SUBs).
We compared our data to historical data from cats with ureteral
stents for ureteral obstruction. Hypotheses included 1) Patients
with SUBs would have the same or better 7–14 day and 3–
4 month post-operative creatinine as historic ureteral stent
patients, 2) SUB patients would experience the same or improved
peri-operative, post-operative and recurrent urinary tract infection
rates as ureteral stent cats, 3) clinical signs related to implants
would be similar or better with the SUB system versus ureteral
stenting.
Adult cats were enrolled retrospectively, subsequent to the 2012
alteration to SUB placement procedure. All cats were managed
per clinician preference pre-operatively. Flushes of SUB systems
were performed every 3–6 months for the majority of patients.
Records from 19 cats from Purdue and Munich Universities
were reviewed. Median age was 9 years at Purdue and 7.7 years at
Munich. There were 12 spayed female and 7 castrated male cats;
13 domestic short-haired cats, 2 domestic longhaired cats, and
three other breeds. 17% of cats had preexisting IRIS Stage II
CKD. Lethargy, vomiting and inappetence were the most common
clinical signs (>25% of patients). Median renal pelvic diameter in
aﬀected kidneys was >0.5 cm at both institutions. Median crea-
tinine immediately post-operatively was 2.6 mg/dL (0.9–2.3 mg/
dL) at Purdue and 1.43 mg/dL at Munich. Major peri-operative
complications were uncommon; one cat had cardiac arrest and
another was transfusion dependent. Post-operative complications
included 2 cats with ﬂuid overload and pleural eﬀusion. 8/19 cats
required a blood transfusion in the peri- or post-operative period.
The median creatinine was 3.6 mg/dL at 3 months and 1.8 mg/dL
at 6 months. 3 patients had repeat surgeries; median time to repeat
surgery was 225 days. Causes of repeated surgery were SUB port
obstruction or encrustation of SUB tubing. Total mortality was
21% with a median disease free interval of 180 days and a 1 year
survival of 83%.
No cats had active urine sediment or culture prior to SUB
placement, but post-operative and follow up urinary tract infec-
tions occurred. 21% of patients had urinary tract infection within
10 days of surgery. Two patients had recurrent multi-drug resis-
tant E. coli infection, one was cultured as a bioﬁlm. Another
patient developed encrustation 10 months post-procedure. Man-
delic acid, EDTA, antibiotic infusions into SUBs failed to resolve
UTI in 2 cats.
Comparing SUB outcomes to ureteral stenting, 6 month post-
procedural creatinine was better in the SUB group (1.8 mg/dL)
than that reported for stents (2.6 mg/dL). One year survival was
similar for stent cats (86%) and SUB cats (83%). Long-term infec-
tion rates were similar (around 31%). Only one SUB patient expe-
rienced dysuria beyond the post-operative period whereas this is
more common in cats with stents.
This study suggests that the SUB system carries similar poten-
tial complications of re-obstruction, encrustation and infection to
ureteral stenting. Recurrent and resistant infections and the poten-
tial for bioﬁlms is a signiﬁcant concern in SUB patients. Protocols
for treatment of resistant UTIs utilizing local instillation and
indwelling bladder treatment should be developed in a prospective
fashion. Further work with more cases could explore risk factors
for UTI and obstruction.
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OCCULT URINARY TRACT INFECTION IN CATS: PREVA-
LENCE AND FINDINGS ON CONTEMPORANEOUS URI-
NALYSIS. Melanie Puchot1, Audrey Cook1, Caitlin Pohlit2.
1Texas A&M University, College Station, TX, USA, 2Michigan
State University, East Lansing, MI, USA
Cats are frequently screened for bacterial urinary tract infection
(UTI) in the absence of clinical signs of lower urinary tract disease
(LUTD) when managing conditions such as chronic kidney disease
and diabetes mellitus. The purposes of this study were to deter-
mine the prevalence of occult UTI in cats and to describe results
of the contemporaneous urinalysis (UA). We hypothesized that a
positive quantiﬁed urine culture (QUC) could be predicted by ﬁnd-
ings on microscopic sediment examination (MSE) such as bacturia,
pyuria (≥3 white blood cells/hpf) and hematuria (≥10 red blood
cells/hpf).
An electronic search identiﬁed all QUCs performed on cats at a
university teaching hospital between 2009 and 2015. Results were
included in the study if there were no signs of LUTD and the
QUC was not performed as follow up to a previous UTI. A QUC
was classiﬁed as positive if growth >1,000 cfu/mL was reported.
For each positive, ﬁve controls were randomly selected from sam-
ples with a negative QUC. Medical records for both groups were
reviewed.
In all, 31/500 (6.2%) samples were positive. Most infections
were a single organism (n = 27); four contained multiple organ-
isms. E. coli was the most common species (58% of isolates) fol-
lowed by Enterococcus species (25% of isolates). Positive
specimens were more likely to be from female cats (n = 24) versus
male (n = 7) (P = 0.0054). Patient age and body weight were not
associated with increased risk of occult UTI. Median urine speciﬁc
gravity was similar for the positive group (1.022) and controls
(1.024). The prevalence of proteinuria on dipstick testing was also
similar (84% v 80%). Occult UTIs were strongly associated with
bacteriuria (60% v 6%; odds ratio 24.3 [CI: 9.0–65.7]; P < 0.0001)
or pyuria (67 v 19%; odds ratio 8.7 [CI: 3.7–20.5]; P < 0.0001) but
not microscopic hematuria. Positive specimens were signiﬁcantly
more likely to have an abnormal sediment exam (odds ratio 13.5
[CI 3.9–45.5]; P < 0.0001).
Occult UTI appears to be uncommon in cats and can usually
be predicted on the basis on an abnormal MSE (bacturia, pyuria).
Based on this study, there is little indication to perform a QUC in
a cat with no clinical signs of LUTD and an unremarkable MSE.
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DIAGNOSTIC PERFORMANCE OF URINARY CANINE CAL-
GRANULINS IN DOGS WITH LOWER URINARY TRACT
CARCINOMA. Romy Heilmann1, Elizabeth McNeil2, David Lan-
erie1, Niels Gr€utzner3, Jan Suchodolski1, Joerg Steiner1. 1Gastroin-
testinal Laboratory, Texas A&M University, College Station, TX,
USA, 2Cummings School of Veterinary Medicine, Tufts Univer-
sity, Boston, MA, USA, 3Farm Animal Clinic, Vetsuisse Univer-
sity Bern, Bern, BE, Switzerland
Aside from its association with several inﬂammatory diseases,
the S100A8/A9 calgranulin complex was shown to be expressed by
epithelial cells after malignant transformation. In humans, S100A9
or S100A8 have been reported to be up-regulated in patients with
prostate carcinoma (PCA) or transitional cell carcinoma (TCC),
respectively. Results of the expression of the S100A12 calgranulin
in TCC/PCA in humans are ambiguous. Pilot data by our group
suggest that the urine canine S100A8/A9-to-S100A12 ratio
(uCalR) may have potential as a marker for TCC/PCA in dogs.
Further evaluation of urinary S100A8/A9, S100A12, and uCalR in
dogs is needed to determine its speciﬁcity for a diagnosis of TCC/
PCA. Thus, this study investigated urinary S100A8/A9, S100A12,
and uCalR in dogs with TCC/PCA, other urinary tract diseases,
or other malignancies.
Urine samples from dogs with TCC/PCA that were treatment-
na€ıve (n = 22) or under treatment (n = 40), dogs with non-neo-
plastic diseases of the urinary tract (n = 22) or other neoplasms
(n = 35), dogs with a urinary tract infection (UTI, n = 45), and a
group of healthy control dogs (n = 75) were used. Urinary canine
S100A8/A9 and S100A12 were measured in all samples using
in-house radioimmunoassays and the uCalR was calculated. All
parameters were tested among the diﬀerent groups of dogs using
non-parametric multiple-/two-group comparisons. Sensitivities and
speciﬁcities were determined for the optimal cut-oﬀ values, and
positive (PPV) and negative predictive values (NPV) were calcu-
lated. Signiﬁcance was set at P < 0.05.
Dogs with TCC/PCA had signiﬁcantly higher urinary S100A8/
A9 and S100A12 concentrations than all other groups of dogs (all
P < 0.016) except for dogs with UTI, whereas uCalR was signiﬁ-
cantly higher in TCC/PCA dogs compared to only those with a
UTI (P < 0.001). Treatment-na€ıve TCC/PCA patients and UTI
dogs were best distinguished by a uCalR of ≥9.1 (sensitivity: 91%,
speciﬁcity: 60%). A urine canine S100A8/A9 concentration (nor-
malized against the urine speciﬁc gravity [USG]) of ≥109.9 had the
highest sensitivity (96%) and speciﬁcity (66%) to diagnose treat-
ment-na€ıve TCC/PCA dogs from all other groups of dogs, and the
speciﬁcity increased to 75% if a UTI had been excluded. Using a
urine S100A8/A9 concentration (normalized against USG) of
≥109.9 to screen dogs ≥6 years of age for TCC/PCA (estimated
prevalence: <1%) yielded a PPV of 4% and a NPV of 100%.
The results of this study show that urine S100A8/A9 and the
uCalR have utility for the diagnosis of TCC/PCA in dogs. The
high sensitivity and NPV of urine S100A8/A9 also suggest that
S100A8/A9 may be a good screening test for TCC/PCA in dogs.
Further studies are warranted to validate our ﬁndings in a larger
cohort of dogs and to evaluate the source of S100A8/A9 and
S100A12 expression in canine TCC/PCA.
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SURVEY OF SUBCUTANEOUS FLUID PRACTICES IN CATS
WITH CHRONIC KIDNEY DISEASE. Crystal Cooley1, Sarah
Caney2, Liberty Sieberg1, Jessica Quimby1. 1Colorado State
University, Fort Collins, CO, USA, 2Vet Professionals, Roslin,
Midlothian, UK
Chronic kidney disease (CKD) is common in elderly cats. The
purpose of this study was to describe subcutaneous ﬂuid (SQ)
administration practices of owners of CKD cats to help more
owners successfully give SQ ﬂuids to their cat.
An anonymous web-based survey was advertised via list serves,
websites and social media. Owners of 468 cats with CKD partici-
pated. 87% of cats were 10 years or older. Cats were IRIS stage I
(1%), II (20%), III (37%), IV (17%), and unknown (25%).
95% of owners said they discussed giving ﬂuids with their vet-
erinarian. 399 respondents stated they gave SQ ﬂuids, 57 did not,
and 12 tried but could not. Only 42% of owners were given addi-
tional educational resources. 79% said the process was ok/easy to
learn. Once experienced, 15% said it was still somewhat/highly
stressful on them, and 11% said it was somewhat/highly stressful
for the cat. To improve tolerance 57% used food for positive rein-
forcement with 59% stating this improved tolerance, 60% warmed
the ﬂuids and 83% felt warming ﬂuids increased tolerance. 74%
felt that length of time it took to administer ﬂuids aﬀected toler-
ance. 82% said needle size aﬀected tolerance. 40% of owners
checked hydration status daily or twice daily and 18% of owners
did not know how. 43% said they skipped/added ﬂuids based on
hydration assessment.
The majority of owners were successful in administering ﬂuids
but additional education materials could be provided. Variables
such as needle size, warming ﬂuids, and length of time of adminis-
tration may improve tolerance.
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QUANTIFYING URINE ELIMINATION BEHAVIORS IN
CATS USING A VIDEO RECORDING SYSTEM. Ryan Dula-
ney, John Kruger, Marie Hopfensperger, Rob Malinowski, Joe
Hauptman, Brenna Lashbrook. Michigan State University, East
Lansing, MI, USA
Feline lower urinary tract disorders often rely on subjective
caregiver quantiﬁcation of clinical signs to establish a diagnosis
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and monitor therapeutic outcomes. The objective of this study was
to investigate use of a video recording system (VRS) to more reli-
ably assess and quantify urination behaviors in cats. Litter box
urination behaviors were quantiﬁed in 11 healthy cats and 8 cats
with abnormal urination patterns using a VRS for 14 days and
compared to daily caregiver observations. Video recordings were
analyzed using a behavior analysis software program.
The mean number of urinations per day detected by VRS
(2.5  0.2) was signiﬁcantly greater compared to caregiver obser-
vations (0.6  0.2; P < 0.0001). Five of 19 cats were never
observed by their caregivers in the litter box. The mean number of
urinations per day detected by VRS was signiﬁcantly higher for
abnormal cats (2.9  0.3) compared to healthy cats (2.1  0.2;
P = 0.02); there were no apparent diﬀerences in frequency between
healthy and abnormal cats reported by caregivers (0.7  0.3 and
0.5  0.3 respectively). There were no diﬀerences in mean urina-
tion time between normal and abnormal cats determined by VRS
or caregivers. Mean cover-up time determined by VRS was signiﬁ-
cantly longer in normal cats (23  4 seconds/urination compared
to abnormal cats (9  5 seconds/urination; P = 0.03); diﬀerences
in cover-up time were not detected by caregiver observations.
In conclusion, there was considerable disparity between care-
giver and video observations with caregivers commonly underesti-
mating urination frequency. VRS appears to facilitate objective
assessment of urination behavior and could be of value in future
clinical studies of feline urinary disorders.
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EVALUATION OF THE EFFECT OF URINE DIP VERSUS
URINE DRIP ON MULTITEST STRIP RESULTS. Alisdair
Boag, Craig Breheny, Adam Gow. Royal (Dick) School of Veteri-
nary Studies, Edinburgh, UK
Standard operating procedures (SOPs) have been established for
in-clinic laboratory tests, such as the World Health Organisation
guidelines for packed cell volume. No independent evidence based
guidelines exist for dipstick urinalysis, however manufacturer’s
instructions state to dip the stick into urine. In veterinary medi-
cine, occasionally urine samples of such small volume are obtained
that this is impractical and dripping urine on the stick from a pip-
ette or syringe is performed. This also has the advantage of con-
serving the sample for additional tests.
The hypothesis of this study was that the method of drip or
drip would have no eﬀect on the test results. Siemens Multistix
10SG strips were used. To standardise the method of strip analy-
sis, a Siemens Clinitek Status+ analyser was used to read the
strips; controlling time of reading the results and user variability
in interpretation of colourimetric changes. Three individuals tested
25 aliquots of urine from dogs with a range of disease processes
by both the dip and drip method. Results were compared for each
variable between drip and dip using Wilcoxon-signed rank test.
Across the nine variables assessed (SG was not), a signiﬁcant
diﬀerence between methods was found for one variable, bilirubin
(P = 0.046). This diﬀerence was accounted for by one dog who
tested negative for bilirubin for all three users using a dip method
and had a trace value for all three users using a drip methodology.
No other signiﬁcant diﬀerences were found between variables.
This study demonstrated a signiﬁcant diﬀerence between dip-
ping and dripping for bilirubin, caused by one dog with the same
level of variability for all three users. This diﬀerence is, in the
authors’ opinion, clinically insigniﬁcant. This study therefore sup-
ports the use of either a dipping or dripping approach to urinaly-
sis. Further studies are required to more fully assess the role of
individual variation when performing the test including level of
experience.
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POSITIVE IMPACT OF NUTRITIONAL INTERVENTIONS
IN CLIENT-OWNED DOGS WITH IRIS STAGE-1 CHRONIC
KIDNEY DISEASE. Jean Hall1, Dale Fritsch2, Maha Yerramilli3,
Edward Obare3, Murthy Yerramilli3, Dennis Jewell2. 1Oregon
State University, Corvallis, OR, USA, 2Hill’s Pet Nutrition, Inc.,
Topeka, KS, USA, 3IDEXX Laboratories, Inc., Westbrook, ME,
USA
A prospective 12-month clinical trial was performed in client-
owned dogs with IRIS stage 1 chronic kidney disease (CKD) to
measure their ease of transition to a commercial renal protective
food and to assess the eﬀects of food on renal biomarkers and
quality of life attributes. Dogs with IRIS stage 1 CKD (n = 36)
were transitioned over 1 week from various grocery brand foods
to a modiﬁed protein, low phosphorus, antioxidant enriched test
food (Prescription Diet k/d, Hill’s Pet Nutrition, Inc.). At
months 0, 3, 6, 9, and 12 owners completed a questionnaire to
assess their pet’s acceptance of the test food and their dog’s qual-
ity of life. Renal biomarkers, including serum creatinine (Cr),
blood urea nitrogen (BUN), and symmetric dimethylarginine
(SDMA), and urinalysis parameters, including urine speciﬁc grav-
ity (USG) and urine protein:creatinine ratio (UPC), were mea-
sured. Of the 36 dogs initially enrolled, 35 (97%) transitioned to
the test food. Pets moderately or extremely liked the test food
88% of the time, ate most or all of the food 84% of the time, and
were moderately or extremely enthusiastic while eating 76% of the
time. Dogs consuming test food showed a decrease in serum Cr
and BUN concentrations across time (both P = 0.01) and a
decrease in serum SDMA concentration and USG across time
(both P = 0.09). All serum renal biomarkers (Cr, BUN, SDMA)
were decreased (P ≤ 0.05) from baseline at 3 months, and
remained decreased from baseline at 12 months in dogs complet-
ing the study (n = 20). This study shows that dogs with IRIS stage
1 CKD readily transition to a commercial renal food, and decreas-
ing serum biomarker concentrations suggest improvement in kid-
ney function. In addition, owners reported improvement in a
consortium of overall health and quality of life attributes
(P < 0.01) and hair and coat quality attributes (P < 0.01).
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FIBROBLAST GROWTH FACTOR 23 (FGF-23) IN DOGS
WITH NATURALLY OCCURRING CHRONIC KIDNEY
DISEASE. Marcia Kogika1, Cinthia Martorelli1, Douglas Carage-
lasco1, Fernanda Chacar1, Luciano Giovaninni2, Dennis Chew3,
Ramiro Toribio3, Katarzyna Dembek3, Camila Rodrigues4, Talita
Sanches4, Lucia Andrade4. 1School of Veterinary Medicine,
University of S~ao Paulo, SP, Brazil, 2Sao Paulo, SP, Brazil,
3College of Veterinary Medicine, The Ohio State University,
Columbus, OH, USA, 4School of Medicine, University of S~ao
Paulo, Sao Paulo, SP, Brazil
Decreased glomerular ﬁltration rate in chronic kidney disease
(CKD) reduces renal phosphorus excretion, leading to increased
total body phosphorus retention and eventually hyperphos-
phatemia. In addition of promoting parathyroid hormone synthe-
sis, hyperphosphatemia stimulates the synthesis of ﬁbroblast
growth factor 23 (FGF-23), a phosphaturic/hypophosphatemic
hormone. There are no reports on serum FGF-23 in healthy dogs
or in dogs with CKD. The goal of this study was to measure
serum FGF-23 concentrations in healthy dogs and in dogs with
CKD, and to determine its association with serum phosphorus
concentrations and severity of renal disease based on IRIS staging
of CKD. We hypothesized that serum FGF-23 will be increased in
dogs with CKD, that its concentrations will be proportional to
CKD severity, and that it will be an early marker of altered phos-
phorus metabolism.
A total of 17 dogs of various breeds and age with CKD (n = 6
in IRIS stage 2; n = 11 in IRIS stage 3) that were being fed a
renal diet, and 15 healthy dogs of diﬀerent breeds and age, being
fed a maintenance diet, were included. Dogs with CKD were fol-
lowed for up to 12 months or until death. A human-speciﬁc FGF-
23 ELISA was validated for this study, showing linearity and
2.8% and 8.8% intra and inter-assay coeﬃcients of variation,
respectively. Serum FGF-23 concentrations were higher in CKD
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dogs in stages 2 and 3 on presentation (2,605.4  872.0 pg/mL;
meanSEM) compared to healthy dogs (258.7  21.2 pg/mL); sig-
niﬁcant diﬀerence was detected between healthy versus CKD dogs
in stage 3 (P < 0.01;one-way ANOVA), and stage 2 versus stage 3
(P < 0.05). On presentation, all dogs in stage 2 CKD were nor-
mophosphatemic (3.8  0.2 mg/dL), serum FGF-23 was
499.1  135.8 and 3/6 dogs showed increased FGF-23 concentra-
tions (505.5 – 1,065.5 pg/mL), and there was no correlation
between FGF-23 and phosphorus concentrations on admission
and follow up (r = 0.286; P = 0.1185).
In stage 3 CKD dogs, on presentation, 7 were normophos-
phatemic (2.5 – 5.0 mg/dL) and 4 were hyperphosphatemic (5.3 –
6.6 mg/dL), but all (n = 11) had increased serum FGF-23 concen-
trations (3,754.3  1,225.2 pg/mL; 957.6–14,193.0 pg/mL) that
remained elevated or increased during follow up (843.9–
184,581.0 pg/mL). Of the normophosphatemic dogs in stage 3
CKD (n = 7), 5 developed hyperphosphatemia (5.6 – 16.0 mg/dL)
after 6 months of follow up. Serum phosphorus was positively cor-
related with FGF-23 in these dogs (r = 0.71; P < 0.0001). In the
study period, 7/11 dogs in stage 3 died.
In conclusion, serum FGF-23 could be used as an early marker
of phosphorus dysregulation in dogs with CKD as increased FGF-
23 concentrations were found in normophosphatemic CKD dogs
in stages 2 and 3. More marked elevated serum levels of FGF-23
were found in advanced renal disease – IRIS stage 3. It is likely
that increased concentrations of FGF-23 contribute to disturbed
calcium and phosphorus homeostasis and altered vitamin D meta-
bolism and parathyroid gland function. Further studies at targeted
control of serum phosphorous and FGF23 concentrations in dogs
with CKD are warranted.
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SERUMCYTOKINE PROFILES OF CATSWITH IDIOPATHIC
CYSTITIS.Maciej Parys, Vilma Yuzbasiyan-Gurkan, John Kruger.
Department of Small Animal Clinical Sciences, Michigan State
University, East Lansing, USA
Idiopathic cystitis (IC) is a common lower urinary tract disorder
in cats that resembles painful bladder syndrome/interstitial cystitis
in humans. In both disorders, the etiology is unknown and speciﬁc
therapy is not available. Diagnosis is based on clinical signs and
exclusion of other disorders due to lack of characteristic patho-
logic ﬁndings, well-deﬁned phenotypes, or objective biomarkers.
Cytokines can serve as noninvasive biomarkers to deﬁne the pres-
ence, severity, and progression of disease, and response to treat-
ment. The objective of this pilot study was to determine
concentrations of selected cytokines in serum from healthy cats
and cats with IC. Thirteen serum samples from healthy cats and
13 from cats with IC were evaluated. Multiplex analysis of 19
cytokines (sFas, TNF-a, SDF-1, SCF, RANTES, PDGF-BB,
MCP-1, KC, IL-18, IL-13, IL-12 (p40), IL-8, IL-6, IL-4, IL-2,
IL-1b, IFN-c, GM-CSF, Flt-3L) was performed with a multiple
antigen Luminex bead-based assay according to manufacturer
recommendations. Results were then analyzed for normality of
data with D’Agostino-Pearson test and groups were compared
using Mann-Whitney test.
Signiﬁcantly increased mean concentrations of IL12(p40)
(1191  484.9 versus 219.6  393.3 pg/mL; P < 0.0001), SDF1
(2015  1131 versus 528.7  1002 pg/mL; P = 0.002), and IL18
(483.8  468.8 versus 92.03  272.6 pg/mL; P = 0.02) were
detected in the serum of cats with IC compared to unaﬀected cats.
Further studies are necessary to evaluate the diagnostic and prog-
nostic utility of serum cytokine biomarkers in cats with IC.
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CYSTOLITH DISSOLUTION IN CATS USING A COMMER-
CIALLY AVAILABLE DIET. Camille Torres-Henderson1, Jamie
Bunkers1, Elena Contreras1, Deborah Greco2, Emily Cross2,
Michael Lappin1. 1Colorado State University, Fort Collins, CO,
USA, 2Nestle Purina PetCare, St. Louis, MO, USA
The most common radiopaque cystoliths in cats are composed
of struvite or calcium oxalate minerals. Struvite cystoliths have
been shown to dissolve with dietary management whereas calcium
oxalate cystoliths must be removed surgically. The commercially
available diet, Purina Pro Plan Veterinary Diets UR Urinary
St/Ox, has been formulated for the dissolution of struvite cys-
toliths and to lessen the recurrence of both struvite and oxalate
cystoliths. The purpose of this study was to describe the clinical
and laboratory ﬁndings in cats with radiopaque cystoliths fed this
commercially available diet.
The study was announced to northern Colorado animals shelters
by list serve. Cats with clinical signs of lower urinary tract disease
and cystoliths conﬁrmed via radiographs were enrolled in this
IACUC approved study. Qualifying cats were transferred and
maintained at the research study site to assure that only the test
diet was fed. Complete blood cell count, serum biochemistry pro-
ﬁle, abdominal ultrasound, and urinalysis with aerobic bacterial
culture and antimicrobial sensitivity were performed on entry to
and exit from the study. The cats were housed in a gang room, fed
the study diet ad libitum, and assessed by abdominal radiographs
weekly. Cats with cystoliths that resolved based on two sequential
weekly radiographs and conﬁrmatory ultrasound examination were
considered diet successes. Cats with no change in cystolith size after
four weeks underwent cystotomy for stone removal, aerobic culture
and antimicrobial susceptibility testing, and analysis at the Univer-
sity of Minnesota Urolith Center. The cats were then adopted to
private homes and when possible, the study diet was continued and
abdominal radiographs were obtained to evaluate for recurrence.
To date, ﬁve cats between the ages of four and eight years of
age have completed the study. All cats accepted the study diet,
weight loss was not noted over the course of the study in any cat,
serum biochemical data were normal for all cats, and urine culture
was negative for all cats when exiting the study. Total cystolith
dissolution was achieved by Week 2 for three cats and two cats
still had radiographic evidence of cystoliths by Week 4. One cat
with persistent cystoliths had a single ammonium urate cystolith
with a struvite nidus (normal pre and post-bile acids) and the
other cat had multiple calcium oxalate cystoliths; cultures were
negative for both cats. Recheck radiographs at two months for
two cats with stone resolution on diet and the cat with calcium
oxalate cystoliths (three month post-cystotomy) showed no evi-
dence of cystolith recurrence.
While larger case numbers are needed, the preliminary results
suggest that feeding Purina Veterinary Diet UR Urinary St/Ox
can successfully dissolve cystoliths that are likely struvite and may
lessen risk of recurrence of struvite and calcium oxalate cystoliths.
OT01
EFFECT OF THREE RESUSCITATIVE FLUID PROTOCOLS
ON N-TERMINAL PROHORMONE BRAIN NATRIURETIC
PEPTIDE IN HEALTHY DOGS. Alison Khoo, Matthew Gaunt,
Anthony Carr, Cheryl Waldner. University of Saskatchewan,
Saskatoon, SK, Canada
The purpose of this crossover design study was to determine if
3 diﬀerent resuscitative ﬂuid therapy protocols would increase
N-terminal proBNP (NT proBNP) levels in healthy dogs. The pro-
tocols included a balanced isotonic replacement crystalloid solu-
tion (Normosol R) administered at 90 mL/kg/h over one hour, a
7.2% hypertonic saline bolus administered at 5 mL/kg over
15 minutes, and a 6% hydroxyethyl starch ﬂuid bolus (Voluven
) administered at 20 mL/kg over 30 minutes. Serum NT-proBNP
concentrations were measured in 6 healthy purpose bred dogs
prior to ﬂuid administration and then 0.5, 1, 1.5, 2, 4, 8, 12, 18,
24, 36 and 48 hours after receiving one of the three ﬂuid therapy
protocols. Each dog was randomly assigned to receive a diﬀerent
ﬂuid protocol each week for 3 weeks, allowing a 5-day washout
period between treatment protocols.
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Serum NT-proBNP concentration was signiﬁcantly more ele-
vated from baseline in dogs receiving 90 mL/kg/hr of crystalloid
solution compared to dogs receiving hypertonic saline or hydrox-
yethyl starch boluses. None of the ﬂuid therapy protocols caused
elevations of serum NT-proBNP above the previously reported
cut-oﬀ concentration used to discriminate between dogs with con-
gestive heart failure and dogs with primary respiratory disease.
Resuscitative ﬂuid therapy does increase serum NT-proBNP
concentrations but does not impact the ability to use serum NT-
proBNP concentration to discriminate between cardiac failure and
respiratory disease in healthy dogs.
OT02
DEXMEDETOMIDINE OROMUCOSAL GEL FOR
ALLEVIATION OF ACUTE ANXIETY AND FEAR
ASSOCIATED WITH NOISE IN DOGS. Mira Korpivaara1,
Kaisa Laapas1, Mirja Huhtinen1, Barbara Sch€oning2, Karen
Overall3. 1Orion Corporation, Espoo, Finland, 2Veterinary
Specialty Practice for Behavior, Hamburg, Germany, 3Biology
Department, University of Pennsylvania, Philadelphia, PA, USA
Distress, fear, and anxiety during exposure to loud noises (e.g.,
storms, ﬁreworks) are behavioral and welfare concerns for dogs,
and aﬀect up to 50% of dogs over their lifetime. Our objective
was to conﬁrm that a sub-sedative dose of dexmedetomidine, an
alpha-2 adrenoceptor agonist, alleviates acute anxiety and fear
associated with noise in dogs.
This randomized, double-blind, placebo-controlled, parallel-
group study was conducted at 17 sites in 2 European countries on
New Year’s Eve. 182 dogs with a history of anxiety or fear due to
ﬁreworks received 125 lg/m2 dexmedetomidine as an oromucosal
gel (89 dogs) or placebo (93 dogs). Owners applied the ﬁrst dose
before or at the onset of distress associated with ﬁreworks. Dosing
could be repeated up to 4 times, every 2 hours. Owners assessed
treatment eﬀect and dog’s behavior. They also reported oral muco-
sal color, observational and functional alertness, adverse events,
and ease of use.
An excellent or good treatment eﬀect was seen in 64 (72%)
dexmedetomidine-treated dogs and in 34 (37%) placebo-treated
dogs. The overall treatment eﬀect was superior with dexmedeto-
midine (P < 0.0001). Dogs on dexmedetomidine displayed less
panting, trembling, and hiding. Transient pale mucous membranes
were observed more frequently with dexmedetomidine, but no
mucosal irritation was reported. Most dogs (82/89, 92%) remained
functional and no adverse events of concern were observed. Most
owners (154/182, 85%) considered the product very easy or quite
easy to use.
This study conﬁrms that oromucosal dexmedetomidine at a sub-
sedative dose alleviates acute anxiety and fear associated with
noise in dogs.
OT03
PROGNOSTIC INDICATORS IN CATS WITH SEPTIC PERI-
TONITIS: 44 CASES (2002–2015). Katherine Scotti1, James
Barr1, Micah Bishop2, Michael Kato3, Matthew Mellema3,
Medora Pashmakova1. 1Texas A&M, College Station, TX, USA,
2Animal Specialty Hospital of Florida, Naples, FL, USA, 3UC
Davis, Davis, CA, USA
Septic peritonitis (SP) in cats carries signiﬁcant mortality (12–
70%) and etiologies may be indeterminate. The aim of this study
was to identify etiologies and prognostic factors in cats with SP.
Medical records of cats hospitalized for SP between 2002 and
2015 at Texas A&M University and University of California
(Davis) were reviewed. Septic peritonitis was diagnosed by intra-
cellular bacteria on cytology or positive bacterial culture. Data
was checked for normality and compared using an unpaired t-test
and a Mann-Whitney test. Fisher’s exact test and Odds ratios were
used to compare variables. Alpha was set at 0.05.
Seventy-nine cats were identiﬁed and 55 met inclusion criteria.
The source of SP was undetermined in 28/55 cats. Gastrointestinal
perforation was the cause of SP in 16/55 cats. Thirty of 44
(68.18%) cats that were surgically managed and 5/11 (45.45%)
that were medically managed survived to discharge. In this popula-
tion, there was no association between leukocytosis, leukopenia,
anemia, hypoalbuminemia, hyperlactatemia, ionized hypocalcemia,
or band neutrophilia and survival. Cats with increased creatinine
were 4.68 times more likely to die (95%CI: 1.40–15.69; P = 0.012).
Hypothermic cats were 4.67 more likely to die (95% CI: 1.36–
15.98; P = 0.014), while febrile cats were 5.409 times more likely
to live (95% CI: 1.58–18.58; P = 0.0063).
The origin of SP was undetermined in half of the cats in this
study. Survival was in agreement with previous reports. Azotemia
and hypothermia, which may reﬂect persistence of shock in this
species, should be closely monitored in septic cats.
OT04
RELIABILITY OF THERMOMETER PROTECTIVE
SHEATHS FOR MEASUREMENT OF RECTAL TEMPERA-
TURE IN DOGS. Franck Jolivet1, Maud Pic1, Didier Concordet2,
Olivier Dossin3. 1Department of Small Animal Clinical Sciences,
INP – National Veterinary School and Federal University of
Toulouse Midi Pyrenees, Toulouse, France, 2UMR1331 Toxalim,
INP - National Veterinary School and Federal University of Tou-
louse Midi Pyrenees, Toulouse, France, 3Department of Small
Animal Clinical Sciences and IRSD INSERM 1220, INP –
National Veterinary School and Federal University of Toulouse
Midi Pyrenees, Toulouse, France
Rectal temperature is commonly used in clinical evaluation of
canine patients. Single-use lubricated protective thermometer
sheaths are largely used in human medicine but this practice is not
routinely reported in veterinary medicine. Therefore the aim of
our study was to compare rectal temperature measured with the
same thermometer with and without protective sheaths in a large
canine population.
Three hundred and eighty two dogs were included in the study.
Rectal temperature was assessed in a standardized manner by two
persons (FJ and MP) with two identical digital rectal thermome-
ters. The thermometers were validated for accuracy and repeatabil-
ity (within-day variability) with a high precision thermometer. The
thermometers validation was performed with and without protec-
tive sheaths. The rectal temperature was measured consecutively in
each dog with and without protective sheaths in a randomized
order. The diﬀerence of temperature measured with the two meth-
ods was analyzed with a generalized linear model with order of
temperature measurement, age, body condition score (underweight,
normal and overweight), format (stratiﬁed as mini, medium and
large) and conscience level (conscious, sedated and anesthetized) as
explanatory variables. Results are presented as mean  SD.
The accuracy of the study thermometers was excellent with
average temperature diﬀerences of 0.067  0.064 and
0.066  0.054 and ranging from 0.28 to +0.15 and from 0.22
to +0.1 with and without sheath respectively. In the ﬁeld study,
the diﬀerence of the temperatures measured with and without
sheaths were within the 0.1 and +0.1 °C range for 80% of the
measurements. Moreover, these diﬀerences were ≤0.5°C and ≥
+0.5°C for 3 and 5 dogs respectively. Except for the body condi-
tion score none of the explanatory variables studied were signiﬁ-
cantly associated with the diﬀerences measured suggesting that the
diﬀerences were more important in overweight dogs that in normal
dogs with average diﬀerences of 0.087 and 0.009°C respectively
(P = 0.013).
This study shows that thermometer protective sheaths can be
used reliably to measure rectal temperature in dogs in a clinical
setting. Therefore, it is strongly advised to use this hygienic protec-
tive measure in daily clinical practice because even in overweight
dogs the diﬀerences between the two methods are clinically non
signiﬁcant.
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OT05
ISOLATION AND IDENTIFICATION OF MICRORNA FROM
THE MATURE FELINE ERYTHROCYTE: A PILOT STUDY.
Katrina Stewart, Pierre Deshuillers, Joanne Messick. Purdue
University, West Lafayette, IN, USA
MicroRNAs have been identiﬁed as sensitive, non-invasive diag-
nostic markers for early detection of human malignancies. To date
there have been very few studies of microRNA expression in the
serum of domestic animals with no known analysis of the micro-
RNA present in mature erythrocytes. Feline erythrocytes are
known to be sensitive to oxidative damage and we are interested
in their potential use as a model for the study of systemic oxida-
tive stress. Identiﬁcation of speciﬁc microRNA which are dysregu-
lated under these conditions may be sensitive biomarkers of
oxidative stress.
This pilot study was aimed at identifying the microRNAs
expressed in mature feline erythrocytes. This speciﬁcally involved
isolation of a puriﬁed population of mature erythrocytes from cat
blood; extraction of high quality microRNA from the puriﬁed
population of mature erythrocytes and sequencing of the micro-
RNA population to form a library from which to facilitate further
study.
We successfully puriﬁed mature feline erythrocytes from whole
blood with a combination of centrifugation and leukoreduction
with a specialized ﬁlter. This removed a majority of the reticulo-
cytes, white blood cells and platelets, however a ﬁnal puriﬁcation
step utilizing magnetic beads coated with antibodies was subse-
quently used to ensure a pure mature population of erythrocytes.
For this immune-depletion step, antibodies were initially tested for
reactivity in the feline, then biotinylated for use within the
columns. The antibodies used in this study were: anti-CD71
(anti-transferrin receptor to remove reticulocytes); anti-CD18
(anti-beta2 integrin to remove leukocytes) and anti-CD61
(anti-beta 3 integrin to remove platelets). Assessment of the
mature red blood cell preparation purity was performed with an
automated ﬂow cytometry-based hematology analyzer to identify
the presence of leukocytes, platelets and reticulocytes.
Isolation of total RNA was performed with a modiﬁed TRIzol
phase separation method with concentration and quality of the
RNA assessed prior to library construction. A small RNA library
was constructed with cluster generation and sequencing followed
by quality trimming and mapping of reads to the Felis catus
genome.
With this study we have successfully isolated mature feline ery-
throcytes from whole blood samples, extracted quality microRNA
from the isolated erythrocytes and developed a library of micro-
RNA present in these cells in a normal population of cats. Further
work will establish comparison of the microRNA proﬁle between
this normal population of cats and those at risk of or with evi-
dence of oxidative damage. This will help to identify new and
potentially informative biomarkers for systemic redox status and
complications associated with oxidative stress in cats.
OT06
EFFECTS OF SEDATION AND ANESTHESIA ON CANINE
HEMATOLOGIC AND SERUM BIOCHEMICAL ANALYSES
DURING PREVENTIVE HEALTHCARE. Laura McPhee,
Xuemei Si, Carolyn Cupp. Nestle Purina Research, St. Louis,
MO, USA
This study aims to determine the eﬀects of sedation and anes-
thesia on complete blood count (CBC) and serum chemistry results
in dogs undergoing routine health and wellness care. Ten healthy
adult dogs were selected based on physical exams and the need to
undergo anesthesia for routine dental prophylaxis. Blood was col-
lected by venipuncture at a series of timepoints: a) before receiving
a premedication, b) prior to induction of anesthesia, c) 5 minutes
after induction of anesthesia, d) 15 minutes after induction of
anesthesia, and e) 45 minutes after induction of anesthesia.
Premedication was a combination of acepromazine (0.025 mg/kg)
and butorphanol (0.2 mg/kg) given as a single subcutaneous injec-
tion 20 minutes prior to induction with propofol. Propofol was
calculated at 4 mg/kg and administered intravenously to eﬀect.
Anesthesia was maintained with inhalation of isoﬂurane gas via
endotracheal intubation. Generalized linear mixed models were
conducted to compare parameters between various time points to
account for the correlated data (the same dog participated in mul-
tiple time points). P-values less than 0.05 are considered as statisti-
cally signiﬁcant. When compared to blood results prior to
premedication, statistically signiﬁcant changes were observed in
average hematocrit, hemoglobin, mean cell volume, red blood cell,
albumin, cholesterol, and protein values after premedication alone.
After induction with propofol, variation was additionally observed
with white blood cell count, alkaline phosphatase, calcium, globu-
lin, potassium, triglycerides, and whole blood DNA concentration.
After 15 minutes of maintenance on isoﬂurane gas, mean cell
hemoglobin concentration, monocytes, phosphorus, and bilirubin
values were additionally aﬀected. This study highlights the signiﬁ-
cant eﬀect that sedation and anesthesia have on blood analyses
and subsequent interpretation and clinical relevance.
OT07
DOES FINE NEEDLE ASPIRATION AFFECT MANAGE-
MENT OF DOGS WITH INCIDENTAL SPLENIC NODULES
OR HETEROGENEOUS PARENCHYMA?. Igor Yankin, Sarah
Nemanic, Silvia Funes, Helio de Morais. Oregon State University,
Corvallis, OR, USA
Splenic nodules and heterogeneous splenic parenchyma are rela-
tively common ﬁndings in older dogs undergoing abdominal ultra-
sound. The impact of ﬁne needle aspiration and cytology in the
management of those patients is not clear.
The aim of this retrospective study was to determine how often
results of ultrasound-guided splenic ﬁne-needle aspirates impact
case management in adult dogs with splenic nodules or heteroge-
neous splenic parenchyma.
Medical records from adult dogs in which ultrasound-guided
splenic ﬁne-needle aspirates were performed at the Oregon State
University Veterinary Teaching Hospital from June 2011 through
July 2015 were retrospectively reviewed. Dogs were included if
splenic nodules or heterogeneous splenic parenchyma was inciden-
tally found under ultrasonographic examination. Only patients
with splenic ﬁne-needle aspirates performed on the same day of
the ultrasonographic examination were included. Dogs were not
included if a disease associated with splenic abnormalities was
known to be present before the ultrasound.
One hundred and twenty six adult client-owned dogs met the
inclusion criteria. Fine-needle aspiration changed the clinical man-
agement of 25 of 126 dogs (20%). Those included patients diag-
nosed with malignant neoplasia or suppurative inﬂammation:
lymphoma (n = 10), sarcoma (n = 3), malignant histiocytosis
(n = 3), suppurative inﬂammation (n = 3), epithelial neoplasm
(n = 2), melanoma (n = 1), hemangiosarcoma (n = 1), carcinoma
(n = 1), and spindle cell tumor (n = 1). In the remaining 101 dogs
(80%), ﬁne-needle aspiration of the spleen did not change the
management of the case. Those include patients with extramedul-
lary hematopoiesis (n = 79), lymphoid reactivity/hyperplasia
(n = 11), normal spleen (n = 9), hyperplastic nodule (n = 1), and
non-diagnostic sample (n = 1).
Splenic ﬁne-needle aspirate is a minimally invasive diagnostic
modality providing information that changed case management in
1/5 adult dogs with splenic nodules or heterogeneous splenic par-
enchyma, and should be considered in this population of patients.
P01
ITRACONAZOLE ABSORPTION FROM PROPRIETARY
AND COMPOUNDED FORMULATIONS IN HEALTHY
CATS. Dianne Mawby1, Leanne Fowler1, Mark Papich2, Jacque-
line Whittemore1. 1University of Tennessee, Knoxville, TN, USA,
2North Carolina State University, Raleigh, NC, USA
Itraconazole is available in FDA-approved oral capsules and
solution (Sporanox), as well as compounded formulations. The
purpose of this study was to determine absorption of proprietary
and compounded itraconazole in cats.
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After a 12 hour fast, 8 cats received 50 mg (~12.7 mg/kg) of
itraconazole (Sporanox capsule, Sporanox solution, com-
pounded capsule, and compounded suspension) in a randomized
crossover with a 21-day washout. Capsules were administered with
a small meal whereas solution was not. Plasma was collected at
pre-determined intervals for analysis using high pressure liquid
chromatography. Compartmental and non-compartmental phar-
macokinetic analyses were performed using Phoenix software
(Certara) on the proprietary Sporanox and compounded formu-
lation data, respectively.
For the Sporanox capsule, the peak concentration (CMAX)
and half-life (t½) were 0.54 µg/mL (37% CV) and 18 hours (21%
CV), respectively. These values for Sporanox solution were
1.82 µg/mL (50% CV) and 23.7 hours (42%CV), respectively.
Absorption of the Sporanox solution was 4.2 times greater than
for the Sporanox capsule based on AUC ratios, and CMAX was
3.4 times higher for the solution. Compounded formulations were
absorbed inconsistently, commonly resulting in undetectable con-
centrations. Complete pharmacokinetic results were obtained from
only 3 and 1 cats in the compounded capsule and suspension
groups, respectively. Relative absorption of compounded itracona-
zole was 8% from capsule and 2% from suspension.
The long half-life of itraconazole in cats allows once daily oral
dosing. Due to much higher absorption of Sporanox solution,
versus capsules, the oral solution dose can be substantially
reduced. Compounded itraconazole should not be used in cats
because of poor oral absorption.
P02
BIOAVAILABILITY OF A NOVEL FORMULATION OF
S-ADENOSYLMETHIOINE GIVEN WITH FOOD IN BEAGLE
DOGS. David Griﬃn, Carolyn Warner. Nutramax Laboratories
Veterinary Sciences, Inc., Lancaster, SC, USA
S-adenosylmethionine (SAMe) is used to support liver function
both in companion animals and humans, and is also used in
humans for mental and joint health. Previous studies have shown
that when SAMe is administered with food there is a substantial
decrease in SAMe bioavability (Table 1). In a blinded crossover
study a new Denamarin (Nutramax Laboratories Veterinary
Sciences, Inc.) chewable tablet containing a novel formulation of
SAMe salt (NMXSS75ATM) was administered to beagle dogs to
assess its bioavailability relative to administration with food. Six
beagles were dosed after an overnight fast with 225 mg SAMe ion
(mean 21.7 mg/kg) in one formulation of the supplement, fol-
lowed by the other formulation 7 days later administered with
food. Plasma values for SAMe before dosing and at 0.5, 1, 2, 4,
6, 8, and 24 hours were determined using an HPLC-ESI-MS/MS
assay. With both supplements SAMe plasma levels increased sub-
stantially above baseline values (21–38 ng/mL) and returned to
baseline after 24 hours. Mean values for Cmax ,Tmax, AUC0–24
and t1/2 were comparable for both formulations with no statisti-
cally signiﬁcant diﬀerences (Table 2). The data indicate that this
novel SAMe salt may be used in dogs with equivalent bioavail-
ability when administered with food which may increase owner
compliance.
Table 1 Eﬀects of Food Consumption on SAMe Tosylate
Absorption.
Table 2 Eﬀects of Novel SAMe Salt with Food Consumption
Compared to SAMe Tosylate Fasted.
P03
POSACONAZOLE PHARMACOKINETICS IN CATS AFTER
ORAL AND IV ADMINISTRATION. Dianne Mawby1, Leanne
Fowler1, Mark Papich2, Jacqueline Whittemore1. 1University of
Tennessee, Knoxville, TN, USA, 2North Carolina State Univer-
sity, Raleigh, NC, USA
Posaconazole is the most active available azole antifungal drug,
but absorption and pharmacokinetics are not available to guide
dosing regimens in cats. The purpose of this study was to deter-
mine pharmacokinetics of oral suspension and IV formulations of
posaconazole in cats to determine the feasibility of oral adminis-
tration for treatment of fungal infections.
After a 12 hour fast, each of 6 healthy cats received 15 mg/kg
of posaconasole (Noxaﬁl) oral suspension with food. Four cats
also received 3 mg/kg IV posaconazole after a 7-day washout per-
iod. Plasma was collected at predetermined intervals for analysis
using high pressure liquid chromatography (HPLC). Concentra-
tion data were analyzed using a two-compartment pharmacoki-
netic analysis for IV data and a one-compartment analysis with
ﬁrst-order input for oral data using Phoenix software (Certara).
After IV dosing, volume of distribution (VSS) was 1.9 (0.3) L/kg
(mean, std. deviation), terminal half-life (t½) was 39.4 (15.9) hours,
and clearance was 28.1 (17.3) mL/kg/hr. After oral dosing, peak
concentration (CMAX) was 1.2 (0.5) µg/mL and terminal t½ was
38.1 (15.0) hours. Bioavailability from oral administration was
15.9% (8.6). No adverse eﬀects were observed from either route of
administration.
Despite low oral absorption, these data allow for simulation of
oral dosage regimens that could be explored in clinical studies.
Two regimens can be considered to maintain targeted trough con-
centrations of 0.5–0.7 µg/mL: 1) 30 mg/kg PO loading dose fol-
lowed by 15 mg/kg q 48 hours, or 2) 15 mg/kg PO loading dose
followed by 7.5 mg/kg q 24 hours.
P04
EVALUATION OF INTRAVENOUS MYCOPHENOLATE
MOFETIL USE IN HEALTHY CATS. JE Slovak, SM Rivera,
JK Hwang, MH Court, N Villarino. Washington State University,
Pullman, WA, USA
Mycophenolic acid (MPA) is the active moiety of the prodrug
mycophenolate mofetil (MMF). It is a selective non-competitive
inhibitor of inosine-5ʹ-monophosphate dehydrogenase. MPA is an
attractive immunosuppressant option in veterinary medicine due
to its rapid onset and commercial availability in multiple formula-
tions. Although MPA is used routinely in humans and canines,
there is a paucity of literature supporting MPA’s use in feline
patients, likely from cats’ limited ability to glucuronidate certain
medications. Our goal for this study was to evaluate the pharma-
cokinetics, pharmacodynamics, and safety of MPA in 9 healthy
cats.
Grams of
Food
Cmax ± Std
0 1,736 907
100 713 350
225 562 512
SAMe Tosylate 
Chewable Tablet
(Mean ± Std)
Novel Salt NMXSS75A™
Chewable Tablet
(Mean ± Std)
Fasted (n=6) Fed (n=6)
Cmax  (ng/ml) 1,202 ± 365 1,157 ± 683
Tmax  (hr) 1.5 ± 0.5 1.9 ± 2.0
AUC0-24 (ng•hr/ml) 7,060 ± 1,431 4,579 ± 1,454
t1/2 (hr) 9.03 ± 3.39 10.78 ± 4.57
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The pharmacokinetics of MPA was evaluated following an intra-
venous infusion of 5 mg/kg (n = 2) and 10 mg/kg (n = 1) of MMF
(CellCept intravenous, Roche Lab Inc.) Surprisingly, the plasma
concentration of MPA in cats at these doses were remarkably low
compared with the plasma levels consistent with immunosuppres-
sive levels in humans. Therefore, we evaluated the PK of MPA
using 20 mg/kg of MMF administered twice 12 hs apart (n = 6).
Following the infusion, all cats metabolized MMF into MPA. The
maximum observed MPA plasma concentration ranged between
3.4 and 22 µg/mL after the ﬁrst dose and between 6.7 and 20 µg/
mL, following the second dose. The evaluation of the concentration
time proﬁle of MPA in plasma revealed additional peaks of MPA
which could correspond to enterohepatic recycling of MPA.
Mycophenolic acid is eliminated by liver biotransformation.
Unexpectedly, the concentration of MPA in plasma decayed
quickly (terminal half-life ~1.5 hs) in all the cats, suggesting a fast
rate of biotransformation, explaining the higher dose of MMF.
The metabolite MPA phenol glucuronide was quantiﬁable in 2 out
of 6 cats while acyl glucuronide was not detected in any of the
cats. In contrast, the metabolite MPA phenol glucoside was quan-
tiﬁable in plasma from all the cats, suggesting that glucosidation
of MPA is a key route for MPA elimination in cats.
The administration of MMF showed a rapid eﬀect on immune
cells. After the second dose of MMF, there was a reduction of the
peripheral blood mononuclear cells (PBMC) by ~24%. The
PBMCs recovered to baseline levels ~36 hs after stopping the infu-
sion of MMF. This indicates that repeated administrations of
MMF are required to maintain a constant suppression of immune
cells in cats. Importantly, there were neither serum biochemistry
changes nor signiﬁcant adverse events associated with the adminis-
tration of MMF in any of the cats.
This study is the ﬁrst step towards improving treatment of vari-
ous autoimmune diseases in cats. The results of this study suggest
that the infusion of MMF once at 20 mg/kg 12 hs apart, provides
a safe and rapid immunosuppressive eﬀect in cats. Future studies
will evaluate the pharmacokinetics and the eﬀect of MPA on tar-
get lymphocyte subpopulations (CD25+CD8+ and CD25+CD4+
T cells) following multi-day intravenous and oral dosing of MMF.
P05
THE ACCURACY, PRECISION AND STABILITY OF COM-
POUNDED MILBEMYCIN OXIME IN AQUEOUS SUSPEN-
SION. Zachary Cochrane, Darren Berger, Dwayne Schrunk,
Johann (Hans) Coetzee. Iowa State University College of Veteri-
nary Medicine, Ames, IA, USA
Production of a veterinary proprietary product solely containing
milbemycin oxime (MO) for use in the United States was tempo-
rally ceased in 2011, resulting in use of compounded MO formula-
tions for the treatment of canine generalized demodicosis. Despite
the return of a labeled single agent product to the veterinary mar-
ketplace, compounded formulations are still available through
national compounding pharmacies. This study describes the accu-
racy, precision and stability of MO strength when compounded as
an aqueous suspension (20 mg/mL).
Preparation choice reﬂected current prescribing practices and
routinely utilized concentration. Samples were acquired by pre-
scription from two national veterinary compounding pharmacies
at three time points spanning a 30-day period. Two diﬀerent stor-
age conditions were evaluated and sampled at four time points
from the order date (Day 7, 14, 21, and 28). MO recovery was
performed by solid-phase extraction and concentration strength
measured via high-performance liquid chromatography.
Overall, accuracy ranged from 67.5 to 135.5% with pharmacy
A having a range of 67.5 to 91.5% and pharmacy B 78.5 to
135.5%. Of the initial Day 7 samples, only 3 of 12 were within the
United States Pharmacopeia’s guideline deﬁning acceptable range
of 90 to 110% compared with labeled strength. The precision for
pharmacy A was 1.0 to 16.9% while for pharmacy B it was 3.9 to
32.8%. Storage condition did not aﬀect stability in the tested
aqueous suspensions. The average decrease in MO concentration
in pharmacy A’s samples was 21.8% (13.3 to 26.1%) while from
pharmacy B it was 18.6% (9.6 to 27.7%).
Compounded MO suspension deviated by more than 10% from
their labeled strength, which could lead to potential over-dosage
and severe neurologic toxicity in predisposed breeds. Bioavailabil-
ity and clinical eﬃcacy of compounded MO suspensions still
remain unknown, and the use of these products should be discour-
aged at this time.
P06
PHARMACOKINETICS OF INTRAVENOUS AND SUBCUTA-
NEOUS DOLASETRON AND PHARMACODYNAMICS OF
SUBCUTANEOUS DOLASETRON IN PURPOSE-BRED
CATS. Andrea Herndon, Liberty Sieberg, Leigh Davis, Amber
Caress, Ryan Hansen, Luke Wittenburg, Daniel Gustafson, Jessica
Quimby. Colorado State University, Fort Collins, CO, USA
Dolasetron is a 5-HT3 receptor antagonist anti-emetic and is
typically dosed at 0.5–1 mg/kg IV or SQ once daily. Pharmacoki-
netic (PK) and pharmacodynamic (PD) studies in cats have not
been previously performed. The purpose of this study was to eval-
uate these parameters in purpose-bred cats.
Five purpose-bred cats with unremarkable complete blood
count, serum biochemistry and urinalyses were utilized. PK study:
Each cat received 0.8 mg/kg subcutaneous (SQ) and intravenous
(IV) dolasetron in a cross-over manner. Serum samples were
obtained via jugular catheter at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36
and 48 hours after administration of dolasetron. Dolasetron and
the active metabolite hydrodolasetron were measured using liquid
chromatography/tandem mass spectrometry. Non-compartmental
pharmacokinetic analysis was performed. PD study: Subcutaneous
dolasetron (0.8 mg/kg or 1.0 mg/kg) or placebo was administered
30 minutes prior to intramuscular administration of 0.44 mg/kg
xylazine in a randomized crossover manner. Number of emetic
events, lip licks, time to onset of vomiting or visual nausea score
were scored by a blinded observer.
PK: Dolasetron was quickly metabolized to hydrodolasetron with
only two cats in each administration route having measurable con-
centrations beyond 2 hours, limiting the assessment of dolasetron
PK parameters. There was no signiﬁcant diﬀerence in exposure to
the active metabolite between the two routes of administration.
Pharmacokinetic parameters are summarized below.
PD: When dolasetron or placebo was administered prior to
xylazine, there was no signiﬁcant diﬀerence in the mean number of
emetic events, lip licks, time to onset of vomiting or visual nausea
score when compared to placebo.
At 0.8 mg/kg dolasetron does not maintain serum concentra-
tions for 24 hours and does not adequately control xylazine-
induced vomiting when given SQ even at 1 mg/kg. Additional dose
studies are needed to determine if a higher dose is more eﬀective.
P07
INVESTIGATION OF THE PHARMACOKINETICS OF
TRANSDERMAL ONDANSETRON IN NORMAL PURPOSE-
BRED CATS. Lara Zajic, Andrea Herndon, Liberty Sieberg,
Amber Caress, Ryan Hansen, Daniel Gustafson, Jessica Quimby.
Colorado State University, Fort Collins, CO, USA
Ondansetron is a 5-HT3 receptor antagonist used as an anti-
emetic in ill cats. Ondansetron can be dosed orally, IV, or
IV administration SQ administration
Dolasetron Hydrodolasetro
n
Dolasetron Hydrodolasetro
n
761.4 ± 
518.9
140.6 ± 106.0 196.6 ± 
253.1
78.3 ± 26.1
0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.63 ± 0.3
5 ± 4.8 13.6 ± 6.1 3.8 ± 3.1 18 ± 6.9
NP 4.2 ± 1.8 NP 4.0 ± 1.0
Parameter
Cmax (ng/ml)
Tmax (hr)
Tlast (hr)
T1/2 λ (hr)
AUC 0-T (hr*ng/mL) 325.0 ± 
210.0
314.0 ± 130.9 92.0 ± 86.7 429.4 ± 165.4
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subcutaneously but has previously been demonstrated to have
poor oral bioavailability and a short elimination half-life requiring
frequent dosing (every 6–8 hours). Because of the impracticality of
dosing (>3 doses/day) at home, it is often resigned to in-hospital
administration. Ondansetron is a candidate for a transdermal med-
ication because it is small in size (294 Daltons) and is moderately
lipophilic (log p ~ 2.1). The purpose of this study was to assess the
pharmacokinetics of transdermal ondansetron administration in
healthy, purpose-bred cats.
Five purpose-bred cats with unremarkable CBC, biochemistry
and urinalysis were utilized. 2 mg transdermal ondansetron Lipo-
derm gel was applied once to the internal ear pinna (total volume
of 0.1 mL). Blood samples were collected via jugular catheter over
a 48 hour period following administration (0, 15 minutes, 30 min-
utes, 1, 2, 4, 8, 12, 24 and 48 hours). Serum was separated and
frozen prior to analysis. Ondansetron was measured via liquid
chromatography coupled to tandem mass spectrometry.
Analysis revealed no appreciable drug was present in serum
after transdermal administration of 2 mg ondansetron, indicating
that this is not an acceptable method of drug delivery despite the
characteristics of the drug that imply that it would adequately pass
the skin barrier.
This study highlights the importance of assessing the potential
of each medication for transdermal administration.
R01
COMPARISON OF BRONCHOALVEOLAR LAVAGE TECH-
NIQUES FOR SAMPLING LOWER AIRWAYS IN CATS.
Kimberly Hooi, Alice Defarges, Andrea Sanchez, Stephanie
Nykamp, Anthony Abrams-Ogg, Scott Weese, Dorothee Bienzle.
Ontario Veterinary College, University of Guelph, Guelph, ON,
Canada
The purpose of this study was to compare bronchoscopic bron-
choalveolar lavage (B-BAL) and non-bronchoscopic bronchoalveo-
lar lavage (NB-BAL) in clinically healthy cats.
Two bronchoalveolar lavages (BAL) were performed 2 weeks
apart in twelve cats free of respiratory disease. BALs were per-
formed in a randomized order under general anesthesia by wedg-
ing a 2.9 mm ﬁber-optic bronchoscope (B-BAL) or an 8Fr red
rubber catheter (NB-BAL). Ten mL aliquots of saline were infused
into the left and right caudal lung ﬁelds and aspirated with a
20 mL syringe. Proportion of ﬂuid retrieved, depth of wedging
and anesthetic complications were recorded. Total nucleated cell
count, diﬀerential cell count and semi-quantitative evaluation of
cytologic quality were performed on all BALF samples. Results
were compared using ANOVA and Wilcoxon signed-rank tests.
Proportion of BALF retrieved and depth of wedging was signiﬁ-
cantly greater for B-BAL than NB-BAL. Diﬀerential cell counts
and cytologic quality did not diﬀer signiﬁcantly between tech-
niques. Results were [median (range)]:
Complications included transient hemoglobin desaturation (24/
24 BALs) and prolonged anesthetic recovery time (4/24 BALs).
However, anesthetic recovery scores did not diﬀer signiﬁcantly
between techniques.
The results suggest that NB-BAL procedure provided BALF
samples of equivalent quality to B-BAL procedure in cats clinically
free of respiratory disease.
R02
CHARACTERIZATION OF THE FELINE RESPIRATORY
MICROBIOME. Aida I. Vientos-Plotts1, Aaron Ericsson2, Hans
Rindt1, Megan Grobman1, Amber Graham1, Kaitlin Bishop1,
Leah Cohn1, Carol Reinero1. 1University of Missouri, College of
Veterinary Medicine Comparative Internal Medicine Laboratory,
Columbia, MO, USA, 2University of Missouri Metagenomics Cen-
ter, Columbia, MO, USA
Although lower airways have been considered sterile by culture,
sequencing 16S rRNA amplicons has revealed diverse bacterial
species in human lungs. Using healthy research cats in a stable
environment, we hypothesized that 16S rRNA amplicon sequenc-
ing of DNA from bronchoalveolar lavage (BAL), oropharyngeal
and fecal swabs, and blood, would reveal distinct microbiomes
from each site.
Six healthy research cats <1 year old had BAL, oropharyngeal
and fecal samples collected at day 0, week 3 and 8; and blood
week 8. Extracted DNA underwent PCR of the 16S rRNA gene.
Once sequenced, number of reads/sample, richness and relative
abundance of representative operational taxonomic units (OTUs)
were determined. Principle component analysis (PCA) described
relatedness of samples.
Fecal and oropharyngeal swabs yielded a meanSD of
65,652  26,069 and 20,632  18,499 reads/sample, respectively.
BAL and blood yielded lower coverage at 1,489  1,822 and
269  43 reads/sample, respectively. Oropharyngeal and fecal
swabs were signiﬁcantly richer than BAL (mean number OTUs 93,
88 and 36, respectively; P < 0.001) with no signiﬁcant diﬀerence
(P = 0.180) in richness between time points. Fusobacterium sp.,
Campylobacter sp., and Bacteroides sp. were predominant fecal
taxa. Pseudomonas sp. was most abundant in the oropharynx (day
0) and Pasteurellaceae and Porphyromonas sp. were most abundant
weeks 3&8. In BAL, Pseudomonas sp., Bradyrhizobiaceae, and Sph-
ingobacteriaceae predominated day 0 and week 3 with abundance
of Pseudomonas sp. declining week 8. Bradyrhizobiaceae and Sphin-
gobacteriaceae were predominant taxa in blood. PCA revealed dis-
tinct microbiomes in each site; however, blood had marked
compositional similarity with BAL. Samples clustered more by
time than by individual, with oropharyngeal swabs having subjec-
tively greater variation than other samples.
Healthy cats have a rich and distinct airway microbiome with
dynamic bacterial populations likely depending on age and envi-
ronment. Further data is necessary to determine how the distinct
feline microbiomes from the upper and lower airways, feces and
blood are established and evolve. These data are relevant for com-
parisons between healthy cats and cats with respiratory disease.
E01
PULMONARY DISPOSITION AND PHARMACOKINETICS
OF ORAL MINOCYCLINE IN THE ADULT HORSE. Kate
Echeverria1, Kara Lascola1, Steve Giguere2, Jon Foreman1, Scott
Austin1, Pamela Wilkins1. 1University of Illinois, College of
Veterinary Medicine, Urbana, IL, USA, 2University of Georgia,
College of Veterinary Medicine, Athens, GA, USA
The objective of this study was to determine the pharmacokinet-
ics and pulmonary disposition of minocycline in adult horses after
multiple intragastric doses.
Minocycline (4 mg/kg) was administered via the intragastric
route to 6 healthy adult horses every 12 hours for a total of 5
doses. Minocycline concentrations were measured in plasma, pul-
monary epithelial lining ﬂuid (PELF), and bronchoalveolar lavage
(BAL) cells via liquid chromatography mass spectrometry at multi-
ple time points over a 96 h time period. Pharmacokinetic variables
were determined after the last dose using a noncompartmental
approach. Comparison of minocycline concentrations between
sampling sites was done using a Friedman repeated measures
ANOVA and signiﬁcance was set at P < 0.05.
After the last dose, the mean + SD maximum plasma concentra-
tion (Cmax) of minocycline was 2.3 + 1.3 µg/mL and the terminal
half-life (T1/2) was 11.8 + 0.5 hours. The median (25th and 75th
percentiles) time to peak concentration (Tmax) was 1.3 (1.0 – 1.5)
hrs. The Cmax and Tmax of minocycline in the PELF were
10.5 + 12.8 µg/mL and 9.0 (5.5 – 12.0) hrs, respectively. The
Cmax and Tmax for BAL cells were 0.24 + 0.1 µg/mL and 6.0
(0.0 – 6.0) hrs, respectively. Peak and trough minocycline
NB-BAL B-BAL P-value 
Proportion of BALF retrieved 
(%)
55.0
(20.0-80.0)
70.0
(10.0-100.0)
0.008*
Depth of wedging (mm)
81.6
(67.0-93.0)
90.3
(72.8-122.0)
<0.001*
Differential 
cell count 
(%)
Macrophages
Eosinophils
Lymphocytes
Neutrophils
68.5 (24.0-90.0)
13.0 (0.0-73.0)
5.0 (1.0-17.0)
8.5 (0.0-36.0)
70.0 (41.0-91.0)
10.0 (0.0-28.0)
5.5 (1.0-23.0)
9.5 (2.0-36.0)
0.851
0.451
0.853
0.270
* p<0.05
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concentrations in PELF were signiﬁcantly higher than in plasma
whereas concentrations in BAL cells were signiﬁcantly lower.
Orally administered minocycline distributes into the PELF and
BAL cells of the horse. Knowledge of speciﬁc minimum inhibitory
concentrations is required to predict eﬃcacy of minocycline for the
treatment of bacterial pneumonia in adult horses.
E02
INTRAVENOUS ADMINISTRATION OF COBALT CHLO-
RIDE IS ASSOCIATED WITH HEMODYNAMIC ALTER-
ATIONS IN HORSES. Teresa Burns, Kasia Dembek, Laura
Dunbar, Sara Brewington, Linda Bednarski, Carl O’Brien, Turi
Aarnes, Brice Dooley, Jeﬀrey Lakritz, Ramiro Toribio. The Ohio
State University, Columbus, OH, USA
Cobalt is a substance of abuse in humans and animals perform-
ing in strenuous athletic competitions. When administered at phar-
macologic doses, it has been associated with induction of
erythropoietin release, increased hematopoiesis, which is thought
to confer competitive advantage. Cobalt chloride (CoCl2) is
reportedly given to racehorses to enhance performance, and
recently, allowable limits for cobalt have been set by several racing
jurisdictions for post-race illicit substance testing of blood and
urine. While preliminary single-dose pharmacokinetic data have
been published for CoCl2 in horses, information regarding the
eﬀects of repeated dosing (which is how the substance is reportedly
used illicitly in performance horses) is unavailable. Even fewer
data have been published describing the pharmacodynamic eﬀects
of CoCl2 administration in horses, particularly at high doses. The
purpose of this pilot study was to describe the physiologic and
biochemical eﬀects of weekly intravenous doses of CoCl2 to Stan-
dardbred horses. This report describes the hemodynamic eﬀects of
CoCl2 in a dose escalation study.
Five Standardbred mares (12–13 years-old; 460–530 kg) were
randomly assigned to receive one of 5 doses of CoCl2 (4, 2, 1, 0.5,
or 0.25 mg/kg) as an intravenous bolus (infused over 1 minute)
once weekly for 5 weeks. Prior to each dose, animals were instru-
mented with pulmonary artery and right atrial catheters, a trans-
verse facial artery catheter, two external jugular venous catheters,
an indwelling urinary catheter, and electrocardiography leads.
Physical examination parameters, blood pressure (systolic arterial
pressure [SAP], diastolic arterial pressure [DAP], and mean arterial
pressure [MAP]), cardiac output, and qualitative ECG assessment
were evaluated every 5–10 minutes for 4 hours immediately after
administration of the ﬁrst and ﬁfth weekly doses of CoCl2.
All mares were subjectively anxious (nostril ﬂaring, muscular
tremor/fasciculation, pawing, straining) by 5 minutes following the
CoCl2 infusion; this persisted for ~60 minutes in mares receiving
higher doses (4, 2, and 1 mg/kg). Mares receiving 4, 2, or 1 mg/kg
doses developed tachycardia immediately after dosing (HR 60–
126 bpm), but this was not observed in mares receiving 0.5 or
0.25 mg/kg (HR 36–52). Paroxysmal ventricular tachycardia was
noted in the ﬁrst 10 minutes post-administration in the mare
receiving the 4 mg/kg dose. Elevations in SAP, DAP, and MAP
were noted following drug administration at most doses; while
profound hypertension was observed at 4 mg/kg (SAP/DAP,
MAP [mmHg] = 291–300/163–213, 218–279), all mares became
hypertensive in the 30–45 minutes following CoCl2 administration.
Mares receiving 4 and 2 mg/kg developed conspicuous oral
mucous membrane congestion that persisted for 20 minutes post-
dosing and subsequently resolved. At all doses, cardiovascular
parameters returned to baseline by 1–2 hours post-administration.
Results of this preliminary study document signiﬁcant, repeat-
able hemodynamic alterations associated with intravenous CoCl2
administration to horses. Further, the degree of hypertension
observed following infusion raises humane and human safety con-
cerns if doses of >1 mg/kg are used.
E03
THE PHARMACOKINETICS OF INTRAVENOUS GENTAM-
ICIN IN HEALTHY YOUNG-ADULT VERSUS GERIATRIC
HORSES. Andrew Gestrich1, Daniela Bedenice1, Michelle Cere-
sia2, Iman Zaghloul2, Nisanne Ghonem2, Mary Rose Paradis1.
1Cummings School of Veterinary Medicine at Tufts University,
North Grafton, MA, USA, 2School of Pharmacy, MCPHS
University, Boston, MA, USA
The study objective was to evaluate the eﬀects of patient age on
aminoglycoside pharmacokinetics in young-adult (5–10 years) ver-
sus geriatric (≥25 years) healthy horses, receiving a single 6.6 mg/
kg intravenous injection of gentamicin (Henry Schein). Hepari-
nized plasma samples were obtained at designated time-points fol-
lowing drug administration and frozen at 80°C until assayed by
a validated immunoassay (QMS). Gentamicin plasma concentra-
tions versus time plots were analyzed using a two-compartment
model and commercial software (WinNonlin-v6.4). Data were
compared between age-groups using independent samples t-test;
P < 0.05 considered signiﬁcant.
Baseline physical examination and hematological parameters
were not signiﬁcantly diﬀerent between young (median age [range]:
7 [6–8] years) and aged (26 [25–41] years) horses, aside from a
lower mean bodyweight in the geriatric group (402  56 versus
477  38 kg). Similarly, pharmacokinetic parameters were not sta-
tistically diﬀerent between age groups (mean SD; P > 0.05):
Peak plasma concentrations (Cpk) at the end of the distribution
phase were 31.7  4.4 µg/mL in young and 32  2.2 µg/mL in
aged horses (P = 0.901), while gentamicin trough levels reached
2 µg/mL (common MIC for equine pathogens) at 6.1  1.2 and
7.3  1.5 hours, respectively (P = 0.09). Considering an expected
post-antibiotic eﬀect of ≤8 hours, dosing adjustments are likely
required to meet therapeutic needs in both study groups.
E04
ENDOTOXIN-INDUCED MICRORNA EXPRESSION IN
EQUINE PERIPHERAL BLOOD MONONUCLEAR CELLS.
Nicholas Parkinson, Virginia Buechner-Maxwell, Sharon Witon-
sky, R. Scott Pleasant, Ansar Ahmed. Virginia-Maryland College
of Veterinary Medicine, Blacksburg, VA, USA
The innate immune response to bacterial lipopolysaccharide
(LPS) mediated by toll-like receptor 4 (TLR4) contributes substan-
tially to the morbidity of a number of important equine disease
syndromes including gastrointestinal disease and neonatal sepsis,
and contributes to other chronic pro-inﬂammatory states. Micro-
RNAs (miRNAs) are small non-coding RNA molecules 17–25
nucleotides in length that function as post-transcriptional regula-
tors of gene expression. miRNAs have recently been found to have
a central role in the modulation of the TLR4 signaling cascade in
other species, and altered expression has been implicated in the
pathogenesis of inﬂammatory diseases. Limited information is
available on miRNA expression in horses, and there is no pub-
lished data on expression in equine inﬂammatory cells. This objec-
tive of this study was to use next generation sequencing to
characterize the basal miRNA transcriptome in isolated equine
peripheral blood mononuclear cells, and to test the hypothesis that
LPS would induce diﬀerential expression of miRNAs.
Peripheral blood mononuclear cells were isolated from four
healthy adult horses. Cells were cultured with LPS (10 ng/mL) or
control for 0, 2 and 4 hours. Tumor necrosis factor alpha (TNFa)
was measured in culture supernatants by ELISA. RNA was
extracted from the cells and the miRNA transcriptome was
sequenced using an Illumina HiSeq 2500 analyzer after size
C0
(μg/mL)
AUC0-∞
(μg*h/mL)
T1/2α
(h)
T1/2β
(h)
Vss
(L)
Cl
(mL/h/kg)
Young-adult (n=8) 86.2±25.9 75.6±12.9 0.1±0.03 1.22±0.2 69.2±12.9 89.3 ±13.8
Geriatric (n=8) 86.6±21.8 82.7±10.3 0.11±0.04 1.42±0.33 60.2±12.2 80.8 ±9.4
C0–Initial plasma concentration; AUC–Area under the curve; T1/2 α and β–Distribution and   
elimination half-life; Vss–Volume of distribution at steady state; Cl–Clearance
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selection. High quality sequence data were mapped to the equine
genome and annotated using the miRNA database miRBase 21.
Diﬀerential expression was analyzed with generalized linear mod-
els, using the Benjamini-Hochberg procedure to control the false
discovery rate at 0.1.
327 mature miRNAs were detected, with 191 present in all
samples. Basal expression was highly consistent between horses.
The most abundant miRNAs in baseline samples were miR-21,
let-7 g and miR-150, miRNAs associated with cell cycle regulation
and both innate and adaptive immunity in other species. TNFa
expression was signiﬁcantly higher in the supernatants from LPS-
treated cells than controls at both 2 and 4 hours (P = 0.016 and
0.0003 respectively). After correction for multiple comparisons,
only miR-155 was signiﬁcantly upregulated by LPS (P = 0.00018,
1.5 to 1.6 fold change versus controls). 9 miRNAs showed statisti-
cally signiﬁcant expression changes with time. These included
miR-146a and miR-146b, which are induced by LPS in other spe-
cies but had non-signiﬁcant upregulation by LPS here. MiR-155
expression was signiﬁcantly correlated to supernatant TNFa
(R2=0.78).
The basal expression characterized by these data provide a
foundation for future research into the roles of speciﬁc miRNAs
in equine inﬂammatory responses. miR-155 is the principal LPS-
induced miRNA in horses, as in humans and mice. This miRNA
has documented roles in TLR4 signaling regulation, including
enhancement of TNFa translation and suppression of intermediate
signal transduction proteins. It is thus likely to inﬂuence the mag-
nitude and nature of the acute inﬂammatory response to LPS in
the horse, and could be a target for immune modulatory interven-
tions. It may also prove a useful marker of TLR activation. Fur-
ther research will be necessary to validate expression changes in a
wider sample set, investigate targets and functions of these miR-
NAs in horses, and to establish roles in naturally occurring
disease.
E05
SEVERE EQUINE ASTHMA (HEAVES) IS ASSOCIATED
WITH AN INCREASED NUMBER OF CIRCULATING LOW-
DENSITY GRANULOCYTES. Nicolas Herteman, Amandine
Vargas, Jean-Pierre Lavoie. Department of Clinical Sciences, Fac-
ulty of Veterinary Medicine, University of Montreal, Saint-Hya-
cinthe, QC, Canada
Airway neutrophilia is a characteristic ﬁnding of severe equine
asthma (heaves), a common and incurable condition of horses.
However, how polymorphonuclear neutrophils (PMNs) contribute
to the disease remains poorly understood. “Low-Density Granulo-
cytes” (LDGs), a subpopulation of PMNs, have been suggested to
have strong pro-inﬂammatory properties, which can promote the
recruitment of PMNs in an autocrine manner and thus amplifying
the inﬂammatory response. We therefore hypothesized that LDGs
are increased in the blood of heaves-aﬀected horses compared to
healthy subjects.
We studied 8 horses with heaves during disease exacerbation
and remission, and 6 healthy animals. LDGs and normal-density
neutrophils were isolated from peripheral blood using Ficoll.
Quantiﬁcation and morphological characterization of LDGs were
performed blindly using an optical microscope. LDGs were further
characterized by ﬂow cytometry using anti-CD90 and anti-myelo-
peroxidase (MPO) antibodies.
The number of LDGs was signiﬁcantly elevated in horses with
heaves during both exacerbation and remission compared to
healthy horses (P = 0.005 and P = 0.029, respectively). No signiﬁ-
cant diﬀerence was found between disease exacerbation and remis-
sion (P > 0.1). LDGs displayed a signiﬁcantly greater percentage of
normally segmented than hyposegmented nuclei in heaves-aﬀected
and control horses (P = 0.0002 and P = 0.0022, respectively).
MPO’s mean ﬂuorescence intensity of LDGs was signiﬁcantly lower
during heaves exacerbation when compared to control horses
(P = 0.0442). PMNs counts in BAL and LDG levels in blood of
horses with heaves were not correlated (P > 0.1 for both disease
exacerbation and remission).
This study describes for the ﬁrst time an association between an
increased subpopulation of PMNs, namely the LDGs, and an
inﬂammatory disease in horses. LDGs appear to be mostly
constituted of mature cells in both healthy and heaves-aﬀected
horses. The signiﬁcance of these ﬁndings remains to be ascer-
tained.
E06
CAN LEVAMISOLE UPREGULATE THE EQUINE CELL-
MEDIATED IMMUNE RESPONSE IN VITRO?. Amy San-
tonastaso1, Bettina Wagner2, Siobhan Ellison3, Virginia Maxwell1,
Scott Pleasant1, David Lindsay4, Sharon Witonsky1. 1Virginia-
Maryland Regional College of Veterinary Medicine, Blacksburg,
VA, USA, 2College of Veterinary Medicine, Cornell University,
Ithaca, NY, USA, 3Pathogenes, Inc., Reddick, FL, USA, 4Depart-
ment of Biomedical Sciences and Pathobiology, Virginia Tech,
Blacksburg, VA, USA
Equine Protozoal Myeloencephalitis (EPM) is arguably the
most common and costly equine neurologic diseases in the United
States. The national seroprevalence is >50%, but only 0.5–1% of
all horses develops disease during their lifetimes. Some EPM
aﬀected horses have decreased immune responses. A cell-mediated
immune response appears to be protective for development of
EPM after infection with S. neurona in mouse models. Therefore,
in addition to speciﬁc anti-protozoal medications, levamisole has
been proposed as an adjunctive therapy to upregulate the immune
response in EPM aﬀected horses. Studies have been performed in
other species to address whether levamisole alters immune function
in vitro or in vivo, but there are very limited studies in equids. We
hypothesized that We hypothesized that levamisole can upregulate
a cell mediated macrophage (M1) dendritic cell (DC1) CD4 T-
helper 1 (Th1) CD8 Tc1 immune response in vitro.
The ﬁrst aim was to determine both the optimal conditions and
eﬀects of levamisole on cellular proliferation. Equine PBMCs were
harvested from ten horses seronegative for S. neurona. Cells were
cultured alone, or with each of the following mitogens: con-
canavalin A (conA), phorbol 12-myristate 13-acetate and iono-
mycin (PMA/I), or with a combination of the above mitogens and
levamisole at several conditions. Cellular proliferation was assessed
using a colorimetric bromodeoxyuridine ELISA assay (Roche Life
Sciences, 11647229001).
The second aim was to determine the ability of levamisole,
under optimized conditions, to upregulate the M1 DC1 CD4Th1
CD8 Tc1 response in vitro, based on activation and function.
PBMCs from the same 10 horses were cultured with each of the
following, no stimulation, conA, and levamisole with and without
conA. To determine proliferation of each speciﬁc subset, cells were
labelled with a ﬂuorescent dye (CellTrace Violet, ThermoFisher
Scientiﬁc, C34557). Proliferation of each subset was determined
based on dye dilution using ﬂow cytometry (FacsAria Flow
Cytometer). To determine the ability of levamisole to upregulate
or alter the immune response, immune subsets were identiﬁed
(CD4, CD8, CD21, CD172a, CD14) using ﬂuorescent labelled
antibodies. Activation was assessed for macrophages and DCs
using MHC class II and CD86 expression. Induction of T-regs
was based on CD4, foxp3 expression. Speciﬁc immune phenotypes
were determined based on intracellular cytokine expression of
speciﬁc subsets (M1 DC1 CD4 Th1 CD8: IFN-gamma) versus
(M2 DC2 CD4 Th2: IL4) versus (CD4 T-reg: IL-10). Signiﬁcant
diﬀerences in response were determined using a mixed model
ANOVA with signiﬁcance set at P < 0.05.
Study results indicated that cells cultured with levamisole alone
did not alter PBMC proliferation compared to the response of
unstimulated cells. Cells cultured with either conA or PMA/I
resulted in a statistically signiﬁcant (P < .05) increase in prolifera-
tion compared to unstimulated cells. Cells cultured with conA and
levamisole at 1 µg/mL resulted in a signiﬁcant (P < .05) decrease
in proliferation compared with cells cultured with conA alone.
Flow cytometry data analysis results to assess how levamisole
directs the immune phenotype are currently pending.
These data demonstrate that, under these conditions, levamisole
downregulates conA stimulated PBMC proliferation. Based on
these in vitro results, further studies to determine the eﬀectiveness
of levamisole on modulating the equine immune system in vivo are
warranted.
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E07
NOVEL PHARMACOLOGICAL TREATMENT REGIMES IN
EQUINE ATRIAL FIBRILLATION. Helena Carstensen1, Eva Z.
Hesselkilde1, Jørgen K. Kanters2, Steen Pehrson3, Maria Mathilde
Haugaard1, Thomas Jespersen2, Rikke Buhl1. 1Department of
Large Animal Sciences, Faculty of Health and Medical Sciences,
University of Copenhagen, Taastrup, Denmark, 2Department of
Biomedical Sciences, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark, 3Department
of Cardiology, The Heart Centre, Copenhagen University Hospi-
tal, Copenhagen, Denmark
Atrial ﬁbrillation (AF) is the most common pathological
arrhythmia diagnosed in horses. Due to the adverse eﬀects encoun-
tered when treating with quinidine sulphate we wanted to improve
the medical treatment of AF. In this study we aimed to evaluate
the eﬀects of the antiarrhythmic compounds dofetilide and ranola-
zine in the equine heart. Furthermore, we hypothesized that the
use of a combination of two antiarrhythmic compounds with dis-
tinct mechanisms would allow us to use lower doses of each com-
pound and thereby minimize the risk of adverse eﬀects.
Three horses were included in a safety study testing administra-
tion of intravenous dofetilide (8.0 µg/kg BWT), ranolazine
(2.4 mg/kg BWT) and a combination of the two using similar
doses. The horses were monitored clinically for adverse reactions
and Holter monitor ECG recordings, as well as blood pressure
measurements, were obtained throughout the study. Following the
safety study, nine horses were included in an electrophysiological
study testing the eﬀects of dofetilide and ranolazine on electrical
induced AF. By placing two intraatrial electrodes we were able to
record atrial electrograms and perform atrial pacing for measure-
ments of atrial eﬀective refractory periods (aERPs) and induction
of AF. All horses went through four procedures (dofetilide and
ranolazine respectively, combination of the two drugs using lower
dosages and a control procedure where only saline was adminis-
tered) with 7 days wash out periods between treatments.
All horses tolerated both drugs and the combination well with-
out development of any clinical signs of discomfort or pain and
neither of the drugs resulted in alterations in blood pressures.
Plasma levels of cardiac Troponin I and creatinine kinase fraction
MB did not increase due to intraatrial pacing or any of the treat-
ments given. Ranolazine alone and the combination therapy termi-
nated AF faster than in control procedures (P = 0.0178). The
combination therapy resulted in decreased AF duration
(P = 0.0469) and AF vulnerability (P = 0.0213) but neither of the
treatments altered the aERP signiﬁcantly. Dofetilide signiﬁcantly
increased the QTc-interval at multiple time points. This was, how-
ever, not the case when lower doses of dofetilide were adminis-
tered in the combination procedures.
In this study dofetilide and ranolazine were safe to administer in
healthy horses and none of the compounds or the electrophysiolog-
ical procedure caused myocardial damage in the horses. When
dofetilide was given at a high dose the QT- interval prolonged indi-
cating altered ventricular repolarization. Ranolazine showed an
antiarrhythmic eﬀect against acutely induced AF in horses. By
combining dofetilide and ranolazine antiarrhythmic eﬀects were
obtained at low doses that would have been ineﬀective when
administered separately. These ﬁndings lead us to believe that com-
bination therapy may be a future treatment regime in equine AF.
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CAN EXERCISING ELECTROCARDIOGRAPHY PREDICT
PERFORMANCE IN YOUNG STANDARDBRED HORSES AT
THE START OF TRAINING?. Linda Frellstedt, Gareth Fitch,
Chris Rogers. Massey University, Palmerston North, New Zealand
The aim of this study was to describe the occurrence of cardiac
arrhythmias in young Standardbred horses that have recently
entered training, to determine whether cardiac arrhythmias are
consistently present during several training sessions and to evalu-
ate if performance can be predicted based on the type and fre-
quency of observed arrhythmias.
Fifty-one Standardbred horses (aged 2–4 years, 16 F, 32 G,
2 M) were examined during multiple training sessions over a three
month period. Resting and exercising electrocardiograms (Holter
monitor, Televet) as well as exercising speeds (GPS, Polar)
were recorded. Descriptive statistics were used to analyze the data.
In total 120 training sessions were recorded. Thirty horses com-
pleted 3 training sessions, 8 horses completed 2 training sessions
and 13 horses completed one training session. Single or multiple
arrhythmias were observed during 42/120 (35%) sessions in a total
of 30/51 horses. Secondary AV-block at rest was observed during
15/120 sessions. Ventricular premature contractions (VPCs) were
recorded during 20/120, supraventricular premature contractions
(SVPCs) during 4/120, and sinus arrhythmias (SAs) during 9/120
sessions. Thirteen horses dropped out of training after their ﬁrst
training session, 7/13 (54%) of these had arrhythmias, 3/7 had
VPCs, 2/7 has SVPCs and 2/7 has SAs. Three horses dropped out
of training after two sessions, all of them had arrhythmias
(100%), 2/3 had VPCs and 1/3 had SA. In 5/51 (9.8%) horses,
arrhythmias were consistently recorded during several training ses-
sions. Horses that dropped out of training had >5 VPCs per ses-
sion (mean of 11.14  7.66).
Cardiac arrhythmias are commonly observed in young Stan-
dardbred horses that have recently entered training. Horses with
cardiac arrhythmias observed during multiple training sessions and
with more signiﬁcant abnormalities may be less likely to continue
training and to reach their ﬁrst trials.
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IS ECG IN HORSES ONLY FOR DYSRHYTHMIA
DIAGNOSIS? INTRODUCING A NEW METHOD FOR
12-LEAD ECG. Eva Z. Hesselkilde1, Helena Carstensen1, Bettina
Vandsø1, Thomas Jespersen2, Jørgen Kanters2, Rikke Buhl1.
1Department of Large Animal Sciences, Faculty of Health and
Medical Sciences, University of Copenhagen, Copenhagen,
Denmark, 2Department of Biomedical Sciences, Faculty of Health
and Medical Sciences, University of Copenhagen, Copenhagen,
Denmark
ECG is an invaluable diagnostic tool in human cardiology
where conditions such as left ventricular hypertrophy (LVH) and
bundle branch block can be diagnosed based on the 12-lead ECG.
Guidelines for 12-lead ECG in horses exist. These guidelines have
imitated the human electrode placement with the limb leads
recorded from the extremities and the precordial leads on the tho-
rax. However, the diﬀerent orientation of the equine heart alters
Einthoven’s triangle and Wilson’s Central Terminal (WCT) and
thereby changing the basis of the recordings.
The aim of this study was to evaluate if a diﬀerent electrode place-
ment based on the physiological ideas of the human Einthoven’s tri-
angle and WCT may provide better information about the equine
atria and ventricles compared to the standard extremity leads.
Development of the new method for 12-lead ECG recordings
was performed by placing the limb electrodes at right and left sca-
pula and in the midline caudal to the xiphoid process. This will
place WCT in the middle of the heart and Einthoven’s triangle will
be nearly perpendicular to the main cardiac depolarization vector.
By placing the precordial leads between the superﬁcial pectoral
muscles (V1), on the ventral part of both the left and right triceps
muscle (V2 and V6), in the 6st intercostal space, in level of the
shoulder joint of the left side (V3) and in level of the elbow joint
on both sides (V4 and V5), information from all heart chambers
would be recorded. 35 Standardbred horses (14 mares, 15 geldings
and 6 stallions. Mean age: 5.8 years range 2–14) had ECGs
recorded using both the existing method and the new modiﬁed
method. All horses had an echocardiographic examination per-
formed to measure atrial (left atrium area (LAA) and left atrium
diameter (LAD)) and ventricular size (including calculation of LV
mass). All waves from each lead were measured and all data were
blinded before analyses.
Comparing the various leads of the ECGs from the two meth-
ods showed a signiﬁcant increase in both P wave amplitude and
duration in the new modiﬁed method (P < 0.0005). Signiﬁcant cor-
relation between P wave duration and LAA and LAD was found
for the new modiﬁed method (P < 0.0005, R2=0.32 and P < 0.005
R2=0.27, respectively). When amplitudes of R and S wave was
added, signiﬁcant correlation to LV mass was found for the new
modiﬁed method (P = 0.0005, R2=0.31) while the existing method
did not (P = 0.08, R2=0.01). Also, signiﬁcant correlation between
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mean QRS duration and LV mass were found for the new modi-
ﬁed method (P < 0.005, R2=0.22) but not for the existing method
(P = 0.54, R2=0.01).
This study shows that the new method were better correlated
with left atrial size and LV mass suggesting that the correction of
Einthoven’s triangle WCT gives better results when obtaining 12-
lead ECGs in horses.
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HUMORAL HYPERCALCEMIA OF MALIGNANCY IN
HORSES: A RETROSPECTIVE STUDY (2010–2015). Kate Hep-
worth-Warren1, Stephanie Caston2. 1Rancocas Veterinary Associ-
ates, Mount Holly, NJ, USA, 2Iowa State University, Ames, IA,
USA
The reported frequency of neoplasia in the horse is low but is
likely under-reported due to the diﬃculty of establishing a deﬁni-
tive diagnosis. Clinical signs may be vague, and neoplasia is often
identiﬁed only at post-mortem examination. Delays in diagnosis
may lead to increased morbidity whereas deﬁnitive diagnoses in
terminal cases provide objective evidence in electing for humane
euthanasia. Humoral hypercalcemia of malignancy is a common
paraneoplastic syndrome in other species, and could be utilized to
aid in the identiﬁcation of equine neoplasia. The objectives of this
study were to identify the prevalence of hypercalcemia among
horses with neoplasia, and to compare calcium, albumin, and the
relationship between these values in horses with neoplasia, systemi-
cally ill horses without neoplasia, and healthy animals.
An electronic medical record search was performed to identify
all horses over 6 months of age on which serum total calcium and
albumin were measured. Eligible cases grouped by diagnosis:
neoplasia (n = 43), sick non-neoplasia (n = 466), and healthy/
orthopedic (n = 55). The sick non-neoplasia group was further
sub-divided based on the body system aﬀected by disease for addi-
tional comparisons. Exclusion criteria included lack of deﬁnitive
diagnosis or a diagnosis of renal disease or rhabdomyolysis.
Preliminary data identiﬁed higher calcium and lower albumin in
the neoplasia group when compared to the sick non-neoplasia
group. The calcium:albumin ratio was higher in the neoplasia
group than in the healthy/orthopedic group, and lower than the
sick non-neoplasia group. This data suggests that hypercalcemia
may support a diagnosis of neoplasia in equine patients.
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DEVELOPMENT OF A TECHNIQUE FOR DETERMINA-
TION OF PULMONARY ARTERY PULSE WAVE VELOCITY
IN HORSES. Goncalo Silva1, Bruce Guest2, Diego Gomez1,
Martine McGregor2, John Runciman2, Laurent Viel1, Luis
Arroyo1. 1Departement of Clinical Studies, University of Guelph,
Guelph, ON, Canada, 2School of Engineering, University of
Guelph, Guelph, ON, Canada
Calciﬁcation of the tunica media of the main pulmonary arteries
has been observed in a large proportion of young racehorses. In
humans, medial calciﬁcation is the most important cause of
increased arterial stiﬀness, and has been implicated in the patho-
genesis of cerebral and renal microvascular diseases. Pulse wave
velocity (PWV) is a marker of arterial stiﬀness. This study aimed
to develop a technique for determination of pulse wave velocity of
the main pulmonary arteries of horses.
A convenience sample of 9 adult horses with no history of respi-
ratory or cardiovascular disease were used. The horses were
sedated for catheter placement, and continuously monitored with
electrocardiography during the procedure. The pulmonary artery
(PA) trunk was cannulated via right heart catheterization, with a
catheter introducer sheath (9Fr x 100 cm). Introducer placement
was guided with echocardiography. A custom-made dual pressure
sensor catheter (PSC) (7Fr x 170 cm) was inserted through the
introducer sheath, and into one of the main branches of the PA.
The position of the PSC in one of the main branches of the PA
was conﬁrmed with thoracic radiography. The catheter was
withdrawn in 5 cm steps and pressure measurements were
recorded at each location. The time delay of the pulse waves
between the two sensors was used to calculate PWV. Histology of
the PA trunk and main branches was performed to investigate the
presence of medial lesions and calciﬁcation.
The PSC placement was successfully achieved in all horses (9/9),
without signiﬁcant complications, aside from transient arrhyth-
mias. The catheter was more commonly located on the left PA
(8/9). At the time of pressure measurements, the level of sedation
was variable between horses. The mean (SD) PWV, was
2.3  0.7 m/s in the proximal PA trunk and 1.1  0.1 m/s further
distal (20 cm), in a main PA branch. The mean (SD) of mean
arterial pressures in the proximal PA trunk was 30.1  5.2 mmHg,
and 22.0  6.0 mmHg further distal (20 cm), in a main PA
branch. The mean (SD) pulse pressure in the proximal PA trunk
was 15.0  4.7 mmHg, and 13.5  3.3 mmHg further distal
(20 cm), in a main PA branch. Five out of nine horses presented
moderate to severe lesions and calciﬁcation of the tunica media of
the PA trunk and/or main branches.
This study demonstrated the feasibility of a technique to deter-
mine PA-PWV in standing horses. The technique developed may
allow further investigation of the eﬀect of calciﬁcation of large
pulmonary arteries in the development of pulmonary microvascu-
lar disorders in horses.
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REPEATED MEASUREMENTS OF AUTONOMIC TONE
MARKERS OVER A TRAINING SEASON IN EVENTING
AND ENDURANCE HORSES. Olivia Lorello1, Alessandra Ram-
seyer1, Dominik Burger1, Vinzenz Gerber1, Rupert Bruckmaier1,
Han Van der Kolk1, Cristobal Navas de Solis2. 1University of
Bern, Bern, Switzerland, 2Texas A&M University, College Station,
TX, USA
The purpose of this study was to describe normal values and
changes over a competition season of markers of autonomic tone
in competing eventing (EV) and endurance (EN) horses, in con-
junction with previously reported variables to monitor training
and compare these to non-competitive breed-matched controls
(EVc and ENc).
26 EV, 13 EVc, 11 EN and 7ENc started the project. Heart rate
variability (HRV), non-invasive blood pressure (NIBP), splenic
volume, pre- and post-exercise hematocrit and cortisol, standard-
ized exercise tests (SETs) and muscle enzyme activities, were mea-
sured pre-season (T1), mid-season (T2) and at the peak/end of the
competition season (T3).
HRV was lower (P < 0.05) in EV than in EVc at all times and
post-exercise cortisol lower at T3. There were no signiﬁcant diﬀer-
ences in EN versus ENc. HRV and post-exercise cortisol did not
change over the season in any group. EV had higher ﬁtness markers
during SETs compared to EVc, but there was no diﬀerence between
EN and ENc. NIBP, splenic volume, hematocrit, pre-exercise corti-
sol, muscle enzyme activities, and weight were not signiﬁcantly dif-
ferent between groups and did not change over the season.
In conclusion, competing eventing horses showed higher sympa-
thetic tone and lower post-exercise cortisol than controls. NIBP,
splenic volume and resting or post-exercise hematocrit did not
detect changes in autonomic tone in this population. The studied
markers of autonomic tone did not change signiﬁcantly through-
out the season in any group and did not detect changes in compet-
ing endurance horses compared to controls.
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EPIDEMIOLOGICAL CHARACTERISTICS OF HORSES
WITH HYPERINSULINEMIA IN A LARGE POPULATION
OF HORSES. Steven Grubbs1, Dwana Neal1, Thomas Keefe2.
1Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA,
2Colorado State University, Fort Collins, CO, USA
Pituitary pars intermedia dysfunction (PPID) and Equine Meta-
bolic Syndrome (EMS) have been described as the most common
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endocrinologic disorders in horses. Few large studies exist that
describe the epidemiological characteristics of horses with these
endocrine diseases. The purpose of this study was to obtain infor-
mation that included age, breed, sex, clinical signs, and ACTH/in-
sulin/glucose status at initial diagnosis of potential endocrine cases
(new cases) to determine the epidemiological characteristics of
horses with hyperinsulinemia.
Horses of any age, breed, and sex from the continental US were
eligible for study enrollment as long as they were documented to
be exhibiting one or more of the following clinical signs: general-
ized or regional hypertrichosis, muscle wasting, abnormal fat dis-
tribution, lethargy, laminitis (unknown etiology), polyuria,
polydipsia, susceptibility to infections, abnormal sweating, and/or
inappropriate lactation. Normal horses were excluded from the
study. At initial visit, demographic data, signalment, a physical
examination was conducted. Clinical signs were documented and
blood was drawn for basal ACTH, fasting insulin, and glucose.
Blood samples were processed and shipped overnight to the Ani-
mal Health Diagnostic Center, Cornell University, Ithaca, NY for
analysis. The association between hyperinsulinemia (based on fast-
ing insulin results), clinical signs and glucose were statistically
evaluated individually using the Pearson chi-square test. Odds
ratios for signiﬁcant predictors of hyperinsulinemia were computed
using corresponding 95% conﬁdence intervals when applying mul-
tiple logistic regression analysis.
Four-hundred eighteen of nine-hundred eighty two horses with
complete epidemiological information were included in the ﬁnal data
analysis. Of the 418 horses, 221 (52.8%) were HI+. Further, horses
were stratiﬁed into 1 of 3 groups based on ACTH and insulin labo-
ratory results (PPID+/HI+), (PPID-/HI+), and (PPID-/HI-). Of the
418 horses, 115 (27.5%) were PPID+/HI+, 106 (25.3%) were
PPID-/HI+, and 197 (47.1%) were (PPID-/HI-). Of the 418 horses
evaluated, 9.6% of horses <15 years of age were PPID+HI+, 23.5%
of horses 15 to 19.9 years of age were PPID+HI+, 27.8% of horses
20 to 24.9 years of age were PPID+HI+, and 39.1% of horses
>25 years of age were PPID+HI+. Further, 47.3% of horses
<15 years of age were HI+, 61.2% of horses 15 to 19.9 years of age
were HI+, 46.7% of horses 20 to 24.9 years of age were HI+, and
44.8% of horses >25 years of age were HI+. One-hundred ninety
seven of 418 horses were PPID-HI-.
Analysis for PPID+/HI+ and PPID-/HI+ horses was evaluated.
Based on the data for clinical signs only in the PPID-/HI+ horses,
HI was signiﬁcantly (P < 0.000) greater among horses with cresty
neck and laminitis present. Although not statistically signiﬁcant
(P > 0.025), HI was greater in horses with 2 other clinical signs;
abnormal sweating and pot belly/weight gain. Based on clinical
signs data, the odds of HI in horses with cresty neck was more
than twice (2.3X) that for horses without this clinical sign. Simi-
larly for horses with laminitis, the odds ratio of HI was more than
twice (2.2X) that for horses without this clinical sign.
Of the 418 enrolled horses, 52.8% were diagnosed with hyperin-
sulinemia. Based on the combined data of clinical signs (11 inter-
pretable), glucose levels and fasting status, cresty neck, laminitis
and high glucose were signiﬁcant predictors of HI. Speciﬁcally,
horses with high glucose levels were seen to have almost four times
the odds (3.5X) of HI compared to those with normal glucose
levels. Therefore, when evaluating horses with suspected endocrine
disease, at a minimum, ACTH, insulin and glucose should be eval-
uated. Long term studies need to be conducted in large popula-
tions of horses to further evaluate endocrinopathies in horses.
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MANAGEMENT OF EARLY PPID IN HORSES. John Haﬀner1,
Christine Cocquyt2, Dwana Neal3, Steven Grubbs3, Thomas
Keefe4. 1Middle Tennessee State University, Murfreesboro, TN,
USA, 2Tennessee Equine Hospital, Thompson Station, TN, USA,
3Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA,
4Colorado State University, Fort Collins, CO, USA
Pituitary Pars Intermedia Dysfunction (PPID) has previously
been diagnosed and managed as an older horse disease with
advanced clinical signs. However, in early PPID, the clinical signs
are typically more subtle. Clinical signs of early PPID include:
decreased athletic performance, change in attitude/lethargy,
delayed hair coat shedding (subtle), regional hypertrichosis, loss of
epaxial muscle mass (topline), regional adiposity, and laminitis.
One of the major limitations of diagnostic testing for PPID is the
sensitivity of available diagnostic assays. Thyrotropin-releasing
hormone (TRH) stimulation test has been shown to have an
increased sensitivity of detecting horses with early PPID compared
to resting ACTH. Few studies exist concerning endocrinologic test-
ing and follow-up monitoring the clinical progression and diagnos-
tic assay results following treatment in horses with early PPID.
The purpose of this study was to identify cases of early PPID
based on clinical signs and laboratory testing then determine
improvements in ACTH levels using resting ACTH, TRH stimula-
tion test, and clinical signs over time.
Sixteen horses were enrolled (January) with at least one clinical
sign of early PPID listed above and diagnostically conﬁrmed by
the TRH stimulation test measuring ACTH at 0 (T0ACTH;
pre-TRH) and 10 (T10ACTH) min following 1 mg i.v. TRH
administration. Fasting insulin and glucose was also determined
pre-treatment and at each follow-up visit. Each horse was adminis-
tered Prascend (pergolide mesylate) orally at a starting dosage of
2 mcg/kg once daily, dosage adjusted to eﬀect if required, but not
to exceed 4 mcg/kg daily, per manufacturers label recommenda-
tions. A history, physical examination, and TRH stimulation test
evaluating T0ACTH and T10ACTH was conducted for 5 months
(February through June) following initial treatment administra-
tion. The comparative changes to the baseline ACTH levels over
time were evaluated using descriptive statistics. The statistical sig-
niﬁcance of the change in ACTH levels to be evaluated using a
conﬁdence interval of 95%.
At initial examination, the most common clinical signs at initial
diagnosis were regional hypertrichosis (9/16), delayed shedding
(5/16) and muscle wasting (4/16). The baseline (arithmetic mean)
for T0ACTH and T10ACTH for all horses was 44.6 pg/mL and
360.5 pg/mL, respectively. Following six-months of treatment, the
resting T0ACTH in 12 of 16 (75%) horses were less than normal
reference range (35 pg/mL), whereas 7 of 16 (44%) of horses had
T10ACTH less than the recommended T10ACTH reference range
(110 pg/mL). In June, the decrease from baseline for T0ACTH
was 7.1%; whereas the decrease from baseline for T10ACTH was
49.1%. All horses with regional hypertrichosis and delayed shed-
ding were considered improved or resolved, whereas body condi-
tion and muscle wasting was slightly improved. Four adverse
events not related to treatment were reported and considered
resolved within 24 hours.
All horses had improvements in clinical signs following treat-
ment. No signiﬁcant changes from baseline were observed in insu-
lin or glucose parameters. Following 5 months of treatment, 12 of
16 (75%) horses T0ACTH decreased below normal range com-
pared to 7/16 (44%) T10ACTH that decreased below the recom-
mended reference range. Although all horses responded clinically,
the T10ACTH in 9/16 (54%) horses remained positive. Even
though T10ACTH did not decrease below reference range, the
option to hold the treatment dosage at the same level is justiﬁable
based on clinical sign improvement. Further long term studies in
large numbers of horses should be conducted in horses with early
PPID.
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DEVELOPMENT OF AN OCTREOTIDE RESPONSE TEST
FOR DETECTION OF INSULIN DYSREGULATION IN
HORSES. Nicholas Frank1, Pilar Hermida1, Alfredo Sanchez-
Londono1, Cassandra Uricchio2, Ranee Singh3. 1Cummings
School of Veterinary Medicine at Tufts University, North Grafton,
MA, USA, 2Stockbridge School of Agriculture, University of Mas-
sachusetts, Amherst, MA, USA, 3Veterinary Medicine Faculty,
Khon Kaen University, Khon Kaen, Thailand
Octreotide is a somatostatin analog that suppresses insulin
secretion and we hypothesized that an octreotide response test
(ORT) could be developed to detect insulin dysregulation (ID).
Twelve Morgan horses were included and insulin status was
assessed with the oral sugar test (OST). An ORT was then per-
formed by fasting horses overnight and administering octreotide
IV at a dosage of 1 lg/kg. Blood was collected at 0, 5, 10, 15,
20, 25, 30, 45, 60, 75, and 90 minutes, and 2, 3, 4, 6, 8, 12,
and 24 h.
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Mean AUCg did not diﬀer signiﬁcantly between normal (n = 5)
and ID (n = 7) groups, but mean glucose concentrations at 75,
180, 240, and 360 minutes were signiﬁcantly (P < 0.05) higher in
the ID group, when compared with t-tests. Mean AUCi was signif-
icantly higher (P = 0.003) in the ID group when compared with
the normal group. Mean plasma insulin concentrations diﬀered
signiﬁcantly between groups at 180, 240, 360, and 480 minutes. A
signiﬁcant time eﬀect (P < 0.001) was detected and there was a
trend towards higher insulin concentrations over time (group 9
time; P = 0.091).
Results show that insulin concentrations decrease within
60 minutes of octreotide administration and hyperglycemia devel-
ops as a result. As the eﬀects of octreotide wane, insulin concen-
trations increase above the pre-injection baseline as more insulin is
secreted to regain glycemic control. The magnitude of the increase
in insulin concentrations reﬂects insulin sensitivity, as evidenced by
the higher AUCi values detected in horses from the ID group.
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INSULIN AND INCRETIN HORMONE CONCENTRATIONS
IN HORSES DURING AN ORAL SUGAR TEST AND
PASTURE CHALLENGE. Nicholas Frank1, Pilar Hermida1,
Alfredo Sanchez-Londono1, Cassandra Uricchio2. 1Cummings
School of Veterinary Medicine at Tufts University, North Grafton,
MA, USA, 2Stockbridge School of Agriculture, University of
Massachusetts, Amherst, MA, USA
An oral sugar test (OST) is used to assess insulin status in
horses and this study was undertaken to test the hypothesis that
test results are closely correlated with blood insulin responses to
grazing on pasture grass. Correlations among insulin and incretin
hormone concentrations were also assessed to better understand
mechanisms of hyperinsulinemia in horses.
Eight Morgan horses from the University of Massachusetts herd
were fasted overnight and then subjected to an OST over 180 min-
utes, immediately followed by turnout on pasture grass. Blood
samples were collected at 0, 30, 60, 75, 90, 120, 150, 180, 240, 300,
360, 420, and 540 minutes. Plasma active and total glucagon-like
peptide-1 (aGLP-1 and tGLP-1, respectively) and glucose-
dependent insulinotropic polypeptide (GIP) concentrations were
measured, along with glucose and insulin concentrations. Peak
concentrations and area under the curve values were compared
between the OST (0 to 180 minutes) and pasture challenge (180 to
540 minutes).
Peak insulin concentration (rs = 0.83; P = 0.015) and area under
the insulin curve values (rs = 0.95; P = 0.001) were positively cor-
related between the OST and pasture challenge. Area under the
tGLP-1 curve (0–540 minutes) and area under the GIP curve were
correlated with one another (rs = 0.76; P = 0.037), but did not cor-
relate with area under the insulin curve. Active GLP-1 concentra-
tions are pending.
Our hypothesis was supported and we conclude that the OST can
be used to predict insulin responses to grazing on pasture grass.
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ASSOCIATION OF ANDROGENS AND PREGNANES
RESPONSE TO ACTH STIMULATION WITH ADRENAL
DYSFUNCTION IN HOSPITALIZED FOALS. Katarzyna
Dembek1, Jillian Minuto1, Teresa Burns1, Bonnie Barr2, Nathan
Slovis3, Ramiro Toribio1. 1The Ohio State University, College of
Veterinary Medicine, Columbus, USA, 2Rood and Riddle Equine
Hospital, Lexington, USA, 3Hagyard Equine Medical Institute,
Lexington, USA
Sepsis continues to cause high mortality in human and equine
neonates. The hypothalamic-pituitary-adrenal axis is activated dur-
ing sepsis to increase cortisol concentrations; however, the secre-
tion of cortisol can be insuﬃcient for the severity of disease in a
number of sick foals. Our group and others have shown that rela-
tive adrenal insuﬃciency (RAI), characterized by a poor cortisol
response to adrenocorticotropin (ACTH), is associated with
mortality and severity of disease in foals. Most studies investigat-
ing RAI in equine patients have been focused on cortisol, while
other adrenocortical steroids have been overlooked.
We hypothesized that a high dose ACTH stimulation test will
stimulate the release of multiple adrenocortical steroids; however,
RAI in septic foals will be characterized by a weak glucocorticoid
and mineralocorticoid response, but normal androgen and preg-
nane response when compared to healthy foals and sick foals with
normal adrenocortical function. We also proposed that the steroid
response to ACTH will be associated with severity of disease.
Foals <1 day of age (n = 25) were categorized into 3 groups:
septic (n = 5), sick non-septic (SNS; n = 10) and healthy (n = 10).
After baseline blood sample collection on admission (time 0), foals
received ACTH (100 µg, IV). Additional samples were collected at
30 and 90 minutes post-ACTH. Hormone concentrations were
determined by immunoassays. The delta hormone was deﬁned as
the percent concentration change between time 0 and 30 minutes
(Delta0–30).
Septic and SNS foals had higher pregnenolone, progesterone,
17a-OH-progesterone and estradiol compared to healthy foals at
all 3 time points (P < 0.05). Cortisol, aldosterone and androstene-
dione concentrations were higher in septic and SNS than healthy
foals at time 0 and 90 minutes (P < 0.05). The Delta0–30 was lower
in septic compared to healthy foals for cortisol and aldosterone
(P < 0.05). Septic foals had higher dehydroepiandrosterone
(DHEA) Delta0–30 than healthy foals (P < 0.05).
This study shows that an impaired response to ACTH in septic
foals involves multiple adrenocortical steroids. The increased
DHEA response to ACTH stimulation might be a good indicator
of RAI in septic foals.
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ASSOCIATION OF OXYTOCIN AND NEUROSTEROIDS
WITH NEONATAL MALADJUSTMENT SYNDROME (NMS)
IN HOSPITALIZED FOALS. Katarzyna Dembek1, Caroline
Brown1, Margaret Mudge1, Steven Reed2, Barry David3, Ramiro
Toribio1. 1The Ohio State University, College Of Veterinary Medi-
cine, Columbus, USA, 2Rood and Riddle Equine Hospital, Lex-
ington, USA, 3Hagyard Equine Medical Institute, Lexington, USA
Neonatal maladjustment syndrome (NMS) is a common illness
of newborn foals. Neuroactive steroids (pregnanes, androgens)
participate in neurological development; imbalances have been
implicated in human disorders, and more recently in the pathogen-
esis of NMS. Oxytocin regulates uterine contraction, lactation,
and social functioning. Oxytocin modulates neurosteroid actions
and neurosteroids (pregnanes) can stimulate oxytocin release in
growing animals. Oxytocin release may be altered in human
patients with a variety of neurological disorders; however, the role
of oxytocin in pathologies of newborn foals, including sepsis and
NMS, has not been investigated.
We hypothesized that foals with NMS and sepsis will have
higher oxytocin and neurosteroids concentrations compared to
healthy foals. We also proposed that concentrations of neuroactive
steroids and oxytocin will be associated with outcome.
Blood samples were collected on admission from 23 foals with
NMS, 37 foals with other neonatal diseases and 15 healthy foals
of <3 days of age. Blood concentrations of steroids and oxytocin
were determined by immunoassays.
Oxytocin concentrations were higher in foals with NMS com-
pared to healthy foals but lower in foals with other disorders
including sepsis compared to healthy and NMS foals (P < 0.05).
Sick foals (NMS and other diseases) had increased cortisol, aldos-
terone, 17a-OH-progesterone, progesterone and pregnenolone con-
centrations compared to healthy foals (P < 0.05). There were no
diﬀerences in steroid concentrations between foals with NMS and
other diseases. Progesterone concentration was higher in sick non-
surviving foals compared to survivors (P < 0.05). Androstenedione
and dehydepiandrosterone concentrations were not diﬀerent
between groups of foals.
Due to its neuronal modulatory actions, our study suggests that
oxytocin concentration may be involved in the pathogenesis of
NMS and other disorders of the equine neonate. Hyperproges-
teronemia was associated with NMS, sepsis, and poor prognosis
for survival in hospitalized foals.
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IDENTIFICATION OF GENETIC LOCI UNDERLYING
EQUINE METABOLIC SYNDROME AND LAMINITIS RISK
IN WELSH PONIES. Elaine Norton1, Nichol Schultz1, James
Mickelson1, Ray Geor2, Molly McCue1. 1University of Minnesota,
Saint Paul, MN, USA, 2Massey University Colllege of Science,
Palmerston North, New Zealand
Equine metabolic syndrome (EMS), a clustering of clinical signs
including insulin resistance and dyslipidemia, is the most common
cause of laminitis, a painful and life-threatening disease of the
horse’s hoof. In a large across-breeds study of metabolic variation
in horses, our lab demonstrated that EMS phenotypic variability
in metabolic traits is inﬂuenced by genetic and environmental fac-
tors. Further, we demonstrated that certain features of the EMS
phenotype are diﬀerent between breeds. The objective of this pro-
ject was to identify genomic regions contributing to EMS by per-
forming a genome-wide association study (GWAS) in a cohort of
232 Welsh ponies phenotyped for 11 metabolic traits. Individuals
were genotyped on one of two SNP arrays (670,000 to 1,800,000
SNPs); the software program Beagle was used to generate a uni-
form set of makers across both platforms (~1.8 million SNPs).
GWAS was performed using a mixed linear regression model that
included a random polygenic term determined from a genomic
relationship matrix calculated from select trait associated SNPs,
random herd eﬀect, and ﬁxed covariates sex and age. Signiﬁcant
loci were identiﬁed for several EMS traits. Speciﬁc examples
include loci on ECA1 (P = 5.04e-08) and ECA15 (P = 5.43e-12)
for fasting adiponectin and triglyceride levels, respectively. For
fasting insulin levels, signiﬁcant loci were identiﬁed on ECA18
(P = 4.77e-10) and ECA6 (P = 4.33e-09). Candidate genes in these
regions include a gene associated with obesity in humans on
ECA18, and a gene associated with height and insulin resistance
on ECA6. Future directions include haplotype analysis and inter-
rogation of these regions through whole genome sequencing.
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THE FIBROBLAST GROWTH FACTOR-23/KLOTHO AXIS
IN HEALTHY AND HOSPITALIZED FOALS. Ahmed Kamr1,
Katarzyna Dembek1, Blake Hildreth III1?^!"number(boolean(fol-
lowing-ibling::degrees))",1, Stephen Reed2, Nathan Slovis3, Bonnie
Barr2, Ahmed Zaghawa4, Ramiro Toribio1. 1College of Veterinary
Medicine, The Ohio State University, Columbus, OH, USA,
2Rood and Riddle Equine Hospital, Lexington, KY, USA, 3Hag-
yard Equine Medical Institute, Lexington, KY, USA, 4Faculty of
Veterinary Medicine, University of Sadat City, Sadat City, Egypt
Hyperphosphatemia, hypocalcemia, increased parathyroid hor-
mone (PTH), and reduced vitamin D metabolite concentrations
were recently documented in critically ill foals by our group. How-
ever, information on ﬁbroblast growth factor-23 (FGF-23) and
klotho, two factors that regulate vitamin D activation and PTH
secretion, and their association with calcium, phosphorus, PTH,
and vitamin D concentrations in healthy and hospitalized foals is
lacking. FGF-23 is released by osteocytes in response to increased
1,25(OH)2D3, PTH, and phosphorus concentrations. FGF-23 sup-
presses renal 1a-hydroxylase activity and PTH synthesis. Klotho is
secreted by the kidneys and acts as a co-receptor for FGF-23. The
goal of this study was to determine the relevance of FGF-23 and
klotho in calcium, phosphorus, PTH, and vitamin D regulation,
including their association with clinical and laboratorial ﬁndings,
disease severity and outcome in hospitalized foals. We hypothe-
sized that elevated FGF-23 and reduced klotho concentrations will
be frequent, associated with calcium and phosphorus dysregula-
tion, PTH and vitamin D metabolite (25(OH)D3, 1,25(OH)2D3)
concentrations, severity of illness, and mortality in critically ill
foals.
One hundred newborn foals ≤ 3 days old divided into hospital-
ized (n = 83; 59 septic, 24 sick non-septic [SNS]) and healthy
(n = 17) groups were included. Blood samples were collected on
admission. Serum FGF-23, klotho, PTH, and vitamin D metabo-
lites were measured by immunoassays. Data were analyzed by
non-parametric methods and logistic regression.
Serum FGF-23 concentrations were signiﬁcantly higher while
klotho, 25(OH)D3, and 1,25(OH)2D3 concentrations were
signiﬁcantly lower in septic and SNS compared to healthy foals
(P < 0.01). Septic foals had higher phosphorus and PTH, and low
calcium concentrations than SNS and healthy foals (P < 0.05). In
hospitalized and septic foals, serum FGF-23 concentrations were
associated with phosphorus and PTH (P < 0.05), but not with cal-
cium and vitamin D metabolite concentrations (P > 0.05). In sep-
tic foals, serum klotho concentrations were positively associated
with 1,25(OH)2D3 concentrations (rs =0.42; P = 0.01). Hospitalized
foals with the highest FGF-23 and lowest klotho concentrations
were more likely to die (OR= 3.1; 95% CI = 1.2–9.1; OR=3.6;
95% CI=1.4–10.0, respectively).
High FGF-23 and low klotho concentrations in the presence of
elevated phosphorus and PTH concentrations suggests that FGF-
23 resistance may be involved in the pathogenesis of mineral and
endocrine disorders of critically ill foals.
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EFFECT OF RRR-ALPHA-TOCOPHEROL FORMULATION
ON SERUM AND CSF ALPHA-TOCOPHEROL CONCEN-
TRATIONS IN VITAMIN E DEFICIENT HORSES. Jennifer C.
Brown1, Stephanie J. Valberg1, Mattie Hogg1, Carrie J. Finno2.
1University of Minnesota, College of Veterinary Medicine, St Paul,
MN, USA, 2University of California, School of Veterinary Medi-
cine, Davis, CA, USA
Alpha-tocopherol (a-TP) deﬁciency in horses can lead to nutri-
tional myodegeneration, neuraxonal dystrophy, vitamin E deﬁcient
myopathy or motor neuron disease depending on its temporal
occurrence and individual susceptibility. In the absence of ade-
quate grass pasture, a-TP supplementation is becoming increas-
ingly important and, due to better bioavailability, the “natural”
isoform of a-TP, RRR-a-TP, is increasingly being used. RRR-a-
TP is available in two formulations, a water-dispersible liquid and
an acetate powder, with a more rapid increase in serum a-TP
occurring with the more expensive liquid RRR-a-TP. RRR-a-TP
acetate is often used for long-term supplementation however, due
to the higher cost of liquid RRR-a-T.
The objective of this eight-week study was to compare serum
and cerebrospinal ﬂuid (CSF) a-TP concentrations in three groups
of horses that had serum a-TP concentrations of <2 µg/mL.
Groups were 1) no a-TP (n = 5), 2) 5000 IU daily of RRR-a-TP
acetate (n = 7) and 3) 5000 IU daily of RRR-a-TP liquid, transi-
tioning to 5000 IU daily of acetate (n = 7). The transition was; liq-
uid RRR- a-TP (2 weeks), transition (4 weeks) and RRR-a-TP
acetate (2 weeks). Horses appeared healthy and were fed the same
diet of hay cubes in a dry lot. Serum samples were obtained weekly
and atlanto-occipital CSF ﬂuid was obtained before and after the
eight-week supplementation period. A GLM ANOVA with post
hoc Bonferroni pair wise comparisons (P < 0.05) was performed.
Beginning in week 1, serum a-TP was signiﬁcantly higher in the
liquid to acetate RRR-a-TP transition group than in the acetate
and the no supplement groups. Serum a-TP increased more gradu-
ally in the RRR-a-TP acetate group and was signiﬁcantly higher
than in the no supplement group. CSF a-TP increased signiﬁcantly
between pre and post supplementation in the liquid to acetate
RRR-a-TP group only.
In conclusion, for horses deﬁcient in a-TP, the fastest and high-
est increase in serum a-TP was obtained using water-dispersible
RRR-a-TP. A regimen of RRR-a-TP water-dispersible product,
tapered to RRR-a-TP acetate, provided an eﬀective means to
rapidly and sustainably increase a-TP in serum and CSF over an
eight-week period.
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DIFFERENTIAL GENE EXPRESSION IN EQUINE SUBCU-
TANEOUS AND INTERNAL ADIPOSE DEPOTS. Ann Kemper,
James Mickelson, Molly McCue. University of Minnesota, St Paul,
MN, USA
Equine metabolic syndrome is characterized by regional adipos-
ity, insulin resistance, predisposition to laminitis, and activated
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inﬂammation. Regional adiposity in horses is characterized by sub-
cutaneous fat deposits at the nuchal ligament, behind the shoulder,
and at the tail head, and increased neck circumference is associated
with insulin resistance. In humans and mice, visceral fat is associ-
ated with insulin resistance and development of diabetes, and is
more metabolically active than other fat depots. In contrast, candi-
date gene expression studies in horses have suggested that nuchal
fat may be more metabolically active than visceral fat. We have
collected samples from six adipose tissue depots within the horse;
nuchal, shoulder, tail head, (subcutaneous, SQ) and visceral, omen-
tal, and retroperitoneal (internal) in six horses of varying age,
breed, and sex. To quantify the diﬀerences in gene expression in
the various depots, an average of 19,085,946 paired-end RNA
sequencing reads per sample were generated on the Illumina HiSeq
platform. Limma-voom and linear modeling identiﬁed 4,252 genes
that were diﬀerentially expressed between SQ and internal adipose
tissue depots. Interestingly, several pathways, including PPAR and
PTEN, associated with metabolically active beige/brown fat were
highly expressed in SQ compared to internal fat depots. Further,
SHOX2 (P = 1.54E-10), a marker for beige fat whose subcutaneous
expression levels are also positively correlated with central obesity
in humans, was overexpressed in SQ. TBX15 (P = 4.72E-8) and
ZIC1 (P = 5.03E-5), genes expressed in brown adipose tissue, were
also overexpressed in subcutaneous tissue. Several diﬀerences in SQ
gene expression were driven by diﬀerences in the nuchal fat.
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EFFECTS OF A COMMERCIAL ANIONIC SUPPLEMENT
ON URINARY ACIDIFICATION IN HORSES. Elizabeth
Nelson, Martha Mallicote, Lori Warren, Ariel Robelen, Sarah
Reuss. University of Florida, Gainesville, FL, USA
There are multiple clinical applications for the acidiﬁcation of
equine urine, including prevention of reoccurrence of urolithiasis.
This study evaluated the eﬃcacy of a commercial anionic supple-
ment (SoyChlor) for urinary acidiﬁcation without altering sys-
temic pH. Eight horses were administered SoyChlor to achieve a
DCAD of 0 mEq/kg or 40 mEq/kg or fed a control diet for
14 days in a randomized crossover trial. Urine and plasma pH,
plasma strong ion diﬀerence, plasma anion gap and fractional
excretion of calcium were measured and compared between treat-
ment groups. Mean urine pH across each collection period was
signiﬁcantly greater in control horses compared to either treatment
group but there was no diﬀerence between treatment groups.
Blood pH and anion gap were not aﬀected by treatment, but
blood pH decreased and anion gap increased over time. Mean
bicarbonate concentration was lower in the 0 mEq/kg group than
the control group, but did not diﬀer between the 0 mEq and
40 mEq/kg treatments. Strong ion diﬀerence of the 0 mEq treat-
ment was lower than the control group. The mean fractional
excretion of calcium over all time points did not diﬀer between
treatment groups but there was an eﬀect of time and treatment.
Both treatment groups had increased fractional excretion of cal-
cium relative to the control group at trial day 7 only. This study
shows SoyChlor supplementation can decrease equine urinary pH.
Systemic pH was not aﬀected but an increase in fractional excre-
tion of calcium did occur.
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EFFECTS OF ABRUPT CONCENTRATE INCREASE AND
PREBIOTIC SUPPLEMENTATION ON EQUINE CECAL PH
AND LACTATE. Katherine Williamson1, Amanda Reeg2, Teresa
Douthit2, Murali Raghavendra Rao1, Mary Beth Gordon1. 1Pur-
ina Animal Nutrition, LLC, Gray Summit, MO, USA, 2Kansas
State University, Manhattan, KS, USA
Abrupt changes in diet have been shown to cause gastrointesti-
nal upset in horses. In particular, sudden large increases in concen-
trate intake can lead to hindgut disruption due to acidosis.
Various dietary additives have been studied to determine if this
response may be ameliorated or blunted by exerting a prebiotic
eﬀect. The objective of this study was to test the hypothesis that
the supplementation of a proprietary yeast fermentation product
would ameliorate the disruptive eﬀects of a sudden increase in
concentrate intake on the cecum.
Nine cecally-cannulated Quarter horses (6–7 years, 4 mares, 5
geldings, approximately 500 kg) were divided into control (n = 4)
and treatment (n = 5) groups based on gender and body weight
and acclimated for 19 d to the diets and housing. The control diet
consisted of 1.5% BW/d prairie grass hay (divided into 2 feedings
at 0700 & 1900) and 0.5% BW/d of a 12% protein commercially-
available concentrate (Omolene 200, Purina Animal Nutrition)
top-dressed with 10 g/45.5 kg BW alfalfa pellet placebo (1 feeding
at 0700). The treatment diet was identical but concentrate was top-
dressed with 10 g/45.5 kg BW of a pelleted proprietary yeast fer-
mentation product. On d 19, cecal ﬂuid samples were collected 1 h
before and after feeding (1 h, +1 h) and at + 4 h, +8 h, +12 h,
+16 h, +20 h and +24 h for 2 additional days to establish baseline
levels. On d 22, the morning meal consisted of 1.25% BW concen-
trate (challenge) followed by 0.75% BW hay. Cecal samples were
collected as on previous days. Cecal ﬂuid pH was measured in sam-
ples at the time of collection. Lactate was later assessed using col-
orimetric analysis. A completely randomized split-split-plot design
was used to test the eﬀects of the yeast fermentation product. Anal-
ysis of variance was done with mixed models (SAS 9.3, SAS Insti-
tute Inc., Cary, NC, USA) and least squares means were compared
using Fisher’s least signiﬁcant diﬀerence (P < 0.05).
No adverse clinical eﬀects were noted following dietary chal-
lenge. Mean cecal pH was decreased at +8 h and +16 h (P = 0.017
& 0.001 respectively) and mean cecal lactate was increased at
+1 h, +8 h and +24 h (P = 0.046, <0.0001 & 0.031 respectively)
after challenge as compared to baseline regardless of treatment.
Treatment group horses had increased mean cecal pH at +4 h
(P = 0.042) and decreased mean cecal lactate at +16 h (P = 0.026)
compared to control group. There were no signiﬁcant diﬀerences
between control and treatment horses’ mean cecal pH and lactate
at other sampling times.
The sudden increase in concentrate intake, from 0.5% BW to
1.25% BW, induced a signiﬁcant, transient decrease in cecal pH
and increase in cecal lactate which was inconsistently blunted by
consumption of a proprietary yeast fermentation product.
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EFFECTS OF A SUPPLEMENT (ALFA-LOX FORAGE) ON
EQUINE GASTRIC ULCER SCORES AND GASTRIC JUICE
PH. Frank Andrews1, Pilar Camacho-Luna1, Kelsey Bailey1, Isa-
belle Nesen2, Michael Keowen1, Frank Garza Jr1?^!"number(boo-
lean(following-ibling::degrees))",1, Chin-Chi Liu1. 1Equine Health
Studies Program, Louisiana State University School of Veterinary
Medicine, Baton Rouge, LA, USA, 2Ecole Nationale Veterinaire,
Toulouse, France
Gastric ulcers are common in stall-conﬁned horses under inter-
mittent feeding conditions. Alfalfa hay feeding has been shown to
buﬀer stomach contents and decrease gastric ulcer scores. The pur-
pose of this study was to determine the eﬀects of a supplement
(ALF; Alfa-Lox Forage, Triple Crown Nutrition, Inc., Wayzata,
MN), containing chopped alfalfa hay, mannanoligosaccharides,
Omega 3 Fatty Acids, and L-Carnitine, top-dressed on grain on
nonglandular gastric ulcer scores and gastric juice pH in horses
after omeprazole treatment and after intermittent feeding. Eight
healthy Thoroughbreds (7 geldings and 1 mare; ages 2–12 years.)
were used in a 2-period crossover study, where horses were fed
ALF (2.0 lbs. [0.91 Kg], twice daily, for 56 days) top dressed on
grain (2.5 Kg; Omelene 100, Purina Animal Nutrition, LLC.,
Grey Summit, MO) or control (grain alone). While being treated
the horses had their stomach scoped on day 0 (before treatment
with ALF or grain only) and the on days 14, 28, 42, 49 and 56. In
addition horses were weighed, body condition score (BCS) recorded
and gastric juice pH measured. During the 56 day periods, from
days 14 to 28 horses were treated with omeprazole paste (OME;
4.0 mg/kg, P.O., Q.D.; GastroGard, Merial Ltd., Duluth, GA)
and from days 42 to 49 horses underwent an intermittent feeding
model.1 Stomach nonglandular gastric ulcer number (NGN) and
severity (NGS) scores were assigned at each scoping by the PI
(FMA), who was masked to treatment. Previous forage analysis
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data was used to compare nutritional quality between the two peri-
ods. Data were analyzed statistically using an ANOVA for
repeated measures and when signiﬁcant diﬀerences were found in
the main model, a post-hoc Least Squares Means test was per-
formed to determine signiﬁcant diﬀerences at P < 0.05. Alfa-Lox
Forage top-dressed on grain was readily eaten by all horses, and
did not result in any adverse eﬀects. When period data were
pooled, Alfa-Lox Forage did not have a treatment by day eﬀect
on gastric ulcer scores or gastric juice pH during the study period.
However, there was an overall period eﬀect on treatment, in that
BCS was higher and gastric ulcer scores were lower in the AFL-
treated horses during the ﬁrst period of the study, but no treatment
by day eﬀect was seen. Forage analysis showed lower digestible
energy in the ﬁrst period of the study. Other signiﬁcant eﬀects seen
during the study included OME-treatment signiﬁcantly decreased
gastric ulcer scores and increased gastric juice pH in both ALF-
treated and control horses and gastric ulcers healed in 6/8 (75%)
horses after 14 days of treatment. In addition, gastric ulcer scores
signiﬁcantly increased 2 weeks after OME treatment and after
feed-deprivation regardless of treatment. Alfa-Lox Forage had no
eﬀect on gastric ulcers scores after OME treatment or during feed-
deprivation when compared to untreated controls. However, when
forage had lower digestible energy and higher ﬁber content, Alfa-
Lox Forage-fed horses had better BCS and fewer ulcers. Thus,
Alfa-Lox Forage might provide gastric support when forage has
marginal nutritional value. It should be pointed out that the quan-
tity of Alfa-Lox Forage fed may not have been adequate to aﬀect
gastric ulcer scores or gastric juice pH in horses in this study, but
other nutritional beneﬁts might result.
1Murray MJ and Eichorn ES. (1996) Am J Vet Res. 57
(11):1599–1603.
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CHANGES OF THE EQUINE NEONATAL INTESTINAL
MICROBIOTA ASSOCIATED WITH AGE AND DIARRHEA.
Angelika Schoster1, Henry Staempﬂi2, Mohammad Jalali3, Luca
Guardabassi4, Scott Weese3. 1University of Zurich, Vetsuisse fac-
ulty, Clinic of Equine Internal Medicine, Zurich, Switzerland,
2University of Guelph, Ontario Veterinary College, Departemnt of
Clinical Science, Guelph, ON, Canada, 3University of Guelph,
Ontario Veterinary College, Departmnet of Pathobiology, Guelph,
ON, Canada, 4Departement of Veterinary Disease Biology, Fac-
ulty of Health and Medical Sciences, University of Copenhagen,
Frederiksberg, Copenhagen, Denmark
Neonatal diarrhea is an important disease complex in foals.
Diarrhea is associated with signiﬁcant changes in composition and
structure of the microbiota in adult horses. The changes associated
with diarrhea in neonatal foals are unknown.
The objective was to investigate changes of the equine neonatal
microbiota associated with age and occurrence of diarrhea in a
ﬁeld trial.
Fecal samples were collected from 20 foals at 2, 4 and 6 weeks
of age and assessed via metagenomic sequencing. Foals were moni-
tored and occurrence of diarrhea was recorded. The Wilcoxon and
Steelman-Dwass tests were used to assess diﬀerences between age
groups and between foals with diarrhea and healthy foals within
an age group.
Age had a signiﬁcant eﬀect on relative abundance of bacterial
taxa on the phylum, order and class level. There was a signiﬁcant
increase in richness over time (P = 0.02). 9/20 (45%) foals developed
diarrhea. The structure of the microbiota was signiﬁcantly diﬀerent
at Week 2 compared to Week 4 (P = 0.09) and Week 6 (P = 0.02).
Diarrhea had a signiﬁcant eﬀect on relative abundance of orders
and classes. Foals with diarrhea had reduced bacterial richness at
four weeks of age (P = 0.04). Diarrhea did not have a signiﬁcant
eﬀect on the beta diversity in any age group (all P > 0.36).
The composition and richness of the equine neonatal microbiota
is changing rapidly after birth. Similar to adults, foals with diar-
rhea have changes in composition and richness of the microbiota.
Further studies are needed to assess whether these changes are the
cause or eﬀect of diarrhea.
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COMPARISON OF TUBE, GEL, AND IMMUNOCHRO-
MATOGRAPHIC STRIP METHODS FOR EVALUATION OF
EQUINE BLOOD TRANSFUSION COMPATIBILITY. Daniela
Luethy1, Sean Owens2, Urs Giger3, Darko Stefanovski1, Rose
Nolen-Walston1. 1School of Veterinary Medicine, University of
Pennsylvania, Clinical Studies-New Bolton Center, Kennett
Square, PA, USA, 2Department of Pathology, Microbiology and
Immunology, School of Veterinary Medicine, University of Cali-
fornia, Davis, CA, USA, 3School of Veterinary Medicine, Univer-
sity of Pennsylvania, Ryan Small Animal Hospital, Philadelphia,
PA, USA
Assessment of compatibility is recommended prior to blood
transfusion in horses, typically using gross or microscopic tube
agglutination and hemolysin crossmatch, or less commonly, as pre-
dicted by blood type and alloantibody assay. In contrast, gel col-
umn and immunochromatographic strip methods are the preferred
techniques for compatibility testing in small animals. The purpose
of this study was to determine agreement between novel and stan-
dard crossmatch and typing methods. 33 blood typed and alloanti-
body screened horses were evaluated. TUBE and GEL
crossmatches were performed on 144 recipient-donor pairs and
compared using non-parametric area under the curve (AUC) recei-
ver operating characteristic (ROC) analysis. With TUBE assigned
as the reference variable, TUBE and GEL had excellent agreement
for agglutination (AUC ROC = 0.87), but borderline for hemolysis
(AUC ROC = 0.64). There was outstanding agreement between
TUBE (gross) and TUBE (microscopic) scores for agglutination
(AUC ROC = 0.91). The predicted crossmatch compatibility based
on blood type and alloantibody assay showed excellent agreement
with TUBE and GEL (AUC ROC = 0.84 and 0.89, respectively).
However, there were more recipient-donor pairs identiﬁed as
incompatible by both TUBE and GEL than predicted by blood
type and antibody screen, suggesting unidentiﬁed alloantibodies. A
blood typing STRIP assay was performed on each aliquot and
exhibited 100% sensitivity and speciﬁcity for 30 Ca+ and 3 Ca-
horses. These ﬁndings show that gel column crossmatch techniques
appear to be a practical and accurate equine blood compatibility
test method, and that immunochromatographic strips are accurate
at identifying the Ca blood type.
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INFLUENZA-SPECIFIC IMMUNE RESPONSES TO A
COMBINATION VACCINE IN NA€IVE PONIES. Amanda
Adams1, Stephanie Reedy1, Melissa Siard1, Sarah Elzinga1,
Thomas Chambers1, Steven Grubbs2. 1Department of Veterinary
Science, Gluck Equine Research Center, University of Kentucky,
Lexington, KY, USA, 2Boehringer Ingelheim Vetmedica, Inc.,
St. Joseph, MO, USA
Equids, like humans and swine, are recognized as natural hosts
for a variety of common viral pathogens, in particular equine
inﬂuenza virus (EIV). EIV has resulted in worldwide disease out-
breaks. Vaccination is essential to prevent or limit disease spread.
Many commercially available vaccines are sold as single pathogen
vaccines, however nowadays several are available as multi-patho-
gen or combination vaccines. A signiﬁcant amount of equine
research has been conducted to measure immune responses to
single pathogen vaccines however data is lacking to determine if
combination vaccines stimulate the immune system in particular
cell-mediated immunity. Thus, the objective of this study was to
characterize the cell-mediated immunity (CMI) and humoral
immune responses to a combination vaccine in inﬂuenza na€ıve ani-
mals. A total of 16 inﬂuenza na€ıve yearling ponies were randomly
assigned to receive one of two treatment groups: (Group 1)
(n = 8) Vetera EWT + EIV/EHV (BIVI) vaccination and (Group
2) (n = 8) controls to receive a saline vaccination. All vaccinate
ponies received a primary vaccination on day 0, followed by a
booster vaccination on day 28. Peripheral blood was collected
from all ponies prior to vaccination on day 0 and every 2 weeks
following for an 8 week period. Serum and peripheral blood
mononuclear cells were isolated to measure inﬂuenza speciﬁc
antibody and cell-mediated immune responses by the following
assays: HI, ELISA, interferon-gamma intracellular staining by
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ﬂow cytometry, and Real-Time PCR. Statistical analysis was per-
formed using SIGMA Plotv12.0TM (Systat Inc., Richmond, CA)
with signiﬁcance determined at the level of (P ≤ 0.05). Non-nor-
mally distributed data was log transformed prior to statistical anal-
ysis. For each variable measured (cell-mediated immunity, etc.), a
mixed model two way ANOVA with repeated measures was used.
In measuring the humoral immune response to the EIV component
of the vaccine, results showed an overall signiﬁcant (P < 0.05)
increase in the change of HI antibody titers in vaccinated ponies
compared to non-vaccinated saline controls. Further, there was an
increase in EIV-speciﬁc IgGa and IgGb antibody titers in the vacci-
nated group of ponies compared to the saline controls, there was
no change in IgGT responses in the vaccinated ponies. Measure-
ment of CMI responses by ﬂow cytometry showed a signiﬁcant
increase in EIV-speciﬁc interferon-gamma being produced per cell
from the vaccinated ponies compared to the saline controls. Mea-
surement of EIV speciﬁc CMI responses by Real-Time PCR
showed a signiﬁcant increase in EIV-speciﬁc interferon gamma and
granzyme B gene expression in the vaccinated ponies compared to
controls. There was no signiﬁcant diﬀerence in the gene expression
of perforin, IL-2 or IL-18 when comparing the vaccinated ponies
to the controls. Overall, the combination killed vaccine induced sig-
niﬁcant humoral and cell-mediated responses in na€ıve animals.
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WNV-SPECIFIC IMMUNE RESPONSES TO A COMBINA-
TION VACCINE IN NA€IVE PONIES. Amanda Adams1, Alex
Betancourt1, Day Barker1, Melissa Siard1, Sarah Elzinga1, Stepha-
nie Reedy1, Steven Grubbs2. 1Department of Veterinary Science,
M.H. Gluck Equine Research Center, University of Kentucky,
Lexington, KY, USA, 2Boehringer Ingelheim Vetmedica, Inc., St.
Joseph, MO, USA
West Nile virus (WNV) mosquito-borne ﬂavivirus and is the
leading cause of arbovirus encephalitis in horses in the United
States. WNV infection can cause severe acute illness, with devas-
tating clinical signs of illness aﬀecting gait and behavioural abnor-
malities often times resulting in a high case fatality rate. Thus,
WNV vaccination is a recommended core vaccine and is an essen-
tial standard of care for all horses in North America as recom-
mended by the AAEP. Many commercially available vaccines are
sold as single pathogen vaccines, however nowadays several are
available as multi-pathogen or combination vaccines. Little data
exists to characterize the immune response to the WNV antigen
following a combination vaccination. We hypothesize that a multi-
pathogen “combination” vaccine will elicit signiﬁcant cell-mediated
and humoral immune responses in na€ıve ponies. A total of 16
inﬂuenza na€ıve yearling ponies were randomly assigned to receive
one of two treatment groups: (Group 1) (n = 8) Vetera EWT +
EIV + WNV (BIVI) vaccination and (Group 2) (n = 8) controls to
receive a saline vaccination. All vaccinate ponies received a pri-
mary vaccination on day 0, followed by a booster vaccination on
day 28. Peripheral blood was collected from all ponies prior to
vaccination on day 0 and every 2 weeks following for an 8 week
period. Serum and peripheral blood mononuclear cells were iso-
lated to measure WNV-speciﬁc antibody and cell-mediated
immune responses by the following assays: ELISA, interferon-
gamma intracellular staining by ﬂow cytometry, and Real-Time
PCR. Statistical analysis was performed using SIGMA
Plotv12.0TM (Systat Inc., Richmond, CA) with signiﬁcance deter-
mined at the level of (P ≤ 0.05). Non-normally distributed data
were log transformed prior to statistical analysis. For each variable
measured (cell-mediated immunity, etc.), a mixed model two way
ANOVA with repeated measures was used. In measuring the
humoral immune response to the WNV component of the vaccine,
results showed a signiﬁcant (P < 0.05) increase in WNV IgG titers
in vaccinated ponies compared to non-vaccinated saline controls.
Measurement of CMI responses by ﬂow cytometry showed a sig-
niﬁcant (P < 0.05) increase in the percentage of WNV-speciﬁc
interferon-gamma producing cells from the vaccinated ponies com-
pared to the saline controls. Measurement of WNV-speciﬁc CMI
responses by RT-PCR showed a signiﬁcant (P < 0.05) increase in
WNV-speciﬁc interferon gamma and IL-2 gene expression in the
vaccinated ponies compared to controls. There was no signiﬁcant
(P > 0.05) diﬀerence in the gene expression of GrzB, IL-6 or IL-18
when comparing the vaccinated ponies to the controls. Overall,
the combination killed vaccine induced signiﬁcant WNV-speciﬁc
humoral and cell-mediated immune responses in na€ıve animals.
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CHARACTERISTICS OF INFECTION CONTROL PRAC-
TICES AT NORTH AMERICAN VETERINARY TEACHING
HOSPITALS. Cristine S. De La Hoz Ulloa1, Katharine M. Bene-
dict2, Paul S. Morley2, Brandy A. Burgess1. 1Virginia Tech,
Blacksburg, VA, USA, 2Colorado State University, Fort Collins,
CO, USA
Infection control is crucial in the operation of all veterinary
hospitals to not only protect the patients and hospital, but to pro-
tect personnel as those in the veterinary ﬁeld have an increased
risk of occupational exposure to zoonotic diseases. In a 2008
study, 50% of Veterinary Teaching Hospitals (VTHs) surveyed
reported signiﬁcant health problems due to zoonotic infections
among hospital personnel. Cryptosporidium parvum infections
accounted for 68% of these infections. The objective of this study
was to characterize current infection control practices in place for
the prevention of zoonotic disease infection, speciﬁcally infection
of C. parvum, in VTHs.
All VTHs located in North America (n = 35) that had been
operational for at least one year were eligible to participate in this
study. Phone surveys of biosecurity experts were conducted from
July - October 2015 which addressed policies for hygiene, surveil-
lance, patient contact, education, awareness, and enteric infectious
disease control.
Among participating VTHs (n = 20/35; 57.1%), greater than
half reported signiﬁcant outbreaks of disease among hospitalized
patients in the previous 5 years; most commonly due to Salmonella
enterica or equine herpesvirus-1. In addition, 50% reported signiﬁ-
cant health problems in personnel, in the previous 2 years, that
most likely resulted from zoonotic infection. Of these, Cryp-
tosporidium was identiﬁed as the most common agent. The major-
ity of VTHs surveyed had a committee that oversaw biosecurity
program activities as well as written biosecurity policy documents.
However, only half conducted mandatory training on the biosecu-
rity and infectious disease control program.
The results of this study will help to improve strategies for pre-
venting healthcare-associated infection, including zoonotic diseases,
among patients and veterinary personnel; and allow for targeted
educational tools to promote a safety culture in veterinary medicine.
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ANTI-ENDOTOXIC PROPERTIES OF KETOROLAC TRO-
METHAMINE AND FLUNIXIN MEGLUMINE IN HORSES.
Alexandra Bianco, George Moore, Sandra Taylor. Purdue Univer-
sity, West Lafayette, IN, USA
Non-steroidal anti-inﬂammatory drugs (NSAIDs) play an inte-
gral role in equine medicine due to their combined analgesic and
anti-inﬂammatory properties. Despite their widespread use, there
are limited NSAIDs available that demonstrate variable adverse
eﬀects and safety. While several NSAIDs have been proven to be
adequate analgesics, few have undergone rigorous evaluation for
anti-inﬂammatory eﬃcacy. Ketorolac tromethamine (KT) is a non-
selective cyclooxygenase inhibitor that has been used in human
patients since 1989. The pharmacokinetic properties of KT have
recently been determined in the horse, and have been previously
determined in several other species. However, there have been only
two previous studies examining KT’s anti-inﬂammatory properties
in animals, both of which were in vivo. There have been no published
studies evaluating the in vitro anti-inﬂammatory eﬀects of KT in any
veterinary species. The purpose of this study was to evaluate the
anti-inﬂammatory eﬀects of KT compared to ﬂunixin meglumine
using an in vitromodel of LPS-stimulated equine monocytes.
Equine monocytes were isolated from whole blood from a single
horse and incubated with either KT or ﬂunixin meglumine at six
concentrations ranging from 2.5 µg/mL to 80 µg/mL for 1 hour.
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After the initial incubation, E. coli 055:B5 LPS was added to each
well at a concentration of 1 µg/mL, which has been shown to con-
sistently activate monocytes. The wells were incubated at 37°C and
5% CO2 for 4, 8, 12, and 24 hours. Samples were collected at each
time point and stored at 80°C until analysis. Equine-speciﬁc
ELISAs were used to measure the eicosanoids PGE2 and TXB2 as
well as the cytokines TNFa, IL-6, and IL-8.
Preliminary results demonstrated that ﬂunixin meglumine sup-
pressed PGE2 production up to 12 hours at concentrations ≥5 µg/
mL and up to 24 hours at concentrations ≥40 µg/mL. Flunixin
meglumine suppressed TXB2 production up to 12 hours at all con-
centrations and up to 24 hours at concentrations ≥20 µg/mL.
Ketorolac tromethamine suppressed PGE2 production up to
12 hours at all concentrations and up to 24 hours at concentra-
tions ≥20 µg/mL. Ketorolac tromethamine also suppressed TXB2
production up to 12 hours at all concentrations but did not sup-
press production up to 24 hours at any concentration. Peak eico-
sanoid concentration in the non-treated samples occurred at
4 hours for PGE2 and 12 hours for TXB2.
While in vitro results cannot be directly correlated to in vivo eﬃ-
cacy, the results thus far indicate both drugs eﬀectively suppress
eicosanoid production after LPS stimulation, with an eﬀect of
both time and drug concentration. Based on the results of this
study, a therapeutic dose of 2.5 µg/mL KT would eﬀectively sup-
press eicosanoid production in cases of endotoxemia. Further
research is needed to correlate in vitro results with in vivo eﬃcacy.
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EFFECTS ON SWEATING OF CHLORAMPHENICOL AND
THE MACROLIDE GAMITHROMYCIN: COMPARISON
WITH ERYTHROMYCIN. Amy Stieler1, Chris Sanchez2, Martha
Mallicote2, Amy Smith2, Jim Burrow2, Rob MacKay2. 1University
of Georgia, Athens, GA, USA, 2Department of Large Animal
Clinical Sciences, University of Florida, Gainesville, FL, USA
Hyperthermia in foals treated with erythromycin (ERY), clar-
ithromycin, or azithromycin is associated with reduction of sweat-
ing by an unknown mechanism. The aims of this study were to
evaluate eﬀects on sweating of (1) chloramphenicol (CHL) which,
like macrolides, binds to the 50S subunit of the bacterial ribosome
and (2) gamithromycin (GAM), a macrolide sub-class 7a azalide
which is not yet licensed for treatment of foals. Over 3 experimen-
tal periods, 12 foals (1 to 3 months old) were treated with ERY
(25 mg/kg PO, 3 times daily for 5 days), GAM (8 mg/kg IM once)
and CHL (50 mg/kg PO, 3 times daily for 5 days) according to a
masked, duplicated, fully counterbalanced design. Quantitative
intradermal terbutaline sweat tests were performed on 3 successive
days before treatment (baseline) and on days 1, 2, 5, 9, 24, and 39
after treatment began. Data were analyzed by 1-, 2-, and 3-factor
repeated measures ANOVA with post hoc pairwise analyses of sig-
niﬁcant tests. There was signiﬁcant (P < 0. 05) suppression of
sweating by ERY but not CHL or GAM. Compared with sweat-
ing at baseline, values when foals were given ERY were signiﬁ-
cantly lower on all test days except day 39. Sweating responses in
foals given ERY were signiﬁcantly lower than when given GAM
or CHL on days 2, 5 and 9 at every terbutaline concentration
except 100 lg/mL. In contrast, there was no diﬀerence between
CHL and GAM. Results show that (1) ability to bind the bacterial
50S ribosome does not by itself confer potential to induce anhidro-
sis and (2) unlike the macrolides ERY and clarithromycin and the
9a-azalide azithromycin, the 7a-azalide GAM did not suppress
sweating responses.
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COMPARISON OF THE CLINICOPATHOLOGIC SIGNA-
TURES OF EQUINE CORONAVIRUS AND SALMONELLA
ENTEROCOLITIS. Arlie Manship, Johanna Elfenbein. North
Carolina State University College of Veterinary Medicine, Raleigh,
NC, USA
Recent worldwide outbreaks of Equine Corona Virus (ECoV)
have led to an increased awareness of this pathogen as a cause of
colitis in adult horses. The objective of this study was to determine
whether ECoV enterocolitis has a distinct clinical and/or clinico-
pathologic signature that can distinguish it from enteric salmonel-
losis or unknown causes of fever and neutropenia.
Data were collected from medical records from North Carolina
State University (2003–2015). Horses >1 year old were divided into
3 groups based on diagnosis: ECoV (fecal PCR), enteric salmonel-
losis (fecal culture or PCR), or unknown diagnosis by ruling out
ECoV and Salmonella (3 negative Salmonella cultures, negative
ECoV and Salmonella PCR). Clinical features, diagnostic test
results, and outcome were compared between groups. Statistical
signiﬁcance was determined using a Mann-Whitney U test with
P < 0.05.
Data were obtained from 7 horses with ECoV, 11 horses with
Salmonella, and 11 horses without a diagnosis. ECoV cases had
signiﬁcantly fewer neutrophils (median 569/uL; range 105-1,029/
uL) compared with all other diagnoses (1,310/uL; 337-9,720/uL)
but there was no diﬀerence in neutrophil count when compared
with Salmonella or unknown diagnosis. There were no diﬀerences
in temperature, lymphocyte or platelet counts, ﬁbrinogen, or any
biochemical parameter between groups.
The results suggest that disease with ECoV and Salmonella share
clinical features and should be included together on a diﬀerential
list for fever and neutropenia. Further investigation is warranted to
determine whether there is an unknown pathogen as the cause of
the fever and leukopenia in the group without a diagnosis.
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PHENOTYPIC CHARACTERIZATION OF SARCOCYSTIS
NEURONA LESIONS IN GRAVELY AFFECTED HORSES.
JunJie Liu1, Micheal Dark1, Lisa Farina1, Robert MacKay2,
Nancy Denslow3, Lei Zhou4, Maureen Long1. 1Department of
Infectious Diseases and Pathology, University of Florida, Gaines-
ville, FL, USA, 2Department of Large Animal Clinical Sciences,
University of Florida, Gainesville, FL, USA, 3Department of
Physiology, University of Florida, Gainesville, FL, USA, 4Depart-
ment of, University of Florida, Gainesville, FL, USA
The primary goal of this research was to contribute new knowl-
edge to the understanding of Sarcocystis neurona (SN) infection in
horses. Our goal was to identify SN infected horses and to use dif-
ferent markers to investigate and characterize the inﬁltration of
inﬂammatory cells and resident cellular changes in EPM-diseased
horses by genetic (PCR) and immunohistochemical (IHC) tech-
niques. The hypothesis investigated was that phenotypic characteri-
zation the CNS of gravely SN aﬀected horses could deﬁne disease
pathogenesis. Tissues from 2 groups of humanely euthanized horses
with either grave or no neurological symptoms were collected under
University of Florida IACUC protocols 3984, 4109, and 4559. Sets
of CNS tissues from all levels of brain and spinal cord were ﬁxed
for pathology and immunohistochemistry and frozen for nucleic
acid extraction. Histopathologically, encephalomyelitis and normal
CNS was conﬁrmed in aﬀected and unaﬀected horses, respectively.
SN, Neospora hughesi, EHV-1, WNV, and EEEV virus PCR was
performed to conﬁrm neuropathogen status in all horses. For RNA
expression analysis, the tissues in which SN was detected, the corre-
sponding section of frozen tissue was cut into 30–50 30 µg sized
cubes. Relative parasite burden was calculated based on the stan-
dard curve generated by the use of cultured SN merozoites. 160
samples were tested and the correlation coeﬃcient (R, Psych pack-
age) between CD3+ and TNF-a expression was 0.874. The correla-
tion coeﬃcient between CD3+ expression and parasite burden was
0.8304 (186 samples) and the correlation coeﬃcient between TNF-a
and parasite burden was 0.7757 (101 samples). Immunohistochemi-
cal phenotypic analysis was conducted for T cells, macrophages, B
cells, microglia and astrocytes for C3 + T cells, B cells, macrophage
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cells, glial cells, and astrocytes and this was performed on 12/14
EPM cases that had SN+ and adjacent SN- tissue formalin ﬁxed tis-
sue (FFPE) blocks. Eleven normal control horses were used and
sections were location matched to lesion sections. All sections were
compared for signiﬁcant diﬀerences by ANOVA (P < 0.05). The
number of CD3+ T cells and microglia/macrophage cells of SN+
tissues were signiﬁcantly increased compared with its adjacent sec-
tion and the sections from the normal horses. Although present in
extremely limited numbers (< 10 cells per site), macrophage only
staining cells had statistically higher cell counts in aﬀected horses
compared to normal horses. Because CD3 + cells were the most
numerous, diﬀerentiation of CD4 + and CD8 + cells was attempted
using IHC by several markers, none of which worked on FFPE sec-
tions. CD4 + and CD8 + relative expression was investigated by
quantitative PCR and the most signiﬁcant change was that of
CD4 + cell marker expression at 144.6 fold (log2) over controls.
The fold change of CD8 + between the lesion group and the normal
group was 10.8. In conclusion, the presence of SN was only present
within inﬂammatory nodules and the presence of parasite burden
was associated with the presence of CD3 + CD4 + T cell markers
compared to that of CD8 + T cells. Based on the presence of
inﬂammatory markers, the presence of SN was not detected outside
of aggregates of either resident or inﬁltrating inﬂammatory cells.
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NORMAL ULTRASONOGRAPHIC PLEURAL THICKNESS
IN CLINICALLY HEALTHY ADULT HORSES. Breanna Shea-
han, Kara Lascola, Scott Austin. University of Illinois, Veterinary
Teaching Hospital, Urbana, IL, USA
The objectives of this study were to establish reference ranges
for normal pleural thickness measurements in healthy adult horses
and to compare measurements between horses < 15 years of age
(YOUNG) and ≥ 15 years of age (OLD). Pleural thickness is
assessed as part of a complete thoracic ultrasonographic examina-
tion but no normal measurements have previously been reported.
We hypothesized that measurements of pleural thickness would be
< 2 mm.
18 clinically healthy adult horses (11 YOUNG; 7 OLD) were
examined with a curvilinear 3.5–8 mHz probe in eight thoracic
locations (four per side): cranioventral (intercostal space (ICS) 6),
mid-thoracic (15 cm dorsal to point of shoulder (POS) in ICS 10),
caudoventral (ICS 10 at POS), and caudodorsal (ICS 14). All mea-
surements were performed post hoc by two observers on three
recorded images from each site. Diﬀerences among locations were
evaluated with Kruskal-Wallis. Diﬀerence between age groups was
evaluated with Mann Whitney U. Inter-observer reliability was
evaluated using intraclass correlation (ICC). Signiﬁcance was set
at P < 0.05.
Pleural thickness median (range) was 1.5 (1.11–2.33) mm in all
horses, 1.47 (1.11–2.09) mm in YOUNG horses and 1.55 (1.18–
2.33) mm in OLD horses. Signiﬁcant diﬀerences among locations
and between age groups were not noted. Mild pleural irregularities
were subjectively more common in older horses. ICC was signiﬁ-
cant for measurements at each location.
Older horses did not have signiﬁcantly greater pleural thickness
measurements. Measurements were reproducible. Measurements
above the normal variation should be cause for further investiga-
tion of respiratory disease.
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SYRINGE VERSUS MECHANICAL SUCTION WITH
N-BUTYLSCOPOLAMMONIUM EFFECTS ON BAL PARAM-
ETERS IN HORSES WITH PASTURE RAO. Jacquelyn Bowser,
Lais Costa, Christine Lopp, Rachel Wilson, Rebecca Byrne,
Melissa Steichen, Santosh Kumar TK, Alba Rodil, Michael Brash-
ier, Cyprianna Swiderski. Mississippi State University College of
Veterinary Medicine, Mississippi State, MS, USA
Bronchoalveolar lavage (BAL) is frequently employed to evalu-
ate lower airway inﬂammation in horses with RAO. In these
horses, bronchial collapse often limits retrieval of BALF. N-
butylscopolammonium bromide (Buscopan), a parasympatholy-
gic agent, safely produces short term bronchodilation, reversing
airway obstruction RAO-aﬀected horses.
Based upon the hypothesis that syringe aspiration would
improve BALF retrieval, we performed BAL in the left and right
lungs of 8 sedated summer pasture associated RAO-aﬀected horses
using a ﬂexible endoscope. Saline (300 cc) was instilled via a poly-
urethane tube inserted through the biopsy port using a 60 cc syr-
inge and aspirated using gentle manual suction (SS) with a 60 cc
syringe or with mechanical suction (MS) using a pressure regulated
suction pump. Pressures of 15–75 mm H2O retrieved BALF with-
out airway collapse. Bilateral BAL was performed twice in each
horse with or without Buscopan (0.3 mg/kg IV) in a crossover
fashion with a 21 day washout period. The eﬀects of suction type
and Buscopan administration on volume yield, cellularlity and
cell viability were determined.
BAL performed using SS demonstrated higher volume yield,
with lower RBC and lower nucleated cell counts. There was a ten-
dency for improved viability with MS. Diﬀerences in yield, nucle-
ated cell count and red blood cell count were not identiﬁed with
Buscopan, with the exception of horses demonstrating profound
collapse.
Use of a modiﬁed BAL technique that includes manual syringe
suction with Buscopan administration may provide an advantage
in horses with signiﬁcant airway hyper-reactivity by limiting air-
way collapse and enhancing the diagnostic utility of BALF
obtained.
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PREVALENCE OF FUNGI IN RESPIRATORY SAMPLES OF
HORSES WITH INFLAMMATORY AIRWAY DISEASE. Julie
Dauvillier, Emmanuelle van Erck. Equine Sports Medicine Prac-
tice, Waterloo, Belgium
Inﬂammatory Airway Disease (IAD) is a common cause of res-
piratory problems and poor performance in horses. It has recently
been suggested that IAD and Recurrent Airway Obstruction
(RAO) could be two forms of a same inﬂammatory process and
recent evidence tends to establish a close parallel between these
equine diseases and asthma in humans. Fungi have been shown to
contribute to the inﬂammatory response of lungs in RAO horses
and in some forms of asthma in humans. The role of fungi in IAD
has not yet been assessed to the knowledge of the authors.
The purpose of this prospective observational clinical study was
(1) to evaluate the prevalence of fungal isolates in the respiratory
samples of horses diagnosed with IAD, (2) to describe clinical
signs associated with the presence of fungi in respiratory samples
of horses diagnosed with IAD and (3) to assess the risk factors
associated with IAD and positive fungal culture and proliferation.
The study was performed in a population of working sport, race
and leisure horses based in France, Belgium and the Netherlands.
A total of 482 cases horses, referred to a specialized ambulatory
internal medicine practice in Europe, were assessed between June
2013 and December 2014. The horses were referred either for res-
piratory problems or loss of performance. For each case, an envi-
ronmental evaluation, a clinical examination, an airway
endoscopy, a tracheal wash (TW) and a bronchoalveolar lavage
(BAL) were performed. The TW and the BAL underwent cyto-
logic evaluation and the TW was submitted for bacteriology and
mycology. Diagnosis of IAD was established based on BAL ﬂuid
cytology, according to the ACVIM consensus statement deﬁnition.
On both cytologic examinations, the presence of fungal elements
(spores, conidiophores, hyphae) was recorded, as well as signs of
active proliferation.
In the population studied, a diagnosis of IAD was established
in 84% of cases. A positive fungal culture was obtained in 49% of
IAD+ cases and in 44% of IAD- cases. The most commonly iso-
lated fungus were Aspergillus sp, Penicillium and Rhizomucor. No
relationship could be established between positive mycology and
cytologic evidence of fungal elements or active proliferation of
fungi in the airways. However horses with fungal elements on the
TW cytology had 3.8 more chances of having IAD than horses
with no fungi (OR=3.8; 95% CI 1.8–7.8; P = 0.0003). Twenty
IAD horses had signs of fungal proliferation in their TW and/or
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BAL, but all mycologies remained negative in these cases. Distinc-
tive respiratory clinical signs such as cough, breathlessness or nasal
discharge showed low sensitivity and high speciﬁcity for IAD diag-
nosis. Concomitant bacterial infection did not increase the risk of
fungal isolation. The degree of inﬂammation (% inﬂammatory
cells in BAL) was higher when horses were housed indoors, bed-
ded on straw versus shavings (Mann-Whitney test, 25.53 + /-17.14
versus 19.9 + /-17.5; P < 0.001) or fed dry hay versus steamed hay
(23.2 + /- 17.5 versus 18.8 + /-18.9; P < 0.001).
The prevalence of fungal contamination in IAD cases is high in
Europe. Horses inhaling aerosolized fungal particles are at a sig-
niﬁcantly higher risk of developing IAD. The type of bedding and
forage as well as other environmental conditions represent signiﬁ-
cant risk factors for IAD and fungal contamination of equine air-
ways. The identiﬁcation of proliferating fungi in the airways is a
sign of fungal infection and warrants further investigation. In the
current study, mycology culture seems to lack sensitivity in the
detection of fungi in respiratory samples.
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INTRAVENOUS MAGNESIUM SULFATE AS A RESCUE
THERAPEUTIC FOR BRONCHOCONSTRICTION IN
HORSES. Jacquelyn Bowser, Caitlin Wenzel, Robert Wills, Noel
Bondi, Rachel Wilson, Rebecca Byrne, Cyprianna Swiderski. Mis-
sissippi State University College of Veterinary Medicine, Missis-
sippi State, MS, USA
Horses with RAO exhibit exacerbations of acute airway
obstruction that cause respiratory distress resulting from bron-
chospasm, mucus accumulation, and airway inﬂammation. Emer-
gency therapeutic options for control and reversal of airway
bronchoconstriction in equine airways include parasympatholytic
agents which inhibit gastrointestinal motility, b2-adrenergic ago-
nists, as well as systemic corticosteroids, which require 4–6 hours
for full eﬀect. Meta-analysis of emergency intervention for asth-
matic adults found that adjunctive infusion of magnesium sulfate
(MgSO4) improves lung function and reduces hospital admissions.
This study examined utility and eﬀectiveness of intravenous
MgSO4 as a novel, inexpensive, easily administered bronchodila-
tory agent for horses with a naturally occurring pasture-associated
form of RAO (SPARAO).
Six SPARAO-aﬀected horses exhibiting naturally occurring dis-
ease exacerbation (CSRE ≥5, DPplmax > 15 cm H2O) were treated
with three doubling dosages of MgSO4 by rapid IV infusion using
three way cross-over design. Horses were instrumented for contin-
uous ECG and blood gas monitoring. Tidal volume (TV), pul-
monary resistance (RL), dynamic compliance (Cdyn), and
maximum change in pleural pressure (DPplmax) were monitored at
5 minute intervals using conventional pulmonary mechanics.
Mixed models were ﬁt for percent change from baseline values
for each outcome using PROC MIXED (SAS, SAS Institute.
Cary, NC). Signiﬁcant decreases in DPplmax, RL and signiﬁcant
increases in Cdyn were identiﬁed at all dosages and were accompa-
nied by increased PaO2 and decreased PaCO2, substantiating
improved ventilation. We conclude that intravenous infusion of
MgSO4 has immediate bronchodilatory eﬀects in horses making
this therapy a valuable adjunct in horses with signs of respiratory
distress referable to bronchoconstriction.
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INVESTIGATION OF MISOPROSTOL AS A NOVEL ANTI-
INFLAMMATORY IN EQUINE LEUKOCYTES. Emily Medlin
Martin, Samuel Jones. North Carolina State University, College of
Veterinary Medicine, Raleigh, NC, USA
E-type prostaglandins (PGEs) play diverse roles throughout the
body, including regulation of gastrointestinal (GI) homeostasis and
modulation of inﬂammation. To treat inﬂammation, anti-inﬂam-
matory medications including nonsteroidal anti-inﬂammatory
drugs (NSAIDs) are designed to inhibit prostaglandin production.
Unfortunately, potential adverse eﬀects of NSAID use in horses
include gastric ulceration and right dorsal colitis. To prevent and
treat NSAID-associated GI injury, equine practitioners commonly
administer the PGE1 analog, misoprostol. In addition to serving as
a gastroprotectant, misoprostol has been shown to have anti-
inﬂammatory eﬀects in cell models, potentially by increasing intra-
cellular cyclic AMP (cAMP). Elevated cAMP is known to dampen
leukocyte eﬀector functions that can damage host tissues, including
cellular adhesion, tissue inﬁltration, and cytokine and superoxide
production. The eﬀects of misoprostol on equine leukocyte eﬀector
functions are undetermined. Thus, the purpose of this study was to
determine the eﬀects of misoprostol on equine leukocyte pro-
inﬂammatory cytokine and superoxide production in vitro. Equine
leukocytes were isolated from whole blood and stimulated with
lipopolysaccharide (LPS) in the presence or absence of misoprostol.
Misoprostol at concentrations of 1–10 lM signiﬁcantly inhibited
tumor necrosis factor-a, interleukin-1b, and interleukin-6 mRNA
production, as measured by qPCR. Misoprostol also elicited con-
centration-dependent decreases in neutrophil superoxide produc-
tion in response to granulocyte-monocyte colony-stimulating factor
priming and LPS stimulation, as measured by luminol-enhanced
chemiluminescence. From this data we conclude that misoprostol
produces anti-inﬂammatory eﬀects in equine leukocytes in vitro,
paving the way for in vivo studies investigating misoprostol as an
anti-inﬂammatory treatment in horses.
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DO ENDOCRINE DISRUPTING CHEMICALS PLAY A ROLE
IN HORSES WITH EQUINE METABOLIC SYNDROME?.
Sian Durward-Akhurst1, Nichol Schulz1, Elaine Norton1, Ray-
mond Geor2, James Mickelson1, Molly Mccue1. 1University of
Minnesota, MN, USA, 2Mmassey University, Palmerston North,
New Zealand
Equine Metabolic Syndrome (EMS) is characterized by abnor-
malities in insulin regulation, increased adiposity and laminitis. In
a large across-breed study (610 individuals) of 11 morphometric
and biochemical metabolic traits, our lab has demonstrated that
51–77% of the phenotypic variability is due to individual factors
including age, breed, sex and genetics and 23–49% of the pheno-
typic variability is the result of shared environment. Despite up to
49% of the variability in EMS phenotype being related to shared
environment; only 4–18% of this variability is explained by diet,
amount and intensity of exercise and season, suggesting that other
environmental factors play a role in EMS development. Recent
work has identiﬁed associations between Endocrine Disrupting
Chemicals (EDCs) and human metabolic syndrome and other
endocrine abnormalities. Our preliminary data demonstrated that
horses from farms within 30 miles of EDC disposal sites (EPA
“Superfund sites”) were more likely to have had laminitis
(P = 0.002) and had higher post oral sugar challenge insulin con-
centrations (OST INS) (P = 0.00005), suggesting EDC exposure is
an EMS risk factor. The objective of this study was to determine
if plasma EDC concentration is correlated to metabolic measure-
ments. Plasma EDC concentrations were measured using the
CALUX-DR bioassay in 158 Morgans and 137 Welsh Ponies from
32 farms. Grams fat extracted from plasma and sex (female) were
negatively correlated with EDC concentration. EDC concentration
was positively associated with OST INS (P = 0.03). The results
suggest that some of the unexplained environmental variance iden-
tiﬁed in individuals with EMS is due to exposure to EDCs.
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EVALUATION OF AN ORAL SUGAR TEST FOR DYNAMIC
ASSESSMENT OF FIVE EQUINE BREEDS’ INSULIN
RESPONSE/SENSITIVITY. Jane Manfredi1, Raymond Geor2,
Patty Sue Weber1, Bo Norby1, L Jill McCutcheon2. 1Michigan
State University, East Lansing, MI, USA, 2Massey University,
Palmerston North, New Zealand
Veterinarians have identiﬁed equine metabolic syndrome (EMS)
as the most common cause of laminitis within equine practice. An
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oral sugar test (OST) has been used clinically to identify “at risk”
horses although it has not been rigorously compared to a “gold
standard” frequently sampled intravenous glucose tolerance test
(FSIGTT) in a large number of horses or across diﬀerent breeds.
Eighty-nine horses/ponies of ﬁve diﬀerent breeds (Quarter
Horses [QH], Arabians, Morgans, Welsh Ponies, and Thorough-
breds) had both an OST (0.25 mL/kg Karo syrup) and an
FSIGTT performed at least 24 hours apart. Optimal time for sam-
pling was determined with a repeated measures ANOVA. A ROC
curve used to identify an optimal threshold insulin value for insu-
lin resistant (IR) equids (insulin sensitivity [SI] < 1). Spearman cor-
relations were utilized to examine possible correlations between
OST outcome measures (area under the curve for insulin [AUCi]
and peak insulin concentration) and SI and the acute insulin
response to glucose (AIRg) (the latter two determined by Minimal
Model analysis of the FSIGTT).
IR horses had OST insulin but not glucose concentrations from
60–120 minutes that were signiﬁcantly higher than insulin sensitive
horses. In this cohort, a single time point insulin concentration of
≥30.2 IU/mL was indicative of insulin resistance. Moderate cor-
relations (rho = 0.6) to SI and strong correlations to AIRg
(rho≥0.74) were evident for AUCi and peak insulin concentration.
Weak correlations existed between glucose concentrations and SI
and AIRg. QHs have signiﬁcantly lower OST AUCi than all
breeds except Morgans.
Diﬀerent from what is currently recommended in the literature,
we advise measuring the insulin concentration of a single blood
sample at 60, 75, 90, or 120 minutes post–Karo syrup administra-
tion and using a ≥ 30.2 IU/mL threshold. Practitioners should be
aware that breed may play a role in insulin concentrations that are
achieved during the OST.
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BASAL INSULIN CONCENTRATION IN COMPETITION
DRAFT HORSES. Harold Schott1, Lisanne Gallant1, Elizabeth
Tadros1, Sarah Jacob1, Jane Woodrow2, Melissa Hines2, Susan
Ewart1. 1Michigan State University, East Lansing, MI, USA,
2University of Tennessee, Knoxville, TN, USA
Measurement of basal insulin (INS) concentration is currently
advocated as the endocrine test of choice for screening horses for
insulin dysregulation. Values >20 µU/mL after overnight fasting
and >50 µU/mL in hay fed horses are considered supportive of insu-
lin dysregulation. Although it is well recognized that INS increases
with body condition (fat mass), recent evidence suggests that there
may also be age and breed diﬀerences with regard to basal insulin
concentrations. However, little data exists for draft breeds. Conse-
quently, we tested the hypothesis that INS diﬀers in various breeds
of draft horses, independent of age and body condition. Age was
obtained from owners/trainers and body condition score (BCS) was
assessed and basal (resting but not fasting) INS was measured in 164
draft horses participating in an international competition, including
48 Belgians, 52 Clydesdales, and 64 Percherons. INS was measured
using a radioimmunoassay validated for equine serum (with average
intra- and inter-assays CVs of 3.4% & 6.9% and 4.7% & 7.2% for
low and high equine control sera, respectively). None of the horses
examined had a history or current evidence of laminitis. Age, BCS,
and INS were not normally distributed; thus, median values and
25% and 75% conﬁdence intervals were determined (Table). Data
were analyzed using ANOVA on ranks, Chi square analysis, and
Spearman rank order correlation.
Median age was not diﬀerent between horses sampled for each
breed. Although the Clydesdale breed had a lower BCS as com-
pared to the Belgian breed, there was no diﬀerence in median INS
between breeds or the proportion of horses with an elevated INS
(>50 µU/mL). Further, there were signiﬁcant, albeit weak, positive
correlations between age and INS (R = 0.32, P < 0.01), BCS and
INS (R = 0.19, P < 0.02), and age and BCS (R = 0.36, P < 0.01).
However, of greatest interest, one-third to nearly half (varying
with breed) of all horses tested had an elevated INS, supportive of
insulin dysregulation despite horses being trained for competition
and without evidence of laminitis. In conclusion, this convenience
sampling study of draft horses provides support that INS may
vary between light breeds and draft breeds and that breed needs to
be considered when interpreting INS results.
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MATRIX METALLOPROTEINASE-2 AND -9 LEVELS IN
HORSES WITH EXPERIMENTAL SMALL COLON INTRA-
LUMINAL OBSTRUCTION. Kamila Gravena1, Beatriz de Assis
Pimenta1, Lina Maria Wehrle Gomide2, Vinicius Athaydes
Canello1, Nara Saraiva Bernardi1, Amanda Festa Sabes1, Guil-
herme Dias Melo2, Paulo Ricardo Dell’Armelina Rocha2, Gisele
Fabrino Machado2, Jose Corre^a Lacerda-Neto1. 1FCAV – Univer-
sity of Estadual Paulista – Unesp, Jaboticabal, S~ao Paulo, Brazil,
2FMVA – University of Estadual Paulista, Aracatuba, S~ao Paulo,
Brazil
Among diﬀerent causes of colic, intestinal obstruction has been
identiﬁed as the major cause of hospitalization and death in horses
around the world. In small colon occurs mainly due to fecalomas
or enteroliths. During ischemic process, decreases in oxygen ten-
sion inside the cell occur, reducing the generation of adenosine
triphosphate (ATP) and resulting in cellular homeostasis disorders.
Calcium accumulation inside the cell produces signiﬁcant increase
in the phospholipase A2 activity, which directly damage cell mem-
brane through increased production of arachidonic acid, lysophos-
phatidylcholine and platelet aggregating factor. The platelet
aggregation factor is a potent inﬂammatory mediator, which has
an important eﬀect on vascular permeability and on neutrophil
activity. Neutrophils adhesion to endothelium may also cause
damage to endothelial cells, thus amplifying the reaction. This
occurs due to release of reactive oxygen species (ROS), proteogly-
cans enzymes such as matrix metalloproteinases (MMPs) and elas-
tase from lysosomes during cell degeneration. Therefore, the aim
of this study was to evaluate neutrophil migration and matrix met-
alloproteinase-2 and -9 activity in horses with experimental intralu-
minal obstruction.
For this purpose, eight healthy adult mixed-breed horses were
subjected to small colon distension using a surgically implanted
latex ball in the lumen (Ethical approval: CEBEA- Protocol
#007568-09). Blood and peritoneal ﬂuid samples were obtained
before intestinal distension (M0), after 4 hours of distension (M4 -
when the ball was deﬂated and removed) and 72 hours after
decompression (M72). Twelve hours after the ball removal was
also collected peritoneal ﬂuid sample for neutrophils count. Data
were submitted to Friedman’s test followed by post-hoc Dunn’s
Multiple Comparison Test.
This model induced alterations in neutrophils migration
into peritoneal ﬂuid, the concentration (x103/lL) at M12 and
M72 was signiﬁcantly higher when compared to M0
(M0 = 0.55  0.14; M4 = 3.21  1.24; M12 = 133.18  35.80;
M72 = 35.07  6.08). There was also alterations in plasma pro-
enzyme form of MMP-2 (pro-MMP-2) at M4 and in peritoneal
ﬂuid pro-MMP-2 at M72 and pro-MMP-9 was signiﬁcantly
increase in M4 when compared to M0. Mean ( standard error)
in arbitrary units of plasma pro-MMP-2 was M0 = 94.25  6.14;
M4 = 63.72  4.57 and M72 = 89.52  6.70. Peritoneal
ﬂuid Pro-MMP-2 was M0 = 53.07  10.90; M4 = 89.42  6.23
and M72 = 128.13  10.86. Plasma Pro-MMP-9 was
M0 = 46.75  6.77; M4 = 50.65  6.45 and M72 = 44.92  4.74.
Peritoneal ﬂuid Pro-MMP-9 was M0 = 16.70  5.10;
M4 = 155.77  5.77 and M72 = 90.21  13.14.
Knowing that multiple proteinases are present in the granules
of neutrophils, it was conclude that increase in pro-enzyme form
after small colon decompression may be associated with neutrophil
migration.
Belgian Clydesdale Percheron P value
Age 5 (3-7.5) 6 (3-8.5) 6 (4-9.5) 0.33
BCS 6 (6-7)a 6 (5-6)b 6 (6-7)a,b 0.007
Insulin 37.1 (29.5-72.0) 36.7 (23.4-
53.5)
38.0 (29.2-
62.5)
0.30
# (%) >50 µU/mL 17 (35%) 15 (29%) 39 (47%) 0.07
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EFFECTS OF COLLAGEN HYDROLYSATES ON EQUINE
GASTRIC ULCER SCORES AND GASTRIC JUICE PH IN
HORSES. Michael Keowen1, Pilar Camacho-Luna1, Lisa
Micheau2, Frank Garza Jr1?^!"number(boolean(following-ibling::
degrees))",1, Jos Olijve3, Brian Lamp3, Chin-Chi Liu1, Frank
Andrews1. 1Equine Health Studies Program, Louisiana State
University, School of Veterinary Medicine, Baton Rouge, LA,
USA, 2Ecole Nationale Veterinaire, Toulouse, France, 3Darling
Ingredients International Holding B.V., Son, The Netherlands
Nonglandular (NG) gastric ulcers, as part of the equine gastric
ulcer syndrome (EGUS), are common in performance horses and the
current FDA-approved pharmaceutical agent, omeprazole is eﬀec-
tive in treatment, but expensive and alters gastric juice pH. Recently,
there has been interest in natural feed supplements that improve
stomach health and can be used in horses competing in drug-free
competitions. The purpose of this study was to evaluate the eﬀect of
a feed supplement containing porcine collagen hydrolysates on gas-
tric ulcer scores and gastric juice pH in stall-conﬁned horses, treated
with omeprazole and undergoing intermittent feeding. Ten Thor-
oughbreds were used in a two-period crossover study. The supple-
ment (CHL; collagen hydrolysates, 45 grams) was mixed with sweet
feed (Omelene 100, Purina Animal Nutrition, LLC, Gray Summit,
MO) or sweet feed only (Control group) twice daily for two 56-day
periods. From days 14 to 28, both treatment groups were adminis-
tered omeprazole (OME; 4.0 mg/kg, P.O., Q.D.; Gastrogard, Mer-
ial Limited, Duluth, GA) and from days 42 to 49, horses underwent
an alternating feed-deprivation period, to induce or worsen ulcers.1
Gastroscopies were performed on all horses on days 1 (before
treatment) and days14, 28, 42, 49 and 56. Gastric juice was aspirated
pH measured at each scoping. Nonglandular gastric ulcer number
(NGN) and severity (NGS) scores were assigned at each examination
by the PI (FMA), who was masked to treatment. Data were analyzed
using an ANOVA for repeated measures and when signiﬁcant diﬀer-
ences were found in the main model, a post-hoc Tukey’s test was
used to determine signiﬁcant diﬀerences of P < 0.05. The CHL-sup-
plement in powder form, mixed with the grain, was readily consumed
by all horses and no adverse eﬀects were seen. Mean NGN and NGS
gastric ulcer scores were lower at each gastroscopy examination and
a signiﬁcant treatment eﬀect was seen on day 56 of the study. In
addition, gastric ulcer scores were signiﬁcantly lower in both groups
on day 28, compared to the other days, due to omeprazole treatment.
By day 42, two weeks after omeprazole was discontinued, ulcers
reoccurred in both groups of horses. On day 49, gastric ulcer scores
were signiﬁcantly increased due to intermittent feeding, but no treat-
ment eﬀect was observed. Gastric juice pH values were low and vari-
able throughout the trial period, except on day 28 when pH was
signiﬁcantly higher in CHL-supplement treated group compared to
control group. Omeprazole treatment was eﬀective in increasing gas-
tric juice pH and signiﬁcantly decreasing gastric ulcers scores. In
addition, the collagen hydrolysate supplement signiﬁcantly increased
gastric juice pH while horses were on omeprazole treatment.
Conclusion: Collagen hydrolysates ameliorated the severity of
gastric ulcers in stall-conﬁned horses undergoing feed stress after
56 days of feeding.
1Murray MJ and Eichorn ES. (1996) Am J Vet Res. 57
(11):1599–1603.
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SAFETY, HUMORAL IMMUNE RESPONSE AND FECAL
SHEDDING OF MODIFIED-LIVE BOVINE CORONAVIRUS
VACCINES GIVEN TO HORSES. James Prutton1, Samantha
Mapes2, Nicola Pusterla2. 1Liphook Equine Hospital, Liphook,
UK, 2University of California, Davis, USA
Equine coronavirus (ECoV) is considered an emerging enteric
virus with reported morbidity rates ranging from 10–83% and a
fatality rates ranging from 7–27% in adult horses.
The objectives of the study were to assess the safety, humoral
response and viral shedding of a commercially available modiﬁed-
live bovine coronavirus (BCoV) vaccine given to healthy adult
horses. Twelve conﬁrmed healthy adult horses were vaccinated
twice, 3 weeks apart, either orally, intra-nasally or intra-rectally.
Two healthy unvaccinated horses served as sentinel controls.
Following each vaccine administration, horses were monitored
daily for physical abnormalities and onset and duration of BCoV
shedding determined by quantitative PCR (qPCR) in nasal secre-
tions and feces. Whole blood was collected every 3 weeks to deter-
mine BCoV-speciﬁc antibodies.
With the exception of transient and self-limiting changes in fecal
character observed in 7 vaccinated and 1 control horse, no addi-
tional abnormal clinical ﬁndings were found in the study horses.
Following the ﬁrst and second vaccine administration, two and
one horse, respectively, tested qPCR-positive for BCoV in nasal
secretions 1 d post intra-nasal vaccination. No vaccinated horses
tested qPCR positive for BCoV in feces following each vaccine
administration. One of the two horses that shed BCoV serocon-
verted to BCoV after the ﬁrst vaccine administration and an addi-
tional 2 vaccinated horses (oral and intra-rectal) seroconverted to
BCoV after the second vaccine administration.
In conclusion, the results show that the modiﬁed-live BCoV is
safe to administer to horses via various routes, causes minimal shed-
ding and detectable antibodies to BCoV in 25% of the vaccinates.
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DO HORSES WITH EQUINE METABOLIC SYNDROME
HAVE REDUCED IMMUNE RESPONSES TO VACCINA-
TION?. Sarah Elzinga, Stephanie Reedy, Day Barker, Tom Cham-
bers, Amanda Adams. University of Kentucky, Lexington, KY,
USA
Recent reports indicate the percentage of overweight horses may
range anywhere from 20.6–41%. Obesity is a key component of
Equine Metabolic Syndrome (EMS), which is typically deﬁned by
criteria set in a 2010 ACVIM consensus statement as; regional (neck
crest, rump, etc.) or general obesity, hyperinsulinemia or insulin
resistance, and a history of or predisposition towards laminitis.
Obese humans and diet-induced obese mice have been shown to have
reduced immune responses to vaccination. However, the immune
response of EMS horses to vaccination is unknown. Therefore, the
objective of this study was to determine the eﬀect of EMS on immune
responses to routine vaccination. We hypothesized that, similar to
other species, EMS horses would have a reduced response to a rou-
tine inﬂuenza vaccine compared to non-EMS age matched controls.
To establish this, 25 horses from a pre-existing herd were used for
this study. Of these, 13 were classiﬁed as EMS by the 2010 AVCIM
consensus statement criteria, and 12 were non-EMS age matched
controls. Within each group, 4 served as saline controls and the
remaining horses served as vaccinates. A low-dose dexamethasone
suppression test and TRH stimulation test were performed on all
horses prior to the start of the study to insure no horses tested posi-
tive for pituitary pars intermedia dysfunction (PPID). Venous blood
was drawn weekly for 6 consecutive weeks, with vaccination or sal-
ine administered intramuscularly on weeks 0 and 3. Horses were
vaccinated with an inactivated inﬂuenza vaccine (Fluvac Innova-
tor, Zoetis). Blood samples were used to determine humoral and
cell mediated immune responses. Humoral immune responses
against KY/97 were measured by hemagglutination assay for total
Ig antibody responses and ELISA for IgGa, IgGb, and IgGt anti-
body isotype responses. Cell mediated immune measures were deter-
mined via PBMC isolation, EIV-stimulation, and subsequent ﬂow
cytometry and RT-PCR analysis for cytokine protein and gene
expression, respectively. Humoral immune data were log trans-
formed and analyzed using a repeated measures design with pro-
tected LSD, adjusting for age. All analyses were completed using
PROC MIXED, SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results are expressed as least square means  standard error of the
mean. Data were considered statistically signiﬁcant when P ≤ 0.05.
Overall, all horses responded to vaccination with a signiﬁcant
increase (P < 0.05) in HI titers following initial vaccination com-
pared to saline controls. Signiﬁcant increases (P < 0.001) in IgGa
and IgGb, but not IgGt EIV speciﬁc antibody responses to vaccina-
tion were also observed. EMS did not signiﬁcantly aﬀect (P > 0.05)
humoral immune responses as measured by HI titers or IgG iso-
types to inﬂuenza vaccination, however more work is needed to
explore possible diﬀerences in CMI responses. It is possible that
obesity as compared to insulin resistance plays a larger role in mod-
ulating the immune process considering that while EMS horses were
insulin resistant and had signiﬁcantly greater regional obesity
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(cresty neck score) compared to non-EMS controls, they had mod-
erate general obesity (body condition score), which may have not
been suﬃcient to impact immune response to vaccination.
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IMMUNOLOGICAL COMPARISONS OF AGED HORSES
WITH VERSUS WITHOUT PITUITARY PARS INTERMEDIA
DYSFUNCTION. Melissa H. Siard, Virgina D. Barker, Stephanie
E. Reedy, Amanda A. Adams. Gluck Equine Research Center,
Lexington, KY, USA
Pituitary pars intermedia dysfunction (PPID) is an endocrinopa-
thy aﬀecting 15–30% of the aged equid population. PPID is charac-
terized by various clinical manifestations, the hallmark of which is
hypertrichosis. Additionally, PPID horses exhibit immunosuppres-
sion, making them more susceptible to opportunistic infections. Our
lab has established that aged horses exhibit both immunosenescence
and inﬂamm-aging, the low-grade chronic inﬂammation occurring
systemically with aging. To determine whether these age-related
changes in cell-mediated immune responses may be aﬀected by the
presence of PPID, peripheral blood mononuclear cell (PBMC) pro-
liferation and cytokine production were compared in age-matched
PPID and non-PPID horses. PPID status was determined using thy-
rotropin releasing hormone (TRH) stimulation testing.
Sixteen aged horses (18–27 yrs), including n = 8 PPID horses
(mean = 24.5  2.2 yrs) and n = 8 non-PPID horses (mean =
23.1  3.1 yrs) of mixed breeds and sex, were sampled to determine
immune function. Heparinized blood was collected aseptically, and
PBMCs were isolated, stimulated with Phorbol 12-myristate 13-acet-
ate (PMA), and stained intracellularly for pro-inﬂammatory cytoki-
nes interferon-c (IFNc) and tumor necrosis factor-a (TNFa). Flow
cytometry was performed to determine the percent of lymphocytes
producing IFNc and TNFa. Real-time polymerase chain reaction
(RT-PCR) was used to determine PBMC gene expression of cytoki-
nes interleukin (IL)-2, IL-4, IL-6, IFNc, and TNFa. PBMC prolifer-
ation was also determined using carboxyﬂuorescein succinimidyl
ester (CFSE) staining and stimulation with various amount of con-
canavalin A (Con A; 2.5, 5, and 10 L/mL). TRH stimulation test-
ing was performed, in which adrenocorticotropin hormone (ACTH)
levels were measured in plasma 10 minutes post (T-10) intravenous
administration of TRH (1 mg/mL saline/horse).
Data was analyzed using the statistical software program Sig-
maPlot version 12.3. To analyze ﬂow cytometry and RT-PCR data
for diﬀerences between PPID and non-PPID horses, t-tests were
performed. To analyze lymphocyte proliferation data at various
concentrations of Con A stimulation, two-way analysis of variance
with repeated measures was performed. No signiﬁcant diﬀerences
between PPID and non-PPID horses were found for any of the
immune measures examined including ﬂow cytometry, RT-PCR,
and proliferation data (P > 0.05). These results indicate that the
immunosuppression associated with PPID does not appear to be
due to diﬀerences in PBMC proliferation or cytokine production
when comparing aged PPID horses with aged non-PPID horses.
Thus, more research is warranted to further understand the
immunological mechanisms responsible for immunosuppression
and susceptibility to opportunistic infections in the PPID horse.
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CORYNEBACTERIUM PSEUDOTUBERCULOSIS ANTIBODY
DETECTION IN HORSES: SYNERGISTIC HEMOLYSIS
INHIBITION TEST AND SMALL RUMINANT ELISA COM-
PARISON. Marta Barba1, Anne A. Wooldridge1, Robert Glass2,
Thomas Passler1, Allison J. Stewart1. 1Auburn University,
Auburn, AL, USA, 2Pan American Veterinary Laboratories,
Hutto, TX, USA
False positive results may occur when testing horses for anti-
bodies against Corynebacterium pseudotuberculosis by synergistic
hemolysis inhibition (SHI). In small ruminants, ELISA tests based
on exotoxin and cell wall antigens have greater accuracy than SHI
in diagnosis of caseous lymphadenitis. The purpose of this study
was to compare the detection of C. pseudotuberculosis antibodies
in equine serum by SHI and a small ruminant ELISA test that
uses exotoxin and cell wall antigens. Sera from 7 ponies experi-
mentally infected with C. pseudotuberculosis were analyzed by both
tests. Correlation and agreement were calculated by Pearson and
Kappa coeﬃcients, respectively. Receiver operating characteristic
analysis was used to obtain the optimal cut-oﬀ value for the calcu-
lated ELISA score (Patient optical density/Negative control optical
density x 100). Antigen reactivity to the sera was evaluated by
immunoblotting. When SHI titers ≥1:128 were considered a posi-
tive result, the optimal ELISA score cut-oﬀ to determine positive
status was 106%, with 73% sensitivity and 72% speciﬁcity with
respect to SHI. Correlation between both tests was strong
[r = 0.904; (95%CI 0.472–0.986, P = 0.005)]. Agreement in deter-
mining positive status was poor (Kappa=0.439; (95%CI 0.226–
0.652). Correlation and agreement were strong in 3/7 ponies, but
weak in 4/7. Immunoblot showed a band 13.4 times more intense
in infected compared to pre-infected sera corresponding with the
exotoxin antigen, but only non-speciﬁc reactivity with the cell wall
antigen. The use of this ELISA test in horses is not recommended.
Development of an ELISA test with speciﬁc antigens from C.
pseudotuberculosis biovar equi is needed.
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EFFECTS OF ERYTHROMYCIN ON RESPONSES INDUCED
IN FOALS BY INTRAVENOUS EPINEPHRINE. Amy Stieler1,
Chris Sanchez2, Martha Mallicote2, Ashley Coxen2, Jim Burrow2,
Rob MacKay2. 1University of Georgia, Athens, GA, USA,
2Department of Large Animal Clinical Sciences, University of
Florida, Gainesville, FL, USA
Macrolide-induced anhidrosis is a concern in foals treated for
Rhodococcus equi pneumonia. Because sweating in horses is caused
by activation of b2-adrenergic receptors on sweat glands, it was of
interest to evaluate responses to IV epinephrine in foals given ery-
thromycin. Four pony-cross foals were treated for 3 days prior to
epinephrine infusion with either erythromycin (25 mg/kg orally, 3
times daily) or a control preparation according to a 2-period ran-
domized masked design. Epinephrine was given by CRI over
10 minutes at 0.5 lg/kg/minute and the following data were col-
lected before and at intervals for 180 minutes after onset of infusion:
sweat (absorbed into absorbent pads), heart and respiratory rates,
systemic arterial BP, pupil size, PCV, plasma protein, and blood glu-
cose concentration. Cardiac rhythm was monitored continuously by
ECG. Univariate and 2-factor repeated measures ANOVA were
used to analyze data. Friedman tests were used for data sets that
failed assumptions for ANOVA. Post hoc pairwise analyses were
performed after ANOVA indicated signiﬁcant (P < 0.05) eﬀect. In
foals given either treatment, there were signiﬁcant (P < 0.05) eﬀects
of epinephrine on heart rate, pupil size, PCV and blood glucose.
Sweating and arterial BP also increased signiﬁcantly in control- but
not erythromycin-treated foals. Signiﬁcant treatment x time interac-
tion was found only for sweating; pairwise comparisons were signiﬁ-
cant at every point after time 0. These results suggest that
erythromycin does not cause generalized suppression of a- and b-
adrenergic responses. Anhidrosis may be a tissue-speciﬁc receptor or
post-receptor eﬀect of erythromycin and other macrolides.
E50
EQUINE VECTOR-BORNE DISEASES DETERMINED BY
SEROLOGICAL AND MOLECULAR DIAGNSOTICS. Barbara
Qurollo1, Barbara Hegarty1, Jeﬀrey Tyrrell1, Edward Breitschw-
erdt1, Susan Tornquist2, Kathryn Schlaich2, Jennifer Kelsey2,
Melissa Beall3, Ramaswamy Chandrashekar3. 1Intracelluar Patho-
gens Research Laboratory, College of Veterinary Medicine, North
Carolina State University, Raleigh, NC, USA, 2Oregon State
University, College of Veterinary Medicine, Corvallis, OR, USA,
3IDEXX Laboratories, Inc., Westbrook, Maine, USA
Vector-borne disease impacts the health and welfare of horses,
worldwide. Recognized vector-borne diseases among horses
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include Anaplasmosis (Anaplasma phagocytophilum), Lyme Disease
(Borrelia burgdorferi), Potomac Horse Fever (Neorickettsia risticii)
and Piroplasmosis (Babesia caballi /Theleria equi). Additionally,
Bartonella, Ehrlichia, Rickettsia, and hemotropic Mycoplasma spe-
cies have been detected in horses with clinical disease spectrums
ranging from nonclinical to fatal. The goal of this study is to
investigate serological and molecular (PCR) tests that will detect
vector-borne disease (VBD) pathogens in horses and apply a
broad diagnostic panel to gain a more deﬁnitive picture of vector-
borne equine pathogens, including novel species and co-infections.
Three populations of horses were used to test serological and
molecular diagnostic tests. Group I (n = 16): EDTA-whole blood
(WB) and serum (S) sets from clinically healthy horses pastured in
North Carolina with no clinical suspicion of VBD; Group II
(n = 20): WB and S sets from horses submitted for diagnostic test-
ing to the VBDDL, where presumably the clinician suspected vec-
tor-borne disease; Group III (n = 15): WB from horses in Merida,
Nicaragua with a high degree of tick exposure. Serologic and PCR
testing were performed retrospectively. DNA was extracted from
WB, and qPCR assays were performed to test samples for infec-
tion by bacterial species within the following genera: Anaplasma,
Babesia, Bartonella, Ehrlichia, Mycoplasma, Neorickettsia, Rick-
ettsia and Theilera. For samples with positive results, the infec-
tious agent was speciated by species-speciﬁc qPCR assay of the
sample and/or DNA sequencing of the PCR amplicon. Seroreac-
tivity to Babesia, Bartonella, Neorickettsia and Rickettsia antigens
was determined using IFA, and seroreactivity to 3 Ehrlichia spe-
cies, 2 Anaplasma species and B. burgdorferi antigens was deter-
mined using both a commercially available SNAP4DXPlus
ELISA and a research-based SNAP MA ELISA. The combined
use of serological and molecular assays in this study gave evidence
of infection (by PCR) or exposure (by seroreactivity) to Ana-
plasma, Babesia, Bartonella, Borrelia, Ehrlichia spp., Theileria, and
Rickettsia spp. None of the samples contained DNA from Myco-
plasma spp. and two samples were positive for infection by Rick-
ettsia felis, constituting the ﬁrst reported instances of equine
infection with R. felis detected by PCR. A novel Equine Ehrlichia
species, reported in horses from Nicaragua, was detected in addi-
tional Nicaraguan horse samples from this study by both PCR,
IFA and ELISA. This study highlights the wide-range of exposure
to and infection with vector-borne pathogens in horses.
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SELENIUM DEFICIENCY ASSOCIATED WITH THE
DEATHS OF FIFTEEN ADULT HORSES. Andrew Allen, Debra
Sellon, Fairﬁeld Bain, Danielle Nelson. Washington State Univer-
sity, Pullman, WA, USA
Nutritional myopathy due to selenium (Se) deﬁciency typically
presents itself in young rapidly growing calves, lambs, kids, and
foals. Reports of myodegeneration secondary to selenium deﬁ-
ciency in adult horses are less frequent. We investigated 2 herds
with nutritional myopathy with generalized skeletal muscle degen-
eration and signiﬁcant death loss in adult horses. In 2014, two
American Paint horses from the same farm presented to our diag-
nostic laboratory for post mortem evaluation. Signiﬁcant necropsy
and histopathology ﬁndings included myonecrosis of the cardiac
and skeletal muscles, widespread subcutaneous edema, pleural
eﬀusion and ulcerative glossitis. An on farm investigation was per-
formed where it was discovered that 13 horses, including the two
presented horses, had died on this farm with similar clinical signs
over the last year. Complete blood counts and serum chemistry
panels were performed on 4 of the 12 remaining horses and physi-
cal examinations were performed on the entire herd. All four
horses had elevated creatinine kinase activity (CK) and aspartate
aminotransferase (AST) levels, the herd had an overall low body
condition score, 3 horses had elevated heart rates, and one horse
had pitting ventral edema. All of the horses had extremely low
blood selenium levels, no box elder trees were found on the farm
and gastric contents of the dead horses and feed supplements were
found to be free of ionophores. An on farm echocardiographic
study was performed 6 months post initial investigation on three
of the most severely aﬀected horses. All ﬁndings appeared within
normal limits. In 2015 a second investigation of two dead horses
revealed a very similar scenario and herd wide myodegeneration
secondary to selenium deﬁciency. Although unusual, selenium deﬁ-
ciency should be considered a rule out with adult horses showing
signs of ventral edema, weakness, and abrupt death.
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EFFECTS OF ALFA-LOX FORAGE ON BLOOD GLUCOSE
AND INSULIN ACTIVITY AFTER GRAIN FEEDING IN
HORSES. Frank Garza Jr1, Pilar Camacho-Luna1, Kelsey Bailey1,
Isabelle Nesen2, Michael Keowen1, Liu Chin-Chi1, Frank
Andrews1. 1Equine Health Studies Program, Louisiana State
University School of Veterinary Medicine, Baton Rouge, LA,
USA, 2Ecole Nationale Veterinaire, Toulouse, France
Processed concentrate feeds contain a high concentration of
sugars and in some cases non-structural carbohydrates (NSC)
exceed 35%. These feeds are commonly fed to stall-conﬁned
horses, especially those in competition. Grains, high in NSC, can
overwhelm glucose receptors in the proximal small intestine and
increase delivery of sugars to the hindgut leading to fermentation
and colonic acidosis. Feed supplements, that might enhance glu-
cose absorption in the small intestine, would provide more energy
substrate for exercise and decrease delivery of sugars to the hind-
gut. The purpose of this study was to determine eﬀects of a feed
supplement (ALF; Alfa-Lox Forage, Triple Crown Nutrition, Inc.,
Wayzata, MN), containing chopped alfalfa hay, mannanoligosac-
charides, Omega 3 Fatty Acids, and L-Carnitine, top-dressed on
grain, on plasma glucose concentration and serum insulin activity
in horses before and after grain feeding. Eight healthy Thorough-
breds (7 geldings and 1 mare; ages 2–12 yrs.) were used in a 2-per-
iod cross over study, where horses were fed ALF (2.0 lbs. [0.91
Kg], twice daily) top dressed on a sweet feed grain (2.5 Kg; Ome-
lene 100, Purina Animal Nutrition, LLC., Grey Summit, MO) or
control (grain alone) for 56 days, as part of another study. On
Days 41 and 48, after withdrawing feed overnight, blood samples
were drawn at 8 am, before the morning grain feeding, with or
without ALF, and then again 2 hours after ALF was top-dressed
on grain (treated) or grain alone (control) was fed. Plasma and
serum were separated within 30 minutes of collection and samples
frozen at 70°C for shipment to the Diagnostic Center for Popu-
lation Animal Health (DCPAH; Michigan State University, East
Lansing, MI). Plasma glucose and serum insulin were analyzed
using an automated chemistry analyzer. Data were analyzed statis-
tically using an ANOVA (PROC Mixed; SAS, Cary, NC) for
repeated measures and when signiﬁcant diﬀerences (P < 0.05) were
found in the main model, post-hoc t-tests were performed to deter-
mine signiﬁcant diﬀerences. Alfa-Lox Forage top-dressed on
grain was readily eaten by all horses, and did not result in any
adverse eﬀects. When period data were pooled, on day 42, fasting
mean (SEM) serum insulin activity signiﬁcantly increased from
65.1 (3.5) pmol/L and 61.9 (5.1) pmol/L in control and ALF-trea-
ted horses, respectively, to 126.3 (24.2) pmol/L and 203.1 (30.1)
pmol/L, respectively, 2 hours after feeding sweet feed. In addition,
on day 48, mean serum insulin activity signiﬁcantly increased from
mean (SEM) serum insulin concentrations of 76.3 (4.3) pmol/L
and 69.9 (3.8) pmol/L in control and ALF-treated horses, respec-
tively to 194.6 pmol/L and 290.0 pmol/L, respectively, two hours
after feeding sweet feed. Mean serum insulin activity was signiﬁ-
cantly higher in ALF-treated horses compared to control horses
2 hours after feeding sweet feed. Mean plasma glucose concentra-
tions did not signiﬁcantly increase 2 hours after feeding. Alfa-
Lox Forage top-dressed on grain resulted in higher blood insulin
values, but not signiﬁcantly increased blood glucose concentrations
2 hours after feeding sweet feed. Alfa-Lox Forage resulted in
increased absorption of sugars from the small intestine and more
eﬃcient utilization for glucose for energy, which likely decreased
the amount of sugars delivered to the large colon.
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VENOUS BLOOD GAS, ELECTROLYTE AND METABOLITE
FINDINGS IN HEALTHY NEONATAL FOALS RECEIVING
SODIUM LACTATE INFUSIONS. Breanna Sheahan1, Pamela
Wilkins1, Ray Boston2, Kara Lascola1, Igor Canisso1, Kevin
Kline3, Scott Austin1, Levent Dirikolu1, Brian Aldridge1. 1Univer-
sity of Illinois College of Veterinary Medicine, Urbana, IL, USA,
2University of Pennsylvania School of Veterinary Medicine, New
Bolton Center, Kennett Square, USA, 3University of Illinois
Department of Animal Science, Urbana, IL, USA
Exogenous sodium L-lactate (LAC) (1 mmol/kg BWT over
15 minutes) was administered to 6 healthy neonatal foals to deter-
mine LAC clearance variables at 12 hours (12Hr) and again at
60 hours (60Hr) of age. We hypothesized there would be diﬀer-
ences in some venous blood gas (VBG) variables associated with
both age (12Hr versus 60Hr) and sample time.
Venous blood was collected into heparinized syringes via a
catheter in the right jugular vein prior to lactate infusion for blood
gas (BG), electrolyte and metabolite analyses and repeated at 0,
15, and 60 minutes after infusion completion using the NOVA
Critical Care Express. Statistical comparisons were by Friedman
analysis between time points of the same infusion, and Wilcoxon
Rank Sum between age groups, P < 0.05. Two-way ANOVA by
general linear model was also used to assess diﬀerences and inter-
actions associated with age at testing and sample time.
There were no appreciable deleterious clinical eﬀects of infusion.
Sodium LAC infusion in normal neonatal foals resulted in clini-
cally unimportant changes in VBG measures. HCT, O2CT, Cl-,
LAC, creatinine and BUN were signiﬁcantly greater in 12Hr foals.
pH, O2SAT, HCO3-, BEecf, K+ and Ca++ were signiﬁcantly
greater in 60Hr foals. Only LAC was diﬀerent related to sample
time, being largest at end infusion. No diﬀerences were found for
pCO2, pO2, Mg++, glucose, TCO2, Gap, or osmolarity.
Infusion of sodium LAC does not importantly impact VBG,
electrolyte or metabolite measures in healthy 12Hr and 60Hr foals,
with the identiﬁed diﬀerences primarily due to age.
E54
GROWTH AND FUNCTION OF EQUINE ENDOTHELIAL
PROGENITOR CELLS LABELED WITH SEMICONDUCTOR
QUANTUM DOTS. Randolph L. Winter1, Wen Seeto2, Yuan
Tian2, Fred J. Caldwell1, Elizabeth A. Lipke2, Anne. A Wool-
dridge1. 1Department of Clinical Sciences, Auburn University Col-
lege of Veterinary Medicine, Auburn, AL, USA, 2Department of
Chemical Engineering, Auburn University, Auburn, AL, USA
Endothelial progenitor cells (EPCs) contribute to neovascular-
ization and vascular repair in vivo and are attractive for clinical
use in ischemic disease. EPC tracking is essential to determine
engraftment after administration. Semiconductor quantum dots
(QD) are promising for cell labeling due to ease of uptake by
many cell lines and their continued presence after many cell gener-
ations. The purpose of this study was to evaluate function and
growth of equine EPCs after QD label.
Equine EPCs were incubated with QD (2 – 20 nM) for 12-hr or
24-hr, and intensity of label was assessed with ﬂuorescent micro-
scopy. Cell proliferation of EPCs labeled with QD for optimum
time and concentration was then assessed by comparing the num-
ber of cell doublings per day (NCD) and the population doubling
time (PDT) in labeled and unlabeled cells. EPC function was
assessed by comparing uptake of acetylated low-density lipopro-
tein (DiO-Ac-LDL) and in vitro tubule formation in labeled and
unlabeled cells.
Equine EPCs readily labeled with QD, showing maximum ﬂuo-
rescence using 20 nM QD, with a 24-hr incubation time. NCD
and PDT were unchanged with QD label (P = 0.95, P = 0.99).
Uptake of DiO-Ac-LDL by EPCs was not aﬀected by the presence
of QD label (97.9% labeled cells; 97.0% unlabeled cells). Tubule
formation on Matrigel was not aﬀected by the presence of QD
label.
Equine EPCs are eﬀectively labeled with QD, and QD concen-
trations up to 20 nM do not aﬀect cell growth or function. The
use of QD labeling with equine EPCs may help track engraftment
of EPCs in clinical applications.
F01
PREVALENCE OF COAGULASE-NEGATIVE STAPHYLO-
COCCI SPECIES IN INTRAMAMMARY INFECTION IN
DAIRY GOATS. Ve´ronique Bernier Gosselin, Pamela R.F.
Adkins, John R. Middleton. University of Missouri, Columbia,
MO, USA
Coagulase negative staphylococci (CNS) are the most prevalent
pathogens isolated from intramammary infection in goats, with
more than 15 diﬀerent species being identiﬁed in goat milk. Unlike
cows, the relationship between CNS infection, somatic cell count
and milk loss in goats is less clear. The conﬂicting results between
studies on CNS mastitis in goats may be explained by the varia-
tion between studies in regard to distribution of CNS species,
varying pathogenicity between species, the presence of confound-
ing factors aﬀecting outcome measures, and variation between
studies in regard to speciation methods. Phenotypic speciation was
used in most studies; however genotyping is considered more reli-
able than phenotyping for identiﬁcation of CNS species in goats.
The objective of this study was to estimate the prevalence of spe-
cies-speciﬁc CNS intramammary infections in a large dairy goat
herd in Missouri.
Composite milk samples were aseptically collected from all 940
lactating goats and aerobic bacteriological culture was performed.
A culture yielding 100 CFU/mL CNS was considered positive. Iso-
lates from milk samples yielding a single colony morphology iden-
tiﬁed as CNS were used to prepare lysates for PCR ampliﬁcation.
Species identiﬁcation was based on PCR ampliﬁcation and
sequencing of either the rpoB, tuf gene, or 16S rRNA. Sequences
were compared with the GenBank database using the NCBI
Nucleotide-BLAST algorithm. For rpoB, species identiﬁcation was
assigned with ≥ 97% identity and ≥ 5% separation between diﬀer-
ent species. For tuf, species identiﬁcation was assigned with ≥ 98%
identity and > 0.8% separation between diﬀerent species. For 16S,
species identiﬁcation was assigned with ≥ 99% identity and >
0.8% separation between diﬀerent species. PCR ampliﬁcation and
sequencing of rpoB, tuf and 16S were performed sequentially until
identiﬁcation was assigned. For instance, tuf was performed on
isolates for which rpoB either yielded unsuccessful ampliﬁcation,
or criterion for identiﬁcation with sequence analysis were not met,
followed by 16S if tuf ampliﬁcation or sequence analysis failed.
From 940 milk samples cultured, 214 yielded growth of CNS of
a single colony morphology. Of these 214 isolates, 184 were suc-
cessfully speciated, of which 157 were identiﬁed with rpoB, 26 with
tuf, and 1 with 16S. The remaining 30 isolates were unable to be
speciated based on the criteria listed above. Overall, 13 diﬀerent
species were identiﬁed (Table 1). Among isolates that could not be
assigned an identiﬁcation, 3 met the criterion for identity but
insuﬃcient separation between the species (S. warneri and S. pas-
teuri) with both rpoB and tuf sequencing.
Table 1. Species-specific prevalence among 184 CNS isolates and
number of isolates successfully speciated by each gene, per species.
Species
Number of 
isolates % rpoB tuf 16S
S. simulans 69 37.5 65 4 0
S. caprae 31 16.8 30 1 0
S. chromogenes 26 14.1 25 0 1
S. epidermidis 19 10.3 17 2 0
S. xylosus 16 8.7 12 4 0
S. equorum 7 3.8 0 7 0
S. cohnii 6 3.3 3 3 0
S. lentus 5 2.7 1 4 0
S. arlettae 1 0.5 1 0 0
S. aureus 1 0.5 1 0 0
S. auricularis 1 0.5 1 0 0
S. gallinarum 1 0.5 1 0 0
S. sciuri 1 0.5 0 1 0
Total 184 100 157 26 0
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Typeability of CNS isolates from goat milk in this study using
gene sequencing was 86%. Typeability with rpoB gene sequencing
alone was 73%, which was lower than expected. This may result
from underrepresentation of isolates of caprine origin in the refer-
ence database. Unsuccessful PCR ampliﬁcation in a proportion of
isolates could reﬂect imperfect match between the primer and the
target sequence. Relative prevalence of diﬀerent species was similar
to that of previous studies using genotyping or phenotyping.
F02
ASSESSMENT OF AN ANTIMICROBIAL-USE ALGORITHM
FOR TREATMENT OF DIARRHEA IN DAIRY CALVES.
Diego E. Gomez1, Luis G. Arroyo2, Laurent Viel2, J. Scott
Weese1. 1Department of Pathobiology, Ontario Veterinary College,
University of Guelph, Guelph, ON, Canada, 2Department of Clin-
ical Studies, Ontario Veterinary College, University of Guelph,
Guelph, ON, Canada
The objective of this study was to evaluate the impact of imple-
menting an antimicrobial-use algorithm on antimicrobial (AB)
treatment and mortality rates of diarrheic calves.
Three commercial dairy farms (F1, F2, F3) were enrolled. Farm
records were obtained to collect data about the incidence of diar-
rhea, AB treatment and mortality rates for the preceding
18 months. Then, an antimicrobial-use algorithm for farm person-
nel based on the presence of three clinical signs (diarrhea, fever
and decreased milk intake) was developed to direct AB therapy in
diarrheic calves (<30 day-old) and the same farm data were col-
lected from the same records systems for 5, 2 and 2 months for
F1, F2 and F3, respectively.
Treatment records of 1208 (F1), 1051 (F2) and 296 (F3) calves
were available for the pre-intervention period. The incidence of
diarrhea was 86, 90 and 57%, AB were administered to 99, 95 and
33% of diarrheic calves and mortality rates attributed to diarrhea
were 3, 3 and 2% in F1, F2 and F3, respectively. After the algo-
rithm implementation, data were available for 105 (F1), 282 (F2)
and 31(F3) calves. Diarrhea developed in 74, 89 and 67% calves
on the three farms, but treatment rates were signiﬁcantly lower;
39, 14 and 0% (P < 0.0001), with no impact on mortality (1.3, 0.8
and 0%, respectively, P > 0.05).
The use of a simple and practical antimicrobial-use algorithm
can provided a signiﬁcant reduction in the use of antimicrobials,
decreasing treatment costs and improving antimicrobial steward-
ship with no negative impacts on calf health.
F03
PREVALENCE OF BOVINE CORONAVIRUS IN FECES OF
HEALTHY AND DIARRHEIC CALVES. Diego E. Gomez1, Luis
G. Arroyo2, Laurent Viel2, J. Scott Weese1. 1Department of
Pathobiology, Ontario Veterinary College, University of Guelph.,
Guelph, Ontario, Canada, 2Department of Clinical Studies,
Ontario Veterinary College, University of Guelph, Guelph, ON,
Canada
Bovine coronavirus (BoCV) is an endemic pathogen that can be
associated with enteric disease, especially in calves. This study was
conducted to assess the prevalence of BCoV in healthy and diar-
rheic calves and to determine whether the presence of BCoV in
feces is associated with the age and health status of the calf.
This was a prospective case-control study. Fecal samples from
89 diarrheic calves from three diﬀerent commercial dairy farms
were tested for BCoV using a PCR assay. For each study case one
age-matched control calf from the same farm was enrolled. Cate-
gorical variables were analyzed using X2 and univariable logistic
regression analyses. Multivariable analysis using a mixed eﬀect
logistic regression model (with farm as a random eﬀect) was per-
formed to determine signiﬁcant association between testing posi-
tive for BCoV in feces with the age and the presence of diarrhea.
Age of the calf was categorized using a cut-oﬀ of 10 days.
The age of healthy and diarrheic calves was 8.5  3 and
9.4  3.9 days, respectively (P = 0.06). There was a signiﬁcant
diﬀerence in the prevalence of BCoV between healthy (54%) and
diarrheic (69%) calves (P = 0.039). Multivariable logistic regres-
sion revealed that calves positive for BCoV were more likely to be
older than 10 days of age (OR: 2.2, CI, 1.21 to 3.95; P = 0.009)
and have diarrhea (OR: 1.73, CI, 1.07 to 2.81; P = 0.025).
This study determined that BCoV can be detected in both
healthy and diarrheic calves; however, the likelihood of BCoV is
higher in diarrheic calves. Future studies investigating whether
BCoV strains detected in healthy and diarrheic calves are geneti-
cally diﬀerent are warranted.
F04
USE OF AN ALIVECOR HEART MONITOR FOR HEART
RATE AND RHYTHM EVALUATION IN DOMESTIC
GOATS. Joe Smith1, Meera Heller2, Fauna Smith2, Mikaela
Mueller3, Jessica Ward1. 1Iowa State University, Ames, IA, USA,
2University of California Davis, Davis, California, USA, 3Blue
Pearl Veterinary Partners, Seattle, WA, USA
The AliveCor Heart Monitor, a smartphone-based electrocar-
diogram (ECG) recording device, is a promising new diagnostic
tool in veterinary medicine. While this device has been validated
for canine, feline, and equine species, its clinical utility in domestic
goats has not yet been evaluated.
Eight healthy adult dairy breed and eight healthy adult meat
breed goats had simultaneous AliveCor and standard base apex
ECGs performed in a standing position. The AliveCor ECG was
recorded using two diﬀerent device positions (over the left cardiac
apex and over the brisket region). Paper speed was 25 mm/sec and
amplitude was 10 mm/mV. All ECGs were evaluated unpaired and
independently by a data-blinded veterinary cardiologist. The aver-
age heart rate was determined using 6 seconds of ECG recording,
rhythm diagnosis was recorded for each tracing, and each ECG
was given a quality score (0–3). The ﬁndings were then reviewed
to determine if the AliveCor device was comparable to the base
apex ECG for rate and rhythm diagnosis via a paired t-test. Dif-
ferences in quality scores between the readings for each goat were
assessed via a Mann-Whitney U-test. Quality score diﬀerences
were assessed with a Mann-Whitney U-test between breeds and
location of AliveCor ECG. Rhythm agreement was assessed by
comparing the blinded rhythm diagnoses made by the cardiologist.
No signiﬁcant diﬀerences were found between heart rates collected
via AliveCor or standard base apex ECGs (P = 0.8151). Quality
scores were signiﬁcantly higher for AliveCor tracings (1.85 + /- 0.66)
compared to standard base apex tracings (0.94 + /- 0.78)
(P < 0.0001). No signiﬁcant diﬀerence in AliveCor quality score was
noted between meat and dairy breeds (P = 0.094). No signiﬁcant
diﬀerences were noted between quality scores of AliveCor readings
taken from the left cardiac apex or sternal region (P = 1.000).
Normal sinus rhythm was present in all goats, and could be diag-
nosed via the AliveCor tracings in 93.75% of cases. Based on this
study, the AliveCor ECG was clinically useful for heart rate determi-
nation and diagnosis of normal sinus rhythm in goats. Interestingly,
AliveCor ECGs had higher quality scores compared to standard
base apex ECGs.
F05
LEFT DISPLACEMENT OF THE ABOMASUM IN FOUR
BEEF CALVES. Rachel Oman1, Robert Streeter1, Emily Rep-
pert2, Clemence Chako3. 1Oklahoma State University, Stillwater,
OK, USA, 2Kansas State University, Manhattan, KS, USA, 3Mid-
western University, Glendale, AZ, USA
Left displaced abomasum (LDA) is an uncommon condition in
beef cattle compared to dairy cattle and is rarely described in
sucking beef calves. The true prevalence of LDA in beef calves is
unknown and diﬃcult to gauge based on the few reported cases.
There remains a paucity of information regarding the diagnosis
and treatment of LDA in beef calves.
Four beef calves (two mixed breed beef, one Beefmaster, and
one Angus) between two weeks and three months of age were
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treated for LDA between November 2013 and March 2015. All
four calves had a history of decreased appetite and left-sided
abdominal distention; two had recently been treated for necrotic
laryngitis and one calf was being treated for suspected clostridial
abomasitis. A high-pitched ping and splash were ausculted with
percussion and succussion of the left abdomen. Ultrasonography
conﬁrmed the abomasum to be displaced between the rumen and
the left body wall in all four calves. Blood gas analysis revealed
hypokalemic, hypochloremic metabolic alkalosis in three of the
calves.
All four calves were initially treated by rolling to correct the left
abomasal displacement, and facilitate correction of metabolic
abnormalities. Following rolling, the abomasum re-displaced in
three of the calves within one hour to 11 days; one calf became
acutely colicky as a result of a mesenteric volvulus. A right para-
median abomasopexy was preformed in all cases. Three of four
calves grew well and remained in the herd six to 18 months later;
one calf was euthanized 10 days after surgery due to complications
associated with necrotic laryngitis.
Based on these ﬁndings, LDA is likely more common in beef
calves than many veterinarians recognize and it should be consid-
ered as a diﬀerential for calves that present with abdominal disten-
tion. Concurrent laryngeal dysfunction has not been previously
described in beef calves with LDA and may be a contributing fac-
tor in the pathogenesis of this disorder. Ultrasonography is a
widely available chute-side diagnostic technique that can rapidly
conﬁrm the diagnosis in beef calves. Rolling is a useful adjunctive
measure for allowing temporary improvement in cases with severe
metabolic alterations, but may be associated with catastrophic
intestinal complications in calves as has been reported in adult
cows. Therefore, surgical correction is recommended, and right
paramedian abomasopexy under sedation and local block is a fea-
sible method of correction of LDA in beef calves.
F06
APPARENT EFFICIENCY OF COLOSTRAL IMMUNOGLOB-
ULIN ABSORPTION IN HOLSTEIN HEIFERS. Jennifer Hal-
leran1,2, Derek Foster1,2. 1Oklahoma State University, Stillwater,
OK, USA, 2North Carolina State University, Raleigh, NC, USA
Adequate absorption of bovine colostrum correlates with
improved neonatal health. The apparent eﬃciency of absorption
(AEA) of immunoglobulins can be measured using a mathematical
equation based on serum and colostral IgG concentration levels,
as well as the volume of colostrum being fed and the body weight
of the calf. While commonly measured in research projects, little
information is available on the normal AEA across a large group
of healthy calves on multiple farms. The purpose of this study was
to observe how contributing factors (volume of feeding, birth-
weight and time of feeding) can alter AEA, and to establish a nor-
mal range of AEA in healthy calves.
One hundred and two Holstein heifer calves from 5 diﬀerent
dairies in North Carolina and Colorado were sampled. After a
normal calving, an aliquot of colostrum being fed to the heifer
was saved and the heifer received either 4 liters or 5.6 liters of
colostrum within 6 hours of birth and a blood sample was col-
lected between 24 and 36 hours after birth. Birthweights were mea-
sured using the same weight tape on each farm. Radial
immunodiﬀusion assay was performed to obtain IgG concentra-
tions in the colostrum and serum samples. From this data, the
AEA was calculated.
AEA ranged from 7.7% to 59.9% with mean of 28.1%  9.5
and median of 27.5%. AEA of 69% (70/102) of the calves fell
between 21–40%. There was a signiﬁcant correlation (P = 0.033,
r = 0.21) between birthweight and AEA and volume fed and AEA
(P = 0.030, r = 0.22). There was no correlation between time of
feeding and AEA or total IgG mass fed and AEA.
AEA varies widely between calves even when feeding is stan-
dardized. There appears to be opportunities to improve the serum
IgG concentration in calves by feeding increased volumes of colos-
trum, as in this study we were unable to saturate the absorption
process. With the wide range of AEA values obtained, there may
be opportunities to improve AEA through genetic selection.
F07
CONCENTRATIONS OF CHLORTETRACYCLINE IN FETAL
TISSUES FOLLOWING ORAL ADMINISTRATION IN THE
EWE. Kevin Washburn1, Virginia Fajt1, Hans Coetzee2, Shannon
Washburn1. 1Texas A&M University, College Station, USA, 2Iowa
State University, Ames, IA, USA
The objective of this study was to determine the disposition of
chlortetracycline (CTC) in pregnant ewes and their unborn fetuses
following oral administration of 500 mg/head/day during the last
trimester of gestation.
Five pregnant sheep were administered 500 mg of CTC in
divided doses for 8 days. On day 7, the fetus was surgically
implanted with venous lines for sampling, and placenta and amni-
otic ﬂuid were harvested. Fetal plasma was sampled for 36 hours
after the last dose of CTC. Subsequently, ewes were sacriﬁced and
samples of amniotic ﬂuid, placenta, fetal kidneys, fetal liver, and
fetal stomach contents were collected.
Observed CTC concentrations were below the limit of quantiﬁ-
cation for all fetal tissues with the exception of liver and kidney in
all but two fetuses. Fetal liver concentrations ranged from 4.6
to125.9 ng/mL, while fetal kidney concentrations ranged from 8.1
to 17.4 ng/mL 36 hours after the last dose of CTC.
Although our study indicated that CTC crosses the placental
barrier based on accumulation in the fetal kidney and liver, con-
centrations achieved were far below the minimum inhibitory con-
centrations (MIC) reported in the literature for isolates from
abortion outbreaks and below our limit of quantiﬁcation in amni-
otic ﬂuid, fetal stomach contents and placenta. No studies demon-
strate the concentrations of CTC that are preventative for
abortion from Campylobacter spp.; our ﬁndings suggest that either
the dosage used in this study is not high enough or that the phar-
macodynamic parameter relating preventive dose to pathogen
MICs is yet to be determined.
F08
HYPERKETONEMIA AS A TOOL TO PREDICT MORTAL-
ITY IN DAIRY GOAT DURING LAST MONTH OF PREG-
NANCY. Vincent Dore1, Jocelyn Dubuc2, Anne-Marie Belanger2,
Sebastien Buczinski2. 1North Carolina State University, Raleigh,
North Carolina, USA, 2Universite de Montreal, Saint-Hyacinthe,
QC, Canada
Increased ketone bodies concentration in blood has been used
to monitor goat during last month of pregnancy to diagnose ani-
mal with subclinical and/or clinical cases pregnancy toxemia (PT).
Since clinical cases of PT are highly fatal, early diagnostic tool to
predict mortality on farm would be useful to producer to save
money on animal with lower chance of survival or to initiate more
aggressive therapy depending on the value of the animal and its
fetuses.
The objective of this study was to determine if increased ketone
bodies concentration were associated with mortality in goats from
herds with a history of pregnancy toxemia.
A prospective cohort study was performed on 1242 lactating
goats from 10 commercial herds in Quebec, Canada. Each goat
was followed weekly during the 5 last weeks of pregnancy or until
parturition. During each farm visit all pregnant goats were sam-
pled until more than 95% of the group had kidded. Blood samples
from jugular vessel were collected and were analyzed directly on
farm using an electronic on-farm test for the quantiﬁcation of
blood b-hydroxybutyrate acid (BHBA) concentration (Precision
Xtra, Abbott Diabetes Care, Saint-Laurent, Canada). Producers
evaluated each goat for presence of PT based on a 4 degrees scale
(absence, low, moderate, or strong suspicion of PT) using a stan-
dardized deﬁnition. Number of fetuses, mortality, diﬃculty of kid-
ding, and presence of treatment, anorexia, lethargy and isolation
from the rest of the herd were evaluated during the ﬁrst week fol-
lowing parturition.
Pregnancy toxemia was diagnosis in 108 goats. Prevalence of
mortality was 5.0% during prepartum and ﬁrst week of lactation
period. There were 26 cases of mortality during prepartum period
(96.2% associated with PT) and 28 cases of mortality during the
ﬁrst week of lactation (71.4% associated with PT). Critical cut-
points for predicting mortality during last month of pregnancy
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and ﬁrst week of lactation were determined based on the highest
sum of sensitivity and speciﬁcity every week. Blood concentration
above 0.6 mmol/L during week 4 before kidding (sensitivity (Se):
44.7%; speciﬁcity (Sp): 86.7%), 3 (Se: 65.4% ; Sp: 82.7%), and 2
(Se: 70.8%; Sp: 76.1%) before kidding, above 1.4 mmol/L during
week 1 before kidding (Se: 51.3% ; Sp: 93.5%) and above 1.7 for
the ﬁrst week of lactation (Se: 28.6% ; Sp: 95.0%) were selected as
the optimal cutpoints in this study. Presence of treatment during
the last month of pregnancy was associated with increased mortal-
ity in dairy goat (OR: 11.79, P < 0.01)
In conclusion, even if hyperketonemia is associated with low to
moderate sensitivity from week to week, the test shows good speci-
ﬁcity with relatively low prevalence of mortality. For this reason
hyperketonemia appeared as a cheap test to assess the risk of mor-
tality during the last month of pregnancy. However, others param-
eters should be evaluated to access prognosis in goat with PT.
F09
EFFICACY AND PHARMACOKINETICS OF INTRAVENOUS
FAMOTIDINE IN ADULT STEERS. Christie Balcomb1, Meera
Heller1, Heather Kynch1, Munashe Chigerwe1, Allison Meyer2.
1University of California, Davis, Davis, CA, USA, 2University of
Missouri, Columbia, MO, USA
The objectives were to measure the pH of abomasal outﬂow
ﬂuid as an indicator of abomasal pH in adult cattle after adminis-
tration of the H2-receptor agonist famotidine as a single dose of
0.4 mg/kg IV or as three doses of 0.4 mg/kg IV every eight hours
to mimic clinical application and secondly to describe the pharma-
cokinetic behavior of intravenous famotidine in adult cattle.
A prospective random two-way crossover study design was
implemented using 4 healthy adult Angus steers previously ﬁtted
with duodenal cannulae located orad to the bile and pancreatic
ducts. The steers were fed alfalfa hay ad-lib and whole corn and
soybean hull meal pellets at 4 lbs/head 12 hours apart. On Day 1,
steers were administered either 0.4 mg/kg famotidine or an equal
volume of saline via jugular catheters. Whole blood and abomasal
outﬂow samples were obtained at intervals for a 12-hour period.
On Day 2, steers were administered either 0.4 mg/kg famotidine or
saline IV at time 0, 8, and 16 hours. After a 24-hour washout per-
iod, the opposite treatments were administered and the study
repeated. Whole blood and abomasal outﬂow samples were
obtained at intervals for a 24-hour period. Abomasal outﬂow ﬂuid
was tested for pH using a commercial bench top pH meter within
5 minutes of sampling. Fluid pH was analysed using a mixed
model in SAS 9.4 with treatment, sampling hour, and treat-
ment*hour as ﬁxed eﬀects and steer and treatment period as ran-
dom eﬀects. Least square means were separated using least
signiﬁcant diﬀerence. Serum was separated and stored at 20°C
until pharmacokinetic analysis. Serum famotidine analysis was per-
formed using tandem liquid chromatography mass spectrometry
and pharmacokinetic analysis was performed using commercial
software.
The treatment*sampling hour interaction aﬀected abomasal out-
ﬂow pH for both a single dose and multiple doses of famotidine
(P < 0.001). A single dose of intravenous famotidine resulted in a
signiﬁcant increase of abomasal outﬂow pH as compared to the
control group for 4 hours after administration (P < 0.05). When
administered every 8 hours, the abomasal outﬂow pH of the famo-
tidine treated group was greater than the control group for
4 hours after the ﬁrst dose (P < 0.05), 2 hours after the second
dose, and 1 hour after the third dose (P < 0.05). Pharmacokinetic
analysis demonstrated that famotidine had a terminal half-life of
3.33 (3.21 – 3.54; median and range) hours, a volume of distribu-
tion of 0.042 (0.014 – 1.89) L/kg and a clearance of 1.26 (0.625 –
11.5) mL/min/kg.
In conclusion, an H2-antagonist, famotidine increases gastric
pH by reducing acid production by parietal cells. This study
showed that a single intravenous dose of famotidine administered
at 0.4 mg/kg is eﬀective at increasing the abomasal outﬂow pH of
adult cattle for up to 4 hours as compared to saline control. When
administered every 8 hours, to mimic clinical therapeutic recom-
mendation, the abomasal outﬂow pH was signiﬁcantly higher for
4 hours after administration of the ﬁrst dose; however, the eﬀect
seemed to decrease after each subsequent dose. Results of this
study indicate that famotidine administered at 0.4 mg/kg IV is
eﬀective at raising the abomasal pH and may be an eﬀective treat-
ment for abomasal ulceration in adult cattle. However, the eﬃcacy
of treatment may decrease over time or may require more frequent
dosing to sustain elevated abomasal pH.
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THE PHARMACOKINETICS OF INTRAVENOUS
GENTAMICIN IN HEALTHY YOUNG-ADULT VERSUS
AGED ALPACAS. Andrew Gestrich1, Daniela Bedenice1, Michelle
Ceresia2, Cheryl Stockman1, Iman Zaghloul2. 1Cummings School
of Veterinary Medicine at Tufts University, North Grafton, MA,
USA, 2School of Pharmacy, MCPHS University, Boston, MA,
USA
The study objective was to evaluate the eﬀects of patient age on
aminoglycoside pharmacokinetics in young-adult (≤5 years) and
aged (≥14 years) healthy alpacas, receiving a single 6.6 mg/kg
intravenous injection of gentamicin (Henry Schein). Heparinized
plasma samples were obtained at designated time-points following
drug administration and frozen at 80°C until assayed by a vali-
dated immunoassay (QMS). Gentamicin plasma concentrations
versus time plots were analyzed using a two-compartment model
and commercial software (WinNonlin-v6.4). Data were compared
between age-groups using independent samples t-test; P < 0.05
considered signiﬁcant.
Baseline physical and hematological parameters were not signiﬁ-
cantly diﬀerent between young (median age [range]: 2.6 [1.7–3.7]
years) and aged (15.5 [14.6–18] years) alpacas, aside from a lower
mean heart rate in older animals (50  13 versus 79  15 beats/
minute). Laboratory results did not diﬀer pre and post-treatment.
Comparative pharmacokinetic parameters are displayed below
(mean SD; †P < 0.05):
Both the peak gentamicin concentration at the end of the distri-
bution phase (23.8  2.1 versus 26.1  2 µg/mL, P = 0.04) and
the mean time-point at which gentamicin trough levels reached
2 µg/mL (common MIC for large-animal pathogens) were signiﬁ-
cantly lower in young-adult versus older animals (6.7  1 versus
8.7  1.9 hours, P = 0.03). These data indicate reduced renal
drug clearance in aged alpacas.
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PROGNOSIS ASSOCIATED WITH CEREBROSPINAL FLUID
ANALYSIS RESULTS IN RECUMBENT DAIRY CATTLE:
RETROSPECTIVE STUDY (2006–2014). Marie-E`ve Bilodeau,
David Francoz, Damien Achard, Andre Desrochers, Sylvain
Nichols, Marie Babkine, Helene Larde, Carolyn Grimes, Gilles
Fecteau. Universite de Montreal, Saint-Hyacinthe, QC, Canada
In recumbent dairy cows, the analysis of the cerebrospinal ﬂuid
(CSF) is an ancillary test frequently used at our referral center.
Interpretation of the CSF analysis results in cattle is challenging,
in part, because reported intervals for this species diﬀer. In a pre-
vious retrospective study, we demonstrated that recumbent cows
with a CSF total nucleated cells count (TNCC) ≥ 4.5 cells/µL and/
or a protein concentration ≥ 0.40 g/L had a spinal cord lesion on
post mortem examination. However, CSF results below those
threshold values did not exclude the presence of such a lesion.
The objective of this study was to determine the short-term and
long-term prognosis in recumbent adult dairy cows who underwent
C0
(μg/mL)
AUC0-∞ †
(μg*h/mL)
T1/2α
(h)
T1/2β
(h)
Vss
(L/kg)
Cl †
(mL/h/kg)
Young-adult (n=8) 54.6±6.5 70.4±10.5 0.13±0.02 1.7±0.02 0.21±0.02 95.5±13.4
Aged (n=8) 65.2±13.2 90.4±17.6 0.12±0.04 2.1±0.5 0.21±0.02 75.6±16.1
C0–Initial plasma concentration; AUC–Area under the curve; T1/2 α and β–Distribution and   
elimination half-life; Vss–Volume of distribution at steady state; Cl–Clearance
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CSF analysis. The previously mentioned threshold values for
TNCC and protein concentration were used. We hypothesized that
recumbent cows with CSF values higher than the pre-determined
threshold values would have a less favorable short-term and long-
term prognosis. All dairy cattle, of 2 years or more of age, that
were recumbent and who have had a CSF analysis were included
in the study (n = 214 cases). CSF analysis was performed by board
certiﬁed pathologists, and only CSF analysis which contained both
the TNCC and protein concentration were included in the study.
A successful short-term prognosis was based on the return to the
farm. A successful long-term prognosis was based on the comple-
tion of at least one lactation using the Canadian Dairy Network
database. Statistical analysis was performed using the Chi-squared
test to compare numbers of cows in each group.
Age of patients ranged from 2.0 to 14.5 years (median
5.6 years). Two hundred and eight cows were Holstein, 4 were
Ayrshire and 2 were Jersey. The duration of hospitalization ranged
from 1 to 48 days (median 7 days). In cows for which the infor-
mation was available, days in milk ranged from 1 to 516 days (me-
dian 25 days) and 18% of the cows (23/130) were dried. Of the
214 cases studied, 167 cows had CSF values for TNCC and pro-
tein concentration below the threshold values, and 47 cows had
CSF values above the pre-determined threshold values.
The results showed that TNCC ≥ 4.5 cells/µL and/or a protein
concentration ≥ 0.40 g/L was associated with a worse short-term
prognosis in recumbent dairy cattle. Indeed, 53% of cows with
CSF values below the pre-determined threshold values were dis-
charged from the hospital, which is comparable to the survival rate
of all recumbent adult dairy cows that present to our referral center
(survival rate of 48% between 1994 and 2014, n = 1271). The
short-term survival rate was 30% in cows where only the TNCC
value was above the threshold (P = 0.035), 28% if only the protein
concentration was above the threshold (P = 0.012), and 34% if
both CSF parameters were above the thresholds (P = 0.024). How-
ever, in cows discharged from the hospital (n = 104), the long-term
prognosis was comparable amongst groups; 60% (53/88) of cows
with CSF values below the thresholds, and 75% (12/16) of cows
with one or more CSF value above the thresholds completed at
least one lactation after their return to the farm (P = 0.37).
Based on this study, we conclude that the short-term prognosis
of recumbent adult dairy cattle with CSF TNCC ≥ 4.5 cells/µL
and/or a protein concentration ≥0.40 g/L is lower than that of
cows with CSF values below those thresholds. However, some cat-
tle with CSF values above the thresholds survive and their long-
term prognosis seems to be acceptable suggesting that these cows
may have a spinal cord lesion that is reversible.
2016 ACVIM Abstracts 1519
